var images_info;if (!images_info) images_info =[]; images_info["70"]={"70000":{"type":"graphic_picture","displayName":"Darier disease - dark skin","title":"Darier disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Darier disease</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/70000_Darier_disease_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented, hyperkeratotic papules are on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70000 Version 6.0</div></div></div>"},"70001":{"type":"graphic_algorithm","displayName":"CDC algorithm for GBS prophylaxis","title":"CDC algorithm for GBS prophylaxis*","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">CDC algorithm for GBS prophylaxis*</div><div class=\"cntnt\"><img style=\"width:554px; height:370px;\" src=\"images/OBGYN/70001_Algo_GBS_penicil_all.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GBS: group B streptococcus; IV: intravenously.<br />* Broader-spectrum agents, including an agent active against GBS, might be necessary for treatment of chorioamnionitis.<br />¶ Doses ranging from 2.5 to 3.0 million units are acceptable for the doses administered every 4 hours following the initial dose. The choice of dose within that range should be guided by which formulations of penicillin G are readily available to reduce the need for pharmacies to specially prepare doses.<br />Δ Penicillin-allergic patients with a history of anaphylaxis, angioedema, respiratory distress, or urticaria following administration of penicillin or a cephalosporin are considered to be at high risk for anaphylaxis and should not receive penicillin, ampicillin, or cefazolin for GBS intrapartum prophylaxis. For penicillin-allergic patients who do not have a history of those reactions, cefazolin is the preferred agent because pharmacologic data suggest it achieves effective intra-amniotic concentrations. Vancomycin and clindamycin should be reserved for penicillin-allergic women at high risk for anaphylaxis.<br /><FONT class=lozenge>◊</FONT> If laboratory facilities are adequate, clindamycin and erythromycin susceptibility testing should be performed on prenatal GBS isolates from penicillin-allergic women at high risk for anaphylaxis. If no susceptibility testing is performed, or the results are not available at the time of labor, vancomycin is the preferred agent for GBS intrapartum prophylaxis for penicillin-allergic women at high risk for anaphylaxis.<br />§ Resistance to erythromycin is often but not always associated with clindamycin resistance. If an isolate is resistant to erythromycin, it might have inducible resistance to clindamycin, even if it appears susceptible to clindamycin. If a GBS isolate is susceptible to clindamycin, resistant to erythromycin, and testing for inducible clindamycin resistance has been performed and is negative (no inducible resistance), then clindamycin can be used for GBS intrapartum prophylaxis instead of vancomycin.</div><div class=\"graphic_reference\">Reproduced from: Verani JR, McGee L, Schrag SJ. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</div><div id=\"graphicVersion\">Graphic 70001 Version 5.0</div></div></div>"},"70002":{"type":"graphic_picture","displayName":"Central line catheter wire","title":"Central venous catheter being threaded onto guidewire","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central venous catheter being threaded onto guidewire</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/70002_Central_line_catheter_wire.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 70002 Version 2.0</div></div></div>"},"70003":{"type":"graphic_picture","displayName":"Cong rubella retinopathy","title":"Congenital rubella retinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital rubella retinopathy</div><div class=\"cntnt\"><img style=\"width:312px; height:550px;\" src=\"images/PEDS/70003_Cong_rubella_retinopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">&quot;Salt and pepper&quot; retinopathy of congenital rubella syndrome. Color fundus photograph (A). Fluorescein angiogram (B).</div><div class=\"graphic_reference\">Reproduced with permission from: Gold, DH, Weingeist, TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70003 Version 1.0</div></div></div>"},"70004":{"type":"graphic_figure","displayName":"Long arm splints","title":"Long arm splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long arm splint</div><div class=\"cntnt\"><img style=\"width:268px; height:360px;\" src=\"images/PEDS/70004_Long_arm_splints.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long (or posterior) arm splint is used for elbow and forearm injuries.</div><div id=\"graphicVersion\">Graphic 70004 Version 1.0</div></div></div>"},"70005":{"type":"graphic_picture","displayName":"Solar lentigines","title":"Solar lentigines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solar lentigines</div><div class=\"cntnt\"><img style=\"width:360px; height:485px;\" src=\"images/PEDS/70005_Solar_lentigines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous tan macules with irregular borders on the posterior neck and shoulder of an adolescent with a history of several severe sunburns.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 70005 Version 1.0</div></div></div>"},"70006":{"type":"graphic_table","displayName":"DSM-IV-TR diagnostic criteria for bulimia nervosa","title":"DSM-IV-TR diagnostic criteria for bulimia nervosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR diagnostic criteria for bulimia nervosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:</td> </tr> <tr> <td class=\"sublist1\">Eating, in a discrete period of time (eg, within any two-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances.</td> </tr> <tr> <td class=\"sublist1\">A sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating).</td> </tr> <tr> <td>Recurrent inappropriate compensatory behavior to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications; fasting; or excessive exercise.</td> </tr> <tr> <td>The binge eating and inappropriate compensatory behaviors both occur, on average, at least twice a week for three months.</td> </tr> <tr> <td>Self-evaluation is unduly influenced by body shape and weight.</td> </tr> <tr> <td>The disturbance does not occur exclusively during episodes of anorexia nervosa.</td> </tr> <tr> <td class=\"sublist1_start\">Specify type:</td> </tr> <tr> <td class=\"sublist1\">Purging type: during the current episode of bulimia nervosa, the person has regularly engaged in self-induced vomiting or the misuse of laxatives, diuretics, or enemas.</td> </tr> <tr> <td class=\"sublist1\">Nonpurging type: during the current episode of bulimia nervosa, the person has used other inappropriate compensatory behaviors, such as fasting or excessive exercise, but has not regularly engaged in self-induced vomiting or the misuse of laxatives, diuretics, or enemas.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC,&nbsp;American Psychiatric Association, 2000.</div><div id=\"graphicVersion\">Graphic 70006 Version 5.0</div></div></div>"},"70007":{"type":"graphic_diagnosticimage","displayName":"Simple silicosis CXR","title":"Simple silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simple silicosis</div><div class=\"cntnt\"><img style=\"width:283px; height:314px;\" src=\"images/PULM/70007_Simple_silicosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a profusion of small rounded densities, predominantly within the upper lung zones.</div><div class=\"graphic_reference\">Courtesy of Dr. E. L. Petsonk.</div><div id=\"graphicVersion\">Graphic 70007 Version 2.0</div></div></div>"},"70008":{"type":"graphic_table","displayName":"Major causes of myopathy","title":"Major causes of myopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of myopathy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td>Polymyositis</td> </tr> <tr> <td>Dermatomyositis</td> </tr> <tr> <td>Inclusion body myositis</td> </tr> <tr> <td>Juvenile dermatomyositis</td> </tr> <tr> <td>Vasculitis</td> </tr> <tr> <td>Overlap syndromes - lupus, scleroderma, rheumatoid arthritis, Sj&#246;gren's syndrome</td> </tr> <tr> <td>Rheumatoid arthritis, Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine disorders</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Cushing's syndrome (or exogenous steroid administration)</td> </tr> <tr> <td class=\"subtitle1_single\">Electrolyte disorders</td> </tr> <tr> <td>Hypokalemia</td> </tr> <tr> <td>Hypophosphatemia</td> </tr> <tr> <td>Hypocalcemia</td> </tr> <tr> <td>Hypernatremia or hyponatremia</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic myopathies</td> </tr> <tr> <td>Disorders of carbohydrate, lipid, and purine metabolism</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs and toxins</td> </tr> <tr> <td>Illicit drugs - cocaine, heroin</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td>Other - colchicine, antimalarial drugs, HMG-CoA reductase inhibitors, penicillamine, zidovudine</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Viral -&nbsp;influenza, parainfluenza, Coxsackie, HIV, cytomegalovirus, echovirus, adenovirus, Epstein-Barr virus</td> </tr> <tr> <td>Bacterial - pyomyositis, lyme myositis</td> </tr> <tr> <td>Fungal</td> </tr> <tr> <td>Parasitic - trichinosis, toxoplasmosis</td> </tr> <tr> <td class=\"subtitle1_single\">Rhabdomyolysis</td> </tr> <tr> <td>Crush trauma</td> </tr> <tr> <td>Seizures</td> </tr> <tr> <td>Alcohol abuse, including hyperkinetic state with delirium tremens</td> </tr> <tr> <td>Exertion, especially with environmental heat illness</td> </tr> <tr> <td>Vascular surgery</td> </tr> <tr> <td>Malignant hyperthermia</td> </tr> <tr> <td class=\"subtitle1_single\">Inherited myopathies</td> </tr> <tr> <td>Acid maltase deficiency</td> </tr> <tr> <td>Muscular dystrophy</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 70008 Version 5.0</div></div></div>"},"70010":{"type":"graphic_picture","displayName":"Listeria","title":"<EM>Listeria </EM>stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Listeria </EM>stain</div><div class=\"cntnt\"><img style=\"width:432px; height:292px;\" src=\"images/ID/70010_Listeria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of blood culture broth containing <EM>Listeria</EM>.</div><div class=\"graphic_reference\">Reproduced with permission from: McClatchey KD, MD, DDS. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70010 Version 4.0</div></div></div>"},"70011":{"type":"graphic_table","displayName":"Risk factors for infection after HCT","title":"Factors affecting risk of infection following hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors affecting risk of infection following hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">High risk</td> <td class=\"subtitle1\">Low risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Net state of immunosuppression</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Underlying disease</td> </tr> <tr> <td class=\"sublist2\">Acute myelogenous leukemia/aplastic anemia*</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Non-first remission malignancy*<sup>&#182;</sup></td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Chronic myelogenous leukemia, chronic phase</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">+</td> </tr> <tr> <td class=\"indent1\">Neutropenia<sup>&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Graft failure</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">CD4 cytopenia &#60;200 cells/microL<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids &#8805;1 mg/kg/day<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Immunomodulating viruses<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Age (in years)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\">&#62;40<sup>&#916;</sup></td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">&#60;19</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Graft characteristics</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">HLA relatedness</td> </tr> <tr> <td class=\"sublist2\">Allogeneic matched unrelated</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Allogeneic mismatched related</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Allogeneic matched related</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">+</td> </tr> <tr> <td class=\"sublist2\">Autologous</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">+</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">T cell depletion</td> </tr> <tr> <td class=\"sublist2\">Yes</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">No</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">+</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">CD34 infused (autologous) X 10<sup>6</sup>/kg</td> </tr> <tr> <td class=\"sublist2\">&#60;2.0</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">&#62;2.5</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Conditioning regimen, allogenic</td> </tr> <tr> <td class=\"indent1\">Ablative</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Reduced intensity</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Organ dysfunction</td> </tr> <tr> <td class=\"indent1\">Severe mucositis<sup>&#9674;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Renal failure<sup>&#9674;</sup><sup>&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Graft failure<sup>&#9674;</sup><sup>&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Graft-versus-host disease<sup>&#167;</sup>, grades II-IV<sup>&#916;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Skin breakdown, breech in skin due to central venous catheter</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Liver insufficiency</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lung insufficiency</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pathogen exposure</td> </tr> <tr> <td class=\"indent1\">Endogeneous: reactivation of latent infection</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Exogeneous:</td> </tr> <tr> <td class=\"sublist2\">Water/food/inanimate objects</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Healthcare worker</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Air</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Donor infection</td> <td class=\"sublist_other_centered\">+</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most important risk factors pre-engraftment.<br />&para; Most important risk factors post-engraftment.<br />&Delta; Immunomodulating viruses: CMV, HIV, ?HHV-6, ?HHV-7.<br /><span class=\"lozenge\">&loz;</span> Risk is intermediate if age is between 19 and 40 years. Lowest risk is among children.<br />&sect; Graft-versus-host disease (especially chronic) and its therapy are major contributors to risk of infection.</div><div class=\"graphic_reference\">Courtesy of Elias J Anaissie, MD.</div><div id=\"graphicVersion\">Graphic 70011 Version 5.0</div></div></div>"},"70013":{"type":"graphic_table","displayName":"Dialysate components in HD","title":"Concentrations of dialysate components used in hemodialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concentrations of dialysate components used in hemodialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sodium (mEq/L)</td> <td>134 to 140*</td> </tr> <tr> <td>Potassium (mEq/L)</td> <td>0 to 4</td> </tr> <tr> <td>Calcium (mmol/L)</td> <td>1.25 to 1.75 (&#60;2.5 mEq/L)</td> </tr> <tr> <td>Magnesium (mmol/L)</td> <td>0 to 0.75 (0 to 1.5 mEq/L)</td> </tr> <tr> <td>Chloride (mEq/L)</td> <td>87 to 120</td> </tr> <tr> <td>Bicarbonate (mEq/L)</td> <td>25 to 40</td> </tr> <tr> <td>Glucose (g/dL)</td> <td>0 to 0.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Remains controversial.</div><div class=\"graphic_reference\">Data from Van Stone JC. Hemodialysis: Hemodialysis apparatus. In: Handbook of Dialysis. Daugirdas JT, Ing TS (Eds). Little, Brown, Boston, 1994. p. 53.</div><div id=\"graphicVersion\">Graphic 70013 Version 3.0</div></div></div>"},"70014":{"type":"graphic_picture","displayName":"Lichen sclerosus with purpura","title":"Lichen sclerosus ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus </div><div class=\"cntnt\"><img style=\"width:297px; height:360px;\" src=\"images/OBGYN/70014_LS_adult_45_yrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">45-year-old woman with purpura from scratching plus loss of labia minora. The white areas of&nbsp;lichen sclerosus&nbsp;show a cellophane-like shiny surface.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 70014 Version 4.0</div></div></div>"},"70015":{"type":"graphic_figure","displayName":"ACE inhibitor survival in moderate HF","title":"ACE inhibitor improves survival in moderate HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor improves survival in moderate HF</div><div class=\"cntnt\"><img style=\"width:397px; height:246px;\" src=\"images/CARD/70015_ACE_inhibitor_moderate_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enalapril, compared with placebo, decreases patient mortality in NYHA classes II and III heart failure (p = 0.0036).</div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; HF: heart failure; NYHA: New York Heart Association.&nbsp;</div><div class=\"graphic_reference\">Data from: The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.</div><div id=\"graphicVersion\">Graphic 70015 Version 3.0</div></div></div>"},"70016":{"type":"graphic_movie","displayName":"Atheroma on 3D","title":"Atheroma on 3D","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atheroma on 3D</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/70016_Atheromaon3Dconv.mp4\" style=\"width:432px;height:336px\"></div><img style=\"width:459px; height:336px;\" src=\"images/SURG/70016_Atheromaon3D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complex atherosclerotic plaque with a mobile component in the aortic arch visualized by 3D TEE.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Dr. Muhamed Saric and Dr. Itzhak Kronzon.</div><div id=\"graphicVersion\">Graphic 70016 Version 4.0</div></div></div>"},"70018":{"type":"graphic_picture","displayName":"Elbow arthrocentesis","title":"Elbow arthrocentesis","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Elbow arthrocentesis</div><div class=\"cntnt\"><img style=\"width:534px; height:360px;\" src=\"images/RHEUM/70018_Elbowjointinject.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The landmarks for injection or aspiration of the elbow joint are the radial head, lateral epicondyle, and tip of the olecranon. A needle inserted into the center of the triangle penetrates only the anconeus muscle and capsule before entering the joint. The patient is supine with the elbow flexed to 90 degrees and the hand tucked under the buttock. A triangle is made with points at the lateral epicondyle, radial head, and olecranon process. The needle is inserted in the center of the triangle, perpendicular to the skin and parallel to the radial head,&nbsp;0.75 to 1 inch (about 2 to 2.5&nbsp;cm)&nbsp;deep.</div><div class=\"graphic_reference\">Photo courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 70018 Version 4.0</div></div></div>"},"70019":{"type":"graphic_table","displayName":"Inherited disorders associated with pancreatic NETs","title":"Inherited disorders associated with pancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inherited disorders associated with pancreatic neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Associated clinical features</td> <td class=\"subtitle1\">Chromosomal location</td> <td class=\"subtitle1\">Pancreatic neuroendocrine tumor type</td> </tr> <tr class=\"divider_bottom\"> <td>MEN1</td> <td> <p class=\"indent1\">Primary hyperparathyroidism</p> <p>Pituitary tumors</p> Less commonly<br /> <ul> <li>Adrenocortical tumors</li> <li>Carcinoid tumors</li> <li>Nonmedullary thyroid tumors</li> </ul> </td> <td>11q13</td> <td> <p>Nonfunctional</p> <p>Gastrinoma</p> <p>Insulinoma</p> Various</td> </tr> <tr class=\"divider_bottom\"> <td>Von Hippel-Lindau disease (VHL)</td> <td> <p>Pheochromocytoma (often bilateral)</p> <p>Retinal and cerebellar hemangioblastomas</p> Renal cell carcinoma</td> <td>3p25-26</td> <td> <p>Nonfunctional</p> Various, including cystic tumors</td> </tr> <tr class=\"divider_bottom\"> <td>Neurofibromatosis 1<br /> (von Recklinghausen disease)</td> <td> <p>Neurofibromas</p> <p>Caf&#233; au lait spots</p> Pheochromocytoma</td> <td>17q11.2</td> <td>&nbsp;</td> </tr> <tr> <td>Tuberous sclerosis</td> <td> <p>Cardiac rhabdomyomas</p> <p>Renal cysts</p> Angiomyolipomas</td> <td>9q33.34 and 16p13.3</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Milan S, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol 2012; 24:46. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70019 Version 5.0</div></div></div>"},"70020":{"type":"graphic_diagnosticimage","displayName":"Endoscopic ultrasound image of pancreatic pseudocyst","title":"Endoscopic ultrasound (EUS) image of a pancreatic pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound (EUS) image of a pancreatic pseudocyst</div><div class=\"cntnt\"><img style=\"width:452px; height:337px;\" src=\"images/GAST/70020_EUSpancpseudocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Raj J Shah, MD.</div><div id=\"graphicVersion\">Graphic 70020 Version 5.0</div></div></div>"},"70022":{"type":"graphic_table","displayName":"Design adjuv trastuzumab trials","title":"Design of adjuvant trials using trastuzumab","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Design of adjuvant trials using trastuzumab</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Trial<br /> (number of patients)</td> <td class=\"subtitle1\">Treatment arms</td> <td class=\"subtitle1\">Definition of severe cardiotoxicity</td> <td class=\"subtitle1\">Monitoring frequency</td> </tr> <tr class=\"divider_bottom\"> <td> <p>NSABP B-31<sup>[1]</sup></p> (n = 2030)</td> <td> <p>AC for four cycles, paclitaxel for four cycles, then observation</p> AC for four cycles, followed by paclitaxel for four cycles, with concurrent trastuzumab, continued for one year</td> <td>Grade III/IV HF or cardiac death; or LVEF decrease &#62;15 percentage points*</td> <td>MUGA three weeks, six months, and nine months after end of initial AC, and three months after last trastuzumab dose</td> </tr> <tr class=\"divider_bottom\"> <td> <p>HERA<sup>[2]</sup></p> (n = 5090)</td> <td> <p>Any chemotherapy regimen, then observation</p> <p>Any chemotherapy regimen, then trastuzumab for one year</p> Any chemotherapy regimen, then trastuzumab for two years</td> <td>Severe HF; symptomatic HF; or LVEF decrease &#62;10 percentage&nbsp;points*</td> <td>LVEF (echo or MUGA) at baseline, 3, 6, 12, 18, 24, 30, 36, and 60 months</td> </tr> <tr class=\"divider_bottom\"> <td> <p>BCIRG-006<sup>[3]</sup></p> (n = 3222)</td> <td> <p>AC for four cycles, docetaxel for four cycles, then observation</p> <p>AC for four cycles, followed by docetaxel for four cycles, with concurrent trastuzumab, continued for one year</p> Docetaxel and carboplatin for six cycles, with concurrent trastuzumab, continued for one year</td> <td>Grade III/IV HF; cardiac death; grade 3 to 4 arrhythmias; grade 3 to 4 ischemia/infarction; or LVEF decrease &#62;10 percentage points*</td> <td>After AC, after second dose of docetaxel, at end of chemotherapy, and 3, 12, and 36 months after randomization</td> </tr> <tr class=\"divider_bottom\"> <td> <p>FinHer<sup>[4]</sup></p> (n = 232)<sup>&#182;</sup></td> <td> <p>Docetaxel (every three weeks) and vinorelbine (weekly) for three cycles, then CEF for three cycles</p> Docetaxel (every three weeks) and vinorelbine (weekly) for three cycles, plus trastuzumab for nine weeks, then CEF for three cycles</td> <td>Myocardial infarction; HF; or LVEF decrease &#62;15 percentage points</td> <td>Echo or MUGA before chemotherapy, after CEF, and 12 and 36 months after chemotherapy</td> </tr> <tr> <td> <p>NCCTG N9831<sup>[5]</sup></p> (n = 3505)</td> <td> <p>AC for four cycles, weekly paclitaxel for 12 weeks, then observation</p> <p>AC for four cycles, weekly paclitaxel for 12 weeks, with concurrent trastuzumab, continued for one year</p> AC for four cycles, weekly placlitaxel for 12 weeks, followed by trastuzumab for one year</td> <td>Grade III/IV HF or cardiac death; or LVEF decrease &#62;15 percentage points*</td> <td>MUGA or echo at entry, after AC, and 6, 9, 18, and 21 months after entry</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AC: doxorubicin and cyclophosphamide; HF: heart failure; LVEF: left ventricular heart failure; MUGA: multi-gated acquisition scan; CEF: cyclophosphamide, epirubicin, and fluorouracil.<br />* Measured from baseline.<br />&para; Only patients with HER2-positive disease.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Romond EH, et al. N Engl J Med 2005; 353:1673. </LI>&#xD;&#xA;<LI>Piccart-Gebhart MJ, et al. N Engl J Med 2005; 353:1659. </LI>&#xD;&#xA;<LI>Slamon D, et al. N Engl J Med 2011; 365:1273. </LI>&#xD;&#xA;<LI>Joensuu H, et al. N Engl J Med 2006; 354:809. </LI>&#xD;&#xA;<LI>Perez A, et al. J Clin Oncol 2011; 29:4491.</LI></OL>Modified from: Bria E, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231 and Telli ML, et al. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525.</div><div id=\"graphicVersion\">Graphic 70022 Version 9.0</div></div></div>"},"70025":{"type":"graphic_table","displayName":"Mediastinal mesenchymal tumors","title":"Mesenchymal tumors of the mediastinum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mesenchymal tumors of the mediastinum</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of lymph vessels</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphangioma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphangiomatosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphangiomyoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of blood\nvessel origin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemangioma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemangioendothelioma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemangiomatosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Epithelioid hemangioendothelioma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angiosarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of pericyte\norigin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemangiopericytoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors and\ntumor-like fibro-histiocytic lesions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fibromatosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fibrosarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malignant fibrous histiocytoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of adipose\ntissue</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lipoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lipomatosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lipoblastomatosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Liposarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of muscle\norigin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rhabdomyoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rhabdomyosarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leiomyoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leiomyosarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of\npluripotential mesenchyme</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Benign mesenchymoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malignant mesenchymoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Synovial sarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Tumors of skeletal\ntissues</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chondroma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Osteogenic sarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chondrosarcoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Other tumors and\ntumor-like conditions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Solitary fibrous tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myxoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Meningioma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chordoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Granular cell tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Extramedullary hematopoiesis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Histiocytosis X</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Amyloid tumor</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Marchevsky, AM, Kaneko. M. Surgical Pathology of the Mediastinum, 2nd ed, Raven Press, New York, 1992.</div><div id=\"graphicVersion\">Graphic 70025 Version 1.0</div></div></div>"},"70026":{"type":"graphic_figure","displayName":"Metabolism of cyclophosphamide","title":"Pathways of cytochrome P450-catalyzed cyclophosphamide metabolism","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Pathways of cytochrome P450-catalyzed cyclophosphamide metabolism</div><div class=\"cntnt\"><img style=\"width:461px; height:492px;\" src=\"images/RHEUM/70026_Metabolism_of_cyclophospham.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Takada, K, Arefayene, M, Desta, Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202. Copyright&#169; 2004 American College of Rheumatology. Permission from John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 70026 Version 1.0</div></div></div>"},"70027":{"type":"graphic_table","displayName":"Involving family and friends in pseudocyesis treatment","title":"Involving family and friends in treatment of pseudocyesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Involving family and friends in treatment of pseudocyesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Reducing negative influences from others</td> <td class=\"subtitle1\">Teaching others to assist with treatment</td> </tr> <tr> <td>Educate others who support the patient's belief in pregnancy (eg, educate a boyfriend who insists patient must be pregnant because she has galactorrhea)</td> <td>Teach others how to encourage patient to accept treatment (eg, coaching spouse to explain that he is worried about patient and would like to come with her to see her doctor)</td> </tr> <tr> <td>Help others reduce pressure on patient to become pregnant (eg, council the patient's mother who repeatedly tells patient that she is not a good wife unless she has a baby)</td> <td>Teach others how to respond therapeutically when patient says she is pregnant (eg, help them think of specific ways to show support apart from pregnancy)</td> </tr> <tr> <td>Help others reduce the secondary gain of pregnancy belief (eg, encourage family members to be solicitous of patient's needs without patient having to be \"pregnant\" to elicit that response from them)</td> <td>Improve communication (eg, help spouse communicate his frustrations directly and respectfully, instead of with avoidance)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70027 Version 2.0</div></div></div>"},"70028":{"type":"graphic_figure","displayName":"Endemic areas P marneffei","title":"Endemic areas of <em>Penicillium marneffei</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endemic areas of <em>Penicillium marneffei</em></div><div class=\"cntnt\"><img style=\"width:372px; height:313px;\" src=\"images/ID/70028_Endemic_areas_P_marneffei.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 70028 Version 1.0</div></div></div>"},"70029":{"type":"graphic_figure","displayName":"Lyme seasonality","title":"Confirmed Lyme disease cases by month of disease onset - United States, 2001 to 2010","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Confirmed Lyme disease cases by month of disease onset - United States, 2001 to 2010</div><div class=\"cntnt\"><img style=\"width:592px; height:432px;\" src=\"images/ID/70029_Lyme_seasonality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lyme disease patients are most likely to have illness onset in June, July, or August and less likely to have illness onset from December through March.</div><div class=\"graphic_reference\">Reproduced from: United States Centers for Disease Control and Prevention. Lyme Disease: Lyme disease graphs. Available at: <a href=\"http://www.cdc.gov/lyme/stats/graphs.html\" target=\"_blank\">http://www.cdc.gov/lyme/stats/graphs.html</a>. (Accessed on July 27, 2016).</div><div id=\"graphicVersion\">Graphic 70029 Version 4.0</div></div></div>"},"70030":{"type":"graphic_figure","displayName":"Regions of endemic trachoma","title":"Regions of endemic trachoma","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Regions of endemic trachoma</div><div class=\"cntnt\"><img style=\"width:527px; height:349px;\" src=\"images/ID/70030_Regions_of_endemic_trachoma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70030 Version 1.0</div></div></div>"},"70031":{"type":"graphic_table","displayName":"Zoonoses from Cats B","title":"Zoonoses cats, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zoonoses cats, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Transmission</td> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Human symptoms</td> <td class=\"subtitle1\">Feline symptoms</td> <td class=\"subtitle1\">Geographic distribution</td> </tr> <tr> <td rowspan=\"3\">Aerosol</td> <td>Bordetella bronchiseptica</td> <td>Asymptomatic to upper respiratory tract infections to pneumonia</td> <td>Kennel cough</td> <td>Worldwide</td> </tr> <tr> <td> <p>Coxiella burnetii</p> </td> <td>Q fever, including a self-limited flu-like illness, +/- pneumonia, +/- hepatitis, +/- endocarditis</td> <td>Asymptomatic; infection may cause abortion or rapid death of newborn kittens</td> <td>Worldwide</td> </tr> <tr> <td>Mycobacterium bovis</td> <td>Tuberculosis</td> <td>Tuberculosis</td> <td>Worldwide</td> </tr> <tr> <td rowspan=\"5\">Tick or flea bites</td> <td>B. burgdorferi</td> <td>Lyme disease</td> <td>Lyme disease</td> <td>Worldwide</td> </tr> <tr> <td>Ehrlichia chaffeensis and Anaplasma phagocytophilum</td> <td>Ehrlichiosis Anaplasmosis</td> <td>Asymptomatic or similar to human disease</td> <td>North America Few cases Europe, Africa, Mexico</td> </tr> <tr> <td>Babesia microti (United States); Babesia divergens (Europe)</td> <td>Babesiosis</td> <td>Asymptomatic or similar to human disease</td> <td>Focal areas of United States and Europe</td> </tr> <tr> <td>Yersinia pestis</td> <td>Plague</td> <td>Fever, loss of appetite, can have severe illness</td> <td>Majority in south central United States</td> </tr> <tr> <td>Francisella tularensis</td> <td>Tularemia</td> <td>Fever, loss of appetite, can have severe illness</td> <td>Worldwide In the United States (Arkansas, Missouri Oklahoma)</td> </tr> <tr> <td rowspan=\"3\">Direct contact</td> <td>Sporothrix schenckii</td> <td>Sporotrichosis</td> <td>Similar to human disease</td> <td>Worldwide</td> </tr> <tr> <td>Microsporum canis</td> <td>Dermatophyte; ringworm</td> <td>Similar to human disease</td> <td>Worldwide</td> </tr> <tr> <td>Methicillin-resistant Staphylococcus aureus</td> <td>Asymptomatic; skin and soft tissue infection</td> <td>Similar to human disease</td> <td>Worldwide</td> </tr> <tr> <td>Urine</td> <td>Leptospira interrogans</td> <td>Leptosiprosis, subclinical to severe, potentially fatal illness</td> <td>Similar to human disease</td> <td>Worldwide</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70031 Version 2.0</div></div></div>"},"70032":{"type":"graphic_table","displayName":"Percent pregnancy loss by maternal age at conception","title":"Percent pregnancy loss by maternal age at conception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percent pregnancy loss by maternal age at conception</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Maternal age\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Spontaneous abortions (percentage)\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Ectopic pregnancies (percentage)\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Stillbirths rate/1000\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>12-19</td>\r\n  \r\n   <td>13.3</td>\r\n  \r\n   <td>2.0</td>\r\n  \r\n   <td>5.0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>20-24</td>\r\n  \r\n   <td>11.1</td>\r\n  \r\n   <td>1.5</td>\r\n  \r\n   <td>4.2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>25-29</td>\r\n  \r\n   <td>11.9</td>\r\n  \r\n   <td>1.6</td>\r\n  \r\n   <td>4.0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>30-34</td>\r\n  \r\n   <td>15.0</td>\r\n  \r\n   <td>2.8</td>\r\n  \r\n   <td>4.4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>35-39</td>\r\n  \r\n   <td>24.6</td>\r\n  \r\n   <td>4.0</td>\r\n  \r\n   <td>5.0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>40-44</td>\r\n  \r\n   <td>51.0</td>\r\n  \r\n   <td>5.8</td>\r\n  \r\n   <td>6.7</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#62;=45</td>\r\n  \r\n   <td>93.4</td>\r\n  \r\n   <td>7.0</td>\r\n  \r\n   <td>8.2</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from: Anderson et al. Figures 2,4,5. The total spontaneous abortion rate is estimated using the assumption that only 80 percent of women with abortions in recognized pregnancies were hospitalized. Adapted from: Anderson FWJ, Johnson TRB. Maternal mortality at Y2K. Postgraduate Obstetrics and Gynecology 2000; 20:1.</div><div id=\"graphicVersion\">Graphic 70032 Version 3.0</div></div></div>"},"70033":{"type":"graphic_table","displayName":"Dose mod neurotox Velcade","title":"Recommended dose modification for neuropathic pain and/or peripheral sensory neuropathy during treatment with bortezomib (Velcade)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended dose modification for neuropathic pain and/or peripheral sensory neuropathy during treatment with bortezomib (Velcade)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Severity of symptoms </td> <td class=\"subtitle1\">Dose modification </td> </tr> <tr> <td>Grade 1 (asymptomatic, loss of deep tendon reflexes or paresthesia without pain or loss of function)</td> <td>No action needed</td> </tr> <tr> <td>Grade 2 (interfering with function but not activities of daily living) or Grade 1 with pain</td> <td>Reduce dose to 1 mg/m<sup>2</sup></td> </tr> <tr> <td>Grade 3 (interfering with activities of daily living) or Grade 2 with pain</td> <td>Withhold until toxicity resolved, may reinitiate at 0.7 mg/m<sup>2</sup> once weekly</td> </tr> <tr> <td>Grade 4 (life-threatening, disabling, eg, paralysis)</td> <td>Discontinue therapy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70033 Version 2.0</div></div></div>"},"70034":{"type":"graphic_diagnosticimage","displayName":"EUS bile duct stone","title":"Choledocholithiasis seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledocholithiasis seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:326px; height:279px;\" src=\"images/GAST/70034_EUS_bile_duct_stone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic image of a stone in the common bile duct with an acoustic shadow.</div><div class=\"graphic_reference\">Courtesy of Maryam Moini, MD, and Seyed Alireza Taghavi, MD.</div><div id=\"graphicVersion\">Graphic 70034 Version 3.0</div></div></div>"},"70035":{"type":"graphic_figure","displayName":"Structure of starches","title":"Starch digestion products","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Starch digestion products</div><div class=\"cntnt\"><img style=\"width:526px; height:345px;\" src=\"images/GAST/70035_Structure_starches_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amylopectin and alpha-amylose. The two molecular forms of starch are digested by luminal alpha-amylase into maltotriose, maltose, and a series of alpha-limit dextrins, a few examples of which are shown.</div><div class=\"graphic_reference\">Adapted from: Traber PG. In: Textbook of Gastroenterology. Yamada T, et al (Eds), JB Lippincott, 1995 Philadelphia. p.408.</div><div id=\"graphicVersion\">Graphic 70035 Version 3.0</div></div></div>"},"70036":{"type":"graphic_waveform","displayName":"ECG acute infero-postero-lateral myocardial infarction","title":"ECG acute infero-postero-lateral myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">ECG acute infero-postero-lateral myocardial infarction</div><div class=\"cntnt\"><img style=\"width:540px; height:264px;\" src=\"images/CARD/70036_Acute_IPL_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing the major features of an inferior (Q waves, ST elevations, and T wave inversions in II, III, and aVF), posterior (tall R waves in V1 and V2), and lateral (T wave inversions in V4 to V6) myocardial infarction.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 70036 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"70037":{"type":"graphic_figure","displayName":"Robiscek sternal closure","title":"Robiscek sternal closure","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Robiscek sternal closure</div><div class=\"cntnt\"><img style=\"width:485px; height:455px;\" src=\"images/SURG/70037_Robiscek-sternal-closure.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70037 Version 1.0</div></div></div>"},"70038":{"type":"graphic_diagnosticimage","displayName":"Aspergillus bronchiolitis and bronchopneumonia HRCT","title":"<em>Aspergillus</em> bronchiolitis and bronchopneumonia","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\"><em>Aspergillus</em> bronchiolitis and bronchopneumonia</div><div class=\"cntnt\"><img style=\"width:534px; height:180px;\" src=\"images/ID/70038_Aspergillusbronch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computed tomography images (1.0 mm collimation) at the level of the right middle lobe bronchus (A) and liver dome (B) show patchy peribronchial consolidation, centrilobular nodules, and branching linear structures (arrows). Cavity formation is seen in both lower lobes.</div><div class=\"graphic_reference\">Reproduced with permission from: Müller NL, Fraser RS, Lee KS, Johkoh T. Pulmonary infections. In: Diseases of the Lung, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70038 Version 14.0</div></div></div>"},"70040":{"type":"graphic_diagnosticimage","displayName":"Septic emboli","title":"Sequelae attributable to septic embolization to the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sequelae attributable to septic embolization to the lung</div><div class=\"cntnt\"><img style=\"width:432px; height:300px;\" src=\"images/PULM/70040_Septic_emboli_final.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, thick-walled cavity in the lingula with enhancing walls, a left pleural effusion, and partial left lower lobe atelectasis, due to septic embolism in an intravenous drug user.</div><div id=\"graphicVersion\">Graphic 70040 Version 4.0</div></div></div>"},"70041":{"type":"graphic_picture","displayName":"Holster sign","title":"Holster sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Holster sign</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/RHEUM/70041_Holster_sign_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jeffrey P Callen, MD.</div><div id=\"graphicVersion\">Graphic 70041 Version 1.0</div></div></div>"},"70042":{"type":"graphic_figure","displayName":"Retinopathy and duration of DM","title":"Incidence of diabetic retinopathy increases over time","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence of diabetic retinopathy increases over time</div><div class=\"cntnt\"><img style=\"width:415px; height:246px;\" src=\"images/ENDO/70042_Retinopathy_and_duration_of.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent of diabetic patients with retinopathy according to duration of disease in patients under the age of 30 years who were treated with insulin (primarily type 1 diabetes) and patients over the age of 30 years who were not treated with insulin (primarily type 2 diabetes). Retinopathy increased over time in both groups, affecting virtually all patients with type 1 diabetes by 20 years. The increased incidence in type 2 diabetes at three years is a probable reflection of the difficulty in determining the time of onset of that disease.</div><div class=\"graphic_reference\">Data from: Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527.</div><div id=\"graphicVersion\">Graphic 70042 Version 3.0</div></div></div>"},"70043":{"type":"graphic_table","displayName":"Treatment summary basal cell carcinoma","title":"Summary of treatment options for basal cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of treatment options for basal cell carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment modality</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Surgical excision</strong></td> <td class=\"subtitle2_left\">Advantages</td> </tr> <tr> <td class=\"indent1\">Margin-controlled. Usually performed under local anesthesia. Area of tissue removed (including important structures) can be more precisely controlled than with cryosurgery, radiation therapy, or electrosurgery - therefore limiting unnecessary damage to critical structures. Resultant scar can be optimized both cosmetically and functionally.</td> </tr> <tr> <td class=\"subtitle2_left\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Invasive. Occasionally performed under conscious sedation or general anesthesia with their inherent risks. Random margin results in both a poorer cure rate compared&nbsp;with Mohs and the unnecessary sacrifice of normal tissues, which in critical, or cosmetically sensitive areas, results in potentially unnecessary disfigurement.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Mohs surgery</strong></td> <td class=\"subtitle2_left\">Advantages</td> </tr> <tr> <td class=\"indent1\">100 percent margin-control. Offers highest cure rate for both primary and recurrent BCCs while maximizing preservation of normal tissue. No sedation or general anesthesia required.</td> </tr> <tr> <td class=\"subtitle2_left\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">More costly than simple excision, cryosurgery, or electrosurgery (not radiation). Invasive. Longer procedure compared&nbsp;with simple excision, cryosurgery, or electrosurgery (not radiation). Requires special training in the technique.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Cryosurgery</strong></td> <td class=\"subtitle2_left\">Advantages</td> </tr> <tr> <td class=\"indent1\">Cost effective, relatively quick, requires a single visit, potential excellent cosmesis and cure rate in appropriately selected tumors, no sedation or general anesthesia required.</td> </tr> <tr> <td class=\"subtitle2_left\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Not margin-controlled. Requires considerable experience on the part of the clinician, wound care, pigmentary changes, possible permanent damage to underlying nerves or other critical structures.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Curettage and electrodessication</strong></td> <td class=\"subtitle2_left\">Advantages</td> </tr> <tr> <td class=\"indent1\">Cost effective, relatively quick, requires a single visit, relatively easy wound care, well suited for multiple lesions, usually affords good to excellent cosmetic results, no sedation or general anesthesia required, and offers low recurrence rates in small primary BCCs that lack \"high-risk\" features.</td> </tr> <tr> <td class=\"subtitle2_left\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Not margin-controlled. Recurrence rate unacceptably high with larger (&#62;5 mm) lesions located in high-risk sites, requires special equipment, requires experience in its use to achieve higher cure rates. Poor choice in most BCCs of the head. Must be cautious in patients with pacemakers.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Radiation therapy</strong></td> <td class=\"subtitle2_left\">Advantages</td> </tr> <tr> <td class=\"indent1\">Noninvasive. High cure rate for selected lesions. Relative sparing of critical structures. Good for patients who are not otherwise candidates for surgery. Relatively painless.</td> </tr> <tr> <td class=\"subtitle2_left\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Not margin-controlled. Requires repeat office visits. Poorer long-term cosmetic results. Generally avoid in younger patients, in lesions located on the trunk or extremities, in deeply invasive lesions, or previously irradiated sites. More expensive than simple excision, Mohs surgery, cryotherapy, and electrosurgery.</td> </tr> <tr> <td rowspan=\"4\"><strong>Topical 5-fluorouracil and imiquimod</strong></td> <td class=\"subtitle2_left\">Advantages</td> </tr> <tr> <td class=\"indent1\">Noninvasive. Rarely causes scarring. Avoids operative risks. Able to use in patients who are otherwise not candidates for surgery.</td> </tr> <tr> <td class=\"subtitle2_left\">Disadvantages</td> </tr> <tr> <td class=\"indent1\">Limited role for superficial BCCs located in low-risk areas. Brisk inflammatory reaction that can be poorly tolerated. Requires prolonged application.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70043 Version 5.0</div></div></div>"},"70044":{"type":"graphic_table","displayName":"Treadmill exercise testing protocols","title":"Treadmill exercise testing protocols","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treadmill exercise testing protocols</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"6\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Protocol name</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Grade<br /> (percent)</td> <td class=\"subtitle1\">Speed<br /> (mph)</td> <td class=\"subtitle1\">Total time<br /> (min)</td> <td class=\"subtitle1\">O<sub>2</sub> uptake<br /> (mL/kg/min)</td> <td class=\"subtitle1\">METS*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Modified Bruce<sup>&#182;</sup></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">1.7</td> <td class=\"centered\">3</td> <td class=\"centered\">9</td> <td class=\"centered\">2.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1/2</td> <td class=\"centered\">5</td> <td class=\"centered\">1.7</td> <td class=\"centered\">3</td> <td class=\"centered\">13</td> <td class=\"centered\">3.4</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Bruce</td> <td class=\"centered\">1</td> <td class=\"centered\">10</td> <td class=\"centered\">1.7</td> <td class=\"centered\">3</td> <td class=\"centered\">17</td> <td class=\"centered\">4.5</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">12</td> <td class=\"centered\">2.5</td> <td class=\"centered\">6</td> <td class=\"centered\">25</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">14</td> <td class=\"centered\">3.4</td> <td class=\"centered\">9</td> <td class=\"centered\">35</td> <td class=\"centered\">10</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">4</td> <td class=\"centered\">16</td> <td class=\"centered\">4.2</td> <td class=\"centered\">12</td> <td class=\"centered\">47</td> <td class=\"centered\">13</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">Cornell</td> <td class=\"centered\">1</td> <td class=\"centered\">0</td> <td class=\"centered\">1.7</td> <td class=\"centered\">2</td> <td class=\"centered\">7</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">5</td> <td class=\"centered\">1.7</td> <td class=\"centered\">4</td> <td class=\"centered\">11</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">10</td> <td class=\"centered\">1.7</td> <td class=\"centered\">6</td> <td class=\"centered\">17</td> <td class=\"centered\">4.5</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">11</td> <td class=\"centered\">2.1</td> <td class=\"centered\">8</td> <td class=\"centered\">19</td> <td class=\"centered\">5.5</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">12</td> <td class=\"centered\">2.5</td> <td class=\"centered\">10</td> <td class=\"centered\">25</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">13</td> <td class=\"centered\">3</td> <td class=\"centered\">12</td> <td class=\"centered\">30</td> <td class=\"centered\">8.5</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">14</td> <td class=\"centered\">3.4</td> <td class=\"centered\">14</td> <td class=\"centered\">35</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">15</td> <td class=\"centered\">3.8</td> <td class=\"centered\">16</td> <td class=\"centered\">40</td> <td class=\"centered\">11.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">9</td> <td class=\"centered\">16</td> <td class=\"centered\">4.2</td> <td class=\"centered\">18</td> <td class=\"centered\">47</td> <td class=\"centered\">13</td> </tr> <tr> <td rowspan=\"7\">Naughton</td> <td class=\"centered\">1</td> <td class=\"centered\">0</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">7</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">3.5</td> <td class=\"centered\">2</td> <td class=\"centered\">4</td> <td class=\"centered\">10.5</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">7</td> <td class=\"centered\">2</td> <td class=\"centered\">6</td> <td class=\"centered\">14</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">10.5</td> <td class=\"centered\">2</td> <td class=\"centered\">8</td> <td class=\"centered\">17.5</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">14</td> <td class=\"centered\">2</td> <td class=\"centered\">10</td> <td class=\"centered\">21</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">17.5</td> <td class=\"centered\">2</td> <td class=\"centered\">12</td> <td class=\"centered\">24.5</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">12.5</td> <td class=\"centered\">3</td> <td class=\"centered\">14</td> <td class=\"centered\">28</td> <td class=\"centered\">8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Metabolic equivalents - 1 MET = 3.5 mL O<SUB>2</SUB>/kg/min.<br />¶ Stages 1 through 4 of the Modified Bruce protocol are identical to stages 1 through 4 of the standard Bruce protocol.</div><div id=\"graphicVersion\">Graphic 70044 Version 7.0</div></div></div>"},"70045":{"type":"graphic_figure","displayName":"Electromagnetic spectrum","title":"Electromagnetic spectrum","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Electromagnetic spectrum</div><div class=\"cntnt\"><img style=\"width:526px; height:266px;\" src=\"images/PC/70045_EM_spectrum_ed.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70045 Version 4.0</div></div></div>"},"70046":{"type":"graphic_table","displayName":"Sources of data for a decision analysis problem","title":"Sources of data for a decision analysis problem","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of data for a decision analysis problem</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Sources of data </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Randomized controlled trials (RCTs)</td> <td>Excellent source of data on effects of therapies. Often the study requirements (entry and exclusion criteria) will make the results of the trial applicable to only a narrow range of patients.</td> </tr> <tr> <td>Cohort studies</td> <td>Useful for risk factor determination, natural history.</td> </tr> <tr> <td>Administrative databases</td> <td>Excellent sources for broad population-based estimates of disease; often more accurate as estimate of effectiveness for various procedures than RCTs, which, in general, estimate efficacy. However, it is difficult to be sure that confounding variables are controlled for.</td> </tr> <tr> <td>Electronic health records (EHRs)</td> <td>Provides additional detail above what administrative databases are able to provide. Very useful for determining the distribution of a particular variable in different diseases.</td> </tr> <tr> <td>Meta-analyses/systematic reviews</td> <td>Provides summary measures over several different studies for a particular parameter. Generally restricted to RCTs, so often global population data are not well-represented.</td> </tr> <tr> <td>Expert opinions</td> <td>Often plagued by biases and dependent upon the method used to assess opinion. Most closely resembles the methods used to make clinical decisions in current clinical practice (use of consultants, etc); therefore, the use of expert opinion has face validity.</td> </tr> <tr> <td>Investigator estimates</td> <td>A last resort, if there are no other good sources of data. When combined with appropriate sensitivity analysis, can be a useful first start.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70046 Version 2.0</div></div></div>"},"70049":{"type":"graphic_figure","displayName":"Echinocandins structure","title":"Structure of the echinocandins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of the echinocandins</div><div class=\"cntnt\"><img style=\"width:341px; height:764px;\" src=\"images/ID/70049_Echinocandins_structure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Caspofungin. Derived from Pneumocandin B<SUB>0</SUB> <EM>(Glarea lozoyensis)</EM>. (B) Micafungin. FR90130 <EM>(Coleophoma empedra)</EM>. (C) Anidulafungin. Echinocandin B<SUB>0</SUB> <EM>(Aspergillus nidulans)</EM>.</div><div class=\"graphic_reference\">Courtesy of Russell Lewis, PharmD, FCCP, BCPS.</div><div id=\"graphicVersion\">Graphic 70049 Version 2.0</div></div></div>"},"70050":{"type":"graphic_movie","displayName":"TR and stenosis four chamber color Doppler echo","title":"Tricuspid regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/70050_4chctrtsconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:238px; height:438px;\" src=\"images/CARD/70050_4chctrts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view from a 2-D echocardiogram with color flow Doppler shows tricuspid regurgitation. The regurgitant &quot;jet&quot; is directed toward the posterior wall of the right atrium which is enlarged. There is also a high velocity, turbulent, and narrow echo into the right ventricle during diastole suggesting the presence of tricuspid stenosis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 70050 Version 2.0</div></div></div>"},"70051":{"type":"graphic_table","displayName":"Osteogenic sarcomas","title":"The family of osteogenic sarcomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The family of osteogenic sarcomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tumor</td> <td class=\"subtitle1\">Usual age at diagnosis</td> <td class=\"subtitle1\">Common primary sites</td> <td class=\"subtitle1\">Radiographic appearance</td> <td class=\"subtitle1\">Distinctive features</td> <td class=\"subtitle1\">Clinical course</td> </tr> <tr> <td class=\"subtitle2_left\">Osteosarcoma&nbsp;</td> <td rowspan=\"5\">Second and third decade</td> <td rowspan=\"5\">Around knee joint and shoulder</td> <td rowspan=\"5\">Variable, depending on degree of mineralization of osteoid</td> <td rowspan=\"5\">Tumor osteoid present; variable degrees of osteo-blastic, chondro-blastic, and fibroblastic differentiation</td> <td rowspan=\"5\">Early dissemination to lungs &#177; skeleton</td> </tr> <tr> <td class=\"sublist2_start\">Conventional</td> </tr> <tr> <td class=\"sublist2\">Osteoblastic&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Chondroblastic</td> </tr> <tr> <td class=\"sublist2\">Fibroblastic</td> </tr> <tr> <td class=\"indent1\">Telangiectatic</td> <td>Second and third decade</td> <td>Similar to conventional osteosarcoma</td> <td>Predominantly lytic lesion with little or no sclerosis</td> <td>Cystic, cavity-like tumor; blood-filled spaces in tumor</td> <td>Similar to conventional osteosarcoma</td> </tr> <tr> <td class=\"indent1\">Small cell</td> <td>Second and third decade</td> <td>Similar to conventional osteosarcoma</td> <td>May be predominantly lytic</td> <td>May be confused with Ewing's sarcoma</td> <td>Similar to conventional osteosarcoma; radioresponsive</td> </tr> <tr> <td class=\"indent1\">Multifocal</td> <td>-</td> <td>Synchronous involvement of multiple bones</td> <td>Multiple skeletal sites showing densely sclerotic lesions</td> <td><span style=\"color: black;\">? Multiple primary tumors versus metastatic primary tumor</span></td> <td>Uniformly fatal</td> </tr> <tr> <td class=\"indent1\">Parosteal (juxtacortical osteosarcoma)</td> <td>Third decade or older</td> <td>Posterior aspect of distal femur</td> <td>Arises from cortex; encircles involved bone; pronounced ossification</td> <td>Low-grade tumor with characteristic radiograph and pathology</td> <td>Indolent clinical course with low propensity for metastases</td> </tr> <tr> <td class=\"indent1\">Periosteal (juxtacortical chondro-sarcoma)</td> <td>First-seventh decade</td> <td>Tibia and femur</td> <td>Tumor located superficially in cortex</td> <td>Tumor limited to periphery of cortex</td> <td>Intermediate prognosis</td> </tr> <tr> <td class=\"subtitle2_left\">Fibrosarcoma</td> <td>Second-sixth decade</td> <td>Similar to osteosarcoma</td> <td>Usually lytic</td> <td>Spindle cells and collagen but no osteoid</td> <td>Similar to osteosarcoma</td> </tr> <tr> <td class=\"subtitle2_left\">Chondrosarcoma</td> <td>Third-seventh decade; usually older adults</td> <td>Most in trunk (especially pelvis) and proximal limbs</td> <td>Bone destruction and fluffy calcification</td> <td>Prolonged history of symptoms; proliferating tissue is fully developed cartilage without tumor osteoid</td> <td>Metastases rare but may appear many years later</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: Principles and Practice of Pediatric Oncology, 5th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadephia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70051 Version 15.0</div></div></div>"},"70052":{"type":"graphic_table","displayName":"Fat soluble vits CF","title":"Fat-soluble vitamins in cystic fibrosis other than vitamin D: Daily intake and monitoring recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fat-soluble vitamins in cystic fibrosis other than vitamin D: Daily intake and monitoring recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vitamin</td> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Intake recommendations for CF patients</td> <td class=\"subtitle1\">Monitoring recommendations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Vitamin A*</td> </tr> <tr> <td rowspan=\"5\">&nbsp;</td> <td>1 to 12 months</td> <td>450&nbsp;micrograms (1500 <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">units</span>)</td> <td rowspan=\"5\"> <p>Annual measurement of serum retinol<sup>[1,2]</sup></p> In the presence of liver disease, serum retinyl binding protein and retinyl esters should be measured annually in addition to serum retinol<sup>[2]</sup></td> </tr> <tr> <td>1 to 3 years</td> <td>1500&nbsp;micrograms (5000 units)</td> </tr> <tr> <td>4 to 8 years</td> <td>1500 to 3000&nbsp;micrograms (5000 to 10,000 units)</td> </tr> <tr> <td>&#62;8 years</td> <td>3000&nbsp;micrograms (10,000 units)</td> </tr> <tr> <td>Adult</td> <td>3000&nbsp;micrograms (10,000 units)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Vitamin E<sup>&#8226;</sup></td> </tr> <tr> <td rowspan=\"5\">&nbsp;</td> <td>1 to 12 months</td> <td>40 to 50 mg</td> <td rowspan=\"5\">Annual measurement of serum alpha tocopherol<sup>[1]</sup></td> </tr> <tr> <td>1 to 3 years</td> <td>80 to 150 mg</td> </tr> <tr> <td>4 to 8 years</td> <td>100 to 200 mg</td> </tr> <tr> <td>9 to 18 years</td> <td>200 to 400 mg</td> </tr> <tr> <td>Adult</td> <td>200 to 400 mg<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Vitamin K</td> </tr> <tr> <td rowspan=\"5\">&nbsp;</td> <td>1 to 12 months</td> <td>0.3 to 0.5 mg</td> <td rowspan=\"5\"> <p>Annual measurement of serum prothrombin time and PIVKA II</p> <p>Additional supplementation may be required during antibiotic therapy</p> If found to be deficient, repeat measurement one to two months following therapy to confirm normalization</td> </tr> <tr> <td>1 to 3 years</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td>4 to 8 years</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td>9 to 18 years</td> <td>0.3 to 0.5 mg</td> </tr> <tr> <td>Adult</td> <td>2.5 to 5 mg/week</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CF: cystic fibrosis; PIVKA: protein induced by vitamin K absence.<br />* Vitamin A doses given as retinol activity equivalents (RAE). 1 RAE = 3.33&nbsp;units = 1&nbsp;microgram retinol = 12&nbsp;microgram beta-carotene.<br /><FONT class=bullet>•</FONT> Vitamin E is measured as alpha-tocopherol; 1 mg alpha tocopherol = 1.47&nbsp;units \"natural source\" vitamin E (RRR-alpha tocopherol), or 2.2 units synthetic vitamin E (\"all-racemic\" vitamin E).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246.</LI>&#xD;&#xA;<LI>Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125 (1 Suppl):1S.</LI></OL>Modified with permission from: Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med 2008; 14:574. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70052 Version 19.0</div></div></div>"},"70053":{"type":"graphic_picture","displayName":"Alternative interfaces","title":"Alternative interfaces","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Alternative interfaces</div><div class=\"cntnt\"><img style=\"width:493px; height:405px;\" src=\"images/PULM/70053_Alternative_interfaces.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Nasal pillows (prongs). B) Hybrid pillows/oral interface. C) Total face mask. D) Mouthpiece. E) Helmet.</div><div id=\"graphicVersion\">Graphic 70053 Version 2.0</div></div></div>"},"70054":{"type":"graphic_figure","displayName":"Mortality HF ACE beta block","title":"Additive benefit with ACE inhibitors and beta blockers in HF","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Additive benefit with ACE inhibitors and beta blockers in HF</div><div class=\"cntnt\"><img style=\"width:462px; height:151px;\" src=\"images/CARD/70054_Mortality_HF_ACE_beta_block.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are the reductions in annual mortality (with 95 percent confidence intervals) in patients with heart failure (HF) achieved with angiotensin converting enzyme (ACE) inhibitor therapy alone, when beta blockers are administered (derived from studies in which patients were often already receiving an ACE inhibitor), and an estimate of the effect with the combination of both therapies.</div><div class=\"graphic_reference\">Redrawn with permission from: Cleland JG, McGowan J, Clark A, Freemantle N. BMJ 1999; 318:824.</div><div id=\"graphicVersion\">Graphic 70054 Version 2.0</div></div></div>"},"70056":{"type":"graphic_picture","displayName":"Straddle injury","title":"Prepubertal child with laceration from straddle injury, note extensive bleeding and difficulty in assessing extent of injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prepubertal child with laceration from straddle injury, note extensive bleeding and difficulty in assessing extent of injury</div><div class=\"cntnt\"><img style=\"width:340px; height:504px;\" src=\"images/EM/70056_Straddleinjury.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70056 Version 11.0</div></div></div>"},"70060":{"type":"graphic_table","displayName":"Common etiologies of cardiac arrest in adults","title":"Common etiologies of cardiac arrest in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common etiologies of cardiac arrest in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td>Acute coronary syndrome (most common)</td> </tr> <tr> <td>Arrhythmia: Secondary to electrolyte disorder, acidosis, other process; abnormal conduction syndromes (eg, prolonged QT, Brugada)</td> </tr> <tr> <td>Pericardial tamponade</td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory</td> </tr> <tr> <td>Airway obstruction: Mucus plug, foreign body, tracheostomy decannulation</td> </tr> <tr> <td>Asthma/COPD exacerbation</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Pulmonary embolus</td> </tr> <tr> <td>Tension pneumothorax</td> </tr> <tr> <td class=\"subtitle1_single\">Hemmorhage and hypovolemia</td> </tr> <tr> <td>Trauma</td> </tr> <tr> <td>Gastrointestinal bleeding</td> </tr> <tr> <td>Abdominal aortic aneursym rupture</td> </tr> <tr> <td>Intracranial hemorrhage</td> </tr> <tr> <td>Profound gastrointestinal fluid loss</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs and poisons</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Calcium-channel blockers</td> </tr> <tr> <td>Benzodiazepines</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>Digoxin</td> </tr> <tr> <td class=\"subtitle1_single\">Electrolyte disturbances</td> </tr> <tr> <td>Potassium</td> </tr> <tr> <td>Magnesium</td> </tr> <tr> <td class=\"subtitle1_single\">Sepsis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70060 Version 3.0</div></div></div>"},"70061":{"type":"graphic_picture","displayName":"Onchocerca volvulus microfilariae","title":"<em>Onchocerca volvulus</em> microfilariae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Onchocerca volvulus</em> microfilariae</div><div class=\"cntnt\"><img style=\"width:422px; height:300px;\" src=\"images/ID/70061_Onchocerca_web.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microfilariae of <em>O. volvulus</em> from a skin nodule of a patient from Zambia, stained with hematoxylin and eosin. Image taken at 1000x oil magnification.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Onchocerciasis. Available at: <a href=\"http://www.cdc.gov/dpdx/onchocerciasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/onchocerciasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 70061 Version 6.0</div></div></div>"},"70062":{"type":"graphic_picture","displayName":"Exanthematous (morbilliform) drug eruption","title":"Exanthematous (morbilliform) drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exanthematous (morbilliform) drug eruption</div><div class=\"cntnt\"><img style=\"width:222px; height:277px;\" src=\"images/ALLRG/70062_Morbilliformdrugeruptedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drug-induced exanthems, such as this morbilliform eruption, often begin in dependent areas and generalize.</div><div class=\"graphic_reference\">Courtesy of Andrew Samel, MD.</div><div id=\"graphicVersion\">Graphic 70062 Version 5.0</div></div></div>"},"70063":{"type":"graphic_movie","displayName":"Apical 5 chamber echo with color Doppler AR","title":"Apical five chamber echocardiogram with color Doppler demonstrating aortic regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical five chamber echocardiogram with color Doppler demonstrating aortic regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/70063_5chcdarmconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:275px; height:458px;\" src=\"images/CARD/70063_5chcdarm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five chamber view from a 2-D echocardiogram shows a moderate amount of aortic regurgitation and left ventricular enlargement.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 70063 Version 4.0</div></div></div>"},"70064":{"type":"graphic_picture","displayName":"Striped fibrosis with CyA","title":"Light micrograph showing \"striped fibrosis\" in cyclosporine-induced nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing \"striped fibrosis\" in cyclosporine-induced nephropathy</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/70064_Striped_fibrosis_with_CyA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focal areas of interstitial fibrosis and tubular atrophy (right side of picture) in cyclosporine nephrotoxicity that, on lower power, would produce a characteristic striped appearance.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 70064 Version 2.0</div></div></div>"},"70065":{"type":"graphic_table","displayName":"Features of isolated dystonia","title":"Clinical features of isolated dystonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of isolated dystonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Presence of:</td> </tr> <tr> <td>Sustained involuntary movement, sometimes overlying spasms</td> </tr> <tr> <td>Consistent directional quality</td> </tr> <tr> <td>Involves same body region(s)</td> </tr> <tr> <td>Enhanced or produced by activity of involved area</td> </tr> <tr> <td>Varies with change in activity or posture</td> </tr> <tr> <td>Sensory tricks (geste antagoniste) may reduce symptoms</td> </tr> <tr> <td>May have associated tremor</td> </tr> <tr> <td class=\"subtitle1_single\">Absence of:</td> </tr> <tr> <td>Weakness</td> </tr> <tr> <td>Amyotrophy</td> </tr> <tr> <td>Spasticity</td> </tr> <tr> <td>Ataxia</td> </tr> <tr> <td>Ocular abnormalities</td> </tr> <tr> <td>Abnormal eye movements</td> </tr> <tr> <td>Retinal changes</td> </tr> <tr> <td>Cognitive impairment</td> </tr> <tr> <td>Seizures</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70065 Version 4.0</div></div></div>"},"70066":{"type":"graphic_table","displayName":"Causes nonimmune hydrops","title":"Conditions associated with nonimmune hydrops","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with nonimmune hydrops</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n   <tr>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Cardiovascular\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1_start\">\n   Malformation\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Left heart hypoplasia\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Atrioventricular canal defect\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Right heart hypoplasia\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Closure of foramen ovale\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Single ventricle\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Transposition of the great arteries\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Ventricular septal defect\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Atrial septal defect\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Tetralogy of Fallot\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Ebstein's anomaly\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Premature closure of ductus\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Truncus arteriosus\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Aortic or pulmonary stenosis\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Valvular insufficiency\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   AV canal defect\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1_start\">\n   Tachyarrhythmia\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Atrial flutter\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Paroxysmal atrial tachycardia\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Wolff-Parkinson-White\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Supraventricular tachycardia\n   </td>\n   </tr>\n   <tr>\n   <td>Bradyarrhythmia including complete heart block</td>\n   </tr>\n   <tr>\n   <td>Other arrhythmia (eg, long QT)</td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1_start\">\n   High-output failure\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Neuroblastoma\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Sacrococcygeal teratoma\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Large fetal angioma\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Placental chorioangioma\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Umbilical cord hemangioma\n   </td>\n   </tr>\n   <tr>\n   <td>Cardiac tumors</td>\n   </tr>\n   <tr>\n   <td>Other cardiac neoplasia</td>\n   </tr>\n   <tr>\n   <td>Cardiomyopathy</td>\n   </tr>\n   <tr>\n   <td>Cardiosplenic syndromes</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Aneuploidy and structural abnormalities of chromosomes\n   </td>\n   </tr>\n   <tr>\n   <td>45, X</td>\n   </tr>\n   <tr>\n   <td>Trisomy 21</td>\n   </tr>\n   <tr>\n   <td>Trisomy 18</td>\n   </tr>\n   <tr>\n   <td>Trisomy 13</td>\n   </tr>\n   <tr>\n   <td>18q +</td>\n   </tr>\n   <tr>\n   <td>13q -</td>\n   </tr>\n   <tr>\n   <td>45,X mosaic</td>\n   </tr>\n   <tr>\n   <td>Triploidy</td>\n   </tr>\n   <tr>\n   <td>17q -</td>\n   </tr>\n   <tr>\n   <td>Duplicated 11p</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Chondrodysplasias\n   </td>\n   </tr>\n   <tr>\n   <td>Thanatophoric dysplasia</td>\n   </tr>\n   <tr>\n   <td>Short rib polydactyly</td>\n   </tr>\n   <tr>\n   <td>Hypophosphatasia</td>\n   </tr>\n   <tr>\n   <td>Osteogenesis imperfecta</td>\n   </tr>\n   <tr>\n   <td>Achondrogenesis</td>\n   </tr>\n   <tr>\n   <td>Camptomelic dysplasia</td>\n   </tr>\n   <tr>\n   <td>Lethal chondroplasia</td>\n   </tr>\n   <tr>\n   <td>Homozygous achondroplasia</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Twin pregnancy\n   </td>\n   </tr>\n   <tr>\n   <td>Twin-twin transfusion syndrome</td>\n   </tr>\n   <tr>\n   <td>Acardiac twin</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Hematologic\n   </td>\n   </tr>\n   <tr>\n   <td>Alpha-thalassemia</td>\n   </tr>\n   <tr>\n   <td>Fetomaternal transfusion</td>\n   </tr>\n   <tr>\n   <td>Parvovirus B19 infection</td>\n   </tr>\n   <tr>\n   <td>In utero hemorrhage</td>\n   </tr>\n   <tr>\n   <td>Glucose-6-phosphate dehydrogenase (G6PD) deficiency</td>\n   </tr>\n   <tr>\n   <td>Red cell enzyme deficiencies</td>\n   </tr>\n   <tr>\n   <td>Thrombosis of major vessels</td>\n   </tr>\n   <tr>\n   <td>Leukemia</td>\n   </tr>\n   <tr>\n   <td>Red cell aplasias</td>\n   </tr>\n   <tr>\n   <td>Pyruvate kinase deficiency</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Thoracic\n   </td>\n   </tr>\n   <tr>\n   <td>Congenital cystic adenomatoid malformation of lung</td>\n   </tr>\n   <tr>\n   <td>Diaphragmatic hernia</td>\n   </tr>\n   <tr>\n   <td>Intrathoracic mass</td>\n   </tr>\n   <tr>\n   <td>Pulmonary sequestration</td>\n   </tr>\n   <tr>\n   <td>Chylothorax</td>\n   </tr>\n   <tr>\n   <td>Airway obstruction</td>\n   </tr>\n   <tr>\n   <td>Pulmonary lymphangiectasia</td>\n   </tr>\n   <tr>\n   <td>Pulmonary neoplasia</td>\n   </tr>\n   <tr>\n   <td>Bronchogenic cyst</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Infections\n   </td>\n   </tr>\n   <tr>\n   <td>Cytomegalovirus (CMV)</td>\n   </tr>\n   <tr>\n   <td>Toxoplasmosis</td>\n   </tr>\n   <tr>\n   <td>Parvovirus B19 (fifth disease)</td>\n   </tr>\n   <tr>\n   <td>Syphilis</td>\n   </tr>\n   <tr>\n   <td>Herpes</td>\n   </tr>\n   <tr>\n   <td>Rubella</td>\n   </tr>\n   <tr>\n   <td>Coxsackievirus</td>\n   </tr>\n   <tr>\n   <td>Leptospirosis</td>\n   </tr>\n   <tr>\n   <td>Trypanosoma cruzi</td>\n   </tr>\n   </table></td>\n   <td class=\"container\"><table cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Malformation sequences and genetic syndromes\n   </td>\n   </tr>\n   <tr>\n   <td>Congenital lymphedema, eg, Noonan's syndrome</td>\n   </tr>\n   <tr>\n   <td>Arthrogryposis</td>\n   </tr>\n   <tr>\n   <td>Multiple pterygium syndrome</td>\n   </tr>\n   <tr>\n   <td>Neu-Laxova syndrome</td>\n   </tr>\n   <tr>\n   <td>Pena-Shokeir syndrome</td>\n   </tr>\n   <tr>\n   <td>Myotonic dystrophy</td>\n   </tr>\n   <tr>\n   <td>Saldino-Noonan syndrome</td>\n   </tr>\n   <tr>\n   <td>Francois syndrome, type III</td>\n   </tr>\n   <tr>\n   <td>Familial Nuchal Bleb</td>\n   </tr>\n   <tr>\n   <td>Acrocephalopolydactylous dysplasia (Elejalde syndrome)</td>\n   </tr>\n   <tr>\n   <td>Thoracoabdominal syndrome</td>\n   </tr>\n   <tr>\n   <td>Lymphedema distichiasis syndrome</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Metabolic\n   </td>\n   </tr>\n   <tr>\n   <td>Gaucher's disease</td>\n   </tr>\n   <tr>\n   <td>GM<sub>1</sub> gangliosidosis</td>\n   </tr>\n   <tr>\n   <td>Sialidosis</td>\n   </tr>\n   <tr>\n   <td>Hurler syndrome</td>\n   </tr>\n   <tr>\n   <td>Mucopolysaccharide (MPS) IVa</td>\n   </tr>\n   <tr>\n   <td>Mucolipidosis type I+II</td>\n   </tr>\n   <tr>\n   <td>Galactosialidosis</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Urinary\n   </td>\n   </tr>\n   <tr>\n   <td>Urethral stenosis or atresia</td>\n   </tr>\n   <tr>\n   <td>Posterior urethral valves</td>\n   </tr>\n   <tr>\n   <td>Congenital nephrosis (Finnish type)</td>\n   </tr>\n   <tr>\n   <td>Prune belly syndrome</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Gastrointestinal\n   </td>\n   </tr>\n   <tr>\n   <td>Midgut volvulus</td>\n   </tr>\n   <tr>\n   <td>Malrotation of the intestines</td>\n   </tr>\n   <tr>\n   <td>Duplication of the intestinal tract</td>\n   </tr>\n   <tr>\n   <td>Meconium peritonitis</td>\n   </tr>\n   <tr>\n   <td>Hepatic fibrosis</td>\n   </tr>\n   <tr>\n   <td>Cholestasis</td>\n   </tr>\n   <tr>\n   <td>Biliary atresia</td>\n   </tr>\n   <tr>\n   <td>Hepatic vascular malformations</td>\n   </tr>\n   <tr>\n   <td>Hepatitis</td>\n   </tr>\n   <tr>\n   <td>Hepatic necrosis</td>\n   </tr>\n   <tr>\n   <td>Liver tumors or cysts</td>\n   </tr>\n   </table></td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 70066 Version 1.0</div></div></div>"},"70067":{"type":"graphic_table","displayName":"Orally available nonopioid analgesic and NSAIDs","title":"Orally available nonopioid analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs): Usual dosing for adults with pain or inflammation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Orally available nonopioid analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs): Usual dosing for adults with pain or inflammation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Optional initial loading dose</td> <td class=\"subtitle1\">Usual analgesic dose<br /> (oral)</td> <td class=\"subtitle1\">Maximum dose per day<br /> (mg)</td> <td class=\"subtitle1\">Selected characteristics and role in therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Para-aminophenol derivative</td> </tr> <tr> <td class=\"indent1\">Acetaminophen* (paracetamol, APAP)</td> <td>None</td> <td> <p>325 to 650 mg every&nbsp;4 to&nbsp;6&nbsp;hours</p> <p>Or</p> 1000 mg every&nbsp;6 hours up to three times per day</td> <td>3000 mg</td> <td> <ul> <li>Effective for noninflammatory pain; may be opioid-sparing. </li> <li>Doses &#60;2000 mg per day do not increase risk of serious GI complications. </li> <li>Does not alter platelet functioning. </li> <li>Can cause hepatotoxicity in chronic or acute overdose. </li> <li>Avoid or use a lower total daily dose (maximum 2000 mg per day) in older adults, patients at risk for hepatotoxicity (eg, regular alcohol use, malnourished) or with organ dysfunction. </li> <li>For short-term or one-time use, may use a total dose of up to 4000 mg per day in selected medically supervised patients. </li> <li>Interacts with warfarin (prolongs INR), isoniazid, and CYP450-inducing drugs<sup>&#182;</sup> (transaminitis). </li> <li>Warn patients about acetaminophen content in combination prescription (eg, oxycodone-acetaminophen) and OTC preparations. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">NSAID agents</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>Applies to all nonselective NSAIDs:</strong> <ul class=\"decimal_heading\"> <li>Effective for treatment of acute and chronic painful and inflammatory conditions. May decrease opioid requirements. Short-to-moderate-acting NSAIDs (eg, naproxen, ibuprofen) are preferred for most patients. </li> <li>Dose- and age-related risk of gastropathy. </li> <li>May cause or worsen renal impairment. </li> <li>Nonselective NSAIDs reversibly inhibit platelet functioning and&nbsp;can alter cardioprotective effects of aspirin. </li> <li>Avoid NSAIDs in patients with renal insufficiency (CrCl &#60;60 mL/minute), GI bleeding, platelet dysfunction, reduced cardiac output, difficult-to-control hypertension, hypovolemia, hyponatremia, aspirin-sensitive asthma, or cirrhosis. </li> <li>Safety concerns&nbsp;of NSAID use in patients with, or at elevated risk&nbsp;for, cardiovascular disease&nbsp;or&nbsp;thrombotic events are addressed in a separate&nbsp;topic in UpToDate. </li> <li>Use with caution or avoid in patients receiving comedication with&nbsp;anticoagulants, systemic glucocorticoids, lithium, loop diuretics, and other interacting drugs. Drug interactions may be checked using the Lexi-Interact program included with UpToDate. </li> <li>Though some older adults may benefit from a brief course of NSAIDs at the lowest effective dose, use in most older adults should be avoided. Refer to the UpToDate topics on treatment of pain in older adults and&nbsp;older adults with&nbsp;organ dysfunction. </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Salicylate (acetylated)</td> </tr> <tr> <td class=\"indent2\">Aspirin*</td> <td>2600 mg</td> <td>325 to 650 mg every&nbsp;4 to&nbsp;6&nbsp;hours</td> <td>4000 mg</td> <td> <ul> <li>Standard for comparison, but <span style=\"color: black;\">now </span>used infrequently for treatment of chronic pain and inflammation. </li> <li>Unlike other NSAIDs, irreversibly inhibits platelet functioning for life of the platelet (7 to 10 days). </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Salicylates (nonacetylated)</td> </tr> <tr> <td class=\"indent2\">Diflunisal</td> <td>1000 mg</td> <td>500 mg every 8 to 12 hours</td> <td>1500 mg</td> <td rowspan=\"3\">Applies to all nonacetylated salicylates: <ul class=\"decimal_heading\"> <li>No significant effect on platelet function at usual analgesic doses. </li> <li>Less frequently associated with GI bleeding than nonselective NSAIDs at usual analgesic doses. </li> <li>Generally tolerated by adults with asthma at lower daily doses: Diflunisal &#8804;1000 mg, choline magnesium trisalicylate and salsalate &#8804;2000 mg. </li> <li>Relatively slow onset. </li> <li>500 mg dose of diflunisal has a comparable analgesic effect with 650 mg acetaminophen or aspirin. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Choline magnesium trisalicylate</td> <td>1500 mg</td> <td>750 mg every 8 to 12 hours</td> <td>3000 mg</td> </tr> <tr> <td class=\"indent2\">Salsalate</td> <td>1500 mg</td> <td>750 to 1000 mg every 8 to 12 hours</td> <td>3000 mg</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Propionic acids (phenyl-propionic acid)</td> </tr> <tr> <td class=\"indent2\">Naproxen*</td> <td> <p>500 mg (naproxen base)</p> 550 mg (naproxen sodium)</td> <td> <p>250 to 500 mg every 12 hours (naproxen base)</p> 275 to 550 mg every 12 hours (naproxen sodium)</td> <td> <p>1250 mg acute, 1000 mg chronic (naproxen base)</p> 1375 mg acute, 1100 mg chronic (naproxen sodium)</td> <td> <ul> <li>A good choice for treatment of acute or chronic pain and inflammation in most patients if NSAID therapy is indicated. </li> <li>High doses (eg, 500 mg twice daily) may have less cardiovascular toxicity than comparable doses of other NSAIDs.<sup>&#9674;</sup> </li> <li>For the treatment of rheumatologic disorders, total daily dose may be increased to a maximum of 1500 mg base (1650 mg naproxen sodium), when needed. </li> <li>Naproxen sodium has more rapid absorption and onset of effect than naproxen base. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Ibuprofen*</td> <td>1600 mg</td> <td>400 mg every&nbsp;4 to&nbsp;6&nbsp;hours</td> <td>3200 mg (acute), 2400 mg (chronic)</td> <td> <ul> <li>200 to 400 mg dose has a comparable analgesic effect with 650 mg acetaminophen or aspirin. </li> <li>Short duration of effect. </li> <li>Useful alternative to naproxen in patients without cardiovascular risks. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Ketoprofen</td> <td>100 mg</td> <td>50 mg every&nbsp;6 hours or 75 mg every&nbsp;8 hours</td> <td>300 mg</td> <td> <ul> <li>25 mg dose has a comparable analgesic effect to 400 mg ibuprofen. </li> <li>Short duration of effect. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Flurbiprofen</td> <td>100 mg</td> <td>50 to 100 mg every 6 to 12 hours</td> <td>300 mg</td> <td> <ul> <li>Lozenge preparation available in some countries. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Oxaprozin</td> <td>None</td> <td>1200 mg once daily</td> <td>26 mg/kg up to 1800 mg (whichever is lower)</td> <td> <ul> <li>Long duration of effect. </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Acetic acids (pyrano-indoleacetic acid)</td> </tr> <tr> <td class=\"indent2\">Diclofenac</td> <td>75 or 100 mg (conventional tablets)</td> <td>50 mg every&nbsp;8 hours</td> <td> <p>150 mg</p> Approved maximum daily dose in some countries is 100 mg</td> <td> <ul> <li>Diclofenac is also available as a topical patch, solution, and gel for treatment of musculoskeletal pain and osteoarthritis of superficial joints, which may be useful in combination with or as an alternative to systemic NSAIDs. Refer to the UpToDate&nbsp;topic on initial treatment of osteoarthritis and separate table. </li> <li>Interacts with drugs that are strong inhibitors or inducers of CYP2C9 drug metabolism; use Lexi-Interact to determine specific interactions. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Etodolac</td> <td>400 to 600 mg</td> <td> <p>Immediate release: 200 to 400 mg every&nbsp;6 to&nbsp;8&nbsp;hours</p> Extended release: 400 to 1000 mg once daily</td> <td> <p>Immediate <span style=\"color: black;\">release: 1000 mg</span></p> <span style=\"color: black;\">Extended release: 1200 mg</span></td> <td> <ul> <li><span style=\"color: black;\">Relatively COX-2 selective at lower total daily dose of 600 to 800 mg. </span></li> <li>200 mg dose has a comparable analgesic effect with 400 mg of ibuprofen. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Indomethacin </td> <td>75 mg</td> <td> <p>Immediate release: 25 to 50 mg every 8 to 12 hours</p> Controlled release: 75 mg once or twice daily</td> <td>150 mg</td> <td> <ul> <li>Useful for treatment of acute gout and specific types of headache. </li> <li>Potent inhibitory effects on renal prostaglandin synthesis. </li> <li>More frequently associated with CNS side effects (eg, headache) compared with other NSAIDs. </li> <li>Carefully select and monitor patients to reduce risk of renal and cardiovascular toxicities. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Tolmetin</td> <td>600 mg</td> <td>400 to 600 mg every&nbsp;8 hours</td> <td>1800 mg</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Sulindac</td> <td>300 mg</td> <td>150 to 200 mg every 12 hours</td> <td>400 mg</td> <td> <ul> <li>More frequently associated with hepatic inflammation (idiosyncratic or with features of hypersensitivity) compared with other NSAIDs. </li> <li>Sulindac metabolites implicated in the formation of renal calculi; refer to the UpToDate topic&nbsp;on nonselective NSAID adverse effects. </li> <li>Prescribing should be limited to specialists with experience in treatment of chronic pain and inflammation. </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Oxicams (enolic acids)</td> </tr> <tr> <td class=\"indent2\">Meloxicam</td> <td>7.5 mg (conventional tablets)</td> <td>7.5 to 15 mg once daily</td> <td>15 mg</td> <td> <ul> <li>Long duration of effect; slow onset. </li> <li><span style=\"color: black;\">Relatively COX-2 selective and minimal effect on platelet function at lower total daily dose of 7.5 mg. </span></li> <li>Rarely associated with serious cutaneous allergic reactions, including Stevens-Johnson syndrome. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Piroxicam</td> <td>10 mg</td> <td>10 to 20 mg once daily</td> <td>20 mg</td> <td> <ul> <li>A long-acting option for treatment of chronic pain and inflammation poorly responsive to other NSAIDs. </li> <li>Daily doses &#8805;20 mg increase risk of serious GI complications. </li> <li>Concurrent pharmacologic gastroprotection is suggested. </li> <li>Rarely associated with serious cutaneous allergic reactions, including Stevens-Johnson syndrome. </li> <li>Prescribing should be limited to specialists with experience in treatment of chronic pain and inflammation. </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Fenamates (anthranilic acids)</td> </tr> <tr> <td class=\"indent2\">Meclofenamate (meclofenamic acid)</td> <td>150 mg</td> <td>50 mg every&nbsp;4 to&nbsp;6&nbsp;hours</td> <td>400 mg</td> <td> <ul> <li>Alternate NSAID choice for treatment of acute or chronic pain, inflammation, and dysmenorrhea. </li> <li>Appears to be associated with higher incidence of GI disturbance (including diarrhea) compared with other nonselective NSAIDs. </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Mefenamic acid</td> <td>500 mg</td> <td>250 mg every&nbsp;6 hours</td> <td>1000 mg</td> <td> <ul> <li>Alternate NSAID choice for treatment of acute pain and dysmenorrhea. </li> <li>Duration of use not to exceed seven days (acute pain) or three days (dysmenorrhea). </li> <li>Anti-inflammatory efficacy is comparatively low. </li> <li>Not indicated for treatment of chronic pain or inflammation. </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Nonacidic (naphthylalkanone)</td> </tr> <tr> <td class=\"indent2\">Nabumetone</td> <td>1000 mg</td> <td>500 to 750 mg every 8 to 12 hours or 1000 to 1500 mg once daily</td> <td>2000 mg</td> <td> <ul> <li><span style=\"color: black;\">Moderate duration of effect; slow onset. </span></li> <li><span style=\"color: black;\">Relatively COX-2 selective at lower total daily dose of 1000 mg or less. </span></li> <li>Minimal effect on platelet function at total daily dose of 1000 mg or less. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective COX-2 inhibitors<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Celecoxib</td> <td>400 mg</td> <td>200 mg daily or 100 mg every 12 hours</td> <td>400 mg</td> <td> <ul> <li>Relative reduction in GI toxicity compared with nonselective NSAIDs. </li> <li>No effect on platelet function. </li> <li>Cardiovascular and renal risks are dose-related and appear similar to those of nonselective NSAIDs. </li> <li>Patients with indications for cardioprotection require aspirin supplement; individuals may require concurrent gastroprotection. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Etoricoxib (not available in the United States)</td> <td>None</td> <td>30 to 60 mg once daily</td> <td> <p>60 mg (chronic pain and inflammation)</p> 120 mg (acute pain for up to eight days)</td> <td> <ul> <li>May be associated with more frequent and severe dose-related cardiovascular effects (eg, hypertension) compared with nonselective and other COX-2 selective NSAIDs. </li> <li>Otherwise, risks and benefits as with celecoxib (see above). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; INR: international normalized ratio; CYP450: cytochrome P450; OTC: over-the-counter, available without prescription;&nbsp;CrCl<SPAN style=\"COLOR: black\">: creatinine clearance; COX-2: cyclooxygenase, isoform 2; CYP2C9: cytochrome 2C9; CNS: central nervous system; SSRIs: selective serotonin reuptake inhibitors.</SPAN><br />* Available without a prescription in the United States.<br />¶ A list of CYP450-inducing drugs is available separately in UpToDate.<br />Δ NSAIDs may interact with aspirin, warfarin, methotrexate, antihypertensives, serotonin reuptake inhibitor antidepressants (eg, SSRIs, cyclic antidepressants, venlafaxine), and other drugs. For specific interactions, use the Lexi-Interact program included with UpToDate.<br /><FONT class=lozenge>◊</FONT> Refer to the UpToDate topic on the cardiovascular effects of nonselective NSAIDs.<br />§ For additional information on gastroprotective strategies, including selective COX-2 inhibitors and other options, refer to the UpToDate topics on the overview of selective COX-2 inhibitors and on NSAIDs (including aspirin) and the primary prevention of gastroduodenal toxicity.</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Anon. Drugs for pain. Treatment guidelines from the Medical Letter; 2013. 11:31.</LI>&#xD;&#xA;<LI>Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: A systematic review. Drug Saf 2012; 35:1127.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 70067 Version 43.0</div></div></div>"},"70068":{"type":"graphic_table","displayName":"Exam reading difficulty","title":"Important aspects of the physical examination in a child with reading difficulty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the physical examination in a child with reading difficulty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\"><sup></sup>Feature</td> <td class=\"subtitle1\">Clinical implications</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General observations and appearance</td> </tr> <tr> <td class=\"indent1\">Sadness, anxiety, attention span, impulsivity, activity</td> <td>Indicators of emotional or behavioral problems that may affect learning</td> </tr> <tr> <td class=\"indent1\">Ability to communicate and respond to instructions</td> <td>Measure of language skills other than phonologic processing</td> </tr> <tr> <td class=\"indent1\">Stigmata of genetic syndromes (eg, Klinefelter, Turner, fragile X)</td> <td> <p>Klinefelter syndrome: Tall stature, small testes</p> <p>Turner syndrome: Short stature, webbed neck, micrognathia, short metacarpals, nail dysplasia widely spaced nipples</p> <p>Fragile X syndrome: Narrow face, large jaw, long, prominent ears, large testes (after puberty)</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Growth parameters</td> </tr> <tr> <td class=\"indent1\">Head circumference</td> <td>Head circumference &#60;10<sup>th</sup> percentile may suggest fetal alcohol syndrome</td> </tr> <tr> <td class=\"indent1\">Height and weight</td> <td>Height and weight &#60;10<sup>th</sup> percentile may suggest fetal alcohol syndrome; short stature is a feature of Turner syndrome; tall stature is a feature of Klinefelter syndrome</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Caf&#233;-au-lait spots, ash leaf spots, adenoma sebaceum</td> <td>Signs of neurocutaneous disorders associated with learning problems (eg, neurofibromatosis, tuberous sclerosis)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Tympanic membranes</td> </tr> <tr> <td class=\"indent1\">Signs of recurrent or chronic otitis media</td> <td>May be associated with hearing impairment</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Genitalia</td> </tr> <tr> <td class=\"indent1\">Delayed sexual maturation</td> <td>May be associated with Turner syndrome, Klinefelter syndrome</td> </tr> <tr> <td class=\"indent1\">Small testes</td> <td>Suggestive of Klinefelter syndrome</td> </tr> <tr> <td class=\"indent1\">Large testes (after puberty)</td> <td>Suggestive of fragile X syndrome</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Sensory screening</td> </tr> <tr> <td class=\"indent1\">Hearing assessment</td> <td>Hearing impairment may affect learning</td> </tr> <tr> <td class=\"indent1\">Vision assessment</td> <td>Vision impairment may affect learning</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70068 Version 4.0</div></div></div>"},"70069":{"type":"graphic_diagnosticimage","displayName":"Distal vertebral bypass","title":"Distal vertebral bypass","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Distal vertebral bypass</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/SURG/70069_Distal_verte_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow-up MRA showing patient distal vertebral bypass.</div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiogram.</div><div id=\"graphicVersion\">Graphic 70069 Version 2.0</div></div></div>"},"70070":{"type":"graphic_diagnosticimage","displayName":"Fibroid embolization 4e","title":"Right uterine angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right uterine angiogram</div><div class=\"cntnt\"><img style=\"width:388px; height:400px;\" src=\"images/OBGYN/70070_Fibroid_embolization_4e.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right uterine angiogram after uterine fibroid embolization demonstrates successful occlusion of the right uterine artery and its branches (arrow). The patient's symptoms subsided after the procedure.</div><div id=\"graphicVersion\">Graphic 70070 Version 2.0</div></div></div>"},"70071":{"type":"graphic_diagnosticimage","displayName":"Sonogram pt on tamoxifen","title":"Transvaginal pelvic sonogram of a patient treated with tamoxifen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal pelvic sonogram of a patient treated with tamoxifen</div><div class=\"cntnt\"><img style=\"width:382px; height:270px;\" src=\"images/OBGYN/70071_Sonogram_pt_on_tamoxifen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central uterine echo measured 18 mm and is heterogeneous in its appearance.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 70071 Version 2.0</div></div></div>"},"70072":{"type":"graphic_table","displayName":"Causes acquired aplastic anemia","title":"Major causes of acquired aplastic anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of acquired aplastic anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Cytotoxic drugs and radiation</td> </tr> <tr> <td>Cancer treatment (anticipated effect)</td> </tr> <tr> <td class=\"subtitle1_single\">Drug reaction</td> </tr> <tr> <td>Anti-seizure agents: carbamazepine, phenytoin, others</td> </tr> <tr> <td>Antibiotics: sulfonamides, chloramphenicol</td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drugs (NSAIDs): phenylbutazone, indomethacin</td> </tr> <tr> <td>Anti-thyroid medications: methimazole, propylthiouracil</td> </tr> <tr> <td>Gold</td> </tr> <tr> <td>Arsenicals</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic chemicals</td> </tr> <tr> <td>Benzene</td> </tr> <tr> <td>Solvents</td> </tr> <tr> <td>Glue vapors</td> </tr> <tr> <td class=\"subtitle1_single\">Viral infections</td> </tr> <tr> <td>Epstein-Barr virus</td> </tr> <tr> <td>Seronegative (non-A through -G) hepatitis</td> </tr> <tr> <td>Human immunodeficiency virus (HIV)</td> </tr> <tr> <td>Other herpes viruses</td> </tr> <tr> <td class=\"subtitle1_single\">Immune disorders</td> </tr> <tr> <td>Eosinophilic fasciitis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td>Thymoma</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Anorexia nervosa</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70072 Version 7.0</div></div></div>"},"70073":{"type":"graphic_table","displayName":"Antimicrob activity abx B","title":"Antimicrobial activity of topical antibiotics used for external otitis: Part B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial activity of topical antibiotics used for external otitis: Part B</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Organism</td> <td class=\"subtitle1\" colspan=\"3\">Aminoglycosides</td> <td class=\"subtitle1\" colspan=\"4\">Miscellaneous</td> </tr> <tr> <td class=\"subtitle2\">Neomycin</td> <td class=\"subtitle2\">Gentamicin</td> <td class=\"subtitle2\">Tobramycin</td> <td class=\"subtitle2\">Bacitracin</td> <td class=\"subtitle2\">Chloramphenicol</td> <td class=\"subtitle2\">Gramicidin</td> <td class=\"subtitle2\">Polymyxin B</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Gram-positive</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium diphtheriae</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus epidermidis</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em> spp</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pyogenes</em> (group A beta-hemolytic)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Gram-negative</td> </tr> <tr> <td class=\"indent1\"><em>Bacteroides fragilis</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Citrobacter</em> spp</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter aerogenes</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella pneumoniae</em></td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> <tr> <td class=\"indent1\"><em>Proteus</em> spp</td> <td>&#8226;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>&nbsp;</td> <td>&#8226;</td> <td>&#8226;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#8226;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bojrab DI, Bruderly T, Abdulrazzak Y, Otolaryngol Clin North Am 1996; 29:761.</div><div id=\"graphicVersion\">Graphic 70073 Version 4.0</div></div></div>"},"70074":{"type":"graphic_figure","displayName":"Angle of bronchial puncture","title":"Angle of transbronchial puncture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angle of transbronchial puncture</div><div class=\"cntnt\"><img style=\"width:255px; height:339px;\" src=\"images/PULM/70074_Angle_of_bronchial_puncture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TBNA needle should make an angle &gt;45&#186; with the airway wall.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 70074 Version 1.0</div></div></div>"},"70081":{"type":"graphic_diagnosticimage","displayName":"Maffucci syndrome","title":"Maffucci syndrome","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Maffucci syndrome</div><div class=\"cntnt\"><img style=\"width:483px; height:414px;\" src=\"images/PEDS/70081_Maffucci_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Plain radiograph demonstrates multiple soft-tissue masses and calcified thrombi in association with expansile bony lesions. <BR>B) Late film from an arteriogram shows contrast material filling many cavernous hemangiomas of the soft tissues.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70081 Version 2.0</div></div></div>"},"70082":{"type":"graphic_diagnosticimage","displayName":"Postoperative cardiac shift CT","title":"Shift in mediastinal position following pneumonectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shift in mediastinal position following pneumonectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/70082_Postoperative_cardiac_shift.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT demonstrates the postoperative change in location of mediastinal organs, with the heart abutting the chest wall. Blind chest tube or needle placement into the postpneumonectomy space may puncture the heart or great vessels.</div><div class=\"graphic_footnotes\">LV: left ventricle, RV: right ventricle, LA: left artium, RA: right artium, a: descending aorta, e: esophagus; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 70082 Version 3.0</div></div></div>"},"70083":{"type":"graphic_table","displayName":"Rx of torsades de pointes","title":"Treatment of torsades de pointes due to long QT syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of torsades de pointes due to long QT syndrome</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"1\" class=\"subtitle1_single\">\r\n  \r\n   Acquired LQTS\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Pharmacologic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Magnesium sulfate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Isoproterenol\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Lidocaine\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Phenytoin\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\" colspan=\"1\">\r\n  \r\n   Sodium bicarbonate (for quinidine-related arrhythmia)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Nonpharmacologic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Temporary pacing (atrial or ventricular)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Congenital LQTS\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Pharmacologic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Beta blockers\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Mexiletine\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Nonpharmacologic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Permanent dual chamber pacemaker\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Left cardiac sympathetic denervation (cardiothoracic sympathectomy)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Implantable cardioverter-defibrillator\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 70083 Version 1.0</div></div></div>"},"70084":{"type":"graphic_picture","displayName":"Lichen sclerosus papules on the chest","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70084_Lichen_sclero_papules_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small polygonal papules are present on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70084 Version 3.0</div></div></div>"},"70085":{"type":"graphic_picture","displayName":"Conjunctival neoplasia","title":"Conjunctival neoplasia with corneal extension","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Conjunctival neoplasia with corneal extension</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/70085_Conjunctival_neoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70085 Version 5.0</div></div></div>"},"70086":{"type":"graphic_figure","displayName":"Nomogram to predict survival in terminally ill cancer patients","title":"Nomogram to predict the probability of survival at 15, 30, and 60 days in terminally ill cancer patients","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Nomogram to predict the probability of survival at 15, 30, and 60 days in terminally ill cancer patients</div><div class=\"cntnt\"><img style=\"width:598px; height:479px;\" src=\"images/ONC/70086_Nomosurvtermcancer2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">1. Using a ruler or straight edge, draw a line from each of the following up to \"Points\" at the top: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Time from initial diagnosis to diagnosis of terminal disease (TTD)</LI>&#xD;&#xA;<LI>Eastern Cooperative Oncology Group Performance Status (ECOG PS)</LI>&#xD;&#xA;<LI>Serum albumin levels</LI>&#xD;&#xA;<LI>Serum lactate dehydrogenase levels (LDH)</LI>&#xD;&#xA;<LI>Lymphocyte count</LI></UL>2. Sum the points for these factors to obtain \"Total points\".<br />3. Draw a line from \"Total points\" straight down to obtain predictions of 15, 30, and 60 days survival.</div><div class=\"graphic_reference\">From: Feliu J, Jim&eacute;nez-Gordo AM, Madero R, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst 2011; 103:1613. By permission of Oxford University Press. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 70086 Version 15.0</div></div></div>"},"70088":{"type":"graphic_diagnosticimage","displayName":"Obstructing CBD stone ERCP","title":"Obstructing stone in common bile duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obstructing stone in common bile duct</div><div class=\"cntnt\"><img style=\"width:225px; height:267px;\" src=\"images/GAST/70088_Obstructing_CBD_stone_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following cannulation of the distal common bile duct during an endoscopic retrograde cholangiopancreatography examination (arrow indicates cannula), contrast material was injected, outlining a large stone producing complete obstruction of the distal duct (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 70088 Version 3.0</div></div></div>"},"70089":{"type":"graphic_picture","displayName":"Carbuncle","title":"Carbuncle","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Carbuncle</div><div class=\"cntnt\"><img style=\"width:504px; height:350px;\" src=\"images/ID/70089_Carbuncle_new_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carbuncle, which is a series of abscesses in the subcutaneous tissue that drain via hair follicles.</div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70089 Version 3.0</div></div></div>"},"70092":{"type":"graphic_figure","displayName":"Regulation of erythropoiesis","title":"Formation of erythyroid progenitors","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Formation of erythyroid progenitors</div><div class=\"cntnt\"><img style=\"width:511px; height:463px;\" src=\"images/HEME/70092_Regulation_of_erythropoiesi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the formation of erythroid progenitors (BFU-E and CFU-E) from hematopoietic stem cells and multipotent progenitor cells. The transcription factors important for the maturation and differentiation of hematopoietic stem cells (HSC) and expansion of the stem/progenitor compartment are indicated on the right, according to whether they are important for primary erythropoiesis in the yolk sac and/or definitive erythropoiesis in the fetal liver and/or bone marrow. Certain growth factors and their receptors, such as Steel factor (SF)/c-kit and erythropoietin (Epo/EpoR), are important or essential for erythropoiesis, respectively; by comparison, other growth factors, such as IL-3 or GM-CSF, act synergistically but are not essential.</div><div class=\"graphic_footnotes\">Epo and EpoR: erythropoietin and its receptor, respectively; SF and W (c-kit): Steel factor and its receptor, respectively; IL-3R: interleukin-3 receptor; BFU-E: Erythroid blast-forming units; and CFU-E: Erythroid colony- forming units.</div><div id=\"graphicVersion\">Graphic 70092 Version 1.0</div></div></div>"},"70095":{"type":"graphic_diagnosticimage","displayName":"Bilateral fetal pleural effusions","title":"Bilateral pleural effusions in a fetus with suspected pulmonary hypoplasia by lung volume estimates","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Bilateral pleural effusions in a fetus with suspected pulmonary hypoplasia by lung volume estimates</div><div class=\"cntnt\"><img style=\"width:584px; height:393px;\" src=\"images/OBGYN/70095_Bilateral_fetal_plrl_effsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral pleural effusion and ascites. Longitudinal image of the fetal chest and abdomen. Arrows point to the pleural effusion and ascites. Arrowheads show the fetal lung with its characteristic wedge shape within the thoracic cavity.</div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD and Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 70095 Version 3.0</div></div></div>"},"70097":{"type":"graphic_picture","displayName":"Premature eruption","title":"Premature eruption of the primary molar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Premature eruption of the primary molar</div><div class=\"cntnt\"><img style=\"width:299px; height:240px;\" src=\"images/PEDS/70097_Premature_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Premature eruption of the primary molar, which was apparent at 6 months of age, in an 18-month-old child with Langerhans cell histiocytosis X.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &#169; 2000 WB Saunders.</div><div id=\"graphicVersion\">Graphic 70097 Version 2.0</div></div></div>"},"70098":{"type":"graphic_table","displayName":"Asthma adherence III","title":"Take steps to solve your medicine-taking problems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Take steps to solve your medicine-taking problems</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Achieve success one step at a time</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Set specific goals such as \"I'll place my inhaler on the\nkitchen table and use it at lunch at least five times this week.\" or\n\"I'll put my antibiotic in the kitchen cabinet next to the salt and\npepper shakers and take it at breakfast, lunch, and supper today.\"</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Make goals large enough to matter, but small enough to achieve; don't set your sights too high, you may fail.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>It's better to set a series of smaller goals that you can easily achieve, then move up to slightly harder goals.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Monitor your progress</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Write down successes as well as problems. Use a medicine record as you did before or develop your own monitoring system.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use small successes to motivate yourself to keep going.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Keep an eye out for remaining problems.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Reward your success</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use small, frequent rewards soon after the successful activity. Don't try to wait too long or build up to a large reward.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Use problem solving methods as necessary</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Make sure you have correctly identified the problem.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Work on just one problem at a time.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>List as many solutions as you can think of.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cross out solutions you know won't work.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Try to come up with positive and negative effects from the solutions that could work.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Choose the solution you think will work best.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Try it out and see if it works. If not, try another solution.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70098 Version 1.0</div></div></div>"},"70099":{"type":"graphic_diagnosticimage","displayName":"Spiral fracture of the middle phalanx","title":"Spiral fracture of the middle phalanx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spiral fracture of the middle phalanx</div><div class=\"cntnt\"><img style=\"width:281px; height:432px;\" src=\"images/EM/70099_Mid_phalanx_spiral_fx1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spiral fractures of the middle phalanx, such as the one pictured above,&nbsp;are an indication for surgical referral, as they are&nbsp;often unstable and lead to rotational deformities.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 70099 Version 4.0</div></div></div>"},"70101":{"type":"graphic_table","displayName":"Reversible causes of ileus","title":"Potentially treatable causes of ileus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potentially treatable causes of ileus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Abdominopelvic abscess</td>\n</tr>\n<tr>\n<td>Anastomotic leaks</td>\n</tr>\n<tr>\n<td>Anticholinergic drugs</td>\n</tr>\n<tr>\n<td>Antihistamines</td>\n</tr>\n<tr>\n<td>Appendicitis</td>\n</tr>\n<tr>\n<td>Cholecystitis</td>\n</tr>\n<tr>\n<td>Hemoperitoneum or retroperitoneal hemorrhage</td>\n</tr>\n<tr>\n<td>Hypokalemia</td>\n</tr>\n<tr>\n<td>Hypomagnesemia</td>\n</tr>\n<tr>\n<td>Opiates</td>\n</tr>\n<tr>\n<td>Pancreatitis</td>\n</tr>\n<tr>\n<td>Sepsis</td>\n</tr>\n<tr>\n<td>Uremia</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70101 Version 1.0</div></div></div>"},"70102":{"type":"graphic_diagnosticimage","displayName":"Massive unilateral edema PA","title":"Unilateral pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unilateral pulmonary edema</div><div class=\"cntnt\"><img style=\"width:358px; height:334px;\" src=\"images/PULM/70102_Massive_unilateral_edema_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral pulmonary edema from massive pulmonary embolism involving the contralateral pulmonary artery. Chest radiograph shows a large opacity involving most of the right lung. Oligemia of the left lung is explained by a large central embolus, proven at autopsy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70102 Version 3.0</div></div></div>"},"70103":{"type":"graphic_picture","displayName":"Shape of thoracostomy tube","title":"Straight and angled thoracostomy tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Straight and angled thoracostomy tube</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/70103_Shape_thoracostomy_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Joseph Friedberg, MD.</div><div id=\"graphicVersion\">Graphic 70103 Version 1.0</div></div></div>"},"70104":{"type":"graphic_diagnosticimage","displayName":"Common bile duct stone on MRCP","title":"Common bile duct stone on MRCP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct stone on MRCP</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/SURG/70104_Common_bile_stone_on_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal thick slab MRCP demonstrates distal common bile duct stone (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Leyendecker, JR, Brown, JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70104 Version 2.0</div></div></div>"},"70105":{"type":"graphic_picture","displayName":"Hypertrichosis lanuginosa","title":"Hypertrichosis lanuginosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrichosis lanuginosa</div><div class=\"cntnt\"><img style=\"width:247px; height:470px;\" src=\"images/DERM/70105_Hypertrichosis_lanuginosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous fine, white hairs are present on the face of this patient with hypertrichosis lanuginosa.</div><div id=\"graphicVersion\">Graphic 70105 Version 1.0</div></div></div>"},"70106":{"type":"graphic_algorithm","displayName":"Management algorithm of GERD patient who failed PPI once daily","title":"Management algorithm of GERD patient who failed PPI once daily","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Management algorithm of GERD patient who failed PPI once daily</div><div class=\"cntnt\"><img style=\"width:726px; height:614px;\" src=\"images/GAST/70106_Mang_algo_GERD_failed_PPI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Management algorithm of gastroesophageal reflux disease (GERD) patient who failed PPI once daily (complete or partial*).</div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor; SSRIs: selective serotonin reuptake inhibitors; SNRIs: serotonin-norepinephrine reuptake inhibitors; TLESR: transient lower esophageal sphincter relaxation; H2RA: histamine 2 receptor antagonist.<br />* Partial or incomplete relief of symptoms.</div><div class=\"graphic_reference\">Original figure modified for this publication. Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol 2010; 24:923. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70106 Version 3.0</div></div></div>"},"70107":{"type":"graphic_picture","displayName":"Acute paronychia 2","title":"Acute paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute paronychia</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/70107_Acute_paronychia_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling, erythema, and a purulent collection are present in this patient with acute paronychia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70107 Version 5.0</div></div></div>"},"70108":{"type":"graphic_diagnosticimage","displayName":"High grade cystic duct leak II","title":"High grade cystic stump leak after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High grade cystic stump leak after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:249px; height:332px;\" src=\"images/GAST/70108_High_grade_cystic_duct_le1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography shows extravasation of contrast (arrow) with minimal filling of the intraheptic bile ducts.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 70108 Version 5.0</div></div></div>"},"70111":{"type":"graphic_table","displayName":"Post-intervention patency definitions","title":"Post-intervention patency definitions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Post-intervention patency definitions</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Primary patency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interval following intervention until next procedure or thrombosis. The interval ends with a treatment of a lesion anywhere within the access circuit from arterial inflow through the superior vena cava.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Assisted primary patency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interval following intervention until thrombosis or surgical intervention (treatment with a different modality). Percutaneous treatments of either restenosis or occlusion of the previously treated lesion or a new lesion are compatible with primary assisted patency.</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Secondary patency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interval following intervention until the access is abandoned because of inability to treat original lesion. Percutaneous thrombectomy or thrombolysis is compatible with secondary patency.</td>\n\n    </tr>\n\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=39289&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Patency_definitions.htm</title></head></div><div class=\"graphic_reference\">Source: Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Society of Interventional Radiology Technology Assessment Committee. J Vasc Interv Radiol 2003; 14:S433.</div><div id=\"graphicVersion\">Graphic 70111 Version 2.0</div></div></div>"},"70112":{"type":"graphic_table","displayName":"Misgav Ladach Joel-Cohen","title":"Misgav Ladach technique (modified Joel-Cohen technique)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Misgav Ladach technique (modified Joel-Cohen technique)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>A straight transverse incision is cut only through the skin 3 cm below the level of the anterior superior iliac spines. By comparison, a traditional Pfannenstiel is curved and placed more inferiorly, about 3 cm above the pubic symphysis.</td> </tr> <tr> <td>The subcutaneous tissues in the middle 3 cm of the incision are incised down to the fascia.</td> </tr> <tr> <td>The fascia is opened transversely in the midline and the fascial incision is extended laterally in both directions using scissors placed underneath the subcutaneous adipose tissue, which is not cut with the scissors.</td> </tr> <tr> <td>The rectus sheath is separated from the rectus muscles by pulling the sheath caudally and cranially using the two index fingers.</td> </tr> <tr> <td>The peritoneum is opened by using one or two fingers to perforate the peritoneum and then the opening is stretched by pulling caudally and cranially with the fingers to create a transverse opening.</td> </tr> <tr> <td>All layers of the abdominal wall are manually stretched laterally to both sides to provide an opening as large as the skin incision.</td> </tr> <tr> <td>A transverse superficial incision is made through the visceral peritoneum 1 cm above the superior aspect of the bladder. The peritoneum with the bladder is reflected inferiorly using fingers or a swab.</td> </tr> <tr> <td>A small transverse hysterotomy incision is made and extended laterally to both sides by pulling with the fingers.</td> </tr> <tr> <td>The hysterotomy incision is closed with a one layer continuous locked stitch. A second layer is placed only if needed.</td> </tr> <tr> <td>The visceral and parietal peritoneum are not reapproximated.</td> </tr> <tr> <td>The fascia is reapproximated with a continuous running stitch.</td> </tr> <tr> <td>The skin is reapproximated with two or three mattress stitches.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=43577&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">A key aspect of the Joel-Cohen approach is minimization of sharp dissection.</div><div class=\"graphic_reference\">Data from: Holmgren G, Sjöholm L, Stark M. The Misgav Ladach method for cesarean section: method description. Acta Obstet Gynecol Scand 1999; 78:615.</div><div id=\"graphicVersion\">Graphic 70112 Version 4.0</div></div></div>"},"70113":{"type":"graphic_algorithm","displayName":"Approach caustic ingestion","title":"Evaluation of a patient with suspected ingestion of caustic substances","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Evaluation of a patient with suspected ingestion of caustic substances</div><div class=\"cntnt\"><img style=\"width:674px; height:492px;\" src=\"images/PEDS/70113_Approach_caustic_ingestion.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UGI: upper gastrointestinal; NG: nasogastric.<br />* A substance is caustic if it is capable of burning or corroding organic tissue by chemical action, typically due to strong acid or alkaline properties. Common caustic ingestions are of household cleaning products, including laundry or dishwasher detergents, household bleach, drain cleaners, toilet bowl or oven cleaners, hair relaxer, and swimming pool products.<br />&#182; If significant respiratory symptoms are present, we suggest consultation with a specialist (eg, ear-nose-throat [ENT]) to evaluate the airway.<br />&#916; If grade 2B burn is present (deep focal or circumferential ulcers), consider placing an NG tube. For a description of grading, refer to text of topic on caustic esophageal injury in children.<br /><span class=\"lozenge\">&#9674;</span> Antibiotics are given prophylactically to selected patients with severe caustic esophageal injury, but there are no standards to guide patient selection. In our practice, we administer antibiotics to patients with grade 3 burns (endoscopic evidence of necrosis), and to those with suspicion of perforation on chest x-ray or endoscopy. We do not recommend treatment with glucocorticoids for patients with caustic esophageal injuries.</div><div class=\"graphic_reference\">Modified with permission from: Ferry GD. Caustic Ingestion. In: Pediatric Gastrointestinal Disease: Pathphysiology, Diagnosis, Management. Wyllie R, Hyams JS (Eds), WB Saunders, Philadelphia 1993. Copyright &copy; 1993 Elsevier.</div><div id=\"graphicVersion\">Graphic 70113 Version 5.0</div></div></div>"},"70115":{"type":"graphic_figure","displayName":"Varicocele PI","title":"Varicocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Varicocele</div><div class=\"cntnt\"><img style=\"width:367px; height:390px;\" src=\"images/PI/70115_Varicocele_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A varicocele is a collection of swollen veins inside the scrotum. These swollen veins make the scrotum look like a bag of worms.</div><div id=\"graphicVersion\">Graphic 70115 Version 3.0</div></div></div>"},"70116":{"type":"graphic_picture","displayName":"Esophageal parakeratosis","title":"Esophageal parakeratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal parakeratosis</div><div class=\"cntnt\"><img style=\"width:324px; height:291px;\" src=\"images/GAST/70116_Esophageal_parakeratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of esophageal parakeratosis showing a characteristic whitish, membranous plaque.</div><div class=\"graphic_reference\">Courtesy of Daniel Wild, MD, and Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 70116 Version 1.0</div></div></div>"},"70118":{"type":"graphic_table","displayName":"Prone positioning technique","title":"Procedure for prone positioning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Procedure for prone positioning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preparation</td> </tr> <tr> <td class=\"sublist1_start\">1. Check for contraindications.</td> </tr> <tr> <td class=\"sublist1\">a.&nbsp;Facial or pelvic fractures</td> </tr> <tr> <td class=\"sublist1\">b. Burns or open wounds on the ventral body surface</td> </tr> <tr> <td class=\"sublist1\">c. Conditions associated with spinal instability (eg, rheumatoid arthritis, trauma)</td> </tr> <tr> <td class=\"sublist1\">d. Conditions associated with increased intracranial pressure</td> </tr> <tr> <td class=\"sublist1\">e. Life-threatening arrhythmias</td> </tr> <tr> <td>2. Consider possible adverse effects of prone positioning on chest tube drainage.</td> </tr> <tr> <td>3. Whenever possible, explain the maneuver to the patient and/or their family.</td> </tr> <tr> <td>4. Confirm from a recent chest roentgenogram that the tip of the endotracheal tube is located 2 to 4 cm above the main carina.</td> </tr> <tr> <td>5. Inspect and confirm that the endotracheal tube and all central and large bore peripheral catheters are firmly secured.</td> </tr> <tr> <td>6. Consider exactly how the patient's head, neck, and shoulder girdle will be supported after they are turned prone.</td> </tr> <tr> <td>7. Stop tube feeding, check for residual, fully evacuate the stomach, and cap or clamp the feeding and gastric tubes.</td> </tr> <tr> <td>8. Prepare endotracheal suctioning equipment, and review what the process will be if copious airway secretions abruptly interfere with ventilation.</td> </tr> <tr> <td>9. Decide whether the turn will be rightward or leftward.</td> </tr> <tr> <td class=\"sublist1_start\">10. Prepare all intravenous tubing and other catheters and tubing for connection when the patient is prone. </td> </tr> <tr> <td class=\"sublist1\">a. Assure sufficient tubing length</td> </tr> <tr> <td class=\"sublist1\">b. Relocate all drainage bags on the opposite side of the bed </td> </tr> <tr> <td class=\"sublist1\">c. Move chest tube drains between the legs</td> </tr> <tr> <td class=\"sublist1\">d. Reposition intravenous tubing toward the patient's head, on the opposite side of the bed</td> </tr> <tr> <td class=\"subtitle1_single\">Turning procedure</td> </tr> <tr> <td>1. Place one (or more) people on both sides of the bed (to be responsible for the turning processes) and another at the head of the bed (to assure the central lines and the endotracheal tube do not become dislodged or kinked).</td> </tr> <tr> <td>2. Increase the FiO<sub>2</sub> to 1 and note the mode of ventilation, the tidal volume, the minute ventilation, and the peak and plateau airway pressures.</td> </tr> <tr> <td>3. Pull the patient to the edge of the bed furthest from whichever lateral decubitus position will be used while turning.</td> </tr> <tr> <td>4. Place a new draw sheet on the side of the bed that the patient will face when in this lateral decubitus position. Leave most of the sheet hanging.</td> </tr> <tr> <td>5. Turn the patient to the lateral decubitus position with the dependent arm tucked slightly under the thorax. As the turning progresses the nondependent arm can be raised in a cocked position over the patient's head. Alternatively, the turn can progress using a log-rolling procedure.</td> </tr> <tr> <td>6. Remove ECG leads and patches. Suction the airway, mouth, and nasal passages if necessary.</td> </tr> <tr> <td>7. Continue turning to the prone position.</td> </tr> <tr> <td>8. Reposition in the center of the bed using the new draw sheet.</td> </tr> <tr> <td>9. If the patient is on a standard hospital bed, turn his/her face toward the ventilator. Assure that the airway is not kinked and has not migrated during the turning process. Suction the airway if necessary.</td> </tr> <tr> <td>10. Support the face and shoulders appropriately avoiding any contact of the supporting padding with the orbits or the eyes.</td> </tr> <tr> <td>11. Position the arms for patient comfort. If the patient cannot communicate, avoid any type of arm extension that might result in a brachial plexus injury.</td> </tr> <tr> <td>12. Auscultate the chest to check for right mainstem intubation. Reassess the tidal volume and minute ventilation.</td> </tr> <tr> <td>13. Adjust all tubing and reassess connections and function.</td> </tr> <tr> <td>14. Reattach ECG patches and leads to the back.</td> </tr> <tr> <td>15. Tilt the patient into reverse Trendelenburg. Slight, intermittent lateral repositioning (20 to 30&#176;) should also be used, changing sides at least every&nbsp;two hours.</td> </tr> <tr> <td>16. Document a thorough skin assessment every shift, specifically inspecting weight bearing, ventral surfaces.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FiO<SUB>2</SUB>: fraction of inspired oxygen.</div><div class=\"graphic_reference\">Reproduced with permission from: Messerole E, Peine P, Wittkopp W, et al. The pragmatics of prone positioning. Am J Respir Crit Care Med 2002; 165:1359. Official Journal of the American Thoracic Society © American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 70118 Version 2.0</div></div></div>"},"70120":{"type":"graphic_figure","displayName":"Foley catheter system","title":"Foley catheter system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foley catheter system</div><div class=\"cntnt\"><img style=\"width:444px; height:642px;\" src=\"images/SURG/70120_Foley_catheter_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ideally urine samples for culture should be obtained by removing the indwelling catheter and obtaining a midstream specimen. If ongoing catheterization is needed, ideally the catheter should be replaced prior to collecting a urine sample for culture, to avoid culturing bacteria present in the biofilm of the catheter but not in the bladder. Many systems have a &quot;needleless&quot; site that can be cleansed prior to specimen collection. If a sample is being collected without catheter removal, urine should be obtained from the port in the drainage system. For circumstances in which the above approaches are not possible, the culture should be obtained by separating the catheter from the drainage system. Although this approach is associated with some risk of introducing microbes into the closed system, culture results from urine collected from the drainage bag cannot be used to guide treatment.</div><div id=\"graphicVersion\">Graphic 70120 Version 1.0</div></div></div>"},"70124":{"type":"graphic_figure","displayName":"Football position PI","title":"Football position for breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Football position for breastfeeding</div><div class=\"cntnt\"><img style=\"width:476px; height:540px;\" src=\"images/PI/70124_Football_position_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The football position allows a woman to easily see the baby at her breast. It is often preferred by women who have an abdominal incision, after a Cesarean section, or by women with large breasts or a small premature baby. The baby is supported by a pillow as the mother sits, which should allow the baby's head to be at the level of the mother's breast.<br />To feed from the right breast as shown above, the baby's body and legs are under the right arm, with the head supported with the mother's right hand. The mother's free hand (the left hand in this example) supports and guides the breast to the infant's wide-open mouth.</div><div id=\"graphicVersion\">Graphic 70124 Version 6.0</div></div></div>"},"70125":{"type":"graphic_picture","displayName":"Optic nerve hypoplasia","title":"Optic nerve hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic nerve hypoplasia</div><div class=\"cntnt\"><img style=\"width:360px; height:285px;\" src=\"images/PEDS/70125_Optic_nerve_hypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At first glance, the disc may appear pale but the actual disc substance is within this pale area. Arrows indicate actual nerve borders.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 70125 Version 1.0</div></div></div>"},"70126":{"type":"graphic_figure","displayName":"Shave biopsy depth","title":"Depth of shave biopsies","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Depth of shave biopsies</div><div class=\"cntnt\"><img style=\"width:582px; height:338px;\" src=\"images/PC/70126_Shave_biopsy_depth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shave biopsies can be either superficial or deep. Superficial shave biopsies are done across or nearly parallel to the skin surface and extend into the epidermis only or epidermis and limited superficial dermis. The slightly deeper shave biopsy allows for sampling of dermis and epidermis, important for assessing basal cell and squamous cell carcinomas.</div><div id=\"graphicVersion\">Graphic 70126 Version 1.0</div></div></div>"},"70128":{"type":"graphic_figure","displayName":"M mode MV dilated CM","title":"Mitral valve motion in dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve motion in dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:366px; height:216px;\" src=\"images/CARD/70128_MmodeMVdilatedCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram, recorded at the level of the mitral valve leaflets, shows a dilated left ventricle. The interventricular septum and posterior left ventricular wall are thinned and hypokinetic. The movement of both the anterior and posterior mitral valve leaflets is well seen and there are prominent echoes from the chordae tendineae due to the enlarged left ventricular chamber.</div><div id=\"graphicVersion\">Graphic 70128 Version 2.0</div></div></div>"},"70130":{"type":"graphic_picture","displayName":"Anemic palmar pallor","title":"Palmar pallor in a patient with severe anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmar pallor in a patient with severe anemia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/70130_Anemic_palmar_pallor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anemic child's palm is cradled in the palm of the less anemic mother.</div><div class=\"graphic_reference\">Courtesy of Terrie Taylor, DO.</div><div id=\"graphicVersion\">Graphic 70130 Version 2.0</div></div></div>"},"70131":{"type":"graphic_table","displayName":"Rx of Pasteurella multocida","title":"Antibiotic susceptibility of <EM>Pasteurella multocida</EM>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic susceptibility of <EM>Pasteurella multocida</EM></div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Highly susceptible</td> </tr> <tr> <td class=\"indent1\">Penicillin G</td> </tr> <tr> <td class=\"indent1\">Penicillin V</td> </tr> <tr> <td class=\"indent1\">Ampicillin</td> </tr> <tr> <td class=\"indent1\">Amoxicillin-clavulanate</td> </tr> <tr> <td class=\"indent1\">Piperacillin</td> </tr> <tr> <td class=\"indent1\">Piperacillin-tazobactam</td> </tr> <tr> <td class=\"indent1\">Cefoxitin</td> </tr> <tr> <td class=\"indent1\">Cefuroxime</td> </tr> <tr> <td class=\"indent1\">Cefpodoxime</td> </tr> <tr> <td class=\"indent1\">Cefotaxime</td> </tr> <tr> <td class=\"indent1\">Ceftriaxone</td> </tr> <tr> <td class=\"indent1\">Ceftaroline</td> </tr> <tr> <td class=\"indent1\">Ertapenem</td> </tr> <tr> <td class=\"indent1\">Imipenem</td> </tr> <tr> <td class=\"indent1\">Meropenem</td> </tr> <tr> <td class=\"indent1\">Doripenem</td> </tr> <tr> <td class=\"indent1\">Aztreonam</td> </tr> <tr> <td class=\"indent1\">Tetracycline</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> </tr> <tr> <td class=\"indent1\">Minocycline</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> </tr> <tr> <td class=\"indent1\">Levofloxacin</td> </tr> <tr> <td class=\"indent1\">Moxifloxacin</td> </tr> <tr> <td class=\"indent1\">Tigecycline</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Moderately susceptible</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> </tr> <tr> <td class=\"indent1\">Gentamicin</td> </tr> <tr> <td class=\"indent1\">Tobramycin</td> </tr> <tr> <td class=\"indent1\">Amikacin</td> </tr> <tr> <td class=\"indent1\">Nafcillin*</td> </tr> <tr> <td class=\"indent1\">Cephalothin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cefazolin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Azithromycin</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Usually resistant</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MIC: minimal inhibitory concentration.<br /><br />* Susceptible by Kirby-Bauer disc but MIC higher than other penicillins.<br />¶ Susceptible by Kirby-Bauer disc but MIC higher than second- and third-generation cephalosporins.</div><div class=\"graphic_reference\">Adapted from: Weber DJ, Hanson AR. Infections resulting from animal bites. Infect Dis Clin North Am 1991; 5:663.</div><div id=\"graphicVersion\">Graphic 70131 Version 4.0</div></div></div>"},"70134":{"type":"graphic_table","displayName":"Pathogen malignancy-related gastroparesis","title":"Pathogenesis of malignancy-related gastroparesis in various cancer types","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathogenesis of malignancy-related gastroparesis in various cancer types</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Disease</td>\n\t    <td class=\"subtitle1\">Pathogenesis</td>\n\t  </tr>\n\t  <tr>\n\t    <td rowspan=\"5\">Pancreatic carcinoma</td>\n\t    <td>Autovagotomy secondary to micrometastasis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Retroperitoneal nerve invasion</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Production of tumor-related gastroparetic factor or hormonal secretion of inhibitory neurotransmitters, such as vasopressin, by the tumor</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Disruption of the neuroendocrine feedback inhibitory system</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Paraneoplastic involvement with antineuronal antibodies</td>\n\t  </tr>\n\t  <tr>\n\t    <td rowspan=\"3\">Gastric carcinoma</td>\n\t    <td>Mass effect from the tumor</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Tumor infiltration into myenteric plexus</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Vagotomy post gastric surgery</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Leiomyosarcoma</td>\n\t    <td>Paraneoplastic process</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Cholangiocarcinoma</td>\n\t    <td>Tumor infiltration of the vagus nerve</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Small cell lung cancer</td>\n\t    <td>Autoimmune antibodies (ANNA-1) causing paraneoplastic visceral neuropathy</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">ANNA-1: antineuronal nuclear antibody type 1, also known as anti-Hu.</div><div class=\"graphic_reference\">Reproduced with permission from: Donthireddy K, Ailawadhi S, Nasser E,&nbsp;et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70134 Version 3.0</div></div></div>"},"70135":{"type":"graphic_picture","displayName":"Verrucous carcinoma Light","title":"Verrucous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verrucous carcinoma</div><div class=\"cntnt\"><img style=\"width:275px; height:363px;\" src=\"images/ONC/70135_Verrucous_carcinoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The warty appearance on visual examination is reflected microscopically by elongated fronds of surface growth. These may occasionally be heavily keratinized. The tumor interface with the underlying connective tissue is relatively blunt (\"pushing\") and extends below the level of adjacent uninvolved squamous mucosa. There is a lymphoid reaction at the base of the lesion.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 70135 Version 5.0</div></div></div>"},"70137":{"type":"graphic_picture","displayName":"Cap polyposis Light","title":"Cap polyposis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cap polyposis</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/GAST/70137_Cap_polyposis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of cap polyposis showing elongated hyperplastic appearing glands and a cap of overyling mucosa composed of mucus, fibrin, and leukocytes.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 70137 Version 2.0</div></div></div>"},"70138":{"type":"graphic_picture","displayName":"Self expanding stent CPC","title":"Self-expanding metal stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Self-expanding metal stent</div><div class=\"cntnt\"><img style=\"width:252px; height:206px;\" src=\"images/GAST/70138_Self_expanding_stent_CPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view after deployment of a self-expanding metal stent in the distal esophagus extending into the stomach.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.</div><div id=\"graphicVersion\">Graphic 70138 Version 1.0</div></div></div>"},"70139":{"type":"graphic_figure","displayName":"Algorithms LV volume","title":"Algorithms of quantitative two-dimensional echocardiography","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Algorithms of quantitative two-dimensional echocardiography</div><div class=\"cntnt\"><img style=\"width:474px; height:554px;\" src=\"images/CARD/70139_AlgorithmsLVvolume.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are seven algorithms used in the planimetric assessment of left ventricular (LV) volume from tomographic images of the LV. The shaded areas represent the portions of the images of the LV that must be obtained and planimetered in order to satisfy the requirements of the various algorithms. Algorithm I (modified Simpson's rule or method of discs), IV (biplane area length), or VII (single plane area length) are most often used; however, whenever possible, algorithm I, now called the method of discs, is used.</div><div class=\"graphic_reference\">Courtesy of Dr. Norman H Silverman.</div><div id=\"graphicVersion\">Graphic 70139 Version 3.0</div></div></div>"},"70140":{"type":"graphic_table","displayName":"Outpatient care for VTE","title":"Minimal requirements for early hospital discharge or outpatient therapy of venous thromboembolic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimal requirements for early hospital discharge or outpatient therapy of venous thromboembolic disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">The responsible physician must ensure that all of the following conditions apply:</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>The patient is ambulatory and in stable condition, with normal vital signs</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td>There is a low a priori risk of bleeding in the patient </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Severe renal insufficiency is not present</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">There is a practical system in place for the following:</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td class=\"sublist1\">Administration of LMW heparin and/or warfarin with appropriate monitoring, <strong>and</strong></td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1\">Surveillance and treatment of recurrent VTE and bleeding complications</td>\n\n    </tr>\n\n    \n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; LMW heparin: low molecular weight heparin.</div><div class=\"graphic_reference\"><br>Adapted from Hyers, TM, Agnelli, G, Hull, RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119:176S. (Sixth ACCP Consensus Conference on Antithrombotic Therapy).</div><div id=\"graphicVersion\">Graphic 70140 Version 2.0</div></div></div>"},"70141":{"type":"graphic_picture","displayName":"Ischemic optic disc in GCA","title":"Ischemic optic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ischemic optic neuropathy</div><div class=\"cntnt\"><img style=\"width:300px; height:245px;\" src=\"images/RHEUM/70141_Ischemic_optic_disc_in_GCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ischemic optic neuropathy in a patient with giant cell artertitis who lost vision abruptly four days prior to this examination. The optic disc is swollen and its margins are blurred.</div><div class=\"graphic_reference\">Courtesy of Gene Hunder, MD.</div><div id=\"graphicVersion\">Graphic 70141 Version 1.0</div></div></div>"},"70142":{"type":"graphic_table","displayName":"Common developmental milestones","title":"Common developmental milestones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common developmental milestones</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Milestone</td> <td class=\"subtitle1\">Age at acquisition</td> </tr> <tr> <td>Fixes gaze briefly, habituates to stereotyped auditory, visual, and tactile stimuli</td> <td>At birth (40 weeks post conceptional age)</td> </tr> <tr> <td>Smiles responsively, gurgles</td> <td>2-3 months</td> </tr> <tr> <td>Visual tracking of a bright object to 180 degrees</td> <td>3 months</td> </tr> <tr> <td>Rolls over, holds head upright when pulled from supine to sitting</td> <td>3 months</td> </tr> <tr> <td>Reaches out for objects</td> <td>4-5 months</td> </tr> <tr> <td>Maintains sitting position independently</td> <td>6 months</td> </tr> <tr> <td>Grasps objects using thumb and index finger pulp</td> <td>8-9 months</td> </tr> <tr> <td>Crawls, babbles, uses non-specific \"Mama\", \"Dada\" sounds</td> <td>9-10 months</td> </tr> <tr> <td>Pulls up to stand and walks with support</td> <td>10-11 months</td> </tr> <tr> <td>Walks independently, uses 2-3 clear words, including specific \"Mama\" and \"Dada\"</td> <td>13-14 months</td> </tr> <tr> <td>Can point to body parts, use simple phrases</td> <td>18-19 months</td> </tr> <tr> <td>Names body parts, states age, uses phrases</td> <td>24 months</td> </tr> <tr> <td>Pedals tricycle, speaks in sentences, asks questions, likely toilet trained, can name primary colors</td> <td>36 months</td> </tr> <tr> <td>Masters concepts of alphabets and numbers</td> <td>4-5 years</td> </tr> <tr> <td>Able to read simple words, add, subtract</td> <td>5-6 years</td> </tr> <tr> <td>Concepts of division, multiplication, geography, general information like cities, states, large rivers, oceans, etc.</td> <td>7-8 years</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Suresh Kotagal.</div><div id=\"graphicVersion\">Graphic 70142 Version 2.0</div></div></div>"},"70143":{"type":"graphic_table","displayName":"Preferred and alternative regimens for ART-naïve patients","title":"Preferred and alternative antiretroviral regimens for nonpregnant treatment-naïve HIV-infected adults and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preferred and alternative antiretroviral regimens for nonpregnant treatment-naïve HIV-infected adults and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preferred regimens</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Dolutegravir plus tenofovir alafenamide-emtricitabine*</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Dolutegravir-abacavir-lamivudine</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide*</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Raltegravir plus tenofovir alafenamide-emtricitabine*</span> </li> </ul> <p>&nbsp;</p> <p><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-weight: bold;\">For most patients, we prefer dolutegravir plus tenofovir alafenamide-emtricitabine, as this regimen has a high barrier to resistance and there is more evidence supporting the NRTI combination tenofovir-emtricitabine versus abacavir-lamivudine. However, selecting a regimen should be individualized based upon comorbid conditions (eg, HBV, kidney disease), pill burden, drug-drug interactions, and results of resistance testing.</span></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Alternative regimens</td> </tr> <tr> <td class=\"indent1\"><strong>PI-based regimens</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Darunavir (boosted with ritonavir or cobicistat) plus <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">tenofovir alafenamide-emtricitabine*<sup><span style=\"font-family: Calibri;\">&#182;</span></sup></span></span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Atazanavir (boosted with ritonavir or cobicistat) plus tenofovir alafenamide-emtricitabine*<sup>&#182;</sup></span> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>NNRTI-based regimens<sup>&#916;</sup></strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"font-size: 11pt; font-family: Calibri; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Efavirenz plus tenofovir alafenamide-emtricitabine*</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Efavirenz-emtricitabine-tenofovir disoproxil fumarate</span> </li> <li><span style=\"font-size: 11pt; font-family: Calibri; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Rilpivirine-emtricitabine-tenofovir alafenamide*<sup>&#9674;</sup></span> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>When tenofovir (TAF or TDF) and&nbsp;abacavir cannot be used<sup>&#167;</sup></strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Darunavir (boosted with ritonavir or cobicistat) plus dolutegravir</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Darunavir (boosted with ritonavir or cobicistat) plus either emtricitabine or lamivudine</span> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Considerations when selecting a regimen (if more than one comorbid condition is present, the clinician should review the options for each relevant scenario and select the most appropriate combination)</td> </tr> <tr> <td class=\"indent1\"><strong>Contraindications: </strong>Abacavir is <strong>contraindicated</strong> in patients who test positive for HLA-B*5701.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Comorbid conditions:</strong></p> <ul> <li>​Cardiovascular disease: Abacavir should generally be avoided in patients with (or at risk for) cardiovascular disease. In addition, if a patient requires a PI, we prefer to use atazanavir over other boosted PIs. </li> <li>HBV: Tenofovir (TAF or TDF)-emtricitabine is the preferred NRTI combination for patients with HIV/HBV coinfection.&nbsp;Emtricitabine and lamivudine&nbsp;should not be used as monotherapy for the treatment of HBV.<sup>&#165;</sup> </li> <li>Kidney disease: <ul> <li>TDF should be avoided in&nbsp;patients with an eGFR&nbsp;&#60;60 mL/min/1.73 m<sup>2</sup>. When TDF is administered with cobicistat, it should not be administered to patients with an eGFR &#60;70 mL/min/1.73 m<sup>2</sup>.&nbsp; </li> <li>TAF can be used in patients with moderately reduced kidney function, but should generally be avoided in patients with acute renal injury or&nbsp;an eGFR &#60;30 mL/min/1.73 m<sup>2</sup>. </li> </ul> </li> <li>Osteoporosis: TDF should be avoided.</li> <li>Tuberculosis: Preferred regimen is efavirenz-emtricitabine-tenofovir disoproxil fumarate. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Adherence concerns:</strong> A regimen that uses the dual-NRTI combination of tenofovir alafenamide-emtricitabine plus either dolutegravir or a pharmacologically boosted PI (preferably ritonavir-boosted darunavir or darunavir-cobicistat). For patients who have a strong preference for a single-pill regimen, dolutegravir-abacavir-lamivudine can be used if the patient is HLA-B*5701 negative, HBsAg negative, and at low cardiovascular risk. </td> </tr> <tr> <td class=\"indent1\"><strong><span class=\"indent2\"></span>Drug interactions: </strong>Antiretroviral medications that require a boosting agent (eg, ritonavir or cobicistat) are associated with the greatest risk of drug interactions. Refer to the Lexicomp drug interaction program available within UpToDate for specific information on drug-drug interactions.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Dosing considerations: </strong>​Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide and dolutegravir-abacavir-lamivudine are available as a single coformulated tablet administered&nbsp;once daily. </p> </td> </tr> <tr> <td class=\"indent1\"><strong>Baseline resistance testing: </strong>If baseline resistance testing is not available when initiating therapy, a regimen using dolutegravir or pharmacologically boosted darunavir as the third agent should be initiated.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The preferred and alternative regimens listed in this table reflect our approach to the choice of antiretroviral therapy for nonpregnant treatment-naïve patients and&nbsp;are a synthesis of guideline recommendations. Refer to the topics that discuss HIV in pregnancy for regimens used to treat pregnant women.<br />ARV separated by \"-\" (eg, tenofovir alafenamide-emtricitabine) are available in single-tablet coformulations. For additional information and specific dosing recommendations, refer to the individual Lexicomp drug monographs available in UpToDate, as well as the topic that provides an overview of the different antiretroviral agents.</div><div class=\"graphic_footnotes\">ARV: antiretroviral; eGFR: estimated glomerular filtration rate; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus;&nbsp;NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor;&nbsp;PI: protease inhibitor; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.<br />*&nbsp;If TAF is not available, TDF remains an effective and well tolerated choice for most patients with normal kidney function. In addition, TDF should be used instead of TAF to avoid certain drug interactions (eg, rifamycins,&nbsp;certain anticonvulsants).&nbsp;<br />¶&nbsp;Pharmacologically boosted&nbsp;darunavir&nbsp;is better tolerated than other PIs. However, it should be used with caution in patients with sulfonamide allergy. When&nbsp;darunavir is used, we prefer a tenofovir-containing nucleoside combination, rather than one that uses abacavir-lamivudine, as there is more experience with this regimen. If&nbsp;a PI&nbsp;is strongly desired and darunavir&nbsp;cannot be used, pharmacologically boosted atazanavir plus tenofovir (TAF or TDF)-emtricitabine can be administered.<br />Δ&nbsp;Efavirenz and&nbsp;rilpivirine should be used with caution in patients with mental health disorders since both agents have been associated with depression and suicide. For information regarding the use of efavirenz in women of child-bearing age, refer to the topics in UpToDate that discuss HIV and women and HIV and pregnancy.<br />◊&nbsp;This regimen should be avoided in patients with a CD4 count &lt;200 cells/microL and/or an HIV RNA ≥100,000 copies/mL.<br />§&nbsp;There are limited data with regimens that do not contain tenofovir or abacavir. Regimens other than those listed in the table include raltegravir (twice daily) plus ritonavir-boosted darunavir, or lopinavir-ritonavir plus lamivudine; some experts prefer these regimens since they have been specifically evaluated in clinical trials. However, we prefer regimens such as pharmacologically boosted darunavir plus dolutegravir, or pharmacologically boosted darunavir plus lamivudine, since these regimens would be expected to be equally effective, are easier to administer (eg, once versus twice daily), and are better tolerated (eg, ritonavir-boosted darunavir versus lopinavir-ritonavir). If raltegravir plus ritonavir-boosted darunavir is used, the combination should be avoided in patients with a CD4 count &lt;200 cells/microL and/or an HIV RNA ≥100,000 copies/mL. See the topic that discusses choosing an antiretroviral regimen in treatment-naïve patients for more information on these regimens.&nbsp;<br />¥ Refer to the topic in UpToDate that discusses the treatment of HIV/HBV-coinfected patients. </div><div class=\"graphic_reference\">References:<br />1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (Accessed October 17, 2017). <br />2. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316:191.</div><div id=\"graphicVersion\">Graphic 70143 Version 13.0</div></div></div>"},"70144":{"type":"graphic_figure","displayName":"Phosphatidylinositol turnover","title":"Phosphatidylinositol-protein kinase C pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phosphatidylinositol-protein kinase C pathway</div><div class=\"cntnt\"><img style=\"width:442px; height:369px;\" src=\"images/NEPH/70144_Phosphatidylinositol_turnov.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the phosphatidylinositol pathway-protein kinase C pathway. The binding of a peptide hormone with its cell surface receptor (R) leads to activation of the associated stimulatory regulatory guanylyl protein (Gs) with a subsequent increase in activity of membrane-bound phospholipase C. This enzyme results in the breakdown of a membrane lipid, phosphatidylinositol 4,5-bisphosphate (PIP2), into two compounds: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mediates the immediate action of the hormone by inducing the release of calcium from stores in the smooth endoplasmic reticulum; and indirectly by enhancing the uptake of extracellular calcium ion. The increased intracellular calcium binds to calmodulin leading to the phosphorylation and activation of specific cell proteins and the physiologic effects of the hormone. Among the proteins phosphorylated and activated, with the cooperation of DAG, is calcium-dependent protein kinase C which initiates a further cascade of protein phosphorylation that mediates the sustained physiologic action of the hormone.</div><div id=\"graphicVersion\">Graphic 70144 Version 2.0</div></div></div>"},"70145":{"type":"graphic_algorithm","displayName":"Hydrocarbon ingestion management","title":"Disposition after hydrocarbon ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disposition after hydrocarbon ingestion</div><div class=\"cntnt\"><img style=\"width:370px; height:563px;\" src=\"images/EM/70145_HC_ingestion_management.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NPO: nothing by mouth; IV: intravenous; CXR: chest radiograph.</div><div id=\"graphicVersion\">Graphic 70145 Version 4.0</div></div></div>"},"70146":{"type":"graphic_diagnosticimage","displayName":"Craniopharyngioma CT","title":"Craniopharyngioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Craniopharyngioma</div><div class=\"cntnt\"><img style=\"width:313px; height:288px;\" src=\"images/ENDO/70146_Craniopharyngioma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan through the midbrain of a 71-year-old woman who presented with bitemporal visual field defects. There is a calcified soft tissue mass arising in the region of the sella turcica (arrows), which proved to be a craniopharyngioma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 70146 Version 3.0</div></div></div>"},"70148":{"type":"graphic_picture","displayName":"Dry AMD w pigment mottling","title":"Dry type age-related macular degeneration (AMD) with drusen and pigmentary mottling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dry type age-related macular degeneration (AMD) with drusen and pigmentary mottling</div><div class=\"cntnt\"><img style=\"width:351px; height:291px;\" src=\"images/PC/70148_Dry_AMD_w_pigment_mottling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An area of pigmentary mottling is evident beneath the retina (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.</div><div id=\"graphicVersion\">Graphic 70148 Version 2.0</div></div></div>"},"70150":{"type":"graphic_table","displayName":"Nodules and tumors","title":"Differential diagnosis of nodules and tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of nodules and tumors</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td>Acrochordon</td></tr>\n\t\t\t\t\t\t<tr><td>Angioma</td></tr>\n\t\t\t\t\t\t<tr><td>Appendageal tumors</td></tr>\n\t\t\t\t\t\t<tr><td>Basal cell carcinoma</td></tr>\n\t\t\t\t\t\t<tr><td>Callus/clavus</td></tr>\n\t\t\t\t\t\t<tr><td>Chondrodermatitis nodularis helicis</td></tr>\n\t\t\t\t\t\t<tr><td>Dermatofibroma</td></tr>\n\t\t\t\t\t\t<tr><td>Dermatofibrosarcoma</td></tr>\n\t\t\t\t\t\t<tr><td>Erythema nodosum</td></tr>\n\t\t\t\t\t\t<tr><td>Hidradenitis suppurativa</td></tr>\n\t\t\t\t\t\t<tr><td>Histiocytosis</td></tr>\n\t\t\t\t\t\t<tr><td>Inclusion cyst</td></tr>\n\t\t\t\t\t\t<tr><td>Kaposi's sarcoma</td></tr>\n\t\t\t\t\t\t<tr><td>Keloid</td></tr>\n\t\t\t\t\t\t<tr><td>Lipoma</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td>Lymphoma (cutaneous)</td></tr>\n\t\t\t\t\t\t<tr><td>Melanoma</td></tr>\n\t\t\t\t\t\t<tr><td>Metastatic carcinoma</td></tr>\n\t\t\t\t\t\t<tr><td>Neurofibroma</td></tr>\n\t\t\t\t\t\t<tr><td>Nevus</td></tr>\n\t\t\t\t\t\t<tr><td>Prurigo nodularis</td></tr>\n\t\t\t\t\t\t<tr><td>Pyogenic granuloma</td></tr>\n\t\t\t\t\t\t<tr><td>Seborrheic keratosis</td></tr>\n\t\t\t\t\t\t<tr><td>Squamous cell carcinoma</td></tr>\n\t\t\t\t\t\t<tr><td>Syphilis</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberous sclerosis</td></tr>\n\t\t\t\t\t\t<tr><td>Venous lake</td></tr>\n\t\t\t\t\t\t<tr><td>Wart</td></tr>\n\t\t\t\t\t\t<tr><td>Xanthoma</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70150 Version 1.0</div></div></div>"},"70151":{"type":"graphic_figure","displayName":"Mechanism platelet activation","title":"Activation of platelets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Activation of platelets</div><div class=\"cntnt\"><img style=\"width:335px; height:396px;\" src=\"images/CARD/70151_Mechanism_platelet_activati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The various stimuli causing platelet activation act by signal transduction through receptors, ultimately increasing the free cytosolic Ca2+ level in platelets. Several calcium mobilization reactions interact with the receptors and regulate cytosolic free Ca2+. Adenosine triphosphate (ATP) is converted to cyclic adenosine monophosphate (cAMP) by the enzyme adenylate cyclase (AC); cAMP is broken down to AMP by the enzyme phosphodiesterase (PDE). When cAMP is elevated, for example by prostacyclin (PGI2) binding to a specific receptor and stimulating adenylate cyclase (AC), some Ca2+ is stored in the dense tubules, reducing cytosolic free Ca2+ and the level of platelet activation. Guanosine triphosphate (GTP) is converted to cGMP by guanylate cyclase (GC); cGMP is broken down by a PDE to produce guanosine monophosphate (GMP). When cGMP is elevated by stimulation of GC by NO, free cytosolic Ca2+ is reduced by inhibition from leaving the dense tubules. Thus, modulating free cytosolic Ca2+ can increase or decrease platelet activity. The final step in platelet-mediated thrombosis is the exposure/activation of the platelet glycoprotein IIb/IIIa fibrinogen receptor, which binds to fibrinogen to create a platelet aggregate.</div><div class=\"graphic_reference\">With permision from Folts JD, Schafer AI, Loscalzo J, et al. J Am Coll Cardiol 1999; 33:295.</div><div id=\"graphicVersion\">Graphic 70151 Version 3.0</div></div></div>"},"70156":{"type":"graphic_table","displayName":"Components fibrinolytic system","title":"Components of the plasma fibrinolytic system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of the plasma fibrinolytic system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">&nbsp;</td> <td class=\"subtitle1_single\">Molecular weight (d)</td> <td class=\"subtitle1_single\">Activity</td> </tr> <tr> <td class=\"subtitle2_left\">Plasminogen</td> <td>88,000 (single chain)</td> <td>Proenzyme form of fibrinolytic enzyme</td> </tr> <tr> <td class=\"subtitle2_left\">Plasmin</td> <td>88,000 (two chain)</td> <td>Active fibrinolytic enzyme</td> </tr> <tr> <td class=\"subtitle2_left\">TPA</td> <td>70,000 (one/two chain)</td> <td>Enzyme present in tissues that coverts plasminogen to plasmin</td> </tr> <tr> <td class=\"subtitle2_left\">UPA</td> <td>54,000 (two chain)<br /> </td> <td>Plasminogen activator (different from tPA)</td> </tr> <tr> <td class=\"subtitle2_left\">&#945;2PI</td> <td>70,000 (single chain) </td> <td>Specific fast-acting inhibitor in plasma</td> </tr> <tr> <td class=\"subtitle2_left\">PAI-1</td> <td>40,000 (single chain)</td> <td>Fast-acting inhibitor of tPA (and UPA) secreted by endothelial cells)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">d: Daltons; TPA: tissue plasminogen activator; UPA: urokinase-like plasminogen activator; &#945;2PI: alpha-2 plasmin inhibitor; PAI-1: plasminogen activator inhibitor-1.</div><div id=\"graphicVersion\">Graphic 70156 Version 3.0</div></div></div>"},"70158":{"type":"graphic_picture","displayName":"Anencephaly","title":"Anencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anencephaly</div><div class=\"cntnt\"><img style=\"width:360px; height:275px;\" src=\"images/PEDS/70158_Anencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most of the cranium is absent, exposing residual neural tissue.</div><div class=\"graphic_reference\">Photo courtesy of Marvin A Fishman, MD.</div><div id=\"graphicVersion\">Graphic 70158 Version 1.0</div></div></div>"},"70162":{"type":"graphic_figure","displayName":"Heaney retractor","title":"Heaney retractor","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Heaney retractor</div><div class=\"cntnt\"><img style=\"width:452px; height:353px;\" src=\"images/OBGYN/70162_Heaney_retractor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This retractor is especially designed for vaginal exposure.</div><div id=\"graphicVersion\">Graphic 70162 Version 1.0</div></div></div>"},"70163":{"type":"graphic_table","displayName":"Clinical features of Laron syndrome","title":"Clinical features of primary growth hormone insensitivity (Laron syndrome)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of primary growth hormone insensitivity (Laron syndrome)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Growth and development</td> </tr> <tr> <td>Birth weight and length near normal</td> </tr> <tr> <td>Postnatal growth failure, moderate to severe</td> </tr> <tr> <td>Bone age delayed relative to chronological age</td> </tr> <tr> <td>Short limb length in relation to trunk length</td> </tr> <tr> <td>Puberty delayed 3 to 7 years</td> </tr> <tr> <td>Normal sexual function and fertility</td> </tr> <tr> <td>Intellectual development normal or modestly impaired</td> </tr> <tr> <td class=\"subtitle1_single\">Head and neck</td> </tr> <tr> <td>Face small in relation to head circumference</td> </tr> <tr> <td>Delayed dentition</td> </tr> <tr> <td>Blue sclerae</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Hypoglycemia, especially in infants and children</td> </tr> <tr> <td>Hyperlipidemia and variable degrees of insulin resistance</td> </tr> <tr> <td>Osteopenia</td> </tr> <tr> <td>Obesity</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Reiter EO, Rosenfeld RG. Growth retardation in: Kronenberg HM et al, Eds. Williams Textbook of Endocrinology, 11th Ed. Saunders Elsevier, Philadelphia, 2008. p.903. </li> <li>Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89:1031. </li> </ol></div><div id=\"graphicVersion\">Graphic 70163 Version 5.0</div></div></div>"},"70164":{"type":"graphic_figure","displayName":"Schematic geographic miss","title":"Schematic representation of geographical miss and edge restenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of geographical miss and edge restenosis</div><div class=\"cntnt\"><img style=\"width:396px; height:321px;\" src=\"images/CARD/70164_Schematic_geographic_miss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During the procedure, there is geographical miss (+) in the proximal segment (treated lesion subjected to injury but not covered by the radiation catheter) ; there is no geographical miss of the distal segment (-) (panel A). During follow-up, the proximal edge with geographic miss (+) developed edge restenosis, which this did not occur at the distal edge without geographic mass (-).</div><div class=\"graphic_reference\">Reproduced with permission from: Kim, HS, Waksman, R, Cottin, Y. Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. J Am Coll Cardiol 2001; 37:1026. Copyright &#169; 2001 American College of Cardiology.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 70164 Version 1.0</div></div></div>"},"70165":{"type":"graphic_diagnosticimage","displayName":"Severe pulmonary regurgitation","title":"Severe pulmonary regurgitation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Severe pulmonary regurgitation</div><div class=\"cntnt\"><img style=\"width:584px; height:413px;\" src=\"images/CARD/70165_Severe_pulm_regurgitation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous-wave Doppler signal showing severe pulmonary regurgitation. In this patient, rapid equalization of pressures between the pulmonary artery and right ventricle results in rapid diastolic decay, shown between the arrows.</div><div class=\"graphic_footnotes\">PR: pulmonary regurgitation.</div><div id=\"graphicVersion\">Graphic 70165 Version 3.0</div></div></div>"},"70167":{"type":"graphic_picture","displayName":"PDR neovascularization retin vessels","title":"Proliferative diabetic retinopathy displaying severe neovascularization along the superior arcade (NVE): Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proliferative diabetic retinopathy displaying severe neovascularization along the superior arcade (NVE): Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/ENDO/70167_PDR_neovasc_retin_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of proliferative diabetic retinopathy displaying severe neovascularization along the superior arcade (NVE).</div><div id=\"graphicVersion\">Graphic 70167 Version 3.0</div></div></div>"},"70168":{"type":"graphic_figure","displayName":"Biliopancreatic diversion AGA","title":"Biliopancreatic diversion with duodenal switch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biliopancreatic diversion with duodenal switch</div><div class=\"cntnt\"><img style=\"width:289px; height:443px;\" src=\"images/GAST/70168_Biliopancreatic_diversion_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: the American Gastroenterological Association. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123:882.</div><div id=\"graphicVersion\">Graphic 70168 Version 2.0</div></div></div>"},"70170":{"type":"graphic_figure","displayName":"HDL and LDL cholesterol levels and CHD risk","title":"Risk of coronary heart disease is associated with HDL and LDL cholesterol levels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of coronary heart disease is associated with HDL and LDL cholesterol levels</div><div class=\"cntnt\"><img style=\"width:447px; height:314px;\" src=\"images/PC/70170_HDLlevelsCHDrisk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low levels of HDL cholesterol are associated with an increased risk for coronary CHD, especially when LDL cholesterol levels are also elevated; the risk is lower as HDL cholesterol increases.</div><div class=\"graphic_footnotes\">CHD: coronary heart disease; HDL: high-density lipoprotein; LDL: low-density lipoprotein.</div><div class=\"graphic_reference\">Data from: Harper CR, Jacobson TA. Arch Intern Med 1999; 159:1049.</div><div id=\"graphicVersion\">Graphic 70170 Version 5.0</div></div></div>"},"70171":{"type":"graphic_table","displayName":"Sclerosing agent for lower extremity venous disease","title":"Sclerosing agent for lower extremity venous disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sclerosing agent for lower extremity venous disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"11\" width=\"9%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Formulation</td> <td class=\"subtitle1\">Composition</td> <td class=\"subtitle1\">Test dose</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Vessel size, mm</td> <td class=\"subtitle1\">Concentration, percent</td> <td class=\"subtitle1\">Injection/vein, mL</td> <td class=\"subtitle1\">Max dose</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Hypertonic saline</td> <td class=\"divider_bottom\" rowspan=\"5\">Osmotic</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>14.6%</p> 23.4%</td> <td class=\"divider_bottom\" rowspan=\"5\">Sodium chloride</td> <td class=\"divider_bottom\" rowspan=\"5\">Not required</td> <td class=\"divider_bottom\" rowspan=\"5\">No allergy</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Pain</p> <p>Muscle cramping</p> <p>Ulceration/necrosis</p> Hyperpigmentation</td> <td>&#60;0.5</td> <td>11.7 to 15</td> <td>0.25</td> <td class=\"divider_bottom\" rowspan=\"5\">None*</td> </tr> <tr> <td>0.5 to 1</td> <td>11.7 to 15</td> <td>0.5</td> </tr> <tr> <td>1 to 3</td> <td>15 to 23.4</td> <td>0.5 to 1</td> </tr> <tr> <td>3 to 5</td> <td>-</td> <td>-</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;5</td> <td>-</td> <td>-</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Polidocanol(Aethoxysclerol)</td> <td class=\"divider_bottom\" rowspan=\"6\">Detergent</td> <td class=\"divider_bottom\" rowspan=\"6\"> <p>1%</p> 3%</td> <td class=\"divider_bottom\" rowspan=\"6\">Hydroxypolyethoxydodecane, distilled, ethyl alcohol</td> <td class=\"divider_bottom\" rowspan=\"6\">.5 mL</td> <td class=\"divider_bottom\" rowspan=\"6\"> <p>Painless</p> <p>Not toxic to tissue</p> <p>Rare ulceration</p> No skin necrosis</td> <td class=\"divider_bottom\" rowspan=\"6\"> <p>Allergy</p> <p>Telangiectatic matting</p> Hyperpigmentation</td> <td>&#60;0.5</td> <td>0.25 to 0.5</td> <td>0.25</td> <td>3% solution</td> </tr> <tr> <td>0.5 to 1</td> <td>0.5 to 0.75</td> <td>0.5</td> <td>50 kg: 5 mL</td> </tr> <tr> <td>1 to 3</td> <td>0.75 to 1</td> <td>0.5 to 0.75</td> <td>60 kg: 6 mL</td> </tr> <tr> <td>3 to 5</td> <td>1 to 2</td> <td>0.75 to 1</td> <td>70 kg: 7 mL</td> </tr> <tr> <td>&#62;5</td> <td>3 to 5</td> <td>to max</td> <td>80 kg: 8 mL</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>90 kg: 9 mL</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Sodium tetradecyl sulfate</td> <td class=\"divider_bottom\" rowspan=\"4\">Detergent</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>1%</p> 3%</td> <td class=\"divider_bottom\" rowspan=\"4\">Sodium 1-isobutyl-4thyloctyl sulfate, benzoyl alcohol 2%, phoshate</td> <td class=\"divider_bottom\" rowspan=\"4\">.5 mL</td> <td class=\"divider_bottom\" rowspan=\"4\">Less telangiectatic matting</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Allergy</p> <p>Hyperpigmentation</p> Ulceration/necrosis</td> <td>0.2 to 1</td> <td>0.1 to 0.3</td> <td>0.25</td> <td class=\"divider_bottom\" rowspan=\"4\">10 mL of 3% solution<sup>&#182;</sup></td> </tr> <tr> <td>1 to 3</td> <td>0.25 to 0.5</td> <td>0.5</td> </tr> <tr> <td>3 to 5</td> <td>0.5 to 1</td> <td>0.5 to 1</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;5</td> <td>1.5 to 3</td> <td>to max</td> </tr> <tr> <td>Glycerin</td> <td>Osmotic</td> <td>72%</td> <td>Glycerol, 1, 2, 3-propanetrial, glycerine</td> <td>.5 mL</td> <td> <p>No matting</p> <p>No ulceration</p> No necrosis</td> <td> <p>Contact sensitivity</p> <p>Rare: hematuria</p> Urethral colic</td> <td>&#60;1</td> <td>25 to 72</td> <td>0.25</td> <td>10 mL of 72% solution</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* None labeled. Limit use as with any product with saline.<br />¶ United States and Canada (elsewhere see drug insert).</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tisi, PV, Beverley, C, Rees, A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; :CD001732.</LI>&#xD;&#xA;<LI>Goldman, MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg 2002; 28:52.</LI>&#xD;&#xA;<LI>Parsi, K, Exner, T, Connor, DE, et al. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34:731.</LI>&#xD;&#xA;<LI>Weiss, RA, Weiss, MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 1990; 16:800.</LI>&#xD;&#xA;<LI>Bukhari, RH, Lohr, JM, Paget, DS, et al. Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy. J Vasc Surg 1999; 29:479.</LI>&#xD;&#xA;<LI>Davis, LT, Duffy, DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol 1990; 16:327.</LI>&#xD;&#xA;<LI>Norris, MJ, Carlin, MC, Ratz, JL. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989; 20:643.</LI></OL></div><div id=\"graphicVersion\">Graphic 70171 Version 5.0</div></div></div>"},"70172":{"type":"graphic_diagnosticimage","displayName":"Air bronchogram CT II","title":"Pneumonia with air bronchogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumonia with air bronchogram</div><div class=\"cntnt\"><img style=\"width:325px; height:211px;\" src=\"images/PULM/70172_Air_bronchogram_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphocytic interstitial pneumonia in a patient with HIV infection. The main changes are ground glass opacification in the right middle lobe and consolidation suggestive of air space disease in the right lower lobe with a clearly visible air bronchogram.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70172 Version 3.0</div></div></div>"},"70173":{"type":"graphic_waveform","displayName":"ECG multifocal atrial tachycardia","title":"Electrocardiogram (ECG) showing multifocal atrial tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing multifocal atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:520px; height:99px;\" src=\"images/CARD/70173_Multifocal_atrial_tachycard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram (ECG) showing multifocal atrial tachycardia in a patient with severe pulmonary disease. The diagnostic criteria include an average atrial rate above 100 beats/min and at least three different non-sinus P waves in the same lead. Note the multiple P wave morphologies - inverted (I), upright (U), and biphasic (B).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 70173 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"70175":{"type":"graphic_diagnosticimage","displayName":"Gallbladder polyp vs stone US","title":"Gallbladder polyp versus gallstone on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Gallbladder polyp versus gallstone on ultrasound</div><div class=\"cntnt\"><img style=\"width:514px; height:229px;\" src=\"images/GAST/70175_Gallbladder_polyp_vs_stone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound images of a gallbladder adenomatous polyp (arrow) compared with a gallstone (arrowhead). Note the shadow cast by the stone (dashed arrow) compared with the absence of a shadow behind the polyp.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 70175 Version 4.0</div></div></div>"},"70176":{"type":"graphic_figure","displayName":"Plasmodium life cycle","title":"Life cycle of <em>Plasmodium</em>*","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Life cycle of <em>Plasmodium</em>*</div><div class=\"cntnt\"><img style=\"width:542px; height:579px;\" src=\"images/ID/70176_Malaria_life_cycle_prevent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(1)</strong> <em>Plasmodium</em>-infected <em>Anopheles</em> mosquito bites a human and transmits sporozoites into the bloodstream. <strong>(2)</strong> Sporozoites migrate through the blood to the liver where they invade hepatocytes and divide to form multinucleated schizonts (pre-erythrocytic stage). Atovaquone-proguanil and primaquine have activity against hepatic-stage schizonts. <strong>(3)</strong> Hypnozoites are a quiescent stage in the liver that exist only in the setting of <em>P. vivax</em> and <em>P. ovale</em> infection. This liver stage does not cause clinical symptoms, but with reactivation and release into the circulation, late-onset or relapsed disease can occur up to many months after initial infection. Primaquine is active against the quiescent hypnozoites of <em>P. vivax</em> and <em>P. ovale</em>. <strong>(4)</strong> The schizonts rupture and release merozoites into the circulation where they invade red blood cells. Within red cells, merozoites mature from ring forms to trophozoites to multinucleated schizonts (erythrocytic stage). Blood-stage schizonticides such as artemisinins, atovaquone-proguanil, doxycycline, mefloquine, and chloroquine interrupt schizogony within red cells. <strong>(5)</strong> Some merozoites differentiate into male or female gametocytes. These cells are ingested by the <em>Anopheles</em> mosquito and mature in the midgut, where sporozoites develop and migrate to the salivary glands of the mosquito. The mosquito completes the cycle of transmission by biting another host.</div><div class=\"graphic_footnotes\">* There is strong evidence that drugs listed in parentheses are active against designated stage of parasitic life cycle.<br />&para; Primaquine is a blood-stage schizonticide with activity against schizonts of <em>P. vivax</em> but not those of <em>P. falciparum</em>.</div><div id=\"graphicVersion\">Graphic 70176 Version 7.0</div></div></div>"},"70178":{"type":"graphic_table","displayName":"Key points emergency birth","title":"Key points in emergency delivery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points in emergency delivery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Call for help. The mother and the baby should each have at least one clinician caring for them.</td> </tr> <tr> <td>2. Briefly assess the mother to determine if delivery is imminent (baby's head is visible or distending the perineum). Ask her if there are obstetrical or medical problems of which you should be aware, such as twin gestation, preterm fetus, congenital anomalies, or maternal bleeding diathesis.</td> </tr> <tr> <td>3. Position the mother on pillows or towels so her hips are raised, flexed, and abducted.</td> </tr> <tr> <td>4. Use an antibacterial cleanser to clean your hands and the perineum. Put on gloves.</td> </tr> <tr> <td>5. Ask the mother to pant or make only modest expulsive efforts in an attempt to achieve a controlled delivery.</td> </tr> <tr> <td>6. Place one hand on the baby's head and apply gentle downward pressure to maintain it in a flexed position and keep it from popping out of the vagina, and use the other hand to ease the perineum over the baby's face. Don't pull on the head, let the mother gradually push it into your hands.</td> </tr> <tr> <td>7. Feel for a loop of umbilical cord around the baby's neck. If present, gently slip it over the head. If it resists, either doubly clamp and cut it or leave it alone.</td> </tr> <tr> <td>8. With the next push, guide the head slightly downward so that the anterior shoulder slips under the symphysis pubis and delivers, then guide the head slightly upward to deliver the posterior shoulder over, rather than through, the perineum. Once both shoulders have delivered, the rest of the baby immediately follows.</td> </tr> <tr> <td>9. The mouth and nose should be wiped out with a clean cloth. The mouth is suctioned before the nose to decrease the risk for aspiration. There is no strong evidence that routine suctioning with a bulb or catheter is beneficial. However, if the infant appears to have an airway obstruction, use a bulb to gently suction the mouth first (avoid the posterior pharynx) and then the nose. The mouth is cleared first so its contents are not aspirated if the newborn gasps when the nose is suctioned. Do not raise the baby higher than the mother's abdomen to avoid backflow of blood into the placenta.</td> </tr> <tr> <td>10. Doubly clamp the umbilical cord and cut between the clamps.</td> </tr> <tr> <td>11. Dry the baby to reduce heat loss. Keep the baby warm by swaddling in warm towels/blankets, providing \"skin to skin\" contact with the mother, and keeping the room temperature warm.</td> </tr> <tr> <td>12. The three classic signs of placental separation are (1) lengthening of the umbilical cord, (2) a gush of blood from the vagina signifying separation of the placenta from the uterine wall, and (3) change in the shape of the uterine fundus from discoid to globular with elevation of the fundal height. Placental separation occurs naturally, usually within&nbsp;5 minutes of delivery, although intervals of&nbsp;30 to 60 minutes are reasonable if bleeding is not profuse. Controlled cord traction can be helpful, with counter traction applied over the woman's pubic symphysis.</td> </tr> <tr> <td>If the placenta is not expelled naturally, ask the mother to bear down and gently tug on the umbilical cord to deliver it. Place a hand on the abdomen to secure the uterine fundus to prevent uterine inversion. The postpartum fundus is palpable as a soft or firm mass at about the level of the umbilicus.</td> </tr> <tr> <td>13. After placental expulsion, massage the uterine fundus to help it contract into a firm globular mass. A flabby fundus suggests atony, which is the most common cause of postpartum hemorrhage.</td> </tr> <tr> <td>14. Administer oxytocin (20 units in 500 mL saline over one hour or 10 units intramuscularly).</td> </tr> <tr> <td>15. Inspect the perineum for lacerations. Deep lacerations should be evaluated and treated by an obstetrician. Apply pressure to lacerations that are bleeding briskly until these lacerations can be repaired.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70178 Version 4.0</div></div></div>"},"70182":{"type":"graphic_table","displayName":"Common pitfalls causing missed Achilles tendon rupture","title":"Common pitfalls causing missed Achilles tendon rupture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common pitfalls causing missed Achilles tendon rupture</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Patient&nbsp;able to&nbsp;plantar flex their foot</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Patient&nbsp;able to&nbsp;walk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tendon is not painful</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Examiner cannot palpate a defect in the Achilles tendon</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 70182 Version 2.0</div></div></div>"},"70184":{"type":"graphic_table","displayName":"Sickle trait alpha thalassemia","title":"Hematologic parameters in sickle cell trait-alpha thalassemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hematologic parameters in sickle cell trait-alpha thalassemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Alpha globin genes</td> <td class=\"subtitle1\">Hemoglobin (g/dL)</td> <td class=\"subtitle1\">MCV (fL)</td> <td class=\"subtitle1\">Hemoglobin S (percent)</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">13 to 15</td> <td class=\"centered\">80 to 90</td> <td class=\"centered\">35 to 45</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">13 to 14</td> <td class=\"centered\">75 to 85</td> <td class=\"centered\">30 to 35</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">12 to 13</td> <td class=\"centered\">70 to 75</td> <td class=\"centered\">25 to 30</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">7 to 10</td> <td class=\"centered\">50 to 55</td> <td class=\"centered\">17 to 25</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the effect of the number of functioning alpha globin genes on hematologic parameters in patients with the combination of alpha thalassemia and sickle cell trait. (The absence of any functional alpha globin genes is incompatible with extrauterine life; the normal complement is four.)</div><div class=\"graphic_footnotes\">MCV: mean corpuscular volume.</div><div class=\"graphic_reference\">Data from: Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68:985.</div><div id=\"graphicVersion\">Graphic 70184 Version 3.0</div></div></div>"},"70185":{"type":"graphic_picture","displayName":"Acromegaly features PI","title":"Facial features of acromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Facial features of acromegaly</div><div class=\"cntnt\"><img style=\"width:242px; height:359px;\" src=\"images/PI/70185_Acromegaly_features_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A man with acromegaly showing the characteristic changes of enlargement of the jaw, nose, and frontal bones, and coarse facial features.</div><div class=\"graphic_reference\">Courtesy of Verna Wright, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 70185 Version 2.0</div></div></div>"},"70186":{"type":"graphic_picture","displayName":"Sectoral disc swelling","title":"Superior sectoral pale disc swelling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior sectoral pale disc swelling</div><div class=\"cntnt\"><img style=\"width:356px; height:287px;\" src=\"images/PEDS/70186_Sectoral_disc_swelling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superior sectoral pale disc swelling in an ischemic optic neuropathy.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 70186 Version 1.0</div></div></div>"},"70189":{"type":"graphic_figure","displayName":"Brachial plexus","title":"Brachial plexus","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Brachial plexus</div><div class=\"cntnt\"><img style=\"width:538px; height:500px;\" src=\"images/SURG/70189_Brachial_plexus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The brachial plexus is formed by the ventral rami of the lower cervical and upper thoracic nerve roots. It is cephalad and posterior to the subclavian artery as it passes posterior to the first rib. The trunks of the brachial plexus (superior [C5,C6], middle [C7], inferior [C8,T1]) pass between the anterior and middle scalene muscles.</div><div class=\"graphic_footnotes\">m.: muscle; a.: artery; n.: nerve.</div><div id=\"graphicVersion\">Graphic 70189 Version 2.0</div></div></div>"},"70190":{"type":"graphic_picture","displayName":"Bladder endometriosis on cystoscopy","title":"Bladder endometriosis: Cystoscopic image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bladder endometriosis: Cystoscopic image</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/70190_Bladder_endometriosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystoscopic appearance of an endometriotic nodule on the posterior bladder wall.</div><div id=\"graphicVersion\">Graphic 70190 Version 1.0</div></div></div>"},"70192":{"type":"graphic_figure","displayName":"Clopidogrel outcome stenting","title":"Clopidogrel reduces event rate after coronary stenting","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Clopidogrel reduces event rate after coronary stenting</div><div class=\"cntnt\"><img style=\"width:464px; height:328px;\" src=\"images/CARD/70192_Clopidogrel_outcome_stentin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the PCI CURE trial of 2658 patients who underwent a percutaneous coronary intervention (PCI), clopidogrel, administered with aspirin for six days before the intervention and continued for four weeks after, significantly reduced the 30-day and one-year incidence of cardiovascular death, myocardial infarction, or repeat revascularization compared&nbsp;with aspirin alone.</div><div class=\"graphic_footnotes\">A: median time from randomization to PCI; B: 30 days after median time of PCI.</div><div class=\"graphic_reference\">Data from Mehta HR, Yusuf S, Peters RJ, et al. Lancet 2001; 358:527.</div><div id=\"graphicVersion\">Graphic 70192 Version 4.0</div></div></div>"},"70194":{"type":"graphic_picture","displayName":"Antibody-mediated rejection in RT biopsy 2","title":"Light microscopy showing antibody-mediated rejection in renal transplant biopsy, polymorphonuclear leukocytes, and endotheliitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy showing antibody-mediated rejection in renal transplant biopsy, polymorphonuclear leukocytes, and endotheliitis</div><div class=\"cntnt\"><img style=\"width:360px; height:284px;\" src=\"images/NEPH/70194_Low_mag_Ab_Mediated_Rej_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A section of a renal biopsy specimen demonstrating numerous intersitial polymorphonuclear cells (PMNs) and an adjacent artery with endotheliitis, another histologic marker suggestive of antibody-mediated rejection.</div><div class=\"graphic_reference\">Courtesy of Dr. Helen Liapis, Washington University School of Medicine.</div><div id=\"graphicVersion\">Graphic 70194 Version 4.0</div></div></div>"},"70196":{"type":"graphic_table","displayName":"Age of suture closure","title":"Age of suture closure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age of suture closure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Suture</td>\n<td class=\"subtitle1\">Begins closure, months</td>\n</tr>\n<tr>\n<td>Metopic</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Sagittal</td>\n<td>22</td>\n</tr>\n<tr>\n<td>Coronal</td>\n<td>24</td>\n</tr>\n<tr>\n<td>Lambdoid</td>\n<td>26</td>\n</tr>\n<tr>\n<td>Palatal</td>\n<td>30 to 35</td>\n</tr>\n<tr>\n<td>Frontonasal</td>\n<td>68</td>\n</tr>\n<tr>\n<td>Frontozygomatic</td>\n<td>72</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70196 Version 1.0</div></div></div>"},"70200":{"type":"graphic_picture","displayName":"Peripheral IV placement 5","title":"Peripheral IV placement: Advancing the catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Advancing the catheter</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/70200_Peripheral_IV_placement_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once a flash of blood appears in the needle chamber, advance the needle another millimeter or two. Then use the index finger of your dominant hand to slide the catheter forward over the needle and into the vein.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 70200 Version 2.0</div></div></div>"},"70202":{"type":"graphic_movie","displayName":"Biologic debridement with larvae","title":"Biologic debridement with larvae","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Biologic debridement with larvae</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/70202_Biodebridmentlarvaemovie.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:432px; height:325px;\" src=\"images/SURG/70202_Biologicdebridmentlarvae.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. David G Armstrong/SALSA. For more information, visit www.toeandflow.com.</div><div id=\"graphicVersion\">Graphic 70202 Version 2.0</div></div></div>"},"70203":{"type":"graphic_table","displayName":"Bacterial pathogens COPD exacerbations","title":"Relative frequency of bacterial pathogens isolated from 14 antibiotic comparison trials in exacerbations of chronic obstructive pulmonary disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative frequency of bacterial pathogens isolated from 14 antibiotic comparison trials in exacerbations of chronic obstructive pulmonary disease*</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Pathogen</td>\r\n                    <td class=\"subtitle1\">Percentage of bacterial isolates (range)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Haemophilus influenzae</em></td>\r\n                    <td>13 to 50</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Moraxella catarrhalis</em></td>\r\n                    <td>9 to 21</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Streptococcus pneumoniae</em></td>\r\n                    <td>7 to 26</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Pseudomonas aeruginosa</em></td>\r\n                    <td>1 to 13</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">8</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=95988&#38;amp;Mode=Edit&quot;&#62;&#60;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&#62;Edit Table&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">* Enterobacteriaceae have been isolated from the respiratory tract of 3 to 19 percent of patients with chronic obstructive pulmonary disease (COPD) exacerbations and <EM>Staphylococcus aureus</EM> has been isolated from the respiratory tract of 1 to 20 percent of patients with COPD exacerbations, but their pathogenic significance in this setting has not been defined. <EM>Haemophilus parainfluenzae</EM> has been isolated from the respiratory tract of 2 to 32 percent of patients with COPD exacerbations, but these organisms are unlikely to cause COPD exacerbations.</div><div class=\"graphic_reference\">Modified with permission from the American Thoracic Society. Copyright © 2004 American Thoracic Society. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2004; 1:109. Official Journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 70203 Version 9.0</div></div></div>"},"70204":{"type":"graphic_diagnosticimage","displayName":"PSLA view epicardial fat pad","title":"PSLA view of epicardial fat pad","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">PSLA view of epicardial fat pad</div><div class=\"cntnt\"><img style=\"width:495px; height:384px;\" src=\"images/EM/70204_PSLA_view_epica_fat_pad_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small epicardial fat pad (red arrow) is seen in this parasternal long axis view of the heart.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 70204 Version 2.0</div></div></div>"},"70205":{"type":"graphic_figure","displayName":"Five-year relative survival ratio in MM","title":"Five-year relative survival ratios for patients with multiple myeloma in Sweden from 1973 to 2003","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Five-year relative survival ratios for patients with multiple myeloma in Sweden from 1973 to 2003</div><div class=\"cntnt\"><img style=\"width:564px; height:645px;\" src=\"images/HEME/70205_Five_year_rel_surv_ratio_MM.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25:1993. Reprinted with permission. Copyright &copy; 2007 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70205 Version 4.0</div></div></div>"},"70207":{"type":"graphic_diagnosticimage","displayName":"Focal tracheal stenosis CT","title":"Focal tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:338px; height:302px;\" src=\"images/PULM/70207_Focal_tracheal_stenosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded surface display reformatting of a high resolution chest computed tomographic data set reveals a focal area of tracheal stenosis (arrows) just above the thoracic inlet.</div><div id=\"graphicVersion\">Graphic 70207 Version 4.0</div></div></div>"},"70209":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CXR VI","title":"Bronchogenic cyst adjacent to aortic arch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchogenic cyst adjacent to aortic arch</div><div class=\"cntnt\"><img style=\"width:360px; height:393px;\" src=\"images/PULM/70209_Med_bronchogen_cyst_CXR_VI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows mass adjacent to the aortic arch.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70209 Version 2.0</div></div></div>"},"70211":{"type":"graphic_diagnosticimage","displayName":"Carpal bones","title":"Carpal bones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carpal bones</div><div class=\"cntnt\"><img style=\"width:344px; height:612px;\" src=\"images/RHEUM/70211_Normal_adult_wrist_AP_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior posterior radiograph of the wrist shows the locations and names of the eight bones of the carpus. The proximal row (from radial to ulnar) is composed of the scaphoid (also known as the navicular), lunate, triquetrum, and pisiform. In the distal row are the trapezium, trapezoid, capitate, and hamate.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 70211 Version 5.0</div></div></div>"},"70212":{"type":"graphic_figure","displayName":"Relative mortality variceal bleed","title":"Risk of death is highest early after variceal hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of death is highest early after variceal hemorrhage</div><div class=\"cntnt\"><img style=\"width:349px; height:220px;\" src=\"images/GAST/70212_Relat_mortality_variceal_bl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative risk of death compared to nonbleeding cirrhotics in patients with a variceal hemorrhage as a function of time from time zero. The risk increases dramatically in the first 48 hours and declines therafter to baseline values by week six.</div><div class=\"graphic_reference\">Data from: Graham DY, Smith JL. Gastroenterology 1982; 82:968.</div><div id=\"graphicVersion\">Graphic 70212 Version 2.0</div></div></div>"},"70213":{"type":"graphic_picture","displayName":"Scleroderma glomerulus light","title":"Light microscopy of glomerulus in scleroderma renal crisis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy of glomerulus in scleroderma renal crisis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/70213_Scleroderma_glomerulus_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing fibrinoid necrosis in the preglomerular afferent arteriole (arrow) in scleroderma renal crisis. The normal muscle layer of the media has been replaced by the fibrinoid material.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 70213 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"70214":{"type":"graphic_table","displayName":"Decision tree","title":"Decision tree – Save tissue for the following potential special studies. Consultation with a clinical geneticist can be helpful in all of these cases.","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Decision tree&nbsp;– Save tissue for the following potential special studies. Consultation with a clinical geneticist can be helpful in all of these cases.</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Skeletal dysplasia/craniosynostosis </td> </tr> <tr> <td>Freeze long bone (at&nbsp;-20 or -80 degrees Celsius)</td> </tr> <tr> <td>Obtain tissue for DNA studies (skeletal muscle, skin)</td> </tr> <tr> <td>Karyotype</td> </tr> <tr> <td class=\"subtitle1_single\">Renal anomalies </td> </tr> <tr> <td>Karyotype</td> </tr> <tr> <td>Urinalysis for protein and crystals</td> </tr> <tr> <td>Freeze skin or renal tissue (at&nbsp;-20 or -80 degrees Celsius) for possible future genetic testing</td> </tr> <tr> <td class=\"subtitle1_single\">Inborn error of metabolism </td> </tr> <tr> <td>Freeze bile (at&nbsp;-20 or -80 degrees Celsius)</td> </tr> <tr> <td>Save fresh bone and skeletal muscle at 4 degrees Celsius for biochemical analysis. Consult with laboratory specialists as to how to obtain and preserve tissue.</td> </tr> <tr> <td class=\"subtitle1_single\">Hydrops fetalis </td> </tr> <tr> <td>Blood smear (if not autolyzed) for morphologic evaluation of cells (eg, congenital dyserythropoetic anemia)</td> </tr> <tr> <td>Hematocrit</td> </tr> <tr> <td>Karyotype</td> </tr> <tr> <td>Viral cultures if suggested by clinical findings</td> </tr> <tr> <td>Blood typing</td> </tr> <tr> <td class=\"subtitle1_single\">Arthrogryposes (any type) </td> </tr> <tr> <td>Karyotype</td> </tr> <tr> <td>Neuropathology consultation for muscle biopsy, spinal cord</td> </tr> <tr> <td>Freeze skin or skeletal muscle (at&nbsp;-20 or -80 degrees Celsius) for possible future genetic testing</td> </tr> <tr> <td class=\"subtitle1_single\">Dysmorphic features </td> </tr> <tr> <td>Karyotype</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70214 Version 3.0</div></div></div>"},"70215":{"type":"graphic_waveform","displayName":"Repetitive automatic AT I","title":"Repetitive automatic AT I","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repetitive automatic AT I</div><div class=\"cntnt\"><img style=\"width:432px; height:118px;\" src=\"images/CARD/70215_Repetitive_automatic_AT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repetitive automatic atrial tachycardia showing sinus tachycardia (s: upright sinus P wave) shifting to an ectopic atrial rhythm (e: inverted ectopic P wave) with a fusion P wave (f).</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 70215 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"70216":{"type":"graphic_table","displayName":"Chemicals requiring specific decontamination","title":"Selected chemicals requiring specific decontamination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected chemicals requiring specific decontamination</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Toxin\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Classification\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Treatment\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bitumen (Tar)</td>\r\n  \r\n   <td>Caustic</td>\r\n  \r\n   <td>\t<p>Copious irrigation with cold water until bitumen cools and hardens.</p>\n\t<p> \t \tBitumen that is adherent to blistered skin should be removed with blister epithelium. Bitumen adherent to unblistered skin should be covered liberally with a hydrocarbon solvent (eg, mineral oil).</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chromic acid</td>\r\n  \r\n   <td>Caustic with systemic toxicity</td>\r\n  \r\n   <td>Standard decontamination with consideration of 10 percent ascorbic acid added to irrigant.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hydrofluoric acid</td>\r\n  \r\n   <td>Caustic with systemic toxicity</td>\r\n  \r\n   <td>\t<p>Standard decontamination followed by application of 10 percent calcium gluconate gel. Parenteral calcium administration by injection or venous or arterial infusion may be required.</p>\n\t<p> \t \tPatient at risk for hypocalcemia.</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lime (calcium oxide)</td>\r\n  \r\n   <td>Caustic</td>\r\n  \r\n   <td>Brush off as much as possible prior to contact with water.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Methyl mercury</td>\r\n  \r\n   <td>Caustic with systemic toxicity</td>\r\n  \r\n   <td>Standard decontamination with blister debridement and blister fluid removal.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Phenol</td>\r\n  \r\n   <td>Caustic with systemic toxicity</td>\r\n  \r\n   <td>Irrigate with polyethylene glycol (PEG) 400.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Phosphorus (elemental yellow phosphorus)</td>\r\n  \r\n   <td>Caustic</td>\r\n  \r\n   <td>\t<p>Avoid exposure to air.</p>\n\t<p> \t \tCopious water irrigation, and keep covered with water.</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Radiation</td>\r\n  \r\n   <td>Acute radiation syndrome</td>\r\n  \r\n   <td>\t<p>Obtain radiation monitoring device.</p>\n\t<p> \t \tProtect personnel if patient is radioactive.</p>\n\t<p> \t \tDecontaminate from periphery to center of area of exposure. Avoid creating new breaks in the skin. Allow wounds to bleed freely. Collect urine and feces for signs of internal decontamination.</p>\n</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Reactive metals (eg, elemental sodium, potassium, lithium)</td>\r\n  \r\n   <td>Caustic</td>\r\n  \r\n   <td>Apply mineral oil and remove visible particles with forceps, gauze, or towels, then store removed particles in mineral oil.</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">1/12/2009--Requested permission (JD). 1/21/2009--Permission granted; figure to Terrence (JD). 2/4/2010--Renewal requested (JD). 3/26/2010--Renewal granted; agreement mailed back to Arnetta (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10730&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Chems_specific_decontam.htm</title></head></div><div class=\"graphic_lgnd\">NOTE: The treatment protocols given here are theoretically optimal, but decontamination efforts should not be delayed for a significant time to institute them.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Henretig FM (Eds). Skin Decontamination. Textbook of Pediatric Emergency Procedures, 2nd ed, Lippincott Williams &amp; Wilkins, 2008.&nbsp;Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70216 Version 11.0</div></div></div>"},"70218":{"type":"graphic_table","displayName":"Pregnancy rate during first year of contraception","title":"Pregnancy rate (percent) during first year of use of contraceptives","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy rate (percent) during first year of use of contraceptives</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Typical use</td> <td class=\"subtitle1\">Correct use</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Most effective</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Intrauterine device</td> </tr> <tr> <td class=\"indent2\">Copper T or Mirena</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"indent1\">Etonogestrel implant</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"indent1\">Female sterilization</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vasectomy</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Effective</td> </tr> <tr> <td class=\"indent1\">Depo-Provera (DMPA) injection</td> <td class=\"centered\">6</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"indent1\">Contraceptive patch</td> <td class=\"centered\">9</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Contraceptive pills</td> </tr> <tr> <td class=\"indent2\">Progestin-only or combination estrogen-progestin</td> <td class=\"centered\">9</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"indent1\">Contraceptive vaginal ring</td> <td class=\"centered\">9</td> <td class=\"centered\">&#60;1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diaphragm</td> <td class=\"centered\">12</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Least effective</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Condom</td> </tr> <tr> <td class=\"indent2\">Male</td> <td class=\"centered\">18</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent2\">Female</td> <td class=\"centered\">21</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Sponge</td> </tr> <tr> <td class=\"indent2\">Previous births</td> <td class=\"centered\">24</td> <td class=\"centered\">20</td> </tr> <tr> <td class=\"indent2\">No previous births</td> <td class=\"centered\">12</td> <td class=\"centered\">9</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Cervical cap (FemCap)</td> </tr> <tr> <td class=\"indent2\">No previous births </td> <td class=\"centered\">14</td> <td class=\"centered\">&nbsp;N/A</td> </tr> <tr> <td class=\"indent2\">Previous births </td> <td class=\"centered\">29</td> <td class=\"centered\">&nbsp;N/A</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Fertility awareness-based methods</td> </tr> <tr> <td class=\"indent2\">Cervical mucus or ovulation</td> <td class=\"centered\">24</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent2\">Symptothermal</td> <td class=\"centered\">24</td> <td class=\"centered\">0.4</td> </tr> <tr> <td class=\"indent2\">TwoDay</td> <td class=\"centered\">24</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent2\">Standards days</td> <td class=\"centered\">24</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Withdrawal</td> <td class=\"centered\">22</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Spermicides</td> <td class=\"centered\">28</td> <td class=\"centered\">18</td> </tr> <tr> <td class=\"indent1\">No method</td> <td class=\"centered\">85</td> <td class=\"centered\">85</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data refer to number of pregnancies per 100 women during first year of use.<br />Typical use: Refers to failure rates for women and men whose use is not consistent or always correct.<br />Correct use: Refers to failure rates for those whose use is consistent and always correct.<br />N/A:&nbsp;Indicates data are not available. </div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Hatcher RA, Trussell J, Nelson A, et al. Contraceptive Technology, 20th ed, Bridging the Gap Communications, Decatur 2011.</LI>&#xD;&#xA;<LI>Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</LI></UL></div><div id=\"graphicVersion\">Graphic 70218 Version 13.0</div></div></div>"},"70219":{"type":"graphic_table","displayName":"Drugs that cause anemia in HIV","title":"Common drug-related causes of anemia in HIV-infected patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common drug-related causes of anemia in HIV-infected patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Antiretroviral agents</td>\n</tr>\n<tr>\n<td>Zidovudine</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Therapy for opportunistic infections</td>\n</tr>\n<tr>\n<td>Ganciclovir</td>\n</tr>\n<tr>\n<td>Trimethoprim-sulfamethoxazole</td>\n</tr>\n<tr>\n<td>Flucytosine</td>\n</tr>\n<tr>\n<td>Amphotericin B</td>\n</tr>\n<tr>\n<td>Pyrimethamine</td>\n</tr>\n<tr>\n<td>Primaquine</td>\n</tr>\n<tr>\n<td>Dapsone</td>\n</tr>\n<tr>\n<td>Trimetrexate</td>\n</tr>\n<tr>\n<td>Ribavirin</td>\n</tr>\n<tr>\n<td>Others</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Chemotherapeutic agents</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Interferon</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Immunoglobulin</td>\n</tr>\n<tr>\n<td>Anti-RhD</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25259&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Drugs_which_cause_anemia_in.htm</title></head></div><div id=\"graphicVersion\">Graphic 70219 Version 2.0</div></div></div>"},"70220":{"type":"graphic_diagnosticimage","displayName":"Adult TB case 1 lateral view","title":"Classic adult TB lateral view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Classic adult TB lateral view</div><div class=\"cntnt\"><img style=\"width:504px; height:497px;\" src=\"images/ID/70220_ClassicadultTBlateralvi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">18-year-old high school student, chest radiograph, lateral view.</div><div class=\"graphic_reference\">Courtesy of John Bernardo, MD.</div><div id=\"graphicVersion\">Graphic 70220 Version 4.0</div></div></div>"},"70221":{"type":"graphic_movie","displayName":"Apical 4 chamber echo tricuspid valve vegetation","title":"Apical 4 chamber echocardiogram showing tricuspid valve vegetation in patient with endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber echocardiogram showing tricuspid valve vegetation in patient with endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/70221_endtv4chconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:260px; height:428px;\" src=\"images/CARD/70221_endtv4ch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Close-up view of tricuspid valve from a four chamber view of a 2-D echocardiogram shows vegetations on the ventricular surface of the tricuspid valve due to endocarditis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 70221 Version 4.0</div></div></div>"},"70223":{"type":"graphic_picture","displayName":"Uropathogenic E coli adhesion","title":"Adhesion of uropathogenic Escherichia coli to epithelial cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adhesion of uropathogenic Escherichia coli to epithelial cells</div><div class=\"cntnt\"><img style=\"width:442px; height:335px;\" src=\"images/NEPH/70223_Uropathogenic_E_coli_adhesi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-powered microscopy demonstrating adherence of uropathogenic Escherichia coli onto uroepithelial cells.</div><div class=\"graphic_reference\">Courtesy of Agnès Labigne, MD, Institut Pasteur, Paris.</div><div id=\"graphicVersion\">Graphic 70223 Version 3.0</div></div></div>"},"70226":{"type":"graphic_picture","displayName":"ACD bone marrow iron stain","title":"Anemia of chronic disease - bone marrow iron stain","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Anemia of chronic disease - bone marrow iron stain</div><div class=\"cntnt\"><img style=\"width:472px; height:325px;\" src=\"images/HEME/70226_Anemia_chron_dis_marrow_iro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of a bone marrow aspirate taken from a patient with the anemia of chronic disease. The slide has been stained for iron (Prussian blue reaction) and counterstained with safranin to show nuclear detail. Note the increased iron staining within the voluminous cytoplasm of macrophages (thick black arrows), while there is no staining for iron within the cytoplasm of red blood cell precursors (thin black arrows). This pattern (abundant iron in macrophages and reduced to absent iron in red cell precursors) is quite typical for the anemia of chronic disease, and contrasts with iron deficiency, in which iron is absent from both macrophages and red cell precursors, while normal subjects demonstrate iron in macrophages and red cell precursors.</div><div class=\"graphic_reference\">Slide provided by Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 70226 Version 2.0</div></div></div>"},"70227":{"type":"graphic_table","displayName":"Prevalence of stages of CKD in the US","title":"Prevalence of stages of chronic kidney disease in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of stages of chronic kidney disease in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CKD</td> <td class=\"subtitle1\">eGFR</td> <td class=\"subtitle1\">Prevalence</td> <td class=\"subtitle1\">Affected patients</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td><strong>Stage 1</strong></td> <td>&#8805;90 mL/min</td> <td>3.3 percent</td> <td>&#8776;5,900,000</td> <td>Renal injury (eg, proteinuria) without reduced eGFR</td> </tr> <tr> <td><strong>Stage 2</strong></td> <td>89 to 60 mL/min</td> <td>3.0 percent</td> <td>&#8776;5,300,000</td> <td>Mildly decreased eGFR</td> </tr> <tr> <td><strong>Stage 3</strong></td> <td>59 to 30 mL/min</td> <td>4.3 percent</td> <td>&#8776;7,600,000</td> <td>Moderately decreased eGFR</td> </tr> <tr> <td><strong>Stage 4</strong></td> <td>29 to 15 mL/min</td> <td>0.2 percent</td> <td>&#8776;400,000</td> <td>Severely decreased eGFR</td> </tr> <tr> <td><strong>Stage 5</strong></td> <td>&#60;15 mL/min</td> <td>0.3 percent</td> <td>&#8776;500,000</td> <td>Kidney failure, mostly indication for renal replacement therapy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The estimation of affected patients refers to the United States&nbsp;population.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate.</div><div class=\"graphic_reference\">Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright &copy; 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 70227 Version 5.0</div></div></div>"},"70228":{"type":"graphic_diagnosticimage","displayName":"Perforation after gastric banding","title":"Perforation after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Perforation after gastric banding</div><div class=\"cntnt\"><img style=\"width:582px; height:303px;\" src=\"images/SURG/70228_Perforation_gastric_banding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This UGI series shows a contained distal esophageal perforation that occurred during placement of an LAGB. The band was removed and the abdominal cavity drained.</div><div class=\"graphic_footnotes\">UGI: upper gastrointestinal; LAGB: laparoscopic adjustable gastric band.</div><div class=\"graphic_reference\">Courtesy of Raul J Rosenthal, MD, FACS, FASMBS.</div><div id=\"graphicVersion\">Graphic 70228 Version 2.0</div></div></div>"},"70229":{"type":"graphic_picture","displayName":"Recluse spider A","title":"Female recluse spider A","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female recluse spider A</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/ALLRG/70229_Recluse_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spider appears larger than actual size. Mature recluse spiders have a body length (not including legs) of 7 to 10 mm.</div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 70229 Version 3.0</div></div></div>"},"70230":{"type":"graphic_figure","displayName":"Chimeric TK in pap thyroid Ca","title":"Chimeric tyrosine kinases in papillary thyroid carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chimeric tyrosine kinases in papillary thyroid carcinoma</div><div class=\"cntnt\"><img style=\"width:427px; height:135px;\" src=\"images/ENDO/70230_Chimeric_TK_in_pap_thyroid.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of chimeric tyrosine kinases in papillary thyroid carcinoma. The <EM>RET </EM>and <EM>NTRK1 </EM>genes code for tyrosine kinases that are not normally expressed in thyroid epithelial cells. Gene rearrangements that elicit expression of these tyrosine kinases in thyroid epithelial cells cause papillary carcinomas; such rearrangements appear to occur more frequently following external beam radiation or exposure to radiation after a nuclear accident. When the appropriate gene rearrangement occurs, a chimeric gene is formed and the resultant chimeric protein is expressed. The new 5' end of the chimeric gene confers expression in thyroid epithelial cells and codes for the amino terminus of the chimeric protein. Expression of the active tyrosine kinases presumably activates growth pathways by a cascade beginning with tyrosine phosphorylation. The chimeric <EM>RET </EM>genes are referred to as RET/PTC and the chimeric <EM>NTRK1 </EM>genes are referred to as TRK.</div><div id=\"graphicVersion\">Graphic 70230 Version 2.0</div></div></div>"},"70231":{"type":"graphic_table","displayName":"Approach fecal incontinence","title":"Approach to patients with fecal incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to patients with fecal incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Obtain history</td>\n</tr>\n<tr>\n<td>Is the patient truly incontinent or does patient have frequency and urgency without incontinence?</td>\n</tr>\n<tr>\n<td>How long have symptoms been present?</td>\n</tr>\n<tr>\n<td>Does the patient have minor or major incontinence?</td>\n</tr>\n<tr>\n<td>Does the patient have urgency?</td>\n</tr>\n<tr>\n<td>Could the patient be impacted?</td>\n</tr>\n<tr>\n<td>Is there a background history of diarrhea? Could medications be contributing?</td>\n</tr>\n<tr>\n<td>Does the patient have a prior history of vaginal delivery or anorectal surgery?</td>\n</tr>\n<tr>\n<td>Does the patient have a history of prior pelvic irradiation?</td>\n</tr>\n<tr>\n<td>Does the patient have a neurological disturbance?</td>\n</tr>\n<tr>\n<td>Does the patient have diabetes mellitus?</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Perform physical examination</td>\n</tr>\n<tr>\n<td>Examine the external anoderm</td>\n</tr>\n<tr>\n<td>Test for an anal wink bilaterally</td>\n</tr>\n<tr>\n<td>Inspect for prolapsing hemorrhoids or other obvious pathology</td>\n</tr>\n<tr>\n<td>Perform a digital examination while asking the patient to bear down and to squeeze</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Obtain specific anorectal testing</td>\n</tr>\n<tr>\n<td>Flexible sigmoidoscopy in most patients</td>\n</tr>\n<tr>\n<td>Specific testing for patients with diarrhea</td>\n</tr>\n<tr>\n<td>Endorectal ultrasonography in patients with suspected sphincter disruption</td>\n</tr>\n<tr>\n<td>Anorectal manometry in patients with structurally intact sphincters</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Specific treatment</td>\n</tr>\n<tr>\n<td>Medical therapy and/or biofeedback for motivated patients who have intact sphincters and manometry showing preserved rectal sensation</td>\n</tr>\n<tr>\n<td>Surgical repair for patients with mechanical sphincter disruption in whom medical therapy is unsuccessful</td>\n</tr>\n<tr>\n<td>Other sphincter restoring procedures in patients with major incontinence in centers with available expertise</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70231 Version 1.0</div></div></div>"},"70232":{"type":"graphic_diagnosticimage","displayName":"Linear EUS celiac ganglia","title":"Linear EUS celiac ganglia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear EUS celiac ganglia</div><div class=\"cntnt\"><img style=\"width:396px; height:320px;\" src=\"images/GAST/70232_Linear_EUS_celiac_ganglia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear endosonography demonstrating three celiac ganglia.</div><div class=\"graphic_reference\">Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 70232 Version 10.0</div></div></div>"},"70233":{"type":"graphic_table","displayName":"Causes of abdominal pain by location","title":"Causes of abdominal pain by location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of abdominal pain by location</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Right upper quadrant</td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td>Cholecystitis</td> </tr> <tr> <td>Cholangitis</td> </tr> <tr> <td>Biliary colic</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Budd-Chiari syndrome</td> </tr> <tr> <td>Pneumonia/empyema pleurisy</td> </tr> <tr> <td>Subdiaphragmatic abscess</td> </tr> <tr> <td class=\"subtitle1_single\">Right lower quadrant</td> </tr> <tr> <td>Appendicitis</td> </tr> <tr> <td>Salpingitis</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Inguinal hernia</td> </tr> <tr> <td>Nephrolithiasis</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Mesenteric adenitis (yersina)</td> </tr> <tr> <td class=\"subtitle1_single\">Epigastric</td> </tr> <tr> <td>Peptic ulcer disease</td> </tr> <tr> <td>Gastroesophageal reflux disease</td> </tr> <tr> <td>Gastritis</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Pericarditis</td> </tr> <tr> <td>Ruptured aortic aneurysm</td> </tr> <tr> <td class=\"subtitle1_single\">Periumbilical</td> </tr> <tr> <td>Early appendicitis</td> </tr> <tr> <td>Gastroenteritis</td> </tr> <tr> <td>Bowel obstruction</td> </tr> <tr> <td>Ruptured aortic aneurysm</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Left upper quadrant</td> </tr> <tr> <td>Splenic abscess</td> </tr> <tr> <td>Splenic infarct</td> </tr> <tr> <td>Gastritis</td> </tr> <tr> <td>Gastric ulcer</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Left lower quadrant</td> </tr> <tr> <td>Diverticulitis</td> </tr> <tr> <td>Salpingitis</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Inguinal hernia</td> </tr> <tr> <td>Nephrolithiasis</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td class=\"subtitle1_single\">Diffuse</td> </tr> <tr> <td>Gastroenteritis</td> </tr> <tr> <td>Mesenteric ischemia</td> </tr> <tr> <td>Metabolic (eg, DKA, porphyria)</td> </tr> <tr> <td>Malaria</td> </tr> <tr> <td>Familial Mediterranean fever</td> </tr> <tr> <td>Bowel obstruction</td> </tr> <tr> <td>Peritonitis</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> </tbody> </table> </td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57134&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis.</div><div id=\"graphicVersion\">Graphic 70233 Version 4.0</div></div></div>"},"70234":{"type":"graphic_picture","displayName":"Salmon patch","title":"Nevus simplex (also called \"salmon patch\" or \"stork bite\")","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevus simplex (also called \"salmon patch\" or \"stork bite\")</div><div class=\"cntnt\"><img style=\"width:324px; height:223px;\" src=\"images/PC/70234_Macular_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This splotchy pink mark fades with age.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher M. Physical Diagnosis in Neonatology. Lippincott-Raven Publishers, Philadelphia 1998. Copyright ©1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70234 Version 4.0</div></div></div>"},"70235":{"type":"graphic_diagnosticimage","displayName":"MAC long-axis","title":"Mitral annular calcification, parasternal long-axis view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral annular calcification, parasternal long-axis view</div><div class=\"cntnt\"><img style=\"width:380px; height:278px;\" src=\"images/CARD/70235_MAClongaxis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long-axis view showing MAC along the posterior mitral annulus.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; MAC: mitral annular calcification; AV: aortic valve.</div><div class=\"graphic_reference\">Courtesy of Rosario V Freeman, MD, MS.</div><div id=\"graphicVersion\">Graphic 70235 Version 4.0</div></div></div>"},"70236":{"type":"graphic_diagnosticimage","displayName":"Acute varicella pneumonia PA","title":"Acute varicella pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute varicella pneumonia</div><div class=\"cntnt\"><img style=\"width:360px; height:355px;\" src=\"images/PULM/70236_Acute_varicella_pneumonia_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph reveals multiple so-called acinar nodules, 5-10 mm in diameter.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70236 Version 3.0</div></div></div>"},"70237":{"type":"graphic_figure","displayName":"Pathogenesis of bronchiolitis","title":"Pathogenesis of bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:255px; height:222px;\" src=\"images/PULM/70237_Pathogenesis_of_bronchiolit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the steps involved in the pathogenesis of bronchiolitis obliterans. An initial insult to the bronchial epithelium eventually leads to either fibrosis or resolution.</div><div id=\"graphicVersion\">Graphic 70237 Version 1.0</div></div></div>"},"70238":{"type":"graphic_picture","displayName":"Vocal cord edema Endosc","title":"Vocal cord edema","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Vocal cord edema</div><div class=\"cntnt\"><img style=\"width:461px; height:228px;\" src=\"images/PULM/70238_Vocal_cord_edema_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic views of normal (left) and edematous (right) vocal cords following extubation.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 70238 Version 1.0</div></div></div>"},"70240":{"type":"graphic_diagnosticimage","displayName":"Xanthogranulomatous PN CT","title":"Xanthogranulomatous pyelonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthogranulomatous pyelonephritis</div><div class=\"cntnt\"><img style=\"width:360px; height:229px;\" src=\"images/NEPH/70240_Xanthogranulomatous_PN_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of xanthogranulomatous pyelonephritis with perinephric extension. There is diffuse enlargement of the left kidney and the renal tissue is replaced by multiple low-attenuation masses (arrow). A calcification is visible within the renal pelvis and there is posterior and pararenal extension of the pseudotumoral inflammatory tissue. The contralateral kidney is normal.</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 70240 Version 2.0</div></div></div>"},"70241":{"type":"graphic_table","displayName":"Pregnancy outcome in eclampsia","title":"Summary of maternal and neonatal outcomes in pregnancies complicated by eclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of maternal and neonatal outcomes in pregnancies complicated by eclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Outcome</td>\n<td class=\"subtitle1\">Frequency, percent</td>\n</tr>\n<tr>\n<td>Abruption</td>\n<td>7 to 10</td>\n</tr>\n<tr>\n<td>Disseminated intravascular coagulation</td>\n<td>7 to 11</td>\n</tr>\n<tr>\n<td>Pulmonary edema</td>\n<td>3 to 5</td>\n</tr>\n<tr>\n<td>Acute renal failure</td>\n<td>5 to 9</td>\n</tr>\n<tr>\n<td>Aspiration pneumonia</td>\n<td>2 to 3</td>\n</tr>\n<tr>\n<td>Cardiopulmonary arrest</td>\n<td>2 to 5</td>\n</tr>\n<tr>\n<td>Liver hematoma</td>\n<td>1</td>\n</tr>\n<tr>\n<td>HELLP syndrome</td>\n<td>10 to 15</td>\n</tr>\n<tr>\n<td>Perinatal death</td>\n<td>5.6 to 11.8</td>\n</tr>\n<tr>\n<td>Preterm birth</td>\n<td>50</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42676&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Eclampsia_outcomes.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Sibai, BM. Obstet Gynecol 2005; 105:402.</div><div id=\"graphicVersion\">Graphic 70241 Version 2.0</div></div></div>"},"70243":{"type":"graphic_picture","displayName":"Toe towel curls PI","title":"Toe towel curls","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Toe towel curls</div><div class=\"cntnt\"><img style=\"width:524px; height:310px;\" src=\"images/PI/70243_Toe_towel_curls_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Curl your toes around a towel. Then grip and release the towel over and over again for 1 to 2 minutes, twice a day.</div><div id=\"graphicVersion\">Graphic 70243 Version 2.0</div></div></div>"},"70244":{"type":"graphic_figure","displayName":"LV function stroke risk in AF","title":"Significant left ventricular dysfunction predicts stroke in AF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Significant left ventricular dysfunction predicts stroke in AF</div><div class=\"cntnt\"><img style=\"width:381px; height:285px;\" src=\"images/CARD/70244_LVfunctionstrokeriskin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a prospective study of 1066 patients entered into three clinical trials evaluating the role of anticoagulation in nonvalvular AF (BAATAF, SPINAF, and SPAF), the incidence of a stroke was 9.3 percent per year in patients with moderate to severe left ventricular dysfunction compared&nbsp;with 4.4 percent per year in those with normal or mildly abnormal left ventricular function.</div><div class=\"graphic_reference\">Data from: Atrial Fibrillation Investigators, Arch Intern Med 1998; 158:1316.</div><div id=\"graphicVersion\">Graphic 70244 Version 4.0</div></div></div>"},"70245":{"type":"graphic_table","displayName":"Available IDUS systems","title":"Available intraductal ultrasound systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available intraductal ultrasound systems</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Electronic ultrasound probe (Endosonics&reg;)</td>\n<td class=\"subtitle1\">Mechanical sector scanner probes (ALOKA&reg;, Olympus&reg;, Microvasive&reg;)</td>\n<td class=\"subtitle1\">Combined sector and linear probes (Fujinon&reg;)</td>\n</tr>\n<tr>\n<td>Scanning method</td>\n<td>Phased array</td>\n<td>Mechanical/radial</td>\n<td>Mechanical/radial or linear</td>\n</tr>\n<tr>\n<td>Frequency (MHz)</td>\n<td>20</td>\n<td>15-20/12-30/20</td>\n<td>12-15-20</td>\n</tr>\n<tr>\n<td>Transducer elements</td>\n<td>64</td>\n<td>1/1/1</td>\n<td>1</td>\n</tr>\n<tr>\n<td>Working length (cm)</td>\n<td>175</td>\n<td>192/205/200</td>\n<td>200</td>\n</tr>\n<tr>\n<td>Diameter (mm)</td>\n<td>1.2/1.6</td>\n<td>2/2.0-2.4-2.9/2.1</td>\n<td>2.0/2.6</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70245 Version 1.0</div></div></div>"},"70246":{"type":"graphic_figure","displayName":"Loop ileostomy","title":"Loop ileostomy","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Loop ileostomy</div><div class=\"cntnt\"><img style=\"width:542px; height:533px;\" src=\"images/SURG/70246_Loop_ileostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A segment of intestine is brought out above the abdominal wall assuring a tension-free placement.<br> (B) An enterotomy is created along the efferent (or distal) end of the loop stoma.<br> (C) Using absorbable maturation sutures, an everting proximal afferent end (left) and a flush distal efferent end (right) are created. This will allow the effluent to come through the proximal spout into the collecting bag system and prevent leakage onto the surrounding skin. The distal flush end will allow venting.</div><div id=\"graphicVersion\">Graphic 70246 Version 3.0</div></div></div>"},"70248":{"type":"graphic_picture","displayName":"Toxic granulations","title":"Toxic granulations and Döhle bodies in infection/inflammation","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Toxic granulations and Döhle bodies in infection/inflammation</div><div class=\"cntnt\"><img style=\"width:496px; height:360px;\" src=\"images/HEME/70248_Toxic_granulations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Peripheral blood smear shows neutrophils with toxic granulations, which are dark coarse granules. A Döhle body is also seen (arrow). Right panel: A neutrophil with toxic granulations, vacuoles (another toxic change), and a Döhle body (arrow). These abnormalities are characteristic of toxic systemic illnesses.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 70248 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"70250":{"type":"graphic_table","displayName":"Systemic effects of elevated intra-abdominal pressure","title":"Systemic effects of elevated intra-abdominal pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic effects of elevated intra-abdominal pressure</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Central nervous system\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; Intracranial pressure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Cerebral perfusion pressure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Cardiac\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hypovolemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Cardiac output</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Venous return</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; PCWP and CVP</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; SVR</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Pulmonary\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; Intrathoracic pressure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; Peak inspiratory pressure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; Airway pressures</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Compliance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; PaO<sub>2</sub></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; PaCO<sub>2</sub></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; Shunt fraction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8593; Vd/Vt</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gastrointestinal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Celiac blood flow</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; SMA blood flow</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Mucosal blood flow</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; pHi</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Renal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Urinary output</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Renal blood flow</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; GFR</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Hepatic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Portal blood flow</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Mitochondrial function</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Lactate clearance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Abdominal wall\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Compliance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#8595; Rectus sheath blood flow</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=64589&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Effects_of_ACS.htm</title></head></div><div id=\"graphicVersion\">Graphic 70250 Version 3.0</div></div></div>"},"70251":{"type":"graphic_picture","displayName":"Thin visceral pleura","title":"Thin visceral pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thin visceral pleura</div><div class=\"cntnt\"><img style=\"width:357px; height:236px;\" src=\"images/PULM/70251_Thin_visceral_pleura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a thin visceral pleura, as seen in some animal species such as dogs and rabbits.</div><div class=\"graphic_reference\">Courtesy of V Courtney Broaddus, MD.</div><div id=\"graphicVersion\">Graphic 70251 Version 2.0</div></div></div>"},"70252":{"type":"graphic_form","displayName":"HAE emergency care","title":"Instructions for emergency care of hereditary angioedema (HAE)","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Instructions for emergency care of hereditary angioedema (HAE)</div><div class=\"cntnt\"><img style=\"width:597px; height:786px;\" src=\"images/ALLRG/70252_HAE_emergency_care_edt3.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70252 Version 10.0</div></div></div>"},"70253":{"type":"graphic_picture","displayName":"Parry-Romberg syndrome","title":"Parry-Romberg syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parry-Romberg syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70253_Parry_Romberg_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetry of the tongue and lower face is present in this patient with Parry-Romberg syndrome.</div><div id=\"graphicVersion\">Graphic 70253 Version 1.0</div></div></div>"},"70254":{"type":"graphic_picture","displayName":"Proper sitting posture","title":"Proper sitting posture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper sitting posture</div><div class=\"cntnt\"><img style=\"width:250px; height:412px;\" src=\"images/RHEUM/70254_proper_sitting_post.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 70254 Version 1.0</div></div></div>"},"70258":{"type":"graphic_figure","displayName":"CAST beta blocker AA drugs","title":"Beta blockers reduce mortality in high-risk patients after MI","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Beta blockers reduce mortality in high-risk patients after MI</div><div class=\"cntnt\"><img style=\"width:538px; height:299px;\" src=\"images/CARD/70258_CAST_beta_blocker_AA_drugs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Cardiac Arrhythmia Suppression Trial (CAST) randomized 1735 postmyocardial infarction (MI) patients with a left ventricular ejection fraction &#8804;40 percent and ventricular arrhythmia to an antiarrhythmic drug (encainide, flecainide, or moricizine) or placebo. Patients who were receiving concomitant beta blocker therapy had a lower incidence of all-cause mortality, arrhythmic death, or cardiac arrest compared to those not receiving beta blockers.</div><div class=\"graphic_reference\">Data from Kennedy HL, Brooks MM, Barker AH, et al, for the CAST Invetigators, Am J Cardiol 1994; 74:674.</div><div id=\"graphicVersion\">Graphic 70258 Version 2.0</div></div></div>"},"70259":{"type":"graphic_table","displayName":"Differential diagnosis of pediatric MS","title":"Differential diagnosis of pediatric multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pediatric multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Inflammatory disease</td> <td>ADEM/MDEM, NMOSD, SLE, PACNS, APS, Sj&#246;gren syndrome, Beh&#231;et syndrome</td> </tr> <tr> <td>CNS malignancy</td> <td>Lymphoma, high grade glioma</td> </tr> <tr> <td>Leukodystrophy</td> <td>Metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Alexander disease</td> </tr> <tr> <td>CNS infection</td> <td>Acute bacterial or viral infections, Lyme disease, West Nile virus, syphilis, HIV</td> </tr> <tr> <td>Vitamin deficiency</td> <td>B12, folate</td> </tr> <tr> <td>Granulomatous disease</td> <td>Neurosarcoidosis, granulomatosis with polyangiitis (Wegener)</td> </tr> <tr> <td>Mitochondrial disease</td> <td>Leber hereditary optic neuropathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADEM: acute disseminated encephalomyelitis; APS: antiphospholipid syndrome; CNS: central nervous system; HIV: human immunodeficiency virus; MDEM: multiphasic disseminated encephalomyelitis; NMOSD: neuromyelitis optica spectrum disorders; PACNS: primary angiitis of the central nervous system; SLE: systemic lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 70259 Version 6.0</div></div></div>"},"70264":{"type":"graphic_picture","displayName":"Contact dermatitis nickel 2","title":"Contact dermatitis due to nickel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis due to nickel</div><div class=\"cntnt\"><img style=\"width:320px; height:333px;\" src=\"images/DERM/70264_Contactdermatitisnickel2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nickel in earrings caused this dermatitis on the ear lobe and neck.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70264 Version 4.0</div></div></div>"},"70267":{"type":"graphic_picture","displayName":"Ulcerated MZL endoscopy","title":"Gastric marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) on endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) on endoscopy</div><div class=\"cntnt\"><img style=\"width:251px; height:221px;\" src=\"images/GAST/70267_Ulcerated_MALT_lymphoma_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a deep benign appearing ulcer crater in the gastric antrum (arrow) with a large blood clot indicating recent hemorrhage. Histology was consistent with a marginal zone lymphoma.</div><div id=\"graphicVersion\">Graphic 70267 Version 4.0</div></div></div>"},"70269":{"type":"graphic_table","displayName":"Vasculitic periph neuropathy","title":"Clinical features of vasculitic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of vasculitic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Granulomatosis with polyangiitis (Wegener's) (GPA)</strong></td> <td>Peripheral neuropathy</td> </tr> <tr class=\"divider_top\"> <td><strong>Polyarteritis nodosa (PAN)</strong></td> <td>Mononeuritis multiplex</td> </tr> <tr class=\"divider_top\"> <td><strong>Churg-Strauss syndrome (CSS)</strong></td> <td>Paranasal granulomas may infiltrate cranial nerves II, VI, VII via extension in WG or CSS</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Rheumatoid arthritis</strong></td> <td>Neuropathy seen in longstanding, usually rheumatoid factor-positive cases</td> </tr> <tr> <td>Evidence for vasculitis includes non-healing leg ulcers and nailfold infarcts</td> </tr> <tr class=\"divider_top\"> <td><strong>Sj&#246;gren's syndrome</strong></td> <td>May present as stocking-glove sensorimotor neuropathy, trigeminal neuropathy, or ataxic large fiber neuronopathy</td> </tr> <tr class=\"divider_top\"> <td><strong>Systemic lupus erythematosus</strong></td> <td>Associated with central nervous system involvement: seizures and psychiatric symptoms</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Human immunodeficiency virus</strong></td> <td>CD4+ count &#62;200: isolated vasculitic neuropathy</td> </tr> <tr> <td>CD4+ count &#60;50: more extensive neuropathy and rapidly progressive; also consider CMV, toxoplasmosis, HZV, lymphoma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Lyme disease</strong></td> <td>Meningitis</td> </tr> <tr> <td>Encephalopathy</td> </tr> <tr> <td>Facial nerve commonly involved</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Essential mixed cryoglubulinemia</strong></td> <td>80 percent of patients have antibodies to hepatitis C</td> </tr> <tr> <td>False positive RF</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Temporal arteritis</strong></td> <td>12 percent of patients have a peripheral neuropathy</td> </tr> <tr> <td>Headache</td> </tr> <tr> <td>Jaw claudication</td> </tr> <tr> <td>Elevated ESR, C-reactive protein</td> </tr> <tr> <td>Ischemic optic neuropathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; HZV: herpes zoster (varicella zoster) virus; ESR: erythrocyte sedimentation rate.</div><div id=\"graphicVersion\">Graphic 70269 Version 4.0</div></div></div>"},"70270":{"type":"graphic_picture","displayName":"Small bowel angiodysplasia","title":"Small bowel angiodysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel angiodysplasia</div><div class=\"cntnt\"><img style=\"width:448px; height:449px;\" src=\"images/GAST/70270_Vascular_malformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiodysplasia detected in the small bowel during double balloon enteroscopy.</div><div class=\"graphic_reference\">Courtesy of Hiroto Kita, MD, PhD.</div><div id=\"graphicVersion\">Graphic 70270 Version 2.0</div></div></div>"},"70271":{"type":"graphic_figure","displayName":"Wrist blocks","title":"Wrist blocks","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Wrist blocks</div><div class=\"cntnt\"><img style=\"width:536px; height:714px;\" src=\"images/SURG/70271_Wrist-blocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wrist block anesthetizes any of the ulnar, median, or radial nerves at the level of the wrist to perform surgery of the hand or fingers. Only a small amount of local anesthetic is needed. Epinephrine should not be added to the anesthetic due to the potential for hand ischemia.</div><div id=\"graphicVersion\">Graphic 70271 Version 5.0</div></div></div>"},"70273":{"type":"graphic_diagnosticimage","displayName":"FDG PET CT axilla","title":"FDG-PET/CT of metastatic disease in an axillary lymph node","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">FDG-PET/CT of metastatic disease in an axillary lymph node</div><div class=\"cntnt\"><img style=\"width:540px; height:262px;\" src=\"images/PULM/70273_FDG_PET_CT_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image demonstrates metastatic disease in an axillary lymph node as seen on an integrated 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) scan. The increased activity of the lymph node is the result of the uptake and accumulation of FDG by the metabolically active tumor cells.</div><div id=\"graphicVersion\">Graphic 70273 Version 4.0</div></div></div>"},"70276":{"type":"graphic_diagnosticimage","displayName":"Cylindrical bronchiectasis RLL","title":"Cylindrical bronchiectasis of right lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cylindrical bronchiectasis of right lower lobe</div><div class=\"cntnt\"><img style=\"width:355px; height:308px;\" src=\"images/PULM/70276_Cylindrical_bronchiectasi1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT shows mild dilatation of the posterobasal and laterobasal segmental bronchi in the right lower lobe (arrow). Multiple ill-defined, peripheral right lower lobe nodules are visible and represent mucous plugs in dilated subsegmental bronchi (arrowhead).</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70276 Version 3.0</div></div></div>"},"70279":{"type":"graphic_diagnosticimage","displayName":"TB tracheal stenosis CT","title":"Severe tracheal stenosis caused by tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe tracheal stenosis caused by tuberculosis</div><div class=\"cntnt\"><img style=\"width:388px; height:224px;\" src=\"images/PULM/70279_TB_tracheal_stenosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan shows critical narrowing of the lower trachea.</div><div id=\"graphicVersion\">Graphic 70279 Version 2.0</div></div></div>"},"70280":{"type":"graphic_figure","displayName":"Shoulder dystocia documentation form B","title":"Documentation of delivery complicated by shoulder dystocia, continued","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Documentation of delivery complicated by shoulder dystocia, continued</div><div class=\"cntnt\"><img style=\"width:525px; height:601px;\" src=\"images/OBGYN/70280_Shoulder_dystocia_doc_B.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70280 Version 2.0</div></div></div>"},"70281":{"type":"graphic_table","displayName":"Mgmt electrolyte abn TLS","title":"Management of electrolyte abnormalities in tumor lysis syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of electrolyte abnormalities in tumor lysis syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormality </td> <td class=\"subtitle1\">Management recommendation </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hyperphosphatemia </td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\">Moderate, &#8805;2.1 mmol/L (6.5 mg/dL) </td> <td>Restrict phosphate intake (avoid IV and oral phosphate; limit dietary sources)</td> </tr> <tr> <td class=\"sublist1_start\">Phosphate binders: </td> </tr> <tr> <td class=\"sublist1\"><strong>Calcium acetate</strong><sup>*</sup> Adult: 2 to 3 tabs (1334 to 2668 mg) with each meal; or </td> </tr> <tr> <td class=\"sublist1\"><strong>Calcium carbonate</strong>* Adult: 1 to 2 grams with each meal; Pediatric: 30 to 40 mg/kg with each meal; or </td> </tr> <tr> <td class=\"sublist1\"><strong>Sevelamer<sup>&#182;</sup></strong> Adult: 800 to 1600 mg with each meal; Pediatric: 40 to 54 mg/kg with each meal; or </td> </tr> <tr> <td class=\"sublist1\"><strong>Lanthanum carbonate </strong>Adult: 500 to 1000 mg with each meal<sup>&#916;</sup>; or </td> </tr> <tr> <td class=\"sublist1\"><strong>Aluminum hydroxide </strong>Adult: 300 to 600 mg with each meal; Pediatric: 12.5 to 37.5 mg/kg four times daily with meals; (avoid use in patients with renal insufficiency) </td> </tr> <tr> <td class=\"indent1\">Severe </td> <td>Dialysis, CAVH, CVVH, CAVHD, or CVVHD</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hypocalcemia, total serum calcium &#8804;1.75 mmol/L (7 mg/dL) or ionized calcium &#8804;0.8 mmol/L (3.2 mg/dL) </td> </tr> <tr> <td class=\"indent1\">Asymptomatic </td> <td>No therapy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Symptomatic </td> <td class=\"sublist1_start\">Calcium gluconate administered slowly with ECG monitoring; patients with acute hypocalcemia and hyperphosphatemia should not be treated with calcium until the hyperphosphatemia is corrected (unless they have tetany or a cardiac arrhythmia from hypocalcemia) </td> </tr> <tr> <td class=\"sublist1\"><strong>Calcium gluconate</strong><sup>&#9674;</sup> Adult: 1 gram (10 mL of 10 percent solution); Pediatric: 50 to 100 mg/kg. Slow IV infusion (maximum 50 to 100 mg per minute) in large vein. May be repeated after 5 to 10 minutes if symptoms or ECG changes persist. </td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hyperkalemia<sup>&#167; </sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Moderate and asymptomatic, &#8805;6.0 mmol/L </td> <td>Avoid IV and oral potassium</td> </tr> <tr> <td>ECG and cardiac rhythm monitoring</td> </tr> <tr> <td><strong>Sodium polystyrene sulfonate</strong><sup>&#165;</sup> Adult: 15 to 30 grams orally; Pediatric: 1 gram/kg orally. Onset 1 to 2 hours. Repeat every 4 to 6 hours up to four times daily as needed based on repeat serum K+ level.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"12\">Severe (&#62;7.0 mmol/L) and/or symptomatic </td> <td><strong>Same as above, plus:</strong></td> </tr> <tr> <td class=\"sublist1_start\">To stabilize cardiac membranes: </td> </tr> <tr> <td class=\"sublist1\">For patients with ECG changes (widening of the QRS complex or loss of p-waves but not peaked t-waves alone), <em>give calcium gluconate by slow IV infusion</em> to prevent life-threatening arrhythmias: </td> </tr> <tr> <td class=\"sublist2\"><strong>Calcium gluconate </strong>Adult: 1 gram (10 mL of 10 percent solution); Pediatric: 50 to 100 mg/kg. Slow IV infusion (maximum 50 to 100 mg per minute) in large vein. May be repeated after 5 to 10 minutes if ECG changes persist. </td> </tr> <tr> <td class=\"sublist1_start\">To temporarily shift potassium into cells: </td> </tr> <tr> <td class=\"sublist1\">Give IV insulin and dextrose: </td> </tr> <tr> <td class=\"sublist2\"><strong>IV insulin and dextrose </strong>Adult: regular insulin (10 units) IV plus 100 mL of a 50 percent dextrose solution (D50) IV; Pediatric: regular insulin (0.1 unit/kg) IV, plus 25 percent dextrose solution (D25) 0.5 gram/kg (2 mL/kg of D25) IV over thirty minutes. May be repeated after thirty to sixty minutes. Monitor fingerstick glucose closely. </td> </tr> <tr> <td class=\"sublist1\">Sodium bicarbonate can be given to induce influx of potassium into cells if patient is acidemic. Sodium bicarbonate and calcium solutions should not be administered through the same line due to incompatibility. </td> </tr> <tr> <td class=\"sublist2\"><strong>Sodium bicarbonate</strong> Adult: 45 to 50 mEq; Pediatric: 1 to 2 mEq/kg. Slow IV infusion over five to ten minutes. </td> </tr> <tr> <td class=\"sublist1\">Beta 2 agonist inhalation: Albuterol per nebulisation or metered dose inhaler </td> </tr> <tr> <td class=\"sublist2\"><strong>Albuterol</strong> Adult: 10 to 20 mg in 4 mL saline nebuilzed over 20 minutes or 10 to 20 puffs per metered dose inhaler over 10 to 20 minutes; Pediatric: 0.1 to 0.3 mg/kg per nebulisation. </td> </tr> <tr> <td>Dialysis</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">&nbsp; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Uremia (renal dysfunction) </td> </tr> <tr> <td rowspan=\"5\">&nbsp; </td> <td>Fluid and electrolyte management</td> </tr> <tr> <td>Uric acid and phosphate management</td> </tr> <tr> <td>Adjust renally excreted drug doses</td> </tr> <tr> <td>Dialysis (hemo- or peritoneal)</td> </tr> <tr> <td>Hemofiltration (CAVH, CVVH, CAVHD, or CVVHD)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pediatric dose should not exceed usual adult dose.</div><div class=\"graphic_footnotes\">IV: intravenous; CAVH: continuous arterial-venous hemofiltration; CVVH: continuous veno-venous hemofiltration; CAVHD: continuous arterial-venous hemodialysis; CVVHD: continuous veno-venous hemodialysis; ECG: electrocardiogram.<br />* Calcium-containing binders are generally preferred in presence of hypocalcemia; avoid if hypercalcemic.<br />¶&nbsp;Preferred binder in presence of hypercalcemia. <br />Δ A pediatric dose of lathanum carbonate 7 mg/kg with each meal has been suggested based on limited experience. US FDA product information states pediatric use is not recommended. <br />◊ 10% calcium gluconate (90 mg elemental calcium/10 mL) or 10% calcium chloride (270 mg elemental calcium/10 mL) can be used. Calcium gluconate is usually preferred because it is less likely to cause tissue necrosis if extravasated. For additional information refer to UpToDate topic on\"Treatment of hypocalcemia\".<br />§ For additional information,&nbsp;refer to UpToDate topic on&nbsp;\"Treatment and prevention of hyperkalemia in adults\".<br />¥ Patients receiving sodium polystyrene sulfonate should be monitored for the development of hypocalcemia and hypomagnesemia.</div><div class=\"graphic_reference\">Data from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.</div><div id=\"graphicVersion\">Graphic 70281 Version 4.0</div></div></div>"},"70282":{"type":"graphic_table","displayName":"Bacterial tracheitis clinical features","title":"Clinical findings in children with bacterial tracheitis: reported frequencies based upon six case series","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in children with bacterial tracheitis: reported frequencies based upon six case series</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Reported frequency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical findings</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>40&nbsp;to 70%</td> </tr> <tr> <td class=\"indent1\">Cough</td> <td>45&nbsp;to 95%</td> </tr> <tr> <td class=\"indent1\">Barking cough</td> <td>45&nbsp;to 50%</td> </tr> <tr> <td class=\"indent1\">Hoarseness</td> <td>30&nbsp;to 60%</td> </tr> <tr> <td class=\"indent1\">Drooling</td> <td>10%</td> </tr> <tr> <td class=\"indent1\">Stridor</td> <td>20&nbsp;to 90%</td> </tr> <tr> <td class=\"indent1\">Dyspnea</td> <td>70%</td> </tr> <tr> <td class=\"indent1\">Retractions</td> <td>30&nbsp;to 90%</td> </tr> <tr> <td class=\"indent1\">Wheezing</td> <td>10&nbsp;to 15%</td> </tr> <tr> <td class=\"indent1\">Cyanosis</td> <td>8&nbsp;to 30%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Toxic appearance</td> <td>10&nbsp;to 60%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\"><span class=\"subtitle2_single\"></span>Duration of symptoms before hospital admission<span class=\"subtitle2_left\"></span></td> <td>&nbsp;2&nbsp;to 2.5 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Radiographic findings</td> </tr> <tr> <td class=\"indent1\">Subglottic narrowing</td> <td>60&nbsp;to 100%</td> </tr> <tr> <td class=\"indent1\">Tracheal irregularity or membranes evident</td> <td>25&nbsp;to 90%</td> </tr> <tr> <td class=\"indent1\">Pulmonary infiltrates</td> <td>20&nbsp;to 80%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Liston SL, Gehrz RC, Jarvis CW. Bacterial tracheitis. Arch Otolaryngol 1981; 107:561.</LI>&#xD;&#xA;<LI>Gallagher PG, Myer CM 3rd. An approach to the diagnosis and treatment of membranous laryngotracheobronchitis in infants and children. Pediatr Emerg Care 1991; 7:337.</LI>&#xD;&#xA;<LI>Conley SF, Beste DJ, Hoffmann RG. Measles-associated bacterial tracheitis. Pediatr Infect Dis J 1993; 12:414.</LI>&#xD;&#xA;<LI>Salamone FN, Bobbitt DB, Myer CM, et al. Bacterial tracheitis reexamined: is there a less severe manifestation?. Otolaryngol Head Neck Surg 2004; 131:871.</LI>&#xD;&#xA;<LI>Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. Pediatrics 2006; 118:1418.</LI>&#xD;&#xA;<LI>Huang YL, Peng CC, Chiu NC, et al. Bacterial tracheitis in pediatrics: 12 year experience at a medical center in Taiwan. Pediatr Int 2009; 51:110.</LI></OL></div><div id=\"graphicVersion\">Graphic 70282 Version 5.0</div></div></div>"},"70283":{"type":"graphic_picture","displayName":"Gingivitis child","title":"Gingivitis in a 14-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingivitis in a 14-year-old child</div><div class=\"cntnt\"><img style=\"width:360px; height:243px;\" src=\"images/PEDS/70283_Gingivitis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque deposits are clearly visible on the teeth at the gingival margin. Erythematous and edematous areas can be seen along the gingival margin. Particularly severe gingivitis with a trace of spontaneous bleeding is seen around the erupting upper left canine tooth. This is due to inadequate plaque removal secondary to malposition and crowding, and to the inflammation associated with eruption.</div><div class=\"graphic_reference\">Courtesy of Ann Griffen, DDS, MS.</div><div id=\"graphicVersion\">Graphic 70283 Version 1.0</div></div></div>"},"70285":{"type":"graphic_table","displayName":"Promotion of general knowledge","title":"Suggestions for enhancing a child's cognitive and general knowledge skills before kindergarten entry","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggestions for enhancing a child's cognitive and general knowledge skills before kindergarten entry</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Parents can promote cognitive\nskills by asking their children to place information or objects* into\ncategories according to:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Function</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Size</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Color</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Shape</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Kind</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Parents can enhance\ntheir child's arithmetic skills by teaching them to:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Count by rote to 100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Understand number concepts to 10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Comprehend the concept of 'each'</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Identify a circle, triangle, and square</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Comprehend the concepts of\n'more than, less than, same'</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">\"Identify which group has\nmore/less/the\nsame amount\"</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Parents can help to\nincrease their children's knowledge of general, musical, artistic,\nscientific, historical, and literary information by:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Visiting museums, exhibits, zoos, and dramatic theatre</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Listening to audio-books-on-tape</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Viewing videos, television, and\nillustrated books with their child</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Discussing what they see or hear as\nthey take walks or drive along roadways</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">The following\ninstructional experiences may be beneficial in helping children learn\nto explain information precisely, respond to questions completely, and\nincrease attention to details:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Describe the attributes and\nfunctions of a familiar object or objects</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Respond to specific questions\nrelated to the name, color, size, use, etc of the object</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Respond to the\nfollowing questions related to situations, pictures of familiar\nobjects:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">What can you tell me about this?\n      </td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">What else can you tell me\nabout it?</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">What more can you think of to\ntell me about it?</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Are there any\nother things about it that are important?</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Eg, toys, laundry, groceries, etc.&#160;</div><div class=\"graphic_reference\">Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 70285 Version 1.0</div></div></div>"},"70287":{"type":"graphic_table","displayName":"Distribution of dengue virus","title":"Alphabetical listing of countries and territories with reported dengue transmission since 2000","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alphabetical listing of countries and territories with reported dengue transmission since 2000</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Anguilla</td> </tr> <tr> <td>Antigua and Barbuda</td> </tr> <tr> <td>Argentina</td> </tr> <tr> <td>Aruba</td> </tr> <tr> <td>Australia</td> </tr> <tr> <td>Bahamas</td> </tr> <tr> <td>Bangladesh</td> </tr> <tr> <td>Barbados</td> </tr> <tr> <td>Belize</td> </tr> <tr> <td>Bhutan</td> </tr> <tr> <td>Bolivia</td> </tr> <tr> <td>Brazil</td> </tr> <tr> <td>Brunei Darussalam</td> </tr> <tr> <td>Cambodia</td> </tr> <tr> <td>Cameroon&nbsp;</td> </tr> <tr> <td>Cape Verde</td> </tr> <tr> <td>Chile (Easter Island)</td> </tr> <tr> <td>China</td> </tr> <tr> <td>Colombia</td> </tr> <tr> <td>Cook Islands</td> </tr> <tr> <td>Costa Rica</td> </tr> <tr> <td>C&#244;te d'Ivoire</td> </tr> <tr> <td>Croatia</td> </tr> <tr> <td>Cuba</td> </tr> <tr> <td>Dominica</td> </tr> <tr> <td>Dominican Republic</td> </tr> <tr> <td>Ecuador</td> </tr> <tr> <td>El Salvador</td> </tr> <tr> <td>Fiji</td> </tr> <tr> <td>France</td> </tr> <tr> <td>French Guiana</td> </tr> <tr> <td>French Polynesia</td> </tr> <tr> <td>Gabon</td> </tr> <tr> <td>Grenada</td> </tr> <tr> <td>Guadeloupe</td> </tr> <tr> <td>Guatemala</td> </tr> <tr> <td>Guyana</td> </tr> <tr> <td>Haiti</td> </tr> <tr> <td>Honduras</td> </tr> <tr> <td>India</td> </tr> <tr> <td>Indonesia</td> </tr> <tr> <td>Jamaica</td> </tr> <tr> <td>Japan</td> </tr> <tr> <td>Kiribati</td> </tr> <tr> <td>Lao People's Democratic Republic</td> </tr> <tr> <td>Madagascar</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Malaysia</td> </tr> <tr> <td>Maldives&nbsp;</td> </tr> <tr> <td>Martinique</td> </tr> <tr> <td>Mauritius&nbsp;</td> </tr> <tr> <td>Mexico</td> </tr> <tr> <td>Micronesia</td> </tr> <tr> <td>Montserrat</td> </tr> <tr> <td>Myanmar</td> </tr> <tr> <td>Nepal</td> </tr> <tr> <td>New Caledonia</td> </tr> <tr> <td>New Zealand</td> </tr> <tr> <td>Nicaragua</td> </tr> <tr> <td>Northern Mariana Islands</td> </tr> <tr> <td>Pakistan</td> </tr> <tr> <td>Palau</td> </tr> <tr> <td>Panama</td> </tr> <tr> <td>Papua New Guinea</td> </tr> <tr> <td>Paraguay</td> </tr> <tr> <td>Peru</td> </tr> <tr> <td>Philippines</td> </tr> <tr> <td>Portugal (Madeira)</td> </tr> <tr> <td>Puerto Rico</td> </tr> <tr> <td>Rarotonga</td> </tr> <tr> <td>Samoa</td> </tr> <tr> <td>Saudi Arabia</td> </tr> <tr> <td>Senegal</td> </tr> <tr> <td>Singapore</td> </tr> <tr> <td>Solomon Islands</td> </tr> <tr> <td>Sri Lanka</td> </tr> <tr> <td>St. Kitts &#38; Nevis</td> </tr> <tr> <td>St. Lucia</td> </tr> <tr> <td>St. Vincent &#38; the Grenadines</td> </tr> <tr> <td>Suriname</td> </tr> <tr> <td>Tahiti</td> </tr> <tr> <td>Taiwan</td> </tr> <tr> <td>Thailand</td> </tr> <tr> <td>Timor-Leste</td> </tr> <tr> <td>Tonga</td> </tr> <tr> <td>Trinidad &#38; Tobago</td> </tr> <tr> <td>United States of America</td> </tr> <tr> <td>Vanuatu</td> </tr> <tr> <td>Venezuela</td> </tr> <tr> <td>Viet Nam</td> </tr> <tr> <td>Virgin Islands (UK)</td> </tr> <tr> <td>Virgin Islands (US)</td> </tr> <tr> <td>Yemen</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Alan L Rothman, MD.</div><div id=\"graphicVersion\">Graphic 70287 Version 3.0</div></div></div>"},"70292":{"type":"graphic_table","displayName":"Indications for fomepizole or ethanol therapy","title":"Indications for antidotal therapy with fomepizole or ethanol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for antidotal therapy with fomepizole or ethanol</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Documented serum methanol or ethylene glycol concentration &#62;20 mg/dL (methanol SI equivalent 6.2 mmol/L; ethylene glycol SI equivalent 3.2 mmol/L)</td> </tr> <tr> <td>OR</td> </tr> <tr> <td>Documented recent history of ingesting toxic amounts of methanol or ethylene glycol and serum osmol gap &#62;10</td> </tr> <tr> <td>OR</td> </tr> <tr> <td class=\"sublist1_start\">Strong clinical suspicion of methanol or ethylene glycol poisoning and at least two of the following:</td> </tr> <tr> <td class=\"sublist1\">a) Arterial pH &#60;7.3</td> </tr> <tr> <td class=\"sublist1\">b) Serum bicarbonate &#60;20 meq/L (mmol/L)</td> </tr> <tr> <td class=\"sublist1\">c) Osmol gap &#62;10</td> </tr> <tr> <td class=\"sublist1\">d) Urinary oxalate crystals present</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70292 Version 3.0</div></div></div>"},"70293":{"type":"graphic_table","displayName":"Causes of osteomalacia","title":"Causes of osteomalacia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of osteomalacia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Abnormal vitamin D metabolism</td> </tr> <tr> <td>(causing secondary hyperparathyroidism and hypophosphatemia)</td> </tr> <tr> <td class=\"subtitle2_single\">Deficient intake or absorption</td> </tr> <tr> <td class=\"indent1\">Dietary</td> </tr> <tr> <td class=\"indent1\">Inadequate sunlight exposure</td> </tr> <tr> <td class=\"indent1\">Malabsorption</td> </tr> <tr> <td class=\"indent1\">Gastrectomy or gastrointestinal bypass</td> </tr> <tr> <td class=\"indent1\">Small bowel disease</td> </tr> <tr> <td class=\"indent1\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Defective 25-hydroxylation</td> </tr> <tr> <td class=\"indent1\">Biliary cirrhosis</td> </tr> <tr> <td class=\"indent1\">Alcoholic cirrhosis</td> </tr> <tr> <td class=\"indent1\">Anticonvulsants</td> </tr> <tr> <td class=\"subtitle2_single\">Loss of vitamin D-binding protein</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Defective 1-alpha 25-hydroxylation</td> </tr> <tr> <td class=\"indent1\">Hypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Vitamin D-dependent rickets, type 1</td> </tr> <tr> <td class=\"subtitle2_single\">Defective target organ response to calcitriol</td> </tr> <tr> <td class=\"indent1\">Vitamin D-dependent rickets, type&nbsp;2 (Hereditary vitamin D-resistant rickets [HVDRR])</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mineralization defects</td> </tr> <tr> <td class=\"subtitle2_single\">Abnormal matrix</td> </tr> <tr> <td class=\"indent1\">Chronic renal failure</td> </tr> <tr> <td class=\"indent1\">Osteogenesis imperfecta</td> </tr> <tr> <td class=\"indent1\">Fibrogenesis imperfecta</td> </tr> <tr> <td class=\"indent1\">Axial osteomalacia</td> </tr> <tr> <td class=\"subtitle2_single\">Enzyme deficiency</td> </tr> <tr> <td class=\"indent1\">Hypophosphatasia</td> </tr> <tr> <td class=\"subtitle2_single\">Inhibitors of mineralization</td> </tr> <tr> <td class=\"indent1\">Fluoride</td> </tr> <tr> <td class=\"indent1\">Aluminium</td> </tr> <tr> <td class=\"indent1\">Bisphosphonates</td> </tr> <tr> <td class=\"subtitle1_single\">Phosphate deficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Decreased intake</td> </tr> <tr> <td class=\"indent1\">Antacids</td> </tr> <tr> <td class=\"subtitle2_single\">Impaired renal reabsorption</td> </tr> <tr> <td class=\"subtitle3_single\">Primary defects</td> </tr> <tr> <td class=\"indent2\">X-linked hypophosphatemic rickets (vitamin D-resistant rickets [VDRR])</td> </tr> <tr> <td class=\"indent2\">Hereditary hypophosphatemic rickets with hypercalciuria</td> </tr> <tr> <td class=\"indent2\">Sporadic acquired hypophosphatemic rickets</td> </tr> <tr> <td class=\"indent2\">Fanconi syndrome, Wilson disease, cystinosis, multiple myeloma</td> </tr> <tr> <td class=\"subtitle3_single\">Secondary defects</td> </tr> <tr> <td class=\"indent2\">Secondary hyperparathyroidism (renal tubular acidosis, type 1 and disorders of vitamin D metabolism)</td> </tr> <tr> <td class=\"indent2\">Tumor-induced osteomalacia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70293 Version 5.0</div></div></div>"},"70294":{"type":"graphic_diagnosticimage","displayName":"Follow up pancreatogram","title":"Residual pancreatic duct stricture following balloon dilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Residual pancreatic duct stricture following balloon dilation</div><div class=\"cntnt\"><img style=\"width:230px; height:357px;\" src=\"images/GAST/70294_Follow_up_pancreatogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow-up pancreatogram after balloon dilation of a pancreatic duct stricture shows an asymptomatic short stricture.</div><div class=\"graphic_reference\">Courtesy of Marc Catalano, MD.</div><div id=\"graphicVersion\">Graphic 70294 Version 3.0</div></div></div>"},"70296":{"type":"graphic_picture","displayName":"Trucut needle","title":"Trucut needle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trucut needle</div><div class=\"cntnt\"><img style=\"width:291px; height:478px;\" src=\"images/GAST/70296_Trucut_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trucut needle extending from the tip of the echoendoscope.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Mauritis J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 70296 Version 1.0</div></div></div>"},"70298":{"type":"graphic_figure","displayName":"Differences among antibodies","title":"Differences among antibodies (isotypic, allotypic, idiotypic)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Differences among antibodies (isotypic, allotypic, idiotypic)</div><div class=\"cntnt\"><img style=\"width:429px; height:627px;\" src=\"images/ALLRG/70298_Diff_among_antibodie_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Isotypic differences</strong> are differences between isotypes of antibodies within a species. For example, the differences between human immunoglobulin G (IgG) and human immunoglobulin A (IgA) are collectively referred to as isotypic differences. Anti-isotypic antibodies could be used to distinguish human IgG from human IgA, but not between IgG from two individuals.<br /><strong>Allotypic differences</strong> exist between antibodies (eg, IgG) from two members of the same species. These differences are due to the presence of multiple alleles of genes within the constant domains of antibodies.<br /><strong>Idiotypic differences</strong> exist between antibodies of the same class within an individual. These arise from the many unique sequences within the variable regions that are generated by the rearrangement of VH and VL genes.</div><div class=\"graphic_footnotes\">VH: heavy chain variable region; VL: light chain variable region.</div><div id=\"graphicVersion\">Graphic 70298 Version 4.0</div></div></div>"},"70299":{"type":"graphic_figure","displayName":"Fiberoptic endotracheal intubation","title":"Fiberoptic endotracheal intubation","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Fiberoptic endotracheal intubation</div><div class=\"cntnt\"><img style=\"width:536px; height:627px;\" src=\"images/EM/70299_Fiberopticendotrachintub.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Once the glottis is identified, the fiberoptic bronchoscope is advanced into the trachea to the level of the carina with the assistance of a standard laryngoscope.<br> (B) Using the fiberoptic bronchoscope as a guide, the endotracheal tube is inserted into the trachea.<br> (C) The bronchoscope is carefully removed while the endotracheal tube is held securely in place.</div><div class=\"graphic_reference\">Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70299 Version 7.0</div></div></div>"},"70300":{"type":"graphic_picture","displayName":"Cutaneous small vessel vasculitis - palpable purpura","title":"Cutaneous small vessel vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous small vessel vasculitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70300_Leukocyto_vasc_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpura.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70300 Version 4.0</div></div></div>"},"70301":{"type":"graphic_table","displayName":"Rush VIT - One-day protocol","title":"One-day rush schedule for venom immunotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">One-day rush schedule for venom immunotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time (min)</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Concentration (micrograms/mL)</td> </tr> <tr> <td>0</td> <td>0.05</td> <td>1</td> </tr> <tr> <td>15</td> <td>0.1</td> <td>1</td> </tr> <tr> <td>30</td> <td>0.2</td> <td>1</td> </tr> <tr> <td>45</td> <td>0.4</td> <td>1</td> </tr> <tr> <td>60</td> <td>0.08</td> <td>10</td> </tr> <tr> <td>75</td> <td>0.2</td> <td>10</td> </tr> <tr> <td>90</td> <td>0.5</td> <td>10</td> </tr> <tr> <td>105</td> <td>0.1</td> <td>100</td> </tr> <tr> <td>120</td> <td>0.2</td> <td>100</td> </tr> <tr> <td>135</td> <td>0.2</td> <td>100</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=93561&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Once the above doses have been administered, the patient receives weekly injections to continue the build-up for the next eight weeks. After that, injections are administered once every four weeks.</div><div class=\"graphic_reference\">Reproduced from: Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73:423. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70301 Version 7.0</div></div></div>"},"70302":{"type":"graphic_figure","displayName":"Blunt mobilization of the right colon","title":"Blunt mobilization of the right colon from retroperitoneal structures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blunt mobilization of the right colon from retroperitoneal structures</div><div class=\"cntnt\"><img style=\"width:368px; height:332px;\" src=\"images/SURG/70302_Blunt-mobilize.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates blunt dissction of the space between the peritoneum of the ascending colon and the underlying retroperitoneal structures (eg, kidney, ureter, gonadal vessels).</div><div id=\"graphicVersion\">Graphic 70302 Version 3.0</div></div></div>"},"70303":{"type":"graphic_table","displayName":"Retinoids for photoaging","title":"Topical retinoids for treatment of photoaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical retinoids for treatment of photoaging</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Topical retinoid</td> <td class=\"subtitle1\">Dose forms</td> </tr> <tr> <td>Tretinoin</td> <td> <p>Avita (0.025% cream and gel)</p> <p>Atralin (0.05% gel)</p> <p>Refissa (0.05% cream)</p> <p>Renova (0.02% cream)</p> <p>Retin-A (0.025%, 0.05%, 0.1% cream; 0.01%, 0.025% gel)</p> <p>Retin-A Micro (0.04% and 0.1% microsphere gel)</p> <p>Tretin-X (0.025%, 0.05%, 0.1% cream; 0.01%, 0.025% gel)</p> </td> </tr> <tr class=\"divider_top\"> <td>Tazarotene</td> <td> <p>Tazorac (0.05%, 0.1% gel and cream)</p> <p>Avage (0.1% cream)</p> </td> </tr> <tr class=\"divider_top\"> <td>Adapalene (off-label use)</td> <td> <p>Differin (0.1% gel, cream, and lotion; 0.3% gel)</p> <p>Generic adapalene (0.1% gel, cream, and lotion; 0.3% gel)</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Chien A, Voorhees JJ, King S. Topical retinoids. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA (Ed), McGraw-Hill, 2012.</div><div id=\"graphicVersion\">Graphic 70303 Version 2.0</div></div></div>"},"70305":{"type":"graphic_diagnosticimage","displayName":"Aortic dissection on noninvasive imaging","title":"Aortic dissection on noninvasive imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic dissection on noninvasive imaging</div><div class=\"cntnt\"><img style=\"width:353px; height:327px;\" src=\"images/CARD/70305_Noninvasive_imaging_dissect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative transesophageal echocardiograms (TEE) (panels A and B) and computed tomograms (CT) (panels C and D) of a section of the descending aorta in distal aortic dissection. Panels A and C are acute studies, while B and D are from follow-up evaluation. Both TEE and CT scan show persistence of the intimal flap forming the true lumen (TL) and a markedly dilated false lumen (FL) with the development of thrombi.</div><div class=\"graphic_reference\">From Song, JK, Kang, DH, Lim, TH, et al. Different remodeling of descending thoracic aorta after acute event in aortic intramural hemorrage versus aortic dissection. Am J Cardiol 1999; 83:937 with permission from Excerpta Medica Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 70305 Version 3.0</div></div></div>"},"70306":{"type":"graphic_figure","displayName":"Modified Allen test","title":"Modified Allen test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Allen test</div><div class=\"cntnt\"><img style=\"width:361px; height:265px;\" src=\"images/PULM/70306_Modified_Allen_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient's hand is initially held high while the fist is clenched and both radial and ulnar arteries are compressed (A); this allows the blood to drain from the hand. The hand is then lowered (B) and the fist is opened (C). After pressure is released over the ulnar artery (D), color should return to the hand within six seconds, indicating a patent ulnar artery and an intact superficial palmar arch.</div><div class=\"graphic_reference\">Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.</div><div id=\"graphicVersion\">Graphic 70306 Version 1.0</div></div></div>"},"70307":{"type":"graphic_table","displayName":"Pulmonary biopsies in farmers","title":"Summary of the morphologic features in pulmonary biopsies of farmer's lung patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the morphologic features in pulmonary biopsies of farmer's lung patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Morphologic criteria</td>\n\n      <td class=\"subtitle1\">Percent of cases</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interstitial infiltrate</td>\n\n      <td>100</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unresolved pneumonia</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Interstitial fibrosis</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bronchiolitis obliterans</td>\n\n      <td>50</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pleural fibrosis</td>\n\n      <td>48</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Foam cells</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Edema</td>\n\n      <td>52</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Granulomas</td>\n\n      <td class=\"sublist_other_start\">70</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">With giant cells*</td>\n\n      <td class=\"sublist_other\">50</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Without giant cells</td>\n\n      <td class=\"sublist_other\">58</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Solitary giant cells</td>\n\n      <td>53</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Foreign bodies</td>\n\n      <td class=\"sublist_other_start\">60</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Birefringent*</td>\n\n      <td class=\"sublist_other\">47</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Non-birefringent</td>\n\n      <td class=\"sublist_other\">40</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* The discrepancy in the total numbers is due to the fact that in some cases, granulomas with and without giant cells may be found. This discrepancy also applies to the foreign bodies.</div><div class=\"graphic_reference\">Adapted from: Reyes, CN, Wenzel, FJ, Lawton, BR, Emanuel, DA. Chest 1982; 82:142.</div><div id=\"graphicVersion\">Graphic 70307 Version 1.0</div></div></div>"},"70309":{"type":"graphic_table","displayName":"Potential nonallergic triggers for mast cell activation","title":"Potential nonallergic triggers for mast cell activation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential nonallergic triggers for mast cell activation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Insect stings, envenomations</td> </tr> <tr> <td class=\"indent1\">Hymenoptera</td> </tr> <tr> <td class=\"indent1\">Jellyfish</td> </tr> <tr> <td class=\"indent1\">Snakes</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Narcotic analgesics (eg, codeine, morphine)</td> </tr> <tr> <td class=\"indent1\">Radiocontrast materials</td> </tr> <tr> <td class=\"indent1\">Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Muscle relaxants</td> </tr> <tr> <td class=\"indent1\">Some antibiotics (eg, vancomycin)</td> </tr> <tr> <td class=\"subtitle1_single\">Changes in temperature</td> </tr> <tr> <td class=\"indent1\">Heat, cold</td> </tr> <tr> <td class=\"subtitle1_single\">Mechanical irritation</td> </tr> <tr> <td class=\"indent1\">Massage, friction, pressure</td> </tr> <tr> <td class=\"subtitle1_single\">Invasive procedures (eg, surgery, biopsies, endoscopy)</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Emotional stress</td> </tr> <tr> <td class=\"indent1\">Exercise</td> </tr> <tr> <td class=\"indent1\">Spicy foods</td> </tr> <tr> <td class=\"indent1\">Infections (viral, bacterial, parasitic)</td> </tr> <tr> <td class=\"indent1\">Fever</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70309 Version 11.0</div></div></div>"},"70311":{"type":"graphic_table","displayName":"X-linked adrenoleukodystrophy","title":"X-linked adrenoleukodystrophy (X-ALD) phenotypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">X-linked adrenoleukodystrophy (X-ALD) phenotypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phenotypes</td> <td class=\"subtitle1\">Total ALD (%)</td> <td class=\"subtitle1\">Symptoms and signs</td> <td class=\"subtitle1\">Age at presentation (years)</td> <td class=\"subtitle1\">Misdiagnosed as</td> <td class=\"subtitle1\">Diagnostic tests</td> <td class=\"subtitle1\">Follow-up tests</td> <td class=\"subtitle1\">Usual therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Males</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"8\">Childhood cerebral ALD</td> </tr> <tr> <td class=\"indent2\">Asymptomatic with normal MRI</td> <td>Increasing</td> <td> <ul> <li>None </li> </ul> </td> <td>0 to &#8805;10</td> <td> <ul> <li>Normal </li> </ul> </td> <td> <ul> <li>Usually comes to light through newborn screening or testing family member of a patient with X-ALD </li> <li>Confirm with DNA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>Monitor MRI </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Corticosteroid replacement therapy, if indicated </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Asymptomatic with abnormal MRI</td> <td>Increasing</td> <td> <ul> <li>None (cognition normal) </li> </ul> </td> <td>2 to &#8805;10</td> <td> <ul> <li>Other white matter disorders </li> </ul> </td> <td> <ul> <li>VLCFA levels </li> <li>Brain MRI </li> <li>Confirm diagnosis with DNA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>Neurologic and neuropsychological testing </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>HCT </li> <li>Corticosteroid replacement therapy, if indicated </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Mild cerebral ALD without AMN</td> <td>45</td> <td> <ul> <li>Behavior changes </li> <li>School failure </li> <li>Dementia </li> <li>Audiovisual changes </li> </ul> </td> <td>3 to 10; rarely presents at age &#62;15 years</td> <td> <ul> <li>ADHD </li> <li>Psychological disorder </li> <li>Autism </li> </ul> </td> <td> <ul> <li>VLCFA levels </li> <li>Brain MRI </li> <li>Confirm diagnosis with DNA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>Neurologic and neuropsychological testing </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>HCT </li> <li>Corticosteroid replacement therapy, if indicated </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Severe cerebral ALD without AMN</td> <td>2 to 3</td> <td> <ul> <li>Dementia </li> <li>Psychoses </li> <li>Paralysis </li> <li>Epilepsy </li> <li>Loss of vision </li> <li>Loss of speech </li> <li>Bulbar palsy </li> </ul> </td> <td>5 to adulthood</td> <td> <ul> <li>Other neurodegenerative diseases </li> <li>Brain tumor </li> <li>Psychosis </li> <li>Epilepsy </li> </ul> </td> <td> <ul> <li>VLCFA levels </li> <li>Brain MRI </li> <li>Confirm diagnosis with DNA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>Neurologic and neuropsychological testing </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Corticosteroid replacement therapy, if indicated </li> <li>Supportive care </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"8\">Adrenomyeloneuropathy (AMN)</td> </tr> <tr> <td class=\"indent2\">Pure AMN</td> <td>35</td> <td> <ul> <li>Paraparesis </li> <li>Sphincter disturbances </li> <li>Sensory changes </li> <li>Incoordination </li> <li>Leg pain </li> <li>Erectile dysfunction </li> </ul> </td> <td>20 to 40</td> <td> <ul> <li>Multiple sclerosis </li> <li>Progressive spastic paraparesis </li> <li>Cervical spondylosis </li> <li>Osteoarthritis </li> <li>Back injury </li> <li>ALS </li> <li>Allgrove syndrome </li> </ul> </td> <td> <ul> <li>VLCFA levels </li> <li>Confirm with DNA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>Brain MRI </li> <li>MTS </li> <li>SSEP </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Corticosteroid replacement therapy, if indicated </li> <li>Physical therapy </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Cerebral AMN</td> <td>15 (increases with age)</td> <td>Like pure AMN plus: <ul class=\"decimal_heading\"> <li>Dementia </li> <li>Behavioral disturbances </li> <li>Psychosis </li> <li>Epilepsy </li> <li>Aphasia </li> <li>Visual loss </li> <li>Bulbar palsy </li> </ul> </td> <td>20 to 40</td> <td> <ul> <li>Other causes of dementia </li> <li>Other neurodegenerative diseases </li> <li>Brain tumor </li> <li>Schizophrenia </li> <li>Alzheimer disease </li> <li>Cerebrovascular disease </li> <li>Epilepsy </li> <li>Alcoholism </li> <li>Drug dependency </li> </ul> </td> <td> <ul> <li>VLCFA levels </li> <li>Brain MRI </li> <li>Confirm with DNA testing </li> </ul> </td> <td>As in pure AMN plus: <ul class=\"decimal_heading\"> <li>Neurologic and neuropsychological testing </li> <li>EEG </li> <li>Psychiatry evaluation </li> </ul> </td> <td> <ul> <li>Corticosteroid replacement therapy, if indicated </li> <li>Physical therapy for AMN symptoms </li> <li>Supportive care </li> <li>Possibly HCT* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Cerebellar</td> <td>2 to 3</td> <td> <ul> <li>Ataxia </li> <li>Brainstem signs </li> </ul> </td> <td>Childhood; adolescence</td> <td> <ul> <li>Olivopontocerebellar degeneration </li> </ul> </td> <td> <ul> <li><span style=\"color: black;\">VLCFA levels</span> </li> <li><span style=\"color: black;\">Brain MRI </span></li> <li>Confirm with DNA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>Neurologic testing </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Corticosteroid replacement therapy, if indicated </li> <li>Physical therapy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"8\">Addison disease only</td> </tr> <tr> <td class=\"indent2\">Addison disease with normal MRI</td> <td>20 (decreases with age)</td> <td> <ul> <li>Primary adrenocortical insufficiency </li> </ul> </td> <td>0 to &#8805;10</td> <td> <ul> <li>Other causes of Addison disease </li> </ul> </td> <td> <ul> <li>Adrenal function <span style=\"color: black;\">tests </span></li> <li><span style=\"color: black;\">VLCFA levels </span></li> <li><span style=\"color: black;\">Confirm with DNA testing </span></li> </ul> </td> <td> <ul> <li><span style=\"color: black;\">Monitor MRI </span></li> <li><span style=\"color: black;\">Neurologic and neuropsychological testing </span></li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Corticosteroid replacement therapy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Addison disease with abnormal MRI</td> <td>1</td> <td> <ul> <li>Primary adrenocortical insufficiency </li> </ul> </td> <td>0 to &#8805;10</td> <td> <ul> <li>Other causes of Addison disease </li> </ul> </td> <td> <ul> <li>Adrenal function <span style=\"color: black;\">tests </span></li> <li><span style=\"color: black;\">VLCFA levels </span></li> <li>Brain MRI </li> <li>Confirm with DNA testing </li> </ul> </td> <td> <ul> <li>Neurologic and neuropsychological testing </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>HCT </li> <li>Corticosteroid replacement therapy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Females heterozygous for ALD</td> </tr> <tr> <td class=\"indent1\">Asymptomatic (normal neurology)</td> <td>50 (estimated)</td> <td> <ul> <li>None </li> </ul> </td> <td>Younger women tend to be asymptomatic<sup>&#182;</sup></td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>DNA testing is required for diagnosis </li> <li>False negatives can occur with VLCFA testing </li> </ul> </td> <td> <ul> <li>Neurologic examination </li> <li>Adrenal function tests </li> <li>Monitor MRI </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Genetic counseling </li> <li>General support </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Symptomatic (neurological abnormalities)</td> <td>50 (estimated)</td> <td> <ul> <li>Paraparesis </li> <li>Sphincter disturbances </li> <li>Leg pain </li> <li>Sensory disturbances </li> <li>Incoordination </li> <li>Fatigue </li> </ul> </td> <td>Rare in women &#60;30 years old; frequency rises sharply with age<sup>&#182;</sup></td> <td> <ul> <li>Multiple sclerosis </li> <li>Spastic paraparesis </li> <li>Peripheral neuropathy </li> <li>Cervical spondylosis </li> <li>Back injury </li> <li>Arthritis </li> <li>Herniated disk </li> </ul> </td> <td> <ul> <li>DNA testing is required for diagnosis </li> <li>False negatives can occur with VLCFA testing </li> </ul> </td> <td> <ul> <li>Adrenal function tests </li> <li>MTS </li> <li>SSEP </li> <li>Family screening </li> </ul> </td> <td> <ul> <li>Genetic counseling </li> <li>Physical therapy </li> <li>Corticosteroid replacement therapy, if indicated </li> <li>General support </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Percentages listed above vary by age group, as the asymptomatic and Addison disease groups decline with age while the ALD and AMN groups increase.</div><div class=\"graphic_footnotes\">ALD: adrenoleukodystrophy; MRI: magnetic resonance imaging; DNA: deoxyribonucleic acid; VLCFA: very long chain fatty acids assay in plasma; AMN: adrenomyeloneuropathy; ADHD: attention deficit hyperactivity disorder; HCT: hematopoietic stem cell transplant; ALS: amyotrophic lateral sclerosis; N/A: not applicable; MTS: magnetization transfer MRI cervical cord; SSEP: somatosensory evoked potential; EEG: electroencephalogram.<br />* HCT may be an option for some adult patients with AMN who have mild cerebral involvement. Refer to UpToDate topic on adrenoleukodystrophy for additional details.<br />¶ The frequency of symptoms rises from &lt;20% in women under 40 years of age, to almost 90% in women older than 60 years.</div><div class=\"graphic_reference\">Adapted with permission from: Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 2005; 294:3131. Copyright © 2005 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70311 Version 22.0</div></div></div>"},"70312":{"type":"graphic_table","displayName":"Lipid lowering tx PI","title":"Lipid lowering medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lipid lowering medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Brand name</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Statins</td> </tr> <tr> <td class=\"indent1\">Atorvastatin</td> <td>Lipitor</td> </tr> <tr> <td class=\"indent1\">Fluvastatin</td> <td>Lescol, Lescol XL</td> </tr> <tr> <td class=\"indent1\">Lovastatin</td> <td>Mevacor, Altoprev</td> </tr> <tr> <td class=\"indent1\">Pitavastatin</td> <td>Livalo</td> </tr> <tr> <td class=\"indent1\">Pravastatin</td> <td>Pravachol</td> </tr> <tr> <td class=\"indent1\">Rosuvastatin</td> <td>Crestor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Simvastatin</td> <td>Zocor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">PCSK9 inhibitors</td> </tr> <tr> <td class=\"indent1\">Alirocumab</td> <td>Praluent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Evolocumab</td> <td>Repatha, Repatha SureClick</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cholesterol absorption inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ezetimibe</td> <td>Zetia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bile acid sequestrants</td> </tr> <tr> <td class=\"indent1\">Cholestyramine</td> <td>Prevalite, Questran, Questran Light</td> </tr> <tr> <td class=\"indent1\">Colesevelam</td> <td>Welchol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Colestipol</td> <td>Colestid</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Niacin (nicotinic acid)</td> </tr> <tr> <td class=\"indent1\">Niacin immediate release</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Niacin extended release</td> <td>Niaspan</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fibrates</td> </tr> <tr> <td class=\"indent1\">Fenofibrate</td> <td>Fenoglide, Tricor, Triglide, others</td> </tr> <tr> <td class=\"indent1\">Gemfibrozil</td> <td>Lopid</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Brand names listed are for medicines available in the United States and some other countries.</div><div id=\"graphicVersion\">Graphic 70312 Version 4.0</div></div></div>"},"70313":{"type":"graphic_table","displayName":"Symptoms serious disease","title":"Symptoms suggesting serious disease in patients with neck pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms suggesting serious disease in patients with neck pain</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>History of recent significant fall or major trauma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Unexplained weight loss</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fever or chills</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>History of cancer</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Immunosuppression</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intravenous drug use</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chronic steroid use</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Neurological signs or symptoms (arm clumsiness, gait difficulty, bowel or bladder dysfunction, Babinski's sign)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 70313 Version 1.0</div></div></div>"},"70318":{"type":"graphic_figure","displayName":"Cutaneous continent reservoir PI","title":"Cutaneous continent reservoir (also called an Indiana pouch)","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Cutaneous continent reservoir (also called an Indiana pouch)</div><div class=\"cntnt\"><img style=\"width:464px; height:652px;\" src=\"images/PI/70318_Cont_reservoir_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts one option for people who have a cystectomy (bladder removal) for bladder treatment. A reservoir (like a pouch) may be created under the skin of the abdomen using tissue from the stomach or intestines. Urine collects in the pouch, and the patient uses a catheter (a thin tube) to empty the pouch periodically. It is not necessary to wear a drainage bag. This is called a continent cutaneous diversion (commonly referred to as an Indiana pouch).</div><div id=\"graphicVersion\">Graphic 70318 Version 4.0</div></div></div>"},"70319":{"type":"graphic_diagnosticimage","displayName":"Primary tracheal tumor CT","title":"Primary tracheal tumor from a minor salivary gland in 49-year-old male","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary tracheal tumor from a minor salivary gland in 49-year-old male</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/ONC/70319_Primary_tracheal_tumor_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of patient who was treated with primary resection and adjuvant radiotherapy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of James R Jett, MD.</div><div id=\"graphicVersion\">Graphic 70319 Version 4.0</div></div></div>"},"70320":{"type":"graphic_picture","displayName":"Atypical nevi borders","title":"Atypical nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical nevus</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/70320_Atypicalneviborders.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical nevus with irregular pigmentation and borders.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 70320 Version 3.0</div></div></div>"},"70323":{"type":"graphic_diagnosticimage","displayName":"CT chondro","title":"Computed tomography image of mesenchymal chondrosarcoma arising from the posterior chest wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography image of mesenchymal chondrosarcoma arising from the posterior chest wall</div><div class=\"cntnt\"><img style=\"width:396px; height:323px;\" src=\"images/ONC/70323_CT_chondro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The large tumor contains extensive areas of matrix mineralization. Aggressive lytic destruction of the posterior part of the rib and the thoracic vertebral body is noted. Histology of these lytic areas shows undifferentiated small round cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright ©2008 AlphaMed Press.</div><div class=\"contractual\"><br/><a href=\"http://www.theoncologist.com/\">http://www.TheOncologist.com</a></div><div id=\"graphicVersion\">Graphic 70323 Version 3.0</div></div></div>"},"70325":{"type":"graphic_figure","displayName":"Cyanosis and Hgb concentration","title":"Cyanosis and hemoglobin concentration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cyanosis and hemoglobin concentration</div><div class=\"cntnt\"><img style=\"width:376px; height:371px;\" src=\"images/PEDS/70325_Cyanosis_and_Hgb_concentrat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arterial oxygen saturation level at which cyanosis is detectable at different total hemoglobin concentrations is illustrated above. The solid red portion of each bar represents 3 g/dL reduced hemoglobin.</div><div class=\"graphic_reference\">Reproduced with permission from: Lees MH. Cyanosis of the newborn infant. J Pediatr 1970; 77:484. Copyright &#169;1970 Mosby.</div><div id=\"graphicVersion\">Graphic 70325 Version 2.0</div></div></div>"},"70326":{"type":"graphic_table","displayName":"Hemodynamic values of normal recumbent adults","title":"Hemodynamic values of normal recumbent adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic values of normal recumbent adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">Range</td> </tr> <tr> <td>Cardiac index, liters/min/m<sup>2</sup></td> <td>3.4</td> <td>2.8-4.2</td> </tr> <tr class=\"divider_top\"> <td>Stroke volume index, mL/m<sup>2</sup>/beat</td> <td>47</td> <td>30-65</td> </tr> <tr class=\"divider_top\"> <td>Arteriovenous oxygen difference, mL per liter of blood</td> <td>38</td> <td>30-48</td> </tr> <tr class=\"divider_top\"> <td>Arterial saturation, percent</td> <td>98</td> <td>94-100</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\" colspan=\"3\">Pressure*, mmHg</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Left ventricle</td> </tr> <tr> <td class=\"sublist2\">Systolic</td> <td class=\"sublist_other\">130</td> <td class=\"sublist_other\">90-140</td> </tr> <tr> <td class=\"sublist2\">End-diastolic</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">4-12</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Left atrium</td> </tr> <tr> <td class=\"sublist2\">Maximum</td> <td class=\"sublist_other\">13</td> <td class=\"sublist_other\">6-20</td> </tr> <tr> <td class=\"sublist2\">Minimum</td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">-2-+9</td> </tr> <tr> <td class=\"sublist2\">Mean</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">4-12</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Pulmonary artery wedge (\"PC\")</td> </tr> <tr> <td class=\"sublist2\">Maximum</td> <td class=\"sublist_other\">16</td> <td class=\"sublist_other\">9-23</td> </tr> <tr> <td class=\"sublist2\">Minimum</td> <td class=\"sublist_other\">6</td> <td class=\"sublist_other\">1-12</td> </tr> <tr> <td class=\"sublist2\">Mean</td> <td class=\"sublist_other\">9</td> <td class=\"sublist_other\">6-15</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Pulmonary artery</td> </tr> <tr> <td class=\"sublist2\">Systolic</td> <td class=\"sublist_other\">24</td> <td class=\"sublist_other\">15-28</td> </tr> <tr> <td class=\"sublist2\">Diastolic</td> <td class=\"sublist_other\">10</td> <td class=\"sublist_other\">5-16</td> </tr> <tr> <td class=\"sublist2\">Mean</td> <td class=\"sublist_other\">16</td> <td class=\"sublist_other\">10-22</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Right ventricle</td> </tr> <tr> <td class=\"sublist2\">Systolic</td> <td class=\"sublist_other\">24</td> <td class=\"sublist_other\">15-28</td> </tr> <tr> <td class=\"sublist2\">End-diastolic</td> <td class=\"sublist_other\">4</td> <td class=\"sublist_other\">0-8</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Right atrium</td> </tr> <tr> <td class=\"sublist2\">Maximum</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">2-14</td> </tr> <tr> <td class=\"sublist2\">Minimum</td> <td class=\"sublist_other\">2</td> <td class=\"sublist_other\">-2-+6</td> </tr> <tr> <td class=\"sublist2\">Mean</td> <td class=\"sublist_other\">4</td> <td class=\"sublist_other\">-1-+8</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Venae cavae</td> </tr> <tr> <td class=\"sublist2\">Maximum</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">2-14</td> </tr> <tr> <td class=\"sublist2\">Minimum</td> <td class=\"sublist_other\">5</td> <td class=\"sublist_other\">0-8</td> </tr> <tr> <td class=\"sublist2\">Mean</td> <td class=\"sublist_other\">6</td> <td class=\"sublist_other\">1-10</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">End-diastolic volume index</td> </tr> <tr> <td class=\"sublist2\">Left ventricular, mL/m<sup>2</sup></td> <td class=\"sublist_other\">70</td> <td class=\"sublist_other\">50-90</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Resistance, dyn&#8226;s/cm<sup>5</sup></td> </tr> <tr> <td class=\"sublist2\">Total systemic</td> <td class=\"sublist_other\">1150</td> <td class=\"sublist_other\">900-1400</td> </tr> <tr> <td class=\"sublist2\">Systemic arteriolar</td> <td class=\"sublist_other\">850</td> <td class=\"sublist_other\">600-900</td> </tr> <tr> <td class=\"sublist2\">Total pulmonary</td> <td class=\"sublist_other\">200</td> <td class=\"sublist_other\">150-250</td> </tr> <tr> <td class=\"sublist2\">Pulmonary arteriolar</td> <td class=\"sublist_other\">70</td> <td class=\"sublist_other\">45-120</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Baseline for pressure measurements one-half of anteroposterior chest diameter. 1 mmHg = 133.332 Pascal (PA) = 0.133 kPa.</div><div class=\"graphic_reference\">Reproduced with permission from: Hurst JW, Rackley CE, Sonnenblick EH, Wenger NK. The Heart: Arteries and veins. 7th ed. McGraw-Hill, Inc, New York 1990. Copyright © 1990 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 70326 Version 18.0</div></div></div>"},"70327":{"type":"graphic_table","displayName":"Infant feeding guide","title":"Infant feeding guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infant feeding guide</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Food</td> <td class=\"subtitle1\" colspan=\"5\">Age (months)</td> </tr> <tr> <td class=\"subtitle2\">0 to 4</td> <td class=\"subtitle2\">4 to 6</td> <td class=\"subtitle2\">6 to 8</td> <td class=\"subtitle2\">8 to 10</td> <td class=\"subtitle2\">10 to 12</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Breast milk</p> <p>(#feedings)</p> </td> <td> <p>Frequent feedings</p> <p>(8 to 12)</p> </td> <td> <p>Frequent feedings</p> <p>(4 to 6)</p> </td> <td> <p>On demand</p> <p>(3 to 5)</p> </td> <td>On demand</td> <td>On demand</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Iron-fortified formula</p> <p>(#feedings)</p> </td> <td> <p>16 to 32 oz</p> <p>(8 to 12)</p> </td> <td> <p>24 to 40 oz</p> <p>(4 to 6)</p> </td> <td> <p>24 to 32 oz</p> <p>(3 to 5)</p> </td> <td> <p>16 to 32 oz</p> <p>(3 to 4)</p> </td> <td> <p>16 to 24 oz</p> <p>(3 to 4)</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Cereals, bread</td> <td>None</td> <td>None</td> <td> <p>Infant cereal</p> <p>1 to 4&nbsp;tablespoons twice per day</p> </td> <td> <p>Infant cereals</p> <p>Cream of wheat</p> <p>Other plain hot cereals</p> <p>Toast, bagel, crackers</p> <p>2 to 3 servings/day*</p> </td> <td> <p>Unsweetened hot or cold cereals</p> <p>Bread</p> <p>Rice</p> <p>Noodles</p> <p>4 servings/day*</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Fruit</td> <td>None</td> <td>None</td> <td> <p>Fresh/cooked pur&#233;ed fruits</p> <p>Mashed bananas</p> <p>Applesauce</p> <p>1/2 cup per day</p> </td> <td> <p>Peeled, soft fruit wedges</p> <p>Bananas, peaches, pears, oranges, apples</p> <p>1 to 2 servings/day*</p> </td> <td> <p>All fresh fruits, peeled and seeded</p> <p>Canned fruits, packed in water or fruit juice</p> <p>2 servings/day*</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Vegetables</td> <td>None</td> <td>None</td> <td> <p>Strained or mashed vegetables</p> <p>Dark yellow, orange, or green (avoid corn)</p> <p>1/2 cup per day</p> </td> <td> <p>Cooked and mashed fresh or frozen vegetables</p> <p>1 to 2 servings/day*</p> </td> <td> <p>Cooked vegetable pieces</p> <p>2 servings/day*</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Protein foods</td> <td>None</td> <td>None</td> <td> <p>Pur&#233;ed meats</p> <p>1 to 2 servings per day*</p> </td> <td> <p>Lean meat, chicken, or fish (strained, chopped, or small tender pieces)</p> <p>Egg yolk</p> <p>Cooked dried beans</p> <p>3 to 4&nbsp;servings per day*</p> </td> <td> <p>Small tender pieces of meat, chicken, or fish (1 to 2 oz)</p> <p>Egg yolk</p> <p>Cheese</p> <p>Cooked dried beans</p> <p>3&nbsp;to&nbsp;4 servings per day*</p> </td> </tr> <tr> <td>Fruit juice</td> <td>None</td> <td>None</td> <td> <p>None</p> </td> <td> <p>None</p> </td> <td> <p>None</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* One serving size is considered to be 1 tablespoon.</div><div class=\"graphic_reference\">Adapted from: Massachusetts WIC program Nutrition Education Task Force.</div><div id=\"graphicVersion\">Graphic 70327 Version 9.0</div></div></div>"},"70330":{"type":"graphic_diagnosticimage","displayName":"Pulmonary osteoarthropathy II","title":"Pulmonary osteoarthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary osteoarthropathy</div><div class=\"cntnt\"><img style=\"width:163px; height:324px;\" src=\"images/PULM/70330_Pulmonary_osteoarthropath1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain film of the lower extremity in a woman who presented with ankle pain demonstrates marked periostitis with cortical and periosteal thickening, which has arisen in this patient with adenocarcinoma of the lung.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 70330 Version 2.0</div></div></div>"},"70331":{"type":"graphic_diagnosticimage","displayName":"Posterior elbow dislocation with radial head fracture","title":"Posterior elbow dislocation with radial head fracture","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Posterior elbow dislocation with radial head fracture</div><div class=\"cntnt\"><img style=\"width:576px; height:586px;\" src=\"images/EM/70331_Post_elb_dis_rad_head_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior posterior and lateral radiographs of the elbow. Posterior elbow dislocation with an associated radial head fracture caused by a fall from a skateboard in a 16-year-old boy.<br />(B) Same patient. Radial head fracture is more easily seen on the post-reduction radiographs.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 70331 Version 4.0</div></div></div>"},"70332":{"type":"graphic_picture","displayName":"Mucocele - lower lip","title":"Mucocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucocele</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70332_Mucocele_lower_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transluscent papule is present on the mucosal surface of the lower lip.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70332 Version 3.0</div></div></div>"},"70333":{"type":"graphic_picture","displayName":"Granulation bed on a chronically open abdomen","title":"Granulation bed on a chronically open abdomen","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Granulation bed on a chronically open abdomen</div><div class=\"cntnt\"><img style=\"width:504px; height:392px;\" src=\"images/SURG/70333_Granul_bed_chronic_open_abd.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70333 Version 1.0</div></div></div>"},"70334":{"type":"graphic_table","displayName":"Cocaine toxicity - Rapid overview","title":"Cocaine toxicity: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cocaine toxicity: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergency consultation with a medical toxicologist, call the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td>Cocaine is a stimulant (sympathomimetic) that increases energy and produces euphoria</td> </tr> <tr> <td>Cocaine produces toxicity in virtually every organ system, principally via hemodynamic effects</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td class=\"subtitle2_single\">History</td> </tr> <tr> <td class=\"indent1\">Cocaine may produce toxicity in virtually any organ; few complaints (particularly focal complaints) can be dismissed</td> </tr> <tr> <td class=\"indent1\">Chest pain, shortness of breath, headache, focal neurologic symptoms, and extremity symptoms are particularly worrisome</td> </tr> <tr> <td class=\"subtitle2_single\">Physical examination</td> </tr> <tr> <td class=\"indent1\">Vital signs: Hypertension and tachycardia almost universal; hyperthermia may occur</td> </tr> <tr> <td class=\"indent1\">CNS: Agitation common; focal signs suggest cerebrovascular accident</td> </tr> <tr> <td class=\"indent1\">Pupils: Mydriasis common</td> </tr> <tr> <td class=\"indent1\">Lungs: Decreased breath sounds after smoking crack suggest pneumothorax</td> </tr> <tr> <td class=\"indent1\">Extremities: Decreased pulses suggest vascular catastrophe, such as aortic dissection</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory evaluation</td> </tr> <tr> <td class=\"subtitle2_single\">General laboratory screening for poisoned patients:</td> </tr> <tr> <td class=\"indent1\">Fingerstick glucose</td> </tr> <tr> <td class=\"indent1\">ECG</td> </tr> <tr> <td class=\"indent1\">Acetaminophen and salicylate levels</td> </tr> <tr> <td class=\"indent1\">Urine pregnancy test in women of childbearing age</td> </tr> <tr> <td class=\"subtitle2_single\">Urine toxicology testing</td> </tr> <tr> <td class=\"indent1\">Confirms cocaine use in last several days but does <strong>not</strong> confirm acute toxicity</td> </tr> <tr> <td class=\"subtitle2_single\">Advanced testing</td> </tr> <tr> <td class=\"indent1\">Driven by clinical symptoms (eg, cardiac biomarkers for suspected myocardial infarction; computerized tomography for suspected thoracic aortic dissection)</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Airway management</td> </tr> <tr> <td class=\"indent1\">Succinylcholine relatively contraindicated in rapid sequence intubation; consider rocuronium (1 mg/kg IV) or other nondepolarizing agent as alternative</td> </tr> <tr> <td class=\"subtitle2_single\">Psychomotor agitation</td> </tr> <tr> <td class=\"indent1\">Administer benzodiazepines (eg, diazepam 5 to 10 mg IV every 3 to 5 minutes until agitation controlled)</td> </tr> <tr> <td class=\"subtitle2_single\">Severe or symptomatic hypertension</td> </tr> <tr> <td class=\"indent1\">Administer diazepam (5 mg IV) or lorazepam (1 mg IV); may repeat q 5 minutes until sedated</td> </tr> <tr> <td class=\"indent1\">Phentolamine (1 to 5 mg IV); repeat as necessary</td> </tr> <tr> <td class=\"indent1\">DO NOT ADMINISTER BETA BLOCKERS, INCLUDING LABETALOL. Beta-blockade is contraindicated in acute cocaine toxicity.</td> </tr> <tr> <td class=\"subtitle2_single\">Cocaine-associated myocardial ischemia</td> </tr> <tr> <td class=\"indent1\">Obtain ECG (accuracy with cocaine-associated chest pain unclear; see text)</td> </tr> <tr> <td class=\"indent1\">Administer diazepam (5 mg IV) or lorazepam (1 mg IV) for agitation or hypertension; may repeat as necessary</td> </tr> <tr> <td class=\"indent1\">Aspirin 325 mg PO (assuming aortic dissection not suspected)</td> </tr> <tr> <td class=\"indent1\">Nitroglycerin 0.4 mg SL with or without continuous infusion</td> </tr> <tr> <td class=\"indent1\">Phentolamine 1 to 5 mg IV, repeat as necessary; hold for SBP &#60;100</td> </tr> <tr> <td class=\"indent1\">DO NOT ADMINISTER BETA BLOCKERS, INCLUDING LABETALOL. Beta-blockade is contraindicated in acute cocaine toxicity.</td> </tr> <tr> <td class=\"subtitle2_single\">QRS widening on ECG (rare; suggests profound toxicity)</td> </tr> <tr> <td class=\"indent1\">Administer sodium bicarbonate, 1 to 2 mEq/kg IV push</td> </tr> <tr> <td class=\"subtitle1_single\">Disposition</td> </tr> <tr> <td>Patients with uncomplicated cocaine toxicity (agitation and sympathomimetic toxicity but no evidence of end-organ damage) may be treated with benzodiazepines and observed until symptoms resolve, then discharged.</td> </tr> <tr> <td>Patients with cocaine-associated chest pain and a normal or unchanged ECG, in whom thoracic aortic dissection is not a concern, should be observed for 9 to 12 hours. If repeat cardiac biomarkers and a repeat ECG are normal, such patients may be discharged.</td> </tr> <tr> <td>Patients with any evidence of end-organ toxicity should be admitted.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; ECG: electrocardiogram; IV: intravenous; SBP: systolic blood pressure.</div><div id=\"graphicVersion\">Graphic 70334 Version 6.0</div></div></div>"},"70335":{"type":"graphic_table","displayName":"Types of DILI","title":"Types of drug-induced liver injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of drug-induced liver injury</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute injury </td> </tr> <tr> <td class=\"subtitle2_single\">Hepatocellular </td> </tr> <tr> <td class=\"indent1\">Acarbose </td> </tr> <tr> <td class=\"indent1\">Acetaminophen </td> </tr> <tr> <td class=\"indent1\">Allopurinol </td> </tr> <tr> <td class=\"indent1\">Aspirin </td> </tr> <tr> <td class=\"indent1\">Bupropion </td> </tr> <tr> <td class=\"indent1\">Bromfenac </td> </tr> <tr> <td class=\"indent1\">Carbon tetrachloride</td> </tr> <tr> <td class=\"indent1\">Diclofenac </td> </tr> <tr> <td class=\"indent1\">Ethanol </td> </tr> <tr> <td class=\"indent1\">Fluoxetine </td> </tr> <tr> <td class=\"indent1\">Halothane </td> </tr> <tr> <td class=\"indent1\">Iron sulfate</td> </tr> <tr> <td class=\"indent1\">Isoniazid </td> </tr> <tr> <td class=\"indent1\">Ketoconazole </td> </tr> <tr> <td class=\"indent1\">Lisinopril </td> </tr> <tr> <td class=\"indent1\">Losartan </td> </tr> <tr> <td class=\"indent1\">Methyldopa </td> </tr> <tr> <td class=\"indent1\">Nefazodone </td> </tr> <tr> <td class=\"indent1\">Nevirapine </td> </tr> <tr> <td class=\"indent1\">Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td class=\"indent1\">Paroxetine </td> </tr> <tr> <td class=\"indent1\">Phenytoin </td> </tr> <tr> <td class=\"indent1\">Pyrazinamide </td> </tr> <tr> <td class=\"indent1\">Rifampin </td> </tr> <tr> <td class=\"indent1\">Risperidone </td> </tr> <tr> <td class=\"indent1\">Ritonavir </td> </tr> <tr> <td class=\"indent1\">Sertraline </td> </tr> <tr> <td class=\"indent1\">Statins </td> </tr> <tr> <td class=\"indent1\">Tetracycline </td> </tr> <tr> <td class=\"indent1\">Trazodone </td> </tr> <tr> <td class=\"indent1\">Thiazolidinediones </td> </tr> <tr> <td class=\"indent1\">Trovafloxacin </td> </tr> <tr> <td class=\"indent1\">Valacyclovir</td> </tr> <tr> <td class=\"indent1\">Valproate </td> </tr> <tr> <td class=\"indent1\">Varenicline&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Cholestasis </td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Amoxicillin-clavulanate </td> </tr> <tr> <td class=\"indent1\">Angiotensin-converting enzyme inhibitors </td> </tr> <tr> <td class=\"indent1\">Anabolic steroids </td> </tr> <tr> <td class=\"indent1\">Azathioprine </td> </tr> <tr> <td class=\"indent1\">Azithromycin&nbsp;</td> </tr> <tr> <td class=\"indent1\">Captopril</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine </td> </tr> <tr> <td class=\"indent1\">Clopidogrel </td> </tr> <tr> <td class=\"indent1\">Cytarabine </td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> </tr> <tr> <td class=\"indent1\">Dicloxacillin</td> </tr> <tr> <td class=\"indent1\">Efavirenz</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> </tr> <tr> <td class=\"indent1\">Estrogens </td> </tr> <tr> <td class=\"indent1\">Ethanol </td> </tr> <tr> <td class=\"indent1\">Ezetimibe</td> </tr> <tr> <td class=\"indent1\">Flutamide</td> </tr> <tr> <td class=\"indent1\">Irbesartan </td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Nafcillin</td> </tr> <tr> <td class=\"indent1\">Naproxen</td> </tr> <tr> <td class=\"indent1\">Nevirapine</td> </tr> <tr> <td class=\"indent1\">Phenothiazines </td> </tr> <tr> <td class=\"indent1\">Rifampin</td> </tr> <tr> <td class=\"indent1\">Rosiglitazone</td> </tr> <tr> <td class=\"indent1\">Sulfonylureas</td> </tr> <tr> <td class=\"indent1\">Sulindac </td> </tr> <tr> <td class=\"indent1\">Terbinafine </td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class=\"indent1\">Tricyclics </td> </tr> <tr> <td class=\"indent1\">Troglitazone</td> </tr> <tr> <td class=\"subtitle2_single\">Mixed </td> </tr> <tr> <td class=\"indent1\">Amitriptyline </td> </tr> <tr> <td class=\"indent1\">Azathioprine </td> </tr> <tr> <td class=\"indent1\">Captopril </td> </tr> <tr> <td class=\"indent1\">Carbamazepine </td> </tr> <tr> <td class=\"indent1\">Clindamycin </td> </tr> <tr> <td class=\"indent1\">Cyproheptadine </td> </tr> <tr> <td class=\"indent1\">Enalapril </td> </tr> <tr> <td class=\"indent1\">Flutamide </td> </tr> <tr> <td class=\"indent1\">Ibuprofen </td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin </td> </tr> <tr> <td class=\"indent1\">Phenobarbital </td> </tr> <tr> <td class=\"indent1\">Phenothiazines </td> </tr> <tr> <td class=\"indent1\">Phenytoin </td> </tr> <tr> <td class=\"indent1\">Sulfonamides </td> </tr> <tr> <td class=\"indent1\">Trazodone </td> </tr> <tr> <td class=\"indent1\">Sulfonamides </td> </tr> <tr> <td class=\"indent1\">Verapamil </td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Chronic injury </td> </tr> <tr> <td class=\"subtitle2_single\">Cholestasis</td> </tr> <tr> <td class=\"indent1\">5-fluorodexoyuridine</td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> </tr> <tr> <td class=\"indent1\">Ampicillin&nbsp;</td> </tr> <tr> <td class=\"indent1\">Amoxicillin-clavulanate</td> </tr> <tr> <td class=\"indent1\">Anabolic steroids</td> </tr> <tr> <td class=\"indent1\">Azithromycin&nbsp;</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> </tr> <tr> <td class=\"indent1\">Chlorpropamide</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> </tr> <tr> <td class=\"indent1\">Cyproheptadine</td> </tr> <tr> <td class=\"indent1\">Erythromycin</td> </tr> <tr> <td class=\"indent1\">Floxuridine</td> </tr> <tr> <td class=\"indent1\">Flucloxacillin</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> </tr> <tr> <td class=\"indent1\">Imipramine</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Organic arsenicals</td> </tr> <tr> <td class=\"indent1\">Prochlorperazine</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Sulpiride</td> </tr> <tr> <td class=\"indent1\">Tenoxicam</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class=\"indent1\">Thiabendazole</td> </tr> <tr> <td class=\"indent1\">Tolbutamide</td> </tr> <tr> <td class=\"indent1\">Tetracycline</td> </tr> <tr> <td class=\"indent1\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"indent1\">Zonisamide</td> </tr> <tr> <td class=\"subtitle2_single\">Steatohepatitis</td> </tr> <tr> <td class=\"indent1\">Amiodarone </td> </tr> <tr> <td class=\"indent1\">Diethylaminoethoxyhexestrol</td> </tr> <tr> <td class=\"indent1\">Ethanol </td> </tr> <tr> <td class=\"indent1\">Irinotecan</td> </tr> <tr> <td class=\"indent1\">L-asparaginase</td> </tr> <tr> <td class=\"indent1\">Perhexiline maleate</td> </tr> <tr> <td class=\"indent1\">Tamoxifen </td> </tr> <tr> <td class=\"indent1\">Valproic acid </td> </tr> <tr> <td class=\"subtitle2_single\">Microvesicular steatosis </td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Camphor</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Didanosine</td> </tr> <tr> <td class=\"indent1\">Ethanol </td> </tr> <tr> <td class=\"indent1\">Methotrexate </td> </tr> <tr> <td class=\"indent1\">NRTIs </td> </tr> <tr> <td class=\"indent1\">Piroxicam</td> </tr> <tr> <td class=\"indent1\">Stavudine</td> </tr> <tr> <td class=\"indent1\">Tetracycline </td> </tr> <tr> <td class=\"indent1\">Tolmetin</td> </tr> <tr> <td class=\"indent1\">Valproic acid </td> </tr> <tr> <td class=\"indent1\">Zidovudine</td> </tr> <tr> <td class=\"subtitle2_single\">Granulomas </td> </tr> <tr> <td class=\"indent1\">Allopurinol </td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Carbamazepine </td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> </tr> <tr> <td class=\"indent1\">Dapsone</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> </tr> <tr> <td class=\"indent1\">Diltiazem </td> </tr> <tr> <td class=\"indent1\">Gold</td> </tr> <tr> <td class=\"indent1\">Hydralazine </td> </tr> <tr> <td class=\"indent1\">Interferon</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Mesalamine</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin</td> </tr> <tr> <td class=\"indent1\">Penicillamine </td> </tr> <tr> <td class=\"indent1\">Penicillin</td> </tr> <tr> <td class=\"indent1\">Phenytoin </td> </tr> <tr> <td class=\"indent1\">Procainamide </td> </tr> <tr> <td class=\"indent1\">Quinidine </td> </tr> <tr> <td class=\"indent1\">Rosiglitazone </td> </tr> <tr> <td class=\"indent1\">Sulfonamides </td> </tr> <tr> <td class=\"indent1\">Sulfonylureas</td> </tr> <tr> <td class=\"subtitle2_single\">Hepatic venous outflow obstruction (Budd-Chiari syndrome)</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"subtitle2_single\">Sinusoidal obstruction syndrome </td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Busulfan </td> </tr> <tr> <td class=\"indent1\">Chemotherapeutic agents (eg, oxaliplatin)</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide </td> </tr> <tr> <td class=\"indent1\">Imuran </td> </tr> <tr> <td class=\"indent1\">Mercaptopurine</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Pyrrolizidine alkaloids (found in herbal remedies)</td> </tr> <tr> <td class=\"indent1\">Tetracycline</td> </tr> <tr> <td class=\"indent1\">Vitamin A</td> </tr> <tr> <td class=\"subtitle2_single\">Fibrosis </td> </tr> <tr> <td class=\"indent1\">Ethanol </td> </tr> <tr> <td class=\"indent1\">Methotrexate </td> </tr> <tr> <td class=\"indent1\">Methyldopa </td> </tr> <tr> <td class=\"subtitle2_single\">Phospholipidosis</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Chloroquine</td> </tr> <tr> <td class=\"indent1\">Chlorpheniramine</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> </tr> <tr> <td class=\"indent1\">Perhexiline maleate</td> </tr> <tr> <td class=\"indent1\">Thioridazine</td> </tr> <tr> <td class=\"subtitle2_single\">Peliosis hepatis </td> </tr> <tr> <td class=\"indent1\">Anabolic steroids </td> </tr> <tr> <td class=\"indent1\">Arsenic</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Danazol</td> </tr> <tr> <td class=\"indent1\">Diethylstilbestrol</td> </tr> <tr> <td class=\"indent1\">Hydroxyurea</td> </tr> <tr> <td class=\"indent1\">Mercaptopurine</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Tamoxifen</td> </tr> <tr> <td class=\"indent1\">Vinyl chloride </td> </tr> <tr> <td class=\"indent1\">Vitamin A</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune hepatitis </td> </tr> <tr> <td class=\"indent1\">Clometacin</td> </tr> <tr> <td class=\"indent1\">Diclofenac</td> </tr> <tr> <td class=\"indent1\">Fenofibrate</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> </tr> <tr> <td class=\"indent1\">Minocycline </td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin </td> </tr> <tr> <td class=\"indent1\">Papaverine</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Propylthiouracil</td> </tr> <tr> <td class=\"indent1\">Statins </td> </tr> <tr> <td class=\"subtitle2_single\">Chronic hepatitis </td> </tr> <tr> <td class=\"indent1\">Diclofenac </td> </tr> <tr> <td class=\"indent1\">Lisinopril</td> </tr> <tr> <td class=\"indent1\">Methyldopa </td> </tr> <tr> <td class=\"indent1\">Minocycline </td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin </td> </tr> <tr> <td class=\"indent1\">Sulfonamides</td> </tr> <tr> <td class=\"indent1\">Tamoxifen</td> </tr> <tr> <td class=\"indent1\">Trazodone </td> </tr> <tr> <td class=\"indent1\">Uracil</td> </tr> <tr> <td class=\"subtitle2_single\">Neoplasm </td> </tr> <tr> <td class=\"indent1\">Anabolic steroids </td> </tr> <tr> <td class=\"indent1\">Arsenic</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Danazol</td> </tr> <tr> <td class=\"indent1\">Inorganic copper</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives </td> </tr> <tr> <td class=\"indent1\">Polyvinyl chloride</td> </tr> <tr> <td class=\"indent1\">Potassium arsenite</td> </tr> <tr> <td class=\"indent1\">Radium</td> </tr> <tr> <td class=\"indent1\">Thorotrast</td> </tr> <tr> <td class=\"indent1\">Vinyl chloride </td> </tr> <tr> <td class=\"subtitle2_single\">Ischemic necrosis </td> </tr> <tr> <td class=\"indent1\">Ergot </td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NRTIs: nucleoside reverse transcriptase inhibitors.<br> Sinusoidal obstruction syndrome (SOS): previously called veno-occlusive disease (VOD).</div><div class=\"graphic_reference\">Adapted and expanded from: Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25:1135.</div><div id=\"graphicVersion\">Graphic 70335 Version 9.0</div></div></div>"},"70338":{"type":"graphic_figure","displayName":"Outcome of carotid endarterectomy by time of surgery","title":"Early carotid endarterectomy is associated with improved outcomes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early carotid endarterectomy is associated with improved outcomes</div><div class=\"cntnt\"><img style=\"width:429px; height:290px;\" src=\"images/NEURO/70338_Outcome_CEA_by_time_of_surg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is the absolute reduction with surgery in the five-year cumulative risk of ipsilateral carotid ischemic stroke and any stroke or death within 30 days after carotid endarterectomy (CEA) in patients with 50 to 69 percent stenosis and &ge;70 percent stenosis without near occlusion stratified by the time from last symptomatic event to randomization. Numbers above the bars indicate actual absolute risk reduction. Vertical bars are 95 percent confidence intervals. These results suggest that CEA is likely to be of greatest benefit if performed within two weeks of the last neurologic event in patients with &ge;70 percent carotid stenosis. For patients with 50 to 69 percent stenosis, CEA may only have benefit if performed within two weeks of the last event.</div><div class=\"graphic_reference\">Data from: Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363:915.</div><div id=\"graphicVersion\">Graphic 70338 Version 3.0</div></div></div>"},"70339":{"type":"graphic_figure","displayName":"ETT maximal HR outcome","title":"Ability to achieve goal heart rate during exercise treadmill testing correlates with better outcomes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ability to achieve goal heart rate during exercise treadmill testing correlates with better outcomes</div><div class=\"cntnt\"><img style=\"width:413px; height:259px;\" src=\"images/CARD/70339_ETT_maximal_HR_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 231 consecutive patients referred for exercise testing who were not taking a beta blocker, the inability to achieve at least 85 percent of age-predicted maximal heart rate was associated with a lower event-free survival compared to those who reached this heart rate (adjusted relative risk 2.2).</div><div class=\"graphic_reference\">Data with permission from: Lauer MS, Mehta R, Pashkow FJ, et al. J Am Coll Cardiol 1998; 32:1280.</div><div id=\"graphicVersion\">Graphic 70339 Version 3.0</div></div></div>"},"70340":{"type":"graphic_picture","displayName":"Congenital lobar emphysema gross pathologic specimen","title":"Gross pathologic specimen from a two-year-old girl with congenital lobar emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross pathologic specimen from a two-year-old girl with congenital lobar emphysema</div><div class=\"cntnt\"><img style=\"width:265px; height:383px;\" src=\"images/PEDS/70340_CLE_gross_pathologic_specim.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left upper lobe is enlarged and pale with a uniform appearance. The adjacent lingula is unaffected; it has a somewhat darker color and is without airspace enlargement.</div><div class=\"graphic_reference\">Courtesy of Claire Langston, MD, and Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 70340 Version 2.0</div></div></div>"},"70341":{"type":"graphic_figure","displayName":"Timing anatomic risk","title":"Timing and anatomy of risk factors for brain injury resulting in neonatal encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Timing and anatomy of risk factors for brain injury resulting in neonatal encephalopathy</div><div class=\"cntnt\"><img style=\"width:486px; height:259px;\" src=\"images/PEDS/70341_Timing_anatomic_risk.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Sidhartha Tan, MD.</div><div id=\"graphicVersion\">Graphic 70341 Version 2.0</div></div></div>"},"70342":{"type":"graphic_picture","displayName":"Chigger mite","title":"Chiggers (<EM>Trombicula</EM> species)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chiggers (<EM>Trombicula</EM> species)</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/PC/70342_Chigger_mite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The adult biting mite (<EM>Trombicula</EM> species) is typically 1 to 2 mm in length, with a bright red or red-brown color.</div><div class=\"graphic_reference\">Courtesy of David Liebman.</div><div id=\"graphicVersion\">Graphic 70342 Version 2.0</div></div></div>"},"70343":{"type":"graphic_table","displayName":"Quick confusion screen for adults ","title":"Quick confusion screen for adults ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quick confusion screen for adults </div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Item</td>\n\t\t\t\t\t<td class=\"subtitle1\">Scoring</td>\n\t\t\t\t\t<td class=\"subtitle1\">Weight</td>\n\t\t\t\t\t<td class=\"subtitle1\">Score</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">What year is it now?</td>\n\t\t\t\t\t<td><p>0 or 1</p><p>(Score 1 if correct, 0 if incorrect)</p></td>\n\t\t\t\t\t<td>x2</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">What month is it?</td>\n\t\t\t\t\t<td><p>0 or 1</p><p>(Score 1 if correct, 0 if incorrect)</p></td>\n\t\t\t\t\t<td>x2</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td  class=\"subtitle2_left\" colspan=\"4\">Repeat phrase and remember: \"John Brown, 42 Market Street, New York\"</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">About what time is it? (answer correct if within one hour)</td>\n\t\t\t\t\t<td><p>0 or 1</p><p>(Score 1 if correct, 0 if incorrect)</p></td>\n\t\t\t\t\t<td>x2</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Count backwards from 20 to 1</td>\n\t\t\t\t\t<td><p>0, 1, or 2</p><p>(Score 2 if correct, 1 if 1 error, and 0 if 2 or more errors)</p></td>\n\t\t\t\t\t<td>x1</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Say the months in reverse</td>\n\t\t\t\t\t<td><p>0, 1, or 2</p><p>(Score 2 if correct, 1 if 1 error, and 0 if 2 or more errors)</p></td>\n\t\t\t\t\t<td>x1</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Repeat memory phrase</td>\n\t\t\t\t\t<td><p>0, 1, 2, 3, 4, 5</p><p>(Score 5 if correct; deduct 1 for each miss)</p></td>\n\t\t\t\t\t<td>x1</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist_other\" colspan=\"4\">&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td colspan=\"3\"><strong>Final score is sum of the total; score less than 15 suggests the presence of altered cognition and need for further assessment.</strong></td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10898&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Confusion_test_ED.htm</title></head></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Huff JS, Farace E, Brady WJ, et al. The quick confusion scale in the ED: comparison with the mini-mental state examination. Am J Emerg Med 2001; 19:461.</LI>&#xD;&#xA;<LI>Irons MJ, Farace E, Brady WJ, Huff JS. Mental status screening of emergency department patients: normative study of the quick confusion scale. Acad Emerg Med 2002; 9:989.</LI></OL>​</div><div id=\"graphicVersion\">Graphic 70343 Version 3.0</div></div></div>"},"70344":{"type":"graphic_figure","displayName":"Odontoid fractures","title":"Odontoid fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Odontoid fractures</div><div class=\"cntnt\"><img style=\"width:418px; height:523px;\" src=\"images/EM/70344_Odontoid_fractures.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70344 Version 3.0</div></div></div>"},"70345":{"type":"graphic_picture","displayName":"Endoloop and hemoclip Endosc","title":"Resection of a pedunculated colonic polyp with a long stalk","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Resection of a pedunculated colonic polyp with a long stalk</div><div class=\"cntnt\"><img style=\"width:472px; height:215px;\" src=\"images/GAST/70345_Endoloop_and_hemoclip_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) 2 cm polyp in the sigmoid; (B) after passing and retracting the endoscope, the long stalk is demonstrated; (C) the polyp is ensnared with an endoloop; (D) the endoloop is closed to ligate the pedicle; (E) the polyp is snared near to the head; (F) after resection a visible vessel is recognized at the resection site; (G) to achieve definitive hemostasis a hemoclip is placed; (H) final appearance.</div><div class=\"graphic_reference\">Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.</div><div id=\"graphicVersion\">Graphic 70345 Version 1.0</div></div></div>"},"70346":{"type":"graphic_picture","displayName":"Klebsiella pneumoniae sputum","title":"<em>Klebsiella pneumoniae</em> in sputum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Klebsiella pneumoniae</em> in sputum</div><div class=\"cntnt\"><img style=\"width:361px; height:240px;\" src=\"images/ID/70346_Kpneumoniaesputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Klebsiella pneumoniae</EM> under high-power magnification (x1000) in sputum.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 70346 Version 5.0</div></div></div>"},"70348":{"type":"graphic_table","displayName":"Nugent score for diagnosis of bacterial vaginosis","title":"Nugent's scoring system for diagnosis of bacterial vaginosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nugent's scoring system for diagnosis of bacterial vaginosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Score</td>\n<td class=\"subtitle1\">Lactobacillus morphotypes</td>\n<td class=\"subtitle1\">Gardnerella and Bacteroides morphotypes</td>\n<td class=\"subtitle1\">Curved gram-variable rods</td>\n</tr>\n<tr>\n<td>0</td>\n<td>4+</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td>1</td>\n<td>3+</td>\n<td>1+</td>\n<td>1+ or 2+</td>\n</tr>\n<tr>\n<td>2</td>\n<td>2+</td>\n<td>2+</td>\n<td>3+ or 4+</td>\n</tr>\n<tr>\n<td>3</td>\n<td>1+</td>\n<td>3+</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>4</td>\n<td>0</td>\n<td>4+</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_lgnd\">The score is determined by the average number of each morphotype seen per oil-immersion field, but varies with the type of bacteria. Excluding lactobacillus morphotypes, a score of 0 means no morphotypes are present; 1, 0 to 1 morphotype present per high power field; 2, 1 to 4 morphotypes present; 3, 5 to 30 morphotypes present; 4, 30 or more morphotypes present. A total score of 7 to 10 is indicative of bacterial vaginosis infection, 4 to 6 is indeterminate, and 0 to 3 is normal. (Total score = lactobacilli score and Gardnerella vaginalis score and Bacteroides species score and curved gram variable rod score).</div><div class=\"graphic_reference\">Adapted from data in Nugent, RP. J Clin Microbiol 1991; 29:291.</div><div id=\"graphicVersion\">Graphic 70348 Version 2.0</div></div></div>"},"70349":{"type":"graphic_table","displayName":"Chronic postsurg pain synd","title":"Chronic post-surgical pain syndromes in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic post-surgical pain syndromes in cancer patients</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Syndrome\n   </td>\n   <td  class=\"subtitle1\">\n   Characteristics\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Post-mastectomy pain syndrome\n   </td>\n   <td>Dull, burning, and aching pain experienced over the axilla, anterior chest wall and medial upper arm, associated with sensory loss and sometimes phantom sensations</td>\n   </tr>\n   <tr>\n   <td>May be accompanied by dysesthesia, allodynia, and scar sensitivity</td>\n   </tr>\n   <tr>\n   <td>Pain can start acutely post-surgery and persist, or onset may occur many months or years after surgery</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Post-radical neck dissection pain\n   </td>\n   <td>Often neuropathic and described as a burning or lancinating dysesthesias in the anterolateral neck extending to the shoulder; reflects injury to the cervical plexus</td>\n   </tr>\n   <tr>\n   <td>Often accompanied by sensory loss</td>\n   </tr>\n   <tr>\n   <td>May experience neck and shoulder pain weeks to months after surgery</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Post-thoracotomy pain\n   </td>\n   <td>Neuropathic pain localized to the region of the thoracotomy scar, experienced months post-surgery; when recurrent rather than persistent, high suspicion for tumor regrowth</td>\n   </tr>\n   <tr>\n   <td>Pain described as aching or burning; potentially associated with sensory and autonomic changes; may be accompanied by ipsilateral arm disability</td>\n   </tr>\n   <tr>\n   <td>Postoperative frozen shoulder</td>\n   <td>Limited shoulder range of motion usually caused by untreated thoracotomy pain and inadequate rehabilitation</td>\n   </tr>\n   <tr>\n   <td>Post-surgery pelvic floor pain</td>\n   <td>Resembles the idiopathic syndrome of tension myalgia of the pelvic floor, with pain that occurs on standing</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Stump pain\n   </td>\n   <td>Neuropathic pain, described as burning, experienced at the site of a surgical scar several months to years post-amputation</td>\n   </tr>\n   <tr>\n   <td>Pain may be exacerbated by movement and is secondary to neuroma formation in the region of amputation</td>\n   </tr>\n   <tr>\n   <td>May be improved or exacerbated by wearing of a prosthesis</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Phantom limb pain\n   </td>\n   <td>Site of pain is away from amputation scar and appears to be where the absent limb was located</td>\n   </tr>\n   <tr>\n   <td>Pain is dysesthetic, often fluctuating</td>\n   </tr>\n   <tr>\n   <td>May or may not be associated with phantom sensations, including nonspecific paresthesia and specific sensations of the limb, with or without distortions</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Phantom pain\n   </td>\n   <td>Phantom breast pain following mastectomy</td>\n   </tr>\n   <tr>\n   <td>Phantom pelvic pain following hemipelvectomy</td>\n   </tr>\n   <tr>\n   <td>Phantom rectal pain following rectal cancer surgery</td>\n   </tr>\n   <tr>\n   <td>Phantom eye pain in patients with eye enucleation</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 70349 Version 1.0</div></div></div>"},"70350":{"type":"graphic_picture","displayName":"Mucosal tag CD","title":"Mucosal tag","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucosal tag</div><div class=\"cntnt\"><img style=\"width:252px; height:408px;\" src=\"images/PEDS/70350_Mucosal_tag_CD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucosal tag on the buccal aspect of the gingiva of a child with Crohn disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright &#169; 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 70350 Version 2.0</div></div></div>"},"70352":{"type":"graphic_picture","displayName":"Bullous pemphigoid tense bullae 2","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70352_Bullouspemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae on skin with one eroded blister base.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70352 Version 5.0</div></div></div>"},"70353":{"type":"graphic_diagnosticimage","displayName":"Displaced fx remodeling","title":"Displaced fx remodeling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced fx remodeling</div><div class=\"cntnt\"><img style=\"width:242px; height:767px;\" src=\"images/EM/70353_Displacedfxremodeling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Anteroposterior and lateral views of displaced radial physeal fracture. Panel B) Healed malunion one month after radial physeal fracture. Panel C) Significant remodeling at five months after fracture. Panel D) Anatomic remodeling with no physeal arrest.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70353 Version 14.0</div></div></div>"},"70354":{"type":"graphic_diagnosticimage","displayName":"Ultrasound normal appendix","title":"Ultrasound normal appendix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound normal appendix</div><div class=\"cntnt\"><img style=\"width:372px; height:274px;\" src=\"images/GAST/70354_Normal_appendix_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal appendix.&nbsp;Image from an abdominal&nbsp;ultrasound shows an appendix (thick red arrow) measuring &lt;6 mm in double-layer thickness (calipers) originating from the cecal base (thin, white arrow). Surrounding normal structures include the cecum (COE), small bowel&nbsp;(DD), and iliac vessels (VI).</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 70354 Version 5.0</div></div></div>"},"70355":{"type":"graphic_diagnosticimage","displayName":"HSG air bubbles in uterus","title":"Hysterosalpingogram showing air bubbles in uterus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram showing air bubbles in uterus</div><div class=\"cntnt\"><img style=\"width:540px; height:203px;\" src=\"images/OBGYN/70355_HSG_air_bubbles_in_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hysterosalpingogram (HSG) showing air bubbles in the uterine cavity and non-filling of the left tube. This is an incomplete study. (B)&nbsp;HSG of the same patient shown in A after more dye was injected, showing a normal HSG.</div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 70355 Version 4.0</div></div></div>"},"70356":{"type":"graphic_figure","displayName":"Toxicodendron range US","title":"US range of Toxicodendron species other than T. radicans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US range of Toxicodendron species other than T. radicans</div><div class=\"cntnt\"><img style=\"width:411px; height:312px;\" src=\"images/PC/70356_Toxicodendron_range_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 70356 Version 1.0</div></div></div>"},"70357":{"type":"graphic_diagnosticimage","displayName":"HRCT ground glass in scleroderma","title":"Interstitial lung disease in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Interstitial lung disease in scleroderma</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/RADIOL/70357_Ground_glass_in_SD_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan through the lung bases in a patient with scleroderma shows bibasilar interstitial lung disease with ground glass changes in the right lower lobe. Note also the patulous esophagus (dashed arrow) and bilateral pleural effusions (black arrows). The heart is also enlarged.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 70357 Version 6.0</div></div></div>"},"70358":{"type":"graphic_diagnosticimage","displayName":"Primary ciliary dyskinesia PA","title":"Primary ciliary dyskinesia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary ciliary dyskinesia</div><div class=\"cntnt\"><img style=\"width:313px; height:349px;\" src=\"images/PULM/70358_Primary_ciliary_dyskinesi2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a 26-year-old man with primary ciliary dyskinesia demonstrates extensive bilateral bronchiectasis. The patient underwent underwent a lobectomy of his left lower lobe at 10 years.</div><div class=\"graphic_reference\">Courtesy of Sten-Erik Bergström, MD.</div><div id=\"graphicVersion\">Graphic 70358 Version 2.0</div></div></div>"},"70359":{"type":"graphic_figure","displayName":"Laparoscopic view of inguinal anatomy","title":"Laparoscopic view of inguinal anatomy","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Laparoscopic view of inguinal anatomy</div><div class=\"cntnt\"><img style=\"width:539px; height:587px;\" src=\"images/SURG/70359_Inguinal_anatomy_lap_view.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70359 Version 6.0</div></div></div>"},"70362":{"type":"graphic_table","displayName":"Positive cultures in miliary TB","title":"Frequency of positive smear or culture in patients with miliary tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of positive smear or culture in patients with miliary tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Maartens, 1990</td> <td class=\"subtitle1\">Kim, 1990</td> </tr> <tr> <td>Sputum smear</td> <td>33*</td> <td>36</td> </tr> <tr> <td>Sputum culture</td> <td>62</td> <td>76</td> </tr> <tr> <td>BAL smear</td> <td>27</td> <td>9</td> </tr> <tr> <td>BAL culture</td> <td>55</td> <td>54</td> </tr> <tr> <td>Gastric aspirate smear</td> <td>43</td> <td>0</td> </tr> <tr> <td>Gastric aspirate culture</td> <td>100</td> <td>75</td> </tr> <tr> <td>Urine smear</td> <td>14</td> <td>7</td> </tr> <tr> <td>Urine culture</td> <td>33</td> <td>59</td> </tr> <tr> <td>CSF smear</td> <td>8</td> <td>0</td> </tr> <tr> <td>CSF culture</td> <td>60</td> <td>0</td> </tr> <tr> <td>Serosal smear</td> <td>6</td> <td>0</td> </tr> <tr> <td>Serosal culture</td> <td>44<sup>&#182;</sup></td> <td>14<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage; CSF: cerebrospinal fluid.<br />* All numbers are percentages.<br />¶&nbsp;9 ascites, 7 pleural, 2 pericardial.<br />Δ All pleural.</div><div id=\"graphicVersion\">Graphic 70362 Version 2.0</div></div></div>"},"70363":{"type":"graphic_picture","displayName":"Cicada killer","title":"Cicada killer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cicada killer</div><div class=\"cntnt\"><img style=\"width:432px; height:402px;\" src=\"images/ALLRG/70363_Cicada_killer.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 70363 Version 1.0</div></div></div>"},"70365":{"type":"graphic_figure","displayName":"Port placement in pregnant women","title":"Port placement in pregnant women","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port placement in pregnant women</div><div class=\"cntnt\"><img style=\"width:372px; height:518px;\" src=\"images/OBGYN/70365_Port_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Our preferred entry technique is use of a Veress needle inserted into the left-upper quadrant. Gastric decompression with an orogastric tube prior to needle insertion minimizes the risk of gastric perforation. The needle should be angled approximately 15 degrees caudad to minimize the risk of splenic injury. Placement of a supraumbilical port 6 cm above the fundus with a Hasson technique is another entry method that reduces the risk of organ perforation.</div><div id=\"graphicVersion\">Graphic 70365 Version 3.0</div></div></div>"},"70369":{"type":"graphic_diagnosticimage","displayName":"Posterior spinal fusion","title":"Posterior spinal fusion","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Posterior spinal fusion</div><div class=\"cntnt\"><img style=\"width:596px; height:472px;\" src=\"images/PEDS/70369_Posterior_spinal_fusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative posteroanterior (PA) and postoperative PA and lateral radiographs (panels A, B, and C, respectively) of a patient who underwent posterior spinal fusion and segmental spinal instrumentation with pedicle screws. Note on the postoperative lateral how the use of segmental instrumentation allows contoured rods to be attached to the spine to better maintain normal physiologic sagittal plane curves (thoracic kyphosis and lumbar lordosis). By orthopedic convention, scoliosis images are viewed as if looking from the patient's back; the left side of the image is the left side of the patient.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 70369 Version 6.0</div></div></div>"},"70370":{"type":"graphic_table","displayName":"Improving our approach to pts","title":"Techniques for improving our approach to patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques for improving our approach to patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Make some quiet time to reflect on satisfying and unsatisfying visits. What did you do, and what did the patient do that made the difference? What life experiences influenced your behavior in that circumstance?</td> </tr> <tr> <td>Observe your interactions with patients directly. Obtain permission from your patients to audiotape or videotape visits for the purpose of self-improvement. Assure your patients about the fate of the recordings (eg, destruction after you have studied them). We all have \"blind spots\" about our behaviors that the recorders can reveal to us.</td> </tr> <tr> <td>Talk with trusted colleagues about challenging interactions with patients, seeking their insights and their strategies for dealing with similar situations.</td> </tr> <tr> <td>Seek feedback about your interactions with patients from colleagues who have opportunities to observe at least parts of your clinician-patient visits. Support staff may have very useful feedback about what patients say to them about you.</td> </tr> <tr> <td>When you sense an absence of rapport with a patient and cannot comprehend the source of the disconnection, put the difficulty in the relationship nonjudgementally \"on the table\" for discussion with the patient.</td> </tr> <tr> <td>Read the world's great literature with an ear to hearing people's stories. Many clinician-authors have contributed their special insights into how we can hear our patients' life stories amid their \"biomedical stories.\"</td> </tr> <tr> <td>Write about your insights into the human condition - in a private journal, or for publication.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70370 Version 3.0</div></div></div>"},"70374":{"type":"graphic_picture","displayName":"Signet ring cancer CPC Endosc","title":"Gastric signet ring cancer","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Gastric signet ring cancer</div><div class=\"cntnt\"><img style=\"width:540px; height:279px;\" src=\"images/GAST/70374_Signet_ring_cancer_CPC_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing diffuse gastric wall thickening with poor distention of the gastric lumen when air was insufflated, suggestive of an infiltrative process. Multiple biopsies were taken throughout the stomach.</div><div class=\"graphic_reference\">Courtesy of Nazem Afdhal, MD and Andres Cardenas, MD.</div><div id=\"graphicVersion\">Graphic 70374 Version 1.0</div></div></div>"},"70375":{"type":"graphic_table","displayName":"AASLD ascites guideline","title":"American Association for the Study of Liver Diseases (AASLD) recommendations for the management of adult patients with ascites due to cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Association for the Study of Liver Diseases (AASLD) recommendations for the management of adult patients with ascites due to cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evaluation and diagnosis</td> </tr> <tr> <td class=\"indent1\">Abdominal paracentesis should be performed and ascitic fluid should be obtained from inpatients and outpatients with clinically apparent new-onset ascites.</td> </tr> <tr> <td class=\"indent1\">Because bleeding is sufficiently uncommon, the routine prophylactic use of fresh frozen plasma or platelets before paracentesis is not recommended.</td> </tr> <tr> <td class=\"subtitle1_single\">Differential diagnosis</td> </tr> <tr> <td class=\"indent1\">The initial laboratory investigation of ascitic fluid should include an ascitic fluid cell count and differential, ascitic fluid total protein, and serum-ascites albumin gradient (SAAG).</td> </tr> <tr> <td class=\"indent1\">If ascitic fluid infection is suspected, ascitic fluid should be cultured at the bedside in blood culture bottles prior to initiation of antibiotics.</td> </tr> <tr> <td class=\"indent1\">Other studies of ascitic fluid can be ordered based on pretest probability of disease.</td> </tr> <tr> <td class=\"indent1\">Testing serum for CA125 is not helpful in the differential diagnosis of ascites. Its use is not recommended in patients with ascites of any type.</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of ascites</td> </tr> <tr> <td class=\"indent1\">Patients with ascites who are thought to have an alcohol component to their liver injury should abstain from alcohol consumption.</td> </tr> <tr> <td class=\"indent1\">Baclofen can be given to reduce alcohol craving and alcohol consumption in patients with ascites in the setting of alcoholic liver disease.</td> </tr> <tr> <td class=\"indent1\">Firstline treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol/day [2000 mg/day]) and diuretics (oral spironolactone with or without oral furosemide).</td> </tr> <tr> <td class=\"indent1\">Fluid restriction is not necessary unless serum sodium is less than 125 mmol/L.</td> </tr> <tr> <td class=\"indent1\">An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated.</td> </tr> <tr> <td class=\"indent1\">Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracenteses.</td> </tr> <tr> <td class=\"indent1\">Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers may be harmful and must be carefully considered in each patient. Patients on one of these agents require blood pressure and renal function monitoring.</td> </tr> <tr> <td class=\"indent1\">The use of nonsteroidal anti-inflammatory drugs should be avoided in patients with cirrhosis and ascites, except in special circumstances.</td> </tr> <tr> <td class=\"indent1\">Liver transplantation should be considered in patients with cirrhosis and ascites.</td> </tr> <tr> <td class=\"subtitle1_single\">Refractory ascites</td> </tr> <tr> <td class=\"indent1\">Patients with refractory ascites may have increased mortality with beta blockers. The risks versus benefits of beta blockers must be carefully weighed in these patients.</td> </tr> <tr> <td class=\"indent1\">Angiotensin converting enzyme inhibitors and angiotensin receptor blockers should be avoided in patients with refractory ascites.</td> </tr> <tr> <td class=\"indent1\">Oral midodrine has been shown to improve clinical outcomes and survival in patients with refractory ascites, and its use should be considered.</td> </tr> <tr> <td class=\"indent1\">Serial therapeutic paracenteses are a treatment option for patients with refractory ascites.</td> </tr> <tr> <td class=\"indent1\">Postparacentesis albumin infusion may not be necessary for a single paracentesis of less than 4 to 5 L.</td> </tr> <tr> <td class=\"indent1\">For large-volume paracenteses, an albumin infusion of 6 to 8 g/L of fluid removed can be considered.</td> </tr> <tr> <td class=\"indent1\">Referral for liver transplantation should be expedited in patients with refractory ascites.</td> </tr> <tr> <td class=\"indent1\">Transjugular intrahepatic portasystemic stent-shunt (TIPS) may be considered in appropriately selected patients who meet criteria similar to those of published randomized trials.</td> </tr> <tr> <td class=\"indent1\">Peritoneovenous shunt, performed by a surgeon experienced with this technique, should be considered for patients with refractory ascites who are not candidates for paracenteses, transplant, or TIPS.</td> </tr> <tr> <td class=\"subtitle1_single\">Hepatorenal syndrome</td> </tr> <tr> <td class=\"indent1\">Urinary biomarkers such as neutrophil gelatinase associated lipocalin may assist in the differential diagnosis of azotemia in patients with cirrhosis.</td> </tr> <tr> <td class=\"indent1\">Albumin infusion plus administration of vasoactive drugs such as octreotide and midodrine should be considered in the treatment of type I hepatorenal syndrome.</td> </tr> <tr> <td class=\"indent1\">Albumin infusion plus administration of norepinephrine should be considered in the treatment of type I hepatorenal syndrome when the patient is in the intensive care unit.</td> </tr> <tr> <td class=\"indent1\">Patients with cirrhosis, ascites, and type I or II hepatorenal syndrome should have an expedited referral for liver transplantation.</td> </tr> <tr> <td class=\"subtitle1_single\">Spontaneous bacterial peritonitis (SBP)</td> </tr> <tr> <td class=\"indent1\">Patients with ascites admitted to the hospital should undergo abdominal paracentesis. Paracentesis should be repeated in patients (whether in the hospital or not) who develop signs or symptoms or laboratory abnormalities suggestive of infection (eg, abdominal pain or tenderness, fever, encephalopathy, renal failure, acidosis, or peripheral leukocytosis).</td> </tr> <tr> <td class=\"indent1\">Patients with ascitic fluid PMN counts &#8805;250 cells/mm<sup>3</sup> (0.25 X 10<sup>9</sup>/L) should receive empiric antibiotic therapy, eg, an intravenous third-generation cephalosporin, preferably cefotaxime 2 g every 8 hours.</td> </tr> <tr> <td class=\"indent1\">Oral ofloxacin (400 mg twice per day) can be considered a substitute for intravenous cefotaxime in inpatients without prior exposure to quinolones, vomiting, shock, grade II (or higher) hepatic encephalopathy, or serum creatinine &#62;3 mg/dL.</td> </tr> <tr> <td class=\"indent1\">Patients with ascitic fluid polymorphonuclear leukocyte (PMN) counts &#60;250 cells/mm<sup>3</sup> (0.25 X 10<sup>9</sup>/L) and signs or symptoms of infection (temperature &#62;100&#176;F or abdominal pain or tenderness) should also receive empiric antibiotic therapy, eg, intravenous cefotaxime 2 g every 8 hours, while awaiting results of cultures.</td> </tr> <tr> <td class=\"indent1\">When the ascitic fluid of a patient with cirrhosis is found to have a PMN count &#8805;250 cells/mm<sup>3</sup> (0.25 X 10<sup>9</sup>/L) and there is high suspicion of secondary peritonitis, it should also be tested for total protein, LDH, glucose, Gram stain, carcinoembryonic antigen, and alkaline phosphatase to assist with the distinction of SBP from secondary peritonitis. Computed tomographic scanning should also be performed.</td> </tr> <tr> <td class=\"indent1\">Patients with ascitic fluid PMN counts &#8805;250 cells/mm<sup>3</sup> (0.25 X 10<sup>9</sup>/L) in a nosocomial setting and/or recent beta-lactam antibiotic exposure and/or culture of an atypical organism(s) or an atypical clinical response to treatment should undergo a follow-up paracentesis after 48-hours of treatment to assess the response in PMN count and culture.</td> </tr> <tr> <td class=\"indent1\">Patients with ascitic fluid PMN counts &#8805;250 cells/mm<sup>3</sup> (0.25 X 10<sup>9</sup>/L) and clinical suspicion of SBP, who also have a serum creatinine &#62;1 mg/dL, blood urea nitrogen &#62;30 mg/dL, or total bilirubin &#62;4 mg/dL should receive 1.5 g albumin/kg body weight within 6 hours of detection and 1.0 g/kg on day three.</td> </tr> <tr> <td class=\"subtitle1_single\">Prevention of spontaneous bacterial peritonitis</td> </tr> <tr> <td class=\"indent1\">Intravenous ceftriaxone for seven days or twice-daily norfloxacin for seven days should be given to prevent bacterial infections in patients with cirrhosis and gastrointestinal hemorrhage.</td> </tr> <tr> <td class=\"indent1\">Patients who have survived an episode of SBP should receive long-term prophylaxis with daily norfloxacin (or trimethoprim/sulfamethoxazole) because this is the most data-supported indication for long-term outpatient prophylaxis.</td> </tr> <tr> <td class=\"indent1\">In patients with cirrhosis and ascites but no gastrointestinal bleeding, long-term use of norfloxacin (or trimethoprim/sulfamethasoxazole) can be justified if the ascitic fluid protein &#60;1.5 g/dL and at least one of the following is present: serum creatinine &#8805;1.2 mg/dL, blood urea nitrogen &#8805;25 mg/dL, serum sodium &#8804;130 mEq/L, or Child-Pugh &#8805;9 points with bilirubin &#8805;3 mg/dL.</td> </tr> <tr> <td class=\"indent1\">Intermittent dosing of antibiotics to prevent bacterial infections may be inferior to daily dosing (due to the development of bacterial resistance) and thus daily dosing should preferentially be used.</td> </tr> <tr> <td class=\"subtitle1_single\">Hepatic hydrothorax</td> </tr> <tr> <td class=\"indent1\">Chest tube insertion is contraindicated in patients with hepatic hydrothorax.</td> </tr> <tr> <td class=\"indent1\">First-line therapy of hepatic hydrothorax consists of dietary sodium restriction and diuretics.</td> </tr> <tr> <td class=\"indent1\">TIPS can be considered as second-line treatment for hepatic hydrothorax once it becomes refractory to sodium restriction and diuretics.</td> </tr> <tr> <td class=\"subtitle1_single\">Additional considerations</td> </tr> <tr> <td class=\"indent1\">The risks versus benefits of hernia repair must be weighed carefully in patients with cirrhosis and ascites. Elective repair can be performed during or after liver transplantation.</td> </tr> <tr> <td class=\"indent1\">Elective repair of a hernia in a patient with cirrhosis is best performed after ascites has been controlled by medical treatment, the patient's overall condition has been optimized, and a multidisciplinary approach with consideration of perioperative TIPS is utilized.</td> </tr> <tr> <td class=\"indent1\">Emergent repair of a strangulated or perforated umbilical hernia is best performed by a surgeon who is experienced in the care of patients with cirrhosis.</td> </tr> <tr> <td class=\"indent1\">Cellulitis can explain pain and fever in patients with cirrhosis and ascites and should be treated with diuretics and antibiotics.</td> </tr> <tr> <td class=\"indent1\">Percutaneous endoscopic gastrostomy tube placement should be avoided in patients with cirrhosis and ascites.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Runyon BA. Management of adult patients with ascites due to cirrhosis: Update 2012. <A href=\"http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf\">http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf</A>&nbsp;(Accessed on April 26, 2013).</div><div id=\"graphicVersion\">Graphic 70375 Version 5.0</div></div></div>"},"70376":{"type":"graphic_table","displayName":"Chronic liver failure","title":"Allogeneic hepatocyte transplantation for patients with chronic liver failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Allogeneic hepatocyte transplantation for patients with chronic liver failure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Diagnosis, [reference]</td>\n\t\t\t\t\t<td class=\"subtitle1\">Age</td>\n\t\t\t\t\t<td class=\"subtitle1\">Outcome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">Cryptogenic cirrhosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">[1]</td>\n\t\t\t\t\t<td>3 weeks</td>\n\t\t\t\t\t<td>Intraportal (7x10<sup>8</sup> cells). NH<sub>3</sub> &#8595;. OLT after 1 week with full recovery.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">TPN + sepsis (Child C)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">[2]</td>\n\t\t\t\t\t<td>6 months</td>\n\t\t\t\t\t<td>Splenic artery infusion (5x10<sup>7</sup> cells). NH<sub>3</sub> &#8595;; encephalopathy improved. Intracranial hemorrhage on d7.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">Alpha-1 antitrypsin disease (PiZZ), cirrhosis; pulmonary insufficiency, encephalopathy grade 4; Child C</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">[2]</td>\n\t\t\t\t\t<td>52 years</td>\n\t\t\t\t\t<td>NH<sub>3</sub> &#8595;, PiMM alpha-1 present in plasma. OLT on d2 with full recovery.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">HCV, cirrhosis, Child C encephalopathy grade 4</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">[2]</td>\n\t\t\t\t\t<td>40 years</td>\n\t\t\t\t\t<td>Intracranial hemorrhage on d2 (hepatocytes in spleen at autopsy).</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">EtoH cirrhosis. Male, Child C; encephalopathy grade 3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">[3]</td>\n\t\t\t\t\t<td>62 years</td>\n\t\t\t\t\t<td>Splenic artery infusion (6x10<sup>8</sup>). Encephalopathy improved, and NH<sub>3</sub> &#8595;, full recovery. Hyperkalemic cardiac arrest at day 33.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">EtoH cirrhosis. Male, encephalopathy grade 3</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">[4]</td>\n\t\t\t\t\t<td>46 years</td>\n\t\t\t\t\t<td>No improvement, death on day 50.</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">1. Soriano HE, Wood RP, Kang DC, et al. Hepatocellular transplantation HCT) in children with fulminant liver failure. Hepatology 1997; 30:239A.<BR>2. Strom SC, Fisher RA, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63:559.<BR>3. Sterling RK, Fisher RA. Liver Transplantation: Living Donor, Hepatocyte, and Xenotransplantation. In: Current Future Treatment Therapies for Liver Disease. Clinics in Liver Disease. Gish, R, ed. Philadelphia: WB Saunders, 2001.<BR>4. Strom SC, Roy-Chowdhury J, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999; 19:39.</div><div id=\"graphicVersion\">Graphic 70376 Version 2.0</div></div></div>"},"70379":{"type":"graphic_figure","displayName":"Circadian pattern SCD I","title":"Circadian variability in sudden death","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Circadian variability in sudden death</div><div class=\"cntnt\"><img style=\"width:456px; height:320px;\" src=\"images/CARD/70379_Circadian_pattern_SCD_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Analysis of death certificates of 2203 individuals with out-of-hospital sudden death demonstrates that the peak frequency is between 9 and 11 am.</div><div class=\"graphic_reference\">Data from Muller, JE, Ludmer, PL, Willich, SN, et al. Circulation 1987; 75:131.</div><div id=\"graphicVersion\">Graphic 70379 Version 1.0</div></div></div>"},"70381":{"type":"graphic_diagnosticimage","displayName":"Proximal phalanx transverse fracture AP radiograph","title":"Transverse fractures of the proximal phalanx: AP radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse fractures of the proximal phalanx: AP radiograph</div><div class=\"cntnt\"><img style=\"width:337px; height:450px;\" src=\"images/EM/70381_Prox_phalanx_trans_fx_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior (AP) radiograph shows a transverse fracture of the proximal phalanx (white arrow). Note the the slight angulation of the two major fragments and the diastasis on the side adjacent to the arrow.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 70381 Version 3.0</div></div></div>"},"70382":{"type":"graphic_figure","displayName":"Normal growth rate in children","title":"Estimates for normal growth rates in children","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">Estimates for normal growth rates in children</div><div class=\"cntnt\"><img style=\"width:682px; height:172px;\" src=\"images/ENDO/70382_Norm_growth_rate_child_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal length or height at various ages during childhood, and the growth rate between those timepoints, are approximated by multiples of five when measured in centimeters (this is sometimes termed the \"rule of fives\"). Actual height and growth rate in a healthy child can vary substantially around these approximations.</div><div class=\"graphic_footnotes\">* Growth rates may be considerably higher in the later end of this age range for children who have entered their pubertal growth spurt. In girls, the pubertal growth spurt typically starts around age 10, but may start as early as age 8 in early-maturing girls. In boys, the pubertal growth spurt typically starts around age 12, but may start as early as age 10 in early-maturing boys.</div><div id=\"graphicVersion\">Graphic 70382 Version 7.0</div></div></div>"},"70383":{"type":"graphic_table","displayName":"Options for emergency contraception","title":"Options for emergency contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Options for emergency contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Timing of&nbsp;use after unprotected intercourse<sup>&#182;</sup>&nbsp;</td> <td class=\"subtitle1\">Reported efficacy</td> </tr> <tr> <td>Levonorgestrel</td> <td>0.75 mg given twice, 12 hours apart <strong>or</strong> 1.5 mg given as a single dose</td> <td>&nbsp;Up to 3 days (72 hours) </td> <td>59 to 94 percent of pregnancies prevented</td> </tr> <tr> <td>Estrogen plus progesterone (Yuzpe regimen)</td> <td>100 to 120 micrograms ethinyl estradiol plus 500 to 600 micrograms levonorgestrel in each dose, given twice, 12 hours apart</td> <td>&nbsp;Up to 5 days (120 hours)</td> <td>47 to 89 percent of pregnancies prevented</td> </tr> <tr> <td>Mifepristone*</td> <td>Single 600 mg dose</td> <td>&nbsp;Up to 5 days (120 hours)</td> <td>99 to 100 percent</td> </tr> <tr> <td>Copper intrauterine device</td> <td>Inserted within 120 hours after intercourse</td> <td>&nbsp;Up to 5 days (120 hours)</td> <td>At least 99 percent</td> </tr> <tr> <td>Ulipristal</td> <td>Single oral dose of 30 mg</td> <td>&nbsp;Up to 5 days (120 hours)</td> <td>98 to 99 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not available for emergency contraception in the United States.<br />¶&nbsp;Emergency contraception is best used as soon as possible after unprotected intercourse.</div><div id=\"graphicVersion\">Graphic 70383 Version 6.0</div></div></div>"},"70384":{"type":"graphic_picture","displayName":"Episcleritis IBD","title":"Episcleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Episcleritis</div><div class=\"cntnt\"><img style=\"width:236px; height:181px;\" src=\"images/GAST/70384_Episcleritis_IBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with episcleritis associated with inflammatory bowel disease showing the characteristic injection of the ciliary vessels.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner- Fenwick, Inc at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 70384 Version 3.0</div></div></div>"},"70385":{"type":"graphic_figure","displayName":"Vaginal uterine fibroid removal","title":"Removal of uterine fibroids at time of vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Removal of uterine fibroids at time of vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:452px; height:296px;\" src=\"images/OBGYN/70385_Uterine_morcellation_B.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70385 Version 3.0</div></div></div>"},"70386":{"type":"graphic_table","displayName":"Symptoms of SLE","title":"Frequency of signs and symptoms of systemic lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of signs and symptoms of systemic lupus erythematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">Percent at onset</td> <td class=\"subtitle1\">Percent at any time</td> </tr> <tr> <td>Fatigue</td> <td>50</td> <td>74 to 100</td> </tr> <tr> <td>Fever</td> <td>36</td> <td>40 to 80+</td> </tr> <tr> <td>Weight loss</td> <td>21</td> <td>44 to 60+</td> </tr> <tr> <td>Arthritis or arthralgia</td> <td>62 to 67</td> <td>83 to 95</td> </tr> <tr> <td class=\"sublist1_start\">Skin</td> <td class=\"sublist_other_start\">73</td> <td class=\"sublist_other_start\">80 to 91</td> </tr> <tr> <td class=\"sublist1\">Butterfly rash</td> <td class=\"sublist_other\">28 to 38</td> <td class=\"sublist_other\">48 to 54</td> </tr> <tr> <td class=\"sublist1\">Photosensitivity</td> <td class=\"sublist_other\">29</td> <td class=\"sublist_other\">41 to 60</td> </tr> <tr> <td class=\"sublist1\">Mucuous membrane lesion</td> <td class=\"sublist_other\">10 to 21</td> <td class=\"sublist_other\">27 to 52</td> </tr> <tr> <td class=\"sublist1\">Alopecia</td> <td class=\"sublist_other\">32</td> <td class=\"sublist_other\">18&nbsp;to 71</td> </tr> <tr> <td class=\"sublist1\">Raynaud's phenomenon</td> <td class=\"sublist_other\">17&nbsp;to 33</td> <td class=\"sublist_other\">22&nbsp;to 71</td> </tr> <tr> <td class=\"sublist1\">Purpura</td> <td class=\"sublist_other\">10</td> <td class=\"sublist_other\">15&nbsp;to 34</td> </tr> <tr> <td class=\"sublist1\">Urticaria</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">4&nbsp;to 8</td> </tr> <tr> <td class=\"sublist1_start\">Renal</td> <td class=\"sublist_other_start\">16&nbsp;to 38</td> <td class=\"sublist_other_start\">34&nbsp;to 73</td> </tr> <tr> <td class=\"sublist1\">Nephrosis</td> <td class=\"sublist_other\">5</td> <td class=\"sublist_other\">11&nbsp;to 18</td> </tr> <tr> <td>Gastrointestinal</td> <td>18</td> <td>38&nbsp;to 44</td> </tr> <tr> <td class=\"sublist1_start\">Pulmonary</td> <td class=\"sublist_other_start\">2&nbsp;to 12</td> <td class=\"sublist_other_start\">24&nbsp;to 98</td> </tr> <tr> <td class=\"sublist1\">Pleurisy</td> <td class=\"sublist_other\">17</td> <td class=\"sublist_other\">30&nbsp;to 45</td> </tr> <tr> <td class=\"sublist1\">Effusion</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">24</td> </tr> <tr> <td class=\"sublist1\">Pneumonia</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">29</td> </tr> <tr> <td class=\"sublist1_start\">Cardiac</td> <td class=\"sublist_other_start\">15</td> <td class=\"sublist_other_start\">20&nbsp;to 46</td> </tr> <tr> <td class=\"sublist1\">Pericarditis</td> <td class=\"sublist_other\">8</td> <td class=\"sublist_other\">8&nbsp;to 48</td> </tr> <tr> <td class=\"sublist1\">Murmurs</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">23</td> </tr> <tr> <td class=\"sublist1\">ECG changes</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">34&nbsp;to 70</td> </tr> <tr> <td>Lymphadenopathy</td> <td>7&nbsp;to 16</td> <td>21&nbsp;to 50</td> </tr> <tr> <td>Splenomegaly</td> <td>5</td> <td>9&nbsp;to 20</td> </tr> <tr> <td>Hepatomegaly</td> <td>2</td> <td>7&nbsp;to 25</td> </tr> <tr> <td class=\"sublist1_start\">Central nervous system</td> <td class=\"sublist_other_start\">12&nbsp;to 21</td> <td class=\"sublist_other_start\">25&nbsp;to 75</td> </tr> <tr> <td class=\"sublist1\">Functional</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Most</td> </tr> <tr> <td class=\"sublist1\">Psychosis</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">5&nbsp;to 52</td> </tr> <tr> <td class=\"sublist1\">Convulsions</td> <td class=\"sublist_other\">0.5</td> <td class=\"sublist_other\">2&nbsp;to 20</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Von Feldt JM, Postgrad Med 1995; 97:79.</div><div id=\"graphicVersion\">Graphic 70386 Version 5.0</div></div></div>"},"70388":{"type":"graphic_figure","displayName":"Secondary hyperfibrinolysis","title":"Secondary hyperfibrinolysis","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Secondary hyperfibrinolysis</div><div class=\"cntnt\"><img style=\"width:593px; height:273px;\" src=\"images/SURG/70388_Second_hyperfibrinolysis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Citrated rapid-TEG showing secondary hyperfibrinolysis. The red tracing indicates a normal study.<br> This study shows a normal ACT, R time, K time, and alpha angle; high LY30 reflecting hyperfibrinolysis; normal MA and G, reflecting onset of fibrinolysis after achieving maximal clot strength.</div><div class=\"graphic_footnotes\">R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing &quot;body&quot; of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.</div><div id=\"graphicVersion\">Graphic 70388 Version 3.0</div></div></div>"},"70389":{"type":"graphic_figure","displayName":"Fenton growth chart premature infants - Girls","title":"Fenton growth chart for premature infants - Girls","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Fenton growth chart for premature infants - Girls</div><div class=\"cntnt\"><img style=\"width:594px; height:783px;\" src=\"images/PEDS/70389_Fenton_gr_ch_pre_infant_gl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fenton growth chart for preterm infant girls.</div><div class=\"graphic_footnotes\">%: Percent.</div><div class=\"graphic_reference\">Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatrics 2013; 13:59. Copyright © 2013 Fenton and Kim. Reproduced from BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 70389 Version 3.0</div></div></div>"},"70390":{"type":"graphic_picture","displayName":"Fasciolopsiasis egg","title":"Fasciolopsiasis egg","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Fasciolopsiasis egg</div><div class=\"cntnt\"><img style=\"width:586px; height:308px;\" src=\"images/ID/70390_Fasciolopsiasis_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Eggs of<EM>&nbsp;Fasciolopsis buski</EM> in unstained wet mounts.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Fasciolopsiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/fasciolopsiasis/index.html\">http://www.cdc.gov/dpdx/fasciolopsiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 70390 Version 5.0</div></div></div>"},"70392":{"type":"graphic_picture","displayName":"Chronic HP Light","title":"Chronic hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:287px; height:185px;\" src=\"images/PULM/70392_Chronic_HP_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph from a patient with chronic hypersensitivity pneumonitis shows a pattern reminiscent of usual interstitial pneumonia. Other areas of the biopsy reveal granulomatous inflammation.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 70392 Version 1.0</div></div></div>"},"70393":{"type":"graphic_diagnosticimage","displayName":"M mode bicuspid AV","title":"Bicuspid aortic valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bicuspid aortic valve</div><div class=\"cntnt\"><img style=\"width:347px; height:226px;\" src=\"images/CARD/70393_MmodebicuspidAV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram (panel B) is obtained from the parasternal long axis view of the two dimensional echocardiogram (panel A); the dotted line indicates the plane of imaging. Although not obvious in the long axis view, the M-mode echocardiogram shows a typical feature of a bicuspid aortic valve (ie, eccentricity of closure; arrow). Normally, the image of the closed valve is centered in the middle of the aortic root. In this example, the closure occurs anterior of the center and the anterior leaflet (right cusp) is thickened. Such eccentricity is typical of congenitally abnormal valves with fused commisures, forming a bicuspid valve.</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; Ao: aorta; LA: left atrium; AL: anterior leaflet.</div><div id=\"graphicVersion\">Graphic 70393 Version 3.0</div></div></div>"},"70395":{"type":"graphic_picture","displayName":"Schneider silicone stent","title":"Schneider covered metal stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schneider covered metal stent</div><div class=\"cntnt\"><img style=\"width:350px; height:200px;\" src=\"images/PULM/70395_Schneider_silicone_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schneider silicone-covered self-expanding metal stent. Note the nonsilicone covered ends of the stent.</div><div id=\"graphicVersion\">Graphic 70395 Version 2.0</div></div></div>"},"70396":{"type":"graphic_diagnosticimage","displayName":"Traction bronchiectasis CT","title":"Postradiation traction bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postradiation traction bronchiectasis</div><div class=\"cntnt\"><img style=\"width:373px; height:298px;\" src=\"images/PULM/70396_Traction_bronchiectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traction bronchiectasis in a patient with Hodgkin's disease and previous mantle irradiation. The main finding is paramediastinal radiation fibrosis, with loss of volume and mild cylindrical bronchiectasis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70396 Version 3.0</div></div></div>"},"70398":{"type":"graphic_figure","displayName":"Fixation in malrotation","title":"Shortened mesenteric attachment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shortened mesenteric attachment</div><div class=\"cntnt\"><img style=\"width:319px; height:369px;\" src=\"images/PEDS/70398_Fixation_in_malrotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mesenteric fixation in malrotation. Most anomalies of rotation result in an abnormally narrow mesenteric base (demonstrated by the red line). The suspension of the midgut on this narrow vascular pedical increases the risk of volvulus.</div><div id=\"graphicVersion\">Graphic 70398 Version 1.0</div></div></div>"},"70399":{"type":"graphic_diagnosticimage","displayName":"Osteoid osteoma RF ablation","title":"CT-guided radiofrequency ablation of an osteoid osteoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT-guided radiofrequency ablation of an osteoid osteoma</div><div class=\"cntnt\"><img style=\"width:225px; height:576px;\" src=\"images/PEDS/70399_Osteoid_osteoma_RF_ablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) CT image of the shoulder joint shows the osteoid osteoma (arrow).<br />(B) CT image shows a cannula (arrow) placed over the bone giving direct line access to the tumor.<br />(C) CT image shows the radiofrequency probe (arrow) placed immediately over the tumor.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner, RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70399 Version 3.0</div></div></div>"},"70403":{"type":"graphic_picture","displayName":"Sebaceous carcinoma","title":"Sebaceous carcinoma of the eyelid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sebaceous carcinoma of the eyelid</div><div class=\"cntnt\"><img style=\"width:432px; height:254px;\" src=\"images/PC/70403_Sebac_cell_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mimic of blepharitis, but with only unilateral findings. Here the bump on the medial upper lid is concerning due to its vascularity and alteration of both the lid margin architecture and the lash line.</div><div id=\"graphicVersion\">Graphic 70403 Version 2.0</div></div></div>"},"70405":{"type":"graphic_picture","displayName":"Myeloma cast II- light microscopy ","title":"Myeloma cast: Light microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myeloma cast: Light microscopy</div><div class=\"cntnt\"><img style=\"width:378px; height:253px;\" src=\"images/NEPH/70405_Myeloma_cast_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing classic features of cast nephropathy including: 1) obstructed tubule with a fractured dense cast; 2) giant cell reaction in the lower left part of the tubule; and 3) interstitial infiltrate with macrophages.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 70405 Version 4.0</div></div></div>"},"70406":{"type":"graphic_table","displayName":"Rotterdam scale for TBI","title":"Rotterdam CT (computed tomography) classification of traumatic brain injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rotterdam CT (computed tomography) classification of traumatic brain injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Predictor value</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Basal cisterns</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Compressed</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Midline shift</td> </tr> <tr> <td class=\"indent1\">No shift or shift &#8804;5 mm</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Shift &#62;5 mm</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Epidural mass lesion</td> </tr> <tr> <td class=\"indent1\">Present</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intraventricular blood or subarachnoid hemorrhage</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Present</td> <td class=\"centered\">1</td> </tr> <tr> <td><strong>Sum score</strong></td> <td class=\"centered\"><strong>Total + 1</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Maas Al, Hukkelhoven CW, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. Neurosurgery 2005; 57:1173. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70406 Version 12.0</div></div></div>"},"70408":{"type":"graphic_figure","displayName":"Adams forward bend test","title":"Adams forward bend test for scoliosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adams forward bend test for scoliosis</div><div class=\"cntnt\"><img style=\"width:331px; height:476px;\" src=\"images/PEDS/70408_Adams_forward_bend_test_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Adams forward bend test demonstrates the rotational component of scoliosis. It is performed by observing the patient from the back while he or she bends forward at the waist until the spine becomes parallel to the horizontal plane. The patient's feet should be together, knees straight ahead, and arms hanging free. Asymmetry of the upper thoracic, midthoracic, thoracolumbar, or lumbar region is noted. The drawing above depicts the right rib hump of thoracic scoliosis.</div><div id=\"graphicVersion\">Graphic 70408 Version 4.0</div></div></div>"},"70409":{"type":"graphic_table","displayName":"Antidotes pediatric poisoning A","title":"Recommended antidotes in pediatric poisonings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended antidotes in pediatric poisonings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antidote</td> <td class=\"subtitle1\">Poisoning indication</td> <td class=\"subtitle1\">Pediatric dose</td> </tr> <tr> <td>N-acetylcysteine</td> <td>Acetaminophen</td> <td> <p>Oral Loading dose: 140 mg/kg orally; oral maintenance doses: 70 mg/kg every four hours for 17 doses</p> <p>Intravenous (IV)&nbsp;administration: 150mg/kg over 1 hour (loading dose); 50 mg/kg IV over 4 hours; 100 mg/kg IV over 16 hours</p> </td> </tr> <tr> <td rowspan=\"2\">Atropine</td> <td>Carbamate insecticide</td> <td rowspan=\"2\">0.02 mg/kg IV bolus (0.1 mg minimum dose; maximum single dose 0.5 mg for children and 1.0 mg for adolescents) repeat doses titrated to effect</td> </tr> <tr> <td>Organophosphate insecticide</td> </tr> <tr> <td>Crotalid antivenin</td> <td>Crotalid snakes</td> <td>4 to 6 vials (more if severe)</td> </tr> <tr> <td rowspan=\"2\">Calcium gluconate and calcium chloride (10 percent)</td> <td>Calcium channel blocker</td> <td rowspan=\"2\">Gluconate: 100 to 200 mg/kg IV Chloride: 20 to 30 mg/kg IV repeat doses and IV infusions are common</td> </tr> <tr> <td>Hydrogen fluoride (HF)</td> </tr> <tr> <td>Cyanide antidote kit (may contain sodium nitrite 3 percent ,sodium thiosulfate, and/or hydroxocobalamin)</td> <td>Cyanide</td> <td> <p>Sodium thiosulfate: 400 mg/kg IV (maximum 12.5 grams)</p> <p>Hydroxocobalamin: 70 mg/kg IV (maximum 5 grams)</p> <p>Sodium nitrite: 6 mg/kg by slow IV infusion (maximum 300 mg, only give if <strong>not</strong> contraindicated and hydroxocobolamin is <strong>not</strong> available), refer to UpToDate topics on cyanide poisoning</p> </td> </tr> <tr> <td>Deferoxamine</td> <td>Iron</td> <td>5 to 15 mg/kg per hour IV infusion, titrated to effect</td> </tr> <tr> <td rowspan=\"3\">Digoxin immune Fab</td> <td>Digoxin</td> <td rowspan=\"3\">Empiric dosing: 10 to 20 vials IV bolus fo life-threatening toxicity; see package insert for other dosing regimens</td> </tr> <tr> <td>Digitoxin</td> </tr> <tr> <td>Natural product (eg, plants, toads)</td> </tr> <tr> <td rowspan=\"3\">Dimercaprol (BAL, British antilewisite)</td> <td>Acute arsenic</td> <td rowspan=\"3\">2.5 to 4 mg/kg IM</td> </tr> <tr> <td>Inorganic mercury</td> </tr> <tr> <td>Lead (with encephalopathy)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Dart, RC, Goldfrank, LR, Chyka, PA, Lotzer, D. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126 and Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.</div><div id=\"graphicVersion\">Graphic 70409 Version 2.0</div></div></div>"},"70410":{"type":"graphic_table","displayName":"Antidepressants in HIV","title":"Antidepressant medications in the HIV-infected adult","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antidepressant medications in the&nbsp;HIV-infected adult</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antidepressant</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Typical dose range</td> <td class=\"subtitle1\">Tolerability profile relevant to management of patients with HIV</td> <td class=\"subtitle1\">Mechanism of potential pharmacokinetic interactions with HIV antiretroviral drugs*</td> <td class=\"subtitle1\">Selected pharmacokinetic interactions with HIV antiretroviral drugs</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Selective serotonin reuptake inhibitors (SSRIs)</td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td>20 mg daily</td> <td>20 to 40 mg daily<sup>&#182;</sup></td> <td>Generally well tolerated; effective for anxiety; low risk of sleep disturbance.</td> <td> <p>Citalopram is metabolized by CYP2C19 and 3A4;</p> Citalopram does not significantly alter CYP450 metabolism</td> <td> <ul> <li>Possible elevated risk of cardiac arrhythmia in combination with agents that significantly increase citalopram concentrations and/or prolong QTc interval (eg, lopinavir, saquinavir).<sup>&#916;</sup> </li> <li>Citalopram dose should not exceed 20 mg per day in patients receiving strong or moderate inhibitors of CYP2C19 and 3A4 (ie, protease inhibitor<sup>&#9674;</sup> and cobicistat-or ritonavir- containing regimens<sup>&#167;</sup>, efavirenz, or&nbsp;etravirine) which may INCREASE citalopram concentrations.<sup>&#182;</sup> </li> <li>Titrate citalopram dose based upon response using a low initial dose (maximum 40 mg daily).<sup><span style=\"font-size: 13px;\">&#182;</span></sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td>10 mg daily</td> <td>10 to 20 mg daily</td> <td>Generally well tolerated; effective for anxiety; low risk of sleep disturbance.</td> <td> <p>Escitalopram is metabolized by CYP2C19 and 3A4;</p> Escitalopram does not significantly alter CYP450 metabolism</td> <td> <ul> <li>Possible elevated risk of cardiac arrhythmia in combination with agents that significantly increase escitalopram concentrations and/or prolong QTc interval (eg, lopinavir, saquinavir). </li> <li>Escitalopram appears to have a relatively low risk of significant interactions with most HIV antiretroviral medications. </li> <li>Titrate escitalopram dose based upon response using a low initial dose.&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>10 mg daily</td> <td>20 to 40 mg daily</td> <td> <p>Activating effect may be useful for treatment of depressed patients with low energy or hypersomnia.</p> Tapering upon discontinuation is not needed due to long half-life.</td> <td> <p>Fluoxetine is metabolized primarily&nbsp;by CYP2D6 and 2C9;</p> Fluoxetine inhibits 2C19 and 2D6</td> <td> <ul> <li>Strong inhibitors of CYP2D6, including cobicistat- and ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE fluoxetine concentrations. </li> <li>Possible elevated risk of cardiac arrhythmia in combination with agents that significantly increase fluoxetine concentrations and/or prolong QTc interval (eg, lopinavir, saquinavir).<sup>&#916;</sup> </li> <li>Strong inducers of CYP2C19 and/or 2D6, including nevirapine, can DECREASE fluoxetine concentrations. </li> <li>Fluoxetine's prolonged half-life may complicate evaluation of drug interactions and wash-out. </li> <li>Titrate fluoxetine dose based upon response using a low initial dose. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td>50 mg each bedtime</td> <td>150 to 250 mg each bedtime (extended release) or in divided doses </td> <td>Somewhat sedating.</td> <td> <p>Fluvoxamine is metabolized by CYP1A2 and 2D6;</p> Fluvoxamine inhibits CYP1A2 and 2C19</td> <td> <ul> <li>Strong inhibitors of CYP1A2 and/or 2D6 including cobicistat- and ritonavir-containing regimens<sup>&#167;</sup>, darunavir, lopinavir,&nbsp;and tipranavir may INCREASE fluvoxamine concentrations. </li> <li>Fluvoxamine interactions with HIV antiretrovirals are difficult to predict; we suggest the use of an alternative antidepressant. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Paroxetine</td> <td>10 mg each bedtime</td> <td>20 to 50 mg each bedtime</td> <td> <p>Sedating; possibly useful for depressed or anxious patients with insomnia.</p> Mild anticholinergic effects.</td> <td> <p>Paroxetine is metabolized by CYP2D6;</p> Paroxetine inhibits CYP2D6</td> <td> <ul> <li>Strong inhibitors of CYP2D6 including cobicistat- and ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE paroxetine concentrations. </li> <li>However, darunavir-ritonavir and fosamprenavir-ritonavir DECREASED paroxetine AUC by 39 and 55%, respectively, in small studies of healthy volunteers. </li> <li>Titrate paroxetine dose based upon response using a&nbsp;low initial dose. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sertraline</td> <td>25 to 50 mg daily</td> <td>100 to 200 mg daily</td> <td> <p>Non-sedating; low risk of insomnia; lacks significant cardiac effects.</p> More frequent diarrhea.</td> <td> <p>Sertraline is metabolized by multiple CYP450 subfamilies;</p> Sertraline inhibits CYP2D6 and CYP2C19 at doses &#8805;200 mg daily</td> <td> <ul> <li>Strong inhibitors of CYP2D6 including cobicistat- and ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE sertraline concentrations. </li> <li>However, efavirenz and darunavir-ritonavir DECREASED sertraline AUCs by 39 and 49%, respectively, in small studies of healthy volunteers. Nevirapine may have a similar effect. </li> <li>Titrate sertraline dose based upon response using a low initial dose. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Serotonin-norepinephrine reuptake inhibitors (SNRIs)</td> </tr> <tr> <td class=\"indent1\">Desvenlafaxine</td> <td>50 mg</td> <td>50 to 100 mg once daily</td> <td>Activating effect may be useful for treatment of melancholic depressed patients with low energy or hypersomnia. Useful for patients with comorbid painful conditions such as diabetic neuropathy.</td> <td> <p>Desvenlafaxine undergoes UDP-UGT conjugation;</p> Desvenlafaxine does not appear to substantially alter CYP metabolism</td> <td> <ul> <li>Desvenlafaxine appears to have a relatively low risk of significant interactions with most HIV antiretrovirals. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> <td>30 mg</td> <td>60 to 120 mg each bedtime or in divided doses</td> <td>Mildly sedating; useful for patients with comorbid painful conditions such as neuropathy or chronic pain.</td> <td> <p>Duloxetine is metabolized by CYP1A2;</p> Duloxetine inhibits CYP2D6</td> <td> <ul> <li>Strong inhibitors of CYP1A2 and/or 2D6 including cobicistat- and ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE duloxetine concentrations. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venlafaxine (extended release)</td> <td>37.5 mg</td> <td>75 to 225 mg once daily</td> <td>Activating effect may be useful for treatment of melancholic depressed patients with low energy or hypersomnia. Useful for patients with comorbid painful conditions such as diabetic neuropathy.</td> <td> <p>Venlafaxine is metabolized by CYP2D6 and 3A4;</p> Venlafaxine does not significantly alter CYP metabolism</td> <td> <ul> <li>Strong inhibitors of CYP2D6 and/or 3A4 including protease inhibitor<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup> may INCREASE venlafaxine concentrations. </li> <li>Venlafaxine co-administered with lopinavir or saquinavir (with or without ritonavir) may prolong QTc interval.<sup>&#916;</sup> </li> <li>AUC of indinavir (without ritonavir) was decreased by 28% by venlafaxine in a small study of healthy volunteers. </li> <li>Strong inducers of CYP2D6 and/or 3A4 including efavirenz (variable effects), etravirine, and nevirapine may DECREASE venlafaxine concentrations. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Noradrenergic and specific serotonergic antidepressant</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mirtazapine</td> <td>7.5 to 15 mg each bedtime</td> <td>15 to 45 mg each bedtime</td> <td>Sedating; useful for patients with insomnia or who may benefit from weight gain which can be substantial. Appetite stimulant and anti-nausea effects can be noted within days.</td> <td> <p>Mirtazapine is metabolized by CYP1A2, 2D6, and 3A4;</p> Mirtazapine does not significantly alter CYP metabolism</td> <td> <ul> <li>Strong inhibitors of CYP1A2, 2D6, and/or 3A4 including protease inhibitor<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens may INCREASE mirtazapine concentrations. </li> <li>Strong inducers of CYP3A4 including efavirenz (variable effects), etravirine (variable effects) and nevirapine may DECREASE mirtazapine concentrations. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Serotonin modulators</td> </tr> <tr> <td class=\"indent1\">Nefazodone</td> <td>50 mg twice per day</td> <td>300 to 400 mg per day in divided doses</td> <td> <p>Somewhat sedating. Low risk of sexual dysfunction.</p> Rare reports of fatal hepatotoxicity led to market withdrawal in many countries.</td> <td> <p>Nefazodone is metabolized by CYP2D6 and 3A4;</p> Nefazodone inhibits CYP3A4 and P-gp</td> <td> <ul> <li>Avoid nefazodone in patients treated with HIV antiretrovirals due to potentially serious drug interaction-associated toxicities. </li> <li>Nefazodone can alter concentrations of numerous HIV antiretrovirals including CYP3A4 and/or P-gp substrates (eg, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, maraviroc, nelfinavir, nevirapine, ritonavir, and saquinavir). </li> <li>Protease inhibitor<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup> may INCREASE concentrations of nefazodone. </li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Trazodone</td> <td rowspan=\"2\">50 to 100 mg each bedtime</td> <td>50 to 150 mg each bedtime for sleep</td> <td rowspan=\"2\">Used in low doses as an adjunct to SSRI for treatment of insomnia.</td> <td rowspan=\"2\"> <p>Trazodone is metabolized by CYP3A4</p> </td> <td rowspan=\"2\"> <ul> <li>Strong inhibitors of CYP1A2, 2D6 and/or 3A4, including protease inhibitor<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup> can INCREASE concentrations of trazodone. </li> <li>Use of saquinavir or saquinavir-ritonavir with trazodone is contraindicated. </li> <li>Strong inducers of CYP3A4 including efavirenz (variable effects), etravirine (variable effects) and nevirapine may DECREASE trazodone levels. </li> <li>Use lowest starting dose of trazodone. Closely monitor effects. </li> </ul> </td> </tr> <tr> <td>200 to 600 mg each bedtime for depression</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vilazodone</td> <td>10 mg once daily 7 days; then 20 mg once daily</td> <td> <p>20 to 40 mg once daily</p> Maximum 20 mg per day with strong or moderate CYP 3A4 inhibitors</td> <td> <p>Low risk of sexual dysfunction. May improve quality of sleep.</p> More frequent diarrhea, nausea and insomnia.</td> <td> <p>Vilazodone is metabolized by CYP3A4;</p> Vilazodone does not appear to significantly alter CYP metabolism</td> <td> <ul> <li>Strong and moderate inhibitors of CYP3A4, including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup> may INCREASE vilazodone concentrations. </li> <li>Maximum vilazodone dose 20 mg per day with strong or moderate CYP3A4 inhibitors. </li> <li>Strong inducers of CYP3A4 including efavirenz, etravirine, and nevirapine may DECREASE vilazodone concentrations. </li> <li>If&nbsp;vilazodone is&nbsp;used with a strong inducer of CYP3A4, the vilazodone&nbsp;daily dose&nbsp;may need to be increased to a maximum of 80 mg depending upon response.&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Dopamine-norepinephrine reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Bupropion SR (sustained release)</td> <td>100 mg each morning</td> <td>150 to 400 mg per day in divided doses (depending on preparation)</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Stimulant effect may be useful for treatment of depressed patients with low energy and apathy.</p> Low risk of cognitive toxicity. Low risk of sexual dysfunction.</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Bupropion is metabolized by CYP2B6 and UDP-UGT glucuronidation;</p> Bupropion inhibits CYP2D6</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Strong inducers of CYP2B6 and/or UDP-UGT including efavirenz, lopinavir-ritonavir, tipranavir-ritonavir, and nevirapine may DECREASE concentrations of bupropion. </li> <li>A 46 to 57% reduction in bupropion concentrations was&nbsp;observed in small studies of healthy volunteers when bupropion was co-administered with ritonavir-boosted lopinavir,&nbsp;tipranavir, or efavirenz. </li> <li>Titrate bupropion dose based upon response. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bupropion XL (extended release)</td> <td>150 mg each morning</td> <td>300 to 450 mg once daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Tricyclic antidepressants (TCAs)<sup>&#916;</sup><sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> <td>10 to 25 mg daily</td> <td>150 to 300 mg daily</td> <td> <p>Sedating; promotes weight gain.<sup>&#165;</sup></p> Established therapeutic serum concentration 80 to 200 ng/mL.<sup>&#165;</sup></td> <td>Amitriptyline is metabolized by CYP2D6</td> <td> <ul> <li>Inhibitors of CYP2D6, including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE amitriptyline concentrations. </li> <li>Use lowest tricyclic antidepressant dose and titrate based on response. </li> <li>Plasma levels may be useful for assessing adherence and risk of toxicity.<sup>&#165;</sup> </li> <li>Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation (eg, lopinavir, saquinavir) and/or increase amitriptyline concentrations.<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>25 mg at bedtime</td> <td>100 to 300 mg at bedtime</td> <td> <p>Sedating; promotes weight gain.<sup>&#165;</sup></p> Established therapeutic serum concentration 230 to 450 ng/mL.<sup>&#165;</sup></td> <td> <p>Clomipramine is metabolized by CYP1A2, 2C19 and 2D6;</p> Clomipramine inhibits CYP2D6</td> <td> <ul> <li>Inhibitors of CYP1A2, 2C19 and/or 2D6, including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE clomipramine concentrations. </li> <li>Use lowest tricyclic antidepressant dose and titrate based on response. </li> <li>Plasma levels may be useful for assessing adherence and risk of toxicity.<sup>&#165;</sup> </li> <li>Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation (eg, lopinavir, saquinavir) and/or increase clomipramine concentrations.<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Desipramine</td> <td>10 to 25 mg daily</td> <td>50 to 300 mg daily</td> <td> <p>Mildly activating; promotes weight gain. Stimulant effect may be useful for depressed patients with low energy and hypersomnia who have not responded to first line antidepressants. Useful for patients with comorbid painful conditions such as diabetic neuropathy.<sup>&#165;</sup></p> Established therapeutic serum concentration 100 to 300 ng/mL.<sup>&#165;</sup></td> <td> <p>Desipramine is metabolized by CYP2D6;</p> Desipramine inhibits CYP2A6 and 2D6</td> <td> <ul> <li>Inhibitors of CYP2D6, including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE desipramine concentrations. </li> <li>Use lowest tricyclic antidepressant dose and titrate based on response. </li> <li>Plasma levels may be useful for assessing adherence and risk of toxicity.<sup>&#165;</sup> </li> <li>Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation (eg, lopinavir, saquinavir) and/or increase desipramine concentrations.<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Doxepin</td> <td>10 to 25 mg at bedtime</td> <td>150 to 300 mg at bed time</td> <td>Sedating; promotes weight gain.<sup>&#165;</sup></td> <td>Doxepin is metabolized by CYP2D6</td> <td> <ul> <li>Inhibitors of CYP2D6, including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE doxepin concentrations. </li> <li>Use lowest tricyclic antidepressant dose and titrate based on response. </li> <li>Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation (eg, lopinavir, saquinavir) and/or increase doxepin concentrations.<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Imipramine</td> <td>10 to 25 mg at bedtime</td> <td>150 to 300 mg at bedtime</td> <td> <p>Sedating; promotes weight gain.<sup>&#165;</sup></p> Established therapeutic serum concentration 200 to 300 ng/mL.<sup>&#165;</sup></td> <td> <p>Imipramine is metabolized by CYP2C19 and 2D6;</p> Imipramine inhibits CYP2D6</td> <td> <ul> <li>Inhibitors of CYP2C19 and/or 2D6 including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE imipramine levels. </li> <li>Use lowest tricyclic antidepressant dose and titrate based on response. </li> <li>Plasma levels may be useful for assessing adherence and risk of toxicity.<sup>&#165;</sup> </li> <li>Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation (eg, lopinavir, saquinavir) and/or increase imipramine concentrations.<sup>&#916;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nortriptyline</td> <td>10 to 25 mg at bed time</td> <td>50 to 150 mg at bedtime</td> <td> <p>Mildly sedating; promotes weight gain. Taken at bed time for depressed patients with insomnia. May be useful for melancholic, anxious, depressed patients who have not responded to first line antidepressants. Useful for patients with comorbid painful conditions such as diabetic neuropathy.<sup>&#165;</sup></p> Established therapeutic serum concentration 50 to 150 ng/mL.<sup>&#165;</sup></td> <td>Nortriptyline is metabolized by CYP2D6</td> <td> <ul> <li>Inhibitors of CYP2D6, including protease inhibitors<sup>&#9674;</sup> and cobicistat- or ritonavir-containing regimens<sup>&#167;</sup>, may INCREASE nortriptyline concentrations. </li> <li>Use lowest tricyclic antidepressant dose and titrate based on response. </li> <li>Plasma levels may be useful for assessing adherence and risk of toxicity.<sup>&#165;</sup> </li> <li>Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation (eg, lopinavir, saquinavir) and/or increase nortriptyline concentrations.<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Herbal products</td> </tr> <tr> <td class=\"indent1\">St John's wort (Hypericum perforatum)</td> <td colspan=\"3\">Do not co-administer St John's wort with HIV antiretrovirals</td> <td>St John's wort induces CYP1A2, 2C9, and 3A4</td> <td> <ul> <li>The use of St John's wort with HIV antiretrovirals is contraindicated. </li> <li>St John's wort can DECREASE antiretroviral levels and cause virologic resistance and treatment failure. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The integrase inhibitors (ie, dolutegravir, raltegravir) in regimens that do not contain a pharmacokinetic boosting agent<SUP>§</SUP> have a low potential for significant drug interactions with commonly seen antidepressants (except for St John's wort use, which is contraindicated).</LI>&#xD;&#xA;<LI>Not all potential interactions are listed. Interactions of medications taken by persons with HIV should be regularly evaluated particularly when there is an adjustment to therapy. The Lexi-Interact drug interactions tool included within UpToDate is available for this purpose. </LI>&#xD;&#xA;<LI>The antidepressant doses listed in this table are&nbsp;generally consistent with&nbsp;the US Food &amp; Drug Administration approved labeling and some patients may require higher or lower doses. For example, use doses at the lower end of range shown for starting and maintenance treatment of depression in patients with HIV who are medically ill, older, debilitated, or in the setting of organ dysfunction.</LI></UL></div><div class=\"graphic_footnotes\">AUC: area under the time versus concentration curve; CYP: cytochrome P450; P-gp: P-glycoprotein efflux transporter; UDP-UGT: uridine 5'-diphospho-glucuronosyltransferase catalyst of glucuronidation.<br />* CYP450 subfamilies that contribute to metabolism of antidepressants and HIV antiretrovirals in a relatively minor way are not listed in this table. These details are available elsewhere; refer to the Lexicomp drug monographs, section on metabolism/transport effects.<br />¶ The maximum recommended daily dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking medications that can increase citalopram levels. For additional information, refer to the UpToDate topic review of selective serotonin reuptake inhibitors (SSRIs) pharmacology, section on cardiac side effects.<br />Δ QTc prolonging antidepressant medications (eg, citalopram, escitalopram, fluoxetine, tricyclic antidepressants) can have additive effects if used with other drugs that prolong the QTc interval, (eg, lopinavir, nelfinavir, saquinavir) and may thereby increase the risk of rare life-threatening ventricular arrhythmias. For additional information refer to separate UpToDate topic reviews of: Treatment of unipolar depression with selective serotonin reuptake inhibitors (SSRIs), tricyclic and tetracyclic antidepressant pharmacology, and acquired long QT syndrome.<br /><FONT class=lozenge>◊</FONT> HIV protease inhibitors include: Atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir (used as a pharmacokinetic boosting-agent), saquinavir, and tipranavir.<br />§ Low-dose ritonavir (ie, 100 to 200 mg daily) and cobicistat are not used as antiretrovirals but instead are used to improve the pharmacokinetic profile (ie, \"boosting\") of other antiretroviral agents. Low-dose ritonavir is a strong inhibitor of CYP3A4 and moderate inhibitor of CYP2D6.<br />¥ Due to significant anticholinergic side effects, tricyclic antidepressants (TCAs) may not be well tolerated in patients with HIV who are medically ill. TCAs may be fatal in overdose and can cause cardiac arrhythmias or orthostatic hypotension. Serum drug concentration monitoring may be useful for guiding treatment with amitriptyline, clomipramine, desipramine, imipramine, and nortriptyline. For additional information refer to separate UpToDate topic review of tricyclic and tetracyclic antidepressant pharmacology.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI>&#xD;&#xA;<LI>Wynn GH, et al (eds) Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington DC. Copyright © 2009.</LI>&#xD;&#xA;<LI>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (January 28, 2016 version).</LI>&#xD;&#xA;<LI>Hill L and Lee KC Pharmacotherapy considerations in patients with HIV and psychiatric disorders: Focus on antidepressants and antipsychotics. Ann Pharmacother 2013; 47:75.</LI></OL></div><div id=\"graphicVersion\">Graphic 70410 Version 21.0</div></div></div>"},"70411":{"type":"graphic_table","displayName":"Rx HACEK endocarditis","title":"Suggested regimens for therapy of native or prosthetic valve endocarditis due to HACEK* microorganisms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of native or prosthetic valve endocarditis due to HACEK* microorganisms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric</td> <td class=\"subtitle2\">Adult</td> </tr> <tr> <td rowspan=\"2\"> <p><strong>One of the following:</strong></p> <p>Ceftriaxone<sup>&#182;</sup> 2 g per 24 hours IV in one dose for 4 weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> <p>Ampicillin<sup>&#9674;</sup> 2 g IV every 4 hours for 4 weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> Ciprofloxacin<sup>&#167;</sup> 1000 mg per 24 hours orally in two divided doses or 800 mg per 24 hours IV in two divided doses for 4 weeks<sup>&#916;</sup></td> <td> <p><strong>Monotherapy:</strong></p> <p>Ceftriaxone<sup>&#182;</sup> 100 mg/kg per 24 hours IV in two divided doses, or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours) for 4 weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> Cefotaxime 200 mg/kg per 24 hours IV in four divided doses (maximum dose: 12 g per 24 hours) for 4 weeks<sup>&#916;</sup></td> <td rowspan=\"2\"><strong>One of the following:</strong> <p>Ceftriaxone<sup>&#182;</sup> 2 g per 24 hours IV in one dose for 4 weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> <p>Combination therapy with: Ampicillin<sup>&#9674;</sup> 12 g per 24 hours IV in six divided doses <strong>plus</strong> Gentamicin<sup>&#165;</sup> 3 mg/kg per 24 hours IV or IM in two or three divided doses for 4 to 6 weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> Ciprofloxacin<sup>&#167;</sup> 750 mg every 12 hours orally or 400 mg every 8 or 12 hours IV for 4 weeks<sup>&#916;</sup></td> </tr> <tr> <td> <p><strong>Combination therapy:</strong></p> <p>Ampicillin<sup>&#9674;</sup> 200 to 300 mg/kg per 24 hours IV divided in four or six divided doses (maximum dose: 12 g per 24 hours) for 4 weeks<sup>&#916;</sup></p> <p><strong>plus</strong></p> Gentamicin<sup>&#165;</sup> 3 to 6 mg/kg per 24 hours IV in three divided doses for 4 weeks<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.<br />Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class=\"graphic_footnotes\">IV: intravenously; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis.<br />* <em>Haemophilus parainfluenzae</em>, <em>Aggregatibacter aphrophilus</em> (formerly <em>Haemophilus aphrophilus</em>), <em>Aggregatibacter actinomycetemcomitans</em> (formerly <em>Actinobacillus actinomycetemcomitans</em>), <em>Cardiobacterium hominis</em>, <em>Eikenella corrodens</em>, and <em>Kingella kingae</em>.<br />&para; Ceftriaxone is preferred. Cefotaxime or another third- or fourth-generation cephalosporin may be substituted. Patients who do not tolerate ceftriaxone should be treated in consultation with an infectious diseases specialist.<br />&Delta; The AHA and ESC favor 4 weeks of therapy for NVE and 6 weeks of therapy for PVE.<br /><span class=\"lozenge\">&loz;</span> If growth in vitro is adequate to obtain definitive susceptibility testing results and susceptibility to ampicillin has been demonstrated (ie, non-beta-lactamase-producing organism).<br />&sect; Fluoroquinolone therapy recommended only for patients unable to tolerate cephalosporin or ampicillin therapy; levofloxacin or moxifloxacin may be substituted. Fluoroquinolone therapy is not generally recommended for patients &lt;18 years. Treatment for 6 weeks is reasonable for patients with PVE.<br />&yen; Renal function and gentamicin serum concentrations should be monitored at least once per week. In adults, aminoglycosides are dosed based on ideal body weight. Gentamicin dosage adjusted for peak serum concentrations 3 to 4 mcg/mL, trough &lt;1 mcg/mL when two to three divided doses used.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</li>&#xD;&#xA;    <li>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</li>&#xD;&#xA;    <li>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</li>&#xD;&#xA;    <li>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 70411 Version 7.0</div></div></div>"},"70414":{"type":"graphic_picture","displayName":"CJD pathology high power","title":"High power photomicrograph of classic CJD demonstrating the typical size variation of CJD vacuoles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High power photomicrograph of classic CJD demonstrating the typical size variation of CJD vacuoles</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEURO/70414_Classic_CJD_high_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Henry G Brown, MD, PhD.</div><div id=\"graphicVersion\">Graphic 70414 Version 2.0</div></div></div>"},"70415":{"type":"graphic_table","displayName":"Indications and timing of the infertility evaluation","title":"Indications and timing of the infertility evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications and timing of the infertility evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infertility evaluation is indicated for couples who seek help because they have not been able to conceive.</td> </tr> <tr> <td class=\"subtitle2_single\">1. Initiate evaluation after 12 months of unprotected and frequent intercourse:</td> </tr> <tr> <td class=\"indent2\">Women under age 35 years without risk factors for infertility.</td> </tr> <tr> <td class=\"subtitle2_single\">2. Initiate evaluation after six months of unprotected and frequent intercourse:</td> </tr> <tr> <td class=\"indent2\">Women age 35 to 40 years.</td> </tr> <tr> <td class=\"subtitle2_single\">3. Initiate evaluation upon presentation despite less than six months of unprotected and frequent intercourse:</td> </tr> <tr> <td class=\"indent2\">Women over age 40 years.</td> </tr> <tr> <td class=\"indent2\">Women with oligomenorrhea/amenorrhea.</td> </tr> <tr> <td class=\"indent2\">Women with a history of chemotherapy, radiation therapy, or advanced stage endometriosis.</td> </tr> <tr> <td class=\"indent2\">Women with known or suspected uterine/tubal disease.</td> </tr> <tr> <td class=\"indent2\">Women whose male partner has a history of groin or testicular surgery, adult mumps, impotence or other sexual dysfunction, chemotherapy and/or radiation, or a history of subfertility with another partner.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70415 Version 4.0</div></div></div>"},"70417":{"type":"graphic_picture","displayName":"Vulva hematoma with drain","title":"Closure of large vulvar hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closure of large vulvar hematoma</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/OBGYN/70417_Vulvahematomawithdrain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note drain left in place due to fact that this was a contaminated wound.</div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ, Laufer MR. Emans, Laufer &amp; Goldstein’s Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70417 Version 8.0</div></div></div>"},"70418":{"type":"graphic_diagnosticimage","displayName":"MRI wrist septic arthritis child","title":"Imaging septic arthritis in sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Imaging septic arthritis in sickle cell disease</div><div class=\"cntnt\"><img style=\"width:348px; height:167px;\" src=\"images/HEME/70418_MRI_wrist_sickle_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an MRI of the wrist in a 4.5-year-old boy with sickle cell disease and septic arthritis. The arrow shows an area of fluid collection, while the arrowheads show areas of diffuse bone marrow signal changes involving the metacarpal bones.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">MRI courtesy of Dr. Sheldon L Kaplan, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.</div><div id=\"graphicVersion\">Graphic 70418 Version 4.0</div></div></div>"},"70419":{"type":"graphic_picture","displayName":"Amiodarone skin pigmentation","title":"Amiodarone-induced pigmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amiodarone-induced pigmentation</div><div class=\"cntnt\"><img style=\"width:263px; height:387px;\" src=\"images/CARD/70419_Amiodaroneskinpigmentatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amiodarone causes a striking slate-gray pigmentation in a photodistribution of the face. The blue color (ceruloderma) is due to the deposition of melanin and lipofuscin contained in macrophages and endothelial cells in the dermis. The pigmentation is reversible, but it may take up to a year or more to complete resolution.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson AB, Wolff K, Suurmond D. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 4th ed, McGraw-Hill, New York 2001. Copyright © 2001 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 70419 Version 6.0</div></div></div>"},"70420":{"type":"graphic_figure","displayName":"Parts of the eye PI","title":"Parts of the eye","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Parts of the eye</div><div class=\"cntnt\"><img style=\"width:538px; height:360px;\" src=\"images/PI/70420_Parts_of_the_eye_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross section of an eye.</div><div id=\"graphicVersion\">Graphic 70420 Version 2.0</div></div></div>"},"70421":{"type":"graphic_picture","displayName":"Pseudoxanthoma elasticum lip","title":"Pseudoxanthoma elasticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoxanthoma elasticum</div><div class=\"cntnt\"><img style=\"width:396px; height:293px;\" src=\"images/DERM/70421_PXE_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow papules are present on the inner aspect of the lower lip. Infiltration of the buccal mucosa of the lip is the most common mucous membrane involvement in pseudoxanthoma elasticum.</div><div class=\"graphic_reference\">Copyright © Franziska Ringpfeil, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 70421 Version 7.0</div></div></div>"},"70424":{"type":"graphic_table","displayName":"Cytology of follicular thyroid lesions","title":"Cytopathologic diagnosis of follicular thyroid lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytopathologic diagnosis of follicular thyroid lesions</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Cytologic pattern</td>\r\n            <td class=\"subtitle1\">Description</td>\r\n            <td class=\"subtitle1\">Histopathology</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Benign macrofollicular fragments</td>\r\n            <td>\r\n            <p>Abundant colloid</p>\r\n            <p>Predominantly large follicles and flat sheets of follicular cells</p>\r\n            </td>\r\n            <td>\r\n            <p>Nodular goiter (colloid adenoma)</p>\r\n            <p>Macrofollicular adenoma</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Follicular lesion or atypia of undetermined significance</td>\r\n            <td>&nbsp;\r\n            <p>Mixed macrofollicular and microfollicular nodules</p>\r\n            <p><strong>OR</strong></p>\r\n            <p>Cells with mild nuclear atypia</p>\r\n            <p><strong>OR</strong></p>\r\n            <p>Extensive oncocytic (H&#252;rthle cell) change</p>\r\n            </td>\r\n            <td>&nbsp;\r\n            <p>Multinodular goiter</p>\r\n            <p>Follicular adenoma</p>\r\n            <p>Follicular cancer</p>\r\n            <p>Papillary cancer (follicular variant)</p>\r\n            <p>Hashimoto's thyroiditis</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">\r\n            <p>Follicular neoplasm</p>\r\n            <p>(microfollicular)</p>\r\n            </td>\r\n            <td>\r\n            <p>Scant colloid</p>\r\n            <p>Small microfollicles</p>\r\n            <p><strong>OR</strong></p>\r\n            <p>Clusters and clumps of cells with varying pleomorphism</p>\r\n            </td>\r\n            <td>\r\n            <p>Microfollicular adenoma</p>\r\n            <p><strong>OR</strong></p>\r\n            <p>Follicular carcinoma</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cells have intranuclear inclusions and clefts</td>\r\n            <td>Follicular variant of papillary carcinoma</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 70424 Version 4.0</div></div></div>"},"70425":{"type":"graphic_table","displayName":"Causes of constipation","title":"Causes of chronic constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic constipation</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Neurogenic disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Peripheral\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Diabetes mellitus\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Autonomic neuropathy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Hirschsprung disease\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Chagas disease\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Intestinal pseudoobstruction\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Central\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Multiple sclerosis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Spinal cord injury\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Parkinson disease\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Irritable bowel syndrome\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Drugs\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>See separate table</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Non-neurogenic disorders\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hypothyroidism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hypokalemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anorexia nervosa</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pregnancy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Panhypopituitarism</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Systemic sclerosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Myotonic dystrophy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Idiopathic constipation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Normal colonic transit</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Slow transit constipation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dyssynergic defecation</td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 70425 Version 1.0</div></div></div>"},"70426":{"type":"graphic_picture","displayName":"Atrophic morphea","title":"Atrophic morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrophic morphea</div><div class=\"cntnt\"><img style=\"width:171px; height:432px;\" src=\"images/DERM/70426_Atrophic_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe atrophy is present in this patient with linear morphea.</div><div id=\"graphicVersion\">Graphic 70426 Version 1.0</div></div></div>"},"70427":{"type":"graphic_table","displayName":"FDA Daily Values for Food Labels","title":"Daily values for nutrients, set by the Food and Drug Administration for the purposes of food labeling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Daily values for nutrients, set by the Food and Drug Administration for the purposes of food labeling</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food component</td> <td class=\"subtitle1\">Daily value</td> <td class=\"subtitle1\">Percent of calories</td> </tr> <tr> <td>Total fat*</td> <td>&#60;65 g</td> <td>&#60;30 percent</td> </tr> <tr> <td>Saturated fat*</td> <td>&#60;20 g</td> <td>&#60;10 percent</td> </tr> <tr> <td>Cholesterol*</td> <td>&#60;300 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Sodium*</td> <td>&#60;2400 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Potassium</td> <td>3500 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Total carbohydrate</td> <td>300 g</td> <td>60 percent</td> </tr> <tr> <td>Dietary fiber<sup>&#182;</sup></td> <td>&#8805;25 g</td> <td>&#8805;12.5 g/1000 calories</td> </tr> <tr> <td>Protein</td> <td>50 g</td> <td>10 percent</td> </tr> <tr> <td>Vitamin A<sup>&#182;</sup></td> <td>&#8805;5000 IU</td> <td>&nbsp;</td> </tr> <tr> <td>Vitamin C<sup>&#182;</sup></td> <td>&#8805;60 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Calcium<sup>&#182;</sup><sup>&#916;</sup></td> <td>&#8805;1000 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Iron<sup>&#182;</sup></td> <td>&#8805;18 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Vitamin D<sup>&#916;</sup></td> <td>400 IU</td> <td>&nbsp;</td> </tr> <tr> <td>Vitamin E</td> <td>30 IU</td> <td>&nbsp;</td> </tr> <tr> <td>Vitamin K</td> <td>80 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Thiamin</td> <td>1.5 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Riboflavin</td> <td>1.7 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Niacin</td> <td>20 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Vitamin B6</td> <td>2 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Folate</td> <td>400 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Vitamin B12</td> <td>6 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Biotin</td> <td>300 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Pantothenic acid</td> <td>10 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Phosphorus</td> <td>1000 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Iodine</td> <td>150 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Magnesium</td> <td>400 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Zinc</td> <td>15 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Selenium</td> <td>70 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Copper</td> <td>2 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Manganese</td> <td>2 mg</td> <td>&nbsp;</td> </tr> <tr> <td>Chromium</td> <td>120 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Molybdenum</td> <td>75 micrograms</td> <td>&nbsp;</td> </tr> <tr> <td>Chloride</td> <td>3400 mg</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These Daily Values are based on a 2000 calorie diet. Note that these values should be adjusted for individuals whose energy intake is significantly above or below this level, including most children.</div><div class=\"graphic_footnotes\">g: grams; mg: milligrams; IU: international units; FDA: US food and drug administration.<br />* Daily Values for fat, cholesterol, and sodium are presented as the uppermost limit that it is desirable to consume, ie, individuals should consume less than this amount.<br />¶ Daily Values for dietary fiber, vitamin A, vitamin C, calcium, and iron are presented as a lower limit that it is desirable to consume, ie, individuals should consume at least this amount.<br />Δ In 2011, the Food and Nutrition Board revised their Dietary Reference Intake recommendations for Vitamin D and Calcium. The FDA has not changed daily value targets.</div><div class=\"graphic_reference\">Reproduced from: U.S. Food and Drug Administration. Guidance for Industry: A Food Labeling Guide (Revised October 2009). Accessed on March 18, 2014.</div><div id=\"graphicVersion\">Graphic 70427 Version 7.0</div></div></div>"},"70429":{"type":"graphic_diagnosticimage","displayName":"Abscess after sleeve gastrectomy","title":"Abscess after sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abscess after sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:426px; height:427px;\" src=\"images/SURG/70429_Abscess_sleeve_gastrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abscess with fluid and air adjacent to the sleeve gastrectomy.</div><div id=\"graphicVersion\">Graphic 70429 Version 4.0</div></div></div>"},"70430":{"type":"graphic_waveform","displayName":"RNS before excercise","title":"Repetitive nerve stimulation pre-exercise, normal","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation pre-exercise, normal</div><div class=\"cntnt\"><img style=\"width:587px; height:202px;\" src=\"images/NEURO/70430_RNS_before_excercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repetitive nerve stimulation before exercise in a normal patient illustrating a 2 percent decrement.</div><div class=\"graphic_reference\">Courtesy of David Weinberg, MD.</div><div id=\"graphicVersion\">Graphic 70430 Version 2.0</div></div></div>"},"70432":{"type":"graphic_diagnosticimage","displayName":"RLL atelectasis I","title":"Right lower lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:368px; height:370px;\" src=\"images/PULM/70432_RLL_atelectasis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atelectasis of the right lower lobe characterized by a triangular opacity in the right lower hemithorax (arrow). It has an oblique sharp border towards the rest of the aerated lung that is formed by the major fissure. The overall volume in the right hemithorax is reduced when compared with the left lung. The right hilum is displaced caudally and is partially obscured by the collapsed lobe. The right cardiac border and the right hemidiaphragm are outlined by the hyperexpanded right middle lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70432 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"70433":{"type":"graphic_picture","displayName":"Ultra mini radial probe","title":"Endobronchial ultrasound (EBUS) ultra mini radial probe","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) ultra mini radial probe</div><div class=\"cntnt\"><img style=\"width:506px; height:249px;\" src=\"images/PULM/70433_Ultra_mini_radial_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) A 20 MHz ultra-miniature radial probe, designed to reach peripheral pulmonary nodules. B) A 20 MHz ultra-miniature radial probe in a guide sheath. The probe and guide sheath are in the 2 mm working channel of a flexible bronchoscope.</div><div id=\"graphicVersion\">Graphic 70433 Version 3.0</div></div></div>"},"70434":{"type":"graphic_picture","displayName":"Hands in RA PI","title":"Rheumatoid arthritis in the hands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis in the hands</div><div class=\"cntnt\"><img style=\"width:370px; height:446px;\" src=\"images/PI/70434_Hands_in_RA_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photos show the hands of a 40-year-old woman who was diagnosed with rheumatoid arthritis as a child.</div><div class=\"graphic_reference\">Courtesy of Patrick J Venables, MD.</div><div id=\"graphicVersion\">Graphic 70434 Version 6.0</div></div></div>"},"70435":{"type":"graphic_picture","displayName":"Lateral anatomy knee joint","title":"Lateral anatomy knee joint","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Lateral anatomy knee joint</div><div class=\"cntnt\"><img style=\"width:478px; height:522px;\" src=\"images/RHEUM/70435_Lateral_knee_anatomy_adult.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70435 Version 4.0</div></div></div>"},"70436":{"type":"graphic_figure","displayName":"Port placement left colectomy","title":"Port placement left colectomy*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Port placement left colectomy*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/70436_Ports_lap_left_colectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port. Two ports are placed under direct vision in the lower abdomen and one or more 5 mm ports placed in the upper midline.<br> The surgeon and the assistant stand on the patient's right side. Either the suprapubic port or the right lower quadrant port can be used to introduce the surgical stapler for transection of the colon. The upper midline port is useful for mobilizing the splenic flexure. The resected colon can be removed through a mini-laparotomy at the umbilicus or through a small Pfannenstiel incision.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 70436 Version 4.0</div></div></div>"},"70437":{"type":"graphic_figure","displayName":"Predicting HIT","title":"Nomogram of logistic regression model for predicting HIT","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Nomogram of logistic regression model for predicting HIT</div><div class=\"cntnt\"><img style=\"width:611px; height:207px;\" src=\"images/HEME/70437_PredictingHIT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of the anti-heparin/platelet factor 4 ELISA test, stated in terms of the optical density of the result (PF4 OD) and results of a confirmatory functional assay (Confirm: Neg indicates negative; and Pos, positive) values are displayed on the outer scales. Connecting a pair of PF4 OD and confirmatory assay results using a straight edge allows one to estimate the probability of heparin-induced thrombocytopenia (HIT) from the center scale.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from Whitlatch NL, Kong DF, Metjian AD, et al, Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia, Blood 2010; 116:1761, Copyright © 2010; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 70437 Version 13.0</div></div></div>"},"70438":{"type":"graphic_picture","displayName":"Telangiectasia reticular veins and mild ankle edema","title":"Telangiectasia, reticular veins and mild ankle edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectasia, reticular veins and mild ankle edema</div><div class=\"cntnt\"><img style=\"width:235px; height:299px;\" src=\"images/PC/70438_Mild_ankle_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticular veins are dilated bluish subdermal veins, one to three millimeters in diameter. The deeper blue reticular veins contrast the bright red, fine telangiectasias. Mild ankle edema in this patient is evident at medial ankle below the malleolus.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 70438 Version 2.0</div></div></div>"},"70439":{"type":"graphic_picture","displayName":"North American paper wasps","title":"North American paper wasps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">North American paper wasps</div><div class=\"cntnt\"><img style=\"width:310px; height:206px;\" src=\"images/PC/70439_North_American_paper_wasps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.</div><div id=\"graphicVersion\">Graphic 70439 Version 2.0</div></div></div>"},"70440":{"type":"graphic_picture","displayName":"Asbestosis histology A","title":"Asbestos-related small airway disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestos-related small airway disease</div><div class=\"cntnt\"><img style=\"width:360px; height:283px;\" src=\"images/PULM/70440_Asbestosis_histology_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">H&amp;E-stained section showing junction of terminal (membranous) bronchiole with a respiratory bronchiole from a person with asbestosis who was an ex-smoker. The walls of the bronchioles are thickened by collagen and show mild smooth muscle hyperplasia. There is a mild chronic inflammatory cell infiltrate in the wall. These features are consistent with asbestos-related small airway disease.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org</div><div id=\"graphicVersion\">Graphic 70440 Version 1.0</div></div></div>"},"70441":{"type":"graphic_figure","displayName":"Diaphragm plication","title":"Diaphragm plication","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Diaphragm plication</div><div class=\"cntnt\"><img style=\"width:538px; height:462px;\" src=\"images/PULM/70441_Diaphragm_plication.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn with permission from: Freeman, RK, Wozniak, TC, Fitzgerald, EB. Functional and physiologic results of video-assisted thoracoscopic diaphragm plication in adult patients with unilateral diaphragm paralysis. Ann Thorac Surg 2006; 81:1853. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70441 Version 1.0</div></div></div>"},"70442":{"type":"graphic_table","displayName":"Nonasthmatic features","title":"Features suggestive of a diagnosis other than asthma in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features suggestive of a diagnosis other than asthma in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>Onset of symptoms in early infancy</td> </tr> <tr> <td>Neonatal respiratory distress +/- ventilatory support</td> </tr> <tr> <td>Neonatal neurologic dysfunction</td> </tr> <tr> <td>Intractable wheezing unresponsive to bronchodilators</td> </tr> <tr> <td>Wheezing associated with feeding or vomiting</td> </tr> <tr> <td>Difficulty swallowing +/- recurrent vomiting</td> </tr> <tr> <td>Diarrhea</td> </tr> <tr> <td>Poor weight gain</td> </tr> <tr> <td>Stridor</td> </tr> <tr> <td>Oxygen requirement &#62;1 week after acute attack</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td>Failure to thrive</td> </tr> <tr> <td>Clubbing</td> </tr> <tr> <td>Cardiac murmur</td> </tr> <tr> <td>Stridor</td> </tr> <tr> <td>Focal lung signs</td> </tr> <tr> <td>Nasal polyps</td> </tr> <tr> <td>Crackles on auscultation</td> </tr> <tr> <td>Cyanosis</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory features</td> </tr> <tr> <td>Focal or persistent chest&nbsp;radiograph abnormalities</td> </tr> <tr> <td>Anemia</td> </tr> <tr> <td>Irreversible airflow obstruction</td> </tr> <tr> <td>Hypoxemia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Canny GJ, Levison H. Childhood asthma:&nbsp;A rational approach to treatment.&nbsp;Ann Allergy 1990; 64:406.</div><div id=\"graphicVersion\">Graphic 70442 Version 4.0</div></div></div>"},"70443":{"type":"graphic_algorithm","displayName":"OSA treatment algorithm","title":"Treatment of obstructive sleep apnea algorithm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of obstructive sleep apnea algorithm</div><div class=\"cntnt\"><img style=\"width:365px; height:352px;\" src=\"images/SLEEP/70443_OSA_treatment_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AHI: apnea-hypopnea index; RERAs: respiratory effort related arousals.</div><div id=\"graphicVersion\">Graphic 70443 Version 7.0</div></div></div>"},"70444":{"type":"graphic_table","displayName":"History AUB adolescent","title":"Questions to aid in the diagnosis of abnormal uterine bleeding in adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to aid in the diagnosis of abnormal uterine bleeding in adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Menstrual history</td> </tr> <tr> <td class=\"indent1\">Age of menarche</td> <td>Earlier age at menarche associated with shorter time to establish ovulatory cycles</td> </tr> <tr> <td class=\"indent1\">Menstrual pattern (eg, frequency, regularity, duration and volume of flow)</td> <td>Allows classification into etiologic categories (eg, amenorrhea, irregular menses, excessive menstrual bleeding, intermenstrual bleeding)*</td> </tr> <tr> <td class=\"indent1\">Events that coincided with change in menstrual pattern (if there was a change)</td> <td>May suggest an etiology (eg, hypothalamic dysfunction if coincided with weight loss, stress, or intensive exercise; breakthrough bleeding if coincided with initiation of hormonal contraception)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">When did abnormal bleeding start (eg, with the first period or sometime thereafter)?</td> <td>May suggest an etiology (eg, heaving bleeding at onset of menarche may indicate bleeding disorder)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sexual/reproductive history</td> </tr> <tr> <td class=\"indent1\">Use, type, and adherence to contraception</td> <td> <p>Estrogen-progestin contraceptives: May cause unscheduled bleeding, particularly with poor adherence</p> <p>Progestin-only contraceptive: May cause irregular bleeding</p> <p>Copper IUD: Increases menstrual flow</p> Levonorgestrel IUD: May cause irregular spotting or bleeding soon after insertion</td> </tr> <tr> <td class=\"indent1\">Use of condoms; number of partners; new partners</td> <td>Affects risk of STI</td> </tr> <tr> <td class=\"indent1\">History of STI or current symptoms of STI (eg, vaginal discharge, pelvic pain)</td> <td>Bleeding may be related to STI</td> </tr> <tr> <td class=\"indent1\">History of sexual abuse<sup>&#182;</sup>, assault, or forced sexual activity</td> <td>Bleeding may be extrauterine (vaginal, cervical) or related to STI</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recent delivery or abortion</td> <td>Endometritis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Past medical history</td> </tr> <tr> <td class=\"indent1\">Chronic medical illness</td> <td>May affect coagulation (eg, liver disease, renal disease, systemic lupus erythematosus) or HPO axis (eg, diabetes mellitus)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Medications, including over-the-counter medications and complementary/alternative agents; ask specifically about aspirin and aspirin-containing medications</td> <td>May affect coagulation (eg, aspirin, valproic acid) or HPO axis (eg, antidepressants, antipsychotics)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Review of systems</td> </tr> <tr> <td class=\"indent1\">Bleeding symptoms (bruising, epistaxis, bleeding gums, postoperative bleeding)</td> <td>Bleeding disorder</td> </tr> <tr> <td class=\"indent1\">Orthostatic symptoms</td> <td>Hypovolemia, significant blood loss</td> </tr> <tr> <td class=\"indent1\">Weight change</td> <td> <p>Weight loss: Hypothalamic dysfunction or other endocrine disorder (eg, diabetes mellitus)</p> Weight gain: PCOS, hypercortisolism</td> </tr> <tr> <td class=\"indent1\">Abdominal pain, fever, and/or vaginal discharge</td> <td>Pelvic inflammatory disease, endometritis</td> </tr> <tr> <td class=\"indent1\">Dysmenorrhea, dyspareunia, infertility</td> <td>Endometriosis and/or adenomyosis</td> </tr> <tr> <td class=\"indent1\">Galactorrhea; heat or cold intolerance, fatigue; visual changes, headaches; hirsutism/acne</td> <td>Endocrine problem (hyperprolactinemia, thyroid dysfunction, pituitary dysfunction, PCOS)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Changes in bowel or bladder function</td> <td>Extrauterine bleeding (eg, hematuria), abdominal mass</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Joint hypermobility, joint dislocations, hyperextensible skin, abnormal scarring</td> <td>Heritable collagen disorders (associated with bleeding abnormalities due to capillary fragility)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td class=\"indent1\">Bleeding disorders</td> <td>Patient may have the same disorder</td> </tr> <tr> <td class=\"indent1\">Menstrual disorders</td> <td>Family members with heavy menstrual bleeding may have undiagnosed bleeding disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Endocrine disorders (eg, thyroid disease, diabetes mellitus)</td> <td>Family history of diabetes mellitus or lipid disorders may suggest PCOS</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Social history</td> </tr> <tr> <td class=\"indent1\">Social stressors, substance use, exercise patterns</td> <td>May affect the HPO axis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IUD: intrauterine device; STI: sexually transmitted infection; HPO: hypothalamic-pituitary-ovarian; PCOS: polycystic ovary syndrome.<br />* Refer to UpToDate content on evaluation of abnormal uterine bleeding in adolescents for details.<br />&para; Sexual abuse should be reported in accordance with local regulations. Refer to UpToDate content on management of sexual abuse in children and adolescents for details.</div><div id=\"graphicVersion\">Graphic 70444 Version 3.0</div></div></div>"},"70445":{"type":"graphic_figure","displayName":"Incidence outcome BBB","title":"Incidence of bundle-branch block increases with age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidence of bundle-branch block increases with age</div><div class=\"cntnt\"><img style=\"width:403px; height:507px;\" src=\"images/CARD/70445_Incidence_outcome_BBB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In men, the cumulative incidence of right (RBBB), left (LBBB), or any bundle branch block (BBB) increases with age (upper panel). The lower panel shows the survival curve for 67-year-old men followed up for 13 years; there is no significant difference in survival between those with and without BBB.</div><div class=\"graphic_reference\">Data from Eriksson, P, Hansson, D, Eriksson, H, et al, Circulation 1998; 98: 2494.</div><div id=\"graphicVersion\">Graphic 70445 Version 1.0</div></div></div>"},"70446":{"type":"graphic_figure","displayName":"Rubella CRS epidemiology US","title":"Number of rubella and congenital rubella syndrome cases – United States, 1966 to 2011","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Number of rubella and congenital rubella syndrome cases – United States, 1966 to 2011</div><div class=\"cntnt\"><img style=\"width:718px; height:354px;\" src=\"images/PEDS/70446_Rubella_CRS_epid_US_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rubella and CRS data provided were reported voluntarily to the Centers for Disease Control and Prevention from state health departments.</div><div class=\"graphic_footnotes\">CRS: congenital rubella syndrome.<br />* By year of birth.</div><div class=\"graphic_reference\">Reproduced from: McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 70446 Version 7.0</div></div></div>"},"70448":{"type":"graphic_table","displayName":"Allergens in allergic rhinitis","title":"Major causes of allergic rhinitis according to timing of symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of allergic rhinitis according to timing of symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Season</td> <td class=\"subtitle1\">Antigens</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Early spring</td> <td>Tree pollens</td> <td>Oaks, maples, elms, birches, etc (trees without showy flowers)</td> </tr> <tr> <td>Spring/summer</td> <td>Grass pollens</td> <td>Ryegrass, bluegrass, Bermuda grass</td> </tr> <tr> <td>Late summer</td> <td>Weed pollens</td> <td>Ragweed</td> </tr> <tr> <td>Throughout the growing season </td> <td>Fungi</td> <td>&nbsp;</td> </tr> <tr> <td>Throughout the year</td> <td>Household allergens</td> <td>House dust mites, cockroaches, animal dander, molds</td> </tr> <tr> <td>Occupational </td> <td>&nbsp;</td> <td>Seed dusts, woods, furs, latex, flour, psyllium, and many others</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Naclerio R, Solomon W, JAMA 1997; 278:1842.</div><div id=\"graphicVersion\">Graphic 70448 Version 3.0</div></div></div>"},"70449":{"type":"graphic_table","displayName":"Drugs that cause or prolong delirium","title":"Drugs believed to cause or prolong delirium or confusional states*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs believed to cause or prolong delirium or confusional states*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Analgesics </td> </tr> <tr> <td>NSAIDs</td> </tr> <tr> <td>Opioids (especially meperidine)</td> </tr> <tr> <td class=\"subtitle1_single\">Antibiotics and antivirals </td> </tr> <tr> <td>Acyclovir</td> </tr> <tr> <td>Aminoglycosides</td> </tr> <tr> <td>Amphotericin B</td> </tr> <tr> <td>Antimalarials</td> </tr> <tr> <td>Cephalosporins</td> </tr> <tr> <td>Cycloserine</td> </tr> <tr> <td>Fluoroquinolones</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Interferon</td> </tr> <tr> <td>Linezolid</td> </tr> <tr> <td>Macrolides</td> </tr> <tr> <td>Metronidazole</td> </tr> <tr> <td>Nalidixic acid</td> </tr> <tr> <td>Penicillins</td> </tr> <tr> <td>Rifampin</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td class=\"subtitle1_single\">Anticholinergics </td> </tr> <tr> <td>Atropine</td> </tr> <tr> <td>Benztropine</td> </tr> <tr> <td>Diphenhydramine</td> </tr> <tr> <td>Scopolamine</td> </tr> <tr> <td>Trihexyphenidyl</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants </td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Levetiracetam</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Valproate</td> </tr> <tr> <td>Vigabatrin</td> </tr> <tr> <td class=\"subtitle1_single\">Antidepressants </td> </tr> <tr> <td>Mirtazapine</td> </tr> <tr> <td>Selective serotonin reuptake inhibitors</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular and hypertension drugs </td> </tr> <tr> <td>Antiarrhythmics</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Clonidine</td> </tr> <tr> <td>Digoxin</td> </tr> <tr> <td>Diuretics</td> </tr> <tr> <td>Methyldopa</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Corticosteroids </td> </tr> <tr> <td class=\"subtitle1_single\">Dopamine agonists </td> </tr> <tr> <td>Amantadine</td> </tr> <tr> <td>Bromocriptine</td> </tr> <tr> <td>Levodopa</td> </tr> <tr> <td>Pergolide</td> </tr> <tr> <td>Pramipexole</td> </tr> <tr> <td>Ropinirole</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal agents </td> </tr> <tr> <td>Antiemetics</td> </tr> <tr> <td>Antispasmodics</td> </tr> <tr> <td>Histamine-2 receptor blockers</td> </tr> <tr> <td>Loperamide</td> </tr> <tr> <td class=\"subtitle1_single\">Herbal preparations </td> </tr> <tr> <td>Atropa belladonna extract</td> </tr> <tr> <td>Henbane</td> </tr> <tr> <td>Mandrake</td> </tr> <tr> <td>Jimson weed</td> </tr> <tr> <td>St. John's Wort</td> </tr> <tr> <td>Valerian</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoglycemics </td> </tr> <tr> <td class=\"subtitle1_single\">Hypnotics and sedatives </td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Benzodiazepines</td> </tr> <tr> <td class=\"subtitle1_single\">Muscle relaxants </td> </tr> <tr> <td>Baclofen</td> </tr> <tr> <td>Cyclobenzaprine</td> </tr> <tr> <td class=\"subtitle1_single\">Other CNS-active agents </td> </tr> <tr> <td>Disulfiram</td> </tr> <tr> <td>Cholinesterase inhibitors (eg, donepezil)</td> </tr> <tr> <td>Interleukin-2</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Phenothiazines</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drugs; CNS: central nervous system.<br />* Not exhaustive, all medications should be considered.</div><div id=\"graphicVersion\">Graphic 70449 Version 6.0</div></div></div>"},"70450":{"type":"graphic_diagnosticimage","displayName":"U-S theca lutein cysts","title":"Ultrasound theca lutein cysts","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound theca lutein cysts</div><div class=\"cntnt\"><img style=\"width:504px; height:562px;\" src=\"images/OBGYN/70450_U-S_theca_lutein_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Theca lutein cysts associated with a complete hydatidiform mole: Ultrasound shows bilateral theca lutein cysts associated with complete molar pregnancy. Image showing 6.5 x 3.8 x 3.7 cm left ovarian cyst.</div><div class=\"graphic_reference\">Courtesy of Department of Radiology, Santa Clara Valley Medical Center.</div><div id=\"graphicVersion\">Graphic 70450 Version 3.0</div></div></div>"},"70451":{"type":"graphic_table","displayName":"Func out men rad cystect","title":"Functional studies in men undergoing radical cystectomy and orthotopic reconstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional studies in men undergoing radical cystectomy and orthotopic reconstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author, year</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients, percent male</td> <td class=\"subtitle1\" rowspan=\"2\">Median follow-up, months</td> <td class=\"subtitle1\" colspan=\"3\">Continence rate, percent</td> <td class=\"subtitle1\" rowspan=\"2\">Intermittent catheterization needed, percent</td> </tr> <tr> <td class=\"subtitle2\">Day</td> <td class=\"subtitle2\">Night</td> <td class=\"subtitle2\">Time of assessment*</td> </tr> <tr> <td>Barre P; 1996</td> <td>110 (100)</td> <td>32</td> <td>93</td> <td>74</td> <td>NR</td> <td>1</td> </tr> <tr> <td>Cancrini A; 1996</td> <td>96 (93)</td> <td>28</td> <td>98</td> <td>74</td> <td>One year</td> <td>NR</td> </tr> <tr> <td>Elmajian D; 1996</td> <td>295 (100)</td> <td>42</td> <td>87</td> <td>86</td> <td>One year</td> <td>8</td> </tr> <tr> <td>Hautmann R; 1999</td> <td>363 (100)</td> <td>57</td> <td>96</td> <td>95</td> <td>NR</td> <td>6</td> </tr> <tr> <td rowspan=\"2\">Steven K; 2000</td> <td rowspan=\"2\">166 (100)</td> <td rowspan=\"2\">32</td> <td>98</td> <td>80</td> <td>Three years</td> <td>NR</td> </tr> <tr> <td>100</td> <td>95</td> <td>Five years</td> <td>NR</td> </tr> <tr> <td>Abol-Enein H; 2001</td> <td>450 (78)</td> <td>38</td> <td>93</td> <td>80</td> <td>NR</td> <td>NR</td> </tr> <tr> <td>Madersbacher S; 2002</td> <td>176 (100)</td> <td>95</td> <td>92</td> <td>70</td> <td>Five years</td> <td>NR</td> </tr> <tr> <td>Carrion R; 2004</td> <td>138 (82)</td> <td>41</td> <td>91</td> <td>70</td> <td>NR</td> <td>12</td> </tr> <tr> <td>Sevin G; 2004</td> <td>124 (100)</td> <td>NR</td> <td>92</td> <td>90</td> <td>Four years</td> <td>NR</td> </tr> <tr> <td>Stein J; 2004</td> <td>209 (81)</td> <td>33</td> <td>87</td> <td>72</td> <td>NR</td> <td>25<sup>​&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.<br />* Time point at which all patients were assessed following surgery.<br />¶ 20 percent of men and 43 percent of women.</div><div id=\"graphicVersion\">Graphic 70451 Version 3.0</div></div></div>"},"70453":{"type":"graphic_table","displayName":"WHO class salivary gld tum","title":"WHO histological classification of tumours of the salivary glands","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO histological classification of tumours of the salivary glands</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"container\">\r\n                    <table cellspacing=\"0\">\r\n                        <tbody>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Malignant epithelial tumours</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Acinic cell carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Mucoepidermoid carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Adenoid cystic carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Polymorphous low-grade adenocarcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Epithelial-myoepithelial carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Clear cell carcinoma, not otherwise specified</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Basal cell adenocarcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Sebaceous carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Sebaceous lymphadenocarcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Cystadenocarcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Low-grade cribriform cystadenocarcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Mucinous adenocarcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Oncocytic carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Salivary duct carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Adenocarcinoma, not otherwise specified</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Myoepithelial carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Carcinoma ex pleomorphic adenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Carcinosarcoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Metastasizing pleomorphic adenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Squamous cell carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Small cell carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Large cell carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Lymphoepithelial carcinoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Sialoblastoma</td>\r\n                            </tr>\r\n                        </tbody>\r\n                    </table>\r\n                    </td>\r\n                    <td class=\"container\">\r\n                    <table cellspacing=\"0\">\r\n                        <tbody>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Benign epithelial tumours</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Pleomorphic adenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Myoepithelioma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Basal cell adenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Warthin tumour</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Oncocytoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Canalicular adenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Sebaceous adenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Lymphadenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Sebaceous</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Non-sebaceous</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Ductal papillomas</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Inverted ductal papilloma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Intraductal papilloma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Sialadenoma papilliferum</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Cystadenoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Soft tissue tumours</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Haemangioma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"subtitle1_single\">Haematolymphoid tumours</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Hodgkin lymphoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Diffuse large B-cell lymphoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Extranodal marginal zone B-cell lymphoma</td>\r\n                            </tr>\r\n                        </tbody>\r\n                    </table>\r\n                    </td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">12/2/2008--Requested permission (JD). 1/26/2009--Permission granted for three cycles; figure to Terrence (JD). 1/16/2010--Renewal requested (JD). 2/5/2010--Renewal granted (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48701&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">Reproduced with permission from: Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours, IARC Press, Lyon 2005. Copyright &copy; 2005 IARC Press.</div><div id=\"graphicVersion\">Graphic 70453 Version 9.0</div></div></div>"},"70454":{"type":"graphic_table","displayName":"Calcium supplements PI","title":"Elemental calcium content per pill of different calcium supplements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elemental calcium content per pill of different calcium supplements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Elemental Ca/tablet</td> <td class=\"subtitle1\">Ca compound</td> <td class=\"subtitle1\">Vitamin D</td> </tr> <tr> <td><strong>Caltrate 600 + D3</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Caltrate 600 + D3 Soft Chews</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Caltrate Gummy Bites</strong></td> <td>250 mg</td> <td>Tribasic calcium phosphate</td> <td>400 units</td> </tr> <tr> <td><strong>Caltrate 600 + D3 Plus Minerals Chewables</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Caltrate 600 + D3 Plus Minerals Minis</strong></td> <td>300 mg</td> <td>Carbonate</td> <td>800 units</td> </tr> <tr> <td><strong>Citracal Petites</strong></td> <td>200 mg</td> <td>Citrate</td> <td>250 units</td> </tr> <tr> <td><strong>Citracal Maximum</strong></td> <td>315 mg</td> <td>Citrate</td> <td>250 units</td> </tr> <tr> <td><strong>Citracal Plus Magnesium &#38; Minerals</strong></td> <td>250 mg</td> <td>Citrate</td> <td>125 units</td> </tr> <tr> <td><strong>Citracal + D Slow Release</strong></td> <td>600 mg</td> <td>Citrate + carbonate blend</td> <td>500 units</td> </tr> <tr> <td><strong>Citracal Calcium Gummies</strong></td> <td>250 mg</td> <td>Tricalcium phosphate</td> <td>500 units</td> </tr> <tr> <td><strong>Citracal Calcium Pearls</strong></td> <td>200 mg</td> <td>Carbonate</td> <td>500 units</td> </tr> <tr> <td><strong>Os-Cal Calcium + D3</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>200 units</td> </tr> <tr> <td><strong>Os-Cal Extra + D3</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>600 units</td> </tr> <tr> <td><strong>Os-Cal Ultra</strong></td> <td>600 mg</td> <td>Carbonate</td> <td>500 units</td> </tr> <tr> <td><strong>Os-Cal Chewable</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>600 units</td> </tr> <tr> <td><strong>Tums</strong></td> <td>200 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Tums Extra Strength</strong></td> <td>300 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Tums Ultra Strength</strong></td> <td>400 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Tums Chewy Delights</strong></td> <td>400 mg</td> <td>Carbonate</td> <td>&ndash;</td> </tr> <tr> <td><strong>Viactiv Calcium plus D + K</strong></td> <td>500 mg</td> <td>Carbonate</td> <td>500 units (or 1000 units in sugar-free)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ca: calcium.</div><div id=\"graphicVersion\">Graphic 70454 Version 8.0</div></div></div>"},"70455":{"type":"graphic_table","displayName":"Depression rating scales","title":"Measures used to monitor clinical improvement of depressive symptoms and global functioning in depressed children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Measures used to monitor clinical improvement of depressive symptoms and global functioning in depressed children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Depressive symptoms</td> </tr> <tr> <td class=\"subtitle2_single\">Children's Depression Rating Scale - Revised</td> </tr> <tr> <td class=\"indent1\">Revised (CDRS-R) Clinician rating scale based on a semi-structured interview with child/adolescent patient and parent informant. The CDRS is the most widely used and highly regarded clinician scale for monitoring response to treatment in children and adolescents. Modeled after the adult Hamilton Rating Scale for Depression, the CDRS was developed to assess current severity of depression in children ages 6 to 12 years and is often used for adolescents as well. The revision of the CDRS examines 17 symptom areas (eg, depressed feelings, sleep disturbance, social withdrawal, etc) and can be administered in 15 to 20 minutes. The CDRS-R can be purchased at www.proedinc.com.</td> </tr> <tr> <td class=\"subtitle2_single\"><span style=\"color: black;\">Patient Health Questionnaire - Nine Item (PHQ-9): Modified for Teens</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Self-report measure that consists of the nine criteria that are used by the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-5), to diagnose major depression. The PHQ-9: Modified for Teens is derived from the PHQ-9, which is the most widely used instrument for measurement based care in adults. The PHQ-9: Modified for Teens requires approximately five minutes to complete and is in the public domain.</span></td> </tr> <tr> <td class=\"subtitle2_single\"><span style=\"color: black;\">Short Mood and Feelings Questionnaire</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">Self-report measure that has a separate form that is completed by the child or adolescent and by the parent. Each form contains 13 items and requires approximately five minutes to complete. The Short Mood and Feelings Questionnaire is in the public domain and is based upon the longer Mood and Feelings Questionnaire.</span></td> </tr> <tr> <td class=\"subtitle2_single\">Revised Hamilton Rating Scale for Depression (RHRSD)</td> </tr> <tr> <td class=\"indent1\">Clinician rating for adult depression that is used often with older adolescents. The revision retains the original Hamilton items, adds items, and includes a self-report version. The RHRSD takes 5 to 10 minutes to administer and is available for purchase at www.wpspublish.com.</td> </tr> <tr> <td class=\"subtitle2_single\">Children's Depression Inventory-2 (CDI-2)</td> </tr> <tr> <td class=\"indent1\">Self report measure designed for assessment of depressive symptoms in children/adolescents ages 7 to 17. CDI-2 is a revision of the CDI. Revision includes new items, revised scales, and updated norms. Assesses current severity of depressive symptoms. Parent and teacher versions of CDI are available. A self rating short form takes about 5 to 10 minutes to complete. All versions are available through www.mhs.com.</td> </tr> <tr> <td class=\"subtitle2_single\">Beck Depression Inventory II (BDI-II)</td> </tr> <tr> <td class=\"indent1\">Widely used self-report rating scale designed for use with adults and adolescents older than 13 years of age. It takes 5 to 10 minutes to complete. It is available for purchase at www.harcourtassessment.com.</td> </tr> <tr> <td class=\"subtitle2_single\">Reynolds Adolescent Depression Scale, Second Edition (RADS-2)</td> </tr> <tr> <td class=\"indent1\">Self-report measure designed for assessment of depressive symptoms in adolescents 11 to 20 years of age. It may be administered in 5 to 10 minutes and is available at www.parinc.com or www.wpspublish.com.</td> </tr> <tr> <td class=\"subtitle2_single\">Center for Epidemiological Studies Depression Scale Modified for Children (CES-DC)</td> </tr> <tr> <td class=\"indent1\">Adapted version of the adult Center for Epidemiological Studies Depression Scale. It is a 20-item scale designed for use with children/adolescents ages 6 to 17. The CES-DC takes approximately five minutes to complete and is available in the public domain. Scores greater than 15 suggest significant levels of depressive symptoms. It can be found at www.brightfutures.org/mentalhealth/pdf/tools.html (scroll to \"Bridges\" section and then will find under a Mood Disorders link).</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical Global Impression (CGI) Scale</td> </tr> <tr> <td class=\"sublist2_start\">The CGI is a three-item clinician rating scale used to assess treatment response (typically in research settings, often as an adjunct outcome measure). It is an unanchored measure (ie, there is no specific assessment). The ratings refer to the global impression of the patient and require substantial clinical experience with the syndrome under assessment. The three items are Severity of Illness, Global Improvement, and an Efficacy Index. Most use only the severity and improvement indices.</td> </tr> <tr> <td class=\"sublist2\">The Severity of Illness item (CGI-S) requires a seasoned clinician to rate the severity of the patient's illness on a 7-point scale from 1 (\"normal,\" not ill) to 7 (extremely ill).</td> </tr> <tr> <td class=\"sublist2\">The Global Improvement item (CGI-I) requires a seasoned clinician (who has knowledge of the patient's history) to rate how much the patient's illness has improved or worsened relative to baseline status. The patient's illness is compared to baseline rated on a 7-point scale from 1 (very much improved) to 7 (very much worse).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Liza Bonin, PhD.</div><div id=\"graphicVersion\">Graphic 70455 Version 5.0</div></div></div>"},"70458":{"type":"graphic_algorithm","displayName":"Fetal cardiac output distribution","title":"Fetal cardiac circulation: Distribution of right (RVO) and left (LVO) ventricular output","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Fetal cardiac circulation: Distribution of right (RVO) and left (LVO) ventricular output</div><div class=\"cntnt\"><img style=\"width:538px; height:390px;\" src=\"images/OBGYN/70458_Fetal_cardiac_output_distri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation of the fetal circulation. Shown is the distribution of right and left ventricular output (RVO, LVO) and the combined cardiac output (CCO) in the circulation of the fetal lamb. The largest proportion of the CCO is distributed to the placenta for oxygenation. Through preferential streaming, well-oxygenated left ventricular blood supplies the brain and heart while right ventricular blood with lower oxygen content is predominantly distributed to the placenta.</div><div class=\"graphic_footnotes\">DV: ductus venosus; IVC: inferior vena cava; SVC: superior vena cava; AAO: ascending aorta.</div><div class=\"graphic_reference\">Originally published in: Fetal cardiology. Yagel S, Silverman NH, Gembruch U (Eds), Taylor &amp; Francis, Oxford, UK 2003. p.125. Reproduced with permission from Taylor &amp; Francis. Copyright &copy; 2003. Algorithm updated from: Baschat AA, Gembruch U. Development of fetal cardiac and extracardiac Doppler flows in early gestation. In: Fetal Cardiology, 2nd ed, Yagel S, Silverman NH, Gembruch U (Eds), Informa Healthcare USA, Inc, New York 2009. p.157.</div><div id=\"graphicVersion\">Graphic 70458 Version 5.0</div></div></div>"},"70461":{"type":"graphic_picture","displayName":"Joint line palpation","title":"Joint line palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Joint line palpation</div><div class=\"cntnt\"><img style=\"width:353px; height:288px;\" src=\"images/EM/70461_Joint_line_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medial and lateral joint lines are formed by the femoral condyles and the tibial plateaus. The meniscal cartilage is located in the space between the bones and these are covered by the synovial membrane and the collateral ligaments. To palpate the joint lines, the superior and inferior poles of the patella are identified and marked. The joint lines are located at the level of the inferior pole of the patella in the midplane.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 70461 Version 2.0</div></div></div>"},"70462":{"type":"graphic_algorithm","displayName":"History incompatible crossmatch","title":"Clinical evaluation of patients with incompatible crossmatch","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Clinical evaluation of patients with incompatible crossmatch</div><div class=\"cntnt\"><img style=\"width:555px; height:322px;\" src=\"images/HEME/70462_History_incompatible_crossm.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70462 Version 2.0</div></div></div>"},"70463":{"type":"graphic_picture","displayName":"Fibrous trabeculae in thymoma","title":"Thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:230px;\" src=\"images/PULM/70463_Fibrous_trabeculae_in_thymo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows the multilobulated architecture characteristic of thymoma, with thick fibrous trabeculae that separate the tumor into lobules of varying size. (Hematoxylin and eosin, magnification 25x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 70463 Version 1.0</div></div></div>"},"70464":{"type":"graphic_diagnosticimage","displayName":"DISH radiograph knee","title":"Knee involvement in diffuse idiopathic skeletal hypertrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee involvement in diffuse idiopathic skeletal hypertrophy</div><div class=\"cntnt\"><img style=\"width:317px; height:322px;\" src=\"images/RHEUM/70464_DISHradiographknee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of knee in patient with DISH. Radiograph shows osteophytes that arise from both the superior and inferior poles of the patella and from the tibial tuberosity (arrow).</div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of John Esdaile, MD.</div><div id=\"graphicVersion\">Graphic 70464 Version 3.0</div></div></div>"},"70466":{"type":"graphic_table","displayName":"BMI waist circumference risk","title":"Classification of overweight and obesity by BMI, waist circumference, and associated disease risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of overweight and obesity by BMI, waist circumference, and associated disease risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"3\">BMI (kg/m<sup>2</sup>)</td> <td class=\"subtitle1\" rowspan=\"3\">Obesity class</td> <td class=\"subtitle1\" colspan=\"2\">Disease risk* relative to normal weight and waist circumference</td> </tr> <tr> <td class=\"subtitle2\">Men &#8804;102 cm<br /> (&#8804;40 in)</td> <td class=\"subtitle2\">&#62;102 cm<br /> (&#62;40 in)</td> </tr> <tr> <td class=\"subtitle2\">Women &#8804;88 cm<br /> (&#8804;35 in) </td> <td class=\"subtitle2\">&#62;88 cm<br /> (&#62;35 in)</td> </tr> <tr> <td>Underweight</td> <td>&#60;18.5</td> <td>&nbsp;</td> <td>-</td> <td>-</td> </tr> <tr> <td>Normal<sup>&#182;</sup></td> <td>18.5 to 24.9</td> <td>&nbsp;</td> <td>-</td> <td>-</td> </tr> <tr> <td>Overweight</td> <td>25.0 to 29.9</td> <td>&nbsp;</td> <td>Increased</td> <td>High</td> </tr> <tr> <td rowspan=\"2\">Obesity</td> <td>30.0 to 34.9</td> <td>I</td> <td>High</td> <td>Very high</td> </tr> <tr> <td>35.0 to 39.9</td> <td>II</td> <td>Very high</td> <td>Very high</td> </tr> <tr> <td>Extreme obesity</td> <td>&#8805;40</td> <td>III</td> <td>Extremely high</td> <td>Extremely high</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.<br />* Disease risk for type 2 diabetes, hypertension, and cardiovascular disease (CVD).<br />&para; Increased waist circumference can also be a marker for increased risk even in persons of normal weight.</div><div class=\"graphic_reference\">Reproduced from: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998; 6:515.</div><div id=\"graphicVersion\">Graphic 70466 Version 6.0</div></div></div>"},"70469":{"type":"graphic_waveform","displayName":"Blocked APB tutorial","title":"Blocked atrial premature beat","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blocked atrial premature beat</div><div class=\"cntnt\"><img style=\"width:428px; height:148px;\" src=\"images/CARD/70469_Blocked_APB_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonconducted or blocked atrial premature beats occur when there is premature activation of the atrial myocardium from an ectopic atrial focus at a time when the atrioventricular node is still refractory due to the previous sinus beat. Since the block is in the atrioventricular node, there is an isolated or nonconducted P wave seen on the ECG. In this case, the P wave is located within T wave of the first beat.</div><div id=\"graphicVersion\">Graphic 70469 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"70470":{"type":"graphic_table","displayName":"Rating of perceived exertion","title":"Rating of perceived exertion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rating of perceived exertion</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Original scale</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>6</td>\n\n      <td colspan=\"1\" rowspan=\"3\">very, very light</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>8</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>9</td>\n\n      <td colspan=\"1\" rowspan=\"2\">very light</td>\n\n    </tr>\n\n    <tr>\n\n      <td>10</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>11</td>\n\n      <td colspan=\"1\" rowspan=\"2\">fairly light</td>\n\n    </tr>\n\n    <tr>\n\n      <td>12</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>13</td>\n\n      <td colspan=\"1\" rowspan=\"2\">somewhat hard</td>\n\n    </tr>\n\n    <tr>\n\n      <td>14</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>15</td>\n\n      <td colspan=\"1\" rowspan=\"2\">hard</td>\n\n    </tr>\n\n    <tr>\n\n      <td>16</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>17</td>\n\n      <td colspan=\"1\" rowspan=\"2\">very hard</td>\n\n    </tr>\n\n    <tr>\n\n      <td>18</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>19</td>\n\n      <td colspan=\"1\" rowspan=\"2\">very, very hard</td>\n\n    </tr>\n\n    <tr>\n\n      <td>20</td>\n\n      \n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70470 Version 1.0</div></div></div>"},"70472":{"type":"graphic_figure","displayName":"Abciximab is more effective than tirofiban at 30 days after PCI","title":"Abciximab is more effective than tirofiban at 30 days after PCI","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Abciximab is more effective than tirofiban at 30 days after PCI</div><div class=\"cntnt\"><img style=\"width:488px; height:264px;\" src=\"images/CARD/70472_Abciximab_v_tirofiban_30_da.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the TARGET trial of 4809 patients undergoing stenting, the primary end point (composite of death, nonfatal myocardial infarction, or urgent target vessel revascularization at 30 days) was lower with abciximab (6 versus 7.6 percent for tirofiban, hazard ratio 1.26). The benefit of abciximab was limited to patients with an acute coronary syndrome.</div><div class=\"graphic_reference\">Data from Topol EJ, Moliterno DJ, Herrmann HC, et al for the TARGET investigators. N Engl J Med 2001; 344:1888.</div><div id=\"graphicVersion\">Graphic 70472 Version 3.0</div></div></div>"},"70473":{"type":"graphic_table","displayName":"Diseases hosts Microsporidia","title":"Hosts and diseases associated with Microsporidia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hosts and diseases associated with Microsporidia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Nonhuman species</td> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">HIV</td> <td class=\"subtitle1\">Non-HIV</td> </tr> <tr> <td><em>Enterocytozooan bieneusi</em></td> <td>Pigs, primates</td> <td>Intestinal, hepatobiliary</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Encephalitozooan intestinalis </em>(<em>Septata intestinalis</em>)</td> <td>Some mammals</td> <td>Disseminated</td> <td>+</td> <td>+/-</td> </tr> <tr> <td><em>Encephalitozooan hellem</em></td> <td>Parakeets</td> <td>Disseminated</td> <td>+</td> <td>-</td> </tr> <tr> <td><em>Encephalitozooan cuniculi</em></td> <td>Rabbits, mice, cats, foxes, dogs</td> <td>Corneal stroma</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Nosema connori</em></td> <td>-</td> <td>Disseminated</td> <td>+</td> <td>-</td> </tr> <tr> <td><em>Nosema ocularum</em></td> <td>-</td> <td>Corneal stroma</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Nosema</em>-like species</td> <td>-</td> <td>Corneal stroma</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Trachipleistophora hominis</em></td> <td>-</td> <td>Skeletal muscle, nasal sinuses</td> <td>+</td> <td>-</td> </tr> <tr> <td><em>Trachipleistophora antropophtera</em></td> <td>-</td> <td>Disseminated</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><em>Pleistophora </em>spp</td> <td>Fish</td> <td>Skeletal muscle</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Vittaforma corneae </em>(<em>Nosema corneae</em>)</td> <td>-</td> <td>Corneal stroma</td> <td>+</td> <td>+</td> </tr> <tr> <td><em>Microsporidum </em>spp (species not fully classified)</td> <td>-</td> <td>Disseminated</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70473 Version 2.0</div></div></div>"},"70475":{"type":"graphic_table","displayName":"Presenting symptoms MG","title":"Presenting symptoms of myasthenia gravis and the major considerations in the differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting symptoms of myasthenia gravis and the major considerations in the differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Presenting symptoms</td>\n<td class=\"subtitle1\">Other disorders to consider</td>\n</tr>\n<tr>\n<td>Ocular (50 percent)</td>\n<td>Brainstem and cranial nerve lesions (including Horner's syndrome), thyroid ophthalmopathy, oculopharyngeal muscular dystrophy, chronic external ophthalmoplegia (mitochondrial disease)</td>\n</tr>\n<tr>\n<td>Bulbar (15 percent)</td>\n<td>Brainstem and multiple cranial nerve lesions, motor neuron disease, obstructive or malignant lesion of the nasal and oropharynx</td>\n</tr>\n<tr>\n<td>Limb weakness (&#60;5 percent)</td>\n<td>Motor neuron disease, chronic inflammatory demyelinating polyneuropathy (CIDP) and other motor neuropathies, multiple radiculopathies, Lambert-Eaton myasthenic syndrome, myopathies</td>\n</tr>\n<tr>\n<td>Isolated neck (uncommon)</td>\n<td>Motor neuron disease, inflammatory myopathy, paraspinous myopathy</td>\n</tr>\n<tr>\n<td>Isolated respiratory (rare)</td>\n<td>Motor neuron disease, acid maltase deficiency, polymyositis</td>\n</tr>\n<tr>\n<td>Distal limb (rare)</td>\n<td>Motor neuron disease, CIDP and other motor neuropathies, distal myopathies</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70475 Version 1.0</div></div></div>"},"70476":{"type":"graphic_figure","displayName":"Types of episiotomy incision","title":"Types of episiotomy incisions","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Types of episiotomy incisions</div><div class=\"cntnt\"><img style=\"width:505px; height:457px;\" src=\"images/OBGYN/70476_Types_of_episiotomy_incisions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">1 = median incision, 1+2 = \"T\" incision, 3 = \"J\" incision, 4 = mediolateral incision, 5 = lateral incision.</div><div id=\"graphicVersion\">Graphic 70476 Version 4.0</div></div></div>"},"70477":{"type":"graphic_table","displayName":"Inherited forms of dystonia","title":"Inherited forms of dystonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inherited forms of dystonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Usual onset</td> <td class=\"subtitle1\">Locus symbol</td> <td class=\"subtitle1\">Gene locus</td> <td class=\"subtitle1\">Gene symbol</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Autosomal dominant</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dystonia is the presenting or predominant manifestation</td> </tr> <tr> <td class=\"indent2\">Early-onset generalized dystonia (DYT-TOR1A)</td> <td>Childhood-adolescence</td> <td>DYT1</td> <td>9q34</td> <td>TOR1A</td> </tr> <tr> <td class=\"indent2\">Dopa-responsive dystonia; Segawa syndrome (DYT-GCH1)</td> <td>Childhood</td> <td>DYT5a</td> <td>14q22</td> <td>GCH1</td> </tr> <tr> <td class=\"indent2\">Adolescent-onset dystonia of mixed type (DYT-THAP1)</td> <td>Adolescence</td> <td>DYT6</td> <td>8p11.21</td> <td>THAP1</td> </tr> <tr> <td class=\"indent2\">Cranial-cervical dystonia (DYT-GNAL)</td> <td>Adulthood</td> <td>DYT25</td> <td>18p11.21</td> <td>GNAL</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dystonia is an associated or secondary feature</td> </tr> <tr> <td class=\"indent2\">Paroxysmal nonkinesigenic dyskinesia 1 (DYT-MR1)</td> <td>Adolescent-adult</td> <td>DYT8</td> <td>2q35</td> <td>MR1</td> </tr> <tr> <td class=\"indent2\">Episodic (paroxysmal) kinesigenic dyskinesia 1 (DYT-PRRT2)</td> <td>Childhood-adolescence</td> <td>DYT10</td> <td>16p11.2</td> <td>PRRT2</td> </tr> <tr> <td class=\"indent2\">Myoclonus-dystonia (DYT-SGCE)</td> <td>Childhood-adolescent</td> <td>DYT11</td> <td>7q</td> <td>SGCE</td> </tr> <tr> <td class=\"indent2\">Rapid-onset dystonia-parkinsonism (DYT-ATP1A3)</td> <td>Childhood-adulthood</td> <td>DYT12</td> <td>19q</td> <td>ATP1A3</td> </tr> <tr> <td class=\"indent2\">Paroxysmal exercise-induced dyskinesia (DYT-SLC2A1)</td> <td>Childhood</td> <td>DYT18</td> <td>1p34.2</td> <td>SLC2A1</td> </tr> <tr> <td class=\"indent2\">Dentatorubral-pallidoluysian atrophy</td> <td>Adulthood</td> <td>N/A</td> <td>12p13.31</td> <td>ATN1</td> </tr> <tr> <td class=\"indent2\">Friedreich ataxia</td> <td>Adolescence-adulthood</td> <td>N/A</td> <td>9q21.11</td> <td>FXN</td> </tr> <tr> <td class=\"indent2\">Huntington disease</td> <td>Adolescence-adulthood</td> <td>N/A</td> <td>4p16.3</td> <td>HTT</td> </tr> <tr> <td class=\"indent2\">Idiopathic basal ganglia calcification 1</td> <td>Adulthood</td> <td>N/A</td> <td>8p11.21</td> <td>SLC20A2</td> </tr> <tr> <td class=\"indent2\">Neuroferritinopathy</td> <td>Adulthood</td> <td>NBIA3</td> <td>19q13.33</td> <td>FTL</td> </tr> <tr> <td class=\"indent2\">Spinocerebellar ataxia 3 (Machado-Joseph disease)</td> <td>Childhood-adulthood</td> <td>SCA3</td> <td>14q32.12</td> <td>ATXN3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Spinocerebellar ataxia 17</td> <td>Adulthood</td> <td>SCA17</td> <td>6q27</td> <td>TBP</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Autosomal recessive</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dystonia is the presenting or predominant manifestation</td> </tr> <tr> <td class=\"indent2\">Dopa-responsive dystonia; Segawa syndrome (DYT-TH)</td> <td>Infancy-childhood</td> <td>DYT5b</td> <td>11p15.5</td> <td>TH</td> </tr> <tr> <td class=\"indent2\">Dopa-responsive dystonia (DYT-SPR)</td> <td>Infancy-childhood</td> <td>N/A</td> <td>2p14-p12</td> <td>SPR</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dystonia is an associated or secondary feature</td> </tr> <tr> <td class=\"indent2\">Aromatic L-amino acid decarboxylase deficiency</td> <td>Infancy</td> <td>N/A</td> <td>7p12.1</td> <td>DDC (AADC)</td> </tr> <tr> <td class=\"indent2\">Ataxia-telangiectasia</td> <td>Childhood</td> <td>N/A</td> <td>11q22.3</td> <td>ATM</td> </tr> <tr> <td class=\"indent2\">Chorea-acanthocytosis</td> <td>Adulthood</td> <td>N/A</td> <td>9q21</td> <td>VPS13A</td> </tr> <tr> <td class=\"indent2\">Fucosidosis</td> <td>Infancy</td> <td>N/A</td> <td>1p36.11</td> <td>FUCA1</td> </tr> <tr> <td class=\"indent2\">Glutaric acidemia</td> <td>Infancy</td> <td>N/A</td> <td>19p13.2</td> <td>GCDH</td> </tr> <tr> <td class=\"indent2\">Huntington disease-like 3</td> <td>Childhood</td> <td>HDL3</td> <td>4p15.3</td> <td>?</td> </tr> <tr> <td class=\"indent2\">Infantile neuroaxonal dystrophy</td> <td>Infancy</td> <td>NBIA2a</td> <td>22q13.1</td> <td>PLA2G6</td> </tr> <tr> <td class=\"indent2\">Juvenile parkinsonism</td> <td>Adolescence-adulthood</td> <td>PARK2</td> <td>6q26</td> <td>PRKN</td> </tr> <tr> <td class=\"indent2\">Kufor-Rakeb syndrome</td> <td>Childhood-adulthood</td> <td>PARK9</td> <td>1p36.13</td> <td>ATP13A2</td> </tr> <tr> <td class=\"indent2\">Methylmalonic aciduria</td> <td>Infancy</td> <td>N/A</td> <td> <p>6p12.3</p> 2q23.2</td> <td> <p>MUT</p> MMADHC</td> </tr> <tr> <td class=\"indent2\">Niemann-Pick disease type C</td> <td>Infancy-adulthood</td> <td>N/A</td> <td> <p>18q11-q12</p> 14q24.3</td> <td> <p>NPC1</p> NPC2 (HE)</td> </tr> <tr> <td class=\"indent2\">Pantothenate kinase-associated neurodegeneration</td> <td>Childhood</td> <td>NBIA1</td> <td>20p13</td> <td>PANK2</td> </tr> <tr> <td class=\"indent2\">Tay-Sachs disease</td> <td>Infancy-adulthood</td> <td>N/A</td> <td>15q23</td> <td>HEXA</td> </tr> <tr> <td class=\"indent2\">Wilson disease</td> <td>Childhood-adulthood</td> <td>N/A</td> <td>13q14.3</td> <td>ATP7B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Woodhouse-Sakati syndrome</td> <td>Adolescent</td> <td>N/A</td> <td>2q31.1</td> <td>DCAF17</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">X-linked</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dystonia is an associated or secondary feature</td> </tr> <tr> <td class=\"indent2\">X-linked dystonia-parkinsonism; Lubag (DYT-TAF1)</td> <td>Adulthood</td> <td>DYT3</td> <td>XR</td> <td>TAF1?</td> </tr> <tr> <td class=\"indent2\">Lesch-Nyhan syndrome</td> <td>Childhood</td> <td>N/A</td> <td>Xq26.2-q26.3</td> <td>HPRT</td> </tr> <tr> <td class=\"indent2\">Mohr-Tranebjaerg dystonia-deafness syndrome</td> <td>Childhood-adulthood</td> <td>N/A</td> <td>Xq22.1</td> <td>TIMM8A (DDP)</td> </tr> <tr> <td class=\"indent2\">Pelizaeus-Merzbacher disease</td> <td>Infancy</td> <td>N/A</td> <td>Xq22.2</td> <td>PLP1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Rett syndrome</td> <td>Infancy</td> <td>N/A</td> <td>Xq28</td> <td>MECP2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Mitochondrial</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Dystonia is an associated or secondary feature</td> </tr> <tr> <td class=\"indent2\">Leber optic atrophy</td> <td>Childhood-adolescence</td> <td>N/A</td> <td>&nbsp;</td> <td>Multiple mitochonridal-encoded genes</td> </tr> <tr> <td class=\"indent2\">Leigh syndrome*</td> <td>Infancy</td> <td>N/A</td> <td>&nbsp;</td> <td>Multiple nuclear and mitochondrial-encoded genes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not assigned.<br />* Leigh syndrome inheritance may be autosomal recessive or mitochondrial.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li><a href=\"http://www.ncbi.nlm.nih.gov/omim\" target=\"_blank\">Online Mendelian Inheritance in Man (OMIM)</a>.</li>&#xD;&#xA;    <li>Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28:863.</li>&#xD;&#xA;    <li>Waugh JL, Sharma N. Clinical neurogenetics: dystonia from phenotype to genotype. Neurol Clin 2013; 31:969.</li>&#xD;&#xA;    <li>Klein C. Genetics in dystonia. Parkinsonism Relat Disord 2014; 20 Suppl 1:S137.</li>&#xD;&#xA;    <li>Moghimi N, Jabbari B, Szekely AM. Primary dystonias and genetic disorders with dystonia as clinical feature of the disease. Eur J Paediatr Neurol 2014; 18:79.</li>&#xD;&#xA;    <li>Marras C, Lohmann K, Lang A, Klein C. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology 2012; 78:1016.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 70477 Version 3.0</div></div></div>"},"70478":{"type":"graphic_table","displayName":"Rotavirus vaccines summary","title":"Comparison of rotavirus vaccines licensed in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of rotavirus vaccines licensed in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Pentavalent human-bovine reassortant vaccine (RV5, PRV)</td> <td class=\"subtitle1\">Attenuated human rotavirus vaccine (RV1, HRV)</td> </tr> <tr> <td><strong>Trade name</strong></td> <td>RotaTeq</td> <td>Rotarix</td> </tr> <tr> <td><strong>Serotypes contained</strong></td> <td>G1, G2, G3, G4, P1[8]</td> <td>G1P[8]</td> </tr> <tr> <td><strong>Dose</strong></td> <td>2 mL</td> <td>1 mL</td> </tr> <tr> <td><strong>Administration</strong></td> <td>Ready-to-use</td> <td>Requires reconstitution</td> </tr> <tr> <td><strong>Number of doses</strong></td> <td>3</td> <td>2</td> </tr> <tr> <td><strong>Recommended schedule</strong></td> <td>2, 4, 6 months</td> <td>2, 4 months</td> </tr> <tr> <td><strong>Minimum age first dose</strong></td> <td>6 weeks</td> <td>6 weeks</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><strong>Maximum age first dose</strong></td> </tr> <tr> <td class=\"sublist1\">United States</td> <td class=\"sublist_other\">14 weeks, 6 days</td> <td class=\"sublist_other\">14 weeks, 6 days</td> </tr> <tr> <td class=\"sublist1\">Europe</td> <td class=\"sublist_other\">12 weeks </td> <td class=\"sublist_other\">12 weeks</td> </tr> <tr> <td><strong>Minimal interval between doses</strong></td> <td>4 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><strong>Maximum age last dose</strong></td> </tr> <tr> <td class=\"sublist1\">United States</td> <td class=\"sublist_other\">8 months, 0 days</td> <td class=\"sublist_other\">8 months, 0 days</td> </tr> <tr> <td class=\"sublist1\">Europe</td> <td class=\"sublist_other\">24 weeks</td> <td class=\"sublist_other\">24 weeks</td> </tr> <tr> <td><strong>Oral applicator</strong></td> <td>Latex-free</td> <td>Contains latex*</td> </tr> <tr> <td><strong>Contains thimerosal</strong></td> <td>No</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Contraindicated in children with a severe (anaphylactic) allergy to latex.</div><div id=\"graphicVersion\">Graphic 70478 Version 8.0</div></div></div>"},"70480":{"type":"graphic_table","displayName":"Common opioids","title":"Frequently encountered opioids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequently encountered opioids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Source</td> <td class=\"subtitle1\">Serum half-life (hours)*</td> <td class=\"subtitle1\">Approximate equivalence to 10 mg morphine injection (mg)</td> <td class=\"subtitle1\">Important clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">IMPORTANT: The doses included here are NOT recommended for the initiation of therapy; they provide equivalents for the purpose of comparing different opioids.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Natural</td> </tr> <tr> <td class=\"indent1\">Morphine</td> <td>1.9 +/&ndash; 0.5</td> <td> <p>10 SC/IM/IV</p> 30 PO</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Codeine</td> <td>2.9 +/&ndash; 0.7</td> <td> <p>75 SC/IM/IV</p> 130 to 200 PO</td> <td>Metabolized by CYP2D6 to active drug (morphine). Metabolism and effects are subject to pronounced individual variability. Single oral doses over 65 mg tend to produce disproportionately greater adverse effects than analgesia.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Semi-synthetic</td> </tr> <tr> <td class=\"indent1\">Hydromorphone</td> <td>2.4 +/&ndash; 0.6</td> <td> <p>1.5 SC/IM/IV</p> 7.5 PO</td> <td>Hepatically metabolized to metabolites that can accumulate in organ failure and prolong effects. Some metabolites have been linked to neurotoxicity.</td> </tr> <tr> <td class=\"indent1\">Oxycodone</td> <td>2.6 (2.1-3.1)</td> <td>20 to 30 PO</td> <td>Metabolized by CYP3A4 and 2D6. Prolonged effects and elevated serum concentrations with renal or hepatic insufficiency. May cause QTc prolongation.</td> </tr> <tr> <td class=\"indent1\">Hydrocodone</td> <td>4.24 +/&ndash; 0.99</td> <td>30 PO</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diacetylmorphine (diamorphine, heroin)</td> <td>&nbsp;</td> <td>5 SC</td> <td>Highly lipophilic causing more rapid CNS effects than morphine. Largely metabolized to morphine. Due to abuse potential is not available for clinical use in many countries.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Synthetic</td> </tr> <tr> <td class=\"indent1\">Meperidine</td> <td>3.2 +/&ndash; 0.8</td> <td> <p>75 to 100 SC/IM</p> 300 PO</td> <td>Excitatory neurotoxicity may occur when normeperidine, a renally-eliminated metabolite, accumulates.</td> </tr> <tr> <td class=\"indent1\">Methadone</td> <td>27 +/&ndash; 12</td> <td>10 SC/IM/IV Highly variable. See clinical features.</td> <td>Used in opioid substitution therapy. Can cause QTc prolongation. May be far more potent than indicated in this table. Metabolized by CYP3A4. Due to its highly variable and prolonged half-life (up to 150 hours), methadone has the highest risk among opioids of accumulation and toxicity during initial titration and after changes in dose.</td> </tr> <tr> <td class=\"indent1\">Tramadol</td> <td>5.5 (4.5-7.5)</td> <td>50 to 100 PO<sup>&#182;</sup></td> <td>Usual initial dose for mild analgesia shown; NOT equivalent to parenteral morphine 10 mg. Effects NOT completely reversed by naloxone. Noted to cause seizures. Metabolized by CYP2D6 and 3A4. Subject to interactions including serotonin excess.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fentanyl</td> <td>3.7 +/&ndash; 0.4</td> <td>0.05 to 0.1 SC/IM/IV</td> <td>Short acting when administered IV/IM as a single dose. Highly lipophilic. Parent drug accumulates with repeated or prolonged administration.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Agonist/antagonist</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pentazocine</td> <td>2 to 3</td> <td> <p>30 to 60 SC/IM</p> 75 to 150 PO</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Partial agonist</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Buprenorphine</td> <td>2.33 +/&ndash; 0.24</td> <td> <p>0.3 to 0.4 IM/IV</p> 0.4 sublingual</td> <td>Used in opioid substitution therapy. Significantly longer duration of effect than 10 mg parenteral morphine. Metabolized by and subject to interactions involving CYP3A4.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gastrointestinally insoluble - not analgesic</td> </tr> <tr> <td class=\"indent1\">Diphenoxylate</td> <td>&nbsp;</td> <td>2.5 to 5 PO (anti-diarrheal dose)<sup>&#182;</sup></td> <td>Poor solubility limits potential for parenteral injection and abuse. Usually formulated with atropine (US trade name Lomotil&#174;, 0.025 mg atropine and 2.5 mg diphenoxylate) to further decrease abuse potential.</td> </tr> <tr> <td class=\"indent1\">Loperamide</td> <td>&nbsp;</td> <td>2 to 4 PO (anti-diarrheal dose)<sup>&#182;</sup></td> <td>CNS depression and cardiac conduction disturbances are observed in large acute and chronic supratherapeutic ingestions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Half-life and equal analgesic dosing approximations apply only to immediate release or SQ/IM preparations, single dose, in opioid naive patients. The actual duration of effect may be longer or shorter than suggested by the serum half-life depending upon the dose, the patient's tolerance, the presence of active metabolites, organ function, and redistribution of the drug.<br />&para; Not a dose equivalent. Usual initial dose shown.</div><div id=\"graphicVersion\">Graphic 70480 Version 8.0</div></div></div>"},"70481":{"type":"graphic_picture","displayName":"Fibrovascular polyp intraop","title":"Esophageal fibrovascular polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal fibrovascular polyp</div><div class=\"cntnt\"><img style=\"width:432px; height:310px;\" src=\"images/GAST/70481_Fibrovascular_polyp_intraop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative view of an esophageal fibrovascular polyp before resection.</div><div class=\"graphic_reference\">Courtesy of Amy Lo, MD, Daniel Wild, MD, and Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 70481 Version 2.0</div></div></div>"},"70483":{"type":"graphic_diagnosticimage","displayName":"Male palpable lump","title":"Male with palpable lump","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Male with palpable lump</div><div class=\"cntnt\"><img style=\"width:462px; height:388px;\" src=\"images/PC/70483_Male_palpable_lump.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CC and MLO views in a male with a palpable lump behind the nipple. The mammograms show an irregular, dense, spiculated mass. The mammographic appearance of breast cancer in a male is similar to that in a female.</div><div class=\"graphic_footnotes\">CC: craniocaudal; MLO: mediolateral oblique.</div><div id=\"graphicVersion\">Graphic 70483 Version 2.0</div></div></div>"},"70484":{"type":"graphic_diagnosticimage","displayName":"Bilateral pneumothoraces CT","title":"CT scan of posttraumatic bilateral pneumothoraces","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of posttraumatic bilateral pneumothoraces</div><div class=\"cntnt\"><img style=\"width:360px; height:305px;\" src=\"images/PULM/70484_Bilateral_pneumothoraces_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows large right and small left anterior pneumothoraces, bibasal pulmonary contusions, and bilateral subcutaneous emphysema.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70484 Version 5.0</div></div></div>"},"70486":{"type":"graphic_picture","displayName":"Dupuytrens contracture","title":"Dupuytren's contracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dupuytren's contracture</div><div class=\"cntnt\"><img style=\"width:306px; height:305px;\" src=\"images/RHEUM/70486_Dupuytrens_contracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular fibrosing lesions with bands radiating distally are features of Dupuytren's contracture. The ulnar side of the hand is affected, with the fourth and fifth fingers usually involved first.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996. Copyright © 1996 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 70486 Version 8.0</div></div></div>"},"70488":{"type":"graphic_figure","displayName":"Synovial sheaths of the hand","title":"Synovial sheaths of the hand","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Synovial sheaths of the hand</div><div class=\"cntnt\"><img style=\"width:515px; height:617px;\" src=\"images/SURG/70488_Synovial_sheaths_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration demonstrates the anatomy of the synovial spaces of the hand and the flexor tendon sheaths.The flexor tendons of the hand are enclosed in a double-layered synovial sheath composed of an inner visceral layer and an outer parietal layer, which creates a closed system. There are seven synovial sheaths, including a digital synovial sheath for each of the five digits and a radial and an ulnar bursa extending from the neck of the thumb metacarpal and small finger metacarpal, respectively.</div><div id=\"graphicVersion\">Graphic 70488 Version 4.0</div></div></div>"},"70491":{"type":"graphic_table","displayName":"Major causes of wide QRS complex","title":"Major causes of a wide ORS complex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of a wide ORS complex</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Intrinsic intraventricular conduction delay</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Left bundle branch block and variants</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Right bundle branch block and variants</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Other nonspecific IVCD patterns</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Extrinsic intraventricular conduction delay</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Hyperkalemia</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>\nDrug-induced - type I antiarrhythmic drugs and related sodium channel\nblocking agents (eg, tricyclic antidepressants and phenothiazines)</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Ventricular beat</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Premature</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Escape</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Paced</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Ventricular preexcitation</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Wolff-Parkinson-White (WPW) pattern and variants</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Factitious</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>ECG unintentionally recorded at fast paper speeds (50 or 100 mm/s)</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Wide QRS complex tachyarrhythmias</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Ventricular tachycardia</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist1_start\">Supraventricular tachycardia or atrial fibrillation or flutter with aberrant intraventricular conduction due to:</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist1\">Bundle branch block</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist1\">Atrioventricular bypass tract (preexcitation syndromes with orthodromic conduction)</td>\n\n\n\n    </tr>\n\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70491 Version 2.0</div></div></div>"},"70492":{"type":"graphic_waveform","displayName":"EEG Rhythmic midtemporal theta","title":"Rhythmical midtemporal theta of drowsiness","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Rhythmical midtemporal theta of drowsiness</div><div class=\"cntnt\"><img style=\"width:554px; height:341px;\" src=\"images/NEURO/70492_Rhythmic_midtemp_theta.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythmical midtemporal theta of drowsiness (RMTD; see arrows); also known as psychomotor variant. This is a normal variant.</div><div class=\"graphic_reference\">Courtesy of Drs. Lawrence Hirsch and Hiba Arif.</div><div id=\"graphicVersion\">Graphic 70492 Version 3.0</div></div></div>"},"70493":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of membrane separation","title":"Ultrasound image of membrane separation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of membrane separation</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/OBGYN/70493_USmembraneseparation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal midline sagittal ultrasound image of the cervix showing funneling (long arrow), membrane separation from the decidua (along the anterior lip of the cervix) (short arrow), and debris (diffuse area of echodensity resting within the amniotic fluid of the funnel on the posterior cervix; thick arrow).</div><div class=\"graphic_reference\">Courtesy of Jay D Iams, MD.</div><div id=\"graphicVersion\">Graphic 70493 Version 4.0</div></div></div>"},"70494":{"type":"graphic_diagnosticimage","displayName":"Radiograph osteosarcoma proximal tibia","title":"Plain radiograph of a conventional osteosarcoma involving the proximal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of a conventional osteosarcoma involving the proximal tibia</div><div class=\"cntnt\"><img style=\"width:342px; height:590px;\" src=\"images/ONC/70494_Xryosteosarcomadstlfmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional radiograph shows mixed lytic and sclerotic lesion with osteoid matrix associated with malignant tumor cells&nbsp;(arrow) and Codman triangle (arrowhead) involving the proximal tibia.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorlick R, Bielack S, Teot L, et al. In: Principles and practice of pediatric oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 70494 Version 16.0</div></div></div>"},"70495":{"type":"graphic_diagnosticimage","displayName":"Drug packets on abdominal CT","title":"Drug packets on abdominal CT","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Drug packets on abdominal CT</div><div class=\"cntnt\"><img style=\"width:468px; height:468px;\" src=\"images/EM/70495_Drug_packets_abdominal_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT image of a body packer with bowel obstruction illustrates the air trapping seen between the packaging materials and at the end of bags.</div><div class=\"graphic_reference\">Courtesy of Robert Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 70495 Version 2.0</div></div></div>"},"70497":{"type":"graphic_table","displayName":"Dyspareunia differential dx2","title":"Differential diagnoses for physical causes of dyspareunia (cont.)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnoses for physical causes of dyspareunia (cont.)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Location affected</td> <td class=\"subtitle1\">Specific condition</td> <td class=\"subtitle1\">Important history</td> <td class=\"subtitle1\">Physical source of dyspareunia</td> <td class=\"subtitle1\">Comments and caveats</td> </tr> <tr> <td rowspan=\"10\">Vestibule and vagina</td> <td>Atrophy: low or absent estrogen</td> <td>Dryness, irritation, hx breast feeding, oligo/amenorrhea, low estrogen/high androgenic OCP, Depo-Provera, anorexia, exercise, premenopausal tamoxifen, chemotherapy, radiation, BSO, aromatase inhibitors</td> <td>Reduction in labial size, mucosal color and textural change, fissures; elevated vaginal pH, atrophic wet prep</td> <td> <p>Can occur at any age</p> For women with breast cancer, consult with oncologist about vaginal estrogen therapy</td> </tr> <tr> <td>Vulvovaginitis: Candida albicans</td> <td>Antibiotics, steroids, estrogen, immunosuppression</td> <td>Itching, erythema, edema, discharge, fissures; or few sx</td> <td>Perform yeast culture with each visit to assess for candidiasis</td> </tr> <tr> <td>Desquamative inflammatory vaginitis</td> <td>Irritative sx, profuse discharge</td> <td>Erythema, sheets of wbc, parabasals, no lactobacilli</td> <td>Can cause abnormal findings on Pap test. Can also cause localized pain in vestibule and/or vaginal pain and tenderness; these may lead to reflex tightening of pelvic floor muscles in response to the pain with sexual intercourse and can eventually lead to pelvic floor dysfunction.</td> </tr> <tr> <td>Vulvovaginitis: Trichomonas</td> <td>Itching, discharge, or few sx</td> <td>Mobile trichomonads; positive culture</td> <td>&nbsp;</td> </tr> <tr> <td>Bartholin cyst or abscess</td> <td>Swelling and pain</td> <td>Cystic mass at base of vestibule</td> <td>&nbsp;</td> </tr> <tr> <td>Seminal plasma allergy</td> <td>Itching on entry or ejaculation</td> <td>Edema and erythema post coitus</td> <td>Trial of condom is diagnostic</td> </tr> <tr> <td>Dermatosis: lichen sclerosus</td> <td>Itching or no symptoms</td> <td>Fissures, scaring around introitus</td> <td>Candida may arise with steroid therapy</td> </tr> <tr> <td>Dermatosis: lichen planus</td> <td>Itching, burning, discharge</td> <td>Erosions, ulceration, scarring</td> <td>As above, atypical Pap smear</td> </tr> <tr> <td>Inadequate lubrication, dryness</td> <td>Poor sexual technique, sexual dysfunction, Sjogren's, OCP, medications, vestibulodynia</td> <td>Dryness, tenderness</td> <td>No good test; hard to judge on exam; history important</td> </tr> <tr> <td>Radiation</td> <td>History of gyn or urinary tumor</td> <td>Pallor, loss of elasticity, scarring</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OCP: oral contraceptive pills; BSO: bilateral salpingo-oophorectomy; hx: history; sx: symptoms.</div><div class=\"graphic_reference\">Courtesy of Elizabeth Gunther Stewart, MD.</div><div id=\"graphicVersion\">Graphic 70497 Version 3.0</div></div></div>"},"70498":{"type":"graphic_table","displayName":"Radiation toxicity gastrointest","title":"Radiation toxicity: Gastrointestinal system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation toxicity: Gastrointestinal system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Degree 1</td> <td class=\"subtitle1\">Degree 2</td> <td class=\"subtitle1\">Degree 3</td> <td class=\"subtitle1\">Degree 4</td> </tr> <tr> <td>Stool (number/day)</td> <td>2 to 3</td> <td>4 to 6</td> <td>7 to 9</td> <td>&#8805;10</td> </tr> <tr> <td>Stool consistency</td> <td>Bulky</td> <td>Loose</td> <td>Loose</td> <td>Watery</td> </tr> <tr> <td>GI bleeding</td> <td>Occult</td> <td>Intermittent</td> <td>Persistent</td> <td>Persistent large amount</td> </tr> <tr> <td>Abdominal cramps or pain</td> <td>Minimal</td> <td>Moderate</td> <td>Intense</td> <td>Excruciating</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">8/26/2004 Perm requested Pull if no perm by 12.3 9/7/2004 Perm granted 6/3/2005 renewal requested 6/17/2005 they emailed for more info 6/28/2005 granted - need to note in each renewal the waselenko is the author since they don't carry over this info 7/24/2006 Renewal Requested 8/21/2006 bugged - informed that they only grant for one version at a time 8/21/2006 renewal granted (renew 15.1) 10/6/2006 renewal requested 10/11/2006 renewal granted for one year 11/28/2007--renewal requested. EM 1/8/2008--renewal granted. EM 12/30/2008--Requested renewal (JD). 1/14/2009--Renewal invoice recevied, to Susan; awaiting formal grant of permission (JD). 1/22/2009--Grant of permission received (JD). 2/4/2010--Renewal requested (JD). 2/12/2010--Renewal granted, paid on my AMEX (JD). The total fee of $&amp;quot;120.00&amp;quot;was originally charged to Radiation_tox_gastrointest Radiation_tox_hematopoietic Radiation_tox_cerebrovascular Radiation_biodosimetry Rx_guide_radiation_exposure Cytokines_radiation_exposure Military_triage_radiation</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26436&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright © 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 70498 Version 17.0</div></div></div>"},"70499":{"type":"graphic_table","displayName":"Epilepsy syndromes in first year of life","title":"Epilepsy syndromes with onset in the first year of life","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epilepsy syndromes with onset in the first year of life</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Benign neonatal convulsions (familial and non-familial)</td> </tr> <tr> <td>Benign familial infantile convulsions</td> </tr> <tr> <td>Paroxysmal kinesigenic dyskinesia/infantile convulsions*</td> </tr> <tr> <td>Early infantile epileptic encephalopathy (Ohtahara's Syndrome)</td> </tr> <tr> <td>Early myoclonic encephalopathy</td> </tr> <tr> <td>Infantile massive spasms</td> </tr> <tr> <td>Benign partial epilepsy with and without secondary generalization</td> </tr> <tr> <td>Benign myoclonic epilepsy in infants</td> </tr> <tr> <td>Severe myoclonic epilepsy in infants</td> </tr> <tr> <td>Lennox-Gastaut syndrome</td> </tr> <tr> <td>Childhood absence epilepsy</td> </tr> <tr> <td>Symptomatic/cryptogenic partial epilepsies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Also known as familial infantile convulsions and paroxysmal choreoathetosis (ICCA).</div><div id=\"graphicVersion\">Graphic 70499 Version 4.0</div></div></div>"},"70500":{"type":"graphic_diagnosticimage","displayName":"Cryptogenic organizing pneumonia CXR III","title":"Cryptogenic organizing pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonia</div><div class=\"cntnt\"><img style=\"width:340px; height:271px;\" src=\"images/PULM/70500_BOOP_PA_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forty-eight year old woman with an eight week history of cough, dyspnea with exertion, fatigue, and slight weight loss. Posteroanterior&nbsp;chest radiograph&nbsp;reveals bilateral volume loss with reticular opacities at both bases. There was improvement following&nbsp;glucocorticoid therapy, but the patient did not return to normal lung function or exercise capacity.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 70500 Version 5.0</div></div></div>"},"70502":{"type":"graphic_figure","displayName":"Eisenmenger syndrome anatomy and physiology","title":"Eisenmenger's syndrome anatomy and physiology","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Eisenmenger's syndrome anatomy and physiology</div><div class=\"cntnt\"><img style=\"width:528px; height:711px;\" src=\"images/CARD/70502_Pathophysiology_Eisenmengers_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eisenmenger syndrome is the triad of systemic-to-pulmonary cardiovascular communication, pulmonary arterial disease, and cyanosis. Pulmonary arterial disease develops as a consequence of increased pulmonary blood flow.</div><div id=\"graphicVersion\">Graphic 70502 Version 7.0</div></div></div>"},"70503":{"type":"graphic_picture","displayName":"DIP joints psoriatic arthritis","title":"Distal interphalangeal joint involvement in psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal interphalangeal joint involvement in psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:360px; height:375px;\" src=\"images/RHEUM/70503_DIP_joints_psoriatic_arthri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Psoriatic arthritis with distal joint involvement in the third and fifth digits (arrow). Onycholysis is also seen in most of the fingernails.</div><div class=\"graphic_reference\">Courtesy of Dafna D Gladman, MD.</div><div id=\"graphicVersion\">Graphic 70503 Version 1.0</div></div></div>"},"70505":{"type":"graphic_waveform","displayName":"EP study APB","title":"Electrophysiology (EP) study showing surface and intracardiac electrocardiogram tracings of an atrial premature beat (APB)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrophysiology (EP) study showing surface and intracardiac electrocardiogram tracings of an atrial premature beat (APB)</div><div class=\"cntnt\"><img style=\"width:353px; height:323px;\" src=\"images/CARD/70505_Atrial_premature_beat_EP_st.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous surface electrocardiographic leads I, II, V1 and intracardiac recordings from the high right atrium (HRA), His bundle (HBE), proximal (CSp) and distal (CSd) coronary sinus, and right ventricular apex (RVA). During sinus rhythm the impulse originates in the HRA and is then conducted through the HBE, CSp, CSd, and ultimately the RVA (blue line 1). An atrial premature beat (ABP), denoted by the red asterisk, originates in the CSp (blue line 2) and is conducted retrogradely to the HRA and antegradely to the CSd and RVA. The APB has a longer AH interval compared to sinus rhythm and is associated with a full compensatory pause.</div><div id=\"graphicVersion\">Graphic 70505 Version 3.0</div></div></div>"},"70509":{"type":"graphic_table","displayName":"Neonatal morbidity by delivery type (SVD, forceps, vacuum)","title":"Neonatal morbidity and mortality data by delivery type for the United States, 1995 to 1998 (rates are per 10,000 deliveries)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neonatal morbidity and mortality data by delivery type for the United States, 1995 to 1998 (rates are per 10,000 deliveries)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Spontaneous</td> <td class=\"subtitle1\">Forceps delivery</td> <td class=\"subtitle1\">Vacuum delivery</td> </tr> <tr> <td>Neonatal death</td> <td>3.7</td> <td>5.0</td> <td>4.7</td> </tr> <tr> <td>Birth injury</td> <td>21.4</td> <td>109.1</td> <td>76.1</td> </tr> <tr> <td>Neonatal seizures</td> <td>5.0</td> <td>8.7</td> <td>6.5</td> </tr> <tr> <td>Assisted ventilation &#60;30 minutes</td> <td>147</td> <td>293</td> <td>250</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data&nbsp;from: Demissie K, Rhoads GG, Smulian JC, et al. Operative vaginal delivery and neonatal and infant adverse outcomes: population based retrospective analysis. BMJ 2004; 329:24.</div><div id=\"graphicVersion\">Graphic 70509 Version 5.0</div></div></div>"},"70510":{"type":"graphic_table","displayName":"Brain CT in stage III melanoma","title":"Computerized tomography of the brain in asymptomatic patients with stage III melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Computerized tomography of the brain in asymptomatic patients with stage III melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Institution</td>\n\n      <td class=\"subtitle1\">N</td>\n\n      <td class=\"subtitle1\">True positive, percent</td>\n\n      <td class=\"subtitle1\">False positive, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>MDACC</td>\n\n      <td>82</td>\n\n      <td>1.2*</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>MSKCC</td>\n\n      <td>104</td>\n\n      <td>0</td>\n\n      <td>3.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>University of Michigan</td>\n\n      <td>99</td>\n\n      <td>6</td>\n\n      <td>12</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">MDACC: The University of Texas M.D. Anderson Cancer Center; MSKCC: Memorial Sloan-Kettering Cancer Center.<br> * This single true-positive case showed bone involvement and not brain metastasis.</div><div class=\"graphic_reference\">Courtesy of Antonio Buzaid, MD.</div><div id=\"graphicVersion\">Graphic 70510 Version 1.0</div></div></div>"},"70511":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 4 example 2","title":"Sacroiliitis grade 4 example 2","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 4 example 2</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/70511_Sacroiliitis_grade_4_ex_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral grade 4 sacroiliitis with fusion of the sacroiliac joints.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 70511 Version 4.0</div></div></div>"},"70512":{"type":"graphic_picture","displayName":"Periorificial dermatitis - periocular","title":"Periorificial dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periorificial dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70512_Periorificial_derm_periocular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules are present in the periorbital region.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70512 Version 3.0</div></div></div>"},"70513":{"type":"graphic_table","displayName":"Indications FNA","title":"Sonographic patterns, estimated risk of malignancy, and FNA guidance for thyroid nodules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sonographic patterns, estimated risk of malignancy, and FNA guidance for thyroid nodules</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sonographic pattern</td> <td class=\"subtitle1\">Ultrasound features</td> <td class=\"subtitle1\">Estimated risk of malignancy</td> <td class=\"subtitle1\">Consider biopsy (FNA size cutoff, largest dimension)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>High suspicion</strong></td> <td>Solid hypoechoic nodule or solid hypoechoic component of a partially cystic nodule WITH one or more of the following features: Irregular margins (infiltrative, microlobulated), microcalcifications, taller than wide shape, rim calcifications with small extrusive soft tissue component, evidence of extrathyroidal extension</td> <td class=\"centered\">&#62;70 to 90%*</td> <td>Recommend FNA at &#62;1 cm</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intermediate suspicion</strong></td> <td>Hypoechoic solid nodule with smooth margins WITHOUT microcalcifications, extrathyroidal extension, or taller than wide shape</td> <td class=\"centered\">10 to 20%</td> <td>Recommend FNA at &#62;1 cm</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Low suspicion</strong></td> <td>Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid areas, WITHOUT microcalcification, irregular margin or extrathyroidal extension, or taller than wide shape</td> <td class=\"centered\">5 to 10%</td> <td>Recommend FNA at &#62;1.5 cm</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Very low suspicion</strong></td> <td>Spongiform or partially cystic nodules WITHOUT any of the sonographic features described in low, intermediate, or high suspicion patterns</td> <td class=\"centered\">&#60;3%</td> <td> <p>Consider FNA at &#62;2 cm</p> Observation without FNA is also a reasonable option</td> </tr> <tr> <td><strong>Benign</strong></td> <td>Purely cystic nodules (no solid component)</td> <td class=\"centered\">&#60;1%</td> <td>No biopsy<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Ultrasound-guided FNA is recommended for cervical lymph nodes that are sonographically suspicious for thyroid cancer.</div><div class=\"graphic_footnotes\">FNA: fine-needle aspiration.<br />* The estimate is derived from high-volume centers; the overall risk of malignancy may be lower given the interobserver variability in sonography.<br />&para; Aspiration of the cyst may be considered for symptomatic or cosmetic drainage.</div><div class=\"graphic_reference\">Reproduced with permission from: Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1. Copyright &copy; 2016 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 70513 Version 9.0</div></div></div>"},"70515":{"type":"graphic_diagnosticimage","displayName":"SVC syndrome SCLC","title":"Superior vena cava syndrome from small cell lung carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior vena cava syndrome from small cell lung carcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:268px;\" src=\"images/ONC/70515_SVC_syndrome_SCLC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A peripheral nodule is visible in the posterior segment of the right upper lobe with adjacent large right paratracheal lymph nodes (white arrows) completely occluding the superior vena cava. Collateral vessels drain the contrast enhanced venous blood towards the inferior vena cava. The internal mammary veins, the left superior intercostal vein, the lateral thoracic vein and the paravertebral veins are clearly visible.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70515 Version 2.0</div></div></div>"},"70518":{"type":"graphic_picture","displayName":"Lichen planus arm","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:353px; height:288px;\" src=\"images/PC/70518_Lichen_planus_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the shiny, flat, polygonal, violaceous papules.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 70518 Version 1.0</div></div></div>"},"70519":{"type":"graphic_table","displayName":"Pacing for SA node dysfunction","title":"Indications for pacing for sinus node dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for pacing for sinus node dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pacemaker necessary</td> <td class=\"subtitle1\">Pacemaker probably necessary</td> <td class=\"subtitle1\">Pacemaker not necessary</td> </tr> <tr> <td>Symptomatic bradycardia</td> <td>Symptomatic patients with sinus node dysfunction with documented rates of &#60;40 bpm without a clear-cut association between significant symptoms and the bradycardia</td> <td>Asymptomatic sinus node dysfunction</td> </tr> <tr> <td>Symptomatic sinus bradycardia due to long-term drug therapy of a type and dose for which there is no accepted alternative</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70519 Version 2.0</div></div></div>"},"70522":{"type":"graphic_waveform","displayName":"AVN reentrant tach tutorial","title":"AV nodal reentrant tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AV nodal reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:378px; height:143px;\" src=\"images/CARD/70522_AVN_reentrant_tach_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrioventricular nodal reentrant tachycardia is a supraventricular tachyarrhythmia that originates within the atrioventricular node. The rate is generally between 140 to 220 beats per minute and there is usually a 1:1 atrial-ventricular association; as a result, every QRS complex has an associated P wave. In this case, atrial and ventricular activation are simultaneous; as a result, the P wave is superimposed upon the QRS complex and therefore not obvious on the surface ECG.</div><div id=\"graphicVersion\">Graphic 70522 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"70524":{"type":"graphic_figure","displayName":"Cardiopul exercise outc HF","title":"Peak VO2 and systolic pressure predict outcome in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peak VO2 and systolic pressure predict outcome in HF</div><div class=\"cntnt\"><img style=\"width:396px; height:186px;\" src=\"images/CARD/70524_CardiopulexerciseoutcHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a series of 500 patients with chronic heart failure (HF), the three-year survival rate was excellent in patients with a peak V<SUB>O2</SUB> above 14 mL/min/kg (top curve). Among patients with a lower peak V<SUB>O2</SUB>, three-year survival was higher in those able to achieve a peak systolic blood pressure above 120 mmHg with exercise (p = 0.02).</div><div class=\"graphic_reference\">Data from: Osada N, Chaitman BR, Miller LW, et al, J Am Coll Cardiol 1998; 31:577.</div><div id=\"graphicVersion\">Graphic 70524 Version 2.0</div></div></div>"},"70525":{"type":"graphic_diagnosticimage","displayName":"Vein of Galen aneurysm","title":"Vein of Galen aneurysm at 32 postmenstrual weeks and 5 days","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vein of Galen aneurysm at 32 postmenstrual weeks and 5 days</div><div class=\"cntnt\"><img style=\"width:343px; height:362px;\" src=\"images/OBGYN/70525_Vein_Galen_aneurysm_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using color Doppler the large vein is seen posterior to the corpus callosum and anterior to the cerebellum. In panel B the pulsatile flow is seen through this large vessel.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 70525 Version 4.0</div></div></div>"},"70527":{"type":"graphic_picture","displayName":"Thumb spica cast 6","title":"Thumb spica cast: Step 6","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 6</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/70527_Thumb_spica_cast_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the stockinette and webril are in place, begin to apply the casting material. Fiberglass cast tape is applied in the photograph above. Apply the tape so each layer overlaps the previous one by about half the width of the material. Be sure to leave the ends of the stockinette extended until you are ready to apply the final layers of casting material.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 70527 Version 5.0</div></div></div>"},"70528":{"type":"graphic_figure","displayName":"Insulin response to arginine","title":"Acute insulin response to arginine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute insulin response to arginine</div><div class=\"cntnt\"><img style=\"width:378px; height:302px;\" src=\"images/ENDO/70528_Insulin_response_to_arginin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The acute serum insulin response to arginine increases in an approximately linear manner as blood glucose concentrations increase from 100 to 300 mg/dL (5.6 to 16.7 mmol/L), reaching a plateau above 450 mg/dL (25 mmol/L). To convert insulin values to pmol/L, multiply by 6; to convert blood glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Data from: Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74:1318.</div><div id=\"graphicVersion\">Graphic 70528 Version 3.0</div></div></div>"},"70530":{"type":"graphic_table","displayName":"Urine molecular markers for bladder cancer ","title":"Urinary molecular markers for the detection of bladder cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urinary molecular markers for the detection of bladder cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Target</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">False positive in</td> </tr> <tr> <td>Bladder tumor antigen</td> <td>50 to 90%</td> <td>90%</td> <td>Urinary tract infection, hematuria, calculi, BPH, prior intravesical treatment</td> </tr> <tr> <td>Nuclear matrix protein (NMP) 22</td> <td>42 to 100%</td> <td>70 to 91%</td> <td>Inflammation</td> </tr> <tr> <td>NMP 52</td> <td>97%</td> <td>94%</td> <td>&nbsp;</td> </tr> <tr> <td>Bladder cancer associated&nbsp;NMP 4 (BLCA-4)</td> <td>89 to 96%</td> <td>95 to 100%</td> <td>&nbsp;</td> </tr> <tr> <td>BLCA-1</td> <td>80%</td> <td>87%</td> <td>&nbsp;</td> </tr> <tr> <td>Survivin</td> <td>64 to 100%</td> <td>93 to 100%</td> <td>&nbsp;</td> </tr> <tr> <td>Cytokeratin (CK) 8 and CK 18</td> <td>35 to 79%</td> <td>68%</td> <td>&nbsp;</td> </tr> <tr> <td>CK 19</td> <td>43 to 96%</td> <td>70%</td> <td>Urinary tract infection, calculi, post-BCG</td> </tr> <tr> <td>Fibrin degradation products (FDP)</td> <td>70%</td> <td>68 to 86%</td> <td>&nbsp;</td> </tr> <tr> <td>Hyaluronic acid, hyaluronidase</td> <td>82 to 100%</td> <td>81 to 90%</td> <td>&nbsp;</td> </tr> <tr> <td>mRNA markers*</td> <td>74 to 95%</td> <td>45 to 81%</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BPH: benign prostatic hyperplasia; BCG: Bacillus Calmette-Guerin.<br />* Cxbladder test: <EM>IGFBP5</EM>, <EM>HOXA13</EM>, <EM>MDK</EM>, <EM>CDK1</EM>, <EM>CXCR2</EM>.</div><div id=\"graphicVersion\">Graphic 70530 Version 4.0</div></div></div>"},"70532":{"type":"graphic_figure","displayName":"Location of cataracts","title":"Locations of cataracts","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Locations of cataracts</div><div class=\"cntnt\"><img style=\"width:542px; height:359px;\" src=\"images/PC/70532_Location_of_cataracts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows common locations of age-related cataracts: nuclear, cortical, and posterior subcapsular. Patients can have more than one type of cataract in a single eye.</div><div id=\"graphicVersion\">Graphic 70532 Version 3.0</div></div></div>"},"70533":{"type":"graphic_picture","displayName":"Balloon dilation","title":"Flexible bronchoscopic balloon dilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexible bronchoscopic balloon dilation</div><div class=\"cntnt\"><img style=\"width:278px; height:353px;\" src=\"images/PULM/70533_Balloon_dilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Balloon dilation of a circumferential mainstem stenosis that developed after lung transplantation.</div><div class=\"graphic_reference\">Courtesy of Armin Ernst, MD</div><div id=\"graphicVersion\">Graphic 70533 Version 3.0</div></div></div>"},"70534":{"type":"graphic_diagnosticimage","displayName":"M-mode obstructive HCM","title":"Hypertrophic obstructive cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic obstructive cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:356px; height:288px;\" src=\"images/CARD/70534_MmodeobstructiveHCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram is from a patient with a hypertrophic cardiomyopahty and resting obstruction. Panel A is from the minor axis of the left ventricle (LV) and demonstrates typical asymmetric ventricular hypertrophy of the interventricular septum (IVS). Systolic anterior motion (SAM) of the mitral valve (MV) and crowded appearance of ventricle are shown in panel B. The degree of contact between the septum and the mitral valve during systole appears minimal, suggesting that obstruction is mild. However, in panel C, the aortic valve (AoV) demonstrates striking midsystolic notching or closure (arrow), strongly suggesting that dynamic obstruction is significant.</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 70534 Version 6.0</div></div></div>"},"70535":{"type":"graphic_picture","displayName":"Merkel cell carcinoma","title":"Merkel cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70535_Merkel_cell_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This blue-red, dome-shaped nodule is a Merkel cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70535 Version 4.0</div></div></div>"},"70536":{"type":"graphic_table","displayName":"Clinical Aeromonas spp","title":"Aeromonas species associated with human disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeromonas species associated with human disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Species name</td> <td class=\"subtitle1\">Occurrence in clinical specimens</td> <td class=\"subtitle1\">Disease association</td> </tr> <tr> <td>A. hydrophila</td> <td>Common</td> <td>Wounds, septicemia, gastroenteritis, leech therapy, peritonitis</td> </tr> <tr> <td>A. dhakensis&nbsp;</td> <td>Common&nbsp;</td> <td>Wounds, septicemia, gastroenteritis, leech therapy, peritonitis&nbsp;</td> </tr> <tr> <td>A. veronii biovar sobria</td> <td>Common</td> <td>Wounds, septicemia (including \"primary septicemia\"), gastroenteritis, leech therapy, peritonitis</td> </tr> <tr> <td>A caviae</td> <td>Common</td> <td>Gastroenteritis (esp. pediatric), septicemia</td> </tr> <tr> <td>A. veronii biovar veronii</td> <td>Rare</td> <td>Gastroenteritis, septicemia</td> </tr> <tr> <td>A. jandaei</td> <td>Rare</td> <td>Wounds, septicemia, gastroenteritis</td> </tr> <tr> <td>A. schubertii</td> <td>Rare</td> <td>Traumatic aquatic wounds, septicemia</td> </tr> <tr> <td>A. trota</td> <td>Rare</td> <td>Gastroenteritis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Martin-Carnahan A, Joseph SW. Aeromonas. In: Bergey's Manual of Systematic Bacteriology, 2nd Ed, Brenner, Krieg, Staley, Garrity (Eds), Williams and Wilkins, Volume 2, Springer-Verlag, New York 2005.</li>&#xD;&#xA;    <li>Janda JM, Abbott SL. Human pathogens. In: The genus: Aeromonas, 1st ed, Austin B, Altwegg M, Gosling PJ, Joseph SW (Eds), John Wiley &amp; Sons, Ltd., Chichester 1996. p.175.</li>&#xD;&#xA;    <li>Figueras MJ. Clinical relevance of Aeromonas. Rev Med Microbiol 2005; 16:145.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Amy Horneman, PhD and J Glenn Morris, MD.</div><div id=\"graphicVersion\">Graphic 70536 Version 5.0</div></div></div>"},"70537":{"type":"graphic_table","displayName":"CADILLAC risk score","title":"CADILLAC risk score for 30-day and one-year mortality after primary percutaneous coronary intervention for ST elevation myocardial infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CADILLAC risk score for 30-day and one-year mortality after primary percutaneous coronary intervention for ST elevation myocardial infarction</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Risk factor</td>\n\n\n      <td class=\"subtitle1\">Points</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">LVEF &#60;40 percent</td>\n\n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Killip class 2/3</td>\n\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\">Renal insufficiency (estimated creatinine clearance &#60;60 mL/min) </td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">TIMI flow grade after PCI of 0 to 2</td>\n\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Age &#62;65 years</td>\n\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\">Anemia (hematocrit &#60;39 percent in men and &#60;36 percent in women)</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">Triple-vessel disease</td>\n\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1\">Risk score</td>\n\n      <td class=\"subtitle1\">30-day mortality</td>\n\n      <td class=\"subtitle1\">One-year mortality</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Low risk (score 0 to 2) </td>\n\n      <td> 0.1 to 0.2 percent</td>\n\n      <td>0.8 to 0.9 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intermediate risk (score 3 to 5)</td>\n\n      <td>1.3 to 1.9 percent</td>\n\n      <td>4.0 to 4.5 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>High risk (score &#8805;6) </td>\n\n      <td>6.6 to 8.1 percent</td>\n\n      <td>12.4 to 13.2 percent</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Halkin A, Singh M, Nikolsky E, et al, J Am Coll Cardiol 2005; 45:1397.</div><div id=\"graphicVersion\">Graphic 70537 Version 2.0</div></div></div>"},"70539":{"type":"graphic_table","displayName":"Doses pediatric resuscitation","title":"Pharmacologic agents for pediatric advanced life support","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic agents for pediatric advanced life support</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Dose</td> </tr> <tr class=\"divider_bottom\"> <td>Adenosine*</td> <td>Supraventricular tachycardia (SVT)</td> <td> <ul> <li>Initial dose 0.1 mg/kg (children &#62;50 kg receive 6 mg) given as rapid IV or IO push closest to central circulation; follow immediately with 5 mL saline flush (10 to 20 mL saline flush for larger child or adolescent) </li> <li>If not responsive in 2 minutes, give second dose of 0.2 mg/kg (children &#62;50 kg receive 12 mg) follow immediately with 5 mL saline flush; if not responsive after additional 2 minutes, give third dose of 0.3 mg/kg (maximum 12 mg) follow immediately&nbsp;with 5 mL saline flush&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Amiodarone<sup>&#182;</sup></td> <td> <p>Pulseless ventricular arrhythmias not responsive to CPR, defibrillation, and epinephrine</p> <p>Stable ventricular tachycardia</p> SVT refractory to adenosine</td> <td> <ul> <li><strong>Cardiac arrest: </strong>5 mg/kg rapid IV or IO bolus (maximum dose 300 mg); may repeat 5&nbsp;mg/kg dose two times up to a maximum of 15 mg/kg&nbsp;&nbsp; </li> <li><strong>Perfusing patient: </strong>5 mg/kg IV or IO (maximum dose 300 mg) dilute to 2 mg/mL or less and infuse over 20 to 60 minutes; may repeat 5 mg/kg dose two times&nbsp;up to a maximum of 15 mg/kg&nbsp;during acute treatment&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Atropine</td> <td> <p>Vagally mediated bradycardia</p> <p>Primary atrioventricular block</p> <p>Bradycardia not responsive to oxygen, airway support, and epinephrine administration</p> Prevention of bradycardia during endotracheal intubation for children &#60;1 year of age, children 1-5 years of age receiving succinylcholine, and children over 5 years of age receiving a second dose of succinylcholine</td> <td> <ul> <li>0.02 mg/kg IV or IO (minimum 0.1 mg<sup>&#916;</sup>, maximum single dose 0.5 mg for child or 1 mg for adolescent); may repeat once in 3 to 5 minutes </li> <li>Maximum total dose 1 mg (child) or 2 mg (adolescent)<sup>&#9674;</sup> </li> <li>Only if IV&nbsp;and IO not available, may give via endotracheal tube (ET)&nbsp;0.04 to 0.06 mg/kg diluted with 3 to 5 mL saline; repeat once if needed (IV or IO are preferred) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Calcium chloride<sup>&#167;</sup></td> <td> <p>Hypocalcemia</p> <p>Hypermagnesemia</p> <p>Hyperkalemia</p> Calcium channel blocker (CCB) overdose</td> <td> <ul> <li><strong>Cardiac arrest:</strong> 20 mg/kg given as 0.2 mL/kg of 10% calcium chloride solution, maximum 2 g (20 mL, 14 mmol) per dose; dilute in an equal amount of D5W or NS and give slow IV or IO push; repeat&nbsp;in 10 minutes if needed&nbsp; </li> <li><strong>Perfusing patient:</strong> 10 to 20 mg/kg given as 0.1 to 0.2 mL/kg of 10% calcium chloride solution, maximum 2 g (20 mL, 14 mmol) per dose; dilute in an equal amount of D5W or NS and give IV or IO over 5 to 10 minutes (for initial stabilization in CCB overdose or severe symptomatic hyperkalemia); or dilute in 10 to 50 mL D5W or NS and give IV or IO over 10 to 20 minutes in perfusing patient with severe symptomatic hypocalcemia (eg, tetany, carpopedal spasm, or seizure); may repeat in 10 minutes if needed </li> <li>Conversions: 10% calcium chloride = 100 mg/mL calcium chloride = 27.3 mg/mL elemental calcium = 0.68 mmol/mL calcium </li> <li>Peripheral administration of calcium chloride is not recommended<sup>&#167;</sup> </li> <li>Forms precipitate with sodium bicarbonate, do not co-infuse </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Calcium gluconate</td> <td> <p>Hypocalcemia</p> <p>Hypermagnesemia</p> <p>Hyperkalemia</p> <p>Calcium channel blocker (CCB) overdose</p> (Alternate to calcium chloride for perfusing patient; provides slower correction of ionized calcium concentration but less likely to cause tissue injury when given by peripheral IV)</td> <td> <ul> <li><strong>Cardiac arrest:</strong>&nbsp;60&nbsp;mg/kg given as 0.6&nbsp;mL/kg of 10% calcium gluconate solution, maximum&nbsp;3 g (30 mL,&nbsp;7 mmol) per dose; dilute in an equal amount of D5W or NS and give slow&nbsp;IV or&nbsp;IO&nbsp;push; repeat&nbsp;in 10 minutes if needed. Calcium chloride preferred if available and patient has central venous access. </li> <li><strong>Perfusing patient:</strong> 60 mg/kg given as 0.6 mL/kg of 10% calcium gluconate solution, maximum 2 g (20 mL, 4.5 mmol) per dose; dilute in an equal amount of D5W or NS and give IV or&nbsp;IO&nbsp;over 5 to 10 minutes for initial stabilization in CCB overdose or severe symptomatic hyperkalemia, may repeat if needed&nbsp;or&nbsp;follow by continuous infusion (CCB overdose); or dilute in 10 to 50 mL D5W or NS and give IV or IO over 10 to 20 minutes in perfusing patient with severe symptomatic hypocalcemia (eg, tetany, carpopedal spasm, or seizures); may repeat in 10 minutes if needed </li> <li>Conversions: 10% calcium gluconate = 100 mg/mL calcium gluconate = 9.3 mg/mL elemental calcium = 0.23 mmol/mL calcium </li> <li>Forms precipitate with sodium bicarbonate, do not co-infuse </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Epinephrine<sup>&#165;</sup></td> <td> <p>Asystole</p> <p>Pulseless electrical activity</p> <p>Pulseless ventricular arrhythmias not responsive to initial defibrillation</p> Bradycardia not responsive to oxygen and support of airway and breathing</td> <td> <ul> <li>0.01 mg/kg IV or IO given as 0.1 mL/kg using the 0.1 mg/mL solution up to 1 mg per dose </li> <li>Repeat every 3 to 5 minutes as needed; not compatible with sodium bicarbonate </li> <li>Only if IV and IO are not available, may give&nbsp;endotracheal (ET)&nbsp;0.1 mg/kg as 0.1 mL/kg using the 1 mg/mL solution up to 2.5 mg per dose diluted to 3 to 5 mL with saline; repeat&nbsp;every 3 to 5 minutes as needed&nbsp;(IV or IO are preferred)&nbsp; </li> <li>Examples of epinephrine infusion for refractory anaphylaxis (perfusing patient) are provided as separate tables in UpToDate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Glucose (dextrose)</td> <td>Documented blood glucose &#8804;40 mg/dL (2.2 mmol/L)<sup>&#135;</sup></td> <td>0.5 to 1 g/kg, IV or IO, as follows: <ul class=\"decimal_heading\"> <li>Infants and children &#60;5 years: 5 to 10 mL/kg of 10% dextrose solution </li> <li>Children &#8805;5 years: 2 to 4 mL/kg of 25% dextrose solution (preferred)&nbsp;or 1 to 2 mL/kg of 50% dextrose solution&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lidocaine</td> <td>Pulseless ventricular arrhythmias not responsive to CPR, defibrillation, and epinephrine</td> <td> <ul> <li>1 mg/kg rapid IV or IO bolus </li> <li>Follow the bolus with&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">an infusion of 20 to 50 mcg/kg/minute. </span><span style=\"font-size: 13px; font-family: Verdana;\">If the start of the infusion will be delayed longer than 15 minutes, then a second IV or IO bolus dose of 1 mg/kg is suggested</span> </li> <li>Only if IV and IO not available, may give via endotracheal tube (ET) 2 to 3 mg/kg, flush with 5 mL NS and follow with 5 assisted manual ventilations (IV and IO are preferred) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Magnesium sulfate</td> <td> <p>Polymorphic ventricular tachycardia (torsades de pointes)</p> Documented hypomagnesemia</td> <td> <ul> <li><strong>Cardiac arrest</strong> (pulseless torsades)<strong>:</strong> 25 to 50 mg/kg; given as 0.05 to 0.1 mL/kg of 50% magnesium sulfate solution up to maximum 2 g (4 mL) per dose; dilute in 10 mL D5W, give IV or IO over 1 to 2 minutes&nbsp;&nbsp; </li> <li><strong>Perfusing patient</strong> (torsades, hypomagnesemia, status asthmaticus)<sup>&#134;</sup><strong>:</strong> Same dose as for cardiac arrest, except dilute dose in 10 to 50 mL D5W or NS and infuse over 15 minutes (maximum 150 mg per minute) </li> <li>Conversions: 50% magnesium sulfate = 500 mg/mL magnesium sulfate = 2 mmol/mL magnesium </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Oxygen</td> <td>All infants and children outside of the neonatal period</td> <td>100% initial dose via nonrebreathing face mask or bag-mask ventilation, wean as clinically indicated</td> </tr> <tr class=\"divider_bottom\"> <td>Procainamide**</td> <td> <p>Stable ventricular tachycardia</p> SVT in patients with WPW syndrome or refractory to adenosine</td> <td> <ul> <li>Loading dose: <ul> <li>Infants and children &#60;1 year: 7 to 10 mg/kg IV or IO over 30 to 60 minutes </li> <li>Children &#8805;1 year: 15 mg/kg IV or IO over 30 to 60 minutes </li> <li>Maximum: 500 mg in 30 minutes </li> </ul> </li> <li>Follow loading dose with a continuous infusion at 40 to 50 mcg/kg per minute (maximum 2 g/24 hours) and obtain plasma levels 4 hours after loading dose </li> </ul> </td> </tr> <tr> <td>Sodium bicarbonate<sup>&#182;&#182;</sup></td> <td> <p>Hyperkalemia</p> <p>Poisoning by sodium channel blocking agents (eg, cyclic antidepressants, type Ia antiarrhythmic agents) with prolongation of QRS interval (&#62;0.1 msec)</p> <p>Prolonged cardiac arrest with documented severe metabolic acidosis (routine use in resuscitation is NOT recommended)</p> Shock with documented metabolic acidosis</td> <td> <ul> <li>Infants &#60;6 months: 1 mEq/kg IV or IO given as 2 mL/kg of 4.2% solution </li> <li>Infants &#8805;6 months and children: 1 mEq/kg IV or IO given as 1 mL/kg of 8.4% solution </li> <li>Maximum single dose 50 mEq (child) to 100 mEq (adolescent) </li> <li>0.5 mEq/kg subsequent doses after 10 minutes given as: <ul> <li>Child: 0.5 mL/kg of 8.4% solution </li> <li>Infants under 6 months: 1 mL/kg of 4.2% solution </li> </ul> </li> <li>Forms precipitate with calcium and can inactivate epinephrine, do not co-infuse </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Recommendations in this table are generally consistent with Pediatric Advanced Life Support (PALS) guidelines and American Academy of Pediatrics (AAP) guidance<sup>[1,2]</sup>. Detail concerning dilution and administration of emergency drugs are based upon recommendations used at experienced pediatric centers. Protocols vary. For additional detail, refer to the individual drug monographs provided by Lexicomp that are included with UpToDate.</div><div class=\"graphic_footnotes\">IV: intravenous; IO: intraosseous; ET: endotracheally; CCB: calcium channel blocker.<br />* May cause atrial fibrillation with progression to ventricular fibrillation in children with Wolff-Parkinson-White syndrome. Avoid in children with wide complex tachycardia because severe hemodynamic deterioration may occur in patients with ventricular tachycardia. Early consultation with pediatric cardiologist is recommended.<br />¶ Amiodarone should not be administered with other drugs that may cause QT prolongation (eg, procainamide) without cardiology consultation or to patients with congenital long QT syndrome. Cardiology consult is recommended prior to use when patient has a perfusing rhythm.<br />Δ A weight based dose of 0.02 mg/kg atropine is used by some experts for infants and small children weighing less than 5 kg. (Refer to UpToDate topics on pediatric resuscitation drugs.)<br /><FONT class=lozenge>◊</FONT> Patients with poisoning from cholinesterase inhibiting agents may require much higher doses of atropine to dry bronchial secretions. (Refer to UpToDate topics on organophosphate and carbamate poisoning.)<br />§ Rapid administration can cause bradycardia or asystole. Calcium chloride should be given through central venous or intraosseous access, if possible to avoid potential tissue necrosis or sloughing in the event of extravasation.<br />¥ To help prevent medication errors, ratio expressions have been removed from epinephrine labels in the United States. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, <STRONG>the 0.1 mg/mL concentration of epinephrine may be labeled as 1:10,000 and the 1mg/mL concentration may be labeled as 1:1,000</STRONG>. <br />‡ Routine administration of glucose without evaluation of the serum glucose is not recommended. Empiric treatment with glucose may be appropriate if bedside glucose determination is not available and the infant or child has symptoms of hypoglycemia or is at risk for developing hypoglycemia. Lower doses of glucose (eg, 0.25 g/kg or 2.5 mL/kg of 10 percent dextrose solution) have been proposed by some experts to avoid osmotic diuresis. (Refer to UpToDate topics on hypoglycemia in infants and children.)<br />† Rapid infusions of magnesium sulfate in perfusing patients are associated with hypotension and asystole.<br />** May be used safely in children with Wolff-Parkinson-White syndrome. Should not be used in patients who have received other drugs that prolong the QT interval (eg, amiodarone) without cardiology consultation or in patients with congenital prolonged QT syndrome.<br />¶¶ Sodium bicarbonate should only be administered to children with adequate ventilation. Flush well with normal saline before and after administration to avoid alkaline inactivation of epinephrine or precipitation with calcium containing solutions.</div><div class=\"graphic_reference\">Courtesy of Pamela Bailey, MD and Susan B Torrey, MD with additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support (PALS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(18 Suppl 3):S876 as updated by de Caen A, Berg M, Chameides L et al. Part 12: Pediatric Advanced Life Support (PALS): 2015 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132(suppl 2):S526. </LI>&#xD;&#xA;<LI>Hegenbarth MA. Preparing for Pediatric Emergencies: Drugs to Consider. Pediatrics 2008; 121:433.</LI></OL></div><div id=\"graphicVersion\">Graphic 70539 Version 18.0</div></div></div>"},"70540":{"type":"graphic_picture","displayName":"Galactocele PI","title":"Blocked milk duct (galactocele)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blocked milk duct (galactocele)</div><div class=\"cntnt\"><img style=\"width:341px; height:300px;\" src=\"images/PI/70540_Galactocele_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blocked or plugged ducts are areas of the breast where the flow of milk is blocked. They can stretch the nearby breast tissue and cause a painful breast lump (as shown by the arrow).</div><div id=\"graphicVersion\">Graphic 70540 Version 6.0</div></div></div>"},"70542":{"type":"graphic_figure","displayName":"Acanthamoeba life cycle","title":"<EM>Acanthamoeba </EM>life cycle","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\"><EM>Acanthamoeba </EM>life cycle</div><div class=\"cntnt\"><img style=\"width:580px; height:368px;\" src=\"images/ID/70542_Acanthamoebalifecycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Acanthamoeba</em> spp have been found in soil; fresh, brackish, and sea water; sewage; swimming pools; contact lens equipment; medicinal pools; dental treatment units; dialysis machines; heating, ventilating, and air conditioning systems; mammalian cell cultures; vegetables; human nostrils and throats; and human and animal brain, skin, and lung tissues. Unlike <em>N. fowleri</em>, <em>Acanthamoeba</em> has only two stages, cysts <strong>(1)</strong> and trophozoites <strong>(2)</strong>, in its life cycle. No flagellated stage exists as part of the life cycle. The trophozoites replicate by mitosis (nuclear membrane does not remain intact) <strong>(3)</strong>. The trophozoites are the infective forms, although both cysts and trophozoites gain entry into the body <strong>(4)</strong> through various means. Entry can occur through the eye <strong>(5)</strong>, the nasal passages to the lower respiratory tract <strong>(6)</strong>, or ulcerated or broken skin <strong>(7)</strong>. When <em>Acanthamoeba</em> spp enters the eye, it can cause severe keratitis in otherwise healthy individuals, particularly contact lens users <strong>(8)</strong>. When it enters the respiratory system or through the skin, it can invade the central nervous system by hematogenous dissemination, causing granulomatous amebic encephalitis (GAE) <strong>(9)</strong> or disseminated disease <strong>(10)</strong>, or skin lesions <strong>(11)</strong> in individuals with compromised immune systems. <em>Acanthamoeba</em> spp cysts and trophozoites are found in tissue.</div><div class=\"graphic_footnotes\">* Results in severe keratitis of the eye <STRONG>(8)</STRONG>.<br /><FONT class=bullet>•</FONT> Results in granulomatous amebic encephalitis <STRONG>(9)</STRONG> and/or disseminated disease <STRONG>(10)</STRONG> in individuals with compromised immune systems.<br />Δ Results in granulomatous amebic encephalitis <STRONG>(9)</STRONG>, disseminated disease <STRONG>(10)</STRONG>, or skin lesions <STRONG>(11)</STRONG> in individuals with compromised immune systems.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites: Acanthamoeba. Available at: <A href=\"https://www.cdc.gov/parasites/acanthamoeba/pathogen.html\">https://www.cdc.gov/parasites/acanthamoeba/pathogen.html</A>.</div><div id=\"graphicVersion\">Graphic 70542 Version 3.0</div></div></div>"},"70543":{"type":"graphic_figure","displayName":"Circulating hot water ablation 2","title":"Circulating hot water endometrial ablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circulating hot water endometrial ablation</div><div class=\"cntnt\"><img style=\"width:419px; height:331px;\" src=\"images/OBGYN/70543_HTA_endometrial_ablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The closed loop system ablates the lining of the endometrium under hysteroscopic visualization by recirculating heated saline within the uterus.</div><div class=\"graphic_reference\">Reproduced with permission from: Brooks, PG. Hydro ThermAblator (HTA) System: Global treatment, direct visualization. OBG Management 2005. Copyright &#169; 2005 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 70543 Version 2.0</div></div></div>"},"70545":{"type":"graphic_figure","displayName":"Platelet G proteins","title":"G-protein coupled platelet receptors","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">G-protein coupled platelet receptors</div><div class=\"cntnt\"><img style=\"width:469px; height:433px;\" src=\"images/HEME/70545_Platelet_G_proteins.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the function of G-protein coupled platelet receptors. Upon stimulation of the receptor by the appropriate agonist (top left), there is a dissociation of the associated heterotrimeric G-protein into a GTP-binding alpha subunit and a beta-gamma heterodimeric subunit, each of which is then free to stimulate those enzymes that produce second messengers within the platelet. As examples, the G alpha-subclass 12/13 subunit induces platelet shape change, the G alpha-subclass s and the G alpha-subclass i subunits stimulate or inhibit adenyl cyclase activity, respectively, and the G alpha-subclass q subunit activates phospholipase C beta (PLC). The separated G beta-gamma subunit also activates PLC beta as well as phosphatidylinositol 3-kinase (PI3K).</div><div id=\"graphicVersion\">Graphic 70545 Version 2.0</div></div></div>"},"70548":{"type":"graphic_table","displayName":"ISHLT cardiac allograft vasculopathy nomenclature","title":"ISHLT cardiac allograft vasculopathy nomenclature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ISHLT cardiac allograft vasculopathy nomenclature</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>ISHLT CAV0 (Not significant):</strong> No detectable angiographic lesion.</td> </tr> <tr> <td><strong>ISHLT CAV1 (Mild):</strong> Angiographic LM &#60;50 percent, primary vessel with maximum lesion of &#60;70 percent, or any branch stenosis &#60;70 percent (including diffuse narrowing) without allograft dysfunction.</td> </tr> <tr> <td><strong>ISHLT CAV2 (Moderate):</strong> Angiographic LM &#8805;50 percent*, a single primary vessel &#8805;70 percent, or isolated branch stenosis &#8805;70 percent in branches of&nbsp;two systems, without allograft dysfunction.</td> </tr> <tr> <td><strong>ISHLT CAV3 (Severe):</strong> Angiographic LM &#8805;50 percent, two or more primary vessels &#8805;70 percent stenosis, or isolated branch stenosis &#8805;70 percent in all&nbsp;three systems; or ISHLT CAV1 or CAV2 with allograft dysfunction (defined as LVEF &#8804;45 percent) or evidence of significant restrictive physiology.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">(A) A \"primary vessel\" denotes the proximal and middle 33 percent of the left anterior descending artery, the left circumflex, the ramus, and the dominant or co-dominant right coronary artery with the posterior descending and posterolateral branches.<br />(B) A \"secondary branch vessel\" includes the distal 33 percent of the primary vessels or any segment within a large septal perforator, diagonals and obtuse marginal branches, or any portion of a non-dominant right coronary artery.<br />(C) Restrictive cardiac allograft physiology is defined as symptomatic heart failure with echocardiographic E to A velocity ratio &gt;2 (&gt;1.5 in children), shortened isovolumetric relaxation time (&lt;60 msec), shortened deceleration time (&lt;150 msec), or restrictive hemodynamic values (right atrial pressure &gt;12 mmHg, pulmonary capillary wedge pressure &gt;25 mmHg, cardiac index &lt;2 L/min/m<SUP>2</SUP>).</div><div class=\"graphic_footnotes\">LM: left main coronary artery stenosis; ISHLT: International Society of Heart and Lung Transplant; LVEF: left ventricular ejection fraction.<br />* Normal graft function.</div><div class=\"graphic_reference\">Reproduced from: Mehra M, Crespo-Leiro M, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29:717. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70548 Version 4.0</div></div></div>"},"70549":{"type":"graphic_picture","displayName":"Dissection of the paraesophageal hernia sac and right crus","title":"Dissection of the paraesophageal hernia sac and right crus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of the paraesophageal hernia sac and right crus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/70549_Dissect_paraesoph_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the dissection of the paraesophageal hernia sac from the right crus. The procedure is performed by the laparoscopic technique. The arrows indicate the edge of the right crus. The forceps are retracting the hernia sac.</div><div class=\"graphic_reference\">Courtesy of Michael Rosen, MD.</div><div id=\"graphicVersion\">Graphic 70549 Version 1.0</div></div></div>"},"70551":{"type":"graphic_figure","displayName":"Hand-sewn colorectal anastomosis with interrupted sutures","title":"Hand-sewn colorectal anastomosis with interrupted sutures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-sewn colorectal anastomosis with interrupted sutures</div><div class=\"cntnt\"><img style=\"width:309px; height:343px;\" src=\"images/SURG/70551_Hand-sewn-colorectal-interrupted.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a hand-sewn anastomosis between the proximal colon and the upper rectum. The Lembert sutures are placed in the seromuscular layer.</div><div id=\"graphicVersion\">Graphic 70551 Version 1.0</div></div></div>"},"70552":{"type":"graphic_diagnosticimage","displayName":"CNS histoplasmosis MRI","title":"Disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:289px; height:321px;\" src=\"images/ID/70552_CNS_histoplasmosis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse enhancing brain lesions in disseminated histoplasmosis. Head and spinal cord magnetic resonance imaging&nbsp;(MRI) showed gadolinium-enhancing lesions in the cerebrum, cerebellum, brainstem, and spinal cord in a patient with mental status changes, cerebellar abnormalities, and loss of sensation in the left leg.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 70552 Version 4.0</div></div></div>"},"70554":{"type":"graphic_table","displayName":"TNM staging gallbladder CA","title":"TNM staging of gallbladder cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging of gallbladder cancer</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Primary tumor (T)\n   </td>\n   </tr>\n   <tr>\n   <td>TX</td>\n   <td  colspan=\"3\">\n   Primary tumor cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>T0</td>\n   <td  colspan=\"3\">\n   No evidence of primary tumor\n   </td>\n   </tr>\n   <tr>\n   <td>Tis</td>\n   <td  colspan=\"3\">\n   Carcinoma in situ\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   T1\n   </td>\n   <td  class=\"sublist_other_start\" colspan=\"3\">\n   Tumor invades lamina propria or muscular layer\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   T1a\n   </td>\n   <td  class=\"sublist_other\" colspan=\"3\">\n   Tumor invades lamina propria\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   T1b\n   </td>\n   <td  class=\"sublist_other\" colspan=\"3\">\n   Tumor invades muscular layer\n   </td>\n   </tr>\n   <tr>\n   <td>T2</td>\n   <td  colspan=\"3\">\n   Tumor invades perimuscular connective tissue; no extension beyond serosa or into liver\n   </td>\n   </tr>\n   <tr>\n   <td>T3</td>\n   <td  colspan=\"3\">\n   Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts\n   </td>\n   </tr>\n   <tr>\n   <td>T4</td>\n   <td  colspan=\"3\">\n   Tumor invades main portal vein or hepatic artery or invades two or more extrahepatic organs or structures\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Regional lymph nodes (N)\n   </td>\n   </tr>\n   <tr>\n   <td>NX</td>\n   <td  colspan=\"3\">\n   Regional lymph nodes cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>N0</td>\n   <td  colspan=\"3\">\n   No regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>N1</td>\n   <td  colspan=\"3\">\n   Metastases to nodes along the cystic duct, common bile duct, hepatic artery, and/or portal vein\n   </td>\n   </tr>\n   <tr>\n   <td>N2</td>\n   <td  colspan=\"3\">\n   Metastases to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Distant metastasis (M)\n   </td>\n   </tr>\n   <tr>\n   <td>M0</td>\n   <td  colspan=\"3\">\n   No distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>M1</td>\n   <td  colspan=\"3\">\n   Distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Anatomic stage/prognostic groups\n   </td>\n   </tr>\n   <tr>\n   <td>Stage 0</td>\n   <td>Tis</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage I</td>\n   <td>T1</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage II</td>\n   <td>T2</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIIA</td>\n   <td>T3</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIIB</td>\n   <td>T1-3</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IVA</td>\n   <td>T4</td>\n   <td>N0-1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Stage IVB\n   </td>\n   <td>Any T</td>\n   <td>N2</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Any T</td>\n   <td>Any N</td>\n   <td>M1</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48420&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>TNM_staging_gallbladder_CA.htm</title></head></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 70554 Version 12.0</div></div></div>"},"70556":{"type":"graphic_table","displayName":"SCN versus SN","title":"Subcutaneous fat necrosis of the newborn versus sclerema neonatorum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Subcutaneous fat necrosis of the newborn versus sclerema neonatorum</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Subcutaneous fat necrosis of the newborn</td> <td class=\"subtitle1\">Sclerema neonatorum</td> </tr> <tr> <td>Onset</td> <td>Zero&nbsp;to&nbsp;four weeks of age</td> <td>Zero&nbsp;to&nbsp;seven days of age</td> </tr> <tr> <td>Gestational age</td> <td>Usually term</td> <td>Usually preterm</td> </tr> <tr> <td>Associated conditions</td> <td>Birth trauma, including asphyxia, mechanical trauma, thermal trauma</td> <td>Serious underlying disease, including congenital malformations, sepsis, respiratory and gastrointestinal disease</td> </tr> <tr> <td>Site and spread</td> <td>Bony prominences; remains localized</td> <td>Begins on trunk or lower limb and may become generalized; spares palms and soles</td> </tr> <tr> <td>Morphology</td> <td>Circumscribed subcutaneous plaques or nodules</td> <td>Hard, wax-like skin and subcutaneous tissue; does not pit</td> </tr> <tr> <td>Mobility</td> <td>Move freely over muscles and bone</td> <td>Bound to underlying muscle and bone</td> </tr> <tr> <td>Histopathology</td> <td>Fat necrosis; extensive granulomatous inflammatory infiltrate; needle-shaped clefts within adipocytes</td> <td>Thickened fibrous septae; sparse nongranulomatous inflammatory infiltrate; needle-shaped clefts within adipocytes</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Zeb A, Darmstadt GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol 2008; 28:453.</div><div id=\"graphicVersion\">Graphic 70556 Version 4.0</div></div></div>"},"70558":{"type":"graphic_table","displayName":"Carcinoid survival by stage and site","title":"Five-year survival rates by carcinoid location (1973-1997)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five-year survival rates by carcinoid location (1973-1997)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Site</td> <td class=\"subtitle1\" colspan=\"2\">All stages<br /> (percent)</td> <td class=\"subtitle1\" colspan=\"2\">Local stage<br /> (percent)</td> <td class=\"subtitle1\" colspan=\"2\">Regional stage<br /> (percent)</td> <td class=\"subtitle1\" colspan=\"2\">Distant stage<br /> (percent)</td> </tr> <tr> <td class=\"subtitle2\">CSS</td> <td class=\"subtitle2\">OS</td> <td class=\"subtitle2\">CSS</td> <td class=\"subtitle2\">OS</td> <td class=\"subtitle2\">CSS</td> <td class=\"subtitle2\">OS</td> <td class=\"subtitle2\">CSS</td> <td class=\"subtitle2\">OS</td> </tr> <tr> <td>Stomach</td> <td class=\"centered\">75.1</td> <td class=\"centered\">55.3</td> <td class=\"centered\">90.2</td> <td class=\"centered\">69.6</td> <td class=\"centered\">40.4</td> <td class=\"centered\">27.2</td> <td class=\"centered\">18.0</td> <td class=\"centered\">9.0</td> </tr> <tr> <td>Small bowel</td> <td class=\"centered\">76.1</td> <td class=\"centered\">54.6</td> <td class=\"centered\">94.5</td> <td class=\"centered\">70.4</td> <td class=\"centered\">84.4</td> <td class=\"centered\">64.1</td> <td class=\"centered\">51.2</td> <td class=\"centered\">32.4</td> </tr> <tr> <td>Appendix</td> <td class=\"centered\">76.3</td> <td class=\"centered\">65.0</td> <td class=\"centered\">95.6</td> <td class=\"centered\">87.8</td> <td class=\"centered\">80.0</td> <td class=\"centered\">67.6</td> <td class=\"centered\">37.5</td> <td class=\"centered\">26.8</td> </tr> <tr> <td>Colon</td> <td class=\"centered\">69.5</td> <td class=\"centered\">41.8</td> <td class=\"centered\">94.1</td> <td class=\"centered\">77.1</td> <td class=\"centered\">72.5</td> <td class=\"centered\">35.3</td> <td class=\"centered\">27.8</td> <td class=\"centered\">4.1</td> </tr> <tr> <td>Rectum</td> <td class=\"centered\">87.5</td> <td class=\"centered\">77.8</td> <td class=\"centered\">94.9</td> <td class=\"centered\">86.2</td> <td class=\"centered\">53.7</td> <td class=\"centered\">42.1</td> <td class=\"centered\">14.6</td> <td class=\"centered\">13.1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Survival rates are all age-adjusted to standard 2000 population.</div><div class=\"graphic_footnotes\">CSS: cancer-specific survival; OS: overall survival.</div><div class=\"graphic_reference\">Reproduced with permission from: Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240:117. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70558 Version 5.0</div></div></div>"},"70559":{"type":"graphic_table","displayName":"FOLFOXIRI","title":"FOLFOXIRI chemotherapy for metastatic colorectal cancer<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFOXIRI chemotherapy for metastatic colorectal cancer<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 14 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Irinotecan</strong>*</td> <td>165 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 mL 5 percent dextrose in water (D5W)<sup>&#916;</sup> to a final concentration of 0.12 to 2.8 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Oxaliplatin</strong><sup>&#9674;</sup></td> <td>85 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 mL D5W and administer over two hours after irinotecan. Administer concurrently with leucovorin in separate bags via y-line connection<sup>[2]</sup>.</td> <td>Day 1</td> </tr> <tr> <td><strong>LEVOleucovorin</strong><sup>&#167;</sup></td> <td>200 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL D5W and administer over two hours, concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr> <td><strong>Fluorouracil (FU)</strong></td> <td>2400 to 3200 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL D5W and administer over 48 hours, after leucovorin. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL). The original protocol used 3200 mg/m<sup>2</sup>, but many US oncologists use a lower starting dose (2400 mg/m<sup>2</sup>) and escalate as tolerated to reach a final dose of 3200 mg/m<sup>2</sup>.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> HIGH (&#62;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Oxaliplatin and fluorouracil are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Routine primary prophylaxis with G-CSF is not warranted (estimated risk of febrile neutropenia 5 percent<sup>[1]</sup>). However, given the high rate of grade 3 or 4 neutropenia (approximately 50 percent), primary prophylaxis may be considered for high-risk patients. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of oxaliplatin and irinotecan may be needed for patients with severe renal insufficiency<sup>[3,4]</sup>. A lower starting dose of irinotecan and FU may be needed for patients with hepatic impairment<sup>[4,5]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Maneuvers to prevent neurotoxicity:</strong> Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion<sup>[3]</sup>. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac issues:</strong> QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Irinotecan is associated with early and late diarrhea, both of which may be severe<sup>[4]</sup>. Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should be provided as needed. For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine for later cycles. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess changes in neurologic function prior to each treatment.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td colspan=\"4\">The specific dose alteration parameters for the FOLFOXIRI regimen in colorectal cancer patients were not published in the original phase III trial<sup>[1]</sup>. The following suggestions are based upon dose reductions used in a trial using a comparable regimen (FOLFIRINOX) for advanced pancreatic cancer<sup>[6]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Do not retreat unless granulocyte count &#8805;1500/microL and platelet count is &#8805;75,000/microL.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neutropenia:</strong> If day 1 treatment delayed for granulocytes &#60;1500/microL or febrile neutropenia or grade 4 neutropenia &#62;7 days, reduce irinotecan dose to 150 mg/m<sup>2</sup> and reduce the continuous infusion FU to 75 percent of original doses. For second occurrence, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and the dose of infusional FU an additional 25 percent. If non-recovery after two weeks, delay or third occurrence of granulocytes &#60;1500/microL on day 1, or febrile neutropenia or grade 4 neutropenia at any time during cycle, discontinue treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Thrombocytopenia:</strong> If day 1 treatment delayed for platelet count &#60;75,000/microL, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and reduce the continuous infusion FU to 75 percent of original doses. For second occurrence, reduce irinotecan dose to 150 mg/m<sup>2</sup>. If non-recovery after two weeks delay or third occurrence of platelets &#60;75,000/microL, discontinue treatment. For grade 3 or 4 thrombocytopenia <em>during</em> treatment, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and the infusional FU dose to 75 percent of the original dose. For the second occurrence, reduce dose of irinotecan to 150 mg/m<sup>2</sup> and the dose of infusional FU an additional 25 percent. Discontinue treatment for third occurrence.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Diarrhea:</strong> Do not retreat with FOLFOXIRI until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. For diarrhea grade 3 or 4, or diarrhea with fever and/or grade 3 or 4 neutropenia, reduce irinotecan dose to 150 mg/m<sup>2</sup> and the continuous FU dose to 75 percent of original dose. For second occurrence, reduce the oxaliplatin dose to 60 mg/m<sup>2</sup> and the dose of infusional FU an additional 25 percent. Discontinue treatment for third occurrence. <strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Mucositis or palmar-plantar erythrodysesthesia:</strong> For grade 3 to 4 toxicity, reduce dose of infusional FU by 25 percent.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurotoxicity:</strong> For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting more than seven days, decrease oxaliplatin dose by 25 percent<sup>[3]</sup>. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other toxicity:</strong> Any other toxicity &#8805;grade 2, except anemia and alopecia, can justify dose reduction if medically indicated.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; US: United States; G-CSF: granulocyte colony stimulating factors; ECG: electrocardiogram; CBC: complete blood count.<br /><SPAN style=\"COLOR: black\">* A lower initial dose of irinotecan&nbsp;may be considered for patients with&nbsp;poor performance status,&nbsp;prior pelvic or abdominal radiotherapy, or increased bilirubin levels<SUP>[4]</SUP>. Whether </SPAN>a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge>◊</FONT> Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.<br />§ Leucovorin dose is given for LEVOleucovorin (l-leucovorin, Fusilev)<SUP>[7]</SUP>. Double the dose if using the d,l-racemic mixture.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Falcone A, et al. J Clin Oncol 2007; 25:1670.</LI>&#xD;&#xA;<LI>Masi G, et al. Ann Oncol 2004; 15:1766.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Conroy T, et al. N Engl J Med 2011; 364:1817.</LI>&#xD;&#xA;<LI>Levoleucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 70559 Version 18.0</div></div></div>"},"70560":{"type":"graphic_diagnosticimage","displayName":"Hepatic hemangioma CT","title":"Hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:271px; height:499px;\" src=\"images/GAST/70560_Hepatic_hemangioma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic CT scans showing a well-demarcated hypodense lesion on non-contrast scan (panel A) in the posterior right lobe of the liver. Panel B shows early phase of contrast enhancement demonstrating peripheral nodular enhancement with gradual \"filling in\" of the lesion. The center of the lesion remains hypodense. Panel C shows the post contrast delayed image, which demonstrates an isodense lesion characteristic of hepatic hemangioma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 70560 Version 4.0</div></div></div>"},"70561":{"type":"graphic_figure","displayName":"Endometrial cryoablation","title":"Endometrial cryoablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometrial cryoablation</div><div class=\"cntnt\"><img style=\"width:434px; height:363px;\" src=\"images/OBGYN/70561_Her_option_cryoablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cryoprobe is first placed at the fundus, angled toward 1 cornu. Probe placement is visualized on ultrasound. When the freeze is initiated, the progress of the iceball is monitored by ultrasound.</div><div class=\"graphic_reference\">Reproduced with permission from: Levy, BS. Her Option Cryoablation Therapy System: Using Ultrasound Guidance. OBG Management 2005. Copyright &#169; 2005 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 70561 Version 2.0</div></div></div>"},"70562":{"type":"graphic_table","displayName":"House-Brackmann scale","title":"House-Brackmann classification of facial nerve dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">House-Brackmann classification of facial nerve dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Grade</td>\r\n            <td class=\"subtitle1\">Characteristics</td>\r\n        </tr>\r\n        <tr>\r\n            <td>I. Normal</td>\r\n            <td>Normal function in all areas</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"8\">II. Mild dysfunction</td>\r\n            <td class=\"sublist1_start\">Gross</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Slight weakness noticeable on close inspection</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">May have slight synkinesis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Normal symmetry and tone at rest</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Motion</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Forehead: Moderate to good function</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Eye: Complete closure with minimal effort</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Mouth: Slight asymmetry</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"8\">III. Moderate dysfunction</td>\r\n            <td class=\"sublist1_start\">Gross</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Obvious but not disfiguring difference between the two sides</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Noticeable but not severe synkinesis, contracture, or hemifacial spasm</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Normal symmetry and tone at rest</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Motion</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Forehead: Slight to moderate movement</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Eye: Complete closure with effort</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Mouth: Slightly weak with maximum effort</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"7\">IV. Moderately severe dysfunction</td>\r\n            <td class=\"sublist1_start\">Gross</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Obvious weakness and/or disfiguring asymmetry</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Normal symmetry and tone at rest</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Motion</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Forehead: None</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Eye: Incomplete closure </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Mouth: Asymmetric with maximum effort</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"7\">V. Severe dysfunction </td>\r\n            <td class=\"sublist1_start\">Gross</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Only barely perceptible motion</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Asymmetry at rest</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Motion</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Forehead: None</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Eye: Incomplete closure</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Mouth: Slight movement</td>\r\n        </tr>\r\n        <tr>\r\n            <td>VI. Total paralysis</td>\r\n            <td>No movement</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 70562 Version 2.0</div></div></div>"},"70564":{"type":"graphic_picture","displayName":"Angiolupoid sarcoidosis - cheek","title":"Angiolupoid sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Angiolupoid sarcoidosis</div><div class=\"cntnt\"><img style=\"width:504px; height:212px;\" src=\"images/DERM/70564_Angiolupoid_sarcoid_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well demarcated, erythematous plaques on the cheek with numerous telangiectasias are characteristic of this clinical variant of sarcoidosis.</div><div id=\"graphicVersion\">Graphic 70564 Version 1.0</div></div></div>"},"70565":{"type":"graphic_figure","displayName":"Morphea stages","title":"Stages of morphea","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Stages of morphea</div><div class=\"cntnt\"><img style=\"width:593px; height:675px;\" src=\"images/DERM/70565_Stages_local_sclero_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70565 Version 1.0</div></div></div>"},"70566":{"type":"graphic_figure","displayName":"Anatomy of the thoracic esophagus posterior","title":"Anatomy of the thoracic esophagus - posterior view","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Anatomy of the thoracic esophagus - posterior view</div><div class=\"cntnt\"><img style=\"width:483px; height:581px;\" src=\"images/SURG/70566_Anatomy-of-the-esophagus-posterior.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70566 Version 1.0</div></div></div>"},"70568":{"type":"graphic_table","displayName":"Ddx miliary infiltrates on CXR","title":"Differential diagnosis of febrile illness with miliary chest radiograph infiltrates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of febrile illness with miliary chest radiograph infiltrates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious diseases</td> </tr> <tr> <td class=\"subtitle2_single\">Mycobacterial</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em></td> </tr> <tr> <td class=\"indent1\">Atypical mycobacteria</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> </tr> <tr> <td class=\"indent1\">Endemic fungi (histoplasmosis, coccidioidomycosis, blastomycosis, paracoccidioidomycosis)</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\"><em>Legionella micdadei </em>infection</td> </tr> <tr> <td class=\"indent1\">Nocardiosis</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em>, <em>Haemophilus influenzae</em>, and other pyogenic bacteria</td> </tr> <tr> <td class=\"indent1\">Psittacosis</td> </tr> <tr> <td class=\"indent1\">Tularemia</td> </tr> <tr> <td class=\"indent1\">Bartonellosis</td> </tr> <tr> <td class=\"indent1\">Brucellosis</td> </tr> <tr> <td class=\"indent1\">Melioidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Varicella</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Influenza</td> </tr> <tr> <td class=\"indent1\">Measles</td> </tr> <tr> <td class=\"subtitle2_single\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> <tr> <td class=\"indent1\">Strongyloidiasis</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic diseases</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Lymphangitic spread of carcinoma</td> </tr> <tr> <td>Mesothelioma</td> </tr> <tr> <td class=\"subtitle1_single\">Other diseases</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Pneumoconioses</td> </tr> <tr> <td>Foreign body-induced vasculitis related to injection drug use</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70568 Version 3.0</div></div></div>"},"70569":{"type":"graphic_picture","displayName":"Foot ankle circles PI","title":"Foot/ankle circles","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Foot/ankle circles</div><div class=\"cntnt\"><img style=\"width:518px; height:454px;\" src=\"images/PI/70569_Foot_ankle_circles_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With your leg resting against something and your foot in the air, point and flex your foot. Then make circles with your foot by rotating your ankle.</div><div id=\"graphicVersion\">Graphic 70569 Version 1.0</div></div></div>"},"70570":{"type":"graphic_algorithm","displayName":"Evaluation of 46 XX infant with virilization","title":"Algorithm for evaluation of an infant with ambiguous genitalia and a 46,XX karyotype (SRY-negative)*","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of an infant with ambiguous genitalia and a 46,XX karyotype (SRY-negative)*</div><div class=\"cntnt\"><img style=\"width:510px; height:518px;\" src=\"images/PEDS/70570_Dx_XX_virilization.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the cause of the disorder of sex development (DSD) remains unclear after the biochemical workup outlined above, we suggest further evaluation with a high-coverage chromosomal microarray analysis (CMA; also known as array-based comparative genomic hybridization, aCGH). If the results are not informative, whole genome sequencing or whole exome sequencing can be considered.</div><div class=\"graphic_footnotes\">SRY: sex-determining region on the Y chromosome; 17-OH-progesterone: 17-hydroxyprogesterone; 3-β-HSD: 3-beta-hydroxysteroid dehydrogenase type 2; AMH: anti-Müllerian hormone (also known as Müllerian inhibiting substance); hCG: human chorionic gonadotropin; DSD: disorder of sex development; SOX 9: SRY box 9.<br />* If SRY is positive in an infant with 46,XX karyotype, this indicates SRY translocation.<br />¶ P450 oxidoreductase deficiency causes genital ambiguity in either 46,XX or 46,XY individuals, usually with glucocorticoid deficiency. Affected individuals tend to have elevated 17-hydroxyprogesterone (which may be mild) and 17-hydroxypregnenolone, and low levels of DHEA and androstenedione. There may be associated craniofacial and orthopedic anomalies (Antley-Bixler syndrome).<br />Δ In 3-β-HSD deficiency, the most characteristic abnormalities are elevations of DHEA and 17-delta-5-hydroxypregnenolone. 17-OH progesterone may be either normal or elevated (because the 3-β-HSD type 1 gene is intact in these patients). Most patients present as neonates or in early infancy with clinical manifestations of both cortisol and aldosterone deficiency, including vomiting, volume depletion, hyponatremia and hypokalemia. 46,XX individuals typically have normal female external genitalia with mild virilization, and 46,XY individuals will be undervirilized.</div><div id=\"graphicVersion\">Graphic 70570 Version 7.0</div></div></div>"},"70571":{"type":"graphic_table","displayName":"Neuraminidase inhibitor dosing for flu treatment in children","title":"Dosing recommendations for neuraminidase inhibiting agents for treatment of influenza in children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing recommendations for neuraminidase inhibiting agents for treatment of influenza in children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug/formulation</td> <td class=\"subtitle1\" colspan=\"4\">Dosing recommendations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Oseltamivir (Tamiflu)<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"6\"> <p>30 mg capsule</p> <p>45 mg capsule</p> <p>75 mg capsule</p> 6 mg/mL suspension<sup>&#9674;</sup></td> <td colspan=\"4\"><strong>1 through 12 years</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Children &#8805;12 months should receive approximately 4 mg/kg per day divided into 2 doses for a 5-day treatment course</td> </tr> <tr> <td class=\"sublist_other indent1\"><strong>&#8804;15 kg</strong></td> <td class=\"sublist_other\"><strong>&#62;15 to 23 kg</strong></td> <td class=\"sublist_other\"><strong>&#62;23 to 40 kg</strong></td> <td class=\"sublist_other\"><strong>&#62;40 kg</strong></td> </tr> <tr> <td class=\"indent2\">60 mg/day divided into 2 doses for 5 days</td> <td>90 mg/day divided into 2 doses for 5 days</td> <td>120 mg/day divided into 2 doses for 5 days</td> <td>150 mg/day divided into 2 doses for 5 days</td> </tr> <tr> <td colspan=\"4\"><strong>&#8805;13 years</strong></td> </tr> <tr> <td class=\"divider_bottom indent1\" colspan=\"4\">150 mg/day divided into 2 doses for 5 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Peramivir (Rapivab)<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"4\">200 mg in 20 mL (10 mg/mL) in a single use vial</td> <td colspan=\"4\"><strong>2 through 12 years</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">12 mg/kg per dose IV as a single dose (maximum dose 600 mg)</td> </tr> <tr> <td colspan=\"4\"><strong>&#8805;13 years</strong></td> </tr> <tr> <td class=\"divider_bottom indent1\" colspan=\"4\">600 mg IV as a single dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Zanamivir (Relenza)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">5 mg per inhalation (Diskhaler)</td> <td colspan=\"4\"><strong>&#8805;7 years</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">2 inhalations (10 mg total per dose), twice daily for 5 days<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* The choice of agent for treatment depends upon the age of the patient and the susceptibility patterns of circulating strains. Refer to UpToDate topic on treatment of seasonal influenza in children for details.<br />¶ Dose adjustment is necessary for patients with renal insufficiency.<br />Δ Refer to UpToDate topic on treatment of seasonal influenza in children for oseltamivir doses for infants younger than one year of age.<br /><FONT class=lozenge>◊</FONT> When dispensing the oral suspension of oseltamivir, providers and pharmacists must take care to provide a dosing device that matches the units of measure on the prescription.<br />§ Zanamivir is not recommended for the treatment of hospitalized patients because of limited data in patients with severe influenza. Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators.<br />¥ Two doses should be administered on Day 1, provided the doses can be spaced at least two hours apart.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Non-HIV antiviral drugs. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL, 2015. p.919.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Safety Alerts for Human Medical Products. Tamiflu (oseltamivir) for Oral Suspension (Accessed on September 23, 2013).</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Safety Alerts for Human Medical Products. Relenza (zanamivir) Inhalation Powder (Accessed on September 23, 2013).</LI>&#xD;&#xA;<LI>Rapivab (peramivir injection) for intravenous use. US Food &amp; Drug Administration (FDA) approved product information. Revised September, 2017. US Food &amp; Drug Administration. Available at: <A href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A> (Accessed on September 25, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 70571 Version 16.0</div></div></div>"},"70572":{"type":"graphic_picture","displayName":"Pseudostrabismus","title":"Pseudostrabismus (pseudoesotropia)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudostrabismus (pseudoesotropia)</div><div class=\"cntnt\"><img style=\"width:416px; height:330px;\" src=\"images/PEDS/70572_Pseudostrabismus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Much more conjunctiva is visible on the temporal side of the cornea in this normal infant. The light reflex is centered in both eyes. B) The illusion of pseudoesotropia is even greater in&nbsp;lateral&nbsp;gaze.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright ©2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70572 Version 2.0</div></div></div>"},"70574":{"type":"graphic_diagnosticimage","displayName":"Endometrial polyp","title":"Polyp and diffuse endometrial thickening in 44-year-old woman who presented with excessive bleeding","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Polyp and diffuse endometrial thickening in 44-year-old woman who presented with excessive bleeding</div><div class=\"cntnt\"><img style=\"width:508px; height:216px;\" src=\"images/OBGYN/70574_Endometrial_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal transvaginal sonogram shows endometrium (cursors) with focal thickness of 10 mm (A). Sagittal sonohysterogram shows 11-mm polyp (arrow) and diffuse endometrial thickening (arrowheads) caused by hyperplasia (B).</div><div class=\"graphic_reference\">Reproduced with permission from Joizzo, JR, Chen, MY, Riccio, GJ, Endometrial Polyps: Sonohysterographic Evaluation. AJR Am J Roentgenol 2001; 176:617. Copyright 2001 American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 70574 Version 3.0</div></div></div>"},"70576":{"type":"graphic_picture","displayName":"Metastatic cancer marrow","title":"Clump of tumor cells in the bone marrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clump of tumor cells in the bone marrow</div><div class=\"cntnt\"><img style=\"width:435px; height:288px;\" src=\"images/HEME/70576_Metastatic_cancer_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with carcinoma metastatic to the bone marrow, illustrating the presence of a large clump of tumor cells (arrow), surrounded by normal marrow elements. Note that the cellular outlines within the clump of tumor cells are indistinct. This is not a characteristic of any group of cells normally seen in the bone marrow.</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and Anna J Mitus, MD.</div><div id=\"graphicVersion\">Graphic 70576 Version 1.0</div></div></div>"},"70577":{"type":"graphic_picture","displayName":"Prolymph leukemia marrow","title":"Prolymphocytic leukemia bone marrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prolymphocytic leukemia bone marrow</div><div class=\"cntnt\"><img style=\"width:427px; height:285px;\" src=\"images/HEME/70577_Prolymph_leukemia_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view (16X) of a bone marrow aspirate from a patient with prolymphocytic leukemia, showing monotonous infiltration with small, round mononuclear cells.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 70577 Version 2.0</div></div></div>"},"70579":{"type":"graphic_table","displayName":"Albinism classification","title":"Molecular classification of albinism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular classification of albinism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of albinism</td> <td class=\"subtitle1\">Responsible gene</td> <td class=\"subtitle1\">Gene location</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oculocutaneous albinism (OCA)</td> </tr> <tr> <td class=\"indent1\">OCA1</td> <td>Tyrosinase</td> <td>11q14-q21</td> </tr> <tr> <td class=\"indent1\">OCA2</td> <td><em>OCA2</em> (<em>P</em> gene)</td> <td>15q11-q12</td> </tr> <tr> <td class=\"indent1\">OCA3</td> <td>Tyrosinase-related protein 1</td> <td>9p23</td> </tr> <tr> <td class=\"indent1\">OCA4</td> <td><em>SLC45A2</em>*</td> <td>5p13</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Ocular albinism (OA)</td> </tr> <tr> <td class=\"indent1\">OA1</td> <td><em>GPR143</em></td> <td>Xp22.3</td> </tr> <tr> <td class=\"indent1\">OA2</td> <td><em>CACNA1F</em></td> <td>Xp11.23</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">21</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=86258&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* Also known as <em>MATP</em> gene, encoding membrane-associated transporter protein.</div><div class=\"graphic_reference\">Data modified and reproduced with permission from: Summers CG. Albinism: Classification, clinical characteristics, and recent findings. Optom Vis Sci 2009; 86:659. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70579 Version 8.0</div></div></div>"},"70580":{"type":"graphic_picture","displayName":"Lichen sclerosus on the wrist","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70580_Lichen_sclerosus_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small papules are present on the wrist of this patient with extragenital lichen sclerosus. Lesions may closely resemble lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70580 Version 3.0</div></div></div>"},"70581":{"type":"graphic_figure","displayName":"Wound healing interactions","title":"Wound healing interactions","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Wound healing interactions</div><div class=\"cntnt\"><img style=\"width:585px; height:506px;\" src=\"images/SURG/70581_Phases_wound_healing_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The major steps and interactions during wound healing.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70581 Version 3.0</div></div></div>"},"70582":{"type":"graphic_picture","displayName":"Acral acanthosis nigricans","title":"Acral acanthosis nigricans (acral acanthotic anomaly)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acral acanthosis nigricans (acral acanthotic anomaly)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70582_Acral_acanthosis_nigricans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented thin plaques are present on the dorsal hand. The lesions are primarily located over the joints.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70582 Version 3.0</div></div></div>"},"70583":{"type":"graphic_figure","displayName":"Kidney arteries PI","title":"Blood vessels supplying the kidneys","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Blood vessels supplying the kidneys</div><div class=\"cntnt\"><img style=\"width:482px; height:466px;\" src=\"images/PI/70583_Kidney-arteries-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The blood vessels leading to the kidney are called the renal arteries (see arrows). If your renal arteries get narrow, your blood pressure rises. This type of high blood pressure is called renovascular hypertension.</div><div id=\"graphicVersion\">Graphic 70583 Version 1.0</div></div></div>"},"70584":{"type":"graphic_picture","displayName":"Chromagar for Candida isolation","title":"Chromagar medium for the identification of Candida species","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromagar medium for the identification of Candida species</div><div class=\"cntnt\"><img style=\"width:366px; height:252px;\" src=\"images/ID/70584_Chromagar_for_Candida_isola.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chromogenic agar culture medium is commercially available which permits presumptive identification of <EM>C. albicans</EM> (green colonies), <EM>C. tropicalis</EM> (bluish-purple colonies), <EM>C. krusei</EM> (filamentous, large pink colonies) and <EM>C. glabrata</EM> (pink yeast colonies).</div><div class=\"graphic_reference\">Reproduced with permission from J Microbiol 1994; 32:1923.</div><div id=\"graphicVersion\">Graphic 70584 Version 2.0</div></div></div>"},"70587":{"type":"graphic_table","displayName":"Range of motion the elbow and wrist","title":"Range of motion of the elbow and wrist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Range of motion of the elbow and wrist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Joint action</td> <td class=\"subtitle1\">Position for examination</td> <td class=\"subtitle1\">Normal range of motion</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Elbow</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Extension</td> <td>Shoulder at 90 degrees&nbsp;abduction</td> <td rowspan=\"2\">0 degrees</td> </tr> <tr> <td>Palm facing up</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Flexion</td> <td>Shoulder at 90 degrees&nbsp;abduction</td> <td rowspan=\"2\">150 degrees</td> </tr> <tr> <td>Wrist supinated</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Supination</td> <td>Elbow flexed at 90 degrees&nbsp;touching the iliac crest</td> <td rowspan=\"2\">90 degrees</td> </tr> <tr> <td>Hand in neutral, perpendicular to ground</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Pronation</td> <td>Elbow flexed at 90 degrees&nbsp;touching the iliac crest</td> <td rowspan=\"2\">90 degrees</td> </tr> <tr> <td>Hand in neutral, perpendicular to ground</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Wrist</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Flexion</td> <td>Elbow at 0 degrees</td> <td rowspan=\"2\">90 degrees</td> </tr> <tr> <td>Hand fully pronated</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Extension</td> <td>Elbow at 0 degrees</td> <td rowspan=\"2\">70 degrees</td> </tr> <tr> <td>Hand fully pronated</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70587 Version 3.0</div></div></div>"},"70589":{"type":"graphic_table","displayName":"Normal urinary values children 24-hour urine collection","title":"Normal urinary values in school-aged children based on 24-hour urine collection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal urinary values in school-aged children based on 24-hour urine collection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Solute</td> <td class=\"subtitle1\">Normal urine value in 24-hour urine collection</td> </tr> <tr> <td>Calcium</td> <td>&#60;4 mg/kg/day</td> </tr> <tr> <td>Oxalate</td> <td>&#60;50 mg/1.73 m<sup>2</sup> per day</td> </tr> <tr> <td>Cystine</td> <td>&#60;60 mg/1.73 m<sup>2</sup> per day</td> </tr> <tr> <td>Citrate</td> <td>&#62;400 mg/g creatinine</td> </tr> <tr> <td>Uric acid*</td> <td>&#60;0.56 mg/dL glomerular filtration rate</td> </tr> <tr> <td>Urine volume</td> <td>&#62;20 mL/kg per day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Uric acid/glomerular filtration rate (GFR) calculated using the following equation, where UCr and PCr are the urine and plasma creatinine concentrations, respectively: Uric acid/GFR, mg/dL = Urine Uric Acid &divide; UCr x PCr.</div><div id=\"graphicVersion\">Graphic 70589 Version 6.0</div></div></div>"},"70590":{"type":"graphic_table","displayName":"Recognizing M-protein in serum and urine","title":"Recognizing a monoclonal protein (M-protein) in the serum and urine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recognizing a monoclonal protein (M-protein) in the serum and urine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Studies on serum</td> </tr> <tr> <td class=\"indent1\">Total serum protein</td> <td>An elevated total serum protein level does not distinguish among the type of protein that is elevated (ie, albumin, immunoglobulin, other) and cannot differentiate a monoclonal from a polyclonal increase.</td> </tr> <tr> <td class=\"indent1\">Serum protein electrophoresis (SPEP)</td> <td>SPEP uses electrophoresis to separate serum proteins and allows for the detection and quantification of a monoclonal protein (M-protein) in the blood. Once detected, the clonality must be confirmed using serum immunofixation, serum immunoelectrophoresis, or serum immunosubtraction.</td> </tr> <tr> <td class=\"indent1\">Serum immunofixation</td> <td>This test uses antibodies directed against heavy chain and light chain components to differentiate a monoclonal from a polyclonal increase in immunoglobulins and to determine the type of immunoglobulin involved (eg, IgG kappa). This test does not quantify the M-protein.</td> </tr> <tr> <td class=\"indent1\">Serum free light chain (FLC) assay</td> <td>The serum FLC assay is an antibody-based system that can detect low concentrations of monoclonal free light chains (ie, kappa or lambda) in the serum. This assay is more sensitive for the detection of light chains than urine immunofixation; however, results may be affected by the presence of renal failure.</td> </tr> <tr> <td class=\"indent1\">Quantitation of immunoglobulins</td> <td>This technique can detect hypogammaglobulinemia and hypergammaglobulinemia, but does not allow an assessment of clonality. Increased levels can be due to polyclonal or monoclonal elevations; clonality needs to be established using SPEP and immunofixation.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Studies on urine</td> </tr> <tr> <td class=\"indent1\">Dipstick testing</td> <td>Although dipsticks are used in many laboratories to screen for the presence of protein in the urine, these tests are unable to detect Bence Jones protein (free kappa or lambda light chains).</td> </tr> <tr> <td class=\"indent1\">Urine protein electrophoresis (UPEP)</td> <td>The UPEP uses electrophoresis to separate urine proteins. A 24-hour urine collection is necessary to determine the quantity of M-protein.</td> </tr> <tr> <td class=\"indent1\">Urine immunofixation</td> <td>Urine immunofixation uses antibodies directed against the light chain components to differentiate a monoclonal from a polyclonal increase in immunoglobulins and to determine the type of light chain involved. Urine immunofixation is more sensitive than UPEP, but cannot estimate the size of the monoclonal protein.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70590 Version 2.0</div></div></div>"},"70591":{"type":"graphic_table","displayName":"Hysterosc steriliz protocol","title":"Hysteroscopic sterilization micro-insert protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hysteroscopic sterilization micro-insert protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Pre-procedure preparation</td> </tr> <tr> <td colspan=\"2\">Review informed consent regarding nonreversible contraception and surgical issues</td> </tr> <tr> <td colspan=\"2\">Conduct medical history and physical examination</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Prescribe pre-procedure medications (eg, progestin for endometrial preparation)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Day of procedure</td> </tr> <tr> <td colspan=\"2\">Rule out pregnancy</td> </tr> <tr> <td colspan=\"2\">Administer ketorolac 30 mg intramuscularly or intravenously (if patient has not taken oral NSAID within 24 hours) to prevent tubal spasm</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Check equipment:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Hysteroscopic sterilization device&nbsp;&ndash; Two individually wrapped devices (more should be available in case a device is damaged or does not deploy properly)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Rigid hysteroscope&nbsp;&ndash; Must have either a 12&#176; or a 30&#176; lens, fluid inflow channel, and instrument channel</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Hysteroscopic grasper&nbsp;&ndash; For use if an errantly deployed device needs to be retrieved from the uterine cavity</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Distension fluid&nbsp;&ndash; Use electrolyte solution (eg, normal saline or lactated Ringer's); use fluid sparingly to avoid fluid overload and endometrial edema that can obscure operative field; manual or automatic system to monitor fluid inflow and deficit; use cystoscopy tubing for better flow</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Procedure</td> </tr> <tr> <td colspan=\"2\">Administer anlagesia and/or anesthesia (type of analgesia or anesthesia will vary by patient or surgeon)</td> </tr> <tr> <td colspan=\"2\">Position and prepare patient for hysteroscopy</td> </tr> <tr> <td colspan=\"2\">Introduce hysteroscope into the endometrial cavity and identify <strong>BOTH</strong> tubal ostia</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Insert and deploy the device:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Open the first device package and insert the introducer sheath into the working channel of the hysteroscope</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Position the hysteroscope at one of the tubal ostium while the assistant threads the first device delivery system into the introducer sheath</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Take hold of the device handle and guide the tip of the micro-insert through the tubal ostium into the fallopian tube<br /> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Thread the device into the tube until the black marker is positioned at the tubal ostium<br /> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Rotate the thumbwheel towards yourself until it can no longer rotate (this will expose the wound down micro-insert)<br /> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Align the gold marker band just outside the tubal ostium<br /> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Press the deployment button<br /> </td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Rotate the thumbwheel towards yourself again until it can no longer rotate (the micro-insert will unwind and detach from the delivery system)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Remove the device delivery system</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">&#8226; Count and record the number of expanded coils extruding from the tubal ostium &ndash;&nbsp;Ideally, there should be 3 to 8 expanded coils trailing into the uterus; if there are 18 or more expanded coils, remove the micro-insert and re-attempt insertion with a new device</td> </tr> <tr> <td colspan=\"2\">Repeat the procedure at the contralateral tubal ostium</td> </tr> <tr> <td colspan=\"2\">Discharge patient to home or post-anesthesia care unit</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Follow-up</td> </tr> <tr> <td colspan=\"2\">Counsel patient to call for fever, excessive vaginal bleeding, or severe or persistent pain</td> </tr> <tr> <td colspan=\"2\">Advise patient to use contraception until confirmation of correct device placement and bilateral tubal occlusion</td> </tr> <tr> <td colspan=\"2\">At&nbsp;three months after procedure, perform hysterosalpingogram to confirm correct placement and bilateral tubal occlusion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drug.</div><div id=\"graphicVersion\">Graphic 70591 Version 3.0</div></div></div>"},"70592":{"type":"graphic_picture","displayName":"Mycosis fungoides blood","title":"Sézary cells within peripheral blood","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sézary cells within peripheral blood</div><div class=\"cntnt\"><img style=\"width:396px; height:294px;\" src=\"images/HEME/70592_Mycosisfungoidesblood.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sézary cells within peripheral blood. Note the cerebriform nuclear convolution.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70592 Version 10.0</div></div></div>"},"70595":{"type":"graphic_figure","displayName":"Anatomy of the eustachian tube","title":"Anatomy of the eustachian tube","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Anatomy of the eustachian tube</div><div class=\"cntnt\"><img style=\"width:506px; height:490px;\" src=\"images/PC/70595_Anat_eustach_tube_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70595 Version 2.0</div></div></div>"},"70596":{"type":"graphic_picture","displayName":"Stasis dermatitis early","title":"Early stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Early stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70596_Stasisdematitisearly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has the earliest sign of stasis dermatitis: erythema, scaling, and slight hyperpigmentation in the medial supramalleolar region.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70596 Version 2.0</div></div></div>"},"70597":{"type":"graphic_table","displayName":"CKD classification based upon GFR and albuminuria","title":"Chronic kidney disease classification based upon glomerular filtration rate and albuminuria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic kidney disease classification based upon glomerular filtration rate and albuminuria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">GFR stages</td> <td class=\"subtitle1\">GFR<br /> (mL/min/1.73 m<sup>2</sup>)</td> <td class=\"subtitle1\">Terms</td> </tr> <tr> <td>G1</td> <td>&#8805;90</td> <td>Normal or high</td> </tr> <tr> <td>G2</td> <td>60 to 89</td> <td>Mildly decreased</td> </tr> <tr> <td>G3a</td> <td>45 to 59</td> <td>Mildly to moderately decreased</td> </tr> <tr> <td>G3b</td> <td>30 to 44</td> <td>Moderately to severely decreased</td> </tr> <tr> <td>G4</td> <td>15 to 29</td> <td>Severely decreased</td> </tr> <tr class=\"divider_bottom\"> <td>G5</td> <td>&#60;15</td> <td>Kidney failure (add D if treated by dialysis)</td> </tr> <tr> <td class=\"subtitle1\">Albuminuria stages</td> <td class=\"subtitle1\">AER<br /> (mg/day)</td> <td class=\"subtitle1\">Terms</td> </tr> <tr> <td>A1</td> <td>&#60;30</td> <td>Normal to mildly increased (may be subdivided for risk prediction)</td> </tr> <tr> <td>A2</td> <td>30 to 300</td> <td>Moderately increased</td> </tr> <tr> <td>A3</td> <td>&#62;300</td> <td>Severely increased (may be subdivided into nephrotic and non-nephrotic for differential diagnosis, management, and risk prediction)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The cause of CKD is also included in the KDIGO revised classification but is not included in this table.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; AER: albumin excretion rate; CKD: chronic kidney disease; KDIGO: Kidney Disease Improving Global Outcomes.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>KDIGO. Summary of recommendation statements. Kidney Int 2013; 3 (Suppl):5.</LI>&#xD;&#xA;<LI>National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 1):S1.</LI></OL></div><div id=\"graphicVersion\">Graphic 70597 Version 16.0</div></div></div>"},"70599":{"type":"graphic_picture","displayName":"PHACE syndrome 1","title":"PHACE syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PHACE syndrome</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/70599_PHACE_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This full term infant was diagnosed with a noncritical coarctation of the aorta when she was&nbsp;two years old. On the third day of life she developed an extensive red mark on the left side of the face extending into the scalp.&nbsp;A brain MRI/MRA revealed multiple intracranial vascular abnormalities. These findings were typical of PHACE (posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta, cardiac defects, and eye abnormalities).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MRA: magnetic resonance angiogram.</div><div class=\"graphic_reference\">Copyright © Albert Yan, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 70599 Version 4.0</div></div></div>"},"70600":{"type":"graphic_table","displayName":"Rabies postexposure prophylaxis","title":"Rabies postexposure prophylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rabies postexposure prophylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vaccination category</td> <td class=\"subtitle1\">Biologic</td> <td class=\"subtitle1\">Schedule</td> </tr> <tr> <td rowspan=\"2\"><strong>Not previously vaccinated</strong></td> <td>RIG</td> <td>Total dose is 20 units/kg body weight. As much of the full dose as feasible should be infiltrated around the wound(s) and any remaining given IM.</td> </tr> <tr> <td>Vaccine</td> <td>Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) 1 mL, IM (deltoid area), 1 each on days 0, 3, 7 and 14*</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Previously vaccinated</strong></td> <td>RIG</td> <td>Not indicated</td> </tr> <tr> <td>Vaccine</td> <td>HDCV or PCECV 1 mL, IM (deltoid area), 1 each on days 0 and 3</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">8</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=32943&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">RIG: rabies immune globulin.<BR>* For persons with immunosuppression, rabies postexposure prophylaxis should be administered using all five doses of vaccine on days 0, 3, 7, 14, and 28.</div><div class=\"graphic_reference\">Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1.</div><div id=\"graphicVersion\">Graphic 70600 Version 7.0</div></div></div>"},"70602":{"type":"graphic_table","displayName":"Clinical interview","title":"Geriatric assessment performed by clinical interview: multidimensional evaluation scale for use in elderly cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Geriatric assessment performed by clinical interview: multidimensional evaluation scale for use in elderly cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Domain</td>\n<td class=\"subtitle1\">Measures</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"5\">Physical function/disability</td>\n<td>1) Activities of Daily Living</td>\n</tr>\n<tr><td> 2) Instrumental Activities of Daily Living</td></tr><tr><td>3) World Health Organization Scale</td></tr><tr><td>4) Physical Performance Test</td></tr><tr><td>5) Balance: FICSIT</td></tr><tr>\n<td>Socioeconomic status</td>\n<td>No scale listed</td>\n</tr>\n<tr>\n<td>Comorbidity</td>\n<td>No scale listed</td>\n</tr>\n<tr>\n<td>Cognition</td>\n<td>Mini Mental Status Exam</td>\n</tr>\n<tr>\n<td>Psychological state</td>\n<td>Geriatric Depression Scale</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_lgnd\">FICSIT: Frailty and Injuries: Cooperative Studies of Intervention Techniques.</div><div class=\"graphic_footnotes\">* Also captures information regarding demographics, cancer characteristics, symptoms, and use of services.</div><div id=\"graphicVersion\">Graphic 70602 Version 3.0</div></div></div>"},"70603":{"type":"graphic_figure","displayName":"Deep veins of the leg PI","title":"Deep veins of the leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep veins of the leg</div><div class=\"cntnt\"><img style=\"width:206px; height:652px;\" src=\"images/PI/70603_Deep_veins_of_the_leg_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In people with deep vein thrombosis, blood clots can form in the deep veins of the legs (shown in blue).</div><div id=\"graphicVersion\">Graphic 70603 Version 2.0</div></div></div>"},"70604":{"type":"graphic_figure","displayName":"TH physiology","title":"Regulation of thyroid hormone supply, metabolism and genomic action","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Regulation of thyroid hormone supply, metabolism and genomic action</div><div class=\"cntnt\"><img style=\"width:598px; height:448px;\" src=\"images/PEDS/70604_TH_physiology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Feedback control that regulates the circulating concentration of thyroid hormone (TH). B) Intracellular metabolism of TH, regulating TH bioactivity. C) Genomic action of TH. For details see text.</div><div class=\"graphic_footnotes\">TRH: TSH releasing hormone; TSH: thyroid stimulating hormone (thyrotropin); T4: 3,3', 5,5'-tetraiodothyronine (thyroxine, T4); T3: 3,3', 5-triiodothyronine (T3); rT3: 3,3', 5'-triiodothyronine (reverse T3, rT3); T2: 3,3'-dioidothyronine; 5'D: deiodination by removal of an iodine from the 5' position of iodothyronine; 5D: 5-deiodination; T2: 3,3'-dioidothyronine; TR: TH receptor; RXR: retinod X receptor; CBP/P300: cAMP-binding protein/general transcription adaptor; TFIIA and TFIIB: transcription intermediary factor II, A and B; TBP: TATA-binding protein; TAF: TBP-associated factor.</div><div class=\"graphic_reference\">Reproduced with permission from: Refetoff, S, Dumitrescu, A. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab 2007; 21(2):277. Copyright ©2007 Elsevier. Illustrations used with permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70604 Version 2.0</div></div></div>"},"70605":{"type":"graphic_figure","displayName":"mRNA processing","title":"Post-transcription modification of mRNA","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Post-transcription modification of mRNA</div><div class=\"cntnt\"><img style=\"width:518px; height:413px;\" src=\"images/PC/70605_mRNA_processing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pre-mRNA transcripts are unsuitable for protein translation. Introns must be removed through a process called splicing to align the exons for their subsequent translation. The spliced RNA is an unstable molecule, with highly reactive moieties at both the 5' and 3' ends. Addition of the 5' cap and the 3' poly-A tail are critical for stabilization of RNA and for their subsequent metabolism.</div><div id=\"graphicVersion\">Graphic 70605 Version 1.0</div></div></div>"},"70606":{"type":"graphic_algorithm","displayName":"Management type 2 diabetes","title":"Management of type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Management of type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:596px; height:461px;\" src=\"images/ENDO/70606_Mgmt_type2_diabetes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for the metabolic management of type 2 diabetes; reinforce lifestyle interventions at every visit and check A1C every three months until A1C is &lt;7% and then at least every six months. The interventions should be changed if A1C is &ge;7%.</div><div class=\"graphic_footnotes\">CHF: congestive heart failure; A1C: glycated hemoglobin; GLP-1: glucagon-like peptide-1; DPP-4: dipeptidyl peptidase-4; SGLT2: sodium-glucose co-transporter 2.<br />* Sulfonylureas other than glybenclamide (glyburide) or chlorpropamide.<br />¶ Alternative agents include: GLP-1 agonists, DPP-4 inhibitors, alpha-glucosidase inhibitors, SGLT2 inhibitors.</div><div class=\"graphic_reference\">Modified with permission from: Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203. Copyright &copy; 2009 American Diabetes.</div><div id=\"graphicVersion\">Graphic 70606 Version 6.0</div></div></div>"},"70607":{"type":"graphic_picture","displayName":"Complete vaginal vault prolapse","title":"Complete vaginal vault prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete vaginal vault prolapse</div><div class=\"cntnt\"><img style=\"width:277px; height:370px;\" src=\"images/OBGYN/70607_Complete_apical_eversion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70607 Version 2.0</div></div></div>"},"70608":{"type":"graphic_picture","displayName":"Mature teratoma","title":"Opened mature cystic teratoma (dermoid cyst) of the ovary","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Opened mature cystic teratoma (dermoid cyst) of the ovary</div><div class=\"cntnt\"><img style=\"width:468px; height:304px;\" src=\"images/OBGYN/70608_Mature_teratoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair (bottom) and a mixture of tissues are evident.</div><div class=\"graphic_reference\">Reproduced with permission from: Crum CP. The Female Genital Tract. In: Pathologic Basis of Disease, 6th ed, Cotran RS, Kumar V, Collins T (Eds), WB Saunders Company, Pennsylvania 1999. Copyright &#169; 1999 Elsevier.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 70608 Version 2.0</div></div></div>"},"70609":{"type":"graphic_picture","displayName":"Hypersegmented neutrophil","title":"Hypersegmented neutrophil in megaloblastic anemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypersegmented neutrophil in megaloblastic anemia</div><div class=\"cntnt\"><img style=\"width:389px; height:257px;\" src=\"images/HEME/70609_Hypersegmented_neutrophil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear from a patient with megaloblastic anemia showing a neutrophil with an increased number of nuclear lobes. At least six discrete lobes are present; normal neutrophils have five lobes or fewer.</div><div class=\"graphic_reference\">Courtesy of Stephen A. Landaw, MD, PhD.</div><div id=\"graphicVersion\">Graphic 70609 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"70611":{"type":"graphic_picture","displayName":"Spherocytes","title":"Spherocytes","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spherocytes</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/HEME/70611_Spherocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows multiple spherocytes, which are small, dark, dense hyperchromic red cells without central pallor (arrows). These findings are compatible with hereditary spherocytosis or autoimmune hemolytic anemia.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 70611 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"70613":{"type":"graphic_picture","displayName":"MDI use with trach","title":"Equipment for aerosol delivery to tracheostomy in spontaneously breathing patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Equipment for aerosol delivery to tracheostomy in spontaneously breathing patients</div><div class=\"cntnt\"><img style=\"width:361px; height:440px;\" src=\"images/PULM/70613_MDI_use_with_trach.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70613 Version 2.0</div></div></div>"},"70615":{"type":"graphic_picture","displayName":"Verruca vulgaris - hand","title":"Verruca vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verruca vulgaris</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70615_Verruca_vulgaris_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A keratotic papule with peripheral hyperpigmentation is present on the hand of this patient with verruca vulgaris (common wart).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70615 Version 4.0</div></div></div>"},"70616":{"type":"graphic_table","displayName":"Systemic autoimmune diseases","title":"Systemic autoimmune diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic autoimmune diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Connective tissue diseases</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus*</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis*</td> </tr> <tr> <td class=\"indent1\">Systemic sclerosis*</td> </tr> <tr> <td class=\"indent1\">Mixed connective tissue disease*</td> </tr> <tr> <td class=\"indent1\">Sjogren syndrome<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Polymyositis and dermatomyositis</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitides</td> </tr> <tr> <td class=\"indent1\">Small vessels: <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</span><sup>&#182;</sup> (also called allergic granulomatosis and angiitis), granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis)</td> </tr> <tr> <td class=\"indent1\">Medium-sized vessels: polyarteritis nodosa, Kawasaki disease<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Large vessels: Takayasu arteritis, giant cell arteritis</td> </tr> <tr> <td class=\"subtitle1_single\">Granulomatous diseases</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Autoinflammatory diseases</td> </tr> <tr> <td class=\"indent1\">Familial Mediterranean fever</td> </tr> <tr> <td class=\"indent1\">TNF receptor-1 associated periodic syndrome (TRAPS)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Diseases with very frequent pericardial involvement (&gt;25 percent).<br />¶ Diseases with frequent pericardial involvement (&gt;10 percent).</div><div id=\"graphicVersion\">Graphic 70616 Version 4.0</div></div></div>"},"70617":{"type":"graphic_table","displayName":"Hypothermia physiology","title":"Physiologic changes by stage of hypothermia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic changes by stage of hypothermia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Core temperature</td> <td class=\"subtitle1\">Physiologic changes</td> </tr> <tr> <td rowspan=\"4\">Mild</td> <td rowspan=\"4\"> <p>32-35&#176;C</p> (90-95&#176;F)</td> <td>Shivering</td> </tr> <tr> <td>Increased metabolism</td> </tr> <tr> <td>Vasoconstriction</td> </tr> <tr> <td>Mild tachycardia</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Moderate</td> <td rowspan=\"6\"> <p>28-32&#176;C</p> (82-90&#176;F)</td> <td>Loss of compensatory shivering</td> </tr> <tr> <td>Decreasing metabolism</td> </tr> <tr> <td>Decreasing cerebral blood flow</td> </tr> <tr> <td>Diuresis</td> </tr> <tr> <td>Extravasation of fluids</td> </tr> <tr> <td>Hypovolemia</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">Severe</td> <td rowspan=\"8\"> <p>&#60;28&#176;C</p> (82&#176;F)</td> <td>Muscle rigidity without shivering</td> </tr> <tr> <td>Loss of thermoregulation</td> </tr> <tr> <td>Vasodilation</td> </tr> <tr> <td>Decreased HR, SV, CO</td> </tr> <tr> <td>Decreased cardiac conduction</td> </tr> <tr> <td>Increased cardiac irritability</td> </tr> <tr> <td>Slowed nerve conduction</td> </tr> <tr> <td>Suspended cerebral activity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HR: heart rate; SV: stroke volume; CO: cardiac output.<br />* Changes are typical of the stage shown, but may vary in temperature of onset.</div><div id=\"graphicVersion\">Graphic 70617 Version 5.0</div></div></div>"},"70623":{"type":"graphic_figure","displayName":"Risk strat RINV","title":"Emetogenic potential of radiotherapy","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Emetogenic potential of radiotherapy</div><div class=\"cntnt\"><img style=\"width:509px; height:281px;\" src=\"images/ONC/70623_Risk_strat_RINV.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Feyer, P. Acta Oncol 2004; 43 Suppl 15:5, and Feyer, P, et al. Support Cancer Care 2005; 13:122.</div><div id=\"graphicVersion\">Graphic 70623 Version 2.0</div></div></div>"},"70624":{"type":"graphic_figure","displayName":"Kraske prone jackknife position","title":"Kraske prone jackknife position","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Kraske prone jackknife position</div><div class=\"cntnt\"><img style=\"width:471px; height:360px;\" src=\"images/SURG/70624_Jackknifeposition.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70624 Version 2.0</div></div></div>"},"70625":{"type":"graphic_figure","displayName":"Presacral venous plexus - Fascial relationship","title":"Presacral venous plexus - Fascial relationship","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Presacral venous plexus - Fascial relationship</div><div class=\"cntnt\"><img style=\"width:496px; height:462px;\" src=\"images/SURG/70625_Presacral-venous-plexus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the location of the presacral venous plexus, the presacral facia, and the posterior rectum in the lateral view. The wise surgeon will not violate the presacral fascia so as to avoid the risk of life-threatening hemorrhage.</div><div id=\"graphicVersion\">Graphic 70625 Version 2.0</div></div></div>"},"70627":{"type":"graphic_diagnosticimage","displayName":"Dilation for achalasia","title":"Efficacy of pneumatic dilation for achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of pneumatic dilation for achalasia</div><div class=\"cntnt\"><img style=\"width:250px; height:142px;\" src=\"images/GAST/70627_Dilation_for_achalasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium radiographs showing the result of pneumatic dilation of the lower esophageal sphincter in a patient with achalasia. Left panel: The balloon is positioned in the lower esophageal sphincter with an hourglass &quot;waist&quot; effect (arrow) caused by the hypertensive sphincter. Right panel: The waist disappears as the dilation progresses.</div><div class=\"graphic_reference\">Adapted from the American Gastroenterological Association©. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432- 8433.</div><div id=\"graphicVersion\">Graphic 70627 Version 2.0</div></div></div>"},"70628":{"type":"graphic_table","displayName":"Five \"R's\" to motivate smokers unwilling to quit","title":"Five \"R's\" to motivate smokers unwilling to quit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five \"R's\" to motivate smokers unwilling to quit</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Technique</td> </tr> <tr> <td><strong>R</strong>elevance</td> <td>Encourage the patient to indicate why quitting is personally relevant, being as specific as possible. Motivational information has the greatest impact if it is relevant to a patient's disease status or risk, family or social situation (eg, having children in the home), health concerns, age, gender, and other important patient characteristics (eg, prior quitting experience, personal barriers to cessation).</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>R</strong>isks</td> <td>Ask the patient to identify potential negative consequences of tobacco use. The clinician may suggest and highlight those that seem most relevant to the patient. The clinician should emphasize that smoking low-tar/low-nicotine cigarettes or use of other forms of tobacco (eg, smokeless tobacco, cigars, and pipes) will not eliminate these risks.</td> </tr> <tr> <td class=\"sublist1_start\">Examples of risks are:</td> </tr> <tr> <td class=\"sublist1\">Acute risks - Shortness of breath, exacerbation of asthma, harm to pregnancy, impotence, infertility, and increased serum carbon monoxide.</td> </tr> <tr> <td class=\"sublist1\">Long-term risks - Heart attacks and strokes, lung and other cancers (larynx, oral cavity, pharynx, esophagus, pancreas, bladder, cervix), chronic obstructive pulmonary diseases (chronic bronchitis and emphysema), long-term disability, and need for extended care.</td> </tr> <tr> <td class=\"sublist1\">Environmental risks - Increased risk of lung cancer and heart disease in spouses; higher rates of smoking in children of tobacco users; increased risk for low birth weight, Sudden Infant Death Syndrome, asthma, middle ear disease, and respiratory infections in children of smokers.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"13\"><strong>R</strong>ewards</td> <td>Ask the patient to identify potential benefits of stopping tobacco use. The clinician may suggest and highlight those that seem most relevant to the patient.</td> </tr> <tr> <td class=\"sublist1_start\">Examples of rewards include:</td> </tr> <tr> <td class=\"sublist1\">Improved health</td> </tr> <tr> <td class=\"sublist1\">Food will taste better</td> </tr> <tr> <td class=\"sublist1\">Improved sense of smell</td> </tr> <tr> <td class=\"sublist1\">Save money</td> </tr> <tr> <td class=\"sublist1\">Feel better about yourself</td> </tr> <tr> <td class=\"sublist1\">Home, car, clothing, breath will smell better</td> </tr> <tr> <td class=\"sublist1\">Can stop worrying about quitting</td> </tr> <tr> <td class=\"sublist1\">Set a good example for and have healthier babies and children</td> </tr> <tr> <td class=\"sublist1\">Not worry about exposing others to smoke</td> </tr> <tr> <td class=\"sublist1\">Feel better physically and perform better in physical activities</td> </tr> <tr> <td class=\"sublist1\">Reduced wrinkling/aging of skin</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\"><strong>R</strong>oadblocks</td> <td>Ask the patient to identify barriers or impediments to quitting and note elements of treatment (problem solving, pharmacotherapy) that could address barriers.</td> </tr> <tr> <td class=\"sublist1_start\">Typical barriers might include:</td> </tr> <tr> <td class=\"sublist1\">Withdrawal symptoms</td> </tr> <tr> <td class=\"sublist1\">Fear of failure</td> </tr> <tr> <td class=\"sublist1\">Weight gain</td> </tr> <tr> <td class=\"sublist1\">Lack of support</td> </tr> <tr> <td class=\"sublist1\">Depression</td> </tr> <tr> <td class=\"sublist1\">Enjoyment of tobacco</td> </tr> <tr class=\"divider_top\"> <td><strong>R</strong>epetition</td> <td>The motivational intervention should be repeated every time an unmotivated patient visits the clinic setting. Tobacco users who have failed in previous quit attempts should be told that most people make repeated quit attempts before they are successful.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fiore MC, Jaen C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. 2008.</div><div id=\"graphicVersion\">Graphic 70628 Version 7.0</div></div></div>"},"70631":{"type":"graphic_picture","displayName":"Functional upper arm brace","title":"Functional upper arm brace","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional upper arm brace</div><div class=\"cntnt\"><img style=\"width:324px; height:370px;\" src=\"images/RHEUM/70631_Functional_upper_arm_brace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a commercially available functional brace that can be used to immobilize fractures of the shaft of the humerus.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 70631 Version 2.0</div></div></div>"},"70632":{"type":"graphic_table","displayName":"Probability of HF men","title":"Probability of heart failure within four years for men aged 45 to 94 years with coronary disease, hypertension, or valvular disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of heart failure within four years for men aged 45 to 94 years with coronary disease, hypertension, or valvular disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n\n  <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Variables</td>\n\n  <td class=\"subtitle1\" colspan=\"10\" rowspan=\"1\">Points</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"subtitle2\">0</td>\n\n  <td class=\"subtitle2\">+1</td>\n\n  <td class=\"subtitle2\">+2</td>\n\n  <td class=\"subtitle2\">+3</td>\n\n  <td class=\"subtitle2\">+4</td>\n\n  <td class=\"subtitle2\">+5</td>\n\n  <td class=\"subtitle2\">+6</td>\n\n  <td class=\"subtitle2\">+7</td>\n\n  <td class=\"subtitle2\">+8</td>\n\n  <td class=\"subtitle2\">+9</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Age, y</td>\n\n  <td>45-49</td>\n\n  <td>50-54</td>\n\n  <td>55-59</td>\n\n  <td>60-64</td>\n\n  <td>65-69</td>\n\n  <td>70-74</td>\n\n  <td>75-79</td>\n\n  <td>&nbsp;</td>\n\n  <td>90-94</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Forced vital capacity, cL</td>\n\n  <td>&#8805;425</td>\n\n  <td>375-424</td>\n\n  <td>325-374</td>\n\n  <td>275-324</td>\n\n  <td>200-274</td>\n\n  <td>150-199</td>\n\n  <td>&#8804;149</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Systolic blood pressure, mmHg</td>\n\n  <td>&#60;120</td>\n\n  <td>120-139</td>\n\n  <td>140-169</td>\n\n  <td>170-189</td>\n\n  <td>190-219</td>\n\n  <td>&#62;219</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Heart rate, bpm</td>\n\n  <td>&#60;55</td>\n\n  <td>55-64</td>\n\n  <td>65-79</td>\n\n  <td>80-89</td>\n\n  <td>90-99</td>\n\n  <td>&#62;99</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>LVH on ECG</td>\n\n  <td>No</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>Yes</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Coronary heart disease</td>\n\n  <td>No</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>Yes</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Valve disease</td>\n\n  <td>No</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>Yes</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Diabetes</td>\n\n  <td>No</td>\n\n  <td>Yes</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td>Cardiomegaly</td>\n\n  <td>No</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>Yes</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  <td>&nbsp;</td>\n\n  </tr>\n\n  <tr>\n\n  <td class=\"subtitle1\">Points</td>\n\n  <td class=\"subtitle1\" rowspan=\"1\" colspan=\"4\">4-Year probability of heart failure, percent</td>\n\n  <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Points</td>\n\n  <td class=\"subtitle1\" rowspan=\"1\" colspan=\"4\">4-Year probability of heart failure, percent</td>\n\n  </tr>\n\n  <tr>\n\n  <td>5</td>\n\n  <td colspan=\"4\" rowspan=\"1\">1</td>\n\n  <td colspan=\"2\" rowspan=\"1\">26</td>\n\n  <td colspan=\"4\" rowspan=\"1\">18</td>\n\n  </tr>\n\n  <tr>\n\n  <td>10</td>\n\n  <td colspan=\"4\" rowspan=\"1\">1</td>\n\n  <td colspan=\"2\" rowspan=\"1\">27</td>\n\n  <td colspan=\"4\" rowspan=\"1\">21</td>\n\n  </tr>\n\n  <tr>\n\n  <td>12</td>\n\n  <td colspan=\"4\" rowspan=\"1\">2</td>\n\n  <td colspan=\"2\" rowspan=\"1\">28</td>\n\n  <td colspan=\"4\" rowspan=\"1\">24</td>\n\n  </tr>\n\n  <tr>\n\n  <td>14</td>\n\n  <td colspan=\"4\" rowspan=\"1\">3</td>\n\n  <td colspan=\"2\" rowspan=\"1\">29</td>\n\n  <td colspan=\"4\" rowspan=\"1\">27</td>\n\n  </tr>\n\n  <tr>\n\n  <td>16</td>\n\n  <td colspan=\"4\" rowspan=\"1\">4</td>\n\n  <td colspan=\"2\" rowspan=\"1\">30</td>\n\n  <td colspan=\"4\" rowspan=\"1\">31</td>\n\n  </tr>\n\n  <tr>\n\n  <td>18</td>\n\n  <td colspan=\"4\" rowspan=\"1\">5</td>\n\n  <td colspan=\"2\" rowspan=\"1\">31</td>\n\n  <td colspan=\"4\" rowspan=\"1\">34</td>\n\n  </tr>\n\n  <tr>\n\n  <td>20</td>\n\n  <td colspan=\"4\" rowspan=\"1\">7</td>\n\n  <td colspan=\"2\" rowspan=\"1\">33</td>\n\n  <td colspan=\"4\" rowspan=\"1\">38</td>\n\n  </tr>\n\n  <tr>\n\n  <td>22</td>\n\n  <td colspan=\"4\" rowspan=\"1\">10</td>\n\n  <td colspan=\"2\" rowspan=\"1\">33</td>\n\n  <td colspan=\"4\" rowspan=\"1\">42</td>\n\n  </tr>\n\n  <tr>\n\n  <td>24</td>\n\n  <td colspan=\"4\" rowspan=\"1\">14</td>\n\n  <td colspan=\"2\" rowspan=\"1\">34</td>\n\n  <td colspan=\"4\" rowspan=\"1\">47</td>\n\n  </tr>\n\n  <tr>\n\n  <td>25</td>\n\n  <td colspan=\"4\" rowspan=\"1\">16</td>\n\n  <td colspan=\"2\" rowspan=\"1\">35</td>\n\n  <td colspan=\"4\" rowspan=\"1\">51</td>\n\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">LVH: left ventricular hypertrophy; ECG: electrocardiogram; cL: centiliter; y: years; bpm: beats per minute.</div><div class=\"graphic_reference\">Data reproduced with permission from: Kannel WB, D'Agostino RB, Silbershatz H, et al. Arch Intern Med 1999; 159:1192.</div><div id=\"graphicVersion\">Graphic 70632 Version 2.0</div></div></div>"},"70633":{"type":"graphic_diagnosticimage","displayName":"Mesenteric venous thrombosis","title":"Mesenteric venous thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mesenteric venous thrombosis</div><div class=\"cntnt\"><img style=\"width:301px; height:404px;\" src=\"images/SURG/70633_Mesent_venous_thrombosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow points to a filling defect in the superior mesenteric vein, consistent with a thrombosis.</div><div id=\"graphicVersion\">Graphic 70633 Version 7.0</div></div></div>"},"70635":{"type":"graphic_picture","displayName":"Eschar in scrub typhus","title":"Eschar in scrub typhus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eschar in scrub typhus</div><div class=\"cntnt\"><img style=\"width:324px; height:322px;\" src=\"images/ID/70635_Eschar_in_scrub_typhus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A localized necrotic skin lesion (eschar) at the site of an infecting chigger bite in a patient with scrub typhus.</div><div class=\"graphic_reference\">Courtesy of Daniel J Sexton, MD.</div><div id=\"graphicVersion\">Graphic 70635 Version 1.0</div></div></div>"},"70637":{"type":"graphic_picture","displayName":"Candidiasis vulva","title":"Candidiasis vulva","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Candidiasis vulva</div><div class=\"cntnt\"><img style=\"width:475px; height:343px;\" src=\"images/OBGYN/70637_Candidiasis_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from&#160;Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 70637 Version 2.0</div></div></div>"},"70638":{"type":"graphic_figure","displayName":"Chemo emetic pathways","title":"Pathways by which chemotherapeutic agents may produce an emetic response","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Pathways by which chemotherapeutic agents may produce an emetic response</div><div class=\"cntnt\"><img style=\"width:533px; height:809px;\" src=\"images/ONC/70638_Chemo_emetic_pathways.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chemotherapy-induced emesis&nbsp;results from stimulation of a multistep reflex pathway that is controlled by the brain and triggered by afferent impulses to the CPG (previously called the \"vomiting center\")&nbsp;from the&nbsp;AP and NTS (previously referred to as the \"chemoreceptor trigger zone\")), gastrointestinal tract (by way of vagal afferent fibers), and possibly, the cerebral cortex. The mechanism that is best supported by research involves an effect of chemotherapy&nbsp;on the upper small intestine.&nbsp;Local generation of&nbsp;free radicals&nbsp;leads to localized exocytotic release of serotonin (5-hydroxytryptamine [5-HT]) from the enterochromaffin cells; 5-HT then interacts with&nbsp;5-HT3 receptors on vagal afferent terminals in the wall of the bowel. This stimulates vagal afferent fibers, which project to the NTS and AP in the dorsal brain stem.&nbsp;This peripheral mechanism of emesis is believed to be 5-HT3 receptor dominant and plays a key role in acute emesis. Afferent stimulation from the vagus also results in the release of Substance P in the NTS and AP. This central mechanism of emesis is believed to be NK1 receptor dominant and plays an important role in delayed emesis. <br /><br />Neural fibers project from the&nbsp;NTS and AP&nbsp;to the final effector of the emetic reflex, the CPG, which is an anatomically indistinct area occupying a more ventral location in the medulla. Antineoplastic agents may also induce emesis through a direct&nbsp;interaction with the AP.&nbsp;Other potential sources of afferent input to the CPG that result in emesis after chemotherapy include a number of structures in the temporal lobe, such as the amygdala. Evidence for this pathway is less well established than for other proposed sites of chemotherapeutic action.</div><div class=\"graphic_footnotes\">CNS: central nervous system; NTS: nucleus tractus solitarius; AP: area postrema; NK1: Neurokinin-1; CPG: central pattern generator; 5-HT3: 5-hydroxytryptamine3; GI: gastrointestinal. </div><div class=\"graphic_reference\">Modified from Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358:2482.</div><div id=\"graphicVersion\">Graphic 70638 Version 7.0</div></div></div>"},"70640":{"type":"graphic_figure","displayName":"Change BMD low dose addback","title":"Effects of GnRH agonist alone (solid lines) versus GnRH agonist plus low-dose estrogen-progestin add-back (dotted line) on bone mineral density at the end of 6 months of treatment and then after 6 months of follow up","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Effects of GnRH agonist alone (solid lines) versus GnRH agonist plus low-dose estrogen-progestin add-back (dotted line) on bone mineral density at the end of 6 months of treatment and then after 6 months of follow up</div><div class=\"cntnt\"><img style=\"width:512px; height:487px;\" src=\"images/OBGYN/70640_Change_BMD_low_dose_addback.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the low-dose estrogen plus progestin add-back was associated with continuing bone loss during treatment, but the bone loss was less than that observed in the group treated with the GnRH agonist alone.</div><div class=\"graphic_reference\">Reproduced with permission from: Howell, R, Edmonds, D, Dowsett, M. Gonadotropin releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized clinical trial. Fertil Steril 1995; 64:474. Copyright &#169; 1995 American Society for Reproductive Medicine.</div><div id=\"graphicVersion\">Graphic 70640 Version 1.0</div></div></div>"},"70642":{"type":"graphic_picture","displayName":"Urticarial vasculitis - annular lesions","title":"Urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/70642_Urtic_vasc_annular_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular lesions in a patient with urticarial vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70642 Version 3.0</div></div></div>"},"70645":{"type":"graphic_figure","displayName":"Obesity family hx and NIDDM","title":"Obesity decreases insulin sensitivity in susceptible subjects","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obesity decreases insulin sensitivity in susceptible subjects</div><div class=\"cntnt\"><img style=\"width:430px; height:216px;\" src=\"images/ENDO/70645_Obesity_family_hx_and_NIDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Responsiveness to insulin (as assessed from the intravenous glucose tolerance test) according to body weight in nondiabetic subjects with no family history of type 2 diabetes mellitus in first-degree relatives and in those with two parents with type 2 diabetes. Both groups had similar insulin responsiveness at near normal ideal body weight, but the degree of insulin resistance (decrease in insulin sensitivity) as body weight increased was more pronounced in the offspring of parents with type 2 diabetes.</div><div class=\"graphic_reference\">Data from: Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes.&nbsp;Diabetes 1994; 43:1066.</div><div id=\"graphicVersion\">Graphic 70645 Version 2.0</div></div></div>"},"70648":{"type":"graphic_algorithm","displayName":"Milstein mapping algorithm localize accessory pathway","title":"Algorithm to localize accessory pathway in preexcitation syndrome","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Algorithm to localize accessory pathway in preexcitation syndrome</div><div class=\"cntnt\"><img style=\"width:524px; height:244px;\" src=\"images/CARD/70648_Milstein_mapping_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mapping algorithm for localization of accessory pathway in the preexcitation syndrome using the morphology of the delta wave on the electrocardiogram.</div><div class=\"graphic_footnotes\">Δ: delta wave; RAS: right anteroseptal; LL: left lateral; PS: posteroseptal; RL: right lateral.<br>* + QRS ≥90 msec in L1 and rS in V1 and V2.</div><div class=\"graphic_reference\">Reproduced with permission from Milstein S, Sharma AD, Guiraudon GM, et al. Pacing Clin Electrophysiol 1987; 10:555. Copyright © 1987 Futura Publishing Company.</div><div id=\"graphicVersion\">Graphic 70648 Version 3.0</div></div></div>"},"70650":{"type":"graphic_table","displayName":"Causes of bronchiolitis","title":"Clinical syndromes associated with bronchiolitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical syndromes associated with bronchiolitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inhalation injury</td> </tr> <tr> <td class=\"indent1\">Toxic fume inhalation (eg, silo fillers, welders, mustard gas)</td> </tr> <tr> <td class=\"indent1\">Mineral dusts</td> </tr> <tr> <td class=\"indent1\">Irritant gases (eg, chlorine, ammonia, paraquat)</td> </tr> <tr> <td class=\"indent1\">Volatile flavoring agents (popcorn factory)</td> </tr> <tr> <td class=\"subtitle1_single\">Postinfectious</td> </tr> <tr> <td class=\"indent1\">Viruses</td> </tr> <tr> <td class=\"indent2\">Respiratory syncytial virus</td> </tr> <tr> <td class=\"indent2\">Adenovirus or rhinovirus</td> </tr> <tr> <td class=\"indent2\">Influenza or parainfluenza</td> </tr> <tr> <td class=\"indent2\">Measles or mumps</td> </tr> <tr> <td class=\"indent2\">Varicella zoster</td> </tr> <tr> <td class=\"indent2\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent2\">Human immunodeficiency virus (HIV)</td> </tr> <tr> <td class=\"indent1\">Other infectious agents</td> </tr> <tr> <td class=\"indent2\">Bordetella pertussis</td> </tr> <tr> <td class=\"indent2\">Mycoplasma pneumoniae</td> </tr> <tr> <td class=\"indent2\">Nocardia</td> </tr> <tr> <td class=\"subtitle1_single\">Drug-induced reactions</td> </tr> <tr> <td class=\"indent1\">Busulfan</td> </tr> <tr> <td class=\"indent1\">Free-base cocaine</td> </tr> <tr> <td class=\"indent1\">Gold</td> </tr> <tr> <td class=\"indent1\">Nimesulide</td> </tr> <tr> <td class=\"indent1\">Penicillamine&nbsp;</td> </tr> <tr> <td class=\"indent1\">Rituximab</td> </tr> <tr> <td class=\"indent1\"><em>Sauropus androgynus</em> leaf (papaverine)</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"indent1\">Sulfamethoxypyridazine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Associated diseases</td> </tr> <tr> <td class=\"indent1\">Organ transplantation</td> </tr> <tr> <td class=\"indent2\">Bone marrow</td> </tr> <tr> <td class=\"indent2\">Heart-lung</td> </tr> <tr> <td class=\"indent2\">Lung</td> </tr> <tr> <td class=\"indent1\">Rheumatic disease</td> </tr> <tr> <td class=\"indent2\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent2\">Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"indent2\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent2\">Polymyositis/dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Rare associations</td> </tr> <tr> <td class=\"indent2\">Adult respiratory distress syndrome (ARDS)</td> </tr> <tr> <td class=\"indent2\">Ataxia telangiectasia</td> </tr> <tr> <td class=\"indent2\">Lysinuric protein intolerance</td> </tr> <tr> <td class=\"indent2\">Malignant histiocytosis</td> </tr> <tr> <td class=\"indent2\">Paraneoplastic pemphigus</td> </tr> <tr> <td class=\"indent2\">Primary biliary cirrhosis*</td> </tr> <tr> <td class=\"indent2\">Ulcerative colitis</td> </tr> <tr> <td class=\"indent2\">Vasculitis, especially granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">Cryptogenic bronchiolitis obliterans</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Primary biliary cirrhosis has been renamed primary biliary cholangitis. </div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Galateau F. [Pulmonary lesions in Wegener's disease. Report of the French Anatomo-clinical Research Group. Study of 40 pulmonary biopsies]. Rev Mal Respir 1992; 9:431.</li>&#xD;&#xA;    <li>Chatt&eacute; G, Streichenberger N, Boillot O. Lymphocytic bronchitis/bronchiolitis in a patient with primary biliary cirrhosis. Eur Respir J 1995; 8:176.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 70650 Version 6.0</div></div></div>"},"70651":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma II CT","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:321px; height:318px;\" src=\"images/PULM/70651_Malignant_mesothelioma_II_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows right-sided circumferential pleural thickening with thickening of the major fissure; there is extension into azygo-esophageal recess and into the anterior mediastinal, pericardial fat.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70651 Version 3.0</div></div></div>"},"70654":{"type":"graphic_diagnosticimage","displayName":"CBD transection MRCP","title":"Complete common bile duct transection after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete common bile duct transection after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:297px; height:300px;\" src=\"images/GAST/70654_CBD_obstruction_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiopancreatography showing absence of the common bile duct and dilated intrahepatic ducts in a patient with complete transection of the common bile duct. A pool of fluid is seen at the confluence of the right and left hepatic ducts (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 70654 Version 5.0</div></div></div>"},"70656":{"type":"graphic_diagnosticimage","displayName":"Coarctation aorta PA","title":"Plain radiograph showing coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph showing coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:296px; height:332px;\" src=\"images/CARD/70656_Coarctation_aorta_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain frontal chest radiograph from a patient with known coarctation of the aorta demonstrates an absence of the proximal descending aortic arch shadow in the expected location (arrow), immediately superior to the left main pulmonary artery. Another plain radiographic finding, not seen in this example, includes notching of the posterior thoracic ribs.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 70656 Version 4.0</div></div></div>"},"70657":{"type":"graphic_table","displayName":"Self administered CGA tool","title":"Primarily self-administered comprehensive geriatric assessment tool*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primarily self-administered comprehensive geriatric assessment tool*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Domain</td> <td class=\"subtitle1\">Measures</td> </tr> <tr> <td rowspan=\"6\">Functional status</td> <td>1) Activities of Daily Living [Subscale of Medical Outcomes Study Physical Health Scale]</td> </tr> <tr> <td>2) Instrumental Activities of Daily Living [Subscale of the OARS]</td> </tr> <tr> <td>3) Karnofsky performance status (Physician-Rated)</td> </tr> <tr> <td>4) Karnofsky performance status (Patient-Rated)</td> </tr> <tr> <td>5) Timed Up and Go</td> </tr> <tr> <td>6) Number of falls in last six months</td> </tr> <tr class=\"divider_top\"> <td>Comorbidity</td> <td>Physical Health Section [Subscale of the OARS]</td> </tr> <tr class=\"divider_top\"> <td>Cognition</td> <td>Blessed Orientation-Memory-Concentration Test</td> </tr> <tr class=\"divider_top\"> <td>Psychological</td> <td>Hospital Anxiety and Depression Scale</td> </tr> <tr class=\"divider_top\"> <td>Social functioning</td> <td>Medical Outcomes Study Social Activity Limitations Measure</td> </tr> <tr class=\"divider_top\"> <td>Social support</td> <td>Medical Outcomes Study Social Support Survey: Emotional/Information &#38; Tangible Subscales</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Nutrition</td> <td>1) Body mass index</td> </tr> <tr> <td>2) Percent unintentional weight loss in the last 6 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OARS: Older Americans Resources and Services.<br />* Also captures information on demographics and cancer characteristics.</div><div id=\"graphicVersion\">Graphic 70657 Version 5.0</div></div></div>"},"70658":{"type":"graphic_table","displayName":"Genetic syndromes associated with obesity","title":"Selected genetic syndromes associated with obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected genetic syndromes associated with obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Obesity onset (type)</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>Albright hereditary osteodystrophy (pseudohypoparathyroidism type 1a) (MIM #103580)</td> <td>20q13.2</td> <td>GNAS1</td> <td>Early (generalized)</td> <td>Short stature, short metacarpals and metatarsals, round facies, delayed dentition, +/&ndash; hypocalcemia and/or subcutaneous calcium or bone deposition (osteoma cutis), precocious puberty, mild cognitive deficit</td> </tr> <tr class=\"divider_top\"> <td>Alstr&#246;m (MIM #203800)</td> <td>2p13</td> <td>ALMS1</td> <td>Age 2-5 yrs (central)</td> <td>Blindness, deafness, acanthosis nigricans, chronic nephropathy, type 2 diabetes, cirrhosis, primary hypogonadism in males only, normal cognition</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"15\">Bardet-Biedl (MIM #209900)</td> <td>11q13</td> <td>BBS1</td> <td rowspan=\"15\">Age 1-2 yrs (central)</td> <td rowspan=\"15\">Mental retardation, hypotonia, retinitis pigmentosa, polydactyly, hypogonadism +/&ndash; glucose intolerance, deafness, renal disease</td> </tr> <tr> <td>16q21</td> <td>BBS2</td> </tr> <tr> <td>3p12-q13</td> <td>BBS3 (ARL6)</td> </tr> <tr> <td>15q22.3-q23</td> <td>BBS4</td> </tr> <tr> <td>2q31</td> <td>BBS5</td> </tr> <tr> <td>20p12</td> <td>BBS6 (MKKS)</td> </tr> <tr> <td>4q27</td> <td>BBS7</td> </tr> <tr> <td>14q32</td> <td>BBS8 (TTC8)</td> </tr> <tr> <td>7p14</td> <td>BBS9</td> </tr> <tr> <td>12q</td> <td>BBS10</td> </tr> <tr> <td>9q33.1</td> <td>BBS11 (TRIM32)</td> </tr> <tr> <td>4q27</td> <td>BBS12</td> </tr> <tr> <td>17q23</td> <td>BBS13 (MKS1)</td> </tr> <tr> <td>12q21.3</td> <td>BBS14 (CEP290)</td> </tr> <tr> <td>2p15</td> <td>BBS15 (C2ORF86)</td> </tr> <tr class=\"divider_top\"> <td>Beckwith-Wiedemann (MIM #130650)</td> <td>11p15.5 in most cases; deregulation of imprinted genes including IGF2</td> <td>multiple</td> <td>&ndash;</td> <td>Hyperinsulinemia, hypoglycemia, hemihypertrophy, intolerance of fasting</td> </tr> <tr class=\"divider_top\"> <td>Carpenter (MIM #201000)</td> <td>6p11</td> <td>RAB23</td> <td>(central)</td> <td>Mental retardation, short stature, brachycephaly, polydactyly, syndactyly of feet, cryptorchidism, umbilical hernia, high-arched palate, hypogonadism in males only</td> </tr> <tr class=\"divider_top\"> <td>Cohen (MIM #216550)</td> <td>8q22</td> <td>COH1</td> <td>Mid-childhood (central)</td> <td>Mental retardation, microcephaly, small hands and feet, cryptorchidism, hypotonia and failure to thrive in infancy, prominent central incisors, long, thin fingers and toes</td> </tr> <tr class=\"divider_top\"> <td>Prader-Willi (MIM #176270)</td> <td>15q</td> <td>&nbsp;</td> <td>Age 1-3 yrs (generalized)</td> <td>Microcephaly, short stature, hypotonia, almond- shaped eyes, high-arched palate, narrow hands and feet, delayed puberty, early failure to thrive with hyperphagia and increased weight gain by 2-3 years, mild to moderate cognitive deficit</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><ol>&#xD;&#xA;    <li>Pediatric Obesity. In: Pediatric Nutrition Handbook, 6th ed, Kleinman R (Ed), American Academy of Pediatrics, Elk Grove Village, IL, 2009. p.751.</li>&#xD;&#xA;    <li>Hoppin AG. Obesity. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario, 2004. p.311.</li>&#xD;&#xA;    <li>Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p.3965.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 70658 Version 11.0</div></div></div>"},"70660":{"type":"graphic_picture","displayName":"Duodenal vessel after Rx Endosc","title":"Combination therapy for a bleeding duodenal ulcer with a visible vessel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combination therapy for a bleeding duodenal ulcer with a visible vessel</div><div class=\"cntnt\"><img style=\"width:320px; height:319px;\" src=\"images/GAST/70660_Duodenal_vessel_after_Rx_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appearance of a duodenal ulcer that had a visible vessel following injection therapy with epinephrine and thermal coagulation. Note that the visible vessel has been flattened.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 70660 Version 2.0</div></div></div>"},"70661":{"type":"graphic_figure","displayName":"Vitamin D absorption Crohns","title":"Poor vitamin D absorption in Crohn's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poor vitamin D absorption in Crohn's disease</div><div class=\"cntnt\"><img style=\"width:377px; height:300px;\" src=\"images/ENDO/70661_Vitamin_D_absorption_Crohns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absorption of both CC and 25-HCC are diminished in patients with Crohn's disease who have had intestinal resection compared&nbsp;with normal (control) subjects.</div><div class=\"graphic_footnotes\">25-HCC: 25-hydroxycholicalciferol;&nbsp;CC: cholecalciferol.</div><div class=\"graphic_reference\">Data from: Leichtmann GA, Bengoa JM, Bolt MJG, Sitrin, MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991; 54:548.</div><div id=\"graphicVersion\">Graphic 70661 Version 3.0</div></div></div>"},"70662":{"type":"graphic_picture","displayName":"Kaposis sarcoma lesions","title":"Endobronchial Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:236px; height:224px;\" src=\"images/PULM/70662_Kaposis_sarcoma_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous lesions of Kaposi's sarcoma in a large airway as visualized during bronchoscopy.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 70662 Version 1.0</div></div></div>"},"70663":{"type":"graphic_figure","displayName":"Hip joint PI","title":"Hip joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip joint</div><div class=\"cntnt\"><img style=\"width:431px; height:586px;\" src=\"images/PI/70663_Hip_joint_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hip joint is a \"ball and socket joint.\" The round part at the top of the thigh bone, or femur, fits into the \"socket\" in the pelvis.&nbsp;</div><div id=\"graphicVersion\">Graphic 70663 Version 6.0</div></div></div>"},"70664":{"type":"graphic_figure","displayName":"Pediatric coronoid fracture classification","title":"Pediatric coronoid fracture classification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediatric coronoid fracture classification</div><div class=\"cntnt\"><img style=\"width:253px; height:572px;\" src=\"images/EM/70664_Coronoidfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Type I: Avulsion of the tip of the coronoid.<br> (B) Type II: A single or somminuted fragment involving ≤50 percent of the coronoid process.<br> (C) Type III: A single or comminuted fragment involving &gt;50 percent of the coronoid process.</div><div class=\"graphic_reference\">Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70664 Version 8.0</div></div></div>"},"70665":{"type":"graphic_figure","displayName":"Superficial veins of hand and forearm","title":"Superficial veins of the hand and forearm","html":"<div class=\"graphic\"><div style=\"width: 711px\" class=\"figure\"><div class=\"ttl\">Superficial veins of the hand and forearm</div><div class=\"cntnt\"><img style=\"width:691px; height:586px;\" src=\"images/EM/70665_Superveinhandforearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The digital veins drain into the dorsal venous network on the dorsum of the hand, which leads to two prominent superficial vessels: the cephalic and basilic veins.<br> (B) The basilic and cephalic veins ultimately drain into the origin and termination of the axillary vein, respectively. The median cubital vein is the communication between the basilic and the cephalic veins in the cubital fossa. Perforating veins connect the superficial veins to the deep veins. Arrows indicate the flow of lymph within lymphatic vessels that converge toward the vein and drain into the cubital and axillary lymph nodes.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70665 Version 9.0</div></div></div>"},"70666":{"type":"graphic_figure","displayName":"Surfactant effect on lung pressure-volume","title":"Surfactant effect on lung pressure-volume in preterm rabbits","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surfactant effect on lung pressure-volume in preterm rabbits</div><div class=\"cntnt\"><img style=\"width:428px; height:304px;\" src=\"images/PEDS/70666_Surfectant_press_vol_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure-volume relationships for the inflation and deflation of surfactant-deficient and surfactant-treated preterm rabbit lungs. The control lungs are from 27-day preterm rabbits. Rabbits with surfactant deficiency have high opening pressure, low maximal volume at a distending pressure of 35 cm H<sub>2</sub>O, and the lack of deflation stability at low pressures on deflation (orange squares). In contrast, treatment of 27-day preterm rabbits with a natural surfactant alters the pressure-volume relationships with lower opening pressure, improved maximal volume at a distending pressure of 35 cm H<sub>2</sub>O, and deflation stability at low deflating pressures (green circles).</div><div class=\"graphic_reference\">Reproduced from: Jobe AH. Lung development and maturation. In: Fanaroff &amp; Martin's Neonatal-Perinatal Medicine - Diseases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier, St. Louis 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70666 Version 3.0</div></div></div>"},"70667":{"type":"graphic_table","displayName":"Causes of anaphylaxis","title":"Causes of anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes&nbsp;of anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Allergens (IgE-dependent immunologic mechanism)</td> </tr> <tr> <td class=\"indent1\">Foods, especially peanut, tree nut, crustacean shellfish, finned fish, milk, egg</td> </tr> <tr> <td class=\"indent1\">Insect stings (eg, Hymenoptera venom) and insect bites (eg, kissing bugs)</td> </tr> <tr> <td class=\"indent1\">Medications (eg, antibiotics, NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Biologic materials, including allergen immunotherapy, monoclonal antibodies, chemotherapy agents, and vaccines*</td> </tr> <tr> <td class=\"indent1\">Natural rubber latex</td> </tr> <tr> <td class=\"indent1\">Food additives, including spices, insect-derived colorants (eg, carmine), and vegetable gums</td> </tr> <tr> <td class=\"indent1\">Inhalants (rare) (eg, horse dander, cat dander, grass pollen)</td> </tr> <tr> <td class=\"indent1\">Human seminal fluid (rare trigger of anaphylaxis in women)</td> </tr> <tr> <td class=\"indent1\">Occupational allergens (eg, stinging insects, natural rubber latex)</td> </tr> <tr> <td class=\"subtitle1_single\">Immunologic triggers (IgE-independent mechanism)</td> </tr> <tr> <td class=\"indent1\">IgG-dependent (rare) (eg, to high-molecular weight dextran, infliximab)</td> </tr> <tr> <td class=\"indent1\">Coagulation system activation (eg, heparin contaminated with oversulfated chondroitin sulfate)</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic anaphylaxis</td> </tr> <tr> <td class=\"indent1\">Consider the possibility of a hidden or previously unrecognized trigger</td> </tr> <tr> <td class=\"indent1\">Consider the possibility of a mast cell activation syndrome, including systemic mastocytosis</td> </tr> <tr> <td class=\"subtitle1_single\">Nonimmunologic triggers (direct activation of mast cells and basophils)</td> </tr> <tr> <td class=\"indent1\">Physical factors (eg, exercise<sup>&#182;</sup>, cold, heat)</td> </tr> <tr> <td class=\"indent1\">Medications (eg, opioids, NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Radiocontrast agents</td> </tr> <tr> <td class=\"indent1\">Alcohol (ethanol) (may augment, rarely induces)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Any food, insect sting or bite, or medication or biologic can potentially trigger anaphylaxis. Novel or unusual allergen triggers include storage mite-contaminated flour and saliva from kissing bugs. They also include&nbsp;mosquitoes, pigeon ticks, green ants, and pharaoh ants and venoms from jellyfish, scorpions, and snakes. Medications include taxanes, platins, and other chemotherapy drugs, biologic agents, including monoclonal antibodies, such as rituximab, cetuximab, infliximab, and uncommonly, omalizumab. Some triggers, such as <FONT color=black>radiocontrast media, </FONT>insect venoms, <FONT color=black>and</FONT> medications (such as NSAIDs) can act through more than one mechanism.</div><div class=\"graphic_footnotes\"><FONT color=black></FONT>IgE: immunoglobulin E; NSAIDs: nonsteroidal anti-inflammatory drugs; IgG: immunoglobulin G.<br /><FONT color=black>* Reactions to vaccines are rare and typically involve an excipient, such as gelatin, rather than microbial content.</FONT><br />¶&nbsp;Often involves a cofactor, such as a food, medication (eg, an NSAID), or exposure to cold air or water.</div><div id=\"graphicVersion\">Graphic 70667 Version 22.0</div></div></div>"},"70668":{"type":"graphic_table","displayName":"Features of Mansonella spp II","title":"Features of mansonella species causing human infection - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of mansonella species causing human infection - II</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&nbsp;</td> <td class=\"subtitle1\"><em>M. streptocera</em></td> <td class=\"subtitle1\"><em>M. ozzardi</em></td> <td class=\"subtitle1\"><em>M. perstans</em></td> </tr> <tr> <td class=\"subtitle2_left\">Diagnosis</td> <td>Microfilariae in skin snips. Differentiated from mf&nbsp;of <em>Onchocerca volvulus</em> by small size (180 to 240 micrometers) and characteristic sharp curve in tip of tail (\"shepherd's crook\").</td> <td>Microfilariae in blood and occasionally in skin snips. Differentiated from other circulating mf by lack of significant periodicity, small size (170 to 240 micrometers long), absence of sheath, and absence of terminal nuclei.</td> <td>Microfilariae in blood (or rarely&nbsp;serosal effusions). Differentiated from other circulating mf by lack of significant periodicity, small size (190 to 200 micrometers), absence of sheath, and round terminal nucleus at the tip of the tail.</td> </tr> <tr> <td class=\"subtitle2_left\">Other laboratory findings</td> <td>Peripheral eosinophilia is common.</td> <td>Peripheral eosinophilia is common.</td> <td>Peripheral eosinophilia and elevated serum IgE are common.</td> </tr> <tr> <td class=\"subtitle2_left\">Treatment</td> <td>Diethylcarbamazine (6 mg/kg/day&nbsp;orally for 14 days) is effective against adults and microfilariae but associated with significant side effects. Ivermectin (150 mcg/kg orally) is effective in reducing microfilariae.<sup>[1]</sup></td> <td>Ivermectin (200 mcg/kg orally) is the treatment of choice.<sup>[2-3] </sup>Diethylcarbamazine is ineffective.<sup>[4]</sup></td> <td>Recommend therapy with albendazole (400 mg&nbsp;orally&nbsp;twice daily&nbsp;for 10 days) or mebendazole (100 mg&nbsp;orally&nbsp;twice daily&nbsp;for 30 days) is generally ineffective.<sup>[5]</sup> Doxycycline (200 mg&nbsp;orally daily for six weeks) clears microfilariae for up to 36 months.<sup>[6]</sup></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>Fischer P, et al. J Infect Dis 1999; 180:1403.</LI>&#xD;&#xA;<LI>Nutman TB, et al. J Infect Dis 1987; 156:662</LI>&#xD;&#xA;<LI>Gonzalez, AA, et al. West Indian Med J 1999; 48:231.</LI>&#xD;&#xA;<LI>Bartholomew CF, et al. Trans R Soc Trop Med Hyg 1978; 72:423.</LI>&#xD;&#xA;<LI>Bregani ER, et al. Trans R Soc Trop Med Hyg 2006; 100:458.</LI>&#xD;&#xA;<LI>Coulibaly YI, et al. N Eng J Med 2009; 361:1448.<br /></LI></OL></div><div id=\"graphicVersion\">Graphic 70668 Version 4.0</div></div></div>"},"70669":{"type":"graphic_table","displayName":"Treatment of odontogenic infections in adults","title":"Antimicrobial regimens for odontogenic soft tissue infections in adults*<sup>¶</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial regimens for odontogenic soft tissue infections in adults*<sup>&para;</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical entity</td> <td class=\"subtitle1\">Common causative organisms</td> <td class=\"subtitle1\">Antimicrobial regimens</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Odontogenic deep space infections</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Normal hosts</td> <td class=\"divider_bottom\" rowspan=\"5\"><em>Viridans</em> and other streptococci, <em>Peptostreptococcus</em> spp, <em>Bacteroides</em> spp, and other oral anaerobes</td> <td>Ampicillin-sulbactam 3 g IV every six hours <strong>OR</strong></td> </tr> <tr> <td>Penicillin G 2 to 4 MU IV every four to six hours <strong>PLUS</strong><br /> Metronidazole 500 mg IV or PO every eight hours <strong>OR</strong></td> </tr> <tr> <td>Cefoxitin 1 to 2 g IV every four hours <strong>OR</strong></td> </tr> <tr> <td>Cefotetan 2 g IV every 12 hours <strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Clindamycin 600 mg IV every six to eight hours<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"6\">Immunocompromised hosts</td> <td rowspan=\"6\"><em>Viridans</em> and other streptococci, <em>Peptostreptococcus</em> spp, <em>Bacteroides</em> spp, and other oral anaerobes, facultative gram-negative bacilli (including <em>Pseudomonas aeruginosa</em>)</td> <td>Piperacillin-tazobactam 4.5 g IV every six hours <strong>OR</strong></td> </tr> <tr> <td>Imipenem-cilastatin 500 mg IV every six hours <strong>OR</strong></td> </tr> <tr> <td>Meropenem 1 g IV every eight hours <strong>OR</strong></td> </tr> <tr> <td class=\"sublist1_start\">Cefepime 1 to 2 g IV every 12 hours <strong>PLUS</strong> either:</td> </tr> <tr> <td class=\"sublist2\"> <p>Clindamycin 600 mg IV every six to eight hours</p> <p><strong>OR</strong></p> Metronidazole 500 mg IV every eight hours <strong>OR</strong> </td> </tr> <tr> <td> <p>Metronidazole 500 mg IV every eight hours</p> <p><strong>PLUS</strong><br /> Ciprofloxacin 400 mg IV every 12 hours<sup>&#182;</sup> </p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; MU: million units; PO: by mouth.<br />* The doses recommended in this table are intended for patients with normal renal and hepatic function.<br />&para; Local and institutional rates of antibiotic resistance should be considered before choosing an antibiotic regimen. This is particularly important for immunocompromised patients, since there are substantial rates of fluoroquinolone resistance among <em>Pseudomonas aeruginosa</em> and other gram-negative bacteria in some regions.<br />&Delta; We reserve clindamycin for penicillin-allergic patients. Resistance to clindamycin among <em>Prevotella</em> and <em>Porphyromonas</em> spp is increasingly reported.</div><div id=\"graphicVersion\">Graphic 70669 Version 8.0</div></div></div>"},"70672":{"type":"graphic_figure","displayName":"Doppler effect echocardiography","title":"Doppler effect with moving structures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler effect with moving structures</div><div class=\"cntnt\"><img style=\"width:417px; height:493px;\" src=\"images/CARD/70672_Doppler_effect_echocardiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pairs of transmitting (T) and receiving (R) transducers illustrate the Doppler effect as it occurs in relationship to targets that are stationary, moving toward, or moving away from the transducer. With a stationary target (panel A), the carrier frequency [f(t)] from the transmitting transducer strikes the target and is reflected back to the receiving transducer at the reflected frequency [f(r)], which is unaltered. An increase in f(r) is seen with a target moving toward the transducer (panel B), while f(r) is reduced with a target moving away from the transducer (panel C). In all cases, the extent to which f(t) is increased or reduced is proportional to the velocity of the target.</div><div id=\"graphicVersion\">Graphic 70672 Version 1.0</div></div></div>"},"70673":{"type":"graphic_figure","displayName":"Progression of fetal acidosis","title":"Continuum of respiratory to metabolic acidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuum of respiratory to metabolic acidosis</div><div class=\"cntnt\"><img style=\"width:176px; height:168px;\" src=\"images/OBGYN/70673_Progression_of_fetal_acidos.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70673 Version 1.0</div></div></div>"},"70675":{"type":"graphic_diagnosticimage","displayName":"Lumbar burst fracture","title":"Lumbar burst fracture","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Lumbar burst fracture</div><div class=\"cntnt\"><img style=\"width:483px; height:512px;\" src=\"images/EM/70675_Lumbarburstfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior (A) and lateral (B) radiographs demonstrating a L3 burst fracture with retropulsion of bony fragments into the spinal canal noted on an axial CT image (C).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Whang PW, Vaccaro AR. Fractures and dislocations of the thoracolumbar spine. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RB, (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 70675 Version 9.0</div></div></div>"},"70676":{"type":"graphic_table","displayName":"ACL hi risk sports","title":"Sports associated with increased risk of ACL injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sports associated with increased risk of ACL injury</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Football (ie, Soccer)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>American football</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Basketball</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Volleyball</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gymnastics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Team handball</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Downhill skiing</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Note: virtually any sport that involves explosive running, jumping, or sudden changing of direction places the athlete at risk for ACL injury.</div><div class=\"graphic_footnotes\">ACL: anterior cruciate ligament.</div><div id=\"graphicVersion\">Graphic 70676 Version 1.0</div></div></div>"},"70680":{"type":"graphic_diagnosticimage","displayName":"Post fossa ependymoma MRI","title":"Posterior fossa ependymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior fossa ependymoma</div><div class=\"cntnt\"><img style=\"width:331px; height:307px;\" src=\"images/ONC/70680_Post_fossa_ependymoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1 weighted sagittal MR image of the brain without contrast identifies a large hypointense mass in the posterior fossa (arrow).</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Mark Kieran, MD.</div><div id=\"graphicVersion\">Graphic 70680 Version 5.0</div></div></div>"},"70683":{"type":"graphic_table","displayName":"Clinical progression of transtentorial herniation","title":"Clinical progression of transtentorial herniation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical progression of transtentorial herniation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Headache</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Altered level of consciousness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dilation of ipsilateral pupil</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Cranial nerve III palsy</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Ptosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Loss of medial gaze</td>\n    </tr>\n    <tr>\n\n      <td>Decerebrate posturing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemiparesis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dilation of opposite pupil</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alteration of respiration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bradycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypertension</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Respiratory arrest</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 70683 Version 2.0</div></div></div>"},"70684":{"type":"graphic_picture","displayName":"Low Dye foot taping","title":"Foot taping for plantar fasciitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Foot taping for plantar fasciitis</div><div class=\"cntnt\"><img style=\"width:540px; height:310px;\" src=\"images/RHEUM/70684_Low_Dye_foot_taping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A technique for taping the foot to treat plantar fasciitis is illustrated. The four panels show the technique from left to right. Panel 1:&nbsp;A strip of adhesive tape (the metatarsal strip) is applied in a circumferential fashion at the level of the metatarsal heads. Panel 2:&nbsp;A strip of tape is started at the lateral aspect of the plantar surface of the metatarsal strip, is applied diagonally across the sole, around the heel, along the lateral border of the foot, and ends on the metatarsal strip. Panels 3 and 4: The third and fourth strips are started at the lateral aspect of the metatarsal strip, are carried around the heel, and end on the metatarsal strip near the base of the great toe.</div><div id=\"graphicVersion\">Graphic 70684 Version 3.0</div></div></div>"},"70685":{"type":"graphic_table","displayName":"BAL studies in immunocompromised hosts with pneumonia","title":"Studies on bronchoalveolar lavage fluid for the assessment of pneumonia in immunocompromised hosts*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies on bronchoalveolar lavage fluid for the assessment of pneumonia in immunocompromised hosts*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of infection or condition</td> <td class=\"subtitle1\">Direct smear/stain</td> <td class=\"subtitle1\">Culture</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td>Bacteria</td> <td>Gram stain</td> <td>Aerobic and anaerobic culture</td> <td>&nbsp;</td> </tr> <tr> <td>Fungi &ndash; molds</td> <td>Calcofluor white/KOH preparation, silver stain</td> <td>Fungal culture<sup>&#182;</sup></td> <td><em>Aspergillus</em> galactomannan antigen, PCR</td> </tr> <tr> <td>Fungi &ndash; endemic</td> <td>Calcofuor white/KOH preparation</td> <td>Fungal culture</td> <td><em>Histoplasma</em> antigen</td> </tr> <tr> <td>Mycobacteria</td> <td>AFB stain</td> <td>Mycobacterial culture</td> <td>&nbsp;</td> </tr> <tr> <td><em>Pneumocystis jirovecii </em>(formerly <em>P. carinii</em>)</td> <td>Fluorescein-conjugated monoclonal antibody<sup>&#916;</sup>​, cytology</td> <td>N/A</td> <td>PCR</td> </tr> <tr> <td><em>Nocardia</em> spp</td> <td>Modified AFB stain</td> <td>Culture<sup>&#9674;</sup></td> <td>&nbsp;</td> </tr> <tr> <td><em>Legionella</em> spp</td> <td>Modified Gimenez stain</td> <td><em>Legionella</em> culture <span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">using&nbsp;BCYE medium<sup>&#167;</sup></span></td> <td>Direct fluorescent antibody</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> <td>N/A</td> <td>N/A</td> <td>PCR</td> </tr> <tr> <td class=\"sublist_other_start\" colspan=\"4\">Viruses</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> <td>N/A</td> <td>Shell vial culture, <span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">viral culture<sup>&#165;</sup></span></td> <td>PCR, cytology<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Influenza virus</td> <td>N/A</td> <td>Viral culture</td> <td>PCR, direct or indirect fluorescent antibody, rapid antigen test<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\">Parainfluenza virus</td> <td>N/A</td> <td>Viral culture</td> <td>PCR, direct or indirect fluorescent antibody</td> </tr> <tr> <td class=\"indent1\">Respiratory syncytial virus</td> <td>N/A</td> <td>Viral culture</td> <td>PCR, rapid antigen test<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> <td>N/A</td> <td>Viral culture</td> <td>PCR</td> </tr> <tr> <td class=\"indent1\">Human metapneumovirus</td> <td>N/A</td> <td>N/A</td> <td>PCR, direct fluorescent antibody</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>N/A</td> <td>Viral culture<sup>&#134;</sup></td> <td>PCR, direct fluorescent antibody<sup>&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> <td>N/A</td> <td>Viral culture</td> <td>PCR, direct fluorescent antibody</td> </tr> <tr> <td class=\"indent1\">Middle East respiratory&nbsp;syndrome coronavirus&nbsp;</td> <td>N/A</td> <td>N/A</td> <td>PCR</td> </tr> <tr> <td>Malignancy**</td> <td>Cytology (Wright-Giemsa stain, Papanicolaou stain)</td> <td>N/A</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KOH: potassium hydroxide; AFB: acid-fast bacillus; N/A: not applicable; BCYE: buffered charcoal yeast extract; PCR: polymerase chain reaction.&nbsp;&nbsp; <br />* The decision of which studies to send depends upon the individual patient's clinical findings and on availability at specific hospital laboratories. When the diagnosis is not established by studies of bronchoalveolar lavage fluid or noninvasive testing, histopathology of lung tissue is often helpful. For detailed discussions regarding the diagnosis of specific causes of pneumonia,&nbsp;refer to the&nbsp;individual UpToDate topic reviews.&nbsp;If mucormycosis is suspected, do not grind culture samples.<br />¶ The detection of <EM>Candida </EM>species from respiratory specimens should generally be interpreted as reflecting colonization of the oropharynx since <EM>Candida</EM> pneumonia is extremely rare. <br />Δ Other stains for <EM>P. jirovecii </EM>include calcofluor white, cresyl echt violet, Gomori methenamine silver, and toluidine blue. <br />◊ Most routine aerobic bacterial, fungal, and mycobacterial culture media can support <EM>Nocardia</EM>, but selective media, such as BCYE, modified Thayer-Martin agar, or Lowenstein-Jensen (LJ) media, may be beneficial in decreasing the overgrowth of other organisms in specimens derived from nonsterile sites.<br />§ If <EM>Legionella</EM> pneumonia is suspected, a <EM>Legionella</EM> urinary antigen should also be obtained.&nbsp;<br />¥ If cytomegalovirus infection is suspected, a peripheral blood sample should also be sent for PCR (from whole blood or plasma) or antigenemia assay (from peripheral blood polymorphonuclear leukocytes). <br />‡ Rapid antigen testing lacks sensitivity. Thus, PCR is considered the gold standard for the detection of respiratory viruses in bronchoalveolar lavage fluid. For patients with a negative rapid antigen test in whom a respiratory virus is suspected, PCR should also be sent.<br />† The detection of herpes simplex virus may represent contamination of the specimen from reactivation within the oropharynx rather than pneumonia.<br />** Cytology is often performed on BAL fluid in immunocompromised hosts to evaluate for malignancy.</div><div id=\"graphicVersion\">Graphic 70685 Version 16.0</div></div></div>"},"70688":{"type":"graphic_table","displayName":"Weakness myotonic dystrophy I and II","title":"Differences in clinical features between myotonic dystrophy type 1 and type 2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences in clinical features between myotonic dystrophy type 1 and type 2</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Adult-onset myotonic dystrophy type 1</td> <td class=\"subtitle1\">Myotonic dystrophy type 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Genetics</td> </tr> <tr> <td class=\"indent1\">Inheritance</td> <td>Autosomal dominant</td> <td>Autosomal dominant</td> </tr> <tr> <td class=\"indent1\">Anticipation</td> <td>Pronounced</td> <td>Exceptionally rare</td> </tr> <tr> <td class=\"indent1\">Congenital form</td> <td>Yes</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Chromosome</td> <td>19q13.3</td> <td>3q21.3</td> </tr> <tr> <td class=\"indent1\">Locus</td> <td><em>DMPK</em></td> <td><em>CNBP</em></td> </tr> <tr> <td class=\"indent1\">Expansion mutation</td> <td>(CTG)<sun />n</td> <td>(CCTG)<sun />n</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Location of the expansion</td> <td>3' untranslated region</td> <td>Intron 1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Core features</td> </tr> <tr> <td class=\"indent1\">Clinical myotonia</td> <td>Typical in adult onset</td> <td>Present in less than 50%</td> </tr> <tr> <td class=\"indent1\">Myotonia on electromyography</td> <td>Generally present</td> <td>Absent and variable in many patients; needs detailed investigation</td> </tr> <tr> <td class=\"indent1\">Muscle weakness</td> <td>Disability often by age 30 to 50 years</td> <td>Disability at age 60 to 85 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cataracts</td> <td>Generally present</td> <td>Present in a few patients at diagnosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Localization of muscle weakness</td> </tr> <tr> <td class=\"indent1\">Face or jaw</td> <td>Generally present</td> <td>Usually absent</td> </tr> <tr> <td class=\"indent2\">Ptosis</td> <td>Often present</td> <td>Rare, mild, or moderate</td> </tr> <tr> <td class=\"indent1\">Bulbar (dysphagia)</td> <td>Generally present later in life</td> <td>Not present</td> </tr> <tr> <td class=\"indent1\">Respiratory muscles</td> <td>Generally present later in life</td> <td>Exceptionally rare cases</td> </tr> <tr> <td class=\"indent1\">Distal limb muscle</td> <td>Generally prominent</td> <td>Flexor digitorum profundus in some patients</td> </tr> <tr> <td class=\"indent1\">Proximal limb muscle</td> <td>Can be absent for many years</td> <td>Main disability in most patients, late onset</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sternocleidomastoid muscle</td> <td>Generally prominent</td> <td>Prominent in few patients</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Muscular symptoms</td> </tr> <tr> <td class=\"indent1\">Myalgic pain</td> <td>Absent or moderate</td> <td>Most disabling symptom in many patients</td> </tr> <tr> <td class=\"indent1\">Muscle strength variations</td> <td>Occasional</td> <td>Can be considerable</td> </tr> <tr> <td class=\"indent1\">Visible muscle atrophy</td> <td>Face, temporal, distal hands, and legs</td> <td>Usually absent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Calf hypertrophy</td> <td>Absent</td> <td>Present in at least 50%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Laboratory findings</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Concentration of creatine kinase in serum</td> <td>Normal-to-moderate increase</td> <td>Normal-to-moderate increase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Muscluar biopsy findings</td> </tr> <tr> <td class=\"indent1\">Fiber atrophy</td> <td>Smallness of type 1 fibers</td> <td>Highly atrophic type 2 fibers</td> </tr> <tr> <td class=\"indent1\">Nuclear clump fibers</td> <td>In late stage only</td> <td>Scattered early before weakness</td> </tr> <tr> <td class=\"indent1\">Sarcoplasmic masses</td> <td>Very frequent in distal muscles</td> <td>Very rare</td> </tr> <tr> <td class=\"indent1\">Ring fibers</td> <td>Frequent</td> <td>May occur</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Internal nuclei</td> <td>Massive in distal muscle</td> <td>Variable and mainly in type 2 fibers</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiac symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Conduction defects</td> <td>Common</td> <td>Highly variable, absent to severe</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other neurological symptoms</td> </tr> <tr> <td class=\"indent1\">Tremors</td> <td>Absent</td> <td>Prominent in many patients</td> </tr> <tr> <td class=\"indent1\">Behavioral changes</td> <td>Common</td> <td>Not apparent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypersomnia</td> <td>Prominent</td> <td>Infrequent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other features</td> </tr> <tr> <td class=\"indent1\">Manifest diabetes</td> <td>Occasional</td> <td>Infrequent</td> </tr> <tr> <td class=\"indent1\">Frontal balding in men</td> <td>Generally present</td> <td>Exceptional</td> </tr> <tr> <td class=\"indent1\">Incapacity (work and activities of daily living)</td> <td>Typically after age 30 to 35 years</td> <td>Rarely younger than 60 years, unless severe pain</td> </tr> <tr> <td class=\"indent1\">Life expectancy</td> <td>Reduced</td> <td>Normal</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Originally published in Acta Neuropathologica, Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2, Vol. 119, 2010, p. 465, Vihola A, Bachinski LL, Sirito M, et al, © Springer-Verlag 2010. Modified with permission of Springer. Reproduced from: Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11:891. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70688 Version 3.0</div></div></div>"},"70689":{"type":"graphic_diagnosticimage","displayName":"Ampullary cancer ENDO","title":"Ampullary cancer endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ampullary cancer endoscopy</div><div class=\"cntnt\"><img style=\"width:329px; height:324px;\" src=\"images/ONC/70689_Ampullary_cancer_ENDO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of an ampullary carcinoma. Note the nodular appearance of the tumor.</div><div class=\"graphic_reference\">Courtesy of David Carr-Locke, MD.</div><div id=\"graphicVersion\">Graphic 70689 Version 2.0</div></div></div>"},"70692":{"type":"graphic_figure","displayName":"Fat pad sign","title":"Radiographic variations of the elbow fat pads","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Radiographic variations of the elbow fat pads</div><div class=\"cntnt\"><img style=\"width:568px; height:434px;\" src=\"images/EM/70692_Ftpdsgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal relationships of the two fat pads.<br />(B) Displacement of both fat pads (arrows) with an intraarticular effusion.<br />(C) In some cases, the effusion may displace only the anterior fat pad (arrows).<br />(D) In extension, the posterior fat pad is normally displaced by the olecranon.<br />(E) An extraarticular fracture may lift the distal periosteum and displace the proximal portion of the posterior fat pad.<SUP>[1]</SUP><br />(F) A radiograph showing displacement of both fat pads (arrows) from an intraarticular effusion.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Redrawn from: Murphy WA, Siegel MJ. Elbow fat pads with new signs and extended differential diagnosis. Radiology 1977; 124:656.</LI></OL>Reproduced with permission from: Beaty JH, Kasser JR. Evaluation of Pediatric Distal Humeral Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins.&nbsp;<A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70692 Version 16.0</div></div></div>"},"70693":{"type":"graphic_picture","displayName":"Hyperpigmentation Nelson syndrome","title":"Hyperpigmentation due to ACTH excess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperpigmentation due to ACTH excess</div><div class=\"cntnt\"><img style=\"width:360px; height:230px;\" src=\"images/ENDO/70693_Hyperpigmentation_Nelsons_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right hand of a 16-year-old woman with Nelson syndrome (right) next to that of a woman without endocrine disease (left), demonstrating skin hyperpigmentation that is accentuated over the knuckles (which are areas of repeated trauma). Similar hyperpigmentation occurs in patients with other causes of chronic ACTH excess, such as Cushing's disease or primary adrenal insufficiency.</div><div class=\"graphic_footnotes\">ACTH: corticotropin.</div><div class=\"graphic_reference\">Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 70693 Version 4.0</div></div></div>"},"70694":{"type":"graphic_picture","displayName":"Lipseal-nasal prong NPPV","title":"Lipseal-nasal prong NPPV","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Lipseal-nasal prong NPPV</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/PULM/70694_Lipseal-nasal_prong_NPPV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John R Bach, MD.</div><div id=\"graphicVersion\">Graphic 70694 Version 4.0</div></div></div>"},"70695":{"type":"graphic_figure","displayName":"Normal cardiac hemodynamics","title":"Normal cardiac hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal cardiac hemodynamics</div><div class=\"cntnt\"><img style=\"width:283px; height:403px;\" src=\"images/CARD/70695_Normal_cardiac_hemodynamics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal cardiac hemodynamics during cardiac catheterization wth a hi-fidelity catheter. One can see the relationships between the surface ECG and simultaneous pressure waves from the aorta (Ao), left ventricle (LV), right atrium (RA), left atrium (LA), and rate of pressure change (dp/dt).</div><div class=\"graphic_reference\">Reproduced with permission from Kern, MJ (Ed). Cardiac Catheterization Handbook, 2nd ed, Mosby-Year Book, Inc, St. Louis.</div><div id=\"graphicVersion\">Graphic 70695 Version 1.0</div></div></div>"},"70696":{"type":"graphic_picture","displayName":"Tracheal stenosis gross","title":"Tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:366px; height:252px;\" src=\"images/PULM/70696_Tracheal_stenosis_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Resected surgical specimen demonstrates a critically narrowed segmant of the trachea, with an internal diameter of only 5-6mm.</div><div class=\"graphic_reference\">Courtesy of Hermes Grillo, MD.</div><div id=\"graphicVersion\">Graphic 70696 Version 1.0</div></div></div>"},"70698":{"type":"graphic_picture","displayName":"Eyelid laceration with orbital fat prolapse","title":"Eyelid laceration with orbital fat prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eyelid laceration with orbital fat prolapse</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/70698_Eyelid_lacer_orbit_fat_prol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of orbital fat in an eyelid laceration indicates damage to the orbital septum and possibly to the underlying levator muscle. Ophthalmology consultation should be obtained.</div><div class=\"graphic_reference\">Courtesy of Peter A D Rubin, MD.</div><div id=\"graphicVersion\">Graphic 70698 Version 1.0</div></div></div>"},"70699":{"type":"graphic_picture","displayName":"Biceps tendon palpation","title":"Biceps tendon palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biceps tendon palpation</div><div class=\"cntnt\"><img style=\"width:432px; height:277px;\" src=\"images/EM/70699_Biceps_tendon_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpation over the proximal long head biceps tendon at the bicipital groove should elicit tenderness if tendinopathy is present. Common problems in examining the biceps tendon include palpating too distally and attempting the examination with the shoulder internally rotated.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD and Bryan Dixon, MD.</div><div id=\"graphicVersion\">Graphic 70699 Version 2.0</div></div></div>"},"70700":{"type":"graphic_movie","displayName":"otoscopy","title":"Pneumatic otoscopy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatic otoscopy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/70700_otoscopyconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:288px; height:288px;\" src=\"images/CARD/70700_otoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 70700 Version 2.0</div></div></div>"},"70704":{"type":"graphic_diagnosticimage","displayName":"Distal basilar artery embolism","title":"MRI images in distal basilar artery embolism","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">MRI images in distal basilar artery embolism</div><div class=\"cntnt\"><img style=\"width:540px; height:402px;\" src=\"images/NEURO/70704_Distal_basilar_artery_embol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted images (A&amp;B) show high signal intensity in the bilateral cerebellar hemispheres (left more than right), pons, and right thalamus. As compared with RPL, diffusion-weighted images (C&amp;D) show marked high signal in these regions and ADC maps (E&amp;F) show low signal consistent with restricted diffusion and infarct.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; RPL: reversible posterior leukoencephalopathy; ADC: apparent diffusion coefficient. </div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 70704 Version 3.0</div></div></div>"},"70705":{"type":"graphic_table","displayName":"Ogilvy Carter grading system","title":"Ogilvy and Carter grading system to predict outcome for surgical management of intracranial aneurysms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ogilvy and Carter grading system to predict outcome for surgical management of intracranial aneurysms</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Criteria</td>\n\n      <td class=\"subtitle1\">Points</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Age 50 or less</td>\n\n      <td>0</td>\n\n    </tr>\n\n    <tr>\n      <td>Age greater than 50</td>\n      <td>1</td>\n    </tr>\n    <tr>\n      <td>Hunt and Hess grade 0 to 3 (no coma)</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <td>Hunt and Hess grade 4 and 5 (in coma)</td>\n      <td>1</td>\n    </tr>\n    <tr>\n      <td>Fisher scale score 0 to 2</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <td>Fisher scale score 3 and 4</td>\n      <td>1</td>\n    </tr>\n    <tr>\n      <td>Aneurysm size 10 mm or less</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <td>Aneurysm size greater than 10 mm</td>\n      <td>1</td>\n    </tr>\n    <tr>\n      <td>Giant posterior circulation aneurysm size 25 mm or more</td>\n      <td>1</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">The total score ranges from 0 to 5, corresponding to grades 0 to 5</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Ogilvy, CS, Carter, BS. A proposed comprehensive grading system to predict outcome for surgical management of intracranial aneurysms. Neurosurgery 1998; 42:959.</div><div id=\"graphicVersion\">Graphic 70705 Version 1.0</div></div></div>"},"70706":{"type":"graphic_table","displayName":"Classification ileal pouch","title":"Classification of ileal pouch disorders and associated complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of ileal pouch disorders and associated complications</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"9\">\r\n  \r\n   Surgical and mechanical\r\n  \r\n   </td>\r\n  \r\n   <td>Anastomotic leaks</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pelvic sepsis and abscess</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pouch sinuses</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pouch fistulae</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Strictures</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Afferent limb syndrome and efferent limb syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Infertility and sexual dysfunction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Portal vein thrombi</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pouch prolapse, twisted pouch bleeding, sphincter injury or dysfunction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"5\">\r\n  \r\n   Inflammatory and infectious\r\n  \r\n   </td>\r\n  \r\n   <td>Pouchitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cuffitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>CD of the pouch</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Proximal small-bowel bacterial overgrowth</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inflammatory polyps</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"3\">\r\n  \r\n   Functional\r\n  \r\n   </td>\r\n  \r\n   <td>Irritable pouch syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anismus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pseudo-obstruction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"2\">\r\n  \r\n   Dysplastic and neoplastic\r\n  \r\n   </td>\r\n  \r\n   <td>Dysplasia or cancer of the pouch</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dysplasia or cancer of the anastomosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"3\">\r\n  \r\n   Systemic and metabolic\r\n  \r\n   </td>\r\n  \r\n   <td>Anemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bone loss</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Vitamin B-12 deficiency</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Shen, B, Remzi, FH, Lavery, IC, et al. A Proposed Classification of Ileal Pouch Disorders and Associated Complications After Restorative Proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145. Copyright &#169;2008 Elsevier.</div><div id=\"graphicVersion\">Graphic 70706 Version 1.0</div></div></div>"},"70707":{"type":"graphic_table","displayName":"Causes of cardiac arrest in pregnancy","title":"Some causes of cardiac arrest in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some causes of cardiac arrest in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pulmonary causes</td> </tr> <tr> <td>Embolism</td> </tr> <tr> <td>Thromboembolism</td> </tr> <tr> <td>Amniotic fluid embolism</td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac causes</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Congenital valvular disease</td> </tr> <tr> <td>Arrhythmias</td> </tr> <tr> <td>Cardiomyopathy of pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Hemorrhagic causes</td> </tr> <tr> <td>Uterine atony</td> </tr> <tr> <td>Abnormally adherent placentation</td> </tr> <tr> <td>Abruptio placentae</td> </tr> <tr> <td>Placenta previa</td> </tr> <tr> <td>Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"subtitle1_single\">Infection/sepsis</td> </tr> <tr> <td class=\"subtitle1_single\">Anesthesia-related causes</td> </tr> <tr> <td>Failed intubation</td> </tr> <tr> <td>Aspiration</td> </tr> <tr> <td>Intravascular injection of local anesthetics</td> </tr> <tr> <td>High neuraxial block</td> </tr> <tr> <td class=\"subtitle1_single\">Hypertensive complications</td> </tr> <tr> <td>Stroke</td> </tr> <tr> <td>Preeclampsia/eclampsia</td> </tr> <tr> <td>Pheochromocytoma&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Medication-related complications</td> </tr> <tr> <td>Tocolytic toxicities</td> </tr> <tr> <td>Illicit drug use</td> </tr> <tr> <td>Hypermagnesemia</td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td>Intimate partner violence</td> </tr> <tr> <td>Motor vehicle accident</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Zelop CM, Grimes EP. Cardiopulmonary resuscitation in pregnancy. In: Textbook of Emergency Cardiovascular Care and CPR, Field JM, Bresler MJ, Mattu A, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 70707 Version 6.0</div></div></div>"},"70708":{"type":"graphic_waveform","displayName":"Saline in occult constriction","title":"Saline loading unmasks occult constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saline loading unmasks occult constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:370px; height:351px;\" src=\"images/CARD/70708_Salineinoccultconstricti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right atrial pressure tracings before (top panel) and after (bottom panel) saline loading in a patient with occult constrictive pericarditis. The previously normal right atrial pressure developed the characteristics of constrictive pericarditis (with equalization of pressures after fluid challenge).</div><div class=\"graphic_reference\">Redrawn from: Bush CA, Stang JM, Wooley CF, Kilman JW. Circulation 1977; 56:924.</div><div id=\"graphicVersion\">Graphic 70708 Version 4.0</div></div></div>"},"70709":{"type":"graphic_diagnosticimage","displayName":"Computed tomography of appendicitis in a child","title":"Computed tomography of appendicitis in a child","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Computed tomography of appendicitis in a child</div><div class=\"cntnt\"><img style=\"width:495px; height:417px;\" src=\"images/EM/70709_CT_of_appendicitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT of the pelvis following administration of intravenous contrast material in an 8-year-old boy with midline pelvic pain, fever, and leucocytosis shows an enlarged, fluid filled, abnormally enhancing appendix and associated mesenteric inflamation to the left of midline (arrow).</div><div class=\"graphic_reference\">Courtesy of George A Taylor, MD.</div><div id=\"graphicVersion\">Graphic 70709 Version 2.0</div></div></div>"},"70710":{"type":"graphic_picture","displayName":"Head-tilt/chin-lift maneuver","title":"Head-tilt/chin-lift maneuver","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Head-tilt/chin-lift maneuver</div><div class=\"cntnt\"><img style=\"width:542px; height:310px;\" src=\"images/EM/70710_Head_tilt_chin_lift_maneuv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To relieve upper airway obstruction, the clinician uses two hands to extend the patient's neck. While one hand applies downward pressure to the patient's forehead, the tips of the index and middle finger of the second hand lift the mandible at the chin, which lifts the tongue from the posterior pharynx. The head-tilt/chin-lift&nbsp;maneuver may be&nbsp;used in any patient in whom cervical spine injury is <STRONG>NOT</STRONG> a concern.</div><div id=\"graphicVersion\">Graphic 70710 Version 6.0</div></div></div>"},"70711":{"type":"graphic_table","displayName":"Antiadrenal antibodies","title":"Incidence of antiadrenal antibodies in patients with autoimmune disease of other endocrine glands","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of antiadrenal antibodies in patients with autoimmune disease of other endocrine glands</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Autoimmune endocrine disease</td> <td class=\"subtitle1\">Incidence of antiadrenal antibodies (%)</td> </tr> <tr> <td>Hypoparathyroidism</td> <td>16</td> </tr> <tr> <td>Goitrous autoimmune thyroiditis</td> <td>1.9</td> </tr> <tr> <td>Atrophic autoimmune thyroiditis</td> <td>1.7</td> </tr> <tr> <td>Hyperthyroidism </td> <td>1.9</td> </tr> <tr> <td>Diabetes mellitus</td> <td>1.2</td> </tr> <tr> <td>Pernicious anemia</td> <td>&#60;1</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70711 Version 2.0</div></div></div>"},"70712":{"type":"graphic_diagnosticimage","displayName":"Ectopic adrenal adenoma CT","title":"Ectopic adrenal adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopic adrenal adenoma</div><div class=\"cntnt\"><img style=\"width:360px; height:278px;\" src=\"images/ENDO/70712_Ectopic_adrenal_adenoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image of a 45-year-old woman with ACTH-independent Cushing's syndrome. A 3 x 3 cm mass, which is a benign ectopic adrenal adenoma, is noted near the left renal pelvis (arrow). This patient had undergone previous bilateral adrenalectomy in the mistaken belief that she had bilateral adrenal micronodular hyperplasia. This was followed by 125-I cholesterol scanning on two occasions, which did not detect the ectopic mass.</div><div class=\"graphic_footnotes\">CT: computed tomography; ACTH: corticotropin; 125-I: Iodine-125.</div><div class=\"graphic_reference\">Courtesy of David N Orth, MD.</div><div id=\"graphicVersion\">Graphic 70712 Version 4.0</div></div></div>"},"70713":{"type":"graphic_picture","displayName":"Placental CMV infection","title":"Cytomegalovirus infection of placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus infection of placenta</div><div class=\"cntnt\"><img style=\"width:393px; height:259px;\" src=\"images/OBGYN/70713_Placental_CMV_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph illustrating placental cytomegalovirus infection. Arrows point to cells with nuclear inclusions.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 70713 Version 3.0</div></div></div>"},"70714":{"type":"graphic_table","displayName":"Diseases of LIP on biopsy","title":"Lymphocytic interstitial pneumonia disease associations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia disease associations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td>Idiopathic without dysproteinemia</td> </tr> <tr> <td>Idiopathic with dysproteinemia</td> </tr> <tr> <td class=\"indent1\">Hypogammaglobulinemia</td> </tr> <tr> <td class=\"indent2\">Adults</td> </tr> <tr> <td class=\"indent2\">Children</td> </tr> <tr> <td class=\"indent1\">Monoclonal gammopathy</td> </tr> <tr> <td class=\"indent1\">Oligoclonal gammopathy</td> </tr> <tr> <td class=\"indent1\">Polyclonal gammopathy</td> </tr> <tr> <td class=\"indent1\">Immunoglobulin G4-related disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Benign hypergammaglobulinemic purpura of Waldenstrom</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"indent1\">Connective tissue disease associated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Primary</td> </tr> <tr class=\"divider_bottom\"> <td>Chronic active hepatitis</td> </tr> <tr class=\"divider_bottom\"> <td>Primary biliary cholangitis</td> </tr> <tr class=\"divider_bottom\"> <td>Myasthenia gravis</td> </tr> <tr class=\"divider_bottom\"> <td>Autoimmune thyroiditis</td> </tr> <tr class=\"divider_bottom\"> <td>Pernicious anemia</td> </tr> <tr class=\"divider_bottom\"> <td>Autoimmune hemolytic anemia</td> </tr> <tr class=\"divider_bottom\"> <td>Systemic lupus erythematosus (SLE)</td> </tr> <tr class=\"divider_bottom\"> <td>Multiple sclerosis</td> </tr> <tr class=\"divider_bottom\"> <td>Multicentric Castleman's disease</td> </tr> <tr class=\"divider_bottom\"> <td>Juvenile rheumatoid arthritis</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary amyloidosis</td> </tr> <tr class=\"divider_bottom\"> <td>Allogenic bone marrow transplantation (graft-versus-host disease)</td> </tr> <tr> <td>Viral infections</td> </tr> <tr> <td class=\"indent1\">Acquired immunodeficiency syndrome (HIV)</td> </tr> <tr> <td class=\"indent2\">Adults</td> </tr> <tr> <td class=\"indent2\">Children</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">Human herpes virus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Human T-cell lymphotrophic virus type 1 (HTLV-1)</td> </tr> <tr> <td>Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Celiac sprue</td> </tr> <tr> <td class=\"indent1\">Dilantin</td> </tr> <tr> <td class=\"indent1\">Post-Legionnaires' pneumonia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Surfactant protein C deficiency</td> </tr> <tr> <td>Familial forms</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From Cosgrove GP &amp; Schwarz MI. Lymphoplasmocytic Infiltrations of the Lung, Table 36-1 (p.1046). In:<EM> Interstitial Lung Disease</EM>, 5th ed, Schwarz MI, King TW, Jr, eds.; used with permission from People's Medical Publishing House-USA (PMPH-USA).</div><div id=\"graphicVersion\">Graphic 70714 Version 6.0</div></div></div>"},"70716":{"type":"graphic_diagnosticimage","displayName":"Post pneumonectomy CT","title":"Pleural calcification after remote right pneumonectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural calcification after remote right pneumonectomy</div><div class=\"cntnt\"><img style=\"width:378px; height:344px;\" src=\"images/PULM/70716_Post_pneumonectomy_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive parietal pleural calcifications after remote right pneumonectomy. CT shows residual liquid in the vacant, small right hemithorax with circumferential dystrophic calcification of the remaining parietal pleura and extensive cardiomediastinal shift to the right. The adjacent right- sided ribs are sclerotic due to postoperative changes.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70716 Version 4.0</div></div></div>"},"70718":{"type":"graphic_table","displayName":"Conditions associated with erythema nodosum","title":"Conditions associated with erythema nodosum in case series*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with erythema nodosum in case series*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Scotland<br /> (1954-68)</td> <td class=\"subtitle1\">New York<br /> (1959-69)</td> <td class=\"subtitle1\">Israel<br /> (1973-82)</td> <td class=\"subtitle1\">France<br /> (1960-95)</td> <td class=\"subtitle1\">Thailand<br /> (1982-92)</td> <td class=\"subtitle1\">Greece<br /> (1984-90)</td> <td class=\"subtitle1\">Spain<br /> (1988-97)</td> <td class=\"subtitle1\">Singapore<br /> (1994-97)</td> </tr> <tr> <td><strong>Idiopathic/unknown</strong></td> <td>17%</td> <td>28%</td> <td>32%</td> <td>55%</td> <td>72%</td> <td>35%</td> <td>34%</td> <td>60%</td> </tr> <tr> <td><strong>Sarcoidosis</strong></td> <td>14%</td> <td>24%</td> <td>1 patient</td> <td>11%</td> <td>0%</td> <td>28%</td> <td>22%</td> <td>0%</td> </tr> <tr> <td><strong>Streptococcal infection</strong></td> <td>48%</td> <td>14%</td> <td>44%</td> <td>28%</td> <td>6%</td> <td> <p>6%</p> </td> <td>7%</td> <td>9%</td> </tr> <tr> <td><strong>TB</strong></td> <td>20%</td> <td>1 patient</td> <td>1 patient</td> <td>1 patient</td> <td>12%</td> <td>1.5%</td> <td>5%</td> <td>3%</td> </tr> <tr> <td><strong>Infections other than TB or strep<sup>&#182;</sup></strong></td> <td>1 patient</td> <td>9%</td> <td>0%</td> <td>2.5%</td> <td>0%</td> <td>11%</td> <td>22%</td> <td>21%</td> </tr> <tr> <td><strong>Pregnancy or OCAs</strong></td> <td>0%</td> <td>0%</td> <td>10%</td> <td>3%</td> <td>0%<sup>&#916;</sup></td> <td>10%</td> <td>1 patient</td> <td>4%</td> </tr> <tr> <td><strong>Drugs other than OCAs</strong></td> <td>0%</td> <td>6%</td> <td>6%</td> <td>0%</td> <td>7%</td> <td>4%</td> <td>2%</td> <td>0%</td> </tr> <tr> <td><strong>Inflammatory bowel disease</strong></td> <td>0%</td> <td>16%</td> <td>1 patient</td> <td>1.5%</td> <td>0%</td> <td>0%</td> <td>3%</td> <td>0%</td> </tr> <tr> <td><strong>Behcet syndrome</strong></td> <td>0%</td> <td>0%</td> <td>0%</td> <td>0%</td> <td>3%</td> <td>4%</td> <td>2%</td> <td>3%</td> </tr> <tr> <td><strong>Other</strong><sup>&#9674;</sup></td> <td>1 patient</td> <td>7%</td> <td>1 patient</td> <td>0%</td> <td>0%</td> <td>1 patient</td> <td>3%</td> <td>0%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis; OCA: oral contraceptive.<br />* These case series involved 136 outpatients in rural Scotland, 57 hospitalized patients in Rochester, New York, 42 inpatients and 8 outpatients at a referral center in Israel, 157 inpatients at a university hospital in Strasbourg, France, 100 hospitalized patients at a university hospital in Bangkok, 45 outpatients and 87 inpatients at a university hospital in Greece, 106 patients at a mixed rural-urban referral center in Spain, and 75 patients seen at the National Skin Center, Singapore.<br />¶ Other infections included a single case of dermatophytic fungal infection (Scotland); single cases of leprosy, pneumococcal pneumonia, influenza, fungal mycetoma, and gonorrhea (New York); single cases of infection with <EM>Yersinia enterocolitica</EM>, <EM>Mycoplasma pneumoniae</EM>, <EM innerHtml>Chlamydia pneumoniae</EM>, and <EM>Chlamydia trachomatis</EM> (France); 21 cases of nonstreptococcal upper respiratory tract infections along with single cases of infection with <EM>Brucella abortus</EM> and <EM>Escherichia coli</EM> (Spain); 13 cases of acute infections with Epstein-Barr virus&nbsp;or&nbsp;cytomegalovirus and&nbsp;two cases of salmonellosis (Greece); and&nbsp;13 cases of viral pharyngitis and single cases of varicella, cat-scratch disease, and gonorrhea (Singapore).<br />Δ Four patients in this series were taking oral contraceptives, but the authors listed these cases as idiopathic on the basis of durations of administration ranging from&nbsp;two months to&nbsp;eight years prior to the development of erythema nodosum.<br /><FONT class=lozenge>◊</FONT> Diagnoses listed under \"other\" included a single case of Hodgkin's disease (Scotland), two&nbsp;systemic lupus erythematosus&nbsp;variants and single cases of pancreatitis and glomerulonephritis (New York), one case of T cell immunodeficiency (Israel), two cases of Sweet's syndrome and one patient with gastric cancer (Spain), and one case of Sjögren's syndrome (Greece).</div><div id=\"graphicVersion\">Graphic 70718 Version 5.0</div></div></div>"},"70720":{"type":"graphic_figure","displayName":"Median sensory territory","title":"Sensory territory of the median nerve","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Sensory territory of the median nerve</div><div class=\"cntnt\"><img style=\"width:532px; height:402px;\" src=\"images/NEURO/70720_Median_sensory_territory.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Preston DC, Shapiro BE. Median neuropathy. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations. Butterworth-Heinemann, Boston 1998.</div><div id=\"graphicVersion\">Graphic 70720 Version 2.0</div></div></div>"},"70721":{"type":"graphic_table","displayName":"Therapies for myasthenia gravis","title":"Commonly used therapies for myasthenia gravis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used therapies for myasthenia gravis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Time to onset of effect*</td> <td class=\"subtitle1\">Time to maximal effect*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Symptomatic therapy</td> </tr> <tr> <td class=\"indent1\">Pyridostigmine</td> <td>10 to 15 minutes</td> <td>2 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chronic immunotherapies</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>2 to 3 weeks</td> <td>5 to 6 months</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> <td>~12 months</td> <td>1 to 2 years</td> </tr> <tr> <td class=\"indent1\">Mycophenolate mofetil</td> <td>6 to 12 months</td> <td>1 to 2 years</td> </tr> <tr> <td class=\"indent1\">Cyclosporine and tacrolimus</td> <td>~6 months</td> <td>~12 months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rapid immunotherapies</td> </tr> <tr> <td class=\"indent1\">Plasmapheresis</td> <td>1 to 7 days</td> <td>1 to 3 weeks</td> </tr> <tr> <td class=\"indent1\">Intravenous immune globulin</td> <td>1 to 2 weeks</td> <td>1 to 3 weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Surgery</td> </tr> <tr> <td class=\"indent1\">Thymectomy</td> <td>1 to 10 years</td> <td>1 to 10 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estimated times are rough guidelines based upon clinical experience in myasthenia gravis.</div><div id=\"graphicVersion\">Graphic 70721 Version 4.0</div></div></div>"},"70724":{"type":"graphic_picture","displayName":"Neuroendocrine chromogranin","title":"Large cell neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large cell neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:385px; height:262px;\" src=\"images/PULM/70724_Neuroendocrine_chromogranin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chromogranin immunoperoxidase study shows that some of the tumor cells contain reactivity for chromogranin confirming that this tumor does show neuroendocrine differentiation. These features are consistent with large cell neuroendocrine carcinoma.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 70724 Version 1.0</div></div></div>"},"70726":{"type":"graphic_table","displayName":"Causes postprandial hypogly","title":"Causes of postprandial hypoglycemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of postprandial hypoglycemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Ackee fruit poisoning</td> </tr> <tr> <td>Post Roux-en-Y gastric bypass</td> </tr> <tr> <td>Factitious hypoglycemia from insulin or sulfonylurea</td> </tr> <tr> <td>Gin and tonic hypoglycemia</td> </tr> <tr> <td>Hereditary fructose intolerance</td> </tr> <tr> <td>Insulin autoimmune hypoglycemia</td> </tr> <tr> <td>Insulinoma</td> </tr> <tr> <td>Noninsulinoma pancreatogenous hypoglycemia syndrome</td> </tr> <tr> <td>Pancreatic transplantation?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 70726 Version 2.0</div></div></div>"},"70729":{"type":"graphic_picture","displayName":"Birdshot retinochoroidopathy","title":"Birdshot retinochoroidopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Birdshot retinochoroidopathy</div><div class=\"cntnt\"><img style=\"width:366px; height:256px;\" src=\"images/RHEUM/70729_Birdshot_retinochoroidopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple discrete, cream-colored foci of depigmentation characteristic of birdshot retinochoroidopathy.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 70729 Version 2.0</div></div></div>"},"70730":{"type":"graphic_table","displayName":"Outcomes of vein grafting for Peyronies disease reconstruction","title":"Outcomes of vein grafting for Peyronies disease reconstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of vein grafting for Peyronies disease reconstruction</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   &nbsp;\n   </td>\n   <td  class=\"subtitle1\">\n   Patients\n   </td>\n   <td  class=\"subtitle1\">\n   \t<p>Straightened penis, </p>\n\t<p>percentage</p>\n   </td>\n   <td  class=\"subtitle1\">\n   \t<p>Shortened penis, </p>\n\t<p>percentage</p>\n   </td>\n   <td  class=\"subtitle1\">\n   \t<p>Postop erectile dysfunction, </p>\n\t<p>percentage</p>\n   </td>\n   </tr>\n   <tr>\n   <td>El-Sakka, Lue<sup> [1] </sup></td>\n   <td>113</td>\n   <td>96</td>\n   <td>17</td>\n   <td>13</td>\n   </tr>\n   <tr>\n   <td>Akkus<sup> [2] </sup></td>\n   <td>42</td>\n   <td>93</td>\n   <td>26</td>\n   <td>9</td>\n   </tr>\n   <tr>\n   <td>Montorsi<sup> [3] </sup></td>\n   <td>50</td>\n   <td>80</td>\n   <td>40</td>\n   <td>6</td>\n   </tr>\n   <tr>\n   <td>Kadioglu<sup> [4] </sup></td>\n   <td>20</td>\n   <td>75</td>\n   <td>0</td>\n   <td>5</td>\n   </tr>\n   <tr>\n   <td>Adenyi<sup> [5] </sup></td>\n   <td>51</td>\n   <td>82</td>\n   <td>35</td>\n   <td>8</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">1. El-Sakka, AI, Rashwan, HM, Lue, TF. Venous patch graft for Peyronie's disease. Part II: outcome analysis. J Urol 1998; 160:2050.<br>2. Akkus, E, Ozkara, H, Alici, B, et al. Incision and venous patch graft in the surgical treatment of penile curvature in Peyronie's disease. Eur Urol 2001; 40:531.<br>3. Montorsi, F, Salonia, A, Maga, T, et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie's disease. J Urol 2000; 163:1704.<br>4. Kadioglu, A, Akman, T, Sanli, O, et al. Surgical Treatment of Peyronie's Disease: A Critical Analysis. Eur Urol 2006; 50:235.<br>5. Adenyi, AA, Goorney, SR, Pryor, JP, Ralph, DJ. The Lue procedure: An analysis of the outcome in Peyronie's disease. BJU 2002; 89:404</div><div id=\"graphicVersion\">Graphic 70730 Version 2.0</div></div></div>"},"70731":{"type":"graphic_waveform","displayName":"Pulsus alternans and pulsus paradoxus arterial waveforms","title":"Pulsus alternans and pulsus paradoxus arterial waveforms","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Pulsus alternans and pulsus paradoxus arterial waveforms</div><div class=\"cntnt\"><img style=\"width:546px; height:658px;\" src=\"images/CARD/70731_Pulsus_alternans_paradoxus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In pulsus alternans, which is associated with severe left ventricular systolic dysfunction, there is variation in the amplitude of the systolic arterial pressure with every other beat. In contrast, pulsus paradoxus varies with the respiratory cycle, such that the duration of arterial pressure reduction is sustained during the inspiratory portion of the respiratory cycle.</div><div class=\"graphic_reference\">Courtesy of Barry A Borlaug, MD.</div><div id=\"graphicVersion\">Graphic 70731 Version 5.0</div></div></div>"},"70732":{"type":"graphic_algorithm","displayName":"Pediatric cervical spine clinical clearance algorithm","title":"Pediatric cervical spine clinical clearance algorithm*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediatric cervical spine clinical clearance algorithm*</div><div class=\"cntnt\"><img style=\"width:346px; height:547px;\" src=\"images/EM/70732_C-spine_clear_algo_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GCS: Glasgow coma scale.<br />* It is possible to clinically clear children of all ages without radiographs when the history does <STRONG>not </STRONG>identify a predisposition to cervical spine injury and there is a normal neurologic and neck examination. Special attention should be paid to the neurologic exam of the infant and young child.&nbsp;<br />¶ High-risk motor vehicle crashes (speed &gt;55 mph [89 kph]), death of occupant, partial or complete ejection, and intrusion into the passenger compartment (12 inches at sides, 18 inches at roof), diving, or mechanisms associated with axial load to the head, hyperextension or hyperflexion of the neck, or acceleration-deceleration of the head. Patients with painful injuries not due to high-risk mechanisms for cervical spine injury (eg, isolated extremity fracture despite low-force mechanism) may still undergo clinical clearance.<br />Δ For example, patients with Down syndrome, Klippel-Feil syndrome, Morquio syndrome, Larsen syndrome, anklylosing spondylitis, cervical arthritis, prior cervical spine injury. For a full listing of conditions, refer to UpToDate topics on evaluation of cervical spine injuries in children and adolescents.<br /><FONT class=lozenge>◊</FONT> Refer to graphics and topics on spinal motion restriction (spinal immobilization) and imaging for cervical spine injuries in children and adolescents.</div><div id=\"graphicVersion\">Graphic 70732 Version 8.0</div></div></div>"},"70734":{"type":"graphic_diagnosticimage","displayName":"Pericarditis mediastinal mass","title":"Unusual presentation of purulent pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unusual presentation of purulent pericarditis</div><div class=\"cntnt\"><img style=\"width:334px; height:317px;\" src=\"images/ID/70734_Pericarditis_mediastinal_ma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT scan shows an anterior mediastinal mass compressing and displacing the heart. This was a case of Staphylococcus aureus purulent pericarditis in a patient on hemodialysis who had been treated twice over a six-month period for S. aureus bacteremia.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted with permission from Nwiloh, JO, Egbe, PA, Tagoe, AT, Weaver, LW. Chest 2000; 118:1832.</div><div id=\"graphicVersion\">Graphic 70734 Version 3.0</div></div></div>"},"70737":{"type":"graphic_figure","displayName":"Infant mortality birth wt","title":"Infant mortality rates by birth weight: United States, 2004","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Infant mortality rates by birth weight: United States, 2004</div><div class=\"cntnt\"><img style=\"width:614px; height:328px;\" src=\"images/PEDS/70737_Infant_mortality_birth_wt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Matthews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. National Center for Health Statistics. Vital Health Stat Series No. 55 (14). 2007.</div><div id=\"graphicVersion\">Graphic 70737 Version 3.0</div></div></div>"},"70738":{"type":"graphic_table","displayName":"Description confidential office visit","title":"An adolescent office visit that supports confidentiality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">An adolescent office visit that supports confidentiality</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">In consultation with</td> <td class=\"subtitle1\">The clinician should</td> </tr> <tr class=\"divider_bottom\"> <td>Patient and parent(s) or guardian(s)</td> <td> <p>Outline structure of visit</p> <p>Obtain general medical and family history</p> Discuss confidentiality</td> </tr> <tr class=\"divider_bottom\"> <td>Patient</td> <td> <p>Obtain health history, including risk-taking behaviors</p> <p>Address patient concerns</p> <p>Provide health guidance</p> Address billing issues</td> </tr> <tr class=\"divider_bottom\"> <td>Parent</td> <td> <p>Address parental concerns</p> Provide guidance about adolescent development</td> </tr> <tr class=\"divider_bottom\"> <td>Patient*</td> <td>Perform physical examination, as indicated</td> </tr> <tr class=\"divider_bottom\"> <td>Patient</td> <td> <p>Summarize findings and recommendations</p> <p>Determine parental involvement</p> Determine method of notification of laboratory results</td> </tr> <tr> <td>Patient and parent(s) or guardian(s)</td> <td> <p>Summarize findings and recommendations, as appropriate</p> Address billing issues</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Parent may be present at patient's discretion.</div><div class=\"graphic_reference\">Reproduced with permission from: Confidentiality in adolescent health care. ACOG educational bulletin #249. Int J Gynecol Obstet 1998; 63:295. Copyright &copy;1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 70738 Version 4.0</div></div></div>"},"70740":{"type":"graphic_figure","displayName":"Clinical features of hepatic encephalopathy","title":"Clinical features of hepatic encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Clinical features of hepatic encephalopathy</div><div class=\"cntnt\"><img style=\"width:568px; height:650px;\" src=\"images/GAST/70740_Stages_hep_encephalopathy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram depicting the grade of hepatic encephalopathy and the clinical features associated with advancing stages.</div><div class=\"graphic_reference\">Data from: Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Lippincott Williams &amp; Wilkins, Baltimore 1979.</div><div id=\"graphicVersion\">Graphic 70740 Version 5.0</div></div></div>"},"70744":{"type":"graphic_picture","displayName":"Posterior leg stretch wall","title":"Posterior leg stretch, wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior leg stretch, wall</div><div class=\"cntnt\"><img style=\"width:234px; height:342px;\" src=\"images/RHEUM/70744_Posteriorlegstretchwall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand facing the wall, feet together, about 24 inches from the wall. With the heels firmly on the floor and the body aligned straight at the hips and knees, lean forward to the wall, stretching the posterior leg tissues. Hold this position for 10 to 30 seconds. Repeat five times per session, at least two sessions daily.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 70744 Version 2.0</div></div></div>"},"70745":{"type":"graphic_figure","displayName":"Retrocolic Roux-en-Y gastric bypass","title":"Retrocolic Roux-en-Y gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retrocolic Roux-en-Y gastric bypass</div><div class=\"cntnt\"><img style=\"width:450px; height:526px;\" src=\"images/SURG/70745_Roux_en_Y_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Roux-en-Y retrocolic gastric bypass configuration is characterized by a small (less than 30 mL) proximal gastric pouch divided and separated from the stomach remnant, with drainage of food to the rest of the gastrointestinal tract via a small gastrojejunal anastomosis and a Roux-en-Y small bowel arrangement. The small intestine is divided at a distance of 30 to 50 cm distal to the Ligament of Treitz and a proximal biliopancreatic limb is created to transport the secretions from the gastric remnant, liver, and pancreas. The Roux limb (or alimentary limb) is anastomosed to the new gastric pouch and functions to drain consumed food. The cut ends of the biliopancreatic limb and the Roux limb are then connected 75 to 150 cm distally from the gastrojejunostomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 70745 Version 8.0</div></div></div>"},"70746":{"type":"graphic_figure","displayName":"Laryngoscopy child","title":"Direct laryngoscopy using a straight blade","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Direct laryngoscopy using a straight blade</div><div class=\"cntnt\"><img style=\"width:457px; height:598px;\" src=\"images/EM/70746_Laryngoscopychild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The head is positioned with the right hand, and the mouth is opened using the fifth finger of the left hand (if necessary). B) Alternatively, the mouth may be opened with the thumb and index finger of the right hand using a &quot;scissor&quot; technique. C) The laryngoscope blade is inserted under direct vision over the tongue and then the tip of the blade is used to directly retract the epiglottis, revealing the vocal cords and glottic opeing.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent Endotracheal Intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70746 Version 10.0</div></div></div>"},"70749":{"type":"graphic_figure","displayName":"Risk of mortality among HD patients according to serum albumin","title":"Risk of mortality among hemodialysis patients according to serum albumin during maintenance dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of mortality among hemodialysis patients according to serum albumin during maintenance dialysis</div><div class=\"cntnt\"><img style=\"width:436px; height:234px;\" src=\"images/NEPH/70749_HD_survival_by_plasma_album.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Odds ratio for death, adjusted for age, sex, race, and underlying disease, according to the plasma albumin concentration in patients on maintenance hemodialysis. The likelihood of dying was inversely related to the plasma albumin concentration, being greatest at a plasma albumin concentration below 3.0 g/dL (30 g/L). All values are signficantly different (p&lt;0.001 to 0.03) from the odds ratio of 1.0 at a normal plasma albumin concentration of 4.0 to 4.4 g/dL (40 to 44 g/L).</div><div class=\"graphic_reference\">Data from Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.&nbsp;N Engl J Med 1993; 329:1001.</div><div id=\"graphicVersion\">Graphic 70749 Version 5.0</div></div></div>"},"70752":{"type":"graphic_table","displayName":"ORS other bev PI","title":"Comparison of oral rehydration solutions (ORS) to other beverages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of oral rehydration solutions (ORS) to other beverages</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Carbohydrate (g/L)</td> <td class=\"subtitle1\">Sodium (mEq/L)</td> <td class=\"subtitle1\">Potassium (mEq/L)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">ORT</td> </tr> <tr> <td class=\"indent1\">CeraLyte</td> <td>40</td> <td>70</td> <td>20</td> </tr> <tr> <td class=\"indent1\">Enfalyte</td> <td>30</td> <td>50</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Pedialyte</td> <td>25</td> <td>45</td> <td>20</td> </tr> <tr> <td class=\"indent1\">Rehydralyte</td> <td>25</td> <td>75</td> <td>20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other beverages (not appropriate for rehydration)</td> </tr> <tr> <td class=\"indent1\">Apple juice</td> <td>100 to 150</td> <td>3</td> <td>20</td> </tr> <tr> <td class=\"indent1\">Chicken broth</td> <td>0</td> <td>250</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Colas</td> <td>100 to 150</td> <td>2</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">Gatorade</td> <td>45</td> <td>20</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Ginger Ale</td> <td>90</td> <td>3.5</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\">Tea</td> <td>0</td> <td>0</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.</div><div id=\"graphicVersion\">Graphic 70752 Version 5.0</div></div></div>"},"70754":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced transverse fracture of little toe: AP view","title":"Nondisplaced transverse fracture of little toe: AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced transverse fracture of little toe: AP view</div><div class=\"cntnt\"><img style=\"width:331px; height:423px;\" src=\"images/EM/70754_Trans_fx_5th_toe_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 70754 Version 5.0</div></div></div>"},"70755":{"type":"graphic_figure","displayName":"Testosterone LH FSH in MI","title":"Serum testosterone and gonadotropin concentrations fall in acute MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum testosterone and gonadotropin concentrations fall in acute MI</div><div class=\"cntnt\"><img style=\"width:398px; height:285px;\" src=\"images/ENDO/70755_Testosterone_LH_FSH_in_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in the serum concentrations of testosterone (dotted line), LH (dashed line), and FSH (solid line) throughout hospitalization in a representative 43-year-old man with an acute MI. All three hormones decreased acutely and then returned to baseline levels during recovery. The dotted horizontal line indicates the lower limit of the normal range for testosterone. The day of transfer from the intensive care unit to the general medical unit is noted. To convert serum testosterone values to ng/dL, divide by 0.0347.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone; MI: myocardial infarction.</div><div class=\"graphic_reference\">Redrawn from Spratt DI, Cox P, Orav J, et al. Reproductive axis suppression in acute illness is related to disease severity. J Clin Endocrinol Metab 1993; 76:1548.</div><div id=\"graphicVersion\">Graphic 70755 Version 2.0</div></div></div>"},"70756":{"type":"graphic_picture","displayName":"Colonic adenoma cancer Light","title":"Colonic adenoma with malignant transformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic adenoma with malignant transformation</div><div class=\"cntnt\"><img style=\"width:436px; height:288px;\" src=\"images/GAST/70756_Colonic_adenoma_cancer_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a colonic adenoma which has undergone malignant transformation.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 70756 Version 1.0</div></div></div>"},"70758":{"type":"graphic_picture","displayName":"DAD histology","title":"Diffuse alveolar damage in a patient with acute interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alveolar damage in a patient with acute interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:402px; height:293px;\" src=\"images/PULM/70758_DAD_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Left panel) Early changes include diffuse alveolar wall thickening by proliferating connective tissue, type II pneumocytes, and hyaline membranes (red arrow). (Right panel) Later, there is diffuse alveolar wall thickening caused by connective tissue proliferation and inflammation.</div><div id=\"graphicVersion\">Graphic 70758 Version 2.0</div></div></div>"},"70759":{"type":"graphic_table","displayName":"Estimates of effective doses of standard MPI protocols","title":"Estimates of effective doses of standard MPI protocols","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimates of effective doses of standard MPI protocols</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Protocol</td> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Injected activity (mCi)</td> <td class=\"subtitle1\" colspan=\"4\">Effective doses, mSv</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">From ICRP tables</td> <td class=\"subtitle2\" colspan=\"2\">From manufacturers' Pls</td> </tr> <tr> <td class=\"subtitle3\">Rest</td> <td class=\"subtitle3\">Stress</td> <td class=\"subtitle3\"><em>E<sub>1</sub></em></td> <td class=\"subtitle3\"><em>E<sub>2</sub></em></td> <td class=\"subtitle3\"><em>E<sub>1</sub></em></td> <td class=\"subtitle3\"><em>E<sub>2</sub></em></td> </tr> <tr> <td><sup>99m</sup>Tc sestamibi rest-stress</td> <td>10.0</td> <td>27.5</td> <td>11.3</td> <td>11.4</td> <td>14.6</td> <td>NR</td> </tr> <tr> <td><sup>99m</sup>Tc sestamibi stress only</td> <td>0.0</td> <td>27.5</td> <td>7.9</td> <td>8.0</td> <td>10.0</td> <td>NR</td> </tr> <tr> <td><sup>99m</sup>Tc sestamibi 2-day</td> <td>25.0</td> <td>25.0</td> <td>15.7</td> <td>15.6</td> <td>20.6</td> <td>NR</td> </tr> <tr> <td><sup>99m</sup>Tc tetrofosmin rest-stress</td> <td>10.0</td> <td>27.5</td> <td>9.3</td> <td>9.9</td> <td>9.7</td> <td>12.9</td> </tr> <tr> <td><sup>99m</sup>Tc tetrofosmin stress only</td> <td>0.0</td> <td>27.5</td> <td>6.6</td> <td>7.1</td> <td>6.7</td> <td>8.8</td> </tr> <tr> <td><sup>99m</sup>Tc tetrofosmin 2-day</td> <td>25.0</td> <td>25.0</td> <td>12.8</td> <td>13.5</td> <td>13.7</td> <td>18.3</td> </tr> <tr> <td><sup>201</sup>Tl stress-redistribution</td> <td>0.0</td> <td>3.5</td> <td>22.0</td> <td>22.0</td> <td> <p>28.7 (PI 1)</p> <p>9.3 (PI 2)</p> <p>28.4 (PI 3)</p> </td> <td> <p>46.6 (PI 1)</p> <p>NR (PI 2)</p> <p>46.6 (PI 3)</p> </td> </tr> <tr> <td><sup>201</sup>Tl stress-reinjection</td> <td>1.5</td> <td>3.0</td> <td>31.4</td> <td>31.5</td> <td> <p>43.0 (PI 1)</p> <p>14.0 (PI 2)</p> <p>42.6 (PI 3)</p> </td> <td> <p>69.9 (PI 1)</p> <p>NR (PI 2)</p> <p>69.9 (PI 3)</p> </td> </tr> <tr> <td>Dual isotope<sup>201</sup>Tl-<sup>99m</sup>Tc sestamibi</td> <td>3.5</td> <td>25.0</td> <td>29.2</td> <td>29.3</td> <td> <p>37.8 (PI 1)</p> <p>18.4 (PI 2)</p> <p>37.5 (PI 3)</p> </td> <td> <p>NR (PI 1)</p> <p>NR (PI 2)</p> <p>NR (PI 3)</p> </td> </tr> <tr> <td><sup>99m</sup>Tc-labeled erythrocytes</td> <td>22.5</td> <td>0.0</td> <td>5.7</td> <td>5.8</td> <td>2.3</td> <td>NR</td> </tr> <tr> <td><sup>82</sup>Rb</td> <td>50.0</td> <td>50.0</td> <td>13.5</td> <td>12.6</td> <td>3.0</td> <td>NR</td> </tr> <tr> <td><sup>13</sup>N-ammonia</td> <td>15.0</td> <td>15.0</td> <td>2.4</td> <td>2.2</td> <td>NA</td> <td>NA</td> </tr> <tr> <td><sup>15</sup>O-water*</td> <td>29.7</td> <td>29.7</td> <td>2.5</td> <td>2.4</td> <td>NA</td> <td>NA</td> </tr> <tr> <td><sup>18</sup>F-FDG</td> <td>10.0</td> <td>0.0</td> <td>7.0</td> <td>7.0</td> <td>NA</td> <td>NA</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">2</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=81808&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\"><em>E<sub>1</sub></em> indicates effective dose estimated from tissue dose coefficients, using ICRP Publication 60 tissue weighting factors. Calculations were performed with the use of the &quot;splitting rule,&quot;<sup>[1]</sup> arithmetic averaging rather than mass averaging of individual remainder organ dose contributions,<sup>[2]</sup> and upper large intestine rather than extrathoracic airways as a remainder organ, as was originally specified in ICRP Publication 60. If dose to the colon was not specified in a data source, then the average of the upper large intestine and lower large intestine doses was substituted. <em>E<sub>2</sub></em> indicates effective dose estimated from effective dose coefficients, using ICRP Publication 60 tissue weighting factors.</div><div class=\"graphic_footnotes\">NR: not reported in PI (total body dose provided rather than effective dose); NA: not available for cyclotron-produced tracers.<br> * American Society of Nuclear Cardiology guidelines<sup>[3]</sup> do not prescribe a recommended dose. Stress and rest doses of 1100 MBq (29.7 mCi) used, as per European Association of Nuclear Medicine/European Society of Cardiology guidelines<sup>[4]</sup>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>1990 Recommendations of the International Commission on Radiological Protection: ICRP Publication 60 Ann ICRP 1991; 21:1. </LI>&#xD;&#xA;<LI>Conversion coefficients for use in radiological protection against external radiation: ICRP Publication 74. Ann ICRP 1996; 26:1.&nbsp; </LI>&#xD;&#xA;<LI>DePuey EG, ed. Imaging guidelines for nuclear cardiology procedures. J Nucl Cardiol 2006; 13:e21. </LI>&#xD;&#xA;<LI>EANM/ESC Group. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005; 32:855. </LI></OL>Reproduced with permission from: Einstein AJ, Moser KW, Thompson RC, et al. Radiation Dose to Patients From Cardiac Diagnostic Imaging. Circulation 2007; 116:1290. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70759 Version 9.0</div></div></div>"},"70762":{"type":"graphic_diagnosticimage","displayName":"Membranous VSD subcostal coronal 2D still frame","title":"Membranous VSD subcostal coronal 2D still frame","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Membranous VSD subcostal coronal 2D still frame</div><div class=\"cntnt\"><img style=\"width:504px; height:396px;\" src=\"images/CARD/70762_Membr_VSD_subcost_coron_2D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal coronal still frame showing a membranous ventricular septal defect (VSD) just apical to the aortic valve.</div><div class=\"graphic_footnotes\">2D: two-dimensional; AO: aorta; LV: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium; IVS: intact trabecular portion of the intraventricular septum; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 70762 Version 4.0</div></div></div>"},"70763":{"type":"graphic_table","displayName":"Entecavir versus lamivudine II","title":"Histologic improvement and change in Ishak Fibrosis Score at week 48, nucleoside-naive patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic improvement and change in Ishak Fibrosis Score at week 48, nucleoside-naive patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">(HBeAg-positive)</td> <td class=\"subtitle1\" colspan=\"2\">(HBeAg-negative)</td> </tr> <tr> <td class=\"subtitle2\">Entecavir 0.5 mg<br /> (n = 314)*</td> <td class=\"subtitle2\">Lamivudine 100 mg<br /> (n = 314)* </td> <td class=\"subtitle2\">Entecavir 0.5 mg<br /> (n = 296)*</td> <td class=\"subtitle2\">Lamivudine 100 mg<br /> (n = 287)* </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Histologic improvement (Knodell scores)</td> </tr> <tr> <td class=\"sublist1\">Improvement<sup>&#182;</sup></td> <td class=\"sublist_other\">72%<sup>&#916;</sup></td> <td class=\"sublist_other\">62%</td> <td class=\"sublist_other\">70%<sup>&#916;</sup></td> <td class=\"sublist_other\">61%</td> </tr> <tr> <td class=\"sublist1\">No improvement</td> <td class=\"sublist_other\">21%</td> <td class=\"sublist_other\">24%</td> <td class=\"sublist_other\">19%</td> <td class=\"sublist_other\">26%</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Ishak Fibrosis Score</td> </tr> <tr> <td class=\"sublist1\">Improvement<sup>&#9674;</sup></td> <td class=\"sublist_other\">39%</td> <td class=\"sublist_other\">35%</td> <td class=\"sublist_other\">36%</td> <td class=\"sublist_other\">38%</td> </tr> <tr> <td class=\"sublist1\">No change</td> <td class=\"sublist_other\">46%</td> <td class=\"sublist_other\">40%</td> <td class=\"sublist_other\">41%</td> <td class=\"sublist_other\">34%</td> </tr> <tr> <td class=\"sublist1\">Worsening<sup>&#9674;</sup></td> <td class=\"sublist_other\">8%</td> <td class=\"sublist_other\">10%</td> <td class=\"sublist_other\">12%</td> <td class=\"sublist_other\">15%</td> </tr> <tr> <td>Missing week 48 biopsy</td> <td>7%</td> <td>14%</td> <td>10%</td> <td>13%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score &ge;2).<br />&para; &ge;2-point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.<br />&Delta; p&lt;0.05.<br /><span class=\"lozenge\">&loz;</span> For Ishak Fibrosis Score, improvement = &ge;1-point decrease from baseline and worsening = &ge;1-point increase from baseline.</div><div id=\"graphicVersion\">Graphic 70763 Version 4.0</div></div></div>"},"70765":{"type":"graphic_figure","displayName":"Glomerular structure","title":"The glomerular filtration barrier","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">The glomerular filtration barrier</div><div class=\"cntnt\"><img style=\"width:599px; height:242px;\" src=\"images/NEPH/70765_Glomerular_structure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood enters the glomerular capillaries and is filtered across the endothelium and the glomerular basement membrane and through the filtration slits between podocyte foot processes to produce the primary urine filtrate. In healthy glomeruli, this barrier restricts the passage of macromolecules. CatL, the expression of which is increased in human proteinuric diseases and in an LPS-induced mouse model of proteinuria, causes proteinuria and foot process effacement through cleavage of the GTPase dynamin, an actin-binding protein. The same effects are induced by gene delivery into mice of dynK44A—a mutant form of dynamin that does not bind GTP—or of the CatL-cleaved product of dynamin (p40). Conversely, gene delivery into proteinuric mice of dynL356Q and dynR725A, two CatL-resistant dynamin mutants, reverses proteinuria and foot process effacement.</div><div class=\"graphic_reference\">Reproduced with permission from: Ronco P. Proteinuria: is it all in the foot?. J Clin Invest 2007; 117:2079. Copyright ©2007 American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 70765 Version 3.0</div></div></div>"},"70766":{"type":"graphic_table","displayName":"Diastolic vel and preg outcome","title":"Absent and reverse end diastolic velocity in the umbilical artery and adverse perinatal outcome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absent and reverse end diastolic velocity in the umbilical artery and adverse perinatal outcome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Perinatal outcome</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">Range</td> </tr> <tr> <td>Perinatal mortality</td> <td>45 percent</td> <td>17 to 100 percent</td> </tr> <tr> <td>Gestational age</td> <td>31.6 weeks</td> <td>29 to 33 weeks</td> </tr> <tr> <td>Birth weight</td> <td>1056 grams</td> <td>910 to 1481 grams</td> </tr> <tr> <td>Small for gestational age</td> <td>68 percent</td> <td>53 to 100 percent</td> </tr> <tr> <td>Cesarean&nbsp;delivery for fetal distress</td> <td>73 percent</td> <td>24 to 100 percent</td> </tr> <tr> <td>Apgar score at 5 minutes &#60;7</td> <td>26 percent</td> <td>7 to 69 percent</td> </tr> <tr> <td>Admission to neonatal intensive care unit</td> <td>84 percent</td> <td>77 to 97 percent</td> </tr> <tr> <td>Congenital anomalies</td> <td>10 percent</td> <td>0 to 24 percent</td> </tr> <tr> <td>Aneuploidy</td> <td>6.4 percent</td> <td>0 to 18 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Maulik, D. Absent end-diastolic velocity in the umbilical artery and its clinical significance. In: Maulik, D (ed) Doppler ultrasound in obstetrics and gynecology, 1997; 362, New York, Springer Verlag. Copyright © 1997 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 70766 Version 3.0</div></div></div>"},"70767":{"type":"graphic_figure","displayName":"CNS tumor child histology","title":"Pediatric primary brain and CNS tumors: Distribution by histology groupings and histology","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Pediatric primary brain and CNS tumors: Distribution by histology groupings and histology</div><div class=\"cntnt\"><img style=\"width:723px; height:409px;\" src=\"images/PEDS/70767_CNS_tumor_child_hstlgy_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution in children and adolescents (age 0-19 years) of primary brain and CNS tumors by CBTRUS histology groupings and histology (n = 23,113), CBTRUS Statistical Report: NPCR and SEER, 2008-2012.</div><div class=\"graphic_footnotes\">CNS: central nervous system; NOS: not otherwise specified; ATRT: atypical teratoid rhabdoid tumor; PNET: primitive neuroectodermal tumor;&nbsp;CBTRUS: Central Brain Tumor Registry of the United States; NPCR: National Program of Cancer Registries; SEER: Surveillance, Epidemiology, and End Results Program.<br />* All or some of this histology are included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.<br />¶ Includes oligodendrogliomas and anaplastic oligodendrogliomas.<br />Δ Includes diffuse astrocytoma, anaplastic astrocytoma, unique astrocytoma variants.<br /><FONT class=lozenge>◊</FONT> Includes choroid plexus tumors, other neuroepithelial tumors, tumors of the pineal region, other tumors of cranial and spinal nerves, mesenchymal tumors, primary melanocytic lesions, other neoplasms related to the meninges, other hematopoietic neoplasms, hemangioma, neoplasm unspecified, all other.<br />§ ICD-O-3 histology\u2028 codes: 9470/3, 9471/3, 9472/3, 9474/3.<br />¥ ICD-O-3 histology code: 9508/3.<br />‡ ICD-O-3 histology code: 9473/3.<br />† ICD-O-3 histology codes: 8963/3, 9364/3, 9480/0, 9480/3, 9490/0, 9490/3, 9500/3, 9501/3, 9502/3.</div><div class=\"graphic_reference\">Reproduced with permission from: Quinn T. Ostrom, Haley Gittleman, Jordonna Fulop, Max Liu, Rachel Blanda, Courtney Kromer, Yingli Wolinsky, Carol Kruchko, and Jill S. Barnholtz-Sloan, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012, Neuro Oncol (2015) 17 (suppl 4): iv1-iv62 doi: 10.1093/neuonc/nov189.</div><div id=\"graphicVersion\">Graphic 70767 Version 4.0</div></div></div>"},"70768":{"type":"graphic_figure","displayName":"Differential splicing mRNA","title":"Differential splicing of mRNAs encoding membrane and secreted forms of IgM","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Differential splicing of mRNAs encoding membrane and secreted forms of IgM</div><div class=\"cntnt\"><img style=\"width:469px; height:343px;\" src=\"images/ALLRG/70768_Differential_splicing_mRNA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The carboxyl terminus of secreted IgM (µ<SUB>s</SUB>) is encoded by the Cµ4 exon. The carboxyl terminus of membrane IgM (µ<SUB>m</SUB>) is encoded by a separate exon a short distance 3' to Cµ4. Differential splicing of the same primary transcript generates mRNA encoding either µ<SUB>s</SUB> or µ<SUB>m</SUB>.</div><div class=\"graphic_footnotes\">IgM: immunoglobulin M.</div><div class=\"graphic_reference\">Reproduced with permission from: Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright © 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 70768 Version 2.0</div></div></div>"},"70769":{"type":"graphic_picture","displayName":"Prayer sign in diabetes","title":"Contractures in the metacarpophalangeal joints in diabetes mellitus: Prayer sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contractures in the metacarpophalangeal joints in diabetes mellitus: Prayer sign</div><div class=\"cntnt\"><img style=\"width:362px; height:289px;\" src=\"images/ENDO/70769_Prayer_sign_in_diabetes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positive prayer sign (with waxy skin on the dorsal surface of the fingers) in a patient with diabetes (left panel) and a negative prayer sign in a normal subject (right panel). Contractures in the metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints prevent the hands from being flattened together.</div><div class=\"graphic_reference\">Courtesy of Verna Wright, MD.</div><div id=\"graphicVersion\">Graphic 70769 Version 2.0</div></div></div>"},"70770":{"type":"graphic_figure","displayName":"T3 nuclear receptor","title":"Schematic representation of the structure of the T3 nuclear receptor","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the structure of the T3 nuclear receptor</div><div class=\"cntnt\"><img style=\"width:566px; height:242px;\" src=\"images/ENDO/70770_T3_nuclear_receptor_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The region labeled \"DNA binding\" is the portion of the receptor that binds to DNA, and the region labeled \"ligand binding\" is the region that binds T3. NH2 denotes the amino-terminal end of the receptor and COOH the carboxy-terminal end.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; TR: thyroid hormone receptor.</div><div class=\"graphic_reference\">Adapted from: Utiger RD. The thyroid: Physiology thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Endocrinology and Metabolism, 3rd ed, Felig R, Baxter JD, Frohman LA (Eds), McGraw-Hill, NY 1995.</div><div id=\"graphicVersion\">Graphic 70770 Version 3.0</div></div></div>"},"70771":{"type":"graphic_figure","displayName":"Action potential currents","title":"Action potential currents","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Action potential currents</div><div class=\"cntnt\"><img style=\"width:608px; height:435px;\" src=\"images/CARD/70771_Action_potential_currents.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiac ion currents responsible for generation of the action potential. The commonly used symbols and name are given for each of the major currents along with the name for the beta-subunit gene and, where different, the α-subunit protein. Most channels and exchangers have beta-subunits and associated proteins not shown here. In some cases alternative earlier gene names are given after the formal gene name. Diagrams of the currents are shown synchronized with the action potential but amplitudes are not drawn to scale.</div><div class=\"graphic_reference\">Courtesy of Jonathan C Makielski, MD, FACC.</div><div id=\"graphicVersion\">Graphic 70771 Version 2.0</div></div></div>"},"70773":{"type":"graphic_figure","displayName":"Ureterocele US VCUG","title":"Ureterocele in bladder","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Ureterocele in bladder</div><div class=\"cntnt\"><img style=\"width:494px; height:561px;\" src=\"images/PEDS/70773_UreteroceleUSVCUG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with a ureterocele and a left kidney with a duplicated collecting (duplex) system. Ureterocele seen by sonogram (A) and voiding cystourethogram (VCUG) (B).</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD. Illustration reproduced with permission from: DiSandro S. Hydroureteronephrosis: Ureteroceles, duplications, and ureteral ectopy. In: Handbook of Pediatric Urology, 2nd Ed, Baskin LS, Kogan BA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70773 Version 11.0</div></div></div>"},"70775":{"type":"graphic_diagnosticimage","displayName":"Radiopaque foreign body","title":"Radiopaque foreign body in the airway","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Radiopaque foreign body in the airway</div><div class=\"cntnt\"><img style=\"width:461px; height:223px;\" src=\"images/PULM/70775_Radiopaque_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiopaque foreign body retrieved from the&nbsp;airway of a one-year-old child. </div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 70775 Version 4.0</div></div></div>"},"70776":{"type":"graphic_figure","displayName":"Glucocorticoid gene suppression","title":"Glucocorticoid suppression of activated inflammatory genes","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid suppression of activated inflammatory genes</div><div class=\"cntnt\"><img style=\"width:519px; height:376px;\" src=\"images/PULM/70776_Steroid_suppr_inflam_genes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory genes are activated by inflammatory stimuli, such as interleukin-1b (IL-1b) or tumor necrosis factor-a (TNF-a), resulting in activation of IKK2 (inhibitor of I-kB kinase-2), which activates the transcription factor nuclear factor kB (NF-kB). A dimer of p50 and p65 NF-kB proteins translocates to the nucleus and binds to specific kB recognition sites and also to coactivators, such as CREB-binding protein (CBP) or p300/CBP-activating factor (pCAF), which have intrinsic histone acetyltransferase (HAT) activity. This results in acetylation of core histone H4, resulting in increased expression of genes encoding multiple inflammatory proteins. Glucocorticoid receptors (GR) after activation by glucocorticoids translocate to the nucleus and bind to coactivators to inhibit HAT activity directly and recruiting histone deacetylase-2 (HDAC2), which reverses histone acetylation leading in suppression of these activated inflammatory genes.</div><div id=\"graphicVersion\">Graphic 70776 Version 2.0</div></div></div>"},"70777":{"type":"graphic_picture","displayName":"Liver biopsy - bleeding from esophageal varices and splenomegaly","title":"Liver biopsy from a 59-year-old man who had recurrent bleeding from large esophageal varices and splenomegaly (high power, Masson trichrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver biopsy from a 59-year-old man who had recurrent bleeding from large esophageal varices and splenomegaly (high power, Masson trichrome)</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/GAST/70777_Liver_biopsy_bleeding_esoph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the enlarged blue-gray stained Kupffer cells filling a sinusoid (arrow).</div><div class=\"graphic_reference\">Courtesy of Marshall M. Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 70777 Version 1.0</div></div></div>"},"70778":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa and surgical unroofing","title":"Hidradenitis suppurativa and surgical unroofing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa and surgical unroofing</div><div class=\"cntnt\"><img style=\"width:360px; height:309px;\" src=\"images/SURG/70778_Initialbevelededgeunroof.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical unroofing is the primary therapy for severe and extensive hidradenitis suppurativa. This picture shows the beveled edges of the wound following the unroofing of the inflamed nodule. Ferric chloride was used to control hemostasis.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 70778 Version 6.0</div></div></div>"},"70779":{"type":"graphic_table","displayName":"Infections associated with hemorrhage","title":"Selected acute infections associated with hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected acute infections associated with hemorrhage</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Dengue fever</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Leptospirosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Meningococcemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rat-bite fever</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rickettsial infections</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Viral hemorrhagic fevers (multiple viruses can be the cause, including Argentine, Bolivian, Crimean-Congo, Ebola, Lassa, Venezuelan, yellow fever among others)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 70779 Version 2.0</div></div></div>"},"70781":{"type":"graphic_picture","displayName":"SLE proliferative IF","title":"Immunofluorescence microscopy showing massive IgG deposition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy showing massive IgG deposition</div><div class=\"cntnt\"><img style=\"width:360px; height:245px;\" src=\"images/NEPH/70781_SLE_Proliferative_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kidney biopsy from a patient with diffuse proliferative lupus nephritis showing, on immunofluorescence microscopy, massive, lumpy deposits of IgG.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 70781 Version 7.0</div></div></div>"},"70782":{"type":"graphic_picture","displayName":"Cutting foreskin off Mogan clamp","title":"Foreskin cut from surface of clamp using a scalpel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foreskin cut from surface of clamp using a scalpel</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/70782_Cutting_foreskin_off_Mogan.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 70782 Version 2.0</div></div></div>"},"70783":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:468px; height:383px;\" src=\"images/ALLRG/70783_Dermatitis_herpetiformis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Herpetiform clusters of vesicles on an erythematous, edematous base with crusts and postinflammatory pigmentation on the upper back and shoulder.</div><div class=\"graphic_reference\">Reproduced with permission from: Skin signs of immune, autoimmune, and rheumatic diseases. In: Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, Fitzpatrick TB, Johnson RA, Wolff K (Eds), McGraw-Hill, New York 1997. p.327. Copyright © 1997 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 70783 Version 3.0</div></div></div>"},"70784":{"type":"graphic_figure","displayName":"Communicating hydrocele","title":"Communicating hydrocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Communicating hydrocele</div><div class=\"cntnt\"><img style=\"width:311px; height:288px;\" src=\"images/PEDS/70784_Communicating_hydrocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A narrowly patent processus vaginalis that only permits passage of peritoneal fluid results in a communicating hydrocele.</div><div class=\"graphic_reference\">Adapted from Paidas, C. Inguinal hernia. In: Oski's Pediatrics. Principles and Practice, 3rd ed, McMillan, JA, DeAngelis, CD, Feigin, RD, et al (Eds), Lippincott Williams &amp;Wilkins, Philadelphia 1999. p.1640.</div><div id=\"graphicVersion\">Graphic 70784 Version 1.0</div></div></div>"},"70785":{"type":"graphic_picture","displayName":"Erythema toxicum face","title":"Erythema toxicum neonatorum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema toxicum neonatorum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70785_Erythematoxicumface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy newborn developed a diffuse, transient eruption composed of red macules with central, pinpoint, whitish-yellow papules and pustules on the second day of life.</div><div class=\"graphic_reference\">Copyright &copy; Douglas Hoffman, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 70785 Version 9.0</div></div></div>"},"70786":{"type":"graphic_diagnosticimage","displayName":"Midshaft greenstick fracture 2","title":"Midshaft greenstick fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Midshaft greenstick fracture</div><div class=\"cntnt\"><img style=\"width:421px; height:193px;\" src=\"images/EM/70786_Midshaft_greenstick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both the radius and ulna are bent and the fracture line does not extend completely through the width of the bone.</div><div class=\"graphic_reference\">Courtesy of Richard G Bachur, MD</div><div id=\"graphicVersion\">Graphic 70786 Version 2.0</div></div></div>"},"70787":{"type":"graphic_picture","displayName":"Painful arc sign for rotator cuff pathology","title":"Painful arc sign for rotator cuff pathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Painful arc sign for rotator cuff pathology</div><div class=\"cntnt\"><img style=\"width:331px; height:504px;\" src=\"images/EM/70787_Painful_arc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain with active abduction beyond 90 degrees (ie, painful arc sign) suggests rotator cuff tendinopathy. The test is most useful when combined with other rotator cuff tests, such as the Neer and Hawkins-Kennedy tests.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD.</div><div id=\"graphicVersion\">Graphic 70787 Version 5.0</div></div></div>"},"70788":{"type":"graphic_table","displayName":"Summary of drug-induced acute pancreatitis based on drug class","title":"Summary of drug-induced acute pancreatitis based on drug class","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of drug-induced acute pancreatitis based on drug class</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class Ia</td> <td class=\"subtitle1\">Class Ib</td> <td class=\"subtitle1\">Class II</td> <td class=\"subtitle1\">Class III</td> <td class=\"subtitle1\">Class IV</td> </tr> <tr> <td> <p>&#945;-methyldopa</p> <p>Azodisalicylate</p> <p>Bezafibrate</p> <p>Cannabis</p> <p>Carbimazole</p> <p>Codeine</p> <p>Cytosine</p> <p>Arabinoside</p> <p>Dapsone</p> <p>Enalapril</p> <p>Furosemide</p> <p>Isoniazid</p> <p>Mesalamine</p> <p>Metronidazole</p> <p>Pentamidine</p> <p>Pravastatin</p> <p>Procainamide</p> <p>Pyritonol</p> <p>Simvastatin</p> <p>Stibogluconate</p> <p>Sulfamethoxazole</p> <p>Sulindac</p> <p>Tetracycline</p> <p>Valproic acid</p> </td> <td> <p>All-trans-retinoic acid</p> <p>Amiodarone</p> <p>Azathioprine</p> <p>Clomiphene</p> <p>Dexamethasone</p> <p>Ifosfamide</p> <p>Lamivudine</p> <p>Losartan</p> <p>Lynestrenol/methoxyethinylestradiol</p> <p>6-mercaptopurine</p> <p>Meglumine</p> <p>Methimazole</p> <p>Nelfinavir</p> <p>Norethindronate/mestranol</p> <p>Omeprazole</p> <p>Premarin</p> <p>Trimethoprimsulfamethazole</p> </td> <td> <p>Acetaminophen</p> <p>Chlorothiazide</p> <p>Clozapine</p> <p>Didanosine</p> <p>Erythromycin</p> <p>Estrogen</p> <p>L-asparaginase</p> <p>Pegaspargase</p> <p>Propofol</p> <p>Tamoxifen</p> </td> <td> <p>Alendronate</p> <p>Atorvastatin</p> <p>Carbamazepine</p> <p>Captopril</p> <p>Ceftriaxone</p> <p>Chlorthalidone</p> <p>Cimetidine</p> <p>Clarithromycin</p> <p>Cyclosporin</p> <p>Gold</p> <p>Hydrochlorothiazide</p> <p>Indomethacin</p> <p>Interferon/ribavirin</p> <p>Irbesartan</p> <p>Isotretinoin</p> <p>Ketorolac</p> <p>Lisinopril</p> <p>Metolazone</p> <p>Metformin</p> <p>Minocycline</p> <p>Mirtazapine</p> <p>Naproxen</p> <p>Paclitaxel</p> <p>Ponatinib</p> <p>Prednisone</p> <p>Prednisolone</p> </td> <td> <p>Adrenocorticotrophic hormone</p> <p>Ampicillin</p> <p>Bendroflumethiazide</p> <p>Benazepril</p> <p>Betamethasone</p> <p>Capecitabine</p> <p>Cisplatin</p> <p>Colchicine</p> <p>Cyclophosphamide</p> <p>Cyproheptadine</p> <p>Danazol</p> <p>Diazoxide</p> <p>Diclofenac</p> <p>Diphenoxylate</p> <p>Doxorubicin</p> <p>Ethacrynic acid</p> <p>Famciclovir</p> <p>Finasteride</p> <p>5-fluorouracil</p> <p>Fluvastatin</p> <p>Gemfibrozil</p> <p>Interleukin-2</p> <p>Ketoprofen</p> <p>Lovastatin</p> <p>Mefenamic acid</p> <p>Nitrofurantoin</p> <p>Octreotide</p> <p>Oxyphenbutazone</p> <p>Penicillin</p> <p>Phenophthalein</p> <p>Propoxyphene</p> <p>Ramipril</p> <p>Ranitidine</p> <p>Rifampin</p> <p>Risperidone</p> <p>Ritonavir</p> <p>Roxithromycin</p> <p>Rosuvastatin</p> <p>Sertraline</p> <p>Strychnine</p> <p>Tacrolimus</p> <p>Vigabatrin/lamotrigine</p> <p>Vincristine</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Badalov N, Baradarian R, Kadirawel I, et al. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol 2007; 5:648. Copyright &copy; 2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 70788 Version 5.0</div></div></div>"},"70789":{"type":"graphic_figure","displayName":"Lunotriquetral shear test","title":"Lunotriquetral shear test for instability of the lunotriquetral ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lunotriquetral shear test for instability of the lunotriquetral ligament</div><div class=\"cntnt\"><img style=\"width:412px; height:482px;\" src=\"images/PEDS/70789_Lunotriquetral_shear_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lunotriquetral shear test is performed by stabilizing the lunate and moving the pisotriquetral mass back and forth past the lunate in the anterior and posterior direction. A positive test is increased movement and pain compared to the other side.</div><div id=\"graphicVersion\">Graphic 70789 Version 2.0</div></div></div>"},"70790":{"type":"graphic_figure","displayName":"Veins lower extremity","title":"Lower extremity veins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lower extremity veins</div><div class=\"cntnt\"><img style=\"width:316px; height:336px;\" src=\"images/PEDS/70790_Veins_lower_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The great saphenous vein is the most accessible vein in the lower extremity because of its large size and consistent anatomy. The veins of the dorsal arch also can be used.</div><div id=\"graphicVersion\">Graphic 70790 Version 1.0</div></div></div>"},"70792":{"type":"graphic_algorithm","displayName":"Pathogenesis of RPC","title":"Hypothetical schema of pathogenesis of relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypothetical schema of pathogenesis of relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:361px; height:270px;\" src=\"images/RHEUM/70792_Pathogenesis_of_RPC.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70792 Version 2.0</div></div></div>"},"70793":{"type":"graphic_picture","displayName":"Multiple solar purpura","title":"Solar purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solar purpura</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70793_Multiple_solar_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple purpuric patches are present on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70793 Version 3.0</div></div></div>"},"70794":{"type":"graphic_table","displayName":"Common headache syndromes in children and adolescents","title":"Characteristics of common headache syndromes in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of common headache syndromes in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Migraine </td> <td class=\"subtitle1\">Tension-type headache</td> <td class=\"subtitle1\">Trigeminal autonomic cephalalgia (eg, cluster headache)</td> </tr> <tr> <td>Location</td> <td>Commonly bilateral in young children; in adolescents and young adults, unilateral in 60 to 70% and bifrontal or global in 30%</td> <td>Bilateral</td> <td>Always unilateral, usually begins around the eye or temple</td> </tr> <tr> <td>Characteristics</td> <td>Gradual in onset, crescendo pattern; pulsating; moderate or severe intensity; aggravated by routine physical activity</td> <td>Pressure or tightness that waxes and wanes</td> <td>Pain begins quickly, reaches a crescendo within minutes; pain is deep, continuous, excruciating, and explosive in quality</td> </tr> <tr> <td>Patient appearance</td> <td>Patient prefers to rest in a dark, quiet room</td> <td>Patient may remain active or may need to rest</td> <td>Patient remains active</td> </tr> <tr> <td>Duration</td> <td>2&nbsp;to 72 hours</td> <td>Variable</td> <td>30 minutes to 3 hours</td> </tr> <tr> <td>Associated symptoms</td> <td>Nausea, vomiting, photophobia*, phonophobia*; may have aura (usually visual, but can involve other senses or cause speech or motor deficits)</td> <td>None</td> <td>Ipsilateral lacrimation and redness of the eye; stuffy nose; rhinorrhea; pallor; sweating; Horner syndrome; focal neurologic symptoms rare; sensitivity to alcohol</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* May be inferred from the behavior of young children.</div><div id=\"graphicVersion\">Graphic 70794 Version 4.0</div></div></div>"},"70795":{"type":"graphic_picture","displayName":"Bile duct injury PSC Light","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:445px; height:287px;\" src=\"images/GAST/70795_Bile_duct_injury_PSC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a liver biopsy from a patient with primary sclerosing cholangitis shows a portal bile duct with periductal sclerosis associated with degeneration of the bile duct epithelium.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 70795 Version 1.0</div></div></div>"},"70797":{"type":"graphic_table","displayName":"Recovery rates anaerobes","title":"Recovery rates of anaerobic bacteria from differing infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recovery rates of anaerobic bacteria from differing infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease category</td> <td class=\"subtitle1\">Number cultured</td> <td class=\"subtitle1\">Percent with anaerobes recovered</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Head and neck</td> </tr> <tr> <td class=\"indent1\">Nontraumatic brain abscess </td> <td>18</td> <td>89 </td> <td>Heineman et al. Am J Med 1963</td> </tr> <tr> <td class=\"indent1\">Subdural empyema </td> <td>84 </td> <td>29</td> <td>Swartz. Academic Press 1989</td> </tr> <tr> <td class=\"indent1\">Chronic sinusitis </td> <td>83</td> <td>53</td> <td>Frederick et al. N Engl J Med 1974</td> </tr> <tr> <td class=\"indent1\">Chronic otitis </td> <td>68</td> <td>51</td> <td>Brook. Am J Otolaryngol 1987</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Perimandibular space infection</td> <td>31 </td> <td>94</td> <td>Bartlett et al. J Oral Surg 1979</td> </tr> <tr> <td>21 </td> <td>100</td> <td>Chow et al. Ann Intern Med 1978</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Peritonsillar abscess</td> <td>30 </td> <td>76</td> <td>Flodstrom et al. Scand J Infect Dis 1976</td> </tr> <tr> <td>45</td> <td>84</td> <td>Mitchelmore. Eur J Clin Microbiol Infect Dis 1995</td> </tr> <tr> <td class=\"indent1\">Dental abscess </td> <td>10</td> <td>90</td> <td>Williams et al. J Clin Mirogid 1983</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Chest infections</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Aspiration pneumonia</td> <td>70 </td> <td>87</td> <td>Bartlett et al. Am Rev Respir Dis 1974</td> </tr> <tr> <td>47 </td> <td>62</td> <td>Lorber et al. Ann Intern Med 1974</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Lung abscess</td> <td>57</td> <td>93</td> <td>Bartlett et al. Am Rev Respir Dis 1974</td> </tr> <tr> <td>26 </td> <td>85</td> <td>Beerens et al. Presses Academiques Euro 1965</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Empyema</td> <td>83</td> <td>76</td> <td>Bartlett et al. Am Rev Respir Dis 1974</td> </tr> <tr> <td>37 </td> <td>62</td> <td>Varkey et al. Arch Intern Med 1981</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis </td> <td>18</td> <td>94</td> <td>Greey. 1932</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Unselected patients</td> <td>89 </td> <td>33</td> <td>Ries et al. Arch Intern Med 1974</td> </tr> <tr> <td>74 </td> <td>22</td> <td>Pollack et al. J Clin Microbiol 1983</td> </tr> <tr> <td class=\"indent1\">Hospital-acquired pneumonia </td> <td>159</td> <td>35</td> <td>Bartlett et al. Arch Intern Med 1986</td> </tr> <tr> <td class=\"subtitle2_left\">Intraabdominal sepsis</td> <td>759</td> <td>83</td> <td>Stone et al Arch Surg 1983</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Abscess or peritonitis</td> <td>72</td> <td>94</td> <td>Gorbach. N Engl J Med 1974</td> </tr> <tr> <td>110 </td> <td>89</td> <td>Brook et al. J Med Microbiol 2000</td> </tr> <tr> <td>64 </td> <td>81</td> <td>Swenson et al. Arch Surg 1974</td> </tr> <tr> <td class=\"indent1\">Appendiceal abscess </td> <td>100</td> <td>96</td> <td>Brook et al. Arch Surg 1999</td> </tr> <tr> <td class=\"indent1\">Liver abscess </td> <td>40</td> <td>52</td> <td>Sabbaj et al. Ann Intern Med 1972</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Female genital tract</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Miscellaneous types</td> <td>33 </td> <td>100</td> <td>Thadepalli et al. Am J Obstet Gynecol 1973</td> </tr> <tr> <td>91 </td> <td>74</td> <td>Swenson et al. Obstet Gynecol 1973</td> </tr> <tr> <td>50 </td> <td>72</td> <td>Ledger et al. Am J Obstet Gynecol 1976</td> </tr> <tr> <td class=\"indent1\">Pelvic abscess </td> <td>25 </td> <td>88</td> <td>Altemeier. Am J Obstet Gynecol 1940</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Pelvic inflammatory disease</td> <td>54</td> <td>25</td> <td>Eschenbach et al. N Engl J Med 1975</td> </tr> <tr> <td>74 </td> <td>77</td> <td>Sweet. Clin Infect Dis 1995</td> </tr> <tr> <td>70 </td> <td>78</td> <td>Sweet et al. Am J Obstet Gynecol 1988</td> </tr> <tr> <td class=\"indent1\">Septic abortion </td> <td>29</td> <td>69</td> <td>Chow et al. J Infect Dis 1977</td> </tr> <tr> <td class=\"indent1\">Postpartum endometritis</td> <td>128</td> <td>38</td> <td>Rosene et al. J Infect Dis 1986</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Soft tissue</td> </tr> <tr> <td class=\"indent1\">Wound infection after elective colon surgery</td> <td>19</td> <td>95</td> <td>Bartlett et al. Ann Surg 1978</td> </tr> <tr> <td class=\"indent1\">Postappendectomy wound </td> <td>65</td> <td>79</td> <td>Sanderson et al. J Clin Pathol 1979</td> </tr> <tr> <td class=\"indent1\">Cutaneous abscess </td> <td>135</td> <td>60</td> <td>Meislin et al. Ann Intern Med 1977</td> </tr> <tr> <td class=\"indent1\">Perirectal abscess </td> <td>74</td> <td>77</td> <td>Whitehead et al. Br J Surg 1982</td> </tr> <tr> <td class=\"indent1\">Diabetic foot ulcer </td> <td>19</td> <td>63</td> <td>Louie et al. Ann Intern Med 1976</td> </tr> <tr> <td class=\"indent1\">Pilonidal sinus </td> <td>45</td> <td>73</td> <td>Pearson et al. Am J Surg 1968</td> </tr> <tr> <td class=\"indent1\">Breast abscess </td> <td>52 </td> <td>79</td> <td>Edmiston et al. J Infect Dis 1990</td> </tr> <tr> <td class=\"indent1\">Necrotizing synergistic cellulitis </td> <td>57</td> <td>89</td> <td>Stone et al. Ann Surg 1972</td> </tr> <tr> <td class=\"indent1\">Necrotizing soft tissue </td> <td>182 </td> <td>47</td> <td>Elliott et al. Am J Surg 2000</td> </tr> <tr> <td class=\"indent1\">Paronychia</td> <td>32 </td> <td>72</td> <td>Brook. Am J Surg 1981</td> </tr> <tr> <td class=\"indent1\">Bite wound infections</td> <td>34</td> <td>53</td> <td>Goldstein et al. Rev Infect Dis 1984</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bacteremia</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">All blood cultures</td> <td>4659</td> <td>6</td> <td>Chandler et al. South Med 2000</td> </tr> <tr> <td>2025</td> <td>4</td> <td>Salonen et al. Clin Infect Dis 1998</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Complete reference citation in text reference list.</div><div id=\"graphicVersion\">Graphic 70797 Version 2.0</div></div></div>"},"70798":{"type":"graphic_picture","displayName":"Gill-Thomas-Cosman frame","title":"Immobilization by the Gill-Thomas-Cosman frame in proton radiosurgery","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Immobilization by the Gill-Thomas-Cosman frame in proton radiosurgery</div><div class=\"cntnt\"><img style=\"width:522px; height:338px;\" src=\"images/ONC/70798_Gill-Thomas-Cosman_frame.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The Gill-Thomas-Cosman (GTC) frame consists of three parts: 1) an impression of the patient's upper dentition mounted to the anterior aspect of the head ring, 2) a mold of the patient's occiput mounted onto the posterior frame, and 3) a biasing strap holding these two components firmly in place. B) The occipital mold from the original GTC frame. (b) Application of the Gill-Thomas-Cosman frame. During treatment, the GTC frame is rigidly fixed to the treatment couch in order to achieve patient immobilization.</div><div class=\"graphic_reference\">Courtesy of Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 70798 Version 2.0</div></div></div>"},"70799":{"type":"graphic_picture","displayName":"Head circumference measure","title":"Measurement of head circumference","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measurement of head circumference</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PEDS/70799_Head_circumference_measure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measuring head circumference. The measuring tape passes just above the eyebrows and around the prominent posterior aspect of the head.</div><div class=\"graphic_reference\">Reproduced with permission from: Keith Cotton. Copyright ©2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 70799 Version 2.0</div></div></div>"},"70800":{"type":"graphic_waveform","displayName":"Intermediate case 10 answer","title":"Multifocal atrial tachycardia","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Multifocal atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:520px; height:99px;\" src=\"images/CARD/70800_Intermediate_case_10_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing multifocal atrial tachycardia in a woman with severe pulmonary disease. The diagnostic criteria include an average atrial rate above 100 beats/min and at least three different consecutive non-sinus P waves in the same lead. Note the multiple P wave morphologies - inverted (I), upright (U), and biphasic (B).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 70800 Version 2.0</div></div></div>"},"70804":{"type":"graphic_table","displayName":"Detection MRD","title":"Maximum sensitivity of procedures for detecting minimal residual disease in hematologic malignancies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maximum sensitivity of procedures for detecting minimal residual disease in hematologic malignancies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Technique and criterion </td>\n\n      <td class=\"subtitle1\"> Blasts per 100,000 nucleated cells*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Standard microscopy (\"complete remission\")</td>\n\n      <td>5,000</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Karyotype analysis (20 mitotic figures)</td>\n\n      <td>5,000</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Microscopy, expert</td>\n\n      <td>1,000</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Immunophenotyping: multi-parameter flow cytometry</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Colony growth</td>\n\n      <td> 1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Polymerase chain reaction</td>\n\n      <td> 0.1</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">The numbers given here are the <strong>maximum</strong> sensitivities reported for each procedure. Note that certain techniques may not be applicable in every patient (see text).<br> * The lower level of minimal residual disease predictive of ultimate relapse (ie, the level at which relapse is more likely than not) is currently unknown, and is likely to differ among the various malignant disorders, between children and adults, and among the techniques which are employed (see text).</div><div id=\"graphicVersion\">Graphic 70804 Version 3.0</div></div></div>"},"70805":{"type":"graphic_picture","displayName":"Normal and abnormal larynx ","title":"Normal and abnormal larynx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal larynx</div><div class=\"cntnt\"><img style=\"width:225px; height:161px;\" src=\"images/PC/70805_Abnormal_larynx_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A normal larynx has open ventricles and sharp ventricular bands.<br />(B) In this abnormal larynx, swelling of the true and false vocal folds obliterates the ventricles. Note the moderate (2+) posterior commissure hypertrophy.</div><div class=\"graphic_reference\">Reproduced with permission from: Belafsky, P, Postma, G, Amin, M, Koufman, J. Symptoms and findings of laryngopharyngeal reflux. Ear Nose Throat J 2002; 81(9 Suppl 2):10. Copyright © 2002 Ear, Nose, and Throat Journal.</div><div id=\"graphicVersion\">Graphic 70805 Version 5.0</div></div></div>"},"70806":{"type":"graphic_table","displayName":"Distribution serum CK","title":"Distribution of serum CK in different population groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of serum CK in different population groups</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Sex and ancestry</td> <td class=\"subtitle1\" rowspan=\"2\">N</td> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" rowspan=\"2\">BMI</td> <td class=\"subtitle1\" colspan=\"3\">Serum CK distribution</td> <td class=\"subtitle1\" rowspan=\"2\">&#62;ULN (N percent)*</td> </tr> <tr> <td class=\"subtitle2\">2.5th percentile</td> <td class=\"subtitle2\">Median</td> <td class=\"subtitle2\">97.5th percentile</td> </tr> <tr> <td class=\"sublist1_start\">All subjects<sup>&#182;</sup></td> <td>1411</td> <td>45 (7)</td> <td>27 (5)</td> <td>40</td> <td>111</td> <td>460</td> <td>508 (36)</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">831</td> <td class=\"sublist_other\">45 (7)</td> <td class=\"sublist_other\">28 (6)</td> <td class=\"sublist_other\">36</td> <td class=\"sublist_other\">95</td> <td class=\"sublist_other\">349</td> <td class=\"sublist_other\">304 (37)</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">580</td> <td class=\"sublist_other\">46 (7)</td> <td class=\"sublist_other\">26 (4)</td> <td class=\"sublist_other\">51</td> <td class=\"sublist_other\">143</td> <td class=\"sublist_other\">616</td> <td class=\"sublist_other\">204 (35)</td> </tr> <tr> <td class=\"sublist1_start\">White subjects</td> <td>503</td> <td>48 (7)</td> <td>26 (5)</td> <td>35</td> <td>88</td> <td>286</td> <td>64 (13)</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">252</td> <td class=\"sublist_other\">47 (7)</td> <td class=\"sublist_other\">26 (5)</td> <td class=\"sublist_other\">29</td> <td class=\"sublist_other\">72</td> <td class=\"sublist_other\">201</td> <td class=\"sublist_other\">21 (8)</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">251</td> <td class=\"sublist_other\">48 (7)</td> <td class=\"sublist_other\">26 (4)</td> <td class=\"sublist_other\">47</td> <td class=\"sublist_other\">110</td> <td class=\"sublist_other\">322</td> <td class=\"sublist_other\">43 (17)</td> </tr> <tr> <td class=\"sublist1_start\">South Asian subjects</td> <td>270</td> <td>44 (6)</td> <td>27 (5)</td> <td>40</td> <td>104</td> <td>382</td> <td>62 (23)</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">147</td> <td class=\"sublist_other\">45 (6)</td> <td class=\"sublist_other\">27 (5)</td> <td class=\"sublist_other\">37</td> <td class=\"sublist_other\">87</td> <td class=\"sublist_other\">313</td> <td class=\"sublist_other\">23 (16)</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">123</td> <td class=\"sublist_other\">44 (6)</td> <td class=\"sublist_other\">26 (5)</td> <td class=\"sublist_other\">47</td> <td class=\"sublist_other\">143</td> <td class=\"sublist_other\">641</td> <td class=\"sublist_other\">39 (32)</td> </tr> <tr> <td class=\"sublist1_start\">Black subjects</td> <td>570</td> <td>44 (6)</td> <td>28 (5)</td> <td>51</td> <td>149</td> <td>627</td> <td>278 (49)</td> </tr> <tr> <td class=\"sublist1\">Women</td> <td class=\"sublist_other\">387</td> <td class=\"sublist_other\">43 (6)</td> <td class=\"sublist_other\">29 (6)</td> <td class=\"sublist_other\">48</td> <td class=\"sublist_other\">124</td> <td class=\"sublist_other\">414</td> <td class=\"sublist_other\">164 (42)</td> </tr> <tr> <td class=\"sublist1\">Men</td> <td class=\"sublist_other\">183</td> <td class=\"sublist_other\">44 (6)</td> <td class=\"sublist_other\">26 (4)</td> <td class=\"sublist_other\">71</td> <td class=\"sublist_other\">213</td> <td class=\"sublist_other\">801</td> <td class=\"sublist_other\">114 (62)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data for age and body mass index (BMI) are means (SD). Data are rounded to the nearest integer. CK is expressed as international units per liter.</div><div class=\"graphic_footnotes\">* Number (percentage) of participants with a CK above the ULN, as recommended by the manufacturer (140 IU/L for women, 174 IU/L for men; with appropriately established reference intervals, 2.5 percent of the subjects are expected to have values above the ULN).<br />¶ Including participants of \"other\" ancestry (n = 68), with the exclusion of outliers (n = 3, 1 South Asian and 2 black participants) and those using statins (n = 30, 21 South Asian, 8 black participants, and 1 of other ancestry).</div><div class=\"graphic_reference\">Reproduced with permission from: Brewster, LM, Mairuhu, G, Sturk, A, van Montfrans, GA. Distribution of creatine kinase in the general population: Implications for statin therapy. Am Heart J 2007; 154:655. Copyright &copy;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 70806 Version 2.0</div></div></div>"},"70807":{"type":"graphic_figure","displayName":"Translocation","title":"Translocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Translocation</div><div class=\"cntnt\"><img style=\"width:320px; height:269px;\" src=\"images/PC/70807_Translocation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70807 Version 1.0</div></div></div>"},"70808":{"type":"graphic_picture","displayName":"Temporary abdominal closure","title":"Temporary abdominal closure","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Temporary abdominal closure</div><div class=\"cntnt\"><img style=\"width:508px; height:224px;\" src=\"images/SURG/70808_Temp_abdominal_closure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporary closure of the abdomen involves (A) covering the bowel with a fenestrated drape, (B) laying drains laterally and covering the bowel with a sterile towel, and (C) covering the wound with a sterile occlusive dressing with the drains exiting the drape superiorly (as shown) or inferiorly.</div><div id=\"graphicVersion\">Graphic 70808 Version 1.0</div></div></div>"},"70809":{"type":"graphic_picture","displayName":"Inflammatory acne","title":"Inflammatory acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory acne</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70809_Inflammatoryacne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and pustules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70809 Version 5.0</div></div></div>"},"70810":{"type":"graphic_figure","displayName":"Cochlear implants","title":"The internal and external components of a cochlear implant","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">The internal and external components of a cochlear implant</div><div class=\"cntnt\"><img style=\"width:521px; height:556px;\" src=\"images/PC/70810_Cochlear-implants-new.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70810 Version 1.0</div></div></div>"},"70811":{"type":"graphic_figure","displayName":"DSRS v endosc sclerotherapy","title":"Survival after distal splenorenal shunt placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival after distal splenorenal shunt placement</div><div class=\"cntnt\"><img style=\"width:384px; height:303px;\" src=\"images/GAST/70811_DSRS_v_endosc_sclerotherapy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves for 72 patients randomized to endoscopic sclerotherapy or a distal splenorenal shunt to prevent recurrent variceal bleeding. Survival was significantly higher with endoscopic sclerotherapy at a median 61-month follow-up. The survival benefit in the sclerotherapy group was due to surgical rescue (indicated by the asterisks) of the 35 percent of patients who failed sclerotherapy. The arrows represent the patients who were still alive (arrows).</div><div class=\"graphic_reference\">Data from: Henderson JM. Surg Clin North Am 1990; 70:405.</div><div id=\"graphicVersion\">Graphic 70811 Version 3.0</div></div></div>"},"70812":{"type":"graphic_picture","displayName":"Budding yeast Gram stain","title":"Skin scraping in disseminated candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin scraping in disseminated candidiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/ID/70812_Budding_yeast_gram_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A budding yeast (arrow) is visible in this Gram stain of a pustular skin lesion from a neutropenic patient.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 70812 Version 4.0</div></div></div>"},"70813":{"type":"graphic_table","displayName":"Dysphagia grading system","title":"Dysphagia grading system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dysphagia grading system</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Dysphagia\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Symptom\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Grade 0</td>\r\n  \r\n   <td>Able to swallow all solid foods without difficulty</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Grade 1</td>\r\n  \r\n   <td>Able to swallow solid foods with some difficulty</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Grade 2</td>\r\n  \r\n   <td>Able to swallow soft or semi solid foods only</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Grade 3</td>\r\n  \r\n   <td>Able to swallow liquefied foods and liquids only</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Grade 4</td>\r\n  \r\n   <td>Unable to swallow liquids/saliva</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995; 31:1213.</div><div id=\"graphicVersion\">Graphic 70813 Version 2.0</div></div></div>"},"70816":{"type":"graphic_table","displayName":"Developmental models ASD","title":"Examples of developmental approaches for children with autism spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of developmental approaches for children with autism spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Model</td> <td class=\"subtitle1\">Description</td> </tr> <tr class=\"divider_bottom\"> <td>Denver model</td> <td>Uses play, interpersonal relationships, and activities to remediate core deficits in imitation, emotion sharing, theory of mind, and social perception</td> </tr> <tr class=\"divider_bottom\"> <td>Early Start Denver Model</td> <td>Integrative program that uses a combination of developmental and relationship-based approaches and intensive applied behavior analytic (ABA) programming; includes parents as therapists</td> </tr> <tr class=\"divider_bottom\"> <td>Developmental Individual Difference (DIR), also called Floortime</td> <td>Focuses on \"floor time\" play sessions and other strategies to enhance relationships and social interactions to facilitate emotional and cognitive development; seeks to address deficits in auditory processing, language, motor planning and sequencing, sensory modulation, and visual-spatial processing</td> </tr> <tr class=\"divider_bottom\"> <td>Milieu therapy</td> <td>Focuses on teaching children new communication skills and behaviors in their natural environments</td> </tr> <tr class=\"divider_bottom\"> <td>More Than Words</td> <td>Family-focused program that provides parents with practical tools to help their child communicate</td> </tr> <tr class=\"divider_bottom\"> <td>Relationship-development intervention (RDI)</td> <td>Focuses on activities that elicit interactive behaviors to engage the child in a social relationship; utilizes play-based scenarios that draw out social behaviors and secondarily motivate the child to be more social</td> </tr> <tr> <td>Responsive teaching</td> <td>Development curriculum implemented by parents during routine interactions in the child's natural environment to address cognitive, communication, and social needs</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Myers SM, Johnson CP. American Academy of Pediatrics Council on Children with Disabilities. Management of Children with Autism Spectrum Disorders. Pediatrics 2007; 120:1162.</div><div id=\"graphicVersion\">Graphic 70816 Version 4.0</div></div></div>"},"70817":{"type":"graphic_table","displayName":"Risk classification diabetic foot","title":"Risk classification based on the comprehensive foot examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk classification based on the comprehensive foot examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk category </td> <td class=\"subtitle1\">Definition </td> <td class=\"subtitle1\">Treatment recommendations </td> <td class=\"subtitle1\">Suggested follow-up </td> </tr> <tr> <td>0</td> <td>No LOPS, no PAD, no deformity</td> <td>Patient education including advice on appropriate footwear.</td> <td>Annually (by generalist and/or specialist)</td> </tr> <tr> <td rowspan=\"2\">1 </td> <td rowspan=\"2\">LOPS &#177; deformity </td> <td>Consider prescriptive or accommodative footwear.</td> <td rowspan=\"2\">Every three to six months (by generalist or specialist) </td> </tr> <tr> <td>Consider prophylactic surgery if deformity is not able to be safely accommodated in shoes. Continue patient education.</td> </tr> <tr> <td rowspan=\"2\">2 </td> <td rowspan=\"2\">PAD &#177; LOPS </td> <td>Consider prescriptive or accommodative footwear.</td> <td rowspan=\"2\">Every&nbsp;two to three&nbsp;months (by specialist) </td> </tr> <tr> <td>Consider vascular consultation for combined follow-up.</td> </tr> <tr> <td rowspan=\"2\">3 </td> <td rowspan=\"2\">History of ulcer or amputation </td> <td>Same as category 1.</td> <td rowspan=\"2\">Every&nbsp;one to&nbsp;two&nbsp;months (by specialist) </td> </tr> <tr> <td>Consider vascular consultation for combined follow-up if PAD present.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LOPS: loss of protective sensation; PAD: peripheral arterial disease.</div><div class=\"graphic_reference\">Reprinted with permission from: Boulton AJM, Armstrong DG, Albert ST, et al. Comprehensive Foot Examination and Risk Assessment: A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31:1679. Copyright ©2008 American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 70817 Version 2.0</div></div></div>"},"70818":{"type":"graphic_picture","displayName":"Adenosarcoma","title":"Uterine adensosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine adensosarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/70818_Adenosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 70818 Version 2.0</div></div></div>"},"70820":{"type":"graphic_table","displayName":"Causes monoclonal gammopathy","title":"Disorders associated with the presence of a monoclonal gammopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with the presence of a monoclonal gammopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Plasma cell disorders </td> </tr> <tr> <td>Monoclonal gammopathy of undetermined significance (MGUS)</td> </tr> <tr> <td>Biclonal gammopathy of undetermined significance</td> </tr> <tr> <td>Idiopathic Bence Jones proteinuria</td> </tr> <tr> <td>Monoclonal gammopathy of renal significance (MGRS)&nbsp;</td> </tr> <tr> <td>POEMS syndrome, Osteosclerotic myeloma</td> </tr> <tr> <td>Castleman's disease</td> </tr> <tr> <td>AL (light chain) amyloidosis, light chain and heavy chain deposition diseases</td> </tr> <tr> <td>Solitary plasmacytoma</td> </tr> <tr> <td>Multiple myeloma, Smoldering multiple myeloma</td> </tr> <tr> <td class=\"subtitle1_single\">B-cell lymphoproliferative disorders </td> </tr> <tr> <td>Non-Hodgkin's lymphoma</td> </tr> <tr> <td>Chronic lymphocytic leukemia</td> </tr> <tr> <td>Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia)</td> </tr> <tr> <td>Post-transplant monoclonal gammopathies</td> </tr> <tr> <td>Heavy chain diseases</td> </tr> <tr> <td class=\"subtitle1_single\">Connective tissue disorders* </td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Sjogren syndrome</td> </tr> <tr> <td>Scleroderma</td> </tr> <tr> <td>Psoriatic arthritis</td> </tr> <tr> <td>(Polymyalgia rheumatica)</td> </tr> <tr> <td class=\"subtitle1_single\">Associated with infections* </td> </tr> <tr> <td>Hepatitis C virus infection</td> </tr> <tr> <td>HIV/AIDS</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic disorders </td> </tr> <tr> <td>Scleredema (scleromyxedema), Lichen myxoedematosus</td> </tr> <tr> <td>Diffuse plane xanthomatosis</td> </tr> <tr> <td>Urticaria and IgM (Schnitzler's syndrome)</td> </tr> <tr> <td>Subcorneal pustular dermatosis</td> </tr> <tr> <td>Necrobiotic xanthogranuloma</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous disorders* </td> </tr> <tr> <td>Acquired von Willebrand disease</td> </tr> <tr> <td>Acquired C1 esterase inhibitor deficiency (angioedema)</td> </tr> <tr> <td>Eosinophilic fasciitis</td> </tr> <tr> <td>Cryoglobulinemia, cryofibrinogenemia</td> </tr> <tr> <td>Myelodysplastic syndrome</td> </tr> <tr> <td>Chronic neutrophilic leukemia</td> </tr> <tr> <td>Sensorimotor neuropathy with MGUS</td> </tr> <tr> <td>Capillary leak syndrome</td> </tr> <tr> <td> <p>T-cell large granular lymphocyte leukemia</p> <p>Cold agglutinin disease</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Some of the disorders listed here may be associated with the presence of an underlying lymphoproliferative disorder.</div><div id=\"graphicVersion\">Graphic 70820 Version 3.0</div></div></div>"},"70822":{"type":"graphic_figure","displayName":"Late potentials in ARVC","title":"Late potentials in arrhythmogenic right ventricular cardiomyopathy (ARVC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late potentials in arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class=\"cntnt\"><img style=\"width:324px; height:175px;\" src=\"images/CARD/70822_Late_potentials_in_ARVD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bipolar leads recorded from the thorax over the right precordium in a patient with arrhythmogenic right ventricular cardiomyopathy (ARVC) shows QRS prolongation (220 msec) due to multiple late potentials after the QRS complex (arrow).</div><div class=\"graphic_reference\">With permission from: Podrid PJ, Kowey PR (Eds). Cardiac Arrhythmia. Mechanisms, Diagnosis, and Management, Williams &amp; Wilkins, Baltimore, 1995.</div><div id=\"graphicVersion\">Graphic 70822 Version 3.0</div></div></div>"},"70824":{"type":"graphic_diagnosticimage","displayName":"Perforated duodenal ulcer on computed tomography","title":"Perforated duodenal ulcer on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforated duodenal ulcer on computed tomography</div><div class=\"cntnt\"><img style=\"width:296px; height:576px;\" src=\"images/SURG/70824_CT_scan_duodenal_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal reformatted computed tomography (CT) of the abdomen demonstrates extravasation of oral contrast through a hole in the duodenum (white arrow) consistent with a perforated duodenal ulcer. Note the&nbsp;inflammatory thickening of the duodenal wall (red arrow head).<BR>(B) Axial CT scan of the abdomen demonstrates extravasation of oral contrast (white arrow) and inflammatory thickening of the duodenal wall (red arrow head) due to a perforated duodenal ulcer.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 70824 Version 5.0</div></div></div>"},"70825":{"type":"graphic_figure","displayName":"Iliotibial band anatomy","title":"Iliotibial band anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iliotibial band anatomy</div><div class=\"cntnt\"><img style=\"width:378px; height:586px;\" src=\"images/EM/70825_Iliotibialbandanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral view of the thigh reveals the iliotibial band (or tract). The gluteus medius lies deep to the gluteus maximus on the external surface of the ilium.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70825 Version 11.0</div></div></div>"},"70826":{"type":"graphic_picture","displayName":"Congenital cholesteatoma in the superior posterior quadrant","title":"Congenital cholesteatoma in the superior posterior quadrant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital cholesteatoma in the superior posterior quadrant</div><div class=\"cntnt\"><img style=\"width:375px; height:372px;\" src=\"images/ALLRG/70826_Con_cholest_sup_post_quad.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70826 Version 1.0</div></div></div>"},"70829":{"type":"graphic_picture","displayName":"Noma lesion","title":"Noma lesion in a 3.5-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Noma lesion in a 3.5-year-old child</div><div class=\"cntnt\"><img style=\"width:432px; height:296px;\" src=\"images/ID/70829_Noma_lesion_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immediately prior to complete perforation of the swollen cheek from inside the oral cavity.</div><div class=\"graphic_reference\">Courtesy of Dr. Cyril O Enwonwu, ScD, PhD, MDS, BDS.</div><div id=\"graphicVersion\">Graphic 70829 Version 3.0</div></div></div>"},"70830":{"type":"graphic_diagnosticimage","displayName":"Adolescent polycystic ovary","title":"Ultrasonographic appearance of a polycystic ovary in a 15-year-old with PCOS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasonographic appearance of a polycystic ovary in a 15-year-old with PCOS</div><div class=\"cntnt\"><img style=\"width:385px; height:265px;\" src=\"images/PEDS/70830_Adolescent_polycystic_ovary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonographic appearance of a polycystic ovary in a 15-year-old with polycystic ovary syndrome (PCOS). Note that in the maximal diameter the ovary is enlarged due to excessive central stroma. In addition, it is polycystic, containing over 10 follicles that are approximately 3 to 8 mm in diameter.</div><div class=\"graphic_reference\">Courtesy of Robert L. Rosenfield, MD.</div><div id=\"graphicVersion\">Graphic 70830 Version 4.0</div></div></div>"},"70835":{"type":"graphic_picture","displayName":"Leiomyosarcoma A","title":"Well differentiated uterine leiomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Well differentiated uterine leiomyosarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/70835_Leiomyosarcoma_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 70835 Version 2.0</div></div></div>"},"70837":{"type":"graphic_picture","displayName":"Contact dermatitis","title":"Contact dermatitis from ear drops","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis from ear drops</div><div class=\"cntnt\"><img style=\"width:219px; height:324px;\" src=\"images/PC/70837_Contact_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient receiving ototopical antibiotic drops with persistent pruritis. Note erythema and crusting focused in auricular conchal bowl inferiorly.</div><div class=\"graphic_reference\">Courtesy of Laura A Goguen, MD.</div><div id=\"graphicVersion\">Graphic 70837 Version 1.0</div></div></div>"},"70838":{"type":"graphic_picture","displayName":"Vitiligo focal leg","title":"Focal vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal vitiligo</div><div class=\"cntnt\"><img style=\"width:396px; height:325px;\" src=\"images/PC/70838_Vitiligo_focal_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Area depigmented by vitiligo.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70838 Version 1.0</div></div></div>"},"70839":{"type":"graphic_picture","displayName":"Cholera cots","title":"Cholera cots","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cholera cots</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/ID/70839_Cholera_cot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These devices, in which patients may defecate directly into a collection bucket, facilitate the rapid measurement of ongoing fluid losses and management of epidemics. Inexpensive hand decontamination between examinations may be facilitated by using a portable locally prepared hand sanitizer with at least 60 percent ethanol or isopropenol and an emollient such as 3 percent glycerol<sup>[1]</sup>.</div><div class=\"graphic_reference\">Reference:<br> <ol> <li>Boyce, JM, Pittet, D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1,45, quiz CE1-4. </li> </ol></div><div id=\"graphicVersion\">Graphic 70839 Version 1.0</div></div></div>"},"70840":{"type":"graphic_picture","displayName":"Meshed skin graft","title":"Meshed skin graft","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Meshed skin graft</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/SURG/70840_Meshed_skin_graft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traditional widely meshed skin grafts leave hypertrophic interstices long after the wounds are mature.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery Scientific Principles and Practice, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70840 Version 1.0</div></div></div>"},"70841":{"type":"graphic_figure","displayName":"GRA chimeric gene formation","title":"GRA chimeric gene formation","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">GRA chimeric gene formation</div><div class=\"cntnt\"><img style=\"width:609px; height:236px;\" src=\"images/ENDO/70841_GRA_chimeric_gene_formation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chimeric gene formation in GRA results from an unequal crossover event. The 5' ACTH-responsive promoter region of the 11-beta-hydroxylase gene is fused to the 3' coding sequence of the aldosterone synthase gene. As a result, aldosterone synthesis is abnormally regulated by ACTH rather than by the renin-angiotensin system.</div><div class=\"graphic_footnotes\">GRA: glucocorticoid-remediable aldosteronism; ACTH: corticotropin.</div><div class=\"graphic_reference\">Reproduced from: Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am 2011; 40:333. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 70841 Version 5.0</div></div></div>"},"70842":{"type":"graphic_waveform","displayName":"Conversion of supraventricular tachycardia with adenosine","title":"Conversion of supraventricular tachycardia with adenosine administration","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Conversion of supraventricular tachycardia with adenosine administration</div><div class=\"cntnt\"><img style=\"width:550px; height:98px;\" src=\"images/EM/70842_Conv_supravent_tach_adeno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram during conversion of supraventricular tachycardia to sinus rhythm with administration of adenosine. During tachycardia at a rate of 230 beats/min, there is a normal-appearing QRS complex without a delta wave (no ventricular preexcitation), and there is no distinct P wave. After conversion to sinus rhythm, there is a short PR interval (80 milliseconds) and wide up-sloping QRS complex (90 milliseconds) representing ventricular preexcitation, indicative of the Wolff-Parkinson-White syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: MacDonald MG, Mullett MD, Seshia MMK. Avery's Neonatology Pathophysiology &amp; Management of the Newborn, 6th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70842 Version 2.0</div></div></div>"},"70843":{"type":"graphic_figure","displayName":"RR of HF lisin vs chlor ALLHAT","title":"Heart failure with lisinopril versus chlorthalidone in ALLHAT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart failure with lisinopril versus chlorthalidone in ALLHAT</div><div class=\"cntnt\"><img style=\"width:401px; height:336px;\" src=\"images/NEPH/70843_RR_of_HF_lisin_vs_chlor_ALL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased relative risk of heart failure with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of heart failure in all studied patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of heart failure in total and in all specific subgroups.</div><div class=\"graphic_reference\">Data from the ALLHAT investigators, JAMA 2002; 288:2981.</div><div id=\"graphicVersion\">Graphic 70843 Version 1.0</div></div></div>"},"70845":{"type":"graphic_picture","displayName":"Light microscopy yolk sac tumor","title":"Yolk sac tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Yolk sac tumor</div><div class=\"cntnt\"><img style=\"width:320px; height:317px;\" src=\"images/ONC/70845_Light_microscopy_yolk_sac_t.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a testicular yolk sac tumor showing one of its many histologic patterns. The cells show less atypia than do those of embryonal carcinoma.</div><div class=\"graphic_reference\">Courtesy of Michael Weinstein, MD, PhD.</div><div id=\"graphicVersion\">Graphic 70845 Version 1.0</div></div></div>"},"70846":{"type":"graphic_figure","displayName":"Shoulder strength PI","title":"Strengthening exercises for the rotator cuff tendons","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strengthening exercises for the rotator cuff tendons</div><div class=\"cntnt\"><img style=\"width:233px; height:492px;\" src=\"images/PI/70846_Shoulder_strength_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Part A: The inward rotation isometric exercise is performed by holding the elbow at 90&#176;, close to the side. The rubber band is hooked onto a door handle and grasped with the hand. The forearm is slowly moved towards the body 2 to 3 inches, and held for 5 seconds. The hand should not rotate as the forearm moves.<br>Part B: The outward rotation isometric exercise is performed with the elbows at 90&#176;, close to the sides. The rubber band is grasped with the hands. The formearms are moved outward 2 to 3 inches and held for 5 seconds. Sets of 15 to 20 exercises, each held for 5 seconds, should be performed daily.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 70846 Version 1.0</div></div></div>"},"70847":{"type":"graphic_picture","displayName":"Alder-Reilly granules","title":"Alder-Reilly granules in a patient with mucopolysaccharidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alder-Reilly granules in a patient with mucopolysaccharidosis</div><div class=\"cntnt\"><img style=\"width:420px; height:279px;\" src=\"images/PEDS/70847_Alder-Reilly_granules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Azurophilic cytoplasmic inclusions (Alder-Reilly granules) in neutrophil of a patient with mucopolysaccharidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson, SC, Poulsen, KB. Anderson's Atlas of Hematology. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Wolters Kluwer Health/Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70847 Version 2.0</div></div></div>"},"70850":{"type":"graphic_table","displayName":"Int prognostic index NHL","title":"International Prognostic Index for non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Prognostic Index for non-Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">International Prognostic Index<sup>[1]</sup> </td> </tr> <tr> <td colspan=\"4\">Age &#62;60 </td> </tr> <tr> <td colspan=\"4\">Serum lactate dehydrogenase concentration above normal </td> </tr> <tr> <td colspan=\"4\">ECOG performance status &#8805;2 </td> </tr> <tr> <td colspan=\"4\">Ann Arbor stage III or IV </td> </tr> <tr> <td colspan=\"4\">Number of extranodal disease sites &#62;1 </td> </tr> <tr> <td colspan=\"4\">One point is given for each of the above characteristics present in the patient, for a total score ranging from zero to five. When applied to the initial group of 2031 patients with aggressive NHL treated with anthracycline-based regimens that did NOT include rituximab, five-year overall survival (OS) and complete response (CR) rates according to score were as follows: </td> </tr> <tr> <td class=\"subtitle2\">Score </td> <td class=\"subtitle2\">Risk group </td> <td class=\"subtitle2\">5-yr OS, percent </td> <td class=\"subtitle2\">CR rate, percent </td> </tr> <tr> <td>0 to 1</td> <td>Low risk</td> <td>73</td> <td>87</td> </tr> <tr> <td>2</td> <td>Low-intermediate risk</td> <td>51</td> <td>67</td> </tr> <tr> <td>3</td> <td>High-intermediate risk </td> <td>43</td> <td>55</td> </tr> <tr> <td>4 to 5</td> <td>High risk</td> <td>26</td> <td>44</td> </tr> <tr> <td colspan=\"4\">This same score applied to 1063 patients with CD20-positive aggressive lymphoma treated with rituximab plus CHOP or CHOP-like chemotherapy predicted the following<sup>[2]</sup>: </td> </tr> <tr> <td class=\"subtitle2\">Score </td> <td class=\"subtitle2\">3-yr EFS </td> <td class=\"subtitle2\">3-yr PFS </td> <td class=\"subtitle2\">3-yr OS </td> </tr> <tr> <td>0 to 1</td> <td>81</td> <td>87</td> <td>91</td> </tr> <tr> <td>2</td> <td>69</td> <td>75</td> <td>81</td> </tr> <tr> <td>3</td> <td>53</td> <td>59</td> <td>65</td> </tr> <tr> <td>4 to 5</td> <td>50</td> <td>50</td> <td>59</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Age adjusted International Prognostic Index<sup>[1]</sup> </td> </tr> <tr> <td colspan=\"4\">For this score, all of the prognostic factors listed above, with the exception of age and number of extranodal sites, are given one point, for a score ranging from zero to three. When applied to the group of 761 patients &#62;60 years of age, five-year OS and CR rates according to the adjusted score were as follows: </td> </tr> <tr> <td class=\"subtitle2\">Score </td> <td class=\"subtitle2\">Risk Group </td> <td class=\"subtitle2\">5-yr OS, percent </td> <td class=\"subtitle2\">CR rate, percent </td> </tr> <tr> <td>0</td> <td>Low risk</td> <td>56</td> <td>91</td> </tr> <tr> <td>1</td> <td>Low-intermediate risk</td> <td>44</td> <td>71</td> </tr> <tr> <td>2</td> <td>High-intermediate risk</td> <td>37</td> <td>56</td> </tr> <tr> <td>3</td> <td>High risk</td> <td>21</td> <td>36</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EFS: event-free survival; PFS: progression-free survival.</div><div class=\"graphic_reference\">1. Adapted from: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987.<br>2. Adapted from: Ziepert, M, Hasenclever, D, Kuhnt, E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:2373.</div><div id=\"graphicVersion\">Graphic 70850 Version 4.0</div></div></div>"},"70851":{"type":"graphic_picture","displayName":"Schistocytes on peripheral smear","title":"Peripheral smear in microangiopathic hemolytic anemia showing presence of schistocytes","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral smear in microangiopathic hemolytic anemia showing presence of schistocytes</div><div class=\"cntnt\"><img style=\"width:370px; height:249px;\" src=\"images/HEME/70851_Schistocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with a microangiopathic hemolytic anemia with marked red cell fragmentation. The smear shows multiple helmet cells (arrows) and&nbsp;other fragmented red cells (small arrowhead); microspherocytes are also seen (large arrowheads). The platelet number is reduced; the large platelet in the center (dashed arrow) suggests that the thrombocytopenia is due to enhanced destruction.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 70851 Version 8.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"70852":{"type":"graphic_table","displayName":"DSM-IV-TR diagnostic criteria for major depression","title":"DSM-IV-TR diagnostic criteria for major depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR diagnostic criteria for major depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">A. Five (or more) of the following symptoms have been present during the same 2-week period,&nbsp;and represent a change from previous functioning. At least one of the symptoms is either depressed mood or loss of interest or pleasure. </td> </tr> <tr> <td class=\"sublist1\">(Note: Do not include symptoms that are clearly due to a general medical condition, or mood-incongruent delusions or hallucinations.) </td> </tr> <tr> <td class=\"sublist2\">Depressed mood most of the day, nearly every day (or alternatively can be irritable mood in children and adolescents) </td> </tr> <tr> <td class=\"sublist2\">Markedly diminished interest or pleasure in all, or almost all, activities, nearly every day&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Significant weight loss while not dieting, weight gain, or decrease or increase in appetite </td> </tr> <tr> <td class=\"sublist2\">Insomnia or hypersomnia nearly every day </td> </tr> <tr> <td class=\"sublist2\">Psychomotor agitation or retardation nearly every day </td> </tr> <tr> <td class=\"sublist2\">Fatigue or loss of energy nearly every day </td> </tr> <tr> <td class=\"sublist2\">Feelings of worthlessness or excessive or inappropriate guilt nearly every day </td> </tr> <tr> <td class=\"sublist2\">Diminished ability to think or concentrate, or indecisiveness, nearly every day&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide </td> </tr> <tr> <td>B. The symptoms do not meet criteria for a Mixed Episode.</td> </tr> <tr> <td>C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td> </tr> <tr> <td>D. The symptoms are not due to the direct physiological effects of substance or a general medical condition.</td> </tr> <tr> <td>E. The symptoms are not better accounted for by Bereavement, ie, after the loss of a loved one, the symptoms persist for longer than two months or are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. American Psychiatric Association, Washington, DC 2000.</div><div id=\"graphicVersion\">Graphic 70852 Version 4.0</div></div></div>"},"70853":{"type":"graphic_figure","displayName":"Treatment for Bennett fracture of the thumb","title":"Treatment for Bennett fracture of the thumb","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Treatment for Bennett fracture of the thumb</div><div class=\"cntnt\"><img style=\"width:510px; height:360px;\" src=\"images/SURG/70853_Tx_Bennett_fx_thumb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Bennett fracture of the thumb is an oblique, intraarticular fracture of the thumb metacarpal base. The fracture is reduced by longitudinal traction, pronation of the thumb (rotate counter-clockwise), and pressure on the dorsal metacarpal base. This is an unstable fracture pattern that requires fixation after reduction of the fracture.</div><div id=\"graphicVersion\">Graphic 70853 Version 4.0</div></div></div>"},"70854":{"type":"graphic_table","displayName":"Glenohumeral joint movements","title":"Glenohumeral joint movements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glenohumeral joint movements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Movement<br /> (function)</td> <td class=\"subtitle1\">Prime mover(s)<br /> (from pendent position)</td> <td class=\"subtitle1\">Synergists</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>Flexion</td> <td>Pectoralis major (clavicular head); deltoid (clavicular and anterior acromial parts)</td> <td>Coracobrachialis (assisted by biceps brachii)</td> <td>From fully extended position to its own (coronal) plane, sternocostal head of pectoralis major is major force</td> </tr> <tr> <td>Extension</td> <td>Deltoid (spinal part)</td> <td>Teres major; latissimus dorsi; long head of triceps brachii</td> <td>Latissimus dorsi, sternocostal head of pectoralis major, and long head of triceps act from fully flexed position to their own (coronal) planes</td> </tr> <tr> <td>Abduction</td> <td>Deltoid (as a whole, but especiallly acromial part)</td> <td>Supraspinatus</td> <td>Supraspinatus is particularly important in initiating movement; also, upward rotation of scapula occurs throughout movement, making a significant contribution</td> </tr> <tr> <td>Adduction</td> <td>Pectoralis major; latissimus dorsi</td> <td>Teres major; long head of triceps brachii</td> <td>In upright position and in absence of resistance, gravity is prime mover</td> </tr> <tr> <td>Medial rotation</td> <td>Subscapularis</td> <td>Pectoralis major; deltoid (clavicular part); latissimus dorsi; teres major</td> <td rowspan=\"2\">With arm elevated, \"synergists\" become more important than prime movers</td> </tr> <tr> <td>Lateral rotation</td> <td>Infraspinatus</td> <td>Teres minor; deltoid (spinal part)</td> </tr> <tr> <td>Tensors of articular capsule (to hold head of humerus against glenoid cavity)</td> <td>Subscapularis; infraspinatus (simultaneously)</td> <td>Supraspinatus; teres minor</td> <td>Rotator cuff (SITS) muscles acting together; when \"resting\", their tonus adequately maintains integrity of joint</td> </tr> <tr> <td>Resisting downward dislocation (shunt muscles)</td> <td>Deltoid (as a whole)</td> <td>Long head of triceps brachii; coracobrachialis; short head of biceps brachii</td> <td>Used especially when carrying heavy objects (suitcases, buckets)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Upper Limb. In: Moore KL, Agur AMR, Dalley AF. Clinically Oriented Anatomy, 7th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 70854 Version 11.0</div></div></div>"},"70855":{"type":"graphic_picture","displayName":"Endometrial polyp histology","title":"Endometrial polyp: Histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometrial polyp: Histology</div><div class=\"cntnt\"><img style=\"width:406px; height:540px;\" src=\"images/OBGYN/70855_Endometrial_polyp_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On microscopic section, a polyp exhibits slightly dilated endometrial glands embedded in a markedly fibrous stroma.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70855 Version 1.0</div></div></div>"},"70856":{"type":"graphic_table","displayName":"Abnl findings prosthetic valves","title":"Abnormal auscultatory findings in patients with prosthetic heart valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormal auscultatory findings in patients with prosthetic heart valves</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Aortic valve</td>\n\n      <td class=\"subtitle1\">Mitral valve</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle2_left\">Caged-ball (Starr-Edwards)</td>\n\n      <td>Aortic diastolic murmur</td>\n\n      <td>Low frequency apical diastolic murmur</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Decreased intensity of opening or closing click</td>\n\n      <td>High frequency holosystolic murmur</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle2_left\">Single-tilting-disk (Bjork-Shiley or Medtronic-Hall)</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Decreased intensity of closing click</td>\n\n      <td>High frequency holosystolic murmur</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Decreased intensity of closing click</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle2_left\">Bileaflet-tilting-disk (St. Jude Medical)</td>\n\n      <td>Aortic diastolic murmur</td>\n\n      <td>High frequency holosystolic murmur</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Decreased intensity of closing click </td>\n\n      <td>Decreased intensity of closing click</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Heterograft bioprosthesis (Hancock or Carpentier-Edwards)</td>\n\n      <td>Aortic diastolic murmur</td>\n\n      <td>High frequency holosystolic murmur</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Vongpatanasin, W, Hillis, LD, Lange, RA, N Engl J Med 1996; 335:407.</div><div id=\"graphicVersion\">Graphic 70856 Version 1.0</div></div></div>"},"70857":{"type":"graphic_picture","displayName":"MRCP stone post Roux-en-Y","title":"Choledocholithiasis after Roux-en-Y gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledocholithiasis after Roux-en-Y gastric bypass</div><div class=\"cntnt\"><img style=\"width:249px; height:240px;\" src=\"images/GAST/70857_MRCP_stone_post_Roux-en-Y.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiopancreatography (MRCP) showing large distally impacted bile duct stone in a patient post Roux-en-Y gastric bypass with jaundice.</div><div class=\"graphic_reference\">Courtesy of ML Freeman, MD.</div><div id=\"graphicVersion\">Graphic 70857 Version 3.0</div></div></div>"},"70858":{"type":"graphic_picture","displayName":"Porcelain gallbladder Light","title":"Porcelain gallbladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porcelain gallbladder</div><div class=\"cntnt\"><img style=\"width:324px; height:315px;\" src=\"images/GAST/70858_Porcelain_gallbladder_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross section of a porcelain gallbladder wall shows replacement of the mucosal and muscularis layers by dense fibrosis and calcification.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD.</div><div id=\"graphicVersion\">Graphic 70858 Version 1.0</div></div></div>"},"70859":{"type":"graphic_movie","displayName":"Left ventricular aneurysm four chamber echocardiogram 2","title":"Left ventricular aneurysm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular aneurysm</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/70859_4chlvanrconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:235px; height:368px;\" src=\"images/CARD/70859_4chlvanr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical long axis view from a 2-D echocardiogram shows a very large dyskinetic left ventricular aneurysm of the apex. The right ventricle appears to be small, perhaps as a result of compression from the aneurysm.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 70859 Version 2.0</div></div></div>"},"70862":{"type":"graphic_table","displayName":"Asperger resources","title":"Resources on Asperger syndrome for healthcare providers, educators, patients, and families","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources on Asperger syndrome for healthcare providers, educators, patients, and families</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Web sites</td> <td class=\"subtitle1_single\">Description</td> </tr> <tr> <td> <p>Asperger's Association of New England (AANE)</p> <p><a href=\"http://www.aane.org/\" target=\"_blank\">www.aane.org</a></p> </td> <td>To foster awareness, respect, acceptance, and support for individuals with Asperger syndrome and related conditions and their families</td> </tr> <tr> <td> <p>Asperger Syndrome Education Network (ASPEN)</p> <p><a href=\"http://www.aspennj.org/\" target=\"_blank\">www.aspennj.org</a></p> </td> <td>Devoted to education, support, and advocacy</td> </tr> <tr> <td> <p>Autism Society</p> <p><a href=\"http://www.autism-society.org/\" target=\"_blank\">www.autism-society.org</a></p> </td> <td>Provides written materials, including newsletters, book lists, and research updates</td> </tr> <tr> <td> <p>Online Asperger Syndrome Information and Support at MAAP</p> <p><a href=\"http://www.aspergersyndrome.org/\" target=\"_blank\">www.aspergersyndrome.org</a></p> </td> <td>Provides information and advice to families of individuals with autism, Asperger syndrome, and pervasive developmental disorders</td> </tr> <tr> <td> <p>University Students with Autism and Asperger's Syndrome</p> <p><a href=\"http://www.users.dircon.co.uk/~cns/\" target=\"_blank\">www.users.dircon.co.uk/~cns/</a></p> </td> <td>Focuses on concerns of young adults in higher education</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Books for providers, educators, and parents</td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>A Parent's Guide to Asperger Syndrome &#38; High-Functioning Autism: How to Meet the Challenges and Help Your Child Thrive</strong> by Sally Ozonoff, Geraldine Dawson, and James McPartland </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger Syndrome: A Guide for Educators and Parents</strong> by Brenda Smith Myles and Richard Simpson </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger Syndrome: A Guide for Parents and Professionals</strong> by Tony Attwood </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger Syndrome: A Practical Guide for Teachers</strong> by Val Cumine, Julia Dunlop, and Gill Stevenson </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger Syndrome and Difficult Moments: Practical Solutions for Tantrums, Rage, and Meltdowns</strong> by Brenda Smith Myles and Jack Southwick </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger Syndrome and Sensory Issues: Practical Solutions for Making Sense of the World</strong> by Brenda Smith Myles, Katherine Tapscott Cook, Nancy E Miller, Louann Rinner, and Lisa A Robbins </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Comic Strip Conversations</strong> by Carol Gray </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>The New Social Story Book</strong> by Carol Gray </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Books for children</td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger's Huh?</strong> by John Strachan and Rosina G Schnurr </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Asperger's: What Does it Mean to Me?</strong> by Catherine Faherty and Gary B Mesibov </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>Finding out About Asperger Syndrome, High Functioning Autism and PDD</strong> by Gunilla Gerland </li> </ul> </td> </tr> <tr> <td colspan=\"2\"> <ul> <li><strong>This Is Asperger Syndrome</strong> by Elisa Ganon and Brenda Smith Myles </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Safran JS. A practitioner's guide to resources on Asperger syndrome. Intervention in School and Clinic 2002; 37:283. </li> <li>Saulnier CA, Volkmar FR. Asperger syndrome. In: Developmental and Behavioral Pediatrics: A handbook for primary care, 2nd ed, Parker S, Zuckerman B, Augustyn M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.110. </li> </ol></div><div id=\"graphicVersion\">Graphic 70862 Version 7.0</div></div></div>"},"70863":{"type":"graphic_figure","displayName":"Nomogram of hour-specific total bilirubin in term infants","title":"Nomogram of hour-specific serum or plasma total bilirubin (TB) concentration in healthy term and near-term newborns","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Nomogram of hour-specific serum or plasma total bilirubin (TB) concentration in healthy term and near-term newborns</div><div class=\"cntnt\"><img style=\"width:522px; height:350px;\" src=\"images/PEDS/70863_NomogramofhourspecificS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The red, blue, and green lines denote the 95th, 75th, and 40th percentiles, respectively. Risk zones are designated according to percentile: high (TB ≥95th), high intermediate (95th &gt;TB ≥75th), low intermediate (75th &gt;TB ≥40th), and low (TB &lt;40th). Infants with values in the high risk zone are at increased risk for the development of clinically significant hyperbilirubinemia requiring intervention.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 114, Pages 297-316, Copyright © 2004 by the AAP.</div><div id=\"graphicVersion\">Graphic 70863 Version 13.0</div></div></div>"},"70864":{"type":"graphic_table","displayName":"Oral TMP-SMX desensitization protocol","title":"Oral TMP-SMX desensitization protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral TMP-SMX desensitization protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">TMP dose (mg)</td> <td class=\"subtitle1\">SMX dose (mg)</td> <td class=\"subtitle1\">Volume&nbsp;and formulation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Day 1</td> </tr> <tr> <td class=\"indent1\">9 AM</td> <td>0.8</td> <td>4</td> <td>1 mL of 1:10 dilution</td> </tr> <tr> <td class=\"indent1\">11 AM</td> <td>1.6</td> <td>8</td> <td>2 mL of 1:10 dilution</td> </tr> <tr> <td class=\"indent1\">1 PM</td> <td>4</td> <td>20</td> <td>5 mL of 1:10 dilution</td> </tr> <tr> <td class=\"indent1\">5 PM</td> <td>8</td> <td>40</td> <td>10 mL of 1:10 dilution</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Day 2</td> </tr> <tr> <td class=\"indent1\">9 AM</td> <td>16</td> <td>80</td> <td>2 mL of undiluted suspension</td> </tr> <tr> <td class=\"indent1\">3 PM</td> <td>32</td> <td>160</td> <td>4 mL of&nbsp;undiluted suspension</td> </tr> <tr> <td class=\"indent1\">9 PM</td> <td>40</td> <td>200</td> <td>5 mL of undiluted suspension</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Day 3</td> </tr> <tr> <td class=\"indent1\">9 AM</td> <td>80</td> <td>400</td> <td>One TMP-SMX&nbsp;single-strength&nbsp;tablet</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The solution used on day 1 may be prepared from the oral suspension (which contains 40 mg of trimethoprim and 200 mg of sulfamethoxazole per 5 mL) by combining 2 mL of suspension and 18 mL of water.</div><div class=\"graphic_footnotes\">TMP: Trimethoprim; SMX: Sulfamethoxazole.</div><div class=\"graphic_reference\">Adapted from: Caumes E, Guermonprez G, Lecompte C, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997; 133:465. Copyright ©1997 American Medical Association.</div><div id=\"graphicVersion\">Graphic 70864 Version 3.0</div></div></div>"},"70865":{"type":"graphic_figure","displayName":"Vertebral fracture raloxifene","title":"Reduction in vertebral fractures with raloxifene","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Reduction in vertebral fractures with raloxifene</div><div class=\"cntnt\"><img style=\"width:505px; height:675px;\" src=\"images/ENDO/70865_Vrtbrlfrctrraloxifeneedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cumulative proportion of women with at least one incident VFx at four years. Women with or without prevalent VFxs and who had a baseline and any follow-up radiograph were treated with placebo, or raloxifene 60 mg/day or 120 mg/day.<br />(A) Total study population (n = 6828).<br />(B) Women (n = 5077) who reported no use of other bone-active agents in year 4. The numbers above each bar indicate the number of women in each group who had a new VFx.</div><div class=\"graphic_footnotes\">RR: relative risk; VFx: vertebral fracture.</div><div class=\"graphic_reference\">Reproduced with permission from: Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609. http://jcem.endojournals.org. Copyright © 2002 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 70865 Version 9.0</div></div></div>"},"70866":{"type":"graphic_algorithm","displayName":"Causes of dysphagia","title":"Diagnosis of dysphagia","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Diagnosis of dysphagia</div><div class=\"cntnt\"><img style=\"width:574px; height:448px;\" src=\"images/GAST/70866_diagnosis_of_dysphagia.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70866 Version 4.0</div></div></div>"},"70867":{"type":"graphic_table","displayName":"Aspirin challenges in AERD","title":"Protocols for aspirin challenge to detect respiratory reactions induced by NSAIDs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocols for aspirin challenge to detect respiratory reactions induced by NSAIDs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Aspirin doses, mg</td> </tr> <tr> <td class=\"subtitle2\">Time</td> <td class=\"subtitle2\">Day 1*</td> <td class=\"subtitle2\">Day 2</td> <td class=\"subtitle2\">Day 3</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Oral challenge protocol performed for patient management and based upon commercially available aspirin tablets</td> </tr> <tr> <td class=\"indent2\">8 AM</td> <td>40.5<sup>&#182;</sup></td> <td>325 (done)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">11 AM</td> <td>81</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">2 PM</td> <td>162</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Alternate protocol performed for research purposes</td> </tr> <tr> <td class=\"indent2\">8 AM</td> <td>Placebo*</td> <td>40.5<sup>&#182;</sup></td> <td>325 (done)</td> </tr> <tr> <td class=\"indent2\">11 AM</td> <td>Placebo</td> <td>81</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">2 PM</td> <td>Placebo</td> <td>162</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For either protocol, begin only if baseline forced expiratory volume in one second (FEV<SUB>1</SUB>) is 70% or greater than patient's best without bronchodilator. Alternatively, if the absolute FEV<SUB>1</SUB> value is greater than 1.5 L and represents the best prior FEV<SUB>1</SUB> value, proceed with oral challenge.<br />Patients are expected to develop some signs and symptoms in response to aspirin (acetylsalicylic acid [ASA]) during the challenge procedure. This confirms the diagnosis of a pseudoallergic NSAID reaction. When this protocol is used to desensitize a patient to aspirin, the provoking dose is repeated once symptoms have been treated and subsided, three hours after the previous dose. Most patients will have minimal or no symptoms to the repeated dose, but the dose should be repeated until the patient no longer reacts. The protocol then proceeds to completion. Most patients will not have additional symptoms.</div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Placebos are essential in research protocols but are usually not needed when the challenge is performed for the sole purpose of patient management. On the placebo day, FEV<SUB>1</SUB> values should vary by &lt;10% from baseline, and starting FEV<SUB>1</SUB> value on day 2 should be within 10% of the starting value on day 1.<br />¶ Dose obtained by cutting an 81 mg tablet with a pill cutter. A lower starting dose of 20 mg is suggested for patients who are not taking a leukotriene-modifying drug, have a baseline FEV<SUB>1</SUB> of &lt;80% of predicted, or who have a history of emergency department visits for acute asthma.</div><div class=\"graphic_reference\">First protocol from: Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: A practice paper. Ann Allergy Asthma Immunol 2007; 98:172.<br />Alternate protocol modified with permission from: Stevenson DD, Simon RA, Zuraw BL. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs. In: Middleton's Allergy: Principles and Practice, 6th Ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1695.</div><div id=\"graphicVersion\">Graphic 70867 Version 14.0</div></div></div>"},"70870":{"type":"graphic_picture","displayName":"Fascial interposition during vasectomy","title":"Fascial interposition during vasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fascial interposition during vasectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/PC/70870_Fascial_interposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vas sheath is sutured over the prostatic vasal end.</div><div class=\"graphic_reference\">Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &#169;1999 Timothy Clenney, MD, MPH.</div><div id=\"graphicVersion\">Graphic 70870 Version 3.0</div></div></div>"},"70871":{"type":"graphic_picture","displayName":"Skin tag","title":"Typical acrochordon (skin tag)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical acrochordon (skin tag)</div><div class=\"cntnt\"><img style=\"width:294px; height:246px;\" src=\"images/PC/70871_Skin_tag.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 70871 Version 4.0</div></div></div>"},"70873":{"type":"graphic_figure","displayName":"Sex-related MIP variation","title":"The mean maximal inspiratory pressure (MIP, shown on the vertical axis in cmH<sub>2</sub>O) declines with age during adulthood and is lower in women than men","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">The mean maximal inspiratory pressure (MIP, shown on the vertical axis in cmH<sub>2</sub>O) declines with age during adulthood and is lower in women than men</div><div class=\"cntnt\"><img style=\"width:515px; height:266px;\" src=\"images/PULM/70873_Sex-related_MIP_variation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Harik-Khan, RI, Wise, RA, Fozard, JL. Determinants of maximal inspiratory pressure: the Baltimore Longitudinal Study of Aging. Am J Respir Crit Care Med 1998; 158:1459.</div><div id=\"graphicVersion\">Graphic 70873 Version 1.0</div></div></div>"},"70874":{"type":"graphic_figure","displayName":"Placement of retropubic midurethral sling","title":"Retropubic midurethral sling: Placement in relation to blood vessels","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Retropubic midurethral sling: Placement in relation to blood vessels</div><div class=\"cntnt\"><img style=\"width:489px; height:331px;\" src=\"images/OBGYN/70874_Placement_retropubic_sling.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Muir TW, Tulikangas PK, Fidela Paraiso M, Walters MD. The relationship of tension-free vaginal tape insertion and the vascular anatomy. Obstet Gynecol 2003; 101:933. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70874 Version 12.0</div></div></div>"},"70875":{"type":"graphic_picture","displayName":"Endobronchial lesion","title":"Polypoid endobronchial lesion (patient 18)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polypoid endobronchial lesion (patient 18)</div><div class=\"cntnt\"><img style=\"width:395px; height:381px;\" src=\"images/ID/70875_Endobronchial_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Phillips, P, Bonner, S, Gataric, N, et al. Nontuberculous Mycobacterial Immune Reconstitution Syndrome in HIV-infected patients spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483. Copyright &#169; 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 70875 Version 1.0</div></div></div>"},"70877":{"type":"graphic_figure","displayName":"Cutaneous innervation head and neck","title":"Cutaneous innervation of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Cutaneous innervation of the head and neck</div><div class=\"cntnt\"><img style=\"width:501px; height:461px;\" src=\"images/NEURO/70877_Cutaneous_fields_head_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sensory distribution of the trigeminal nerve (cranial nerve V) and its three divisions (V1, V2, V3) is shown along with branches of the cervical spinal nerves that innervate cutaneous regions of the head and neck.</div><div id=\"graphicVersion\">Graphic 70877 Version 4.0</div></div></div>"},"70878":{"type":"graphic_table","displayName":"Exchange system menu PI","title":"Sample exchange system meal plan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample exchange system meal plan</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Time</td>\r\n            <td class=\"subtitle1\">Exchange pattern</td>\r\n            <td class=\"subtitle1\">Sample menu</td>\r\n            <td class=\"subtitle1\">Carbohydrate count (g)</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"5\">8 am</td>\r\n            <td class=\"sublist1_start\" colspan=\"3\">3 carbohydrate group</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">2 starch</td>\r\n            <td class=\"sublist_other\">1 English muffin</td>\r\n            <td class=\"sublist_other\">30</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 fruit</td>\r\n            <td class=\"sublist_other\">1 1/4 c strawberries</td>\r\n            <td class=\"sublist_other\">15</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 protein group</td>\r\n            <td>1/4 c cottage cheese</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 fat group</td>\r\n            <td>1 tsp margarine</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td>\r\n            <td class=\"subtitle2_left\">Total: 45</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"7\">12 noon</td>\r\n            <td class=\"sublist1_start\" colspan=\"3\">4 carbohydrate group</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">2 starch</td>\r\n            <td class=\"sublist_other\">2 slices of bread</td>\r\n            <td class=\"sublist_other\">30</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 fruit</td>\r\n            <td class=\"sublist_other\">1 orange</td>\r\n            <td class=\"sublist_other\">15</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 vegetable</td>\r\n            <td class=\"sublist_other\">1 c salad</td>\r\n            <td class=\"sublist_other\">-</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 milk</td>\r\n            <td class=\"sublist_other\">8 oz skim milk</td>\r\n            <td class=\"sublist_other\">12</td>\r\n        </tr>\r\n        <tr>\r\n            <td>3 protein group</td>\r\n            <td>3 oz chicken</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 fat group</td>\r\n            <td>1 tbsp low fat mayo</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td>\r\n            <td class=\"subtitle2_left\">Total: 57</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">3 pm</td>\r\n            <td class=\"sublist1_start\" colspan=\"3\">1 carbohydrate group</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 fruit or 1 starch</td>\r\n            <td class=\"sublist_other\">1 apple or 6 crackers</td>\r\n            <td class=\"sublist_other\">15</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td>\r\n            <td class=\"subtitle2_left\">Total: 15</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"7\">6 pm</td>\r\n            <td class=\"sublist1_start\" colspan=\"3\">4 carbohydrate group</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">2 starch</td>\r\n            <td class=\"sublist_other\">1 c potato</td>\r\n            <td class=\"sublist_other\">30</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 fruit</td>\r\n            <td class=\"sublist_other\">1/2 c fruit salad</td>\r\n            <td class=\"sublist_other\">15</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 vegetable</td>\r\n            <td class=\"sublist_other\">1 c salad</td>\r\n            <td class=\"sublist_other\">-</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 milk</td>\r\n            <td class=\"sublist_other\">8 oz skim milk</td>\r\n            <td class=\"sublist_other\">12</td>\r\n        </tr>\r\n        <tr>\r\n            <td>6 protein group</td>\r\n            <td>6 oz fish</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 fat group</td>\r\n            <td>2 tbsp low fat salad dressing</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td>\r\n            <td class=\"subtitle2_left\"><strong>Total: 57</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"3\">9 pm</td>\r\n            <td class=\"sublist1_start\" colspan=\"3\">1 carbohydrate group</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">1 starch</td>\r\n            <td class=\"sublist_other\">6 crackers</td>\r\n            <td class=\"sublist_other\">15</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 protein</td>\r\n            <td>2 tbsp peanut butter</td>\r\n            <td>-</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td>\r\n            <td class=\"subtitle2_left\"><strong>Total: 15</strong></td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 70878 Version 2.0</div></div></div>"},"70879":{"type":"graphic_table","displayName":"Body composition of healthy children","title":"Body composition of healthy children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Body composition of healthy children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Gender</td>\r\n                    <td class=\"subtitle1\">Race/ethnicity</td>\r\n                    <td class=\"subtitle1\">Age (years)</td>\r\n                    <td class=\"subtitle1\">Height (cm) </td>\r\n                    <td class=\"subtitle1\">Weight (kg)</td>\r\n                    <td class=\"subtitle1\">Fat-free mass (kg)</td>\r\n                    <td class=\"subtitle1\">Fat mass (kg)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" rowspan=\"16\">Female</td>\r\n                    <td rowspan=\"4\">Multiracial</td>\r\n                    <td>Birth</td>\r\n                    <td>50</td>\r\n                    <td>3.3</td>\r\n                    <td>2.8</td>\r\n                    <td>0.5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>0.5</td>\r\n                    <td>66</td>\r\n                    <td>7</td>\r\n                    <td>5.1</td>\r\n                    <td>1.9</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>1</td>\r\n                    <td>74</td>\r\n                    <td>9</td>\r\n                    <td>6.8</td>\r\n                    <td>2.2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>2</td>\r\n                    <td>85</td>\r\n                    <td>12</td>\r\n                    <td>9.6</td>\r\n                    <td>2.4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">Caucasian</td>\r\n                    <td>4</td>\r\n                    <td>107</td>\r\n                    <td>18</td>\r\n                    <td>14</td>\r\n                    <td>4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>127 </td>\r\n                    <td>28</td>\r\n                    <td>20</td>\r\n                    <td>7</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12 </td>\r\n                    <td>151</td>\r\n                    <td>44</td>\r\n                    <td>30</td>\r\n                    <td>12</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16</td>\r\n                    <td>164</td>\r\n                    <td>56</td>\r\n                    <td>38</td>\r\n                    <td>15</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">African-American</td>\r\n                    <td>4</td>\r\n                    <td>106</td>\r\n                    <td>18</td>\r\n                    <td>14</td>\r\n                    <td>4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>133</td>\r\n                    <td>33</td>\r\n                    <td>23</td>\r\n                    <td>9</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12</td>\r\n                    <td>157</td>\r\n                    <td>54</td>\r\n                    <td>36</td>\r\n                    <td>16</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16</td>\r\n                    <td>162</td>\r\n                    <td>63</td>\r\n                    <td>40</td>\r\n                    <td>21</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">Hispanic</td>\r\n                    <td>4</td>\r\n                    <td>106</td>\r\n                    <td>19</td>\r\n                    <td>14</td>\r\n                    <td>4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>124</td>\r\n                    <td>30</td>\r\n                    <td>19</td>\r\n                    <td>8</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12</td>\r\n                    <td>153</td>\r\n                    <td>57</td>\r\n                    <td>32</td>\r\n                    <td>17</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16</td>\r\n                    <td>161</td>\r\n                    <td>67</td>\r\n                    <td>39</td>\r\n                    <td>25</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" rowspan=\"16\">Male</td>\r\n                    <td rowspan=\"4\">Multiracial</td>\r\n                    <td>Birth</td>\r\n                    <td>52</td>\r\n                    <td>3.5</td>\r\n                    <td>3.0</td>\r\n                    <td>0.5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>0.5</td>\r\n                    <td>68 </td>\r\n                    <td>8</td>\r\n                    <td>6.0</td>\r\n                    <td>2.0</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>1</td>\r\n                    <td>76</td>\r\n                    <td>10</td>\r\n                    <td>7.8</td>\r\n                    <td>2.2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>2</td>\r\n                    <td>87</td>\r\n                    <td>13</td>\r\n                    <td>10.5</td>\r\n                    <td>2.5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">Caucasian</td>\r\n                    <td>4</td>\r\n                    <td>103</td>\r\n                    <td>17</td>\r\n                    <td>13</td>\r\n                    <td>3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>126</td>\r\n                    <td>26</td>\r\n                    <td>20</td>\r\n                    <td>5</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12</td>\r\n                    <td>157</td>\r\n                    <td>52</td>\r\n                    <td>38</td>\r\n                    <td>12</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16</td>\r\n                    <td>174</td>\r\n                    <td>67</td>\r\n                    <td>54</td>\r\n                    <td>10</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">African-American</td>\r\n                    <td>4</td>\r\n                    <td>105</td>\r\n                    <td>18</td>\r\n                    <td>15</td>\r\n                    <td>2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>127</td>\r\n                    <td>29</td>\r\n                    <td>23</td>\r\n                    <td>4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12</td>\r\n                    <td>161</td>\r\n                    <td>60</td>\r\n                    <td>46</td>\r\n                    <td>13</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16</td>\r\n                    <td>176</td>\r\n                    <td>83</td>\r\n                    <td>66</td>\r\n                    <td>8</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">Hispanic</td>\r\n                    <td>4</td>\r\n                    <td>99</td>\r\n                    <td>16</td>\r\n                    <td>12</td>\r\n                    <td>1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8</td>\r\n                    <td>127</td>\r\n                    <td>30</td>\r\n                    <td>21</td>\r\n                    <td>4</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12</td>\r\n                    <td>158</td>\r\n                    <td>56</td>\r\n                    <td>39</td>\r\n                    <td>9</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16</td>\r\n                    <td>172</td>\r\n                    <td>69</td>\r\n                    <td>54</td>\r\n                    <td>6</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Data from:<BR>1. Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Am J Clin Nutr 1982; 35:1169.<BR>2. Ellis KJ, Abrams SA, Wong WW. Am J Clin Nutr 1997; 65:724.<BR>3. Ellis KJ. Am J Clin Nutr 1997; 66:1323.</div><div id=\"graphicVersion\">Graphic 70879 Version 3.0</div></div></div>"},"70880":{"type":"graphic_figure","displayName":"Holoprosencephaly spectrum","title":"Holoprosencephaly spectrum","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Holoprosencephaly spectrum</div><div class=\"cntnt\"><img style=\"width:501px; height:557px;\" src=\"images/PEDS/70880_Holoprosencephaly_spectrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Features of cebocephaly include an absent or defective single-nostril nose and closely-set eyes (hypotelorism). Ethmocephaly is characterized by small, narrow-set eyes (hypotelorism and microphthalmia) separated by a primative, nonfunctioning nasal structure (proboscis). Cyclopia is marked by a single central orbital fossa and proboscis. The globe can be absent, underdeveloped, or apparently normal, and there can be one or two globes.</div><div id=\"graphicVersion\">Graphic 70880 Version 6.0</div></div></div>"},"70882":{"type":"graphic_diagnosticimage","displayName":"Inferior shoulder dislocation radiograph","title":"Radiograph of inferior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Radiograph of inferior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:503px; height:266px;\" src=\"images/EM/70882_Shoulder_inf_DL_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior (AP)&nbsp;radiograph shows the humoral head lying inferior to the glenoid. Note that the arm is fully abducted.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 70882 Version 3.0</div></div></div>"},"70883":{"type":"graphic_figure","displayName":"McBurney incision 3","title":"McBurney incision 3","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">McBurney incision 3</div><div class=\"cntnt\"><img style=\"width:476px; height:303px;\" src=\"images/SURG/70883_Closure_McBurney_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(E) External oblique closed with running suture. (F) Delayed closure of skin.</div><div id=\"graphicVersion\">Graphic 70883 Version 3.0</div></div></div>"},"70884":{"type":"graphic_figure","displayName":"Amlodipine in HF I","title":"Lack of overall benefit with amlodipine in HF","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lack of overall benefit with amlodipine in HF</div><div class=\"cntnt\"><img style=\"width:590px; height:211px;\" src=\"images/CARD/70884_Amlodipine_in_HF_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier plot of time to the first primary event (left) or cumulative survival in in patients with heart failure randomized to therapy with amlodipine or placebo. There was no overall benefit seen with amlodipine.</div><div class=\"graphic_reference\">Data from: Packer M, O'Connor CM, Ghali JK, et al. N Engl J Med 1996; 335:1107.</div><div id=\"graphicVersion\">Graphic 70884 Version 2.0</div></div></div>"},"70885":{"type":"graphic_diagnosticimage","displayName":"RLL BAC PET","title":"Bronchioloalveolar carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchioloalveolar carcinoma</div><div class=\"cntnt\"><img style=\"width:264px; height:243px;\" src=\"images/PULM/70885_RLL_BAC_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal view of PET scan shows intense uptake of FDG in the right lower lobe. The left sided activity in the left ventricle (arrow) is normal.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; FDG: 18-fluoro-2-deoxyglucose.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70885 Version 3.0</div></div></div>"},"70886":{"type":"graphic_figure","displayName":"Ventilatory effects of SNOs","title":"How S-nitrosothiols (SNOs) work on the brainstem to control breathing","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">How S-nitrosothiols (SNOs) work on the brainstem to control breathing</div><div class=\"cntnt\"><img style=\"width:478px; height:251px;\" src=\"images/PULM/70886_Ventilatory_effects_of_SNOs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(a) Hemoglobin is oxygenated in the lungs; one of its cysteine residues is then modified with SNO. (b) Oxygen levels in the brain (and other peripheral tissues) are lower than in blood. Hemoglobin releases its oxygen and changes its shape in a way that ultimately promotes transfer of its NO group to another cysteine residue, in this case on glutathione (c), by transnitrosylation. S-nitrosoglutathione is cleaved by the enzyme gamma-glutamyl transpeptidase in neuronal tissue to form S-nitrosocysteinyl glycine. It is also possible that S-nitrosocysteinyl glycine is then cleaved by a peptidase to produce S-nitroso-L-cysteine. One of these two molecules is then proposed to transnitrosylate a cysteine residue in a target protein in the nucleus tractus solitarius region of the brainstem, regulating the central neuronal circuitry that controls breathing.</div><div class=\"graphic_footnotes\">SNO: S-nitrosothiols; O<SUB>2</SUB>: oxygen; NO: nitric oxide.</div><div class=\"graphic_reference\">Reproduced with permission from: Lipton SA. Physiology: Nitric oxide and respiration. Nature 2001; 413:118. Copyright © 2001 Nature.</div><div id=\"graphicVersion\">Graphic 70886 Version 3.0</div></div></div>"},"70888":{"type":"graphic_figure","displayName":"MUNE statistical method","title":"Motor unit number estimation (MUNE) by the statistical method","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Motor unit number estimation (MUNE) by the statistical method</div><div class=\"cntnt\"><img style=\"width:495px; height:444px;\" src=\"images/NEURO/70888_MUNE_stat_method.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recordings from a normal patient (left) and a patient with denervating disease (right). For each patient, a series of 30 progressively more intense stimuli (x axis) are plotted against the size of the waveforms, expressed as a percentage of the full compound motor action potential (CMAP) area (y axis). The superimposed waveforms resulting from the 30 stimuli appear above each graph. The smooth progression of small incremental steps in the normal patient (left) contrasts markedly with the curve of the patient with denervating disease, which is interrupted by numerous large increments corresponding with larger, reinnervated single motor unit action potentials (S-MUAPs).</div><div class=\"graphic_reference\">Reproduced with permission from: Daube JR. Estimating the number of motor units in a muscle. J Clin Neurophysiol 1995; 12:585. Copyright © 1995 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70888 Version 9.0</div></div></div>"},"70889":{"type":"graphic_picture","displayName":"Histopathology Aspergillus spp","title":"Histopathologic examination of Aspergillus species","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathologic examination of Aspergillus species</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/70889_Histo_exam_asper_species.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Special stains for histopathologic examination of aspergillus species (eg, periodic acid-Schiff or methenamine silver stain) demonstrate septate hyphae with characteristic acute angle branching (see arrows). Invasive disease is diagnosed when these hyphae are found to be eroding into tissue structures, in this case an ocular tumor.</div><div class=\"graphic_reference\">Courtesy of John W Baddley, MD.</div><div id=\"graphicVersion\">Graphic 70889 Version 2.0</div></div></div>"},"70890":{"type":"graphic_diagnosticimage","displayName":"Pelvic xray intertrochanteric hip fracture","title":"Pelvic radiograph of intertrochanteric hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic radiograph of intertrochanteric hip fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:341px;\" src=\"images/EM/70890_Hip_fx_intertroch1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A left intertrochanteric fracture with severe valgus angulation and displacement of the lesser trochanter is seen on this anteroposterior radiograph of the pelvis.</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, MD and Zuckerman, JD, MD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70890 Version 2.0</div></div></div>"},"70892":{"type":"graphic_picture","displayName":"Gram stain CSF 5B with answer","title":"Listeria monocytogenes on blood agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Listeria monocytogenes on blood agar</div><div class=\"cntnt\"><img style=\"width:365px; height:246px;\" src=\"images/ID/70892_Gram_stain_CSF_5B_with_answ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clear areas around each colony of <EM>Listeria monocytogenes</EM> are characteristic small zones of beta-hemolysis.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 70892 Version 3.0</div></div></div>"},"70893":{"type":"graphic_figure","displayName":"Rapid diuretic therapy  in cirrhosis","title":"Graph showing the effect of rapid diuretic therapy on plasma volume in cirrhotic patients with ascites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing the effect of rapid diuretic therapy on plasma volume in cirrhotic patients with ascites</div><div class=\"cntnt\"><img style=\"width:386px; height:230px;\" src=\"images/NEPH/70893_Rateofdiuresisincirrhos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of rapid diuretic therapy on the plasma volume in patients with cirrhosis and ascites with or without peripheral edema. Compared&nbsp;with those with edema (column one) or untreated patients (column two), the patients without peripheral edema (including edematous patients in column one studied after peripheral edema, but not ascites, had resolved) developed significant plasma volume depletion due to an inability to adequately mobilize the ascitic fluid.</div><div class=\"graphic_reference\">Data from: Pockros PJ, Reynolds TB. Gastroenterology 1986; 90:1827.</div><div id=\"graphicVersion\">Graphic 70893 Version 5.0</div></div></div>"},"70894":{"type":"graphic_picture","displayName":"Inflammatory breast cancer with peau d orange appearance","title":"Clinical presentation of inflammatory breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical presentation of inflammatory breast cancer</div><div class=\"cntnt\"><img style=\"width:389px; height:264px;\" src=\"images/ONC/70894_Inflammatory_breast_CA_appe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The characteristic &quot;peau d'orange&quot; appearance of the breast skin, which is similar to the appearance of the skin of an orange, is apparent.</div><div class=\"graphic_reference\">Reproduced with permission from: Giordano SH. Update on locally advanced breast cancer. Oncologist 2003; 8:526. Copyright &#169; 2003 AlphaMed Press.</div><div class=\"contractual\"><br/><a href=\"http://www.theoncologist.com/\">http://www.TheOncologist.com</a></div><div id=\"graphicVersion\">Graphic 70894 Version 3.0</div></div></div>"},"70895":{"type":"graphic_figure","displayName":"Skin anatomy PI","title":"Normal skin","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Normal skin</div><div class=\"cntnt\"><img style=\"width:542px; height:367px;\" src=\"images/PI/70895_Skin_anatomy_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70895 Version 5.0</div></div></div>"},"70896":{"type":"graphic_diagnosticimage","displayName":"Anomalous pancreaticobiliary union type B-P","title":"Choledochal cyst with anomalous pancreaticobiliary union, type B-P","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledochal cyst with anomalous pancreaticobiliary union, type B-P</div><div class=\"cntnt\"><img style=\"width:363px; height:496px;\" src=\"images/PEDS/70896_Chol_cyst_long_Y_type_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) showing a choledochal cyst, type IV-A, in a 12-year-old female. Note an anomalous&nbsp;pancreaticobiliary union, type \"BP\" (arrow).</div><div class=\"graphic_footnotes\">BP: bileopancreatic.</div><div class=\"graphic_reference\">Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright © 1997 Taylor and Francis.</div><div id=\"graphicVersion\">Graphic 70896 Version 14.0</div></div></div>"},"70897":{"type":"graphic_diagnosticimage","displayName":"Proximal phalanx condylar fracture lateral radiograph","title":"Condylar fracture of the proximal phalanx: Lateral radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condylar fracture of the proximal phalanx: Lateral radiograph</div><div class=\"cntnt\"><img style=\"width:400px; height:517px;\" src=\"images/EM/70897_Prox_phal_condylar_fx_lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph shows a condylar fracture of the proximal phalanx. Although less apparent here than on the anterior-posterior (AP) view, the fracture is reflected in the irregularity of the cortex before the white arrow.</div><div id=\"graphicVersion\">Graphic 70897 Version 3.0</div></div></div>"},"70898":{"type":"graphic_diagnosticimage","displayName":"Ulcerative colitis CT","title":"CT scan of ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:396px; height:288px;\" src=\"images/GAST/70898_Ulcerative_colitis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan through the pelvis shows marked thickening of the wall of the rectum and sigmoid colon with some free fluid in the pelvis (arrow). These features are not specific and may be seen in any form of colitis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 70898 Version 2.0</div></div></div>"},"70900":{"type":"graphic_diagnosticimage","displayName":"2D TTE harmonic imaging ","title":"Two-dimensional transthoracic echocardiogram (2D TTE) with and without harmonic imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) with and without harmonic imaging</div><div class=\"cntnt\"><img style=\"width:305px; height:531px;\" src=\"images/CARD/70900_Harmonic_imaging_echocardio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis precordial view in a technically difficult subject is shown in panel A. The transducer of the instrument insonates tissues at a center line carrier frequency of 3 MHz and receives the resulting reflected signals at the same or fundamental frequency. Harmonic imaging from the same subject is shown in panel B; the instrument insonates tissues at 1.8 MHz and detects their first harmonic reflections at 3.6 MHz. The fundamental frequency reflections are not used. Note that this technique improves the visualization of the walls and valves by creating surfaces that appear to be more continuous. This technique is particularly helpful in stress echocardiography.</div><div id=\"graphicVersion\">Graphic 70900 Version 4.0</div></div></div>"},"70901":{"type":"graphic_picture","displayName":"Mixed gonadal dysgenesis 2","title":"Mixed gonadal dysgenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed gonadal dysgenesis</div><div class=\"cntnt\"><img style=\"width:288px; height:291px;\" src=\"images/PEDS/70901_Mix_gonad_dysgenesi_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 70901 Version 2.0</div></div></div>"},"70902":{"type":"graphic_table","displayName":"Airway complications","title":"Classification of airway complications after lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of airway complications after lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1_single\">1. Stenosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3_single\">Anastomotic bronchial stenosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Stenosis &#60;50 percent of bronchial diameter</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Stenosis &#62;50 percent of bronchial diameter</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3_single\">Segmental non-anastomotic bronchial stenosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Stenosis &#60;50 percent of bronchial diameter</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Stenosis &#62;50 percent of bronchial diameter</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Vanishing Bronchus Intermedius Syndrome (VBIS)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">2. Necrosis &amp; dehiscence</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3_single\">Grade I</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">No slough or necrosis reported. Anastomosis healing well.</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3_single\">Grade II</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Any necrotic mucosal slough reported, but no bronchial wall necrosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3_single\">Grade III</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Bronchial wall necrosis within 2 cm of anastomosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle3_single\">Grade IV</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Extensive bronchial wall necrosis extending &#62;2 cm from anastomosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">3. Exophytic granulation tissue</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Granulation tissue with &#60;50 percent diameter narrowing</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Granulation tissue with &#62;50 percent diameter narrowing</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">4. Malacia</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Diffuse tracheo-bronchial malacia</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Anastomotic malacia (1 cm proximal or distal)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">5. Fistulae</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Broncho-pleural fistula</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Broncho-mediastinal fistula</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Broncho-vascular fistula</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">6. Infections</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Anastomotic infections</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent2\">Non-anastomotic infections (tracheitis, bronchitis, etc)</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &#169; 2009. Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc 2009; 6:79. Official Journal of the American Thoracic Society. Diane Gern, Publisher.</div><div id=\"graphicVersion\">Graphic 70902 Version 3.0</div></div></div>"},"70903":{"type":"graphic_diagnosticimage","displayName":"Goiter CXR","title":"Extrinsic tracheal compression caused by a giant intrathoracic goiter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extrinsic tracheal compression caused by a giant intrathoracic goiter</div><div class=\"cntnt\"><img style=\"width:299px; height:271px;\" src=\"images/PULM/70903_Goiter_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph reveals a large mass in the right hemithorax with displacement and narrowing of the cervical and proximal intrathoracic trachea.</div><div id=\"graphicVersion\">Graphic 70903 Version 2.0</div></div></div>"},"70904":{"type":"graphic_picture","displayName":"Gottrons sign in DM I","title":"Gottron's sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gottron's sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:229px; height:323px;\" src=\"images/RHEUM/70904_Gottrons_sign_in_DM_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, scaly eruption over the extensor surfaces of the metacarpophalangeal joints and digits in a patient with dermatomyositis. These lesions, called Gottron's sign, can mimic psoriasis.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH</div><div id=\"graphicVersion\">Graphic 70904 Version 2.0</div></div></div>"},"70906":{"type":"graphic_figure","displayName":"TNF-alpha inhibitors and TB","title":"Tuberculosis following first exposure to anti-tumor necrosis factor-alpha therapy","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">Tuberculosis following first exposure to anti-tumor necrosis factor-alpha therapy</div><div class=\"cntnt\"><img style=\"width:810px; height:564px;\" src=\"images/ID/70906_TNF_blockers_versus_anti_TN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of tuberculosis (TB) following first exposure to anti-tumor necrosis factor (anti-TNF) therapy (most recent drug model, with person-years censored at death, last returned follow-up form, or date of switching to second anti-TNF). Numbers in table represent the number of patients eligible for follow-up at the specified follow-up time points.</div><div class=\"graphic_footnotes\">ADA: adalimumab; DMARD: disease-modifying antirheumatic drug; ETA: etanercept; INF: infliximab.</div><div class=\"graphic_reference\">Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-8. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2010.</div><div id=\"graphicVersion\">Graphic 70906 Version 5.0</div></div></div>"},"70909":{"type":"graphic_picture","displayName":"Chondrosarcoma Light","title":"Chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ONC/70909_Chondrosarcoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a moderately well differentiated chondrosarcoma.</div><div class=\"graphic_reference\">Courtesy of Silloo B Kapadia, MD.</div><div id=\"graphicVersion\">Graphic 70909 Version 1.0</div></div></div>"},"70910":{"type":"graphic_picture","displayName":"Mastoiditis","title":"Mastoiditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mastoiditis</div><div class=\"cntnt\"><img style=\"width:275px; height:311px;\" src=\"images/PEDS/70910_Mastoiditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: B. Welleschik. Available at: http://commons.wikimedia.org/wiki/File:Mastoiditis1.jpg.</div><div id=\"graphicVersion\">Graphic 70910 Version 2.0</div></div></div>"},"70911":{"type":"graphic_figure","displayName":"Tongue protrusion measure","title":"Measurement of tongue protrusion","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Measurement of tongue protrusion</div><div class=\"cntnt\"><img style=\"width:491px; height:577px;\" src=\"images/PEDS/70911_Tongue_protrusion_measure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tongue is protruded as far as possible. The measurement (in millimeters) is taken from the lower incisors to the tip of the tongue, as illustrated above.</div><div id=\"graphicVersion\">Graphic 70911 Version 1.0</div></div></div>"},"70912":{"type":"graphic_figure","displayName":"Construction of a double barrel loop colostomy - maturing","title":"Construction of a double barrel loop colostomy - anchoring and maturing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a double barrel loop colostomy - anchoring and maturing</div><div class=\"cntnt\"><img style=\"width:358px; height:236px;\" src=\"images/SURG/70912_Double-barrel-loop-colostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the loop colostomy anchored to the abdominal wall.</div><div id=\"graphicVersion\">Graphic 70912 Version 1.0</div></div></div>"},"70914":{"type":"graphic_figure","displayName":"Neuropathy and glycemic control I","title":"Glycemic control prevents diabetic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glycemic control prevents diabetic neuropathy</div><div class=\"cntnt\"><img style=\"width:427px; height:274px;\" src=\"images/NEURO/70914_Neuropathy_and_control_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of the development of clinically evident diabetic neuropathy at five years in patients with type 1 diabetes treated with conventional or intensive insulin therapy. Glycemic control was beneficial in both the primary prevention (no retinopathy) and secondary intervention (background retinopathy) cohorts. Patients with confirmed clinical neuropathy at baseline were excluded from the study. This comprised 3.5 percent of patients in the primary prevention cohort and 9.4 percent in the secondary intervention cohort.</div><div class=\"graphic_reference\">Data from The Diabetes Control and Complications Research Group, N Engl J Med 1993; 329:977.</div><div id=\"graphicVersion\">Graphic 70914 Version 2.0</div></div></div>"},"70915":{"type":"graphic_picture","displayName":"Eosinophilic esophagitis CPC Light","title":"Eosinophilic esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic esophagitis</div><div class=\"cntnt\"><img style=\"width:302px; height:447px;\" src=\"images/GAST/70915_Eos_esophagitis_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophageal biopsies from a patient with eosinophilic esophagitis. There is severe active esophagitis characterized by marked basal zone hyperplasia (top panel) and large numbers of eosinophils (greater than 40 per high power field, bottom panel). Biopsies obtained from the proximal, mid and distal esophagus showed similar findings. The long linear extent of the esophagitis plus the large numbers of eosinophils are characteristic pathologic features of eosinophilic esophagitis.</div><div class=\"graphic_reference\">Courtesy of Maria Botero, MD and Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 70915 Version 2.0</div></div></div>"},"70916":{"type":"graphic_picture","displayName":"Inflammatory acne PI","title":"Inflammatory acne ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory acne </div><div class=\"cntnt\"><img style=\"width:396px; height:267px;\" src=\"images/PI/70916_Inflammatory_acne_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acne can cause the skin to become inflamed, turn red, and swell.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70916 Version 5.0</div></div></div>"},"70918":{"type":"graphic_diagnosticimage","displayName":"Sarcoid arthropathy","title":"Sarcoid arthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoid arthropathy</div><div class=\"cntnt\"><img style=\"width:254px; height:360px;\" src=\"images/RHEUM/70918_Sarcoid_arthropathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hand radiograph shows multiple phalangeal cysts with erosion of the cortex in a patient with sarcoid arthropathy.</div><div id=\"graphicVersion\">Graphic 70918 Version 2.0</div></div></div>"},"70919":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - papules on leg","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/70919_Kaposis_sarcoma_papules_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple violaceous papules are present on the lower leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70919 Version 3.0</div></div></div>"},"70920":{"type":"graphic_figure","displayName":"Boari flap","title":"Boari flap","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Boari flap</div><div class=\"cntnt\"><img style=\"width:535px; height:648px;\" src=\"images/SURG/70920_Boari-flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures represent the Boari flap technique used to repair extensively damaged middle third ureters.</div><div id=\"graphicVersion\">Graphic 70920 Version 1.0</div></div></div>"},"70922":{"type":"graphic_waveform","displayName":"Basic case 14","title":"Basic case 14","html":"<div class=\"graphic normal\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Basic case 14</div><div class=\"cntnt\"><img style=\"width:462px; height:309px;\" src=\"images/CARD/70922_Basic_case_14.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70922 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"70923":{"type":"graphic_table","displayName":"Labs for fever in travelers","title":"Initial laboratory evaluation for fever and tropical exposures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial laboratory evaluation for fever and tropical exposures</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Routine laboratory tests</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Complete blood count with differential</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver enzyme and function tests</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Blood cultures</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Urinalysis (culture if abnormal sediment)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Rapid diagnostic test (if available) and blood smears for malaria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Other tests to consider (depends upon physical examination and exposure history)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Stool culture and/or examination for blood, fecal leukocytes, ova and parasites</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chest radiograph</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Serologic tests</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Urinary antigens (eg, for Legionella)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Blood smears for Babesia, Borrelia, filaria</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bone marrow aspirate/biopsy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Biopsy of skin lesion, lymph nodes, other masses</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Examination of cerebrospinal fluid</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Other imaging studies</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 70923 Version 2.0</div></div></div>"},"70926":{"type":"graphic_diagnosticimage","displayName":"Amniotic band sequence with cranial defect","title":"Amniotic band sequence with cranial defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amniotic band sequence with cranial defect</div><div class=\"cntnt\"><img style=\"width:324px; height:360px;\" src=\"images/OBGYN/70926_ABS_cranial_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique axial image through the fetal head shows the orbits, but no ossified cranium.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 70926 Version 2.0</div></div></div>"},"70927":{"type":"graphic_picture","displayName":"Hematoma umbilical cord","title":"Hematoma umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Hematoma umbilical cord</div><div class=\"cntnt\"><img style=\"width:483px; height:297px;\" src=\"images/OBGYN/70927_Hematoma_umbilical_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross section of umbilical cord revealing localized hematoma.</div><div id=\"graphicVersion\">Graphic 70927 Version 3.0</div></div></div>"},"70928":{"type":"graphic_waveform","displayName":"ECG ventricle parasystole tutorial","title":"Electrocardiogram (ECG) showing ventricular parasystole","html":"<div class=\"graphic normal\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing ventricular parasystole</div><div class=\"cntnt\"><img style=\"width:462px; height:171px;\" src=\"images/CARD/70928_Ventricle_parasystole_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unifocal parasystolic ventricular premature beats (VPBs) occur at a rate which is slower than the underlying sinus rhythm and manifest different coupling intervals (ie, the distance between the VPB and the prior QRS complex). The ectopic focus does not always activate the ventricular myocardium (and therefore does not produe a VPB and the ECG) since it may arrive at a time when the ventricle is refractory due to activation from the normal conduction pathway. However, the interval between two successive VPBs is always some integer of the underlying rate of the ectopic focus (the interectopic intervals have a common denominator) since the ectopic focus is undisturbed and continues to fire at its own intrinsic rate.</div><div id=\"graphicVersion\">Graphic 70928 Version 4.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"70935":{"type":"graphic_figure","displayName":"Lateral viewing telescope","title":"Lateral viewing telescope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral viewing telescope</div><div class=\"cntnt\"><img style=\"width:358px; height:406px;\" src=\"images/PULM/70935_Lateral_viewing_telescope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing of a lateral viewing telescope inserted through a rigid bronchoscope for the purpose of examining the right upper lobe bronchus.</div><div id=\"graphicVersion\">Graphic 70935 Version 1.0</div></div></div>"},"70936":{"type":"graphic_table","displayName":"Carnitine in disorders of fatty acid metabolism","title":"Plasma carnitine levels in disorders of fatty acid metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plasma carnitine levels in disorders of fatty acid metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Enzyme defect</td> <td class=\"subtitle1\">Total carnitine</td> <td class=\"subtitle1\">Free carnitine</td> <td class=\"subtitle1\">Free:total carnitine ratio</td> </tr> <tr> <td>Carnitine transporter</td> <td>Very low</td> <td>Low</td> <td>Normal</td> </tr> <tr> <td>CPT I</td> <td>Normal or high</td> <td>High</td> <td>High</td> </tr> <tr> <td>Translocase and CPT II</td> <td>Low</td> <td>Very low</td> <td>Low</td> </tr> <tr> <td>VLCAD, LCAD, MCAD, SCAD, LCHAD, SCHAD ETF and ETF dehydrogenase, 2,4-dienoyl-CoA reductase</td> <td>Normal or low</td> <td>Low</td> <td>Normal or low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CoA: coenzyme A; CPT: carnitine palmitoyl transferase; ETF: electron transfer flavoprotein; LCAD: long-chain acyl-CoA dehydrogenase; LCHAD: long-chain 3-hydroxyacyl-CoA dehydrogenase; MCAD: medium-chain acyl-CoA dehydrogenase; SCAD: short-chain acyl-CoA dehydrogenase; SCHAD: short-chain 3-hydroxyacyl-CoA dehydrogenase; VLCAD: very long-chain acyl-CoA dehydrogenase.</div><div class=\"graphic_reference\">Adapted from: Vockley J. Mayo Clin Proc 1994; 69:249.</div><div id=\"graphicVersion\">Graphic 70936 Version 3.0</div></div></div>"},"70937":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of duodenal atresia","title":"Prenatal ultrasound image of duodenal atresia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of duodenal atresia</div><div class=\"cntnt\"><img style=\"width:514px; height:221px;\" src=\"images/OBGYN/70937_Prenatal_diag_duod_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetus at 22 weeks of gestation.<br />(A) Axial ultrasound of the fetal abdomen shows a dilated stomach next to a dilated duodenum.<br />(B) Coronal T2w magnetic resonance image confirms the presence of a \"double bubble\" with high signal fluid in the stomach and dilated duodenum. Amniocentesis revealed trisomy 21.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 70937 Version 4.0</div></div></div>"},"70939":{"type":"graphic_picture","displayName":"Indinavir crystals","title":"Photomicrographs showing urine sediment of a patient with indinavir sulfate crystalluria","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Photomicrographs showing urine sediment of a patient with indinavir sulfate crystalluria</div><div class=\"cntnt\"><img style=\"width:451px; height:224px;\" src=\"images/NEPH/70939_Indinavir_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopic photographs of a fresh unstained preparation of urinary sediment showing three different forms of indinavir sulfate crystals.<br />(A) Rectangular plates of various sizes containing needle-shaped crystals. The plates have irregular borders with occasional tapering, and internal layering evident in the largest forms (arrows). Small, triangular pieces (arrowheads) represent broken ends of needles.<br />(B) A sheaf of densely packed indinavir sulfate needles.<br />(C) Several indinavir crystal groupings are arranged in a rosette.</div><div class=\"graphic_reference\">Reprinted with permission from: Gagnon RF, Tsoukas CM, Watters AK, Ann Intern Med 1998; 128:321.</div><div id=\"graphicVersion\">Graphic 70939 Version 4.0</div></div></div>"},"70941":{"type":"graphic_figure","displayName":"Breech1","title":"The fetus emerges spontaneously (A), while uterine contractions maintain cephalic flexion","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">The fetus emerges spontaneously (A), while uterine contractions maintain cephalic flexion</div><div class=\"cntnt\"><img style=\"width:541px; height:262px;\" src=\"images/OBGYN/70941_Breech1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Premature aggressive traction (B) encourages deflexion of the fetal vertex and increases the risk of head entrapment or nuchal arm entrapment.</div><div class=\"graphic_reference\">Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 70941 Version 1.0</div></div></div>"},"70943":{"type":"graphic_figure","displayName":"Probability of incomplete pulmonary nodule resection ","title":"Probability of incomplete resection according to number of pulmonary nodules on preoperative computed tomography (CT)","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Probability of incomplete resection according to number of pulmonary nodules on preoperative computed tomography (CT)</div><div class=\"cntnt\"><img style=\"width:508px; height:358px;\" src=\"images/ONC/70943_Prob_incomplete_resection.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Filled circles are actual probabilities, and the solid line (enclosed within dashed 68 percent confidence limits) is the logistic regression estimate.</div><div class=\"graphic_reference\">Reproduced with permission from: Murthy, SC, Kim, K, Rice, TW, et al. Can we predict long-term survival after pulmonary metastatectomy for renal cell carcinoma? Ann Thorac Surg 2005; 79:996. Copyright ©2005 Society of Thoracic Surgeons.</div><div id=\"graphicVersion\">Graphic 70943 Version 2.0</div></div></div>"},"70945":{"type":"graphic_figure","displayName":"Established neuropathy glycemic control","title":"Benefit of glycemic control in established diabetic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit of glycemic control in established diabetic neuropathy</div><div class=\"cntnt\"><img style=\"width:408px; height:450px;\" src=\"images/NEURO/70945_Established_neuropathy_cont.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histogram of peroneal motor nerve conduction velocities after five years of conventional (blue bars) or intensive (red bars) insulin treatment for patients with possible or definite neuropathy in the primary prevention (upper panel) or secondary intervention (lower panel) cohorts. Nerve conduction velocity was significantly higher in both intensive therapy groups.</div><div class=\"graphic_reference\">Data from: Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38:869.</div><div id=\"graphicVersion\">Graphic 70945 Version 4.0</div></div></div>"},"70948":{"type":"graphic_diagnosticimage","displayName":"Inflammatory bowel disease CT","title":"Pulmonary parenchymal involvement in Crohn's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary parenchymal involvement in Crohn's disease</div><div class=\"cntnt\"><img style=\"width:407px; height:288px;\" src=\"images/PULM/70948_Inflammatory_bowel_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT scan shows multiple necrobiotic nodules (biopsy-proven) in a patient with Crohn's disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 70948 Version 3.0</div></div></div>"},"70950":{"type":"graphic_diagnosticimage","displayName":"Lateral tibial plateau fracture","title":"Lateral tibial plateau fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral tibial plateau fracture</div><div class=\"cntnt\"><img style=\"width:307px; height:426px;\" src=\"images/EM/70950_Lateral_tib_platea_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a nondisplaced lateral tibial plateau fracture.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 70950 Version 3.0</div></div></div>"},"70951":{"type":"graphic_figure","displayName":"Two incision leg fasciotomy","title":"Two incision leg fasciotomy","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Two incision leg fasciotomy</div><div class=\"cntnt\"><img style=\"width:509px; height:703px;\" src=\"images/SURG/70951_Two_incision_leg_fasciotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medial and lateral incisions are depicted. Arrows represent the subcutaneous flaps that will be developed to gain access to the respective compartments. The four compartments to be decompressed are outlined in color. The approximate location for the fascial incision for each compartment is represented by a black line.</div><div id=\"graphicVersion\">Graphic 70951 Version 2.0</div></div></div>"},"70952":{"type":"graphic_figure","displayName":"TIMI flow and survival after thrombolysis","title":"Survival after thrombolytic therapy is better with TIMI grade 3 flow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival after thrombolytic therapy is better with TIMI grade 3 flow</div><div class=\"cntnt\"><img style=\"width:339px; height:234px;\" src=\"images/CARD/70952_TIMI_flow_and_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among all patients with acute ST elevation myocardial infarction entered into the GUSTO-I trial, those with TIMI grade 3 (normal) flow in the infarct-related artery at 90 minutes after thrombolytic therapy had a significantly higher rate of two-year survival than patients with TIMI grades 0, 1, or 2. Partial restoration of flow (TIMI grade 2) did not improve outcomes compared to no or or faint flow (TIMI grade 0 or 1). A similar relationship was seen when the analysis was limited to patients who were alive at 30 days after the infarction (not shown).</div><div class=\"graphic_reference\">Data from Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiography Investigators. Circulation 1998; 97:1549.</div><div id=\"graphicVersion\">Graphic 70952 Version 4.0</div></div></div>"},"70953":{"type":"graphic_picture","displayName":"Pasteurella multocida microscopy","title":"<EM>Pasteurella multocida</EM>: Gram stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Pasteurella multocida</EM>: Gram stain</div><div class=\"cntnt\"><img style=\"width:360px; height:302px;\" src=\"images/ID/70953_Pasteurella_multocida_wound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of purulent drainage from a wound on the finger following a cat bite (x1000) shows inflammatory cells and small, gram-negative rods and coccobacilli. <EM>Pasteurella multocida </EM>grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 70953 Version 5.0</div></div></div>"},"70954":{"type":"graphic_figure","displayName":"ApoE mutations","title":"Structure and mutations of apolipoprotein E (apoE)","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Structure and mutations of apolipoprotein E (apoE)</div><div class=\"cntnt\"><img style=\"width:597px; height:565px;\" src=\"images/NEPH/70954_ApoE_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The underlined mutations were detected in patients with LPG.</div><div class=\"graphic_footnotes\">Del: deletion of amino acid residues; LDL: low-density lipoprotein.</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Saito T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright &copy; 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 70954 Version 5.0</div></div></div>"},"70956":{"type":"graphic_figure","displayName":"Coronary artery anatomy","title":"Coronary artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Coronary artery anatomy</div><div class=\"cntnt\"><img style=\"width:471px; height:466px;\" src=\"images/CARD/70956_Coronary_artery_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 70956 Version 1.0</div></div></div>"},"70959":{"type":"graphic_diagnosticimage","displayName":"Trapped lung hematoma CT","title":"CT scan of a trapped lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of a trapped lung</div><div class=\"cntnt\"><img style=\"width:360px; height:326px;\" src=\"images/PULM/70959_Trapped_lung_hematoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic left pneumothorax in patient post CABG due to trapped lung. CT scan shows left pneumothorax with chest tube in place, filiform posterior adhesions, and a thick visceral pleura encasing the collapsed left lung.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70959 Version 4.0</div></div></div>"},"70960":{"type":"graphic_diagnosticimage","displayName":"Takayasu arteritis aneurysm 2","title":"Fusiform aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fusiform aneurysm</div><div class=\"cntnt\"><img style=\"width:374px; height:273px;\" src=\"images/RHEUM/70960_Takayasu_arteritis_aneury1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlargement of the contrast-filled descending thoracic aneurysm has occurred despite treatment with glucocorticoids.</div><div class=\"graphic_reference\">Reproduced with permission from: Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. Am J Roentgenology 2000; 175:1727. Copyright © 2000 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 70960 Version 5.0</div></div></div>"},"70961":{"type":"graphic_figure","displayName":"Slow action potential","title":"Spontaneous action potential from the sinoatrial node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spontaneous action potential from the sinoatrial node</div><div class=\"cntnt\"><img style=\"width:437px; height:471px;\" src=\"images/CARD/70961_Slow_action_potential.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal sinoatrial node generates a spontaneous slow action potential (panel A), mediated primarily by calcium currents (panel B). The resting membrane potential is -65 mV and manifests spontaneous diastolic depolarization (phase 4), due to an inward leak of sodium ions via a hyperpolarization- dependent pacemaker current (If) and a gradual decline in the delayed rectifier current (Ik), resulting in a decline in the outward flow of potassium ions; these changes are superimposed upon a background current (Ib). The net result is an increase in intracellular positivity with the potential gradually reaching -40 mV, at which point a spontaneous action potential is generated, resulting from a marked increase in the influx of calcium (ICa), followed by a slow inward calcium current (Isi), and activation of Ik and the outward movement of potassium ions.</div><div id=\"graphicVersion\">Graphic 70961 Version 1.0</div></div></div>"},"70962":{"type":"graphic_picture","displayName":"Nail psoriasis pits","title":"Nail pits in psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail pits in psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/70962_Nail_psoriasis_pits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous pits are present on the nail of this patient with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 70962 Version 5.0</div></div></div>"},"70963":{"type":"graphic_figure","displayName":"Percutaneous transtracheal ventilation procedure","title":"Needle cricothyroidotomy","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Needle cricothyroidotomy</div><div class=\"cntnt\"><img style=\"width:528px; height:588px;\" src=\"images/EM/70963_PTVprocedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Performing needle cricothyroidotomy:<br />(A) The needle is angled caudally at 30 to 45 degrees and inserted through the cricothyroid membrane until bubbles are seen in the fluid-filled syringe, indicating puncture of the trachea. <br />(B) The catheter is advanced to the hub as the needle and syringe are removed. <br />(C) The catheter is secured in place and connected to the oxygen delivery system.</div><div class=\"graphic_reference\">Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 70963 Version 12.0</div></div></div>"},"70966":{"type":"graphic_figure","displayName":"Sensitivity analysis thrombolys","title":"One-way sensitivity analysis (example for decision analysis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">One-way sensitivity analysis (example for decision analysis)</div><div class=\"cntnt\"><img style=\"width:408px; height:355px;\" src=\"images/PC/70966_Sensitivity_analysis_thromb.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One-way sensitivity analysis of the probability of a complication from thrombolytic therapy. As the likelihood of a complication (x-axis) rises, the expected value of the thrombolysis strategy declines. The point at which the probability of survival is equivalent between the two strategies is called the threshold.</div><div class=\"graphic_reference\">Data from: Krumholz HM, Pasternak RC, Weinstein MC, et al. N Engl J Med 1992; 327:7.</div><div id=\"graphicVersion\">Graphic 70966 Version 6.0</div></div></div>"},"70967":{"type":"graphic_diagnosticimage","displayName":"Congenital emphysema right","title":"Newborn with congenital lobar emphysema, right upper lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Newborn with congenital lobar emphysema, right upper lobe</div><div class=\"cntnt\"><img style=\"width:360px; height:316px;\" src=\"images/PULM/70967_Congenital_emphysema_right.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph demonstrates marked hyperexpansion of right upper lobe with cardiomediastinal shift to left.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 70967 Version 3.0</div></div></div>"},"70968":{"type":"graphic_figure","displayName":"Muscle length and force","title":"Muscle length and force","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Muscle length and force</div><div class=\"cntnt\"><img style=\"width:521px; height:470px;\" src=\"images/PULM/70968_Muscle_length_and_force.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperinflation (decreased muscle length) causes a reduced maximal inspiratory pressure (MIP) in many patients with COPD. The MIP is 100 percent of its predicted value when the muscle length is in its normal range. MIP decreases as muscle length decreases.</div><div id=\"graphicVersion\">Graphic 70968 Version 1.0</div></div></div>"},"70970":{"type":"graphic_table","displayName":"Comparison MHC class I and II","title":"Table showing molecular comparison of MHC class I and class II molecules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Table showing molecular comparison of MHC class I and class II molecules</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Class I MHC</td> <td class=\"subtitle1\">Class II MHC</td> </tr> <tr> <td><strong>Structure</strong></td> <td>MHC encoded chain, beta-2 microglobulin</td> <td>MHC encoded chain, MHC encoded beta-chain</td> </tr> <tr> <td><strong>Antigen binding groove</strong>*</td> <td>Closed</td> <td>Open</td> </tr> <tr> <td><strong>Peptide length</strong></td> <td>9 to 10 amino acids</td> <td>12 to 28 amino acids</td> </tr> <tr> <td><strong>Source of antigen</strong></td> <td>Intracellular</td> <td>Extracellular</td> </tr> <tr> <td><strong>Expression</strong></td> <td>All nucleated cells</td> <td>B cells, macrophages, dendritic cells</td> </tr> <tr> <td><strong>Antigen presented to:</strong></td> <td>CD8+ T cells</td> <td>CD4+ T cells</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MHC: major histocompatibility complex.<br />* The length of peptide and the conformation of the antigen binding groove differs between class I and II molecules. In the class I MHC molecule, the distal ends of the -helical regions meet, and so the antigen binding cleft is completely enclosed apart from the uppermost surface. In contrast, the -helical regions of the class II MHC molecule do not meet. Thus, the molecule is able to present a longer peptide.</div><div id=\"graphicVersion\">Graphic 70970 Version 4.0</div></div></div>"},"70975":{"type":"graphic_algorithm","displayName":"Evaluation viable myocardium","title":"Indications for intervention and investigative strategy in patients with viable myocardium","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Indications for intervention and investigative strategy in patients with viable myocardium</div><div class=\"cntnt\"><img style=\"width:492px; height:441px;\" src=\"images/CARD/70975_Evaluationviablemyocardiu.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft; HF: heart failure; PET: positron emission tomography.</div><div class=\"graphic_reference\">Adapted from: Marwick TH. Lancet 1998; 351:815.</div><div id=\"graphicVersion\">Graphic 70975 Version 3.0</div></div></div>"},"70976":{"type":"graphic_figure","displayName":"Rapid cricothyrotomy step four","title":"Rapid four-step cricothyrotomy technique: Step 4","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Rapid four-step cricothyrotomy technique: Step 4</div><div class=\"cntnt\"><img style=\"width:463px; height:444px;\" src=\"images/EM/70976_Cric_rapid_step_four.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insert the tracheostomy tube into the trachea.</div><div id=\"graphicVersion\">Graphic 70976 Version 3.0</div></div></div>"},"70977":{"type":"graphic_table","displayName":"AIs fracture","title":"Fractures in the major randomized aromatase inhibitor trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fractures in the major randomized aromatase inhibitor trials</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Trial\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   N/n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   F/U, mo\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Treatment\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Clinical fracture rate, percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"5\">\r\n  \r\n   AI vs TAM\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   ATAC\r\n  \r\n   </td>\r\n  \r\n   <td>9366/609</td>\r\n  \r\n   <td>100</td>\r\n  \r\n   <td>ANA vs TAM</td>\r\n  \r\n   <td>11.0 vs 7.7 [p&#60;0.001]</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   BIG 1-98\r\n  \r\n   </td>\r\n  \r\n   <td>4922/352</td>\r\n  \r\n   <td>51</td>\r\n  \r\n   <td>LET vs TAM</td>\r\n  \r\n   <td>8.6 vs 5.8 [p&#60;0.01]</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"5\">\r\n  \r\n   AI after 2-3 years of TAM\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   IES\r\n  \r\n   </td>\r\n  \r\n   <td>4724/277</td>\r\n  \r\n   <td>58</td>\r\n  \r\n   <td>EXE vs TAM</td>\r\n  \r\n   <td>7.0 vs 5.0 [p = 0.003]</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   ABCSG8/ARNO\r\n  \r\n   </td>\r\n  \r\n   <td>3224/50</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   <td>ANA vs TAM</td>\r\n  \r\n   <td>2.0 vs 1.0 [p = 0.015]</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\" colspan=\"5\">\r\n  \r\n   AI after 5 years of TAM\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   MA-17\r\n  \r\n   </td>\r\n  \r\n   <td>5187/256</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   <td>LET vs Placebo</td>\r\n  \r\n   <td>5.3 vs 4.6 [p = 0.25]</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">ANA: anastrozole; TAM: tamoxifen; EXE: exemestane; LET: letrozole; F/U: follow-up; BMD: bone mineral density; N: number of patients treated; n: total number of fractures.</div><div class=\"graphic_reference\">Reproduced with permission from: Pant, S, Shapiro, CL. Aromatase inhibitor-associated bone loss. Drugs 2008; 68:2591. Copyright &#169;2008 Adis Data Information BV.</div><div id=\"graphicVersion\">Graphic 70977 Version 1.0</div></div></div>"},"70978":{"type":"graphic_figure","displayName":"Alosetron and IBS","title":"Benefit of alosetron in diarrhea-predominant IBS","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Benefit of alosetron in diarrhea-predominant IBS</div><div class=\"cntnt\"><img style=\"width:498px; height:289px;\" src=\"images/GAST/70978_Alosetron_and_IBS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of a controlled trial of 647 women with irritable bowel syndrome (IBS) that was either diarrhea-predominant or had alternating diarrhea and constipation. The women were randomly assigned to alosetron (1 mg twice daily) or placebo for 12 weeks. A significantly greater proportion of women treated with alosetron (41 verses 29 percent with placebo) described adequate relief for all three months of therapy. This difference disappeared with cessation of therapy.</div><div class=\"graphic_reference\">Data from Camilleri, M, Northcutt, AR, Kong, S, et al. Lancet 2000; 355:1035.</div><div id=\"graphicVersion\">Graphic 70978 Version 1.0</div></div></div>"},"70981":{"type":"graphic_diagnosticimage","displayName":"C spine fusion systemic JIA","title":"Cervical spine fusion in systemic juvenile idiopathic arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical spine fusion in systemic juvenile idiopathic arthritis</div><div class=\"cntnt\"><img style=\"width:240px; height:359px;\" src=\"images/RHEUM/70981_C_spine_fusion_systemic_JRA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fusion of the cervical spine may affect up to 50% of children with systemic juvenile idiopathic arthritis&nbsp;in the first decade of life. Apophyseal joint space narrowing and bony ankylosis occur, especially at C2-C3. These changes are not usually present elsewhere in the spine.</div><div id=\"graphicVersion\">Graphic 70981 Version 7.0</div></div></div>"},"70982":{"type":"graphic_table","displayName":"OSA scoring system","title":"Obstructive sleep apnea (OSA) severity scoring system: American Society of Anesthesiologists example","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obstructive sleep apnea (OSA) severity scoring system: American Society of Anesthesiologists example</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">A. Severity of sleep apnea based on sleep study (or clinical indicators if sleep study not available).</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>Severity of OSA</strong></td> </tr> <tr> <td class=\"indent3\">None (apnea hypopnea index [AHI]) 0 to 5 adults; 0 children)</td> <td>0 points</td> </tr> <tr> <td class=\"indent3\">Mild (AHI 6 to 20 adults; 1 to 5 children)</td> <td>1 points</td> </tr> <tr> <td class=\"indent3\">Moderate (AHI 21 to 40 adults; 6 to 10 children)</td> <td>2 points</td> </tr> <tr> <td class=\"indent3\">Severe (AHI greater than 40 adults; greater than 10 children)</td> <td>3 points</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Point score ____ (0 to 3)</strong>*<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">B. Invasiveness of surgery and anesthesia.</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>Type of surgery and anesthesia</strong></td> </tr> <tr> <td class=\"indent3\">Superficial surgery under local or peripheral nerve block anesthesia without sedation</td> <td>0 points</td> </tr> <tr> <td class=\"indent3\">Superficial surgery with moderate sedation or general anesthesia</td> <td>1 points</td> </tr> <tr> <td class=\"indent3\">Peripheral surgery with spinal or epidural anesthesia (with no more than moderate sedation)</td> <td>1 points</td> </tr> <tr> <td class=\"indent3\">Peripheral surgery with general anesthesia</td> <td>2 points</td> </tr> <tr> <td class=\"indent3\">Airway surgery with moderate sedation</td> <td>2 points</td> </tr> <tr> <td class=\"indent3\">Major surgery, general anesthesia</td> <td>3 points</td> </tr> <tr> <td class=\"indent3\">Airway surgery, general anesthesia </td> <td>3 points</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Point score ____ (0 to 3)</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">C. Requirement for postoperative opioids.</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>Opioid requirement</strong></td> </tr> <tr> <td class=\"indent3\">None</td> <td>0 points</td> </tr> <tr> <td class=\"indent3\">Low-dose oral opioids </td> <td>1 points</td> </tr> <tr> <td class=\"indent3\">High-dose oral opioids, parenteral or neuraxial opioids</td> <td>3 points</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Point score ____ (0 to 3)</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">D. Estimation of perioperative risk. Overall score = the score for A plus the greater of the score for either B or C.</td> </tr> <tr> <td class=\"indent2\"><strong>Total point score ____ (0 to 6)</strong><sup>&#916;</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* One point may be subtracted if a patient has been on continuous positive airway pressure or noninvasive positive pressure ventilation before surgery and will be using his or her appliance consistently during the postoperative period.<br />¶ One point should be added if a patient with mild or moderate obstructive sleep apnea (OSA) also has a resting arterial carbon dioxide tension (PaCO<SUB>2</SUB> greater than 50 mmHg).<br />Δ Patients with a score of 4 may be at increased perioperative risk from OSA; patients with a score of 5 or 6 may be at significantly increased perioperative risk from OSA.</div><div class=\"graphic_reference\">Reproduced with permission from: American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Anesthesiology 2006; 104:1081. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70982 Version 11.0</div></div></div>"},"70984":{"type":"graphic_algorithm","displayName":"Role of LDL in atherosclerosis","title":"Role of LDL in atherosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Role of LDL in atherosclerosis</div><div class=\"cntnt\"><img style=\"width:386px; height:370px;\" src=\"images/CARD/70984_Role_of_LDL_in_atherosclero.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the effects of LDL and oxidized LDL in the pathogenesis of atherosclerosis. Other coronary risk factors, low HDL levels, smoking, hypertension, diabetes mellitus, and estrogen deficiency also enhance the oxidation of LDL.</div><div id=\"graphicVersion\">Graphic 70984 Version 4.0</div></div></div>"},"70985":{"type":"graphic_picture","displayName":"Iron overload liver Light","title":"Liver biopsy in hereditary hemochromatosis (H and E staining)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver biopsy in hereditary hemochromatosis (H and E staining)</div><div class=\"cntnt\"><img style=\"width:437px; height:288px;\" src=\"images/GAST/70985_Iron_overload_liver_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a liver biopsy from a patient with hereditary hemochromatosis showing brown pigmentation of hepatocytes due to iron deposition (hematoxylin and eosin stain). The presence of iron can be confirmed by Perls' Prussian blue stain.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 70985 Version 2.0</div></div></div>"},"70986":{"type":"graphic_picture","displayName":"Aeromonas cellulitis","title":"Aeromonas cellulitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aeromonas cellulitis</div><div class=\"cntnt\"><img style=\"width:403px; height:253px;\" src=\"images/ID/70986_Aeromonas_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This immunocompromised patient developed cellulitis due to <EM>Aeromonas</EM> spp.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD.</div><div id=\"graphicVersion\">Graphic 70986 Version 3.0</div></div></div>"},"70989":{"type":"graphic_picture","displayName":"Nickel allergy","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:402px; height:255px;\" src=\"images/PEDS/70989_Nickelallergy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subumbilical allergic contact dermatitis from metal fasteners in pants (nickel allergy).</div><div class=\"graphic_reference\">Courtesy of William L Weston, MD.</div><div id=\"graphicVersion\">Graphic 70989 Version 2.0</div></div></div>"},"70990":{"type":"graphic_waveform","displayName":"Junctional premature tutorial","title":"Junctional premature complexes","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Junctional premature complexes</div><div class=\"cntnt\"><img style=\"width:385px; height:84px;\" src=\"images/CARD/70990_Junctional_premature_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrioventricular junctional premature beats (beats 2 and 4) are early ectopic beats which originate in or near the AV junction and have a QRS morphology that resembles the sinus complex. Although their timing and morphology are similar to that of an atrial premature beat, there is no P wave present before the QRS complex.</div><div id=\"graphicVersion\">Graphic 70990 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"70992":{"type":"graphic_picture","displayName":"Normal ileostomy stoma","title":"Healthy-appearing \"bud\" ileostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healthy-appearing &quot;bud&quot; ileostomy</div><div class=\"cntnt\"><img style=\"width:371px; height:183px;\" src=\"images/GAST/70992_Normal_ileostomy_stoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ideal ileostomy stoma with a well-protruding &quot;bud&quot;. The stoma should be lying on a flat 3 to 4 inches of abdominal skin within easy reach of the patient</div><div class=\"graphic_reference\">Courtesy of Jeffrey B Matthews, MD.</div><div id=\"graphicVersion\">Graphic 70992 Version 1.0</div></div></div>"},"70994":{"type":"graphic_picture","displayName":"Tattooed PET following preoperative EUS-FNT","title":"Tattooed pancreatic endocrine tumor following preoperative endoscopic ultrasound-guided fine-needle tattooing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tattooed pancreatic endocrine tumor following preoperative endoscopic ultrasound-guided fine-needle tattooing</div><div class=\"cntnt\"><img style=\"width:376px; height:581px;\" src=\"images/GAST/70994_Tattooed_PET_preop_EUS_FNT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Intraoperative photo demonstrating tattooed pancreatic endocrine tumor (PET) following preoperative endoscopic ultrasound-guided fine-needle tattooing. The PET was excised with laparoscopic enucleation. Arrow denotes tattoo.<br> (B) Laparoscopic enucleation successfully removed the tumor with negative margins, while preserving the normal pancreatic parenchyma. Arrow denotes site of laparoscopic enucleation of PET.</div><div id=\"graphicVersion\">Graphic 70994 Version 1.0</div></div></div>"},"70995":{"type":"graphic_figure","displayName":"Right colectomy for malignancy","title":"Right colectomy for malignancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right colectomy for malignancy</div><div class=\"cntnt\"><img style=\"width:426px; height:528px;\" src=\"images/SURG/70995_Right_colectomy_for_malignancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the extent of a right colectomy. For malignant lesions, the resection involves isolating and dividing the ileocolic vessels, right colic vessels, and either the right or hepatic branch of the middle colic artery and vein&nbsp;at their origins.</div><div id=\"graphicVersion\">Graphic 70995 Version 2.0</div></div></div>"},"70996":{"type":"graphic_picture","displayName":"Alopecia areata 5","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:380px; height:272px;\" src=\"images/DERM/70996_Alopecia_areata_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child has smooth, well-demarcated, noninflammatory, asymptomatic patches of alopecia.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 70996 Version 2.0</div></div></div>"},"70997":{"type":"graphic_table","displayName":"Minor heat illness treatment in children","title":"Evaluation and management of minor heat illness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and management of minor heat illness in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Core body temperature</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Miliaria (heat rash)</td> <td>Normal</td> <td>Pruritic erythematus or skin colored papular, vesicular, or pustular rash</td> <td> <p>Light clothing to decrease sweating</p> Symptomatic treatment of pruritus</td> </tr> <tr class=\"divider_bottom\"> <td>Heat edema</td> <td>Normal</td> <td>Swelling of feet, ankles, and/or lower legs</td> <td> <p>Cool environment*</p> <p>Elevation of legs</p> Compression stockings</td> </tr> <tr class=\"divider_bottom\"> <td>Heat syncope</td> <td>Normal</td> <td>Dizziness, orthostatic hypotension, and syncope after exertion with rapid return to normal mental status when supine</td> <td> <p>Move to cool environment*</p> <p>Supine position</p> Oral rehydration with salt-containing fluids<sup>&#182;</sup> or intravenous normal saline (initial infusion 20 mL per kg)</td> </tr> <tr class=\"divider_bottom\"> <td>Heat cramps</td> <td>Normal or elevated up to 40&#176;C (104&#176;F)</td> <td>Painful cramps of large muscle groups in the legs (eg, quadriceps, gastrocnemius) occurring after exertion</td> <td> <p>Passively stretch affected muscle</p> Oral rehydration with salt-containing fluids<sup>&#182;</sup> or intravenous normal saline (initial infusion 20 mL per kg, maximum initial volume: 1 L)</td> </tr> <tr class=\"divider_bottom\"> <td>Heat tetany</td> <td>Normal or elevated up to 40&#176;C (104&#176;F)</td> <td>Hyperventilation with carpopedal spasm, paresthesias</td> <td> <p>Move to cool environment*</p> If symptoms persistent, low flow (&#60;5 L per min.) oxygen via a partial rebreathing mask to encourage rebreathing of CO2</td> </tr> <tr> <td rowspan=\"3\">Heat exhaustion</td> <td rowspan=\"3\">Elevated up to 40&#176;C (104&#176;F)</td> <td rowspan=\"3\"> <p>Normal mental status, dizziness, brief episode of syncope, or mild confusion that rapidly normalizes within 30 minutes of treatment</p> <p>Tachycardia with normal blood pressure and mild to moderate dehydration</p> Nausea, vomiting, headache, fatigue, weakness, thirst, sweating, or, in some patients, hyponatremia or hypernatremia</td> <td> <p>Cease exertion immediately</p> <p>Move to cool environment*</p> <p>Remove excess clothing</p> Oral rehydration with cool, salt-containing liquids<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\">If symptoms continue despite above measures or if altered mental status:</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Measure rectal temperature </li> </ul> <ul> <li>Measure serum electrolytes </li> </ul> <ul> <li>Administer IV normal saline (initial infusion 20 mL per kg, maximum initial volume: 1 L) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cool environments include natural shade, an air conditioned vehicle, or air conditioned building.<br />&#182; Flavored sports drinks may be used.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Howe AS, Boden BP. Heat-related illness in athletes. Am J Sports Med 2007; 35:1384.</li>&#xD;&#xA;    <li>DeFranco MJ, Baker CL 3rd, DaSilva JJ, et al. Environmental issues for team physicians. Am J Sports Med 2008; 36:2226.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 70997 Version 5.0</div></div></div>"},"70998":{"type":"graphic_picture","displayName":"Superficial diabetic foot ulcer","title":"Superficial diabetic foot ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial diabetic foot ulcer</div><div class=\"cntnt\"><img style=\"width:378px; height:232px;\" src=\"images/ENDO/70998_Wagner_1_foot_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foot from a diabetic patient showing a superficial ulcer that involves a partial thickness of the skin but no involvement of the underlying tissues. This lesion healed quickly with rest and local foot care.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 70998 Version 3.0</div></div></div>"}};